PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10353694-3	1999	However, GM-CSF did prime the cells for enhanced PA formation in the presence of a secondary stimulus (fMet-Leu-Phe or PAF).	Protactinium	49-51	colony stimulating factor 2	Homo sapiens	9-15
10353694-3	1999	However, GM-CSF did prime the cells for enhanced PA formation in the presence of a secondary stimulus (fMet-Leu-Phe or PAF).	Protactinium	49-51	PCNA clamp associated factor	Homo sapiens	119-122
10353694-4	1999	GM-CSF also caused a time-dependent stimulation of diacylglycerol formation in adherent, but not suspended, cells and elicited a time-dependent stimulation of phosphatidylethanol formation, with a concomitant decrease in the formation of PA only at early (< 7 min) times.	Protactinium	238-240	colony stimulating factor 2	Homo sapiens	0-6
10353694-8	1999	Taken together the data indicate that GM-CSF rapidly activates PLD in adherent cells, which is responsible for the generation of PA.	Protactinium	129-131	colony stimulating factor 2	Homo sapiens	38-44
10353694-8	1999	Taken together the data indicate that GM-CSF rapidly activates PLD in adherent cells, which is responsible for the generation of PA.	Protactinium	129-131	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	63-66
10050042-10	1999	BA-2-PA was detected in all the PA-sugar chain fractions prepared from Hexa, Hexb, and both Hexa and Hexb (double knockout) gene-disrupted mice, but BA-1 was not found in the fractions from Hexb gene-disrupted and double knockout mice.	Protactinium	5-7	hexosaminidase A	Mus musculus	92-96
9950855-4	1999	VEGF (10(-10) M) induced a two- to threefold increase in Pa, which was blocked by a monoclonal antibody directed against the VEGF receptor Flk-1/KDR, the phospholipase C (PLC) antagonist U-73122, or the protein kinase C (PKC) antagonist bisindolylmaleimide (BIM).	Protactinium	57-59	vascular endothelial growth factor A	Homo sapiens	0-4
9950855-4	1999	VEGF (10(-10) M) induced a two- to threefold increase in Pa, which was blocked by a monoclonal antibody directed against the VEGF receptor Flk-1/KDR, the phospholipase C (PLC) antagonist U-73122, or the protein kinase C (PKC) antagonist bisindolylmaleimide (BIM).	Protactinium	57-59	vascular endothelial growth factor A	Homo sapiens	125-129
9950855-4	1999	VEGF (10(-10) M) induced a two- to threefold increase in Pa, which was blocked by a monoclonal antibody directed against the VEGF receptor Flk-1/KDR, the phospholipase C (PLC) antagonist U-73122, or the protein kinase C (PKC) antagonist bisindolylmaleimide (BIM).	Protactinium	57-59	kinase insert domain receptor	Homo sapiens	139-144
9950855-4	1999	VEGF (10(-10) M) induced a two- to threefold increase in Pa, which was blocked by a monoclonal antibody directed against the VEGF receptor Flk-1/KDR, the phospholipase C (PLC) antagonist U-73122, or the protein kinase C (PKC) antagonist bisindolylmaleimide (BIM).	Protactinium	57-59	kinase insert domain receptor	Homo sapiens	145-148
9987172-2	1999	Spleen cells from BALB/c mice immunized intramuscularly with this vaccine were stimulated to secrete IFN gamma and IL-4 when exposed to PA in vitro.	Protactinium	136-138	interleukin 4	Mus musculus	115-119
10591990-6	1999	In view of the findings based on Strauss" work (1974) the PAS has been added to the SANS, SAPS and BPRS, whose results were examined by factor analysis.	Protactinium	58-61	USH1 protein network component sans	Homo sapiens	84-88
9987172-2	1999	Spleen cells from BALB/c mice immunized intramuscularly with this vaccine were stimulated to secrete IFN gamma and IL-4 when exposed to PA in vitro.	Protactinium	136-138	interferon gamma	Mus musculus	101-110
10027556-2	1999	The formation of dPER-dTIM complex is based on the interaction between dPER"s PAS domain and dTIM"s PAS binding domain.	Protactinium	78-81	period	Drosophila melanogaster	17-21
10027556-2	1999	The formation of dPER-dTIM complex is based on the interaction between dPER"s PAS domain and dTIM"s PAS binding domain.	Protactinium	78-81	timeless	Drosophila melanogaster	22-26
10027556-2	1999	The formation of dPER-dTIM complex is based on the interaction between dPER"s PAS domain and dTIM"s PAS binding domain.	Protactinium	78-81	period	Drosophila melanogaster	71-75
10027556-2	1999	The formation of dPER-dTIM complex is based on the interaction between dPER"s PAS domain and dTIM"s PAS binding domain.	Protactinium	78-81	timeless	Drosophila melanogaster	93-97
10027556-2	1999	The formation of dPER-dTIM complex is based on the interaction between dPER"s PAS domain and dTIM"s PAS binding domain.	Protactinium	100-103	period	Drosophila melanogaster	17-21
10027556-2	1999	The formation of dPER-dTIM complex is based on the interaction between dPER"s PAS domain and dTIM"s PAS binding domain.	Protactinium	100-103	timeless	Drosophila melanogaster	22-26
10027556-2	1999	The formation of dPER-dTIM complex is based on the interaction between dPER"s PAS domain and dTIM"s PAS binding domain.	Protactinium	100-103	period	Drosophila melanogaster	71-75
10027556-2	1999	The formation of dPER-dTIM complex is based on the interaction between dPER"s PAS domain and dTIM"s PAS binding domain.	Protactinium	100-103	timeless	Drosophila melanogaster	93-97
10027556-3	1999	As an initial step to understand the molecular mechanism of mammalian circadian clock, we screened His-tagged dPER/PAS binding proteins from rat brain nuclear extracts, using Ni2+-NTA affinity chromatography.	Protactinium	115-118	period	Drosophila melanogaster	110-114
10027556-4	1999	As a result of screening, we identified two proteins (192 and 180 kDa), which specifically bound to His-dPER/PAS in rat brain extracts.	Protactinium	109-112	period	Drosophila melanogaster	104-108
10372653-6	1999	Morphometry revealed that neuronal loss was present in the hippocampal area CA1 in all groups with PA and that morphological alterations were significantly higher in the cerebellar granular layer.	Protactinium	99-101	carbonic anhydrase 1	Rattus norvegicus	76-79
9888180-5	1999	This study determines the PA values of such segments (Pep), i.e., cyclic and linear dipeptides and a relevant oxazolone, based on the dissociations of proton-bound dimers [Pep + Bi]H+ in which Bi is a reference base of known PA value (Cooks kinetic method).	Protactinium	26-28	progestagen associated endometrial protein	Homo sapiens	54-57
9888180-5	1999	This study determines the PA values of such segments (Pep), i.e., cyclic and linear dipeptides and a relevant oxazolone, based on the dissociations of proton-bound dimers [Pep + Bi]H+ in which Bi is a reference base of known PA value (Cooks kinetic method).	Protactinium	26-28	progestagen associated endometrial protein	Homo sapiens	172-175
9888180-5	1999	This study determines the PA values of such segments (Pep), i.e., cyclic and linear dipeptides and a relevant oxazolone, based on the dissociations of proton-bound dimers [Pep + Bi]H+ in which Bi is a reference base of known PA value (Cooks kinetic method).	Protactinium	225-227	progestagen associated endometrial protein	Homo sapiens	54-57
9893120-1	1999	BACKGROUND: Human mesothelial cells (HMCs) have an important role in maintaining an adequately functioning fibrinolytic system in the peritoneal cavity by secreting the fibrinolytic enzymes tissue-type and urokinase-type plasminogen activator (t-PA and u-PA), as well as a specific PA inhibitor, PA inhibitor type 1 (PAI-1).	Protactinium	246-248	MKKS centrosomal shuttling protein	Homo sapiens	37-41
9845367-0	1998	Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain.	Protactinium	97-100	potassium voltage-gated channel subfamily H member 2	Homo sapiens	49-53
10420461-6	1999	PA was in CRF and TRF patients 4-5 times higher than in healthy controls.	Protactinium	0-2	telomeric repeat binding factor 1	Homo sapiens	18-21
9845368-2	1998	Using a yeast two-hybrid screen, we have identified a phytochrome-interacting factor, PIF3, a basic helix-loop-helix protein containing a PAS domain.	Protactinium	138-141	phytochrome interacting factor 3	Arabidopsis thaliana	86-90
9829559-5	1998	At d 3 and 120 after silica treatment, a significant increase in cell-associated PA activity was found in uPA+/+ mice compared to that of saline controls.	Protactinium	81-83	plasminogen activator, urokinase	Mus musculus	106-109
9813390-6	1998	The PAS-AB index was calculated as a proportion of the PAS-AB-positive mucin area to the total epithelial area, using a computerized image analyzer.	Protactinium	4-7	LOC100508689	Homo sapiens	71-76
9813174-1	1998	The aryl hydrocarbon receptor (AhR) shares a common PAS domain with a number of genes that exhibit a pronounced circadian rhythm.	Protactinium	52-55	aryl hydrocarbon receptor	Rattus norvegicus	4-29
9813174-1	1998	The aryl hydrocarbon receptor (AhR) shares a common PAS domain with a number of genes that exhibit a pronounced circadian rhythm.	Protactinium	52-55	aryl hydrocarbon receptor	Rattus norvegicus	31-34
9813174-7	1998	This preliminary report is the first study to suggest that the PAS proteins, AhR and Arnt, exhibit a daily oscillation pattern within multiple target tissues which may give insight into the tissue-specific toxic and biochemical responses mediated through this dimerization pair, as well as the physiological function of these proteins.	Protactinium	63-66	aryl hydrocarbon receptor	Rattus norvegicus	77-80
9813174-7	1998	This preliminary report is the first study to suggest that the PAS proteins, AhR and Arnt, exhibit a daily oscillation pattern within multiple target tissues which may give insight into the tissue-specific toxic and biochemical responses mediated through this dimerization pair, as well as the physiological function of these proteins.	Protactinium	63-66	aryl hydrocarbon receptor nuclear translocator	Rattus norvegicus	85-89
9813390-6	1998	The PAS-AB index was calculated as a proportion of the PAS-AB-positive mucin area to the total epithelial area, using a computerized image analyzer.	Protactinium	55-58	LOC100508689	Homo sapiens	71-76
9755245-5	1998	In HTC cells, the volume-dependent Cl- current response (-46 +/- 5 pA/pF) was inhibited by down-regulation of PKC (100 nmol/L phorbol 12-myristate 13-acetate for 18 hours [PMA]; -1.97 +/- 1.5 pA/pF), chelation of cytosolic Ca2+ (2 mmol/L EGTA; -5.3 +/- 4.0 pA/pF), depletion of cytosolic adenosine triphosphate (ATP) (3 U/mL apyrase; -12.58 +/- 1.	Protactinium	67-69	protein kinase C, gamma	Rattus norvegicus	110-113
9755105-9	1998	In PA rings obtained from human organ donors, ET-1 causes a concentration-dependent increase in tension.	Protactinium	3-5	endothelin 1	Homo sapiens	46-50
9806333-6	1998	Both NDO 008 and the two enantiomers of 8-OH-DPAT induced the serotonin syndrome at the dose range that produced inhibition of the PA response, thus, indicating activation of postsynaptic 5-HT1A receptors.	Protactinium	46-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	188-194
9755245-5	1998	In HTC cells, the volume-dependent Cl- current response (-46 +/- 5 pA/pF) was inhibited by down-regulation of PKC (100 nmol/L phorbol 12-myristate 13-acetate for 18 hours [PMA]; -1.97 +/- 1.5 pA/pF), chelation of cytosolic Ca2+ (2 mmol/L EGTA; -5.3 +/- 4.0 pA/pF), depletion of cytosolic adenosine triphosphate (ATP) (3 U/mL apyrase; -12.58 +/- 1.	Protactinium	192-194	protein kinase C, gamma	Rattus norvegicus	110-113
9755245-5	1998	In HTC cells, the volume-dependent Cl- current response (-46 +/- 5 pA/pF) was inhibited by down-regulation of PKC (100 nmol/L phorbol 12-myristate 13-acetate for 18 hours [PMA]; -1.97 +/- 1.5 pA/pF), chelation of cytosolic Ca2+ (2 mmol/L EGTA; -5.3 +/- 4.0 pA/pF), depletion of cytosolic adenosine triphosphate (ATP) (3 U/mL apyrase; -12.58 +/- 1.	Protactinium	192-194	protein kinase C, gamma	Rattus norvegicus	110-113
9707434-2	1998	Like mPer1, mPer2 and Drosophila period, mPer3 has a dimerization PAS domain and a cytoplasmic localization domain.	Protactinium	66-69	period circadian clock 3	Mus musculus	41-46
9789840-13	1998	AChE reactivation was only observed in the PA group, although it was not statistically significant (r = 0.4747).	Protactinium	43-45	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-4
9733792-4	1998	The exon/intron arrangement of mArnt gene differs greatly from those of the other members of the same basic-helix-loop-helix/PAS family.	Protactinium	125-128	aryl hydrocarbon receptor nuclear translocator	Mus musculus	31-36
9722667-4	1998	However, the activity of PA-PGC was about 3-fold higher than that of PA-PGA.	Protactinium	25-27	progastricsin	Homo sapiens	28-31
9731218-1	1998	Hypoxia inducible factor-1 (HIF-1) is a heterodimeric complex of two basic-helix-loop-helix proteins of the PAS family which is critical for oxygen-dependent expression of many mammalian genes.	Protactinium	108-111	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-26
9731218-1	1998	Hypoxia inducible factor-1 (HIF-1) is a heterodimeric complex of two basic-helix-loop-helix proteins of the PAS family which is critical for oxygen-dependent expression of many mammalian genes.	Protactinium	108-111	hypoxia inducible factor 1 subunit alpha	Homo sapiens	28-33
9704006-2	1998	This protein, termed Arnt3, showed the highest similarity to Arnt and Arnt2 in the bHLH and PAS regions.	Protactinium	92-95	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	21-25
9872599-8	1998	Plasmin activation and triggering of the proteolytic cascade involved in Matrigel invasion is blocked by antibodies against uPA (especially by anti- A-chain of uPA which interacts with uPAR) and by PA inhibitors such as p-aminobenzamidine which may regulate levels of cell-bound uPA.	Protactinium	125-127	plasminogen	Homo sapiens	0-7
9872599-8	1998	Plasmin activation and triggering of the proteolytic cascade involved in Matrigel invasion is blocked by antibodies against uPA (especially by anti- A-chain of uPA which interacts with uPAR) and by PA inhibitors such as p-aminobenzamidine which may regulate levels of cell-bound uPA.	Protactinium	125-127	plasminogen activator, urokinase receptor	Homo sapiens	160-163
9872599-8	1998	Plasmin activation and triggering of the proteolytic cascade involved in Matrigel invasion is blocked by antibodies against uPA (especially by anti- A-chain of uPA which interacts with uPAR) and by PA inhibitors such as p-aminobenzamidine which may regulate levels of cell-bound uPA.	Protactinium	125-127	plasminogen activator, urokinase receptor	Homo sapiens	185-189
9872599-8	1998	Plasmin activation and triggering of the proteolytic cascade involved in Matrigel invasion is blocked by antibodies against uPA (especially by anti- A-chain of uPA which interacts with uPAR) and by PA inhibitors such as p-aminobenzamidine which may regulate levels of cell-bound uPA.	Protactinium	125-127	plasminogen activator, urokinase receptor	Homo sapiens	160-163
9725565-7	1998	A proportional relationship was observed between BMP-2 expression and chondroid formation, although BMP-2 was also stained in occasional PAs without chondroid formation.	Protactinium	137-140	bone morphogenetic protein 2	Homo sapiens	100-105
9704006-2	1998	This protein, termed Arnt3, showed the highest similarity to Arnt and Arnt2 in the bHLH and PAS regions.	Protactinium	92-95	aryl hydrocarbon receptor nuclear translocator 2	Homo sapiens	70-75
9694045-1	1998	We studied the effects of acute and chronic administration of methylmalonic (MMA) and propionic (PA) acids on the in vitro incorporation of 32P into neurofilament subunits (NF-M and NF-L), alpha and beta tubulins, from cerebral cortex of rats.	Protactinium	97-99	neurofilament medium chain	Rattus norvegicus	173-177
9694045-1	1998	We studied the effects of acute and chronic administration of methylmalonic (MMA) and propionic (PA) acids on the in vitro incorporation of 32P into neurofilament subunits (NF-M and NF-L), alpha and beta tubulins, from cerebral cortex of rats.	Protactinium	97-99	neurofilament light chain	Rattus norvegicus	182-186
9694045-7	1998	The acute administration of MMA decreased the in vitro 32P incorporation into NF-L and alpha-tubulin subunit, whereas PA administration decreased the 32P in vitro incorporation into NF-M, NF-L, and tubulins.	Protactinium	118-120	neurofilament medium chain	Rattus norvegicus	182-186
9694045-7	1998	The acute administration of MMA decreased the in vitro 32P incorporation into NF-L and alpha-tubulin subunit, whereas PA administration decreased the 32P in vitro incorporation into NF-M, NF-L, and tubulins.	Protactinium	118-120	neurofilament light chain	Rattus norvegicus	188-192
9696953-1	1998	OBJECTIVE: The Effect of omeprazole, a proton pump inhibitor, and cimetidine, and H 2-receptor antagonist, on plasma aldosterone (PA) response to angiotensin II (AII) were evaluated.	Protactinium	130-132	angiotensinogen	Homo sapiens	146-160
9603941-1	1998	The DPP1-encoded diacylglycerol pyrophosphate (DGPP) phosphatase enzyme accounts for half of the Mg2+-independent phosphatidate (PA) phosphatase activity in Saccharomyces cerevisiae.	Protactinium	129-131	bifunctional diacylglycerol diphosphate phosphatase/phosphatidate phosphatase	Saccharomyces cerevisiae S288C	4-8
9603941-11	1998	Moreover, the analyses of the mutants showed that the LPP1 and DPP1 gene products played a role in the regulation of phospholipid metabolism and the cellular levels of phosphatidylinositol and PA.	Protactinium	193-195	phosphatidate phosphatase LPP1	Saccharomyces cerevisiae S288C	54-58
9603941-11	1998	Moreover, the analyses of the mutants showed that the LPP1 and DPP1 gene products played a role in the regulation of phospholipid metabolism and the cellular levels of phosphatidylinositol and PA.	Protactinium	193-195	bifunctional diacylglycerol diphosphate phosphatase/phosphatidate phosphatase	Saccharomyces cerevisiae S288C	63-67
9611123-8	1998	The time courses for [32P]PA production and contraction were similar in response to high (100 nM) and to low (1 nM) ET-1.	Protactinium	26-28	endothelin-1	Sus scrofa	116-120
9696953-5	1998	Significant correlations between plasma AII and PA were obtained in the control and omeprazole trial, but not in the cimetidine trial.	Protactinium	48-50	angiotensinogen	Homo sapiens	40-43
9696953-1	1998	OBJECTIVE: The Effect of omeprazole, a proton pump inhibitor, and cimetidine, and H 2-receptor antagonist, on plasma aldosterone (PA) response to angiotensin II (AII) were evaluated.	Protactinium	130-132	angiotensinogen	Homo sapiens	162-165
9510527-7	1998	HIF-1 itself consists of a heterodimer of two basic-helix-loop-helix proteins of the PAS family, termed HIF-1alpha and HIF-1beta, although other closely related members of this family may also contribute to the response to hypoxia.	Protactinium	85-88	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-5
9646552-3	1998	The immunomodulating properties of PA were expressed by enhancement of phagocytic and bactericidal activities of blood leukocytes, accompanied by elevated serum levels of interferon-gamma and interleukin-1 and higher Con-A-induced transformation rates of lymphocytes.	Protactinium	35-37	interferon gamma	Canis lupus familiaris	171-205
9545558-3	1998	The recent cloning of ARNT and HIF1(homologues (ARNT2 and HIF2 alpha) indicates that at least six distinct bHLH-PAS heterodimeric combinations can occur in response to a number of environmental stimuli.	Protactinium	112-115	aryl hydrocarbon receptor nuclear translocator	Mus musculus	22-26
9545558-3	1998	The recent cloning of ARNT and HIF1(homologues (ARNT2 and HIF2 alpha) indicates that at least six distinct bHLH-PAS heterodimeric combinations can occur in response to a number of environmental stimuli.	Protactinium	112-115	aryl hydrocarbon receptor nuclear translocator 2	Mus musculus	48-53
9545558-3	1998	The recent cloning of ARNT and HIF1(homologues (ARNT2 and HIF2 alpha) indicates that at least six distinct bHLH-PAS heterodimeric combinations can occur in response to a number of environmental stimuli.	Protactinium	112-115	endothelial PAS domain protein 1	Mus musculus	58-68
9520101-3	1998	Reconstruction from serial electron microscopy was used to determine the location and size of PA in the stratum radiatum of hippocampal area CA1, where many of the previous functional studies have been performed.	Protactinium	94-96	carbonic anhydrase 1	Rattus norvegicus	141-144
9571636-8	1998	From the promoter sequence analysis, we also identified a sequence similar to pas, a cadmium-responsive element of the ParA gene in tobacco.	Protactinium	78-81	probable glutathione S-transferase parA	Nicotiana tabacum	119-123
9518719-9	1998	Pa,O2 at VO2,max was inversely related to the alveolar to arterial O2 difference (A-aDO2) (r = -0.93; 35-52 mmHg) and to arterial PCO2 (Pa,CO2) (r = -0.62; 26-39 mmHg).	Protactinium	0-2	complement C2	Homo sapiens	136-142
9292570-2	1997	In IgAN, only three patients with nephrotic syndrome were PA positive.	Protactinium	58-60	IGAN1	Homo sapiens	3-7
9475660-5	1998	The mean peak oxygen uptake was 22.6 and 15.1 mL x kg(-1) x min(-1) among PA and CO, respectively.	Protactinium	74-76	CD59 molecule (CD59 blood group)	Homo sapiens	60-66
9575575-2	1998	Lipid A and LPS stimulate LPAAT activity (and hence unsaturated PA formation) in RMC membranes and whole cells.	Protactinium	27-29	interferon regulatory factor 6	Homo sapiens	12-15
9575575-15	1998	LSF, which reduces rodent deaths in sepsis models, reduces unsaturated acyl incorporation into PA in monoblastic cell lines, and reduces serum FFA increase in human sepsis, also reduces unsaturated acyl incorporation into PA in ECV304 cells.	Protactinium	95-97	transcription factor CP2	Homo sapiens	0-3
9575575-15	1998	LSF, which reduces rodent deaths in sepsis models, reduces unsaturated acyl incorporation into PA in monoblastic cell lines, and reduces serum FFA increase in human sepsis, also reduces unsaturated acyl incorporation into PA in ECV304 cells.	Protactinium	222-224	transcription factor CP2	Homo sapiens	0-3
9575575-16	1998	LPAAT-alpha transfection increases linolenate incorporation into PA at the expense of linoleate incorporation, which is reversed by LSF.	Protactinium	1-3	transcription factor CP2	Homo sapiens	132-135
9575575-17	1998	LPAAT-beta increases both linoleate and linolenate incorporation into PA, which is also reduced by LSF.	Protactinium	1-3	transcription factor CP2	Homo sapiens	99-102
9575575-18	1998	We conclude that LPAAT and PA remodeling may play a role in diffuse renal toxicity in sepsis due to induction of cellular phenotype changes associated with PA induction by Lipid A and/or LPS.	Protactinium	18-20	interferon regulatory factor 6	Homo sapiens	187-190
9575575-18	1998	We conclude that LPAAT and PA remodeling may play a role in diffuse renal toxicity in sepsis due to induction of cellular phenotype changes associated with PA induction by Lipid A and/or LPS.	Protactinium	27-29	interferon regulatory factor 6	Homo sapiens	187-190
9395531-9	1997	The implication that an amino acid within the PAS region may be involved in DNA binding indicates that the DNA binding behavior of AHR may be more anomalous than previously suspected.	Protactinium	46-49	aryl hydrocarbon receptor	Homo sapiens	131-134
9391097-3	1997	As part of a phylogenetic approach to understanding the function and evolutionary origin of the AHR, we sequenced the PAS homology domain of AHRs from several species of early vertebrates and performed phylogenetic analyses of these AHR amino acid sequences in relation to mammalian AHRs and 24 other members of the PAS family.	Protactinium	118-121	aryl hydrocarbon receptor	Homo sapiens	96-99
9391097-3	1997	As part of a phylogenetic approach to understanding the function and evolutionary origin of the AHR, we sequenced the PAS homology domain of AHRs from several species of early vertebrates and performed phylogenetic analyses of these AHR amino acid sequences in relation to mammalian AHRs and 24 other members of the PAS family.	Protactinium	118-121	aryl hydrocarbon receptor	Homo sapiens	141-144
9434908-1	1997	NMR and crystal structure of many components of tissue-type plasminogen activator (t-PA) are now available: the finger-EGF pair and the kringle-2 domain structures have been solved, as have the proteolytic domains of vampire bat PA and human t-PA in two- and single-chain forms.	Protactinium	85-87	plasminogen activator, tissue type	Homo sapiens	48-81
9374783-7	1997	Blockage of the NOS-PKG cascade inhibited the increase in Pa, whereas the endothelial calcium was still elevated on administration of ionomycin.	Protactinium	58-60	protein kinase cGMP-dependent 1	Homo sapiens	20-23
9374783-9	1997	Stimulation of PKC with phorbol 12-myristate 13-acetate (PMA) dramatically increased basal Pa without significantly changing the cytosolic calcium level.	Protactinium	91-93	proline rich transmembrane protein 2	Homo sapiens	15-18
9333243-7	1997	Clock, a mammalian clock gene encoding a PAS-containing polypeptide, has now been cloned: it is likely that the Per homologues dimerize with other molecule(s) such as Clock through PAS-PAS interaction in the circadian clock system.	Protactinium	41-44	period	Drosophila melanogaster	112-115
9445393-5	1998	Addition of di(C18:1)PS or di(C18:1)PA to the ATPase in the short-chain dimyristoleoylphosphatidylcholine [di(C14:1)PC] reverse the effects of the short-chain lipid on ATPase activity and on Ca2+ binding, as revealed by the response of tryptophan fluorescence intensity to Ca2+ binding.	Protactinium	35-38	dynein axonemal heavy chain 8	Homo sapiens	46-52
9445393-5	1998	Addition of di(C18:1)PS or di(C18:1)PA to the ATPase in the short-chain dimyristoleoylphosphatidylcholine [di(C14:1)PC] reverse the effects of the short-chain lipid on ATPase activity and on Ca2+ binding, as revealed by the response of tryptophan fluorescence intensity to Ca2+ binding.	Protactinium	35-38	dynein axonemal heavy chain 8	Homo sapiens	168-174
9508786-4	1998	MATERIALS AND METHODS: To test this hypothesis in a model system, amino acids 410-419 of the human p62(c-myc) epitope were fused to the C-terminus of PA to redirect PA to the c-Myc-specific hybridoma cell line 9E10.	Protactinium	150-152	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	175-180
9508786-6	1998	Similar results were obtained with PA, which suggests that PA-c-Myc used the endogenous PA receptor to enter the cells.	Protactinium	35-37	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	62-67
9508786-7	1998	By blocking the endogenous PA receptors on 9E10 cells with the competitive inhibitor PA SNKEDeltaFF, the PA-c-Myc was directed to an alternate receptor, i.e., the anti-c-Myc antibodies presented on the cell surface.	Protactinium	27-29	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	108-113
9508786-7	1998	By blocking the endogenous PA receptors on 9E10 cells with the competitive inhibitor PA SNKEDeltaFF, the PA-c-Myc was directed to an alternate receptor, i.e., the anti-c-Myc antibodies presented on the cell surface.	Protactinium	27-29	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	168-173
9508786-8	1998	The c-Myc IgG were proven to act as receptors because the addition of a synthetic peptide containing the c-Myc epitope along with PA SNKEDeltaFF further reduced the toxicity of PA-c-Myc + FP59.	Protactinium	130-132	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	4-9
10822605-4	1998	However, for L16, whilst the bulk of the di(C18 : 1)PA molecules bound with a binding constant relative to di(C18 : 1)PC close to 1, a small number of di(C18 : 1)PA molecules bound much more strongly.	Protactinium	52-54	immunoglobulin kappa variable 3D-15	Homo sapiens	13-16
9389709-11	1997	The outcome is attributed to IFNalpha therapy, as the Pa methylation status was not reversed in any of the patients treated with hydroxyurea.	Protactinium	54-56	interferon alpha 1	Homo sapiens	29-37
9489955-5	1997	Although correlations between glomerular deposition of PAS positive material and serum creatinine tended to be positive in MPGN, IgAN and MCGN-I, they were weak and not significant.	Protactinium	55-58	IGAN1	Homo sapiens	129-133
9532638-8	1997	Plasma levels of C-reactive protein are all within normal limits, which may suggest that PA activity is restricted to a local inflammatory reaction in the airway mucosa.	Protactinium	89-91	C-reactive protein	Homo sapiens	17-35
9342362-6	1997	Cells treated with this fusion protein (LF254-gp120) in the presence of PA effectively processed gp120 and presented an epitope recognized by HIV-1 gp120 V3-specific CTL.	Protactinium	72-74	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	46-51
9342362-6	1997	Cells treated with this fusion protein (LF254-gp120) in the presence of PA effectively processed gp120 and presented an epitope recognized by HIV-1 gp120 V3-specific CTL.	Protactinium	72-74	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	97-102
9342362-6	1997	Cells treated with this fusion protein (LF254-gp120) in the presence of PA effectively processed gp120 and presented an epitope recognized by HIV-1 gp120 V3-specific CTL.	Protactinium	72-74	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	97-102
9311502-7	1997	During exercise, the arterial ET-1 levels were significantly correlated with arterial oxygen (Pa,O2) (r = -0.6, p = 0.04), alveolar-arterial oxygen difference (r = 0.8, p = 0.01), and Ppa (r = 0.6, p = 0.04) in ILD patients, but not in those with emphysema.	Protactinium	94-96	endothelin 1	Homo sapiens	30-34
11596274-3	1997	After Rg1 infusion, the activity of t-PA was found to be increased, so did the percentage of active-type t-PA, but the activity of PA-I decreased.	Protactinium	38-40	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	6-9
9271372-2	1997	This protein is a member of a rapidly expanding family of gene products possessing basic helix-loop-helix (bHLH) and hydrophobic PAS (designated a conserved region among PER, ARNT [aryl hydrocarbon receptor nuclear translocator] and SIM) protein association domains.	Protactinium	129-132	aryl hydrocarbon receptor nuclear translocator	Mus musculus	175-179
9271372-2	1997	This protein is a member of a rapidly expanding family of gene products possessing basic helix-loop-helix (bHLH) and hydrophobic PAS (designated a conserved region among PER, ARNT [aryl hydrocarbon receptor nuclear translocator] and SIM) protein association domains.	Protactinium	129-132	aryl hydrocarbon receptor nuclear translocator	Mus musculus	181-227
9234799-3	1997	Because furin-deficient cells retain some sensitivity to PA and DT, it is evident that other cellular proteases can activate these toxins.	Protactinium	57-59	furin	Cricetulus griseus	8-13
9316883-7	1997	Additionally, PDE3A transcripts (8 and 10 kb) were increased (3.8 +/- 1.6-fold and 3.9 +/- 1.2-fold; n = 3, respectively) in PAs from rats with HPH compared with normal controls.	Protactinium	125-128	phosphodiesterase 3A	Rattus norvegicus	14-19
9278140-4	1997	The HIF-1 heterodimer is composed of a HIF-1alpha and an ARNT subunit, both belonging to the explosively growing PAS subfamily of bHLH transcription factors.	Protactinium	113-116	hypoxia inducible factor 1 subunit alpha	Homo sapiens	4-9
9278140-4	1997	The HIF-1 heterodimer is composed of a HIF-1alpha and an ARNT subunit, both belonging to the explosively growing PAS subfamily of bHLH transcription factors.	Protactinium	113-116	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	57-61
9283062-7	1997	There was a statistical correlation between PA and ET-1 levels in patients with low-renin essential hypertension (r = 0.619, P < 0.024).	Protactinium	44-46	endothelin 1	Homo sapiens	51-55
9283062-7	1997	There was a statistical correlation between PA and ET-1 levels in patients with low-renin essential hypertension (r = 0.619, P < 0.024).	Protactinium	44-46	renin	Homo sapiens	84-89
9066784-3	1997	Moreover, ANF stimulates PA formation at an intermediate stage between early and late DAG formation.	Protactinium	25-27	natriuretic peptide A	Rattus norvegicus	10-13
10497620-11	1997	CONCLUSIONS: Several alterations in the PA function, suggestive of decreased 21-hydroxylase activity, mild cortisol deficiency and slight adrenal hyperplasia, are associated with abdominal obesity which, in turn, appears to be an important prelude to insulin resistance and dyslipidaemia.	Protactinium	40-42	insulin	Homo sapiens	251-258
9160733-9	1997	They support the concept that PA of the urokinase type plays an important role in extracellular matrix remodeling during TGF alpha-induced granulosa cell proliferation and ovarian follicular growth.	Protactinium	30-32	transforming growth factor alpha	Homo sapiens	121-130
9121557-1	1997	The arylhydrocarbon-receptor nuclear translocator (ARNT) is a member of the basic-helix-loop-helix-PAS family of heterodimeric transcription factors which includes the arylhydrocarbon receptor (AHR), hypoxia-inducible factor-1alpha (HIF-1alpha) and the Drosophila single-minded protein (Sim).	Protactinium	99-102	tango	Drosophila melanogaster	4-49
9121557-1	1997	The arylhydrocarbon-receptor nuclear translocator (ARNT) is a member of the basic-helix-loop-helix-PAS family of heterodimeric transcription factors which includes the arylhydrocarbon receptor (AHR), hypoxia-inducible factor-1alpha (HIF-1alpha) and the Drosophila single-minded protein (Sim).	Protactinium	99-102	tango	Drosophila melanogaster	51-55
9121557-1	1997	The arylhydrocarbon-receptor nuclear translocator (ARNT) is a member of the basic-helix-loop-helix-PAS family of heterodimeric transcription factors which includes the arylhydrocarbon receptor (AHR), hypoxia-inducible factor-1alpha (HIF-1alpha) and the Drosophila single-minded protein (Sim).	Protactinium	99-102	spineless	Drosophila melanogaster	194-197
9121557-1	1997	The arylhydrocarbon-receptor nuclear translocator (ARNT) is a member of the basic-helix-loop-helix-PAS family of heterodimeric transcription factors which includes the arylhydrocarbon receptor (AHR), hypoxia-inducible factor-1alpha (HIF-1alpha) and the Drosophila single-minded protein (Sim).	Protactinium	99-102	similar	Drosophila melanogaster	233-243
9121557-2	1997	ARNT forms heterodimeric complexes with the arylhydrocarbon receptor, HIF-1alpha, Sim and the PAS protein Per.	Protactinium	94-97	aryl hydrocarbon receptor nuclear translocator	Mus musculus	0-4
9066784-1	1997	We have investigated the involvement of specific phospholipase systems and their possible mutual relationship with the mechanism by which atrial natriuretic factor (ANF) increases phosphatidate (PA) and diacylglycerol (DAG) in rat aortic smooth muscle cells (RASMC), one of the major targets of this hormone.	Protactinium	195-197	natriuretic peptide A	Rattus norvegicus	138-163
9066784-1	1997	We have investigated the involvement of specific phospholipase systems and their possible mutual relationship with the mechanism by which atrial natriuretic factor (ANF) increases phosphatidate (PA) and diacylglycerol (DAG) in rat aortic smooth muscle cells (RASMC), one of the major targets of this hormone.	Protactinium	195-197	natriuretic peptide A	Rattus norvegicus	165-168
9099673-8	1997	DGPP inhibited the ability of PAP2 to dephosphorylate PA, and PA inhibited the dephosphorylation of DGPP.	Protactinium	54-56	non-canonical poly(A) polymerase PAP2	Saccharomyces cerevisiae S288C	30-34
9079689-2	1997	We characterized five new "members of the PAS superfamily," or MOPs 1-5, that are similar in size and structural organization to the AHR and ARNT.	Protactinium	42-45	MOP-1	Homo sapiens	63-71
9079689-2	1997	We characterized five new "members of the PAS superfamily," or MOPs 1-5, that are similar in size and structural organization to the AHR and ARNT.	Protactinium	42-45	aryl hydrocarbon receptor	Homo sapiens	133-136
9079689-2	1997	We characterized five new "members of the PAS superfamily," or MOPs 1-5, that are similar in size and structural organization to the AHR and ARNT.	Protactinium	42-45	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	141-145
9079689-3	1997	MOPs 1-4 have N-terminal bHLH and PAS domains and C-terminal variable regions.	Protactinium	34-37	MOP-1	Homo sapiens	0-8
9079689-4	1997	MOP5 contained the characteristic PAS domain and a variable C terminus; it is possible that the cDNA contains a bHLH domain, but the entire open reading frame has yet to be completed.	Protactinium	34-37	neuronal PAS domain protein 1	Homo sapiens	0-4
9518044-6	1997	When PA binding was studied at 37 degrees C, HUVEC bound more t-PA than r-PA to both specific and non-specific binding sites.	Protactinium	5-7	plasminogen activator, tissue type	Homo sapiens	62-66
9033655-8	1997	Thus, the transmigration of T-leukemia cells through a barrier of extracellular matrix requires PA-dependent proteolysis, which can be provided either by u-PA or t-PA.	Protactinium	96-98	plasminogen activator, urokinase	Homo sapiens	154-158
9049150-3	1997	PAS staining of mucin blotted onto nitrocellulose served to quantify the secretion of total mucin.	Protactinium	0-3	LOC100508689	Homo sapiens	16-21
9049150-3	1997	PAS staining of mucin blotted onto nitrocellulose served to quantify the secretion of total mucin.	Protactinium	0-3	LOC100508689	Homo sapiens	92-97
9020169-3	1997	Both the helix-loop-helix and the PAS regions of SIM1 and of ARNT are required for efficient heterodimerization.	Protactinium	34-37	aryl hydrocarbon receptor nuclear translocator	Mus musculus	61-65
9033655-8	1997	Thus, the transmigration of T-leukemia cells through a barrier of extracellular matrix requires PA-dependent proteolysis, which can be provided either by u-PA or t-PA.	Protactinium	96-98	plasminogen activator, tissue type	Homo sapiens	162-166
9027737-5	1997	Structural analysis of HIF-1 alpha revealed that dimerization with HIF-1 beta (ARNT) requires the HLH and PAS domains, DNA binding is mediated by the basic domain, and that HIF-1 alpha contains a carboxyl-terminal transactivation domain.	Protactinium	106-109	hypoxia inducible factor 1 subunit alpha	Homo sapiens	23-34
9027737-5	1997	Structural analysis of HIF-1 alpha revealed that dimerization with HIF-1 beta (ARNT) requires the HLH and PAS domains, DNA binding is mediated by the basic domain, and that HIF-1 alpha contains a carboxyl-terminal transactivation domain.	Protactinium	106-109	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	79-83
9009157-10	1997	Our data demonstrate an interaction between PA and the MAPK signalling pathway and suggest that the latter may be involved in ODC-induced transformation of mammary epithelial cells.	Protactinium	44-46	mitogen-activated protein kinase 1	Homo sapiens	55-59
9012850-2	1997	Both proteins, neuronal PAS domain protein (NPAS) 1 and NPAS2, are members of the basic helix-loop-helix-PAS family of transcription factors.	Protactinium	24-27	neuronal PAS domain protein 2	Mus musculus	56-61
9009157-10	1997	Our data demonstrate an interaction between PA and the MAPK signalling pathway and suggest that the latter may be involved in ODC-induced transformation of mammary epithelial cells.	Protactinium	44-46	ornithine decarboxylase 1	Homo sapiens	126-129
8943951-3	1996	Immunohistochemistry, in situ hybridization, and Northern blot analysis demonstrated induction of tenascin in adult rat central and peripheral PA.	Protactinium	143-145	tenascin C	Rattus norvegicus	98-106
9006343-2	1997	Serial sections from 25 adenomas were used to identify PA-related caseinolytic activities by in situ zymography, blocking selectively uPA or tPA.	Protactinium	55-57	plasminogen activator, urokinase	Homo sapiens	134-137
9006343-2	1997	Serial sections from 25 adenomas were used to identify PA-related caseinolytic activities by in situ zymography, blocking selectively uPA or tPA.	Protactinium	55-57	plasminogen activator, tissue type	Homo sapiens	141-144
8948635-6	1996	We identified the N-terminal region of PB1 protein as responsible for the interaction with the PA subunit by two-hybrid assays in mammalian cells.	Protactinium	95-97	polybromo 1	Homo sapiens	39-42
8886888-9	1996	In all patients the serum TNF-alpha levels in PA-blood were temporarily elevated following IPHP from less than 10 pg/ml before IPHP to 42.8 +/- 26.6 pg/ml; endotoxin levels were not altered.	Protactinium	46-48	tumor necrosis factor	Homo sapiens	26-35
8977672-6	1996	The central PA system component plasminogen, which is present in plasma and interstitial fluids, is bound to the keratinocyte surface via plasmin(ogen) binding sites, where it can be activated by uPA-R-bound uPA.	Protactinium	12-14	plasminogen activator, urokinase	Homo sapiens	196-199
8977672-6	1996	The central PA system component plasminogen, which is present in plasma and interstitial fluids, is bound to the keratinocyte surface via plasmin(ogen) binding sites, where it can be activated by uPA-R-bound uPA.	Protactinium	12-14	plasminogen activator, urokinase	Homo sapiens	208-211
8923213-7	1996	Expression of mRNA for the tissue inhibitor of metalloproteinases (TIMP)-1, and of the smaller of two mRNA species for the PA inhibitor PAI-1, ceased by P14.	Protactinium	123-125	cyclin dependent kinase inhibitor 2A	Homo sapiens	153-156
8855796-10	1996	We suggest that the PA generation induced by PLD stimulation could contribute to the stimulated H2O2 formation and iodide organification observed with the agonists inducing PtdBut accumulation.	Protactinium	20-22	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	45-48
8843153-3	1996	By contrast, the PLD-induced generation of PA was significantly higher in the old than in the young.	Protactinium	43-45	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	17-20
8756498-5	1996	We named the sequence in the parA promoter pas.	Protactinium	43-46	probable glutathione S-transferase parA	Nicotiana tabacum	29-33
8707840-5	1996	We found that p58 contains regions with FG (Phe, Gly) and PA (Pro, Ala) repeats at both its NH2 and COOH termini separated by a predicted alpha-helical coiled-coil region, while p54 has an NH2-terminal FG and PA repeat region and a COOH-terminal predicted coiled-coil region.	Protactinium	58-60	DNA primase subunit 2	Rattus norvegicus	14-17
8840284-4	1996	We found that the patients immunized with PA and receiving rEPO therapy (N = 15) had IgG anti-PA responses comparable to that of those not receiving rEPO therapy (N = 15).	Protactinium	94-96	erythropoietin	Rattus norvegicus	59-63
8805276-1	1996	BACKGROUND: Agonist-stimulated phospholipase D (PLD) catalyzes the hydrolysis of phosphatidylcholine, generating the putative messenger phosphatidate (PA).	Protactinium	151-153	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	31-46
8793299-2	1996	Neutrophils and HL60 cells secrete lysosomal enzymes from azurophilic granules; this secretion is inhibited by 1% ethanol, indicating that phosphatidate (PA) produced by phospholipase D (PLD) activity may be involved.	Protactinium	154-156	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	170-185
8793299-2	1996	Neutrophils and HL60 cells secrete lysosomal enzymes from azurophilic granules; this secretion is inhibited by 1% ethanol, indicating that phosphatidate (PA) produced by phospholipase D (PLD) activity may be involved.	Protactinium	154-156	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	187-190
8793299-3	1996	PLD can use primary alcohols in preference to water during the hydrolytic step, generating the corresponding phosphatidylalcohol instead of PA, its normal product.	Protactinium	140-142	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	0-3
8793299-15	1996	In comparison, ARF1 activates PLD, producing PA, which is a known activator of phosphatidylinositol-4-phosphate 5 kinase, the enzyme responsible for PIP2 synthesis.	Protactinium	45-47	ADP ribosylation factor 1	Homo sapiens	15-19
8793299-15	1996	In comparison, ARF1 activates PLD, producing PA, which is a known activator of phosphatidylinositol-4-phosphate 5 kinase, the enzyme responsible for PIP2 synthesis.	Protactinium	45-47	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	30-33
8793299-15	1996	In comparison, ARF1 activates PLD, producing PA, which is a known activator of phosphatidylinositol-4-phosphate 5 kinase, the enzyme responsible for PIP2 synthesis.	Protactinium	45-47	phosphatidylinositol-5-phosphate 4-kinase type 2 gamma	Homo sapiens	79-120
8810131-2	1996	The SOD activity in RA and OA knee joint fluids was higher than in the control patients with PA.	Protactinium	93-95	superoxide dismutase 1	Homo sapiens	4-7
8661115-6	1996	In addition, the N-terminal domain of MSIM contains two PAS dimerization motifs also featured in the Drosophila sim gene product, as well as a small number of other transcription factors.	Protactinium	56-59	single-minded family bHLH transcription factor 2	Mus musculus	38-42
8661115-6	1996	In addition, the N-terminal domain of MSIM contains two PAS dimerization motifs also featured in the Drosophila sim gene product, as well as a small number of other transcription factors.	Protactinium	56-59	single-minded	Drosophila melanogaster	112-115
8828811-10	1996	Thus, the AhR appears to be a unique member of the PAS domain family of proteins that binds a known ligand and stably interacts with hsp90.	Protactinium	51-54	aryl-hydrocarbon receptor	Mus musculus	10-13
8828811-10	1996	Thus, the AhR appears to be a unique member of the PAS domain family of proteins that binds a known ligand and stably interacts with hsp90.	Protactinium	51-54	heat shock protein 86, pseudogene 1	Mus musculus	133-138
8652650-14	1996	Propranolol, an inhibitor of PA phosphohydrolase, totally abolished the bradykinin-induced increase in 12-HETE DAG while increasing the magnitude and duration of 12-HETE PA release.	Protactinium	29-31	kininogen 1	Bos taurus	72-82
8805276-10	1996	In PAE cells, the stimulation of actin stress fibre formation was a consequence of PA generation and, therefore, PLD activation.	Protactinium	3-5	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	113-116
8805276-1	1996	BACKGROUND: Agonist-stimulated phospholipase D (PLD) catalyzes the hydrolysis of phosphatidylcholine, generating the putative messenger phosphatidate (PA).	Protactinium	151-153	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	48-51
8630585-7	1996	Aerosolized PGI2 (7.5 +/- 2.5 ng/kg min) augmented Pa O2/FI O2 from 114 +/- 12 to 135 +/- 12 mm Hg (p<0.01), and decreased shunt from 33.5 +/- 3.8 to 26.0 +/- 3.9% (p<0.05).	Protactinium	51-53	immunoglobulin kappa variable 1D-39	Homo sapiens	54-71
8756022-0	1996	Mucin secretion by gastric carcinoma cells: PAS alcian blue stain study.	Protactinium	44-47	LOC100508689	Homo sapiens	0-5
8657146-3	1996	The predicted Arnt2 polypeptide carries a characteristic basic helix-loop-helix (bHLH)/PAS motif in its N-terminal region with close similarity (81% identity) to that of mouse Arnt and has an overall sequence identity of 57% with Arnt.	Protactinium	87-90	aryl hydrocarbon receptor nuclear translocator 2	Mus musculus	14-19
8657146-3	1996	The predicted Arnt2 polypeptide carries a characteristic basic helix-loop-helix (bHLH)/PAS motif in its N-terminal region with close similarity (81% identity) to that of mouse Arnt and has an overall sequence identity of 57% with Arnt.	Protactinium	87-90	aryl hydrocarbon receptor nuclear translocator	Mus musculus	14-18
8674399-6	1996	MT-TGF-alpha mice demonstrated increased numbers of DR-PAS-staining mucous cells and lower parietal cell numbers per gland unit.	Protactinium	55-58	transforming growth factor alpha	Mus musculus	3-12
22097391-3	1996	First, PL D hydrolysis of stable 1,2-diacyl-sn-glycero-3-phosphocholine (PC) films by PL D generated a stable 1,2-diacyl-sn-glycero-3-phosphate (PA) film and water-soluble choline.	Protactinium	145-147	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	7-11
22097391-3	1996	First, PL D hydrolysis of stable 1,2-diacyl-sn-glycero-3-phosphocholine (PC) films by PL D generated a stable 1,2-diacyl-sn-glycero-3-phosphate (PA) film and water-soluble choline.	Protactinium	145-147	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	86-90
8592156-6	1996	The results offer the possibility that CDP-DAG or PA at critical membrane sites may exert functionally significant metabolic regulation at the point of convergence of the PI 3-kinase-directed and the PI 4-kinase-directed phosphoinositide signal transduction pathways.	Protactinium	50-52	peptidase inhibitor 3	Homo sapiens	171-175
8648901-10	1996	In vitro PLA2 activity in the control tubular extracts was compared to that following addition of AA or PA. PLA2 activity decreased significantly with AA but not with PA in a dose dependent manner.	Protactinium	104-106	phospholipase A2 group IB	Rattus norvegicus	108-112
9112653-8	1996	The effect of PAI-1 cleavage by HNE on tissue type PA (tPA) induced clot lysis was studied in a purified system.	Protactinium	14-16	plasminogen activator, tissue type	Homo sapiens	55-58
8731662-2	1996	These PAs are subject to regulation by PA inhibitors (PAI), including PAI type-2 (PAI-2).	Protactinium	6-8	serpin family B member 2	Homo sapiens	70-80
8731662-2	1996	These PAs are subject to regulation by PA inhibitors (PAI), including PAI type-2 (PAI-2).	Protactinium	6-8	serpin family B member 2	Homo sapiens	82-87
8592156-6	1996	The results offer the possibility that CDP-DAG or PA at critical membrane sites may exert functionally significant metabolic regulation at the point of convergence of the PI 3-kinase-directed and the PI 4-kinase-directed phosphoinositide signal transduction pathways.	Protactinium	50-52	serpin family A member 4	Homo sapiens	200-204
8932441-5	1996	For these Ang II antagonists, Pa values larger than 3 x 10(-6) cm sec-1 and in situ ka values of 2 x 10(-4) min-1 cm-1 or above were associated with good in vivo absorption.	Protactinium	30-32	angiotensinogen	Homo sapiens	10-16
8797002-4	1996	PAs trigger a proteinase cascade that results is the generation of high local concentrations of plasmin and active MMPs.	Protactinium	0-3	plasminogen	Homo sapiens	96-103
8807834-5	1996	RESULTS: Polyacrylamides with multiple C-sialosides (PA(Neu5Ac)) were 2-20 fold more effective as inhibitors of virally mediated hemagglutination when assayed in the presence of Neu2en-NH2, a potent monomeric inhibitor of influenza neuraminidase (NA).	Protactinium	53-55	neuraminidase 1	Homo sapiens	232-245
8807834-5	1996	RESULTS: Polyacrylamides with multiple C-sialosides (PA(Neu5Ac)) were 2-20 fold more effective as inhibitors of virally mediated hemagglutination when assayed in the presence of Neu2en-NH2, a potent monomeric inhibitor of influenza neuraminidase (NA).	Protactinium	53-55	neuraminidase 1	Homo sapiens	247-249
8807834-7	1996	CONCLUSIONS: We propose that inhibitors of NA act by competing with the C-sialosides of PA(Neu5Ac) for binding to the active sites of the NA.	Protactinium	88-90	neuraminidase 1	Homo sapiens	43-45
8807834-7	1996	CONCLUSIONS: We propose that inhibitors of NA act by competing with the C-sialosides of PA(Neu5Ac) for binding to the active sites of the NA.	Protactinium	88-90	neuraminidase 1	Homo sapiens	138-140
8550736-12	1996	Net PA activity reflects the balance between PA and PAI-1.	Protactinium	4-6	serpin family E member 1	Homo sapiens	52-57
7592839-7	1995	Coprecipitation experiments using various PAS proteins and ARNT were consistent with the idea that the ARNT protein has a broad range of interactions among the bHLH-PAS proteins, while the other members appear more restricted in their interactions.	Protactinium	42-45	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	103-107
7586231-6	1995	When Ca2+ served as the charge carrier, the density of peak ICa,T in IZs (0.89 +/- 0.5 pA/pF, n = 28) was similar to that in myocytes from normal noninfarcted hearts (NZs) (1.1 +/- 0.5 pA/pF, n = 32).	Protactinium	87-89	calcium voltage-gated channel subunit alpha1 C	Canis lupus familiaris	60-63
8772230-9	1995	PA activity, identified as u-PA by functional and immunological criteria, was measured in CM of six of the eight u-PA producing cell lines, whereas PAI activity was undetectable or very low in CM of all cell lines, suggesting that PAI-1 was largely inactive.	Protactinium	0-2	plasminogen activator, urokinase	Homo sapiens	27-31
8772230-9	1995	PA activity, identified as u-PA by functional and immunological criteria, was measured in CM of six of the eight u-PA producing cell lines, whereas PAI activity was undetectable or very low in CM of all cell lines, suggesting that PAI-1 was largely inactive.	Protactinium	0-2	plasminogen activator, urokinase	Homo sapiens	113-117
8772230-9	1995	PA activity, identified as u-PA by functional and immunological criteria, was measured in CM of six of the eight u-PA producing cell lines, whereas PAI activity was undetectable or very low in CM of all cell lines, suggesting that PAI-1 was largely inactive.	Protactinium	0-2	serpin family E member 1	Homo sapiens	231-236
8772230-10	1995	Functional assays of cell extracts demonstrated the presence of PA activity, again identified as u-PA, only in samples (five lines) containing u-PA antigen in excess over PAI-2.	Protactinium	64-66	plasminogen activator, urokinase	Homo sapiens	97-101
8812055-2	1996	We report here the identification of two murine homologs of sim, Sim1 and Sim2, whose products show a high degree of sequence conservation with Drosophila SIM in their amino-terminal halves, with each containing a basic helix-loop-helix domain as well as a PAS domain.	Protactinium	257-260	single-minded family bHLH transcription factor 2	Mus musculus	60-63
8812055-2	1996	We report here the identification of two murine homologs of sim, Sim1 and Sim2, whose products show a high degree of sequence conservation with Drosophila SIM in their amino-terminal halves, with each containing a basic helix-loop-helix domain as well as a PAS domain.	Protactinium	257-260	single-minded family bHLH transcription factor 2	Mus musculus	74-78
8735973-4	1996	Moreover, precontraction of PA rings with adrenotensin selectively attenuated the pulmonary vasorelaxant response to ADM but not to other vasodilator substances, including isoproterenol, pinacidil, nifedipine, and adenosine.	Protactinium	28-30	adrenomedullin	Homo sapiens	117-120
7493958-4	1995	One HSP90 molecule appears to bind within the PAS region.	Protactinium	46-49	heat shock protein 86, pseudogene 1	Mus musculus	4-9
7493958-5	1995	The other molecule of HSP90 appears to require interaction at two sites: one over the basic helix-loop-helix region, and the other located within the PAS region.	Protactinium	150-153	heat shock protein 86, pseudogene 1	Mus musculus	22-27
7481773-5	1995	A restricted segment of TIM binds directly to a part of the PER dimerization domain PAS.	Protactinium	84-87	timeless	Drosophila melanogaster	24-27
7474111-0	1995	A 48-amino-acid region of influenza A virus PB1 protein is sufficient for complex formation with PA.	Protactinium	97-99	polybromo 1	Homo sapiens	44-47
7474111-4	1995	To identify domains of PB1 involved in binding PA, a two-hybrid system adapted for mammalian cells (CV-1) was implemented.	Protactinium	47-49	polybromo 1	Homo sapiens	23-26
7474111-6	1995	Subsequent analyses with a set of chimeric proteins with truncations of the PB1 C termini, N termini, or internal sequences led to the identification of a region at the N terminus of PB1 responsible for binding PA.	Protactinium	211-213	polybromo 1	Homo sapiens	76-79
8544403-3	1995	Patients using PS/PA membranes disclosed a further decreased CD14 expression than patients with CU/HE membranes.	Protactinium	18-20	CD14 molecule	Homo sapiens	61-65
7474111-6	1995	Subsequent analyses with a set of chimeric proteins with truncations of the PB1 C termini, N termini, or internal sequences led to the identification of a region at the N terminus of PB1 responsible for binding PA.	Protactinium	211-213	polybromo 1	Homo sapiens	183-186
7474111-7	1995	Forty-eight amino acids at the N terminus of PB1 were sufficient for binding PA in vivo with the same efficiency as the complete PB1 protein.	Protactinium	77-79	polybromo 1	Homo sapiens	45-48
7474111-8	1995	This region of PB1 responsible for binding PA does not overlap with other previously described PB1 functional domains involved in nuclear transport and RNA polymerization.	Protactinium	43-45	polybromo 1	Homo sapiens	15-18
7474111-9	1995	We propose to name this region of interaction with PA domain alpha, to differentiate it from other functional domains described for PB1.	Protactinium	51-53	polybromo 1	Homo sapiens	132-135
8564710-1	1995	When granulocyte-macrophage colony-stimulating factor (GM-CSF)-treated human neutrophils were challenged with the chemotactic factor fMet-Leu-Phe, it was possible to detect a time-dependent increase in the hydrolytic (as measured by the production of phosphatidic acid, PA) and the transphosphatidylation (as measured by the production of phosphatidylethanol, PEt) activities of phospholipase D in intact cells prelabeled with a radioactive fatty acid.	Protactinium	270-272	colony stimulating factor 2	Homo sapiens	5-53
7488247-6	1995	By using the yeast two-hybrid system with the N-terminal half of AHR as a probe, which contains the bHLH and PAS regions, to screen cDNA libraries prepared from human lymphocytes and C57BL mouse liver for clones encoding proteins capable of binding to these regions, we isolated a partial ARNT cDNA clone.	Protactinium	109-112	spineless	Drosophila melanogaster	65-68
7565793-4	1995	As with most pas mutants, pas7 cells exhibit a pronounced deficiency in import of peroxisomal matrix proteins that contain either the type 1 peroxisomal targeting signal (PTS1) or the type 2 PTS (PTS2).	Protactinium	13-16	Pex7p	Saccharomyces cerevisiae S288C	26-30
8564710-1	1995	When granulocyte-macrophage colony-stimulating factor (GM-CSF)-treated human neutrophils were challenged with the chemotactic factor fMet-Leu-Phe, it was possible to detect a time-dependent increase in the hydrolytic (as measured by the production of phosphatidic acid, PA) and the transphosphatidylation (as measured by the production of phosphatidylethanol, PEt) activities of phospholipase D in intact cells prelabeled with a radioactive fatty acid.	Protactinium	270-272	colony stimulating factor 2	Homo sapiens	55-61
7654172-1	1995	The PAS domain of a teleost Ah receptor was amplified using reverse transcription-PCR with degenerate primers containing inosine.	Protactinium	4-7	aryl hydrocarbon receptor	Homo sapiens	28-39
7670960-10	1995	Also, strong tPA and uPA staining was detected in neomicrovessels of the plaques, suggesting that PAs may play a role in plaque angiogenesis.	Protactinium	98-101	plasminogen activator, tissue type	Homo sapiens	13-16
7670960-10	1995	Also, strong tPA and uPA staining was detected in neomicrovessels of the plaques, suggesting that PAs may play a role in plaque angiogenesis.	Protactinium	98-101	plasminogen activator, urokinase	Homo sapiens	21-24
8562904-4	1995	Thus, the uPA receptor might present uPA saporm to alpha 2MR for internalization of the conjugate, a mechanism similar to that of uPA complexed to specific PA inhibitors.	Protactinium	11-13	plasminogen activator, urokinase	Homo sapiens	37-40
8562904-4	1995	Thus, the uPA receptor might present uPA saporm to alpha 2MR for internalization of the conjugate, a mechanism similar to that of uPA complexed to specific PA inhibitors.	Protactinium	11-13	plasminogen activator, urokinase	Homo sapiens	37-40
8855126-8	1995	Goblet cells and extracellular mucin were intensely positive for the PAS-reagent.	Protactinium	69-72	solute carrier family 13 member 2	Rattus norvegicus	31-36
7482438-2	1995	To determine whether the other major PA, urokinase (u-PA), which also complexes with PAI-1, is metabolised via the same mechanism, 125I-labelled high (hmw) and low (lmw) molecular weight forms of u-PA were incubated with Hep G2 cells at 4 degrees C for 2 hr in the absence and presence of a 100-fold excess of unlabelled ligand in order to detect specific binding.	Protactinium	37-39	plasminogen activator, urokinase	Homo sapiens	52-56
7611439-7	1995	Plasminogen activator inhibitor-1 (PAI-1) inhibited PA activity of preformed uPA/uPAR complexes and increased cycling of the receptor from the cell surface.	Protactinium	35-37	serpin family E member 1	Homo sapiens	0-33
7558248-3	1995	Although TNF-alpha suppresses the induced increase in steady-state mRNA levels of u-PA and PAI-1 during maturation of extracellular matrix (ECM), the u-PA/PAI-1 ratio is altered in such a way that PA activity associated with the ECM is higher than control cells.	Protactinium	84-86	tumor necrosis factor	Homo sapiens	9-18
7570576-10	1995	These data plus PAS and Alcian blue binding to the isolate indicate a mucin-like glycoprotein.	Protactinium	16-19	solute carrier family 13 member 2	Rattus norvegicus	70-75
7619856-6	1995	The difference between Jurcat cells and PBML was not dependent on culture conditions, because phytohemagglutinin and interleukin-2 activated PBML, kept in culture, showed the same PA preference as freshly prepared non-activated PBML.	Protactinium	180-182	interleukin 2	Homo sapiens	117-130
7559224-8	1995	PA medial thickness and the percentage of muscularized small PAs were significantly lower in EPO-treated hypoxic rats.	Protactinium	0-2	erythropoietin	Rattus norvegicus	93-96
7559224-8	1995	PA medial thickness and the percentage of muscularized small PAs were significantly lower in EPO-treated hypoxic rats.	Protactinium	61-64	erythropoietin	Rattus norvegicus	93-96
7539918-0	1995	Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.	Protactinium	55-58	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-26
7539918-2	1995	We show that both HIF-1 subunits are basic-helix-loop-helix proteins containing a PAS domain, defined by its presence in the Drosophila Per and Sim proteins and in the mammalian ARNT and AHR proteins.	Protactinium	82-85	similar	Drosophila melanogaster	18-23
7539918-2	1995	We show that both HIF-1 subunits are basic-helix-loop-helix proteins containing a PAS domain, defined by its presence in the Drosophila Per and Sim proteins and in the mammalian ARNT and AHR proteins.	Protactinium	82-85	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	178-182
7539918-2	1995	We show that both HIF-1 subunits are basic-helix-loop-helix proteins containing a PAS domain, defined by its presence in the Drosophila Per and Sim proteins and in the mammalian ARNT and AHR proteins.	Protactinium	82-85	aryl hydrocarbon receptor	Homo sapiens	187-190
7611439-7	1995	Plasminogen activator inhibitor-1 (PAI-1) inhibited PA activity of preformed uPA/uPAR complexes and increased cycling of the receptor from the cell surface.	Protactinium	35-37	plasminogen activator, urokinase	Homo sapiens	77-80
7611439-7	1995	Plasminogen activator inhibitor-1 (PAI-1) inhibited PA activity of preformed uPA/uPAR complexes and increased cycling of the receptor from the cell surface.	Protactinium	35-37	plasminogen activator, urokinase receptor	Homo sapiens	81-85
7757960-2	1995	Three key enzymes involved in the PA biosynthetic/catabolic pathway (ornithine-decarboxylase (ODC), S-adenosylmethionine decarboxylase (SAMDC), and spermidine/spermine N"-acetyltransferase (SSAT)) were measured in tumors at different stages of progression.	Protactinium	34-36	ornithine decarboxylase 1	Rattus norvegicus	69-92
7757960-2	1995	Three key enzymes involved in the PA biosynthetic/catabolic pathway (ornithine-decarboxylase (ODC), S-adenosylmethionine decarboxylase (SAMDC), and spermidine/spermine N"-acetyltransferase (SSAT)) were measured in tumors at different stages of progression.	Protactinium	34-36	ornithine decarboxylase 1	Rattus norvegicus	94-97
7757960-2	1995	Three key enzymes involved in the PA biosynthetic/catabolic pathway (ornithine-decarboxylase (ODC), S-adenosylmethionine decarboxylase (SAMDC), and spermidine/spermine N"-acetyltransferase (SSAT)) were measured in tumors at different stages of progression.	Protactinium	34-36	adenosylmethionine decarboxylase 1	Rattus norvegicus	100-134
7757960-2	1995	Three key enzymes involved in the PA biosynthetic/catabolic pathway (ornithine-decarboxylase (ODC), S-adenosylmethionine decarboxylase (SAMDC), and spermidine/spermine N"-acetyltransferase (SSAT)) were measured in tumors at different stages of progression.	Protactinium	34-36	adenosylmethionine decarboxylase 1	Rattus norvegicus	136-141
7757960-2	1995	Three key enzymes involved in the PA biosynthetic/catabolic pathway (ornithine-decarboxylase (ODC), S-adenosylmethionine decarboxylase (SAMDC), and spermidine/spermine N"-acetyltransferase (SSAT)) were measured in tumors at different stages of progression.	Protactinium	34-36	spermidine/spermine N1-acetyl transferase 1	Rattus norvegicus	148-188
7757960-2	1995	Three key enzymes involved in the PA biosynthetic/catabolic pathway (ornithine-decarboxylase (ODC), S-adenosylmethionine decarboxylase (SAMDC), and spermidine/spermine N"-acetyltransferase (SSAT)) were measured in tumors at different stages of progression.	Protactinium	34-36	spermidine/spermine N1-acetyl transferase 1	Rattus norvegicus	190-194
7757960-7	1995	We conclude that, among the three enzymes tested, ODC overexpression is the most significant alteration in the PA metabolic pathway associated with breast cancer progression in this experimental system.	Protactinium	111-113	ornithine decarboxylase 1	Rattus norvegicus	50-53
7722124-1	1995	OBJECTIVES: The aim of the present study was to evaluate the effectiveness of prolonged administration of thrombolytic therapy with low doses of recombinant tissue-type plasminogen activator (rt-PA) in patients with refractory unstable angina.	Protactinium	195-197	plasminogen activator, tissue type	Homo sapiens	157-190
7538404-9	1995	These results suggest that the interaction of Pa with its target sequence(s) prevent PC2 binding and thereby contribute towards increased IGFBP-1 gene transcription.	Protactinium	46-48	chromobox 4	Homo sapiens	85-88
7538404-9	1995	These results suggest that the interaction of Pa with its target sequence(s) prevent PC2 binding and thereby contribute towards increased IGFBP-1 gene transcription.	Protactinium	46-48	insulin like growth factor binding protein 1	Homo sapiens	138-145
7840657-4	1995	In this study, another member of the furin family, PC1 (SPC3), was tested as a putative processing enzyme for PA.	Protactinium	110-112	furin, paired basic amino acid cleaving enzyme	Bos taurus	37-42
7540231-5	1995	Intact forms of adhesion proteins were predominantly (fibrinogen) or exclusively (vitronectin) found in PA eluates.	Protactinium	104-106	vitronectin	Homo sapiens	82-93
7892203-3	1995	Arnt formed a homodimer with itself as well as heterodimers with the others by means of the PAS and HLH domains in a cooperative way.	Protactinium	92-95	tango	Drosophila melanogaster	0-4
7544991-1	1995	Interleukin-11 (IL-11) stimulated [3H]phosphatidic acid (PA) formation in [3H]arachidonic acid (AA) prelabelled quiescent mouse 3T3-L1 cells.	Protactinium	57-59	interleukin 11	Mus musculus	0-14
7544991-1	1995	Interleukin-11 (IL-11) stimulated [3H]phosphatidic acid (PA) formation in [3H]arachidonic acid (AA) prelabelled quiescent mouse 3T3-L1 cells.	Protactinium	57-59	interleukin 11	Mus musculus	16-21
7544991-2	1995	When IL-11 stimulated 3T3-L1 cells were incubated with NaF, a phosphatidic acid phosphohydrolase (PAP) inhibitor, increased PA formation was observed.	Protactinium	98-100	interleukin 11	Mus musculus	5-10
7544991-4	1995	These results indicated that the formation of PA upon IL-11 stimulation was a result of phospholipase D (PLD) activation.	Protactinium	46-48	interleukin 11	Mus musculus	54-59
7544991-5	1995	Endogenous accumulation of PA by NaF treatment or exogenously added PA enhanced tyrosine phosphorylation of two proteins of 44 KDa (p44) and 47 KDa (p47) whereas tyrosine phosphorylation of other proteins was not affected.	Protactinium	27-29	NSFL1 (p97) cofactor (p47)	Mus musculus	149-152
7544991-5	1995	Endogenous accumulation of PA by NaF treatment or exogenously added PA enhanced tyrosine phosphorylation of two proteins of 44 KDa (p44) and 47 KDa (p47) whereas tyrosine phosphorylation of other proteins was not affected.	Protactinium	68-70	NSFL1 (p97) cofactor (p47)	Mus musculus	149-152
7544991-9	1995	These studies suggest that one of the cellular signalling mechanisms of IL-11 in 3T3-L1 cells involves the activation of phospholipase D to produce the second messenger PA.	Protactinium	169-171	interleukin 11	Mus musculus	72-77
7544991-10	1995	The increased level of PA enhances tyrosine phosphorylation of p44 and p47 which belong to the members of MAP kinase family and thus transduces some of the mitogenic signals of IL-11 in this cell line.	Protactinium	23-25	NSFL1 (p97) cofactor (p47)	Mus musculus	71-74
7544991-10	1995	The increased level of PA enhances tyrosine phosphorylation of p44 and p47 which belong to the members of MAP kinase family and thus transduces some of the mitogenic signals of IL-11 in this cell line.	Protactinium	23-25	interleukin 11	Mus musculus	177-182
7778059-3	1995	Spontaneous PA was significantly higher in PBMC from persons with low HDL, combined with lower release of uPA to the media and higher uPA-receptor (uPA-R) bound uPA on PBMC.	Protactinium	12-14	plasminogen activator, urokinase	Homo sapiens	106-109
7778059-3	1995	Spontaneous PA was significantly higher in PBMC from persons with low HDL, combined with lower release of uPA to the media and higher uPA-receptor (uPA-R) bound uPA on PBMC.	Protactinium	12-14	plasminogen activator, urokinase receptor	Homo sapiens	134-146
7778059-3	1995	Spontaneous PA was significantly higher in PBMC from persons with low HDL, combined with lower release of uPA to the media and higher uPA-receptor (uPA-R) bound uPA on PBMC.	Protactinium	12-14	plasminogen activator, urokinase receptor	Homo sapiens	148-153
7778059-3	1995	Spontaneous PA was significantly higher in PBMC from persons with low HDL, combined with lower release of uPA to the media and higher uPA-receptor (uPA-R) bound uPA on PBMC.	Protactinium	12-14	plasminogen activator, urokinase	Homo sapiens	134-137
7778059-8	1995	2) PBMC from persons with low HDL showed higher spontaneous PA, due to higher uPA-R bound uPA, probably of importance in cell migration during the early events of atherosclerosis.	Protactinium	60-62	plasminogen activator, urokinase	Homo sapiens	90-93
7599699-2	1995	Endometrial cells are known to release a major PA inhibitor, PAI-1.	Protactinium	47-49	serpin family E member 1	Homo sapiens	61-66
7822431-7	1995	The formation of a capillary network by HOME cells on Matrigel appears to be balanced by angiogenic EGF and anti-angiogenic TGF-beta through modulation of PA activity.	Protactinium	155-157	transforming growth factor beta 1	Homo sapiens	124-132
7536737-5	1995	Analysis of the species reactivity revealed that 182 cross-reacted with one or more (t-)PAs originating from other species including rat t-PA, human t-PA, and vampire bat-PA.	Protactinium	88-90	plasminogen activator, tissue type	Rattus norvegicus	137-141
7536737-5	1995	Analysis of the species reactivity revealed that 182 cross-reacted with one or more (t-)PAs originating from other species including rat t-PA, human t-PA, and vampire bat-PA.	Protactinium	88-90	plasminogen activator, tissue type	Homo sapiens	149-153
21556599-5	1995	Most of the cell lines that were sensitive to anti-Pas antibody showed evidence of enhanced apoptosis when the cells were pretreated with interferon-gamma.	Protactinium	51-54	interferon gamma	Homo sapiens	138-154
7882615-5	1995	Laminin-induced production of MMP-2 is attenuated by 1-butanol, a competitive substrate of PLD that reduces PLD-catalyzed production of PA.	Protactinium	136-138	matrix metallopeptidase 2	Homo sapiens	30-35
7882615-5	1995	Laminin-induced production of MMP-2 is attenuated by 1-butanol, a competitive substrate of PLD that reduces PLD-catalyzed production of PA.	Protactinium	136-138	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	91-94
7882615-5	1995	Laminin-induced production of MMP-2 is attenuated by 1-butanol, a competitive substrate of PLD that reduces PLD-catalyzed production of PA.	Protactinium	136-138	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	108-111
7840657-4	1995	In this study, another member of the furin family, PC1 (SPC3), was tested as a putative processing enzyme for PA.	Protactinium	110-112	proprotein convertase subtilisin/kexin type 1	Bos taurus	51-54
7840657-5	1995	Recombinant PC1, partially purified from the medium of stably transfected L-cells, cleaved PA to a 63-kDa fragment (PA63) and a 20-kDa fragment (PA20).	Protactinium	91-93	proprotein convertase subtilisin/kexin type 1	Bos taurus	12-15
7840657-11	1995	Mutants of PA containing basic residues in positions -1 and either -2 or -4 of the cleavage site were predicted to be substrates for PC1 and were more toxic to L-cells expressing PC1 than to untransfected L-cells.	Protactinium	11-13	proprotein convertase subtilisin/kexin type 1	Bos taurus	133-136
7840657-11	1995	Mutants of PA containing basic residues in positions -1 and either -2 or -4 of the cleavage site were predicted to be substrates for PC1 and were more toxic to L-cells expressing PC1 than to untransfected L-cells.	Protactinium	11-13	proprotein convertase subtilisin/kexin type 1	Bos taurus	179-182
7840657-12	1995	These results demonstrate that PA is cleaved by PC1 in vivo.	Protactinium	31-33	proprotein convertase subtilisin/kexin type 1	Bos taurus	48-51
7840657-13	1995	Membranes from bovine intermediate lobe secretory vesicles which contain both prohormone convertases, PC1 and PC2, also cleaved PA to PA63 with a pH optimum of 5.5.	Protactinium	128-130	proprotein convertase subtilisin/kexin type 1	Bos taurus	102-105
7840657-13	1995	Membranes from bovine intermediate lobe secretory vesicles which contain both prohormone convertases, PC1 and PC2, also cleaved PA to PA63 with a pH optimum of 5.5.	Protactinium	128-130	proprotein convertase subtilisin/kexin type 2	Bos taurus	110-113
7840657-14	1995	Immunodepletion studies using antisera against PC1 and PC2 showed that these are the enzymes primarily responsible for the cleavage of PA in the membrane preparation.	Protactinium	135-137	proprotein convertase subtilisin/kexin type 1	Bos taurus	47-50
7840657-14	1995	Immunodepletion studies using antisera against PC1 and PC2 showed that these are the enzymes primarily responsible for the cleavage of PA in the membrane preparation.	Protactinium	135-137	proprotein convertase subtilisin/kexin type 2	Bos taurus	55-58
7840657-15	1995	Thus, both recombinant PC1 and a membrane preparation containing endogenous PC1 can activate PA.	Protactinium	93-95	proprotein convertase subtilisin/kexin type 1	Bos taurus	23-26
7840657-15	1995	Thus, both recombinant PC1 and a membrane preparation containing endogenous PC1 can activate PA.	Protactinium	93-95	proprotein convertase subtilisin/kexin type 1	Bos taurus	76-79
10603527-4	1995	Then PA was induced by ADP, collagen, thrombin, and ristocetin in the PRP without NPC 15669 and in NPC 15669-treated samples.	Protactinium	5-7	coagulation factor II, thrombin	Homo sapiens	38-46
7806387-2	1995	Previously, it was shown that PA and DT can be activated by furin.	Protactinium	30-32	furin	Cricetulus griseus	60-65
7806387-4	1995	In vitro cleavage of PA and cleavage site mutants of PA by furin demonstrated that native PA (RKKR) and PA with the cleavage sequence RAAR are substrates for furin.	Protactinium	21-23	furin	Cricetulus griseus	59-64
7806387-4	1995	In vitro cleavage of PA and cleavage site mutants of PA by furin demonstrated that native PA (RKKR) and PA with the cleavage sequence RAAR are substrates for furin.	Protactinium	21-23	furin	Cricetulus griseus	158-163
7806387-4	1995	In vitro cleavage of PA and cleavage site mutants of PA by furin demonstrated that native PA (RKKR) and PA with the cleavage sequence RAAR are substrates for furin.	Protactinium	53-55	furin	Cricetulus griseus	59-64
7806387-4	1995	In vitro cleavage of PA and cleavage site mutants of PA by furin demonstrated that native PA (RKKR) and PA with the cleavage sequence RAAR are substrates for furin.	Protactinium	53-55	furin	Cricetulus griseus	158-163
7806387-6	1995	Furin-deficient cells were resistant to PE, whose cleavage site, RQPR, constitutes a furin recognition site and to all PA cleavage site mutants, but were sensitive to DT (EC50 = 2.9 ng/ml) and PA (EC50 = 23 ng/ml), whose respective cleavage sites, RKKR and RVRR, contain additional basic residues.	Protactinium	119-121	furin	Cricetulus griseus	0-5
7806387-6	1995	Furin-deficient cells were resistant to PE, whose cleavage site, RQPR, constitutes a furin recognition site and to all PA cleavage site mutants, but were sensitive to DT (EC50 = 2.9 ng/ml) and PA (EC50 = 23 ng/ml), whose respective cleavage sites, RKKR and RVRR, contain additional basic residues.	Protactinium	193-195	furin	Cricetulus griseus	0-5
7806387-7	1995	Furin-deficient cells that were transfected with the furin gene regained sensitivity to PE and PA cleavage site mutants.	Protactinium	95-97	furin	Cricetulus griseus	0-5
7806387-7	1995	Furin-deficient cells that were transfected with the furin gene regained sensitivity to PE and PA cleavage site mutants.	Protactinium	95-97	furin	Cricetulus griseus	53-58
7899461-3	1995	EGF, IGF-I, and bFGF caused significant and dose-dependent increases in [3H]phosphatidic acid (PA) accumulation in the presence of propranolol, a phosphatidic acid phosphohydrolase inhibitor.	Protactinium	95-97	epidermal growth factor	Rattus norvegicus	0-3
7899461-3	1995	EGF, IGF-I, and bFGF caused significant and dose-dependent increases in [3H]phosphatidic acid (PA) accumulation in the presence of propranolol, a phosphatidic acid phosphohydrolase inhibitor.	Protactinium	95-97	insulin-like growth factor 1	Rattus norvegicus	5-10
7899461-3	1995	EGF, IGF-I, and bFGF caused significant and dose-dependent increases in [3H]phosphatidic acid (PA) accumulation in the presence of propranolol, a phosphatidic acid phosphohydrolase inhibitor.	Protactinium	95-97	fibroblast growth factor 2	Rattus norvegicus	16-20
7899461-5	1995	PA production in response to all three factors was dose dependent with maximal responses to EGF at 25 nM, to IGF-I at 16.5 nM, and to bFGF at 50 pM.	Protactinium	0-2	epidermal growth factor	Rattus norvegicus	92-95
7899461-5	1995	PA production in response to all three factors was dose dependent with maximal responses to EGF at 25 nM, to IGF-I at 16.5 nM, and to bFGF at 50 pM.	Protactinium	0-2	insulin-like growth factor 1	Rattus norvegicus	109-114
7899461-5	1995	PA production in response to all three factors was dose dependent with maximal responses to EGF at 25 nM, to IGF-I at 16.5 nM, and to bFGF at 50 pM.	Protactinium	0-2	fibroblast growth factor 2	Rattus norvegicus	134-138
7899461-8	1995	In the presence of 1% ethanol, EGF, IGF-I, and bFGF caused significant phosphatidylethanol production after 20 min of incubation, thus confirming the involvement of PLD in PA production.	Protactinium	172-174	epidermal growth factor	Rattus norvegicus	31-34
7899461-8	1995	In the presence of 1% ethanol, EGF, IGF-I, and bFGF caused significant phosphatidylethanol production after 20 min of incubation, thus confirming the involvement of PLD in PA production.	Protactinium	172-174	insulin-like growth factor 1	Rattus norvegicus	36-41
7899461-8	1995	In the presence of 1% ethanol, EGF, IGF-I, and bFGF caused significant phosphatidylethanol production after 20 min of incubation, thus confirming the involvement of PLD in PA production.	Protactinium	172-174	fibroblast growth factor 2	Rattus norvegicus	47-51
7989319-4	1994	Previous mapping studies of the AHR have demonstrated that the PAS domain contains sequences required for ligand recognition, dimerization, and interaction with the 90-kDa heat shock protein.	Protactinium	63-66	spineless	Drosophila melanogaster	32-35
21043698-3	1995	In aspirinated platelets NO inhibited thrombin (0.05 U/ml)-induced formation of [(32)P]phosphatidic acid (PA), secretion of ATP + ADP from the dense granules and secretion of acid glycosidases in a dose-dependent manner.	Protactinium	106-108	coagulation factor II, thrombin	Homo sapiens	38-46
21043698-5	1995	In aspirinated platelets in the presence of creatine phosphate/creatine phosphokinase (CP/CPK) to remove secreted ADP, increasing concentrations of NO still produced strong inhibition of [(32)P] PA-formation and secretory responses.	Protactinium	195-197	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	44-93
7929404-8	1994	When assayed toward an AA-containing substrate, PA was able to enhance phospholipase A2 activity from cell homogenates in the absence of calcium.	Protactinium	48-50	phospholipase A2, group IB, pancreas	Mus musculus	71-87
7533330-2	1994	The results showed that PA inhibited delayed outward K+ current (IK), and to a less extend, that the Na+ current (INa).	Protactinium	24-26	internexin neuronal intermediate filament protein, alpha	Mus musculus	114-117
7973905-5	1994	PA and its precursor steroids also responded poorly to graded angiotensin II infusion and rapid ACTH injection.	Protactinium	0-2	angiotensinogen	Homo sapiens	62-76
7929404-11	1994	These findings suggest a role for PA in the cascade of events leading to AA release in macrophages through Ca(2+)-independent stimulation of an AA-selective phospholipase A2.	Protactinium	34-36	phospholipase A2, group IB, pancreas	Mus musculus	157-173
7943331-1	1994	The human serum albumin (HSA)-dependent unbound clearance (Clu) of [3H]palmitic acid (PA) by hepatocyte suspensions isolated from immature and mature male and female and pregnant female rats was studied.	Protactinium	86-88	albumin	Rattus norvegicus	10-23
8065341-10	1994	Therefore, both the PAS A and PAS B segments, besides contributing to dimerization, apparently fulfill additional, unknown functions required for biological activity of ARNT.	Protactinium	20-23	aryl hydrocarbon receptor nuclear translocator	Mus musculus	169-173
7892041-4	1994	A naturally occurring model utilizing a genetic polymorphism (O-acetyltransferase) allows the development of unicryptal loss of heterozygosity (LOH) to be detected by means of mild PAS histochemistry and quantified.	Protactinium	181-184	CAS1 domain containing 1	Homo sapiens	62-81
7962281-8	1994	These results suggest an increased sensitivity of the hypothalamic-pituitary-adrenal axis to changes in ACTH secretion in this subgroup of patients with PA.	Protactinium	153-155	proopiomelanocortin	Homo sapiens	104-108
7844643-6	1994	PAS staining revealed that DMH treatment lowered mucin secretion in crypts, which was substantially lowered by food deprivation.	Protactinium	0-3	solute carrier family 13 member 2	Rattus norvegicus	49-54
8056534-6	1994	RESULTS: Free PA activity ranged widely (0.072 to 0.47 IU/ml; mean, 0.20 +/- 0.10 IU/ml) and was almost completed inactivated (> or = 89%) by antibody against human t-PA but not by the u-PA antibody.	Protactinium	14-16	plasminogen activator, tissue type	Homo sapiens	168-172
8056534-6	1994	RESULTS: Free PA activity ranged widely (0.072 to 0.47 IU/ml; mean, 0.20 +/- 0.10 IU/ml) and was almost completed inactivated (> or = 89%) by antibody against human t-PA but not by the u-PA antibody.	Protactinium	14-16	plasminogen activator, urokinase	Homo sapiens	188-192
8188336-4	1994	The purposes of this study were to determine (i) if gram-negative bacterial challenge affects circulating PA and mortality as Candida challenge does and (ii) if proteinase inhibitor treatment with aprotinin, antithrombin III, and alpha 1-proteinase inhibitor decreases circulating PA and increases the survival of burned mice infected with a bacterium.	Protactinium	281-283	serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1	Mus musculus	208-224
8055919-3	1994	Cathepsin C was as active towards tcu-PA/T as the bacterial proteinase thermolysin and about 300-times more active than plasmin.	Protactinium	38-40	cathepsin C	Homo sapiens	0-11
8039304-10	1994	Northern blot analysis demonstrated expression of urokinase-type plasminogen activator (uPA), tissue-type PA (tPA) and PA inhibitor-1 (PAI-1) in some of the above cell lines.	Protactinium	89-91	plasminogen activator, urokinase	Homo sapiens	50-86
8020601-6	1994	Anti-bFGF antibodies completely suppressed the mitogenic activity of bFGF, but did not have any effect on that of u-PA and t-PA; the activity of both PAs was inhibited by anti-fibronectin IgG concentrations ineffective on bFGF.	Protactinium	150-153	fibroblast growth factor 2	Homo sapiens	5-9
8020601-6	1994	Anti-bFGF antibodies completely suppressed the mitogenic activity of bFGF, but did not have any effect on that of u-PA and t-PA; the activity of both PAs was inhibited by anti-fibronectin IgG concentrations ineffective on bFGF.	Protactinium	150-153	fibronectin 1	Homo sapiens	176-187
8062099-8	1994	These results indicate that MEP may facilitate the use of radiolabeled PA as an in vivo probe of brain lipid metabolism using quantitative autoradiography or positron emission tomography.	Protactinium	71-73	neurolysin	Rattus norvegicus	28-31
8014197-3	1994	A rapid generation of PA and DAG was observed after ras-p21 microinjection, suggesting the activation of both PLC and PLD enzymes.	Protactinium	22-24	cyclin-dependent kinase inhibitor 1A L homeolog	Xenopus laevis	56-59
8014197-3	1994	A rapid generation of PA and DAG was observed after ras-p21 microinjection, suggesting the activation of both PLC and PLD enzymes.	Protactinium	22-24	heparan sulfate proteoglycan 2 L homeolog	Xenopus laevis	110-113
8130729-2	1993	The two types of plasminogen activator, tissue-type (tPA) and urokinase-type (uPA), are produced by osteoblasts, as is the specific PA inhibitor, PAI-1.	Protactinium	54-56	serpin family E member 1	Homo sapiens	146-151
8007599-3	1994	Our results showed that two of four IgG3 anti-TNP monoclonal cryoglobulins were capable of inducing glomerular lesions, characterized by voluminous intracapillary thrombi and mesangial deposition of PAS-positive materials, which differed from "wire-loop" lesions generated by IgG3 monoclonal cryoglobulins with autoantibody activities.	Protactinium	199-202	Immunoglobulin heavy constant gamma 3	Mus musculus	36-40
8052969-4	1994	Plasminogen activation assays showed that this tPA-like-PA could induce plasminogen activation to form plasmin.	Protactinium	48-50	plasminogen	Homo sapiens	72-79
8052969-7	1994	Fibrin zymographic analysis of affinity-purified tPA-like-PA demonstrated a major and a minor fibrin lysis zone, which approximately corresponded to the tPA-like-PA and its complex with PAI-1 observed by Western blots.	Protactinium	50-52	serpin family E member 1	Homo sapiens	186-191
8052969-7	1994	Fibrin zymographic analysis of affinity-purified tPA-like-PA demonstrated a major and a minor fibrin lysis zone, which approximately corresponded to the tPA-like-PA and its complex with PAI-1 observed by Western blots.	Protactinium	57-60	serpin family E member 1	Homo sapiens	186-191
8052969-9	1994	We conclude that platelets contain a functionally active tPA-like-PA, whose low fibrinolytic activity might be due to its readily forming a complex with PAI-1.	Protactinium	65-68	serpin family E member 1	Homo sapiens	153-158
8120414-6	1994	Moreover, [32P]phosphatidic acid (PA) production stimulated by IL-8 was minimal and transient as compared to the response activated by N-formyl peptide.	Protactinium	34-36	C-X-C motif chemokine ligand 8	Homo sapiens	63-67
8311121-11	1994	Intraepithelial mucin storage (AB/PAS-positive material quantified by image analysis) within the trachea decreased with dose.	Protactinium	34-37	solute carrier family 13 member 2	Rattus norvegicus	16-21
8307118-7	1994	The present study suggests that serotonergic dysfunction may decrease the efficacy of cholinesterase inhibitors to reverse the defect in WM and PA behavior occurring as a consequence of a decrease in activity of nicotinic-mediated functions.	Protactinium	144-146	butyrylcholinesterase	Rattus norvegicus	86-100
8113739-1	1994	The mutated non-structural NS2 protein of an influenza A virus mutant, Wa-182, has been shown to be responsible for the production of defective interfering (DI) particles lacking the PA gene after a single cycle high-multiplicity infection.	Protactinium	183-185	NS2	Homo sapiens	27-30
8113739-6	1994	Such aberrant replication of the PA gene was found to be attributable to an amino acid change in the NS2 protein at position 32, from isoleucine to threonine.	Protactinium	33-35	NS2	Homo sapiens	101-104
8109229-6	1993	Asthma in the high PA flow group was associated with other allergic diseases in 30 (77%) of 39 patients, including food allergy in nine (23%), atopic dermatitis in 14 (36%), allergic rhinitis in seven (18%) and abnormally high total IgE levels in 14 (36%).	Protactinium	19-21	immunoglobulin heavy constant epsilon	Homo sapiens	233-236
8090436-6	1994	These data implicate one mechanism by which PC-PLD may modulate PI-PLC activity through changing the phospholipid composition in the membrane, specifically the ratio of PA/PC.	Protactinium	169-171	phospholipase C beta 1	Homo sapiens	64-70
8130729-3	1993	Some hormones which activate bone resorption increase PA activity produced by osteoblasts, by decreasing the production of PAI-1.	Protactinium	54-56	serpin family E member 1	Homo sapiens	123-128
8130729-6	1993	TGF beta itself is a powerful inhibitor of PA activity, an effect achieved by enhancing mRNA and protein for PAI-1.	Protactinium	43-45	transforming growth factor beta 1	Homo sapiens	0-8
8130729-6	1993	TGF beta itself is a powerful inhibitor of PA activity, an effect achieved by enhancing mRNA and protein for PAI-1.	Protactinium	43-45	serpin family E member 1	Homo sapiens	109-114
8223875-5	1993	Stimulation of [3H]PA production upon CD3 cross-linking was 77% lower in permeabilized CD45- cells than in CD45+ cells, consistent with the reduced activity of p59fyn in CD45- cells.	Protactinium	19-21	protein tyrosine phosphatase receptor type C	Homo sapiens	87-91
8126437-5	1993	Transcription of orfX is mediated by a PA promoter.	Protactinium	39-41	hypothetical protein	Escherichia coli	17-21
8242773-5	1993	Since monocyte/macrophage PA activity is likely to be important in tissue remodeling and cell migration at sites of inflammation and in fibrinolysis, it is proposed from these studies that PAI-1, as well as the usually considered PAI-2, may be involved in the negative control of PA activity in this cell type.	Protactinium	26-28	serpin family E member 1	Homo sapiens	189-194
8223875-5	1993	Stimulation of [3H]PA production upon CD3 cross-linking was 77% lower in permeabilized CD45- cells than in CD45+ cells, consistent with the reduced activity of p59fyn in CD45- cells.	Protactinium	19-21	protein tyrosine phosphatase receptor type C	Homo sapiens	107-111
8223875-5	1993	Stimulation of [3H]PA production upon CD3 cross-linking was 77% lower in permeabilized CD45- cells than in CD45+ cells, consistent with the reduced activity of p59fyn in CD45- cells.	Protactinium	19-21	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	160-166
8223875-5	1993	Stimulation of [3H]PA production upon CD3 cross-linking was 77% lower in permeabilized CD45- cells than in CD45+ cells, consistent with the reduced activity of p59fyn in CD45- cells.	Protactinium	19-21	protein tyrosine phosphatase receptor type C	Homo sapiens	107-111
8223875-7	1993	The CD3-induced increase in total inositol phosphates (InsP) in permeabilized cells was similar to the stimulated production of [3H]PA production in both CD45+ and CD45- cells.	Protactinium	132-134	protein tyrosine phosphatase receptor type C	Homo sapiens	154-158
8223875-7	1993	The CD3-induced increase in total inositol phosphates (InsP) in permeabilized cells was similar to the stimulated production of [3H]PA production in both CD45+ and CD45- cells.	Protactinium	132-134	protein tyrosine phosphatase receptor type C	Homo sapiens	164-168
8394074-3	1993	In the presence of ethanol, PLD catalyzed a transphosphatidylation reaction in which LTB4 increased [3H]alkyl-phosphatidylethanol formation and simultaneously decreased LTB4-induced PA and DG accumulation.	Protactinium	182-184	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	28-31
8287061-6	1993	Adjacent to the PAS domain in the AH-receptor, ARNT and Sim proteins is a basic/helix-loop-helix (bHLH) domain that appears to mediate heterodimerization and sequence specific DNA binding properties.	Protactinium	16-19	aryl-hydrocarbon receptor	Mus musculus	34-45
8287061-6	1993	Adjacent to the PAS domain in the AH-receptor, ARNT and Sim proteins is a basic/helix-loop-helix (bHLH) domain that appears to mediate heterodimerization and sequence specific DNA binding properties.	Protactinium	16-19	aryl hydrocarbon receptor nuclear translocator	Mus musculus	47-51
7968541-4	1993	The permeabilizing activity of PA was limited to a proteolytically activated form (PAN) and was dependent on acidic pH for membrane insertion (optimal at pH 5.0), but not for sustained ion flux.	Protactinium	31-33	adenosine deaminase 2	Homo sapiens	83-86
8375622-5	1993	Intraduodenal administration of EGF significantly increased the PAS-stained mucus in the duodenal mucosa, but not in Brunner"s glands.	Protactinium	64-67	epidermal growth factor like 1	Rattus norvegicus	32-35
8315289-4	1993	In addition, both PAs can be complexed with the plasminogen activator inhibitors PAI-I or PAI-2.	Protactinium	18-21	serpin family B member 2	Homo sapiens	90-95
8396050-4	1993	The ACTH injection induced similar increases in plasma cortisol, plasma 18-hydroxycorticosterone (18-OHB) and PA in the two groups.	Protactinium	110-112	proopiomelanocortin	Homo sapiens	4-8
8396050-5	1993	The graded AII infusions also produced increases in plasma 18-OHB and PA in the two groups.	Protactinium	70-72	angiotensinogen	Homo sapiens	11-14
8400063-2	1993	Therefore, adrenal Ang II receptor binding was characterized in a patient with APA who had a blocked PA response to Ang II infusion before adrenalectomy.	Protactinium	80-82	angiotensinogen	Homo sapiens	19-25
8315289-5	1993	Monoclonal antibodies specific for uPA or tPA were selected that recognized the distinct molecular forms of the PAs, even in the presence of fetal calf serum, which is a common--relatively ill-defined--ingredient of cell culture media.	Protactinium	112-115	plasminogen activator, urokinase	Homo sapiens	35-38
8315289-5	1993	Monoclonal antibodies specific for uPA or tPA were selected that recognized the distinct molecular forms of the PAs, even in the presence of fetal calf serum, which is a common--relatively ill-defined--ingredient of cell culture media.	Protactinium	112-115	plasminogen activator, tissue type	Homo sapiens	42-45
8454047-2	1993	Upon VP-treatment, the formation of [3H] and [14C]phosphatidic acid (PA) and phosphatidylethanol (PEt) was accompanied by the loss of radioactivity from PC and PI.	Protactinium	69-71	arginine vasopressin	Rattus norvegicus	5-7
8370213-6	1993	Although repeated cultures for bacteria or fungi were negative, PAS stains for CSF sediments showed a large number of yeasts morphologically consistent with a Malassezia species.	Protactinium	64-67	colony stimulating factor 2	Homo sapiens	79-82
8508786-3	1993	Using gonadotropin-induced ovulation as a model, we have studied how two components of the PA system, tissue-type plasminogen activator (tPA) and plasminogen-activator-inhibitor type 1 (PAI-1), are regulated temporally and spatially by gonadotropins, leading to the initiation and termination of a well-directed proteolytic process.	Protactinium	91-93	plasminogen activator, tissue type	Homo sapiens	102-135
8508786-3	1993	Using gonadotropin-induced ovulation as a model, we have studied how two components of the PA system, tissue-type plasminogen activator (tPA) and plasminogen-activator-inhibitor type 1 (PAI-1), are regulated temporally and spatially by gonadotropins, leading to the initiation and termination of a well-directed proteolytic process.	Protactinium	91-93	serpin family E member 1	Homo sapiens	146-184
8473292-4	1993	Inhibition of GPI-PLD by PAs (IC50 approximately 1 microM) was relatively independent of the length or degree of unsaturation of the fatty acyl chains.	Protactinium	25-28	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	14-21
8392417-4	1993	When the differentiated state is reached the phosphorylation level of PIP2 increases in isolated nuclei and this is accompanied by a concomitant decrease of PIP and PA, hinting at a correlation between polyphosphoinositide metabolism and TdT expression.	Protactinium	165-167	prolactin induced protein	Homo sapiens	70-73
8449955-15	1993	Thus, PEA-15 is an endogenous substrate for PKC, the kinase mediating the transition from Pa to Pb.	Protactinium	90-92	proliferation and apoptosis adaptor protein 15	Homo sapiens	6-12
8449955-15	1993	Thus, PEA-15 is an endogenous substrate for PKC, the kinase mediating the transition from Pa to Pb.	Protactinium	90-92	proline rich transmembrane protein 2	Homo sapiens	44-47
8457452-8	1993	Sweat PA activity was 94% inhibited by epidermal PA inhibitor and anti-uPA IgG, but not by anti-tPA IgG.	Protactinium	6-8	plasminogen activator, urokinase	Homo sapiens	71-74
7685989-0	1993	Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.	Protactinium	99-101	plasminogen activator, urokinase	Rattus norvegicus	0-36
8435350-7	1993	Although albumin and hyaluronan concentrations did not differ from those of controls, fibronectin concentrations were significantly (p < 0.001) increased one year after exposure both in PA exposed and SA exposed rats.	Protactinium	189-191	fibronectin 1	Rattus norvegicus	86-97
8435350-10	1993	The late pronounced increase of fibronectin in both PA and SA exposed rats indicates a delayed effect of alumina on the extracellular matrix.	Protactinium	52-54	fibronectin 1	Rattus norvegicus	32-43
11885255-9	1993	The presence of PAS positive, alcianophilic and metachromatic secretory substance in the acinar lumen and the luminal content of ducts suggests that mucin secretion begins during intrauterine life.	Protactinium	16-19	LOC100508689	Homo sapiens	149-154
8433044-8	1993	In contrast, bradykinin- or ATP-induced phosphorus 32-labeled PA and [32P]-labeled PEt formation was only partially blocked (70% inhibition) by either staurosporine (10 mumol/L) or PKC down-regulation, suggesting that part of agonist-stimulated PLD activity may occur in the absence of PKC activation.	Protactinium	62-64	kininogen 1	Bos taurus	13-23
8338512-5	1993	Addition of ethanol inhibited both secretion and [3H]PA formation and led to the accumulation of [3H]phosphatidylethanol ([3H]PEt), indicating that [3H]PA was formed largely by activation of PLD.	Protactinium	152-154	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	191-194
8209783-4	1993	In all cases, secretion correlated with the activation of phospholipase D (PLD), as detected by the formation of [3H]phosphatidic acid (PA) in the absence of ethanol or of [3H]phosphatidylethanol (PEt) in the presence of ethanol.	Protactinium	136-138	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	58-73
8209783-4	1993	In all cases, secretion correlated with the activation of phospholipase D (PLD), as detected by the formation of [3H]phosphatidic acid (PA) in the absence of ethanol or of [3H]phosphatidylethanol (PEt) in the presence of ethanol.	Protactinium	136-138	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	75-78
8209783-10	1993	The results suggest that PA formed by activation of PLD may mediate secretion from permeabilized platelets by PKC-dependent and independent mechanisms.	Protactinium	25-27	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	52-55
8392354-3	1993	When these cells were first exposed to 50 microM ET-16-OCH3-GPC for 30 min prior to activation with TPA, the activity of DGK was inhibited by about 70%, as measured by the ability of enzyme to form [32P]phosphatidic acid ([32P]PA).	Protactinium	101-103	diacylglycerol kinase, beta	Mus musculus	121-124
8209783-11	1993	However, in intact platelets stimulated by thrombin, PLD accounted for only 10-20% of the total PA formed and can only play a major role in secretion if this PA fraction is distinct from that formed by the combined actions of PLC and DAG kinase.	Protactinium	96-98	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	53-56
8209783-11	1993	However, in intact platelets stimulated by thrombin, PLD accounted for only 10-20% of the total PA formed and can only play a major role in secretion if this PA fraction is distinct from that formed by the combined actions of PLC and DAG kinase.	Protactinium	158-160	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	53-56
21584599-2	1992	The two PAs, urokinase-type (u-PA) and tissue-type (t-PA), have quite different biological significance in breast cancer cells.	Protactinium	8-11	plasminogen activator, urokinase	Homo sapiens	29-33
1467649-4	1992	Previously we have demonstrated that PA and Iwt, but not Imu, can bind to the tobacco transcription activator TAF-1 in vitro, with the PA sequence showing a 70-fold higher affinity as compared to Iwt.	Protactinium	37-39	transcriptional activator TAF-1	Nicotiana tabacum	110-115
1467649-8	1992	RNA gel blot analysis showed that the expression pattern of TAF-1 mRNA is similar to that directed by PA, suggesting that TAF-1 may be involved in the transcriptional regulation of PA.	Protactinium	102-104	transcriptional activator TAF-1	Nicotiana tabacum	122-127
1334028-7	1992	The two siderophores, DFO and Pa, appeared to have a lower antiradical activity toward .OH than hydroxypyrid-4-one CP22.	Protactinium	30-32	sorcin	Homo sapiens	115-119
21584599-2	1992	The two PAs, urokinase-type (u-PA) and tissue-type (t-PA), have quite different biological significance in breast cancer cells.	Protactinium	8-11	plasminogen activator, tissue type	Homo sapiens	52-56
1279104-3	1992	Western blot analysis revealed that PA-positive anti-VZV sera reacted with the HTLV-1 gag p19 protein in HTLV-1-infected cells and recombinant p19 protein produced in Escherichia coli.	Protactinium	36-38	interleukin 23 subunit alpha	Homo sapiens	90-93
1279104-3	1992	Western blot analysis revealed that PA-positive anti-VZV sera reacted with the HTLV-1 gag p19 protein in HTLV-1-infected cells and recombinant p19 protein produced in Escherichia coli.	Protactinium	36-38	interleukin 23 subunit alpha	Homo sapiens	143-146
1510691-11	1992	Besides the injured neurons themselves, tissues which are connected or associated with these neurons may be potential targets where PAs could act to stimulate neurotrophic factor production.	Protactinium	132-135	neurotrophin 3	Homo sapiens	159-178
1360777-1	1992	The duration of the incubation period for scrapie, a fatal transmissible neurodegenerative disorder of sheep and goats, is mainly determined by the Sip gene, which has 2 alleles (sA--susceptible and pA--resistant).	Protactinium	199-201	major prion protein	Ovis aries	148-151
1360777-9	1992	Results indicated that b+ and b- are markers for the Sip sA and pA alleles, respectively.	Protactinium	64-66	major prion protein	Ovis aries	53-56
1520875-14	1992	Therefore, heparin, at therapeutic concentrations, may enhance or stabilize the association of PAs with endothelial cell-associated PAI-1.	Protactinium	95-98	serpin family E member 1	Homo sapiens	132-137
1357079-12	1992	Transcription of lytR is initiated at two start sites, one of which corresponds to a highly intense PA promoter whereas the other does not seem to share much homology with any of the known promoter consensus sequences.	Protactinium	100-102	teichoic acid-peptidoglycan tethering enzyme (LCP component) with transcription regulator domain of major autolysin expression	Bacillus subtilis subsp. subtilis str. 168	17-21
1644824-6	1992	Indeed, PA was cleaved by purified furin at the proposed consensus site (-Arg-X-Lys/Arg-Arg decreases-) at a rate (8 mumol/min/mg total protein) 400-fold higher than that observed with synthetic peptides.	Protactinium	8-10	furin, paired basic amino acid cleaving enzyme	Homo sapiens	35-40
1644824-7	1992	In addition, the processing of mutant PA molecules with altered cleavage sites suggests that furin-catalyzed endoproteolysis minimally requires an -Arg-X-X-Arg- recognition sequence for efficient cleavage.	Protactinium	38-40	furin, paired basic amino acid cleaving enzyme	Homo sapiens	93-98
1644824-8	1992	Together, these results support the hypothesis that furin processes protein precursors containing this cleavage site motif in the exocytic pathway and in addition, raises the possibility that the enzyme also cleaves extracellular substrates, including PA.	Protactinium	252-254	furin, paired basic amino acid cleaving enzyme	Homo sapiens	52-57
1597474-8	1992	We found that interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) upregulated PA activity in A549 human pulmonary epithelial cells.	Protactinium	101-103	tumor necrosis factor	Homo sapiens	49-76
1510161-4	1992	Pa at an intraluminal hydrostatic pressure of 12 cmH2O and a flow velocity of 7 mm/s was 4.01 +/- 0.53 x 10(-6) cm/s.	Protactinium	0-2	troponin T2, cardiac type	Homo sapiens	49-53
1322417-8	1992	The reduction of PAI-1 protein by PTH results in enhanced action of both tPA and uPA, and would contribute to the specific roles of these PAs in bone.	Protactinium	138-141	serpin family E member 1	Rattus norvegicus	17-22
1322417-8	1992	The reduction of PAI-1 protein by PTH results in enhanced action of both tPA and uPA, and would contribute to the specific roles of these PAs in bone.	Protactinium	138-141	plasminogen activator, tissue type	Rattus norvegicus	73-76
1643094-4	1992	These were shifted to a single band at pI 6.2 for PAS-6 and at pI 6.5 for PAS-7 by neuraminidase.	Protactinium	74-77	neuraminidase 1	Bos taurus	83-96
1330791-8	1992	In addition, antibody directed against the beta 1 integrin subunit can also specifically elicit increased PA production.	Protactinium	106-108	integrin subunit beta 1	Homo sapiens	43-58
1320642-4	1992	In this study, neutrophils activated with C5a exhibited two distinct G protein-dependent signal pathways involving different phosphoinositides: 1) [32P]PI(4,5)P2 hydrolysis and [32P]PA production, and 2) the transient formation of D-3-phosphorylated phosphoinositides, [32P]PIP3 and [32P]PI(3,4)P2.	Protactinium	182-184	complement C5a receptor 1	Homo sapiens	42-45
1320642-5	1992	When neutrophils were preincubated with C5a for 5 min before stimulation with formyl peptide, [32P]PI(4,5)P2 hydrolysis was unchanged, and [32P]PA production and O2- formation were slightly enhanced compared with controls stimulated with formyl peptide in the absence of C5a.	Protactinium	144-146	complement C5a receptor 1	Homo sapiens	40-43
1447488-11	1992	In PA cases serum SHBG levels (50 +/- 27 nM) were significantly lower (p less than 0.05) with respect to normal prepubertal patients.	Protactinium	3-5	sex hormone binding globulin	Homo sapiens	18-22
1597474-8	1992	We found that interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) upregulated PA activity in A549 human pulmonary epithelial cells.	Protactinium	101-103	interleukin 1 beta	Homo sapiens	14-32
1597474-8	1992	We found that interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) upregulated PA activity in A549 human pulmonary epithelial cells.	Protactinium	101-103	interleukin 1 beta	Homo sapiens	34-43
1597474-8	1992	We found that interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) upregulated PA activity in A549 human pulmonary epithelial cells.	Protactinium	101-103	tumor necrosis factor	Homo sapiens	78-87
1595087-4	1992	I50 values for Asc-S, Asc-P, SA and PA were 15, 45, 83 and 78 microM, respectively, for partially purified human fetal liver GSTs and 21, 6, 88 and 117 microM, respectively, for partially pure rat liver GSTs.	Protactinium	36-38	glutathione S-transferase kappa 1	Homo sapiens	125-129
1384428-4	1992	PSS and PAS, but not PVS and PAMPS, interfered with the binding of OKT4A/Leu3a to the CD4 receptor.	Protactinium	8-11	CD4 molecule	Homo sapiens	86-98
1612297-4	1992	The activity in unstimulated PMNs was 0.64 +/- 0.11 nmol of PA hydrolyzed.mg protein-1.min-1 in particulate and 4.20 +/- 0.42 in soluble fractions.	Protactinium	60-62	CD59 molecule (CD59 blood group)	Homo sapiens	87-92
1590479-9	1992	NPY significantly decreased SAP, DAP, Pa, PP, HR, respiratory rate, and minute volume in normal animals.	Protactinium	38-40	neuropeptide Y	Rattus norvegicus	0-3
1590479-10	1992	In diabetic animals, NPY also decreased SAP, DAP, and Pa but pronouncedly increased PP.	Protactinium	54-56	neuropeptide Y	Rattus norvegicus	21-24
1590479-11	1992	Although NPY decreased the SAP and Pa in diabetic animals, the response was attenuated compared with normal animals.	Protactinium	35-37	neuropeptide Y	Rattus norvegicus	9-12
1597707-11	1992	On removal of this satellite cell influence, the neurons respond to NGF treatment by increasing their ACh current densities: the median ACh current density for neurons grown for 2-3 wk with NGF was 32.5 pA/pF, whereas, the median ACh current density for neurons cultured without NGF for the same time was 4.5 pA/pF.	Protactinium	203-205	nerve growth factor	Rattus norvegicus	68-71
1597707-11	1992	On removal of this satellite cell influence, the neurons respond to NGF treatment by increasing their ACh current densities: the median ACh current density for neurons grown for 2-3 wk with NGF was 32.5 pA/pF, whereas, the median ACh current density for neurons cultured without NGF for the same time was 4.5 pA/pF.	Protactinium	203-205	nerve growth factor	Rattus norvegicus	190-193
1597707-11	1992	On removal of this satellite cell influence, the neurons respond to NGF treatment by increasing their ACh current densities: the median ACh current density for neurons grown for 2-3 wk with NGF was 32.5 pA/pF, whereas, the median ACh current density for neurons cultured without NGF for the same time was 4.5 pA/pF.	Protactinium	203-205	nerve growth factor	Rattus norvegicus	190-193
1595087-1	1992	Glutathione-S-transferase (GST) activity from human term placenta and human fetal liver towards 1-chloro-2,4-dinitrobenzene as the second substrate was significantly inhibited by the saturated fatty acids, stearic (SA) and palmitic (PA) acids and fatty acid esters, ascorbyl stearate (Asc-S) and ascorbyl palmitate (Asc-P).	Protactinium	233-235	glutathione S-transferase kappa 1	Homo sapiens	0-25
1595087-1	1992	Glutathione-S-transferase (GST) activity from human term placenta and human fetal liver towards 1-chloro-2,4-dinitrobenzene as the second substrate was significantly inhibited by the saturated fatty acids, stearic (SA) and palmitic (PA) acids and fatty acid esters, ascorbyl stearate (Asc-S) and ascorbyl palmitate (Asc-P).	Protactinium	233-235	glutathione S-transferase kappa 1	Homo sapiens	27-30
1595087-2	1992	The nature of inhibition of human placental GST was competitive towards CDNB with Ki values of 3.1, 10.0, 13.5 and 18.5 microM for Asc-S, Asc-P, PA and SA, respectively.	Protactinium	145-147	glutathione S-transferase kappa 1	Homo sapiens	44-47
1595087-4	1992	I50 values for Asc-S, Asc-P, SA and PA were 15, 45, 83 and 78 microM, respectively, for partially purified human fetal liver GSTs and 21, 6, 88 and 117 microM, respectively, for partially pure rat liver GSTs.	Protactinium	36-38	glutathione S-transferase kappa 1	Homo sapiens	203-207
1595087-5	1992	The evidence suggests that Asc-S, Asc-P, SA and PA are potent inhibitors especially of the pi-class of GST.	Protactinium	48-50	glutathione S-transferase kappa 1	Homo sapiens	103-106
1310905-2	1992	In human erythrocyte membranes, membrane binding of spin-labeled TPA-analogous phorbol (doxyl)esters [(n,m)PA] was investigated during measurement of the kinetics of the decay of their electron paramagnetic resonance signal by ascorbate reduction.	Protactinium	66-68	spindlin 1	Homo sapiens	52-56
1594678-5	1992	Ibotenate lesions of rACE did produce a deficit in PA, consistent with views of a role of this part of the amygdala in fear.	Protactinium	51-53	angiotensin I converting enzyme	Rattus norvegicus	21-25
1546850-4	1992	Six weeks later, we found by review of PAS-hematoxylin-stained 1-micron sections of plastic-embedded lung tissue that large intrapulmonary airways of animals given cathepsin B contained a significantly greater number of secretory cells per millimeter of airway (64.8 +/- 7.3 versus 47.5 +/- 10.3 for control animals, p less than 0.005) in association with a significant increase in the number of total cells per millimeter of airway, from 149 +/- 14 for control animals to 164 +/- 11 for cathepsin-B-treated animals (p less than 0.025).	Protactinium	39-42	cathepsin B	Bos taurus	164-175
1738371-3	1992	The cyclic nucleotide analog 8-bromo-cAMP (cA) causes a greater than 50-fold increase in PA activity, the result of a 90% decrease in PAI-1 and a sustained 2-fold increase in tPA mRNA accumulation.	Protactinium	89-91	serpin family E member 1	Rattus norvegicus	134-139
1734031-4	1992	Incubation of wounded monolayers with either purified bovine uPA or agents able to induce PA activity, such as phorbol myristate acetate (PMA), vanadate, or bFGF, resulted in enhanced migration of cells (28-50%).	Protactinium	62-64	fibroblast growth factor 2	Bos taurus	157-161
1597662-6	1992	The potentiation of LAK cell induction associated with its cytotoxic and lytic potential by low doses of IL-2/PA regiment may be helpful in the development of LAK immunotherapy of the cancer patients.	Protactinium	110-112	alpha kinase 1	Homo sapiens	20-23
1597662-6	1992	The potentiation of LAK cell induction associated with its cytotoxic and lytic potential by low doses of IL-2/PA regiment may be helpful in the development of LAK immunotherapy of the cancer patients.	Protactinium	110-112	alpha kinase 1	Homo sapiens	159-162
1323998-8	1992	D-Phe6,BN(6-13)PA similarly inhibited the specific binding of 125I-GRP, cross-linked to a approximately 80 kilodalton binding protein on the MC-26 tumor membranes.	Protactinium	14-17	gastrin releasing peptide	Mus musculus	67-70
1738371-3	1992	The cyclic nucleotide analog 8-bromo-cAMP (cA) causes a greater than 50-fold increase in PA activity, the result of a 90% decrease in PAI-1 and a sustained 2-fold increase in tPA mRNA accumulation.	Protactinium	89-91	plasminogen activator, tissue type	Rattus norvegicus	175-178
1738371-4	1992	Dexamethasone and cA in combination cause a 150-fold increase in PA activity, the result of an 80% decrease in PAI-1 and a synergistic 15-fold increase in tPA mRNA.	Protactinium	65-67	serpin family E member 1	Rattus norvegicus	111-116
1738371-4	1992	Dexamethasone and cA in combination cause a 150-fold increase in PA activity, the result of an 80% decrease in PAI-1 and a synergistic 15-fold increase in tPA mRNA.	Protactinium	65-67	plasminogen activator, tissue type	Rattus norvegicus	155-158
1939533-2	1991	PA, expressed as a function of PRA, the PA/PRA ratio, provides an index of adrenal sensitivity in normal subjects under routine conditions.	Protactinium	0-2	S100 calcium binding protein A6	Homo sapiens	31-34
1770131-8	1991	The majority, 95% (P less than 0.001) of PA couples and 83% of SA couples, had at least one C4A or C4B null in their phenotypes compared to 66% among Finnish controls.	Protactinium	41-43	complement C4B (Chido blood group)	Homo sapiens	99-102
1809396-6	1991	ET-1 action was dose-dependent with a half-maximal effect at 1.0 x 10(-9) M. With increasing ethanol concentrations, [3H]PEt formation increased at the expense of [3H]phosphatidic acid (PA).	Protactinium	186-188	endothelin 1	Rattus norvegicus	0-4
1809396-11	1991	The effect of ET-1 on thymidine incorporation into DNA in the overexpressing cells was also dose-dependent with a half-maximal effect at 0.3 x 10(-9) M. Enhanced PLD activity induced by ET-1 in the overexpressing cells may contribute to the mitogenic response, especially in light of a possible role of the PLD product, PA, in regulation of cell growth.	Protactinium	320-322	endothelin 1	Rattus norvegicus	14-18
1809396-11	1991	The effect of ET-1 on thymidine incorporation into DNA in the overexpressing cells was also dose-dependent with a half-maximal effect at 0.3 x 10(-9) M. Enhanced PLD activity induced by ET-1 in the overexpressing cells may contribute to the mitogenic response, especially in light of a possible role of the PLD product, PA, in regulation of cell growth.	Protactinium	320-322	endothelin 1	Rattus norvegicus	186-190
1939533-2	1991	PA, expressed as a function of PRA, the PA/PRA ratio, provides an index of adrenal sensitivity in normal subjects under routine conditions.	Protactinium	0-2	S100 calcium binding protein A6	Homo sapiens	43-46
1939533-4	1991	A single elevated PA/PRA ratio, i.e. more than 920, associated with elevated PA in 4 patients or normal PA in 6 patients indicated primary hyperaldosteronism in 10 patients.	Protactinium	77-79	S100 calcium binding protein A6	Homo sapiens	21-24
1939533-7	1991	A single PA/PRA ratio of less than 28 associated with low PA in 18 patients and a normal PA in 1 patient indicated primary adrenal insufficiency, while a low PA associated with a normal PA/PRA ratio indicated hyporeninemic hypoaldosteronism in 7 patients.	Protactinium	58-60	S100 calcium binding protein A6	Homo sapiens	12-15
1939533-7	1991	A single PA/PRA ratio of less than 28 associated with low PA in 18 patients and a normal PA in 1 patient indicated primary adrenal insufficiency, while a low PA associated with a normal PA/PRA ratio indicated hyporeninemic hypoaldosteronism in 7 patients.	Protactinium	58-60	S100 calcium binding protein A6	Homo sapiens	12-15
1911713-12	1991	Clot-bound PAI-1 may inhibit PAs in the immediate vicinity of the clots, whereas circulating PAI-1 may act systemically by controlling overall levels of PAs present in the blood.	Protactinium	29-32	serpin family E member 1	Rattus norvegicus	11-16
1802340-12	1991	produces a deficit in performance of a PA response in rats and that this effect can be attenuated by an ACE inhibitor, AII-1 receptor ligands, but not AII-2 receptor blocker.	Protactinium	39-41	angiotensin I converting enzyme	Rattus norvegicus	104-107
1839605-3	1991	Both unstimulated and IFN-gamma-exposed metabolically labeled R8RP.3 cells synthesized more Pa than RT1.Aa antigen.	Protactinium	92-94	interferon gamma	Rattus norvegicus	22-31
1915841-3	1991	(1) Porcine urine PA exhibits an Mr of 65,000 similar to the Mr of human t-PA (64-70,000) but distinct from the Mr of human u-PA (55,000).	Protactinium	18-20	plasminogen activator, tissue type	Homo sapiens	73-77
1915841-4	1991	(2) Antibodies against human t-PA bind and inhibit crude and purified porcine urine PA, while human u-PA-specific antibodies do not react with porcine urine PA.	Protactinium	84-86	plasminogen activator, tissue type	Homo sapiens	29-33
1911713-12	1991	Clot-bound PAI-1 may inhibit PAs in the immediate vicinity of the clots, whereas circulating PAI-1 may act systemically by controlling overall levels of PAs present in the blood.	Protactinium	153-156	serpin family E member 1	Rattus norvegicus	93-98
1662315-8	1991	Zymographic analysis of secreted PA related compounds revealed production of free urokinase (u-PA) and type 1 plasminogen activator inhibitor (PAI-1) complexed to tissular plasminogen activator (t-PA).	Protactinium	33-35	plasminogen activator, urokinase	Homo sapiens	93-97
1662315-8	1991	Zymographic analysis of secreted PA related compounds revealed production of free urokinase (u-PA) and type 1 plasminogen activator inhibitor (PAI-1) complexed to tissular plasminogen activator (t-PA).	Protactinium	33-35	serpin family E member 1	Homo sapiens	143-148
1929608-9	1991	In PA cultures, IL-2 synthesis was impaired as well but not as precipitously as in PC.	Protactinium	3-5	interleukin 2	Homo sapiens	16-20
1932892-5	1991	Prostaglandin E2, Interleukin-1 beta, Tumor Necrosis Factor alpha and 1,25-dihydroxyvitamin D3 increased in general the production of both PA"s by all three cell types.	Protactinium	139-141	interleukin 1 beta	Rattus norvegicus	18-36
1932892-8	1991	In all three types of cells, under control as well as under stimulated conditions, a high molecular weight form of PA was demonstrated by the gel overlay technique, most likely a complex of tPA with the PA-inhibitor PAI-1.	Protactinium	115-117	serpin family E member 1	Rattus norvegicus	216-221
1932892-9	1991	The uniform increase in production of PA"s by osteoblast-like cells in response to bone resorbing factors and its decrease by TGF beta supports the notion that PA"s are involved in bone resorption.	Protactinium	160-162	transforming growth factor, beta 1	Rattus norvegicus	126-134
1894692-1	1991	Saccharomyces cerevisiae pas3-mutants are described which conform the pas-phenotype recently reported for the peroxisomal assembly mutants pas1-1 and pas2 (Erdmann, R., M. Veenhuis, D. Mertens, and W.-H Kunau, 1989, Proc.	Protactinium	25-28	AAA family ATPase peroxin 1	Saccharomyces cerevisiae S288C	139-143
1894692-1	1991	Saccharomyces cerevisiae pas3-mutants are described which conform the pas-phenotype recently reported for the peroxisomal assembly mutants pas1-1 and pas2 (Erdmann, R., M. Veenhuis, D. Mertens, and W.-H Kunau, 1989, Proc.	Protactinium	25-28	E2 ubiquitin-protein ligase peroxin 4	Saccharomyces cerevisiae S288C	150-154
1796298-6	1991	In both the stomach and colorectal carcinomas, the highest value of u-PA/total PA (sum of u-PA and t-PA) was observed in the central part of the carcinoma, followed by the marginal part of the carcinoma, and was lowest in the normal mucosa.	Protactinium	70-72	plasminogen activator, urokinase	Homo sapiens	90-94
1796298-6	1991	In both the stomach and colorectal carcinomas, the highest value of u-PA/total PA (sum of u-PA and t-PA) was observed in the central part of the carcinoma, followed by the marginal part of the carcinoma, and was lowest in the normal mucosa.	Protactinium	70-72	plasminogen activator, tissue type	Homo sapiens	99-103
1851181-6	1991	In the diabetic subjects, however, the responses of plasma 18-OHB and PA to both ACTH injection and graded AII infusions on a 100-mmol, but not on a 170-mmol, sodium intake were subnormal (P less than 0.05 or P less than 0.01) and were similar to those on a 170-mmol sodium intake.	Protactinium	70-72	proopiomelanocortin	Homo sapiens	81-85
1904404-6	1991	In both the stomach and colorectal carcinomas, the highest value of u-PA/total PA (sum of u-PA and t-PA) was observed in the central part of the carcinoma, followed by the marginal part of the carcinoma, and was lowest in the normal mucosa.	Protactinium	70-72	plasminogen activator, urokinase	Homo sapiens	90-94
1904404-6	1991	In both the stomach and colorectal carcinomas, the highest value of u-PA/total PA (sum of u-PA and t-PA) was observed in the central part of the carcinoma, followed by the marginal part of the carcinoma, and was lowest in the normal mucosa.	Protactinium	70-72	plasminogen activator, tissue type	Homo sapiens	99-103
1851181-5	1991	ACTH injection produced significant increases in plasma cortisol, plasma corticosterone, plasma 18-OHB, and PA (P less than 0.005 or P less than 0.001), and graded AII infusions produced significant increases in plasma 18-OHB and PA (P less than 0.05 or P less than 0.01) during both 170- and 100-mmol sodium intakes in the two groups.	Protactinium	108-110	proopiomelanocortin	Homo sapiens	0-4
1851181-6	1991	In the diabetic subjects, however, the responses of plasma 18-OHB and PA to both ACTH injection and graded AII infusions on a 100-mmol, but not on a 170-mmol, sodium intake were subnormal (P less than 0.05 or P less than 0.01) and were similar to those on a 170-mmol sodium intake.	Protactinium	70-72	angiotensinogen	Homo sapiens	107-110
1902065-3	1991	We now report that these cells also secrete heat-stable PA inhibitory activity having the characteristics of PA inhibitor type 1 (PAI-1).	Protactinium	56-58	serpin family E member 1	Rattus norvegicus	109-128
1902201-4	1991	Assessment of the relationship between PA activity and biological behavior of gastric cancer revealed total-PA and u-PA levels to be significantly higher in differentiated than in undifferentiated tumors (p less than 0.001), and in aneuploid than in diploid ones (p less than 0.01).	Protactinium	39-41	plasminogen activator, urokinase	Homo sapiens	115-119
1902194-1	1991	Lipopolysaccharide (LPS) treatment of mice 1 to 5 days prior to administration of Pseudomonas aeruginosa exotoxin A (PA) induced full or partial protection against PA intoxication.	Protactinium	117-119	toll-like receptor 4	Mus musculus	20-23
1902194-3	1991	Simultaneous administration of LPS and PA to mice, however, increased their sensitivity to PA two- to fourfold.	Protactinium	91-93	toll-like receptor 4	Mus musculus	31-34
1902194-4	1991	Mice pretreated with LPS demonstrated a markedly enhanced clearance rate of 125I-labeled PA from peripheral blood, livers, and kidneys.	Protactinium	89-91	toll-like receptor 4	Mus musculus	21-24
1902194-5	1991	In mice exposed to LPS and PA simultaneously, the rate of elimination of labeled PA was lower than that in control mice.	Protactinium	81-83	toll-like receptor 4	Mus musculus	19-22
1902194-6	1991	While protein synthesis was inhibited significantly in livers and other organs of PA-exposed mice, in LPS-pretreated mice, PA-induced inhibition of protein synthesis was either diminished or totally prevented and elongation factor 2 (EF2) levels were normal.	Protactinium	82-84	eukaryotic translation elongation factor 2	Mus musculus	213-232
1902194-6	1991	While protein synthesis was inhibited significantly in livers and other organs of PA-exposed mice, in LPS-pretreated mice, PA-induced inhibition of protein synthesis was either diminished or totally prevented and elongation factor 2 (EF2) levels were normal.	Protactinium	82-84	eukaryotic translation elongation factor 2	Mus musculus	234-237
1902194-6	1991	While protein synthesis was inhibited significantly in livers and other organs of PA-exposed mice, in LPS-pretreated mice, PA-induced inhibition of protein synthesis was either diminished or totally prevented and elongation factor 2 (EF2) levels were normal.	Protactinium	123-125	toll-like receptor 4	Mus musculus	102-105
1902194-6	1991	While protein synthesis was inhibited significantly in livers and other organs of PA-exposed mice, in LPS-pretreated mice, PA-induced inhibition of protein synthesis was either diminished or totally prevented and elongation factor 2 (EF2) levels were normal.	Protactinium	123-125	eukaryotic translation elongation factor 2	Mus musculus	213-232
1902194-6	1991	While protein synthesis was inhibited significantly in livers and other organs of PA-exposed mice, in LPS-pretreated mice, PA-induced inhibition of protein synthesis was either diminished or totally prevented and elongation factor 2 (EF2) levels were normal.	Protactinium	123-125	eukaryotic translation elongation factor 2	Mus musculus	234-237
1902194-7	1991	In mice treated only with LPS, enhanced protein synthesis and increased levels of EF2 were observed, suggesting that LPS protection against PA intoxication was perhaps a consequence of excessive amounts of EF2 induced by LPS.	Protactinium	140-142	toll-like receptor 4	Mus musculus	26-29
1902194-7	1991	In mice treated only with LPS, enhanced protein synthesis and increased levels of EF2 were observed, suggesting that LPS protection against PA intoxication was perhaps a consequence of excessive amounts of EF2 induced by LPS.	Protactinium	140-142	toll-like receptor 4	Mus musculus	117-120
1902194-7	1991	In mice treated only with LPS, enhanced protein synthesis and increased levels of EF2 were observed, suggesting that LPS protection against PA intoxication was perhaps a consequence of excessive amounts of EF2 induced by LPS.	Protactinium	140-142	eukaryotic translation elongation factor 2	Mus musculus	206-209
1902194-7	1991	In mice treated only with LPS, enhanced protein synthesis and increased levels of EF2 were observed, suggesting that LPS protection against PA intoxication was perhaps a consequence of excessive amounts of EF2 induced by LPS.	Protactinium	140-142	toll-like receptor 4	Mus musculus	117-120
1708207-6	1991	The bombesin (BN) analogue D-Phe6-BN-(6-13)propylamide (PA) stimulated contractions (ED50, 3.3 nM) with low efficacy (29% of that of GRP).	Protactinium	56-58	gastrin releasing peptide	Homo sapiens	4-12
1902065-3	1991	We now report that these cells also secrete heat-stable PA inhibitory activity having the characteristics of PA inhibitor type 1 (PAI-1).	Protactinium	56-58	serpin family E member 1	Rattus norvegicus	130-135
1902065-5	1991	As alveolar epithelial cells differentiated in vitro, secreted PA inhibitor activity increased significantly from 104 +/- PAI U/ml (n = 5, mean +/- SE) on day 2 to 442 +/- 150 on day 7 in parallel with increases in secreted and matrix-associated immunoreactive PAI-1.	Protactinium	63-65	serpin family E member 1	Rattus norvegicus	122-125
1902065-5	1991	As alveolar epithelial cells differentiated in vitro, secreted PA inhibitor activity increased significantly from 104 +/- PAI U/ml (n = 5, mean +/- SE) on day 2 to 442 +/- 150 on day 7 in parallel with increases in secreted and matrix-associated immunoreactive PAI-1.	Protactinium	63-65	serpin family E member 1	Rattus norvegicus	261-266
2171912-2	1990	Basic fibroblast growth factor (bFGF), an angiogenic factor found in many organs including the ovary, modulates steroidogenesis in granulosa cells and increases PA activity in endothelial cells.	Protactinium	161-163	fibroblast growth factor 2	Homo sapiens	0-30
1850243-4	1991	The effect of propranolol on enhancement of PA levels in neutrophils treated with FMLP alone strongly correlated with enhancement of FMLP-induced O2- generation.	Protactinium	44-46	formyl peptide receptor 1	Homo sapiens	133-137
1900139-2	1991	A prospective, serial, 2-dimensional echocardiographic study of patients with myocardial infarction who received recombinant tissue-type plasminogen activator (rt-PA) was undertaken to address this issue.	Protactinium	163-165	plasminogen activator, tissue type	Homo sapiens	125-158
1826912-11	1991	These findings suggest that the increased plasma ANP levels could contribute to the antihypertensive effects of the beta-adrenoreceptor blockers, by a reduction in PRA and PA levels and a vasodilatative effect.	Protactinium	172-174	natriuretic peptide A	Homo sapiens	49-52
1848829-6	1991	PAS staining showed intracellular mucin granules.	Protactinium	0-3	LOC100508689	Homo sapiens	34-39
1801752-3	1991	Zymographic analysis by using fibrin agar indicator gels indicated that part of the PA activity in culture supernatants of the HaCaT line is complexed with putative PA inhibitors (PAI).	Protactinium	84-86	serpin family E member 1	Homo sapiens	165-178
1801752-3	1991	Zymographic analysis by using fibrin agar indicator gels indicated that part of the PA activity in culture supernatants of the HaCaT line is complexed with putative PA inhibitors (PAI).	Protactinium	84-86	serpin family E member 1	Homo sapiens	180-183
1850243-4	1991	The effect of propranolol on enhancement of PA levels in neutrophils treated with FMLP alone strongly correlated with enhancement of FMLP-induced O2- generation.	Protactinium	44-46	formyl peptide receptor 1	Homo sapiens	82-86
1866473-6	1991	In MTC patients (n = 57) with raised levels of PAS-57 and CT, the molar ratio between PAS-57 and CT was 1.7-times higher than in normal subjects (P less than 0.01).	Protactinium	47-50	calcitonin related polypeptide alpha	Homo sapiens	97-99
1866473-6	1991	In MTC patients (n = 57) with raised levels of PAS-57 and CT, the molar ratio between PAS-57 and CT was 1.7-times higher than in normal subjects (P less than 0.01).	Protactinium	86-89	calcitonin related polypeptide alpha	Homo sapiens	58-60
1840232-10	1991	Analysis of the relationship between PA, plasma K+, PRA, and plasma hANF indicated that PRA is the primary determinant of PA in patients with CHF.	Protactinium	122-124	HESX homeobox 1	Homo sapiens	68-72
1719364-6	1991	Our data suggest that in diabetic patients there is an impairment in secretory capacity of the pancreas and that the the PA is the more sensitive enzyme to the local levels of insulin.	Protactinium	121-123	insulin	Homo sapiens	176-183
2124935-1	1990	The vampire bat salivary plasminogen activator (Bat-PA) is a potent PA that exhibits remarkable selectivity toward fibrin-bound plasminogen (Gardell et al, J Biol Chem 256: 3568, 1989).	Protactinium	52-54	bile acid CoA:amino acid N-acyltransferase	Rattus norvegicus	48-51
2124935-5	1990	The lytic activities exhibited by finger-domain minus Bat-PA (F- rBat-PA) and finger and epidermal growth factor-like domains minus Bat-PA (FG- rBat-PA) were less than rBat-PA, especially at low concentrations of PA; nevertheless, these truncated forms also possessed a strict requirement for a fibrin cofactor.	Protactinium	58-60	bile acid CoA:amino acid N-acyltransferase	Rattus norvegicus	54-57
2124935-6	1990	The loss of PA activity following the addition of rBat-PA to plasma was slower than that observed when either rt-PA or two-chain rt-PA was added.	Protactinium	12-14	bile acid CoA:amino acid N-acyltransferase	Rattus norvegicus	50-54
2128968-3	1990	The activity of this, so-called, contact-system dependent PA accounts for 30% of the PA activity in the dextran sulphate euglobulin fraction of plasma and was shown not to be an intrinsic property of one of the contact-system components, nor could it be inhibited by inhibitory antibodies against t-PA or u-PA.	Protactinium	58-60	plasminogen activator, tissue type	Homo sapiens	297-301
2128968-3	1990	The activity of this, so-called, contact-system dependent PA accounts for 30% of the PA activity in the dextran sulphate euglobulin fraction of plasma and was shown not to be an intrinsic property of one of the contact-system components, nor could it be inhibited by inhibitory antibodies against t-PA or u-PA.	Protactinium	58-60	plasminogen activator, urokinase	Homo sapiens	305-309
2128968-3	1990	The activity of this, so-called, contact-system dependent PA accounts for 30% of the PA activity in the dextran sulphate euglobulin fraction of plasma and was shown not to be an intrinsic property of one of the contact-system components, nor could it be inhibited by inhibitory antibodies against t-PA or u-PA.	Protactinium	85-87	plasminogen activator, tissue type	Homo sapiens	297-301
2128968-3	1990	The activity of this, so-called, contact-system dependent PA accounts for 30% of the PA activity in the dextran sulphate euglobulin fraction of plasma and was shown not to be an intrinsic property of one of the contact-system components, nor could it be inhibited by inhibitory antibodies against t-PA or u-PA.	Protactinium	85-87	plasminogen activator, urokinase	Homo sapiens	305-309
2171912-2	1990	Basic fibroblast growth factor (bFGF), an angiogenic factor found in many organs including the ovary, modulates steroidogenesis in granulosa cells and increases PA activity in endothelial cells.	Protactinium	161-163	fibroblast growth factor 2	Homo sapiens	32-36
1702231-2	1990	In the antral mucosa the intracellular PAS-AB-stained mucin content was significantly smaller in patients with infection than in patients without infection, whereas in the oxyntic gland mucosa the intracellular mucin content showed no significant change between patients with and without infection.	Protactinium	39-42	LOC100508689	Homo sapiens	54-59
1967002-4	1990	When the platelets pretreated with neuraminidase were incubated with human serum, %PA-IgG was remarkably decreased in ITP patients.	Protactinium	83-85	neuraminidase 1	Homo sapiens	35-48
2170380-6	1990	In cells prelabeled with [3H]myristic acid, which is predominantly incorporated into cellular PC, VP elicited the generation of [3H]myristoyl phosphatidate (PA) as early as 15 s, in the absence of an increase in labeled DG.	Protactinium	157-159	arginine vasopressin	Rattus norvegicus	98-100
2170380-13	1990	These data demonstrate that VP elicits the coordinated hydrolysis of PIP2 by phospholipase C and PC hydrolysis by phospholipase D. This event results in the prolonged generation of PA and biphasic formation of DG.	Protactinium	181-183	arginine vasopressin	Rattus norvegicus	28-30
2170365-2	1990	The PRI A protein (factor Y, protein n") is a PAS sequence-specific (d)ATPase as well as a DNA helicase and is believed to direct the assembly of the primosome at a PAS.	Protactinium	46-49	DNA primase	Escherichia coli	4-7
2170365-2	1990	The PRI A protein (factor Y, protein n") is a PAS sequence-specific (d)ATPase as well as a DNA helicase and is believed to direct the assembly of the primosome at a PAS.	Protactinium	165-168	DNA primase	Escherichia coli	4-7
2170365-4	1990	First, the PRI A protein gains entry to the DNA via an ATP-independent, PAS sequence-specific binding event.	Protactinium	72-75	DNA primase	Escherichia coli	11-14
2213017-2	1990	These cells also produce and secrete the endothelial cell-type PA inhibitor (PAI-1), which forms sodium dodecyl sulfate-stable tPA/PAI-1 complexes in the culture medium.	Protactinium	63-65	serpin family E member 1	Homo sapiens	77-82
2213017-2	1990	These cells also produce and secrete the endothelial cell-type PA inhibitor (PAI-1), which forms sodium dodecyl sulfate-stable tPA/PAI-1 complexes in the culture medium.	Protactinium	63-65	serpin family E member 1	Homo sapiens	131-136
2151017-0	1990	Specificity of acidic phospholipids (CL & PA) in the activation of mitochondrial F0F1 ATPase by Mg2+.	Protactinium	46-48	ATP synthase F1 subunit epsilon	Homo sapiens	85-96
2143025-0	1990	Mutation in NS2, a nonstructural protein of influenza A virus, extragenically causes aberrant replication and expression of the PA gene and leads to generation of defective interfering particles.	Protactinium	128-130	NS2	Homo sapiens	12-15
2378936-6	1990	PAS were secreted during outgrowth on fibronectin-coated plastic in serum-free medium, but not by blastocysts held in a non-attachment state during culture in serum-free medium on uncoated plastic.	Protactinium	0-3	fibronectin 1	Mus musculus	38-49
2143025-5	1990	Analysis of nucleotide sequence demonstrated that the NS gene of Wa-182 contained three point mutations relative to the wild-type NS gene that resulted in two amino acid substitutions in the nonstructural protein NS2, suggesting that the mutation in NS2 protein affected the normal replication of the PA gene of Wa-182.	Protactinium	301-303	NS2	Homo sapiens	250-253
2107884-14	1990	Whereas TNF and bacterial lipopolysaccharide (LPS) have similar effects on the production of PA inhibitor by human endothelial cells, LPS has no or only a relatively small effect on the fibrinolytic properties of mesothelial cells.	Protactinium	93-95	tumor necrosis factor	Homo sapiens	8-11
2252707-5	1990	Percent changes in diastolic augmentation pressure (% DAP) in the main PA was measured.	Protactinium	71-73	death-associated protein 1	Canis lupus familiaris	54-57
2363126-6	1990	The PAI appears to bind to the carboxy-terminal chain of both PAs, because the part of the band corresponding to the carboxy-terminal chain of PAs moved to an upper position as a result of complex formation when two-chain form of PAs were incubated with the PAI and analyzed by SDS-PAGE followed by immunoblotting.	Protactinium	62-65	serpin family E member 1	Homo sapiens	4-7
2363126-6	1990	The PAI appears to bind to the carboxy-terminal chain of both PAs, because the part of the band corresponding to the carboxy-terminal chain of PAs moved to an upper position as a result of complex formation when two-chain form of PAs were incubated with the PAI and analyzed by SDS-PAGE followed by immunoblotting.	Protactinium	62-65	serpin family E member 1	Homo sapiens	258-261
2363126-6	1990	The PAI appears to bind to the carboxy-terminal chain of both PAs, because the part of the band corresponding to the carboxy-terminal chain of PAs moved to an upper position as a result of complex formation when two-chain form of PAs were incubated with the PAI and analyzed by SDS-PAGE followed by immunoblotting.	Protactinium	143-146	serpin family E member 1	Homo sapiens	4-7
2363126-6	1990	The PAI appears to bind to the carboxy-terminal chain of both PAs, because the part of the band corresponding to the carboxy-terminal chain of PAs moved to an upper position as a result of complex formation when two-chain form of PAs were incubated with the PAI and analyzed by SDS-PAGE followed by immunoblotting.	Protactinium	143-146	serpin family E member 1	Homo sapiens	258-261
2363126-6	1990	The PAI appears to bind to the carboxy-terminal chain of both PAs, because the part of the band corresponding to the carboxy-terminal chain of PAs moved to an upper position as a result of complex formation when two-chain form of PAs were incubated with the PAI and analyzed by SDS-PAGE followed by immunoblotting.	Protactinium	143-146	serpin family E member 1	Homo sapiens	4-7
2363126-6	1990	The PAI appears to bind to the carboxy-terminal chain of both PAs, because the part of the band corresponding to the carboxy-terminal chain of PAs moved to an upper position as a result of complex formation when two-chain form of PAs were incubated with the PAI and analyzed by SDS-PAGE followed by immunoblotting.	Protactinium	143-146	serpin family E member 1	Homo sapiens	258-261
2113968-2	1990	Species of PAs and PAI secreted from the GECs were urokinase-type PA (u-PA) and tissue-type PA (t-PA), while the major species was a single chain u-PA in the amount of 28.6 +/- 2.34 ng/10(5) cells for 24 hours (N = 4, mean +/- SD), and PAI-1.	Protactinium	11-14	plasminogen activator, urokinase	Homo sapiens	51-74
2113968-2	1990	Species of PAs and PAI secreted from the GECs were urokinase-type PA (u-PA) and tissue-type PA (t-PA), while the major species was a single chain u-PA in the amount of 28.6 +/- 2.34 ng/10(5) cells for 24 hours (N = 4, mean +/- SD), and PAI-1.	Protactinium	11-14	plasminogen activator, tissue type	Homo sapiens	80-94
2113968-2	1990	Species of PAs and PAI secreted from the GECs were urokinase-type PA (u-PA) and tissue-type PA (t-PA), while the major species was a single chain u-PA in the amount of 28.6 +/- 2.34 ng/10(5) cells for 24 hours (N = 4, mean +/- SD), and PAI-1.	Protactinium	11-14	plasminogen activator, tissue type	Homo sapiens	96-100
2113968-2	1990	Species of PAs and PAI secreted from the GECs were urokinase-type PA (u-PA) and tissue-type PA (t-PA), while the major species was a single chain u-PA in the amount of 28.6 +/- 2.34 ng/10(5) cells for 24 hours (N = 4, mean +/- SD), and PAI-1.	Protactinium	11-14	plasminogen activator, urokinase	Homo sapiens	70-74
2113968-2	1990	Species of PAs and PAI secreted from the GECs were urokinase-type PA (u-PA) and tissue-type PA (t-PA), while the major species was a single chain u-PA in the amount of 28.6 +/- 2.34 ng/10(5) cells for 24 hours (N = 4, mean +/- SD), and PAI-1.	Protactinium	11-14	serpin family E member 1	Homo sapiens	236-241
2113968-5	1990	All thrombin effects, however, were suppressed by the simultaneous addition of cycloheximide, indicating that the enhancing effects of thrombin were due to an increase in the production of PAs and PAI-1, via protein synthesis.	Protactinium	189-192	coagulation factor II, thrombin	Homo sapiens	4-12
2113968-5	1990	All thrombin effects, however, were suppressed by the simultaneous addition of cycloheximide, indicating that the enhancing effects of thrombin were due to an increase in the production of PAs and PAI-1, via protein synthesis.	Protactinium	189-192	coagulation factor II, thrombin	Homo sapiens	135-143
2347174-2	1990	Patch testing revealed contact allergy to the paint Pa Tra Lasur, and to chlorothalonil.	Protactinium	0-2	T cell receptor alpha locus	Homo sapiens	55-58
2329253-4	1990	Ten patients had urine collections that permitted computation of the ratio between the renal clearance of procainamide and CrCl (PA/CrCl) and the renal clearance of n-acetyl-procainamide (NAPA) and CrCl (NAPA/CrCl).	Protactinium	129-131	CRCL	Homo sapiens	123-127
2105879-2	1990	She was given 70 mg recombinant tissue plasminogen activator (rt-PA) by continuous intravenous drip over two hours.	Protactinium	65-67	chromosome 20 open reading frame 181	Homo sapiens	32-60
2130511-18	1990	Activation of phospholipase D (PLD) was demonstrated by the finding that phosphatidic acid increased in response to PMA or carbachol prior to the increase in PA.	Protactinium	158-160	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	14-29
2105930-8	1990	Thus, both wild-type rt-PA and S478A rt-PA interact with the HUVEC monolayer through PAI-1.	Protactinium	24-26	serpin family E member 1	Homo sapiens	85-90
2297544-2	1990	No stimulation of plasminogen activator activity was seen in response to either preparation of interleukin 1, and in more than half of the cell cultures interleukin 1 caused a significant decrease in the secreted levels of PA activity.	Protactinium	223-225	interleukin 1 alpha	Homo sapiens	153-166
1697059-7	1990	Sputum PA density declined from 3.0 to 1.2 x 10(8) cfu/mL 1 week post-infusion (P approximately equal to 0.05), and returned to baseline at follow-up.	Protactinium	7-9	L1 cell adhesion molecule	Mus musculus	55-59
2130511-18	1990	Activation of phospholipase D (PLD) was demonstrated by the finding that phosphatidic acid increased in response to PMA or carbachol prior to the increase in PA.	Protactinium	158-160	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	31-34
1973000-3	1990	The proteinaceous PAS-positive casts in the loops of Henle and the collecting ducts stained for Alk Phos and GGT (from 12 hr) and for ATPase (from 18 hr).	Protactinium	18-21	ALK receptor tyrosine kinase	Rattus norvegicus	96-99
33813027-10	2021	In addition, PA compounds downregulated the expression of VCAM-1, VE-cadherin, VEGFa, VEGFR2, TGF-beta, and IL-1beta, in inflamed ECs.	Protactinium	13-15	vascular cell adhesion molecule 1	Homo sapiens	58-64
2132531-2	1990	One of these mechanisms involves a pertussis toxin-sensitive Gi alpha, which probably serves to couple the insulin receptor to a PI-glycan phospholipase C, which, in turn, leads to the release of HGM and consequent activation of de novo PA synthesis.	Protactinium	237-239	insulin	Homo sapiens	107-114
3113299-3	1987	Two PA Inhibitors have been described: PA Inhibitor 1 from endothelial cells, hepatocytes and platelets and PA Inhibitor 2 from placenta.	Protactinium	4-6	protein phosphatase 1 regulatory inhibitor subunit 1A	Homo sapiens	42-53
3113299-5	1987	They show that plasma levels of PA Inhibitor are very low under normal conditions, but a considerable increase (X10 or 20) is found in several pathological conditions (thrombo embolic disease, atherosclerosis, thrombotic risk factors (obesity, hypertriglyceridemia, diabetes) inflammatory syndrome, post operative period for PA Inhibitor 1, and in some physiological conditions (pregnancy for PA Inhibitor 2).	Protactinium	32-34	protein phosphatase 1 regulatory inhibitor subunit 1A	Homo sapiens	328-339
3113299-6	1987	These results plead for a pathogenic role of PA Inhibitor 1 in the development of thrombosis.	Protactinium	45-47	protein phosphatase 1 regulatory inhibitor subunit 1A	Homo sapiens	48-59
33813027-10	2021	In addition, PA compounds downregulated the expression of VCAM-1, VE-cadherin, VEGFa, VEGFR2, TGF-beta, and IL-1beta, in inflamed ECs.	Protactinium	13-15	cadherin 5	Homo sapiens	66-77
33813027-10	2021	In addition, PA compounds downregulated the expression of VCAM-1, VE-cadherin, VEGFa, VEGFR2, TGF-beta, and IL-1beta, in inflamed ECs.	Protactinium	13-15	vascular endothelial growth factor A	Homo sapiens	79-84
33813027-10	2021	In addition, PA compounds downregulated the expression of VCAM-1, VE-cadherin, VEGFa, VEGFR2, TGF-beta, and IL-1beta, in inflamed ECs.	Protactinium	13-15	kinase insert domain receptor	Homo sapiens	86-92
33813027-10	2021	In addition, PA compounds downregulated the expression of VCAM-1, VE-cadherin, VEGFa, VEGFR2, TGF-beta, and IL-1beta, in inflamed ECs.	Protactinium	13-15	transforming growth factor alpha	Homo sapiens	94-102
33813027-10	2021	In addition, PA compounds downregulated the expression of VCAM-1, VE-cadherin, VEGFa, VEGFR2, TGF-beta, and IL-1beta, in inflamed ECs.	Protactinium	13-15	interleukin 1 alpha	Homo sapiens	108-116
33798173-6	2021	The results demonstrated that PA imaging could be a noninvasive and timely tool for clinically monitoring CS.	Protactinium	30-32	citrate synthase	Rattus norvegicus	106-108
33941757-9	2021	Multivariable linear regression analysis showed that C4 levels were closely related to DP (P<0.05) and that CD4 and CD8 levels were closely related to PA (P<0.01).	Protactinium	151-153	CD4 antigen	Mus musculus	108-111
33235044-3	2021	METHODS: VEGF release kinetics from PA gels were evaluated.	Protactinium	36-38	vascular endothelial growth factor A	Homo sapiens	9-13
33800509-6	2021	All oocytes matured with IL-7 treatment during IVM exhibited significantly higher cleavage and blastocyst formation rates after PA than the non-treatment group.	Protactinium	128-130	interleukin 7	Homo sapiens	25-29
33800509-9	2021	Collectively, the present study suggests that IL-7 supplementation during porcine IVM improves oocyte maturation and the developmental potential of porcine embryos after PA.	Protactinium	170-172	interleukin 7	Homo sapiens	46-50
33235044-8	2021	RESULTS: VEGF was released from PA in a controlled-release manner.	Protactinium	32-34	vascular endothelial growth factor A	Homo sapiens	9-13
33235044-13	2021	CONCLUSION: Our observations suggest that this bioengineered construct successfully acts as a chemo- attractant for circulating MSCs due to controlled release of VEGF from the PA gels.	Protactinium	176-178	vascular endothelial growth factor A	Homo sapiens	162-166
34878207-3	2022	By virtue of the high-resolution PA imaging modality, a "smart" photoacoustic (PA) probe Cypate-CBT, which can self-assemble to cypate-containing nanoparticles in response to abundant GSH and CTSB inside tumor cells, was developed for the sensitive and specific detection of CTSB activity.	Protactinium	33-35	cathepsin B	Homo sapiens	192-196
34882312-5	2022	After X-ray irradiation, caspase-3 was activated to cut DEVD, turning on both NIR-II FL and PA imaging signals.	Protactinium	92-94	caspase 3	Homo sapiens	25-34
34882312-6	2022	The increased NIR-II FL/PA signals exhibited positive correlation with the content of caspase-3.	Protactinium	24-26	caspase 3	Homo sapiens	86-95
33237174-9	2020	PA treatment did not alter the expression of IL-10 and MPO level, but increased EGF (epidermal growth factor) and decrease IL-13 in the colonic tissue.	Protactinium	0-2	epidermal growth factor like 1	Rattus norvegicus	80-83
33237174-9	2020	PA treatment did not alter the expression of IL-10 and MPO level, but increased EGF (epidermal growth factor) and decrease IL-13 in the colonic tissue.	Protactinium	0-2	epidermal growth factor like 1	Rattus norvegicus	85-108
33237174-9	2020	PA treatment did not alter the expression of IL-10 and MPO level, but increased EGF (epidermal growth factor) and decrease IL-13 in the colonic tissue.	Protactinium	0-2	interleukin 13	Rattus norvegicus	123-128
33237174-10	2020	PA inhibited the rise of NOSs (nitric oxide synthase) and decreased the serum IL-4 level.	Protactinium	0-2	interleukin 4	Rattus norvegicus	78-82
28415766-5	2017	The higher inhibition index observed for rLF alone as compared to LeTx is contrary to the existing knowledge on LF, which explains the requirement of PA dependent endocytosis for its enzymatic activity.	Protactinium	150-152	RLF zinc finger	Rattus norvegicus	41-44
28415766-5	2017	The higher inhibition index observed for rLF alone as compared to LeTx is contrary to the existing knowledge on LF, which explains the requirement of PA dependent endocytosis for its enzymatic activity.	Protactinium	150-152	RLF zinc finger	Rattus norvegicus	42-44
28415766-6	2017	Therefore, the plausible existence of PA independent mode of action of LF including direct receptor mediated endocytosis or modulation of signal transduction cascade via unknown means is hypothesized.	Protactinium	38-40	RLF zinc finger	Rattus norvegicus	71-73
9795233-4	1998	The thrombin-induced (0.1 U/ml) increase in production of [32P]PA, "overshoots" in [32P]PIP and [32P]PIP2 ([32P]phosphatidylinositol 4,5-bisphosphate), and the increase in [32P]PI and secretion of ADP+ATP were abolished by forskolin (10-7 M).	Protactinium	63-65	coagulation factor II, thrombin	Homo sapiens	4-12
9795233-4	1998	The thrombin-induced (0.1 U/ml) increase in production of [32P]PA, "overshoots" in [32P]PIP and [32P]PIP2 ([32P]phosphatidylinositol 4,5-bisphosphate), and the increase in [32P]PI and secretion of ADP+ATP were abolished by forskolin (10-7 M).	Protactinium	63-65	prolactin induced protein	Homo sapiens	88-91
9795233-9	1998	The inverse relation between forskolin-produced DeltaPIP and [32P]PA production suggests that the PLC reaction is inhibited by elevated cAMP through reduction of substrate (PIP2) resynthesis, and not by inhibition of the PLC enzyme.	Protactinium	66-68	cathelicidin antimicrobial peptide	Homo sapiens	136-140
34227715-6	2022	AS-Cy-NO 2 , composed of a new NIRF/PA scaffold thioxanthene-hemicyanine (AS-Cy) and a 4-nitrobenzene moiety, showed a 10-fold ratiometric NIRF enhancement (I 773 /I 733 ) and 2.4-fold ratiometric PA enhancement (PA 730 /PA 670 ) upon activation by a biomarker (nitroreductase, NTR) associated with tumor hypoxia.	Protactinium	197-199	neurotensin receptor 1	Homo sapiens	278-281
34878207-3	2022	By virtue of the high-resolution PA imaging modality, a "smart" photoacoustic (PA) probe Cypate-CBT, which can self-assemble to cypate-containing nanoparticles in response to abundant GSH and CTSB inside tumor cells, was developed for the sensitive and specific detection of CTSB activity.	Protactinium	33-35	cathepsin B	Homo sapiens	275-279
34861335-7	2022	The farther the horizontal sampling conducted from the Pa and Sa, the greater the structural similarity of the microbial community at the genus level, higher the catalase, acidic protease, and neutral phosphatase activities, and lower the alkaline phosphatase activity.	Protactinium	55-57	catalase	Homo sapiens	162-187
34871548-2	2022	PA binds to either of two receptors, capillary morphogenesis protein-2 (CMG-2) or tumor endothelial marker-8 (TEM-8), which triggers the binding and cytoplasmic translocation of LF and EF.	Protactinium	0-2	anthrax toxin receptor 2	Mus musculus	72-77
34976150-12	2022	The apoptosis rate of PA-SMCs increased with the overexpression of miR-30d-5p compared with control group.	Protactinium	22-24	microRNA 30d	Homo sapiens	67-74
34871548-2	2022	PA binds to either of two receptors, capillary morphogenesis protein-2 (CMG-2) or tumor endothelial marker-8 (TEM-8), which triggers the binding and cytoplasmic translocation of LF and EF.	Protactinium	0-2	anthrax toxin receptor 1	Mus musculus	110-115
34963064-8	2022	Parallel assays in fruitfull (ful) mutants, which do not undergo PA, have revealed that FUL may promote PA via repression of these CK-dependent pathways.	Protactinium	104-106	AGAMOUS-like 8	Arabidopsis thaliana	88-91
34817777-4	2022	We focused on SNX2 protein, which interacts with the PA in the yeast cells.	Protactinium	53-55	sorting nexin 2	Homo sapiens	14-18
34817777-5	2022	By using the co-immunoprecipitation assays, it has been demonstrated that the amino-terminal part of the PA was important for binding to the SNX2.	Protactinium	105-107	sorting nexin 2	Homo sapiens	141-145
34749061-11	2022	Thus, SIRT1 is partially required for VK2 improvement the proportion of slow-twitch fiber in PA-treated C2C12 cells.	Protactinium	93-95	sirtuin 1	Mus musculus	6-11
34956386-5	2021	Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect.	Protactinium	24-26	heat shock protein family A (Hsp70) member 5	Homo sapiens	185-190
34965971-6	2022	PA loss results in aberrant localization of Claudin 5 and VE-Cadherin in endothelial cell junctions as well as robust microgliosis.	Protactinium	0-2	claudin 5	Homo sapiens	44-53
34965971-6	2022	PA loss results in aberrant localization of Claudin 5 and VE-Cadherin in endothelial cell junctions as well as robust microgliosis.	Protactinium	0-2	cadherin 5	Homo sapiens	58-69
34956386-5	2021	Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect.	Protactinium	24-26	heat shock protein 90 beta family member 1	Homo sapiens	192-197
34956386-5	2021	Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect.	Protactinium	24-26	DNA damage inducible transcript 3	Homo sapiens	199-203
34956386-5	2021	Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect.	Protactinium	24-26	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	233-237
34956386-5	2021	Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect.	Protactinium	24-26	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	242-251
34956386-5	2021	Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect.	Protactinium	24-26	BCL2 associated X, apoptosis regulator	Homo sapiens	286-289
34956386-5	2021	Our results showed that PA-induced oxidative stress, calcium disequilibrium, and subsequent endoplasmic reticulum stress (ERS) mediated cellular injury, with elevated protein levels of GRP78, GRP94, CHOP, and hyperphosphorylation of PERK and IRE1alpha as well as the increased ratio of Bax/Bcl-2, which was restored by PCB2 in a concentration-dependent manner, proving the excellent antiapoptosis effect.	Protactinium	24-26	BCL2 apoptosis regulator	Homo sapiens	290-295
34956386-7	2021	What is more, upregulated protein expression of p-IKKalpha/beta, p-NF-kappaB p65, NLRP3, cleaved caspase 1, and mature IL-1beta occurred in HepG2 cells in response to PA stress while rescued with the PCB2 intervention.	Protactinium	167-169	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	50-63
34956386-7	2021	What is more, upregulated protein expression of p-IKKalpha/beta, p-NF-kappaB p65, NLRP3, cleaved caspase 1, and mature IL-1beta occurred in HepG2 cells in response to PA stress while rescued with the PCB2 intervention.	Protactinium	167-169	RELA proto-oncogene, NF-kB subunit	Homo sapiens	67-80
34956386-7	2021	What is more, upregulated protein expression of p-IKKalpha/beta, p-NF-kappaB p65, NLRP3, cleaved caspase 1, and mature IL-1beta occurred in HepG2 cells in response to PA stress while rescued with the PCB2 intervention.	Protactinium	167-169	NLR family pyrin domain containing 3	Homo sapiens	82-87
34956386-7	2021	What is more, upregulated protein expression of p-IKKalpha/beta, p-NF-kappaB p65, NLRP3, cleaved caspase 1, and mature IL-1beta occurred in HepG2 cells in response to PA stress while rescued with the PCB2 intervention.	Protactinium	167-169	caspase 1	Homo sapiens	97-106
34956386-7	2021	What is more, upregulated protein expression of p-IKKalpha/beta, p-NF-kappaB p65, NLRP3, cleaved caspase 1, and mature IL-1beta occurred in HepG2 cells in response to PA stress while rescued with the PCB2 intervention.	Protactinium	167-169	interleukin 1 alpha	Homo sapiens	119-127
34956386-8	2021	In conclusion, our study demonstrated that PA induces ERS in HepG2 cells and subsequently activates downstream NLRP3 inflammasome-mediated cellular injury, while PCB2 inhibits NLRP3/caspase 1/IL-1beta pathway, inflammation, and apoptosis with the presence of ERS, thereby promoting cell survival, which may provide pharmacological evidence for clinical approaches on NAFLD.	Protactinium	43-45	NLR family pyrin domain containing 3	Homo sapiens	111-116
34956386-8	2021	In conclusion, our study demonstrated that PA induces ERS in HepG2 cells and subsequently activates downstream NLRP3 inflammasome-mediated cellular injury, while PCB2 inhibits NLRP3/caspase 1/IL-1beta pathway, inflammation, and apoptosis with the presence of ERS, thereby promoting cell survival, which may provide pharmacological evidence for clinical approaches on NAFLD.	Protactinium	43-45	caspase 1	Homo sapiens	182-191
34956386-8	2021	In conclusion, our study demonstrated that PA induces ERS in HepG2 cells and subsequently activates downstream NLRP3 inflammasome-mediated cellular injury, while PCB2 inhibits NLRP3/caspase 1/IL-1beta pathway, inflammation, and apoptosis with the presence of ERS, thereby promoting cell survival, which may provide pharmacological evidence for clinical approaches on NAFLD.	Protactinium	43-45	interleukin 1 alpha	Homo sapiens	192-200
34782897-6	2021	Meanwhile, the ratio of the PA signal at 768 nm to that at 900 nm (PA768/PA900) decreases over time due to the destruction of fluorescence resonance energy transfer effect from Cy7 to MoS2 NSs and the rapid clearance of small Cy7 molecules from tissues.	Protactinium	28-30	mago homolog, exon junction complex core component	Mus musculus	184-188
34782897-7	2021	Thus, the simultaneous change in NIRF and ratiometric PA signals enables the imaging of endogenous furin activity in real time, and with high sensitivity, and high selectivity in both tumor cells and tumor-bearing mice.	Protactinium	54-56	furin (paired basic amino acid cleaving enzyme)	Mus musculus	99-104
34808477-3	2021	Therefore, this study aimed to analyse the role of BNP in patients with ischemic stroke who received intravenous recombinant tissue plasminogen activator (rt-PA) therapy.	Protactinium	157-160	natriuretic peptide B	Homo sapiens	51-54
34808477-3	2021	Therefore, this study aimed to analyse the role of BNP in patients with ischemic stroke who received intravenous recombinant tissue plasminogen activator (rt-PA) therapy.	Protactinium	157-160	chromosome 20 open reading frame 181	Homo sapiens	125-153
34229786-3	2021	To solve this problem and extend the applications of CS, polyamide/chitosan/tetraethyl orthosilicate (PA/CS/TEOS) composite nanofibers were successfully prepared as drug carriers in this study via electrospinning.	Protactinium	102-104	citrate synthase	Homo sapiens	53-55
34926305-11	2021	Tumor proliferation by the Ki67 staining was significantly decreased in mice treated with PAS monotherapy or the combination therapy.	Protactinium	90-93	antigen identified by monoclonal antibody Ki 67	Mus musculus	27-31
34926305-14	2021	These results confirm the significance of the gastrin-CCK-BR signaling pathway in gastric cancer and suggest that the addition of a gastrin vaccine, PAS, to therapy with an immune checkpoint antibody may decrease growth and metastases of gastric cancer by altering the tumor microenvironment.	Protactinium	149-152	cholecystokinin B receptor	Homo sapiens	54-60
34926305-14	2021	These results confirm the significance of the gastrin-CCK-BR signaling pathway in gastric cancer and suggest that the addition of a gastrin vaccine, PAS, to therapy with an immune checkpoint antibody may decrease growth and metastases of gastric cancer by altering the tumor microenvironment.	Protactinium	149-152	gastrin	Homo sapiens	132-139
34558738-13	2021	The CD34+ cells collected was 274.16 +- 216.31 x 106 in the PV group and 246.63 +- 127.94 x 106 in the PA group.	Protactinium	103-105	CD34 molecule	Homo sapiens	4-8
34229786-3	2021	To solve this problem and extend the applications of CS, polyamide/chitosan/tetraethyl orthosilicate (PA/CS/TEOS) composite nanofibers were successfully prepared as drug carriers in this study via electrospinning.	Protactinium	102-104	citrate synthase	Homo sapiens	105-107
34762436-7	2021	This study provides insight into the relationship between beta-sheet twist and self-assembled nanostructures including a possible design rule for PA self-assembly.	Protactinium	146-148	twist family bHLH transcription factor 1	Homo sapiens	69-74
34884246-9	2021	Our results show that the best fit indices (CFI = 0.97, SRMR = 0.04) showed a model with direct influence of PA self-efficacy on MVPA (p < 0.01) and indirect influence on LPA (p < 0.001).	Protactinium	109-111	complement factor I	Homo sapiens	44-47
34773993-11	2021	Mechanically, rhFGF21 induced AMPK activation in DOCA-salt-treated mice and PA-stimulated HK-2 cells, which inhibited NF-kappaB-regulated inflammation and Nrf2-mediated oxidative stress and thus, is important for rhFGF21 protection against DOCA-salt-induced nephropathy.	Protactinium	76-78	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	118-127
34783223-9	2021	The results showed that Pa pretreatment could significantly inhibit the expression and secretion of the inflammatory cytokine IL-1beta, and significantly reduce the protein level of the proinflammatory protease iNOS, in both in vivo and in vitro models induced by LPS.	Protactinium	24-26	interleukin 1 alpha	Mus musculus	126-134
34783223-9	2021	The results showed that Pa pretreatment could significantly inhibit the expression and secretion of the inflammatory cytokine IL-1beta, and significantly reduce the protein level of the proinflammatory protease iNOS, in both in vivo and in vitro models induced by LPS.	Protactinium	24-26	nitric oxide synthase 2, inducible	Mus musculus	211-215
34783223-10	2021	Further mechanism studies showed that Pa could significantly inhibit the activation of the protein kinase B (Akt)/nuclear factor-kappaB (NF-kappaB) signaling pathway in the LPS-induced ALI mode and in LPS-induced RAW264.7 cells.	Protactinium	38-40	protein tyrosine kinase 2 beta	Homo sapiens	91-107
34783223-10	2021	Further mechanism studies showed that Pa could significantly inhibit the activation of the protein kinase B (Akt)/nuclear factor-kappaB (NF-kappaB) signaling pathway in the LPS-induced ALI mode and in LPS-induced RAW264.7 cells.	Protactinium	38-40	AKT serine/threonine kinase 1	Homo sapiens	109-112
34783223-10	2021	Further mechanism studies showed that Pa could significantly inhibit the activation of the protein kinase B (Akt)/nuclear factor-kappaB (NF-kappaB) signaling pathway in the LPS-induced ALI mode and in LPS-induced RAW264.7 cells.	Protactinium	38-40	nuclear factor kappa B subunit 1	Homo sapiens	137-146
34783223-11	2021	Through molecular dynamics simulation, we observed that Pa was bound to the catalytic pocket of Akt and effectively inhibited the biological activity of Akt.	Protactinium	56-58	thymoma viral proto-oncogene 1	Mus musculus	96-99
34783223-11	2021	Through molecular dynamics simulation, we observed that Pa was bound to the catalytic pocket of Akt and effectively inhibited the biological activity of Akt.	Protactinium	56-58	thymoma viral proto-oncogene 1	Mus musculus	153-156
34783223-12	2021	These results indicated that Pa significantly relieves LPS-induced ALI by activating the Akt/NF-kappaB signaling pathway.	Protactinium	29-31	thymoma viral proto-oncogene 1	Mus musculus	89-92
34783223-12	2021	These results indicated that Pa significantly relieves LPS-induced ALI by activating the Akt/NF-kappaB signaling pathway.	Protactinium	29-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	93-102
34811650-14	2022	Therefore, radiologists should be aware that in patients with high serum PTH levels and without a discernible PV, PA might be difficult to localize.	Protactinium	114-116	parathyroid hormone	Homo sapiens	73-76
34802421-0	2021	PA and OA induce abnormal glucose metabolism by inhibiting KLF15 in adipocytes.	Protactinium	0-2	Kruppel-like factor 15	Mus musculus	59-64
34802421-9	2021	In 3T3-L1 adipocytes, 1500 muM PA inhibited KLF15 through a GPR120/P-p38 MAPK signal pathway, and 750 muM OA inhibited KLF15 mainly through GPR120 while not dependent on P-p38 MAPK, ultimately resulting in abnormal glucose metabolism.	Protactinium	31-33	Kruppel-like factor 15	Mus musculus	44-49
34802421-9	2021	In 3T3-L1 adipocytes, 1500 muM PA inhibited KLF15 through a GPR120/P-p38 MAPK signal pathway, and 750 muM OA inhibited KLF15 mainly through GPR120 while not dependent on P-p38 MAPK, ultimately resulting in abnormal glucose metabolism.	Protactinium	31-33	free fatty acid receptor 4	Mus musculus	60-66
34802421-11	2021	CONCLUSIONS: Both PA and OA inhibit KLF15 expression through GPR120, leading to abnormal glucose metabolism in adipocytes.	Protactinium	18-20	Kruppel-like factor 15	Mus musculus	36-41
34802421-11	2021	CONCLUSIONS: Both PA and OA inhibit KLF15 expression through GPR120, leading to abnormal glucose metabolism in adipocytes.	Protactinium	18-20	free fatty acid receptor 4	Mus musculus	61-67
34802421-12	2021	Notably, the inhibition of KLF15 expression by PA depends on phosphorylation of p38 MAPK.	Protactinium	47-49	Kruppel-like factor 15	Mus musculus	27-32
34802421-12	2021	Notably, the inhibition of KLF15 expression by PA depends on phosphorylation of p38 MAPK.	Protactinium	47-49	mitogen-activated protein kinase 14	Mus musculus	80-88
34773993-11	2021	Mechanically, rhFGF21 induced AMPK activation in DOCA-salt-treated mice and PA-stimulated HK-2 cells, which inhibited NF-kappaB-regulated inflammation and Nrf2-mediated oxidative stress and thus, is important for rhFGF21 protection against DOCA-salt-induced nephropathy.	Protactinium	76-78	nuclear factor, erythroid derived 2, like 2	Mus musculus	155-159
34869748-12	2021	After PA, the cleavage rates significantly increased in the 10 and 100 ng/mL NT-4 treatment groups.	Protactinium	6-8	neurotrophin 4	Sus scrofa	77-81
34635915-5	2021	For PA localiser scans, a non-linear relationship between miscentring and CTDIvol was observed, attributable to the presence of the patient bed being misinterpreted as the patient width.	Protactinium	4-6	BED	Homo sapiens	140-143
34528700-9	2021	RESULTS: The content of IL-10 and the ratio of IL-10+ T cells were enhanced in pa-tients with sepsis.	Protactinium	79-81	interleukin 10	Homo sapiens	24-29
34834784-8	2021	Results showed that enzymes involved in the biosynthesis of PAs (ornithine decarboxylase as ODC and S-adenosylmethionine decarboxylase as SAMDC) were significantly downregulated by 1000 microM Co in the tissues of both inbred lines.	Protactinium	60-63	ornithine decarboxylase	Zea mays	65-88
34655676-2	2021	Herein, a nanoplatform Mn/CaCO3@PL/SLC is developed, which is based on palmitoyl ascorbate (PA)-liposome (PL) loaded with Mn-doped CaCO3 nanoparticles (Mn/CaCO3 NPs) and carbonic anhydrase (CAIX) inhibitor SLC-0111.	Protactinium	92-94	C-C motif chemokine ligand 21	Homo sapiens	35-38
34528700-9	2021	RESULTS: The content of IL-10 and the ratio of IL-10+ T cells were enhanced in pa-tients with sepsis.	Protactinium	79-81	interleukin 10	Homo sapiens	47-52
34716468-12	2022	Based on the PA polymorphism of BoFLC, we designed a codominant marker for the vernalization trait, which can be used for breeding programs of B. oleracea crops.	Protactinium	13-15	MADS-box protein FLOWERING LOCUS C-like	Brassica oleracea	32-37
34500284-17	2021	In the current study, PA was substituted with anti-CD19 immunoliposome to make it targeted to CD19+ while keeping the normal cells intact.	Protactinium	22-24	CD19 molecule	Homo sapiens	94-98
34716939-11	2022	DISCUSSION: PA-IgG is a potential disease biomarker in GNE myopathy patients, although its significance needs to be clarified.	Protactinium	12-14	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Homo sapiens	55-58
34391785-2	2021	In this work, the temperature-sensitive polymer of PA-loaded cysteine (Cys) modified chitosan (Cs) grafted PNIPAM (Cs-Cys-PN/PA) with aggregation-induced emission enhancement (AIEE) properties that reversible hydrogel in an aqueous solution is synthesized.	Protactinium	51-53	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	122-127
34519218-6	2021	We show that the Caj1 interaction with liposomes containing PA is modulated by pH and PE lipids and depends on two patches of positively charged residues near the C-terminus of the protein.	Protactinium	60-62	Caj1p	Saccharomyces cerevisiae S288C	17-21
34685705-5	2021	PA impeded myogenic differentiation, concomitantly suppressed CFL2 and induced miR-325-3p.	Protactinium	0-2	cofilin 2	Homo sapiens	62-66
34685705-9	2021	The roles of miR-325-3p on CFL2 expression, F-actin modulation, and myogenic differentiation suggest a novel miRNA-mediated regulatory mechanism of myogenesis and PA-inducible miR-325-3p may be a critical mediator between obesity and muscle wasting.	Protactinium	163-165	cofilin 2	Homo sapiens	27-31
34704081-4	2021	A serial mediation model utilizing a large epidemiologic dataset (final N = 527) supported our central hypothesis that the direct effect of childhood maltreatment on IL-6 was fully serially statistically mediated by SA symptoms and low PA (but not high negative affect).	Protactinium	236-238	interleukin 6	Homo sapiens	166-170
34704081-6	2021	Trait mindfulness moderated the association between low PA and IL-6, to the exclusion of any paths related to negative affect.	Protactinium	56-58	interleukin 6	Homo sapiens	63-67
34704081-8	2021	Overall, we conclude that childhood maltreatment and SA symptoms have a significant influence on IL-6, albeit indirectly via low PA, and the influence of PA on IL-6 may be uniquely susceptible to influence by individual differences in mindfulness.	Protactinium	129-131	acyl-CoA synthetase medium chain family member 3	Homo sapiens	53-55
34704081-8	2021	Overall, we conclude that childhood maltreatment and SA symptoms have a significant influence on IL-6, albeit indirectly via low PA, and the influence of PA on IL-6 may be uniquely susceptible to influence by individual differences in mindfulness.	Protactinium	129-131	interleukin 6	Homo sapiens	97-101
34704081-8	2021	Overall, we conclude that childhood maltreatment and SA symptoms have a significant influence on IL-6, albeit indirectly via low PA, and the influence of PA on IL-6 may be uniquely susceptible to influence by individual differences in mindfulness.	Protactinium	154-156	interleukin 6	Homo sapiens	160-164
34689159-3	2021	We report that the lymphokine LIGHT/TNFSF14 was upregulated in the murine NAFLD livers and in hepatocytes treated with free fatty acids (palmitate, PA).	Protactinium	148-150	tumor necrosis factor (ligand) superfamily, member 14	Mus musculus	36-43
34689159-5	2021	Similarly, knockdown or blockade of LTbetaR, the receptor for LIGHT, ameliorated apoptosis in hepatocytes exposed to PA.	Protactinium	117-119	lymphotoxin B receptor	Mus musculus	36-43
34473357-3	2021	Both AD and PA contain amyloid plaques dominated by amyloid beta (Abeta) peptides.	Protactinium	12-14	amyloid beta precursor protein	Homo sapiens	52-64
34473357-3	2021	Both AD and PA contain amyloid plaques dominated by amyloid beta (Abeta) peptides.	Protactinium	12-14	amyloid beta precursor protein	Homo sapiens	66-71
34358729-7	2021	It was concluded that PA stress resistance in WT and hy4 plants depends on the light intensity and reduced stress resistance of hy4 at HBL, is likely linked to low UAP and carotenoid contents as well as lowered APX and GPX enzyme activities in hy4 mutants.	Protactinium	22-24	cryptochrome 1	Arabidopsis thaliana	53-56
34314869-4	2021	We examine two important aspects required for clinical application of the biomaterials, if SHH PA suppresses intrinsic (caspase 9) and extrinsic (caspase 8) apoptotic mechanisms, and if suppressing one apoptotic mechanism forces apoptosis to occur via a different mechanism.	Protactinium	95-97	sonic hedgehog signaling molecule	Homo sapiens	91-94
34314869-4	2021	We examine two important aspects required for clinical application of the biomaterials, if SHH PA suppresses intrinsic (caspase 9) and extrinsic (caspase 8) apoptotic mechanisms, and if suppressing one apoptotic mechanism forces apoptosis to occur via a different mechanism.	Protactinium	95-97	caspase 9	Homo sapiens	120-129
34314869-4	2021	We examine two important aspects required for clinical application of the biomaterials, if SHH PA suppresses intrinsic (caspase 9) and extrinsic (caspase 8) apoptotic mechanisms, and if suppressing one apoptotic mechanism forces apoptosis to occur via a different mechanism.	Protactinium	95-97	caspase 8	Homo sapiens	146-155
34314869-5	2021	We show that SHH PA suppresses both caspase 9 and 8 apoptotic mechanisms, and suppressing caspase 9 did not shift signaling to caspase 8.	Protactinium	17-19	sonic hedgehog signaling molecule	Homo sapiens	13-16
34314869-5	2021	We show that SHH PA suppresses both caspase 9 and 8 apoptotic mechanisms, and suppressing caspase 9 did not shift signaling to caspase 8.	Protactinium	17-19	caspase 9	Homo sapiens	36-45
34431177-4	2021	Here we give further evidence of this PA/PDE4/PKA pathway using biosensors of PA, cAMP and PKA in living cells.	Protactinium	78-80	phosphodiesterase 4A	Homo sapiens	41-45
34431177-5	2021	Propranolol used to inhibit PA hydrolysis triggers this pathway, which then activates p38 and ERK1/2 downstream PKA inhibition.	Protactinium	28-30	mitogen-activated protein kinase 1	Homo sapiens	86-89
34431177-5	2021	Propranolol used to inhibit PA hydrolysis triggers this pathway, which then activates p38 and ERK1/2 downstream PKA inhibition.	Protactinium	28-30	mitogen-activated protein kinase 3	Homo sapiens	94-100
34738406-6	2021	Compared with the NC group, the PA group showed decreased cell viability and MMP(P<0.01, P<0.01), elevated apoptosis(P<0.01), and up-regulated phosphorylated levels of p38, ERK1/2, and JNK1/2(P<0.01, P<0.01, P<0.01).	Protactinium	32-34	mitogen-activated protein kinase 1	Homo sapiens	168-171
34738406-6	2021	Compared with the NC group, the PA group showed decreased cell viability and MMP(P<0.01, P<0.01), elevated apoptosis(P<0.01), and up-regulated phosphorylated levels of p38, ERK1/2, and JNK1/2(P<0.01, P<0.01, P<0.01).	Protactinium	32-34	mitogen-activated protein kinase 3	Homo sapiens	173-179
34738406-6	2021	Compared with the NC group, the PA group showed decreased cell viability and MMP(P<0.01, P<0.01), elevated apoptosis(P<0.01), and up-regulated phosphorylated levels of p38, ERK1/2, and JNK1/2(P<0.01, P<0.01, P<0.01).	Protactinium	32-34	mitogen-activated protein kinase 8	Homo sapiens	185-191
34738406-7	2021	Compared with the PA group, the GXZT-H, GXZT-M, and GXZT-L groups showed increased cell viability and MMP(P<0.01, P<0.01, P<0.01), reduced apoptosis(P<0.01), and down-regulated protein expression and phosphorylated levels of p38, ERK1/2 and JNK1/2 in the MAPK signaling pathway(P<0.01, P<0.01, P<0.01).	Protactinium	18-20	mitogen-activated protein kinase 1	Homo sapiens	225-228
34738406-7	2021	Compared with the PA group, the GXZT-H, GXZT-M, and GXZT-L groups showed increased cell viability and MMP(P<0.01, P<0.01, P<0.01), reduced apoptosis(P<0.01), and down-regulated protein expression and phosphorylated levels of p38, ERK1/2 and JNK1/2 in the MAPK signaling pathway(P<0.01, P<0.01, P<0.01).	Protactinium	18-20	mitogen-activated protein kinase 3	Homo sapiens	230-236
34738406-7	2021	Compared with the PA group, the GXZT-H, GXZT-M, and GXZT-L groups showed increased cell viability and MMP(P<0.01, P<0.01, P<0.01), reduced apoptosis(P<0.01), and down-regulated protein expression and phosphorylated levels of p38, ERK1/2 and JNK1/2 in the MAPK signaling pathway(P<0.01, P<0.01, P<0.01).	Protactinium	18-20	mitogen-activated protein kinase 8	Homo sapiens	241-247
34358729-7	2021	It was concluded that PA stress resistance in WT and hy4 plants depends on the light intensity and reduced stress resistance of hy4 at HBL, is likely linked to low UAP and carotenoid contents as well as lowered APX and GPX enzyme activities in hy4 mutants.	Protactinium	22-24	cryptochrome 1	Arabidopsis thaliana	128-131
34358729-7	2021	It was concluded that PA stress resistance in WT and hy4 plants depends on the light intensity and reduced stress resistance of hy4 at HBL, is likely linked to low UAP and carotenoid contents as well as lowered APX and GPX enzyme activities in hy4 mutants.	Protactinium	22-24	ascorbate peroxidase 1	Arabidopsis thaliana	211-214
34358729-7	2021	It was concluded that PA stress resistance in WT and hy4 plants depends on the light intensity and reduced stress resistance of hy4 at HBL, is likely linked to low UAP and carotenoid contents as well as lowered APX and GPX enzyme activities in hy4 mutants.	Protactinium	22-24	cryptochrome 1	Arabidopsis thaliana	244-247
34575281-9	2021	PA using COX-3 inhibitors, as compared to that of the T group, resulted in less overall PONV (p < 0.05).	Protactinium	0-2	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	9-14
34685530-7	2021	Comparisons of the cell surface expression of a large panel of NK receptors revealed an increased mean fluorescence intensity of NKG2D+ on NK cells from patients with PA compared with non-PA patients, especially on the CD56dim subset.	Protactinium	167-169	killer cell lectin like receptor K1	Homo sapiens	129-134
34685530-7	2021	Comparisons of the cell surface expression of a large panel of NK receptors revealed an increased mean fluorescence intensity of NKG2D+ on NK cells from patients with PA compared with non-PA patients, especially on the CD56dim subset.	Protactinium	167-169	neural cell adhesion molecule 1	Homo sapiens	219-223
34685530-7	2021	Comparisons of the cell surface expression of a large panel of NK receptors revealed an increased mean fluorescence intensity of NKG2D+ on NK cells from patients with PA compared with non-PA patients, especially on the CD56dim subset.	Protactinium	188-190	killer cell lectin like receptor K1	Homo sapiens	129-134
34556193-5	2021	In vitro, oleic and palmitic acids (OA and PA) treatments strongly increased angptl4 mRNA expression in croaker hepatocytes.	Protactinium	43-45	angiopoietin-related protein 4	Larimichthys crocea	77-84
34556193-7	2021	Moreover, inhibition of PPARgamma abrogated OA or PA-induced angptl4 mRNA expression.	Protactinium	50-52	angiopoietin-related protein 4	Larimichthys crocea	61-68
34556193-8	2021	Beyond that, PA might increase angptl4 expression partly via the insulin signaling.	Protactinium	13-15	angiopoietin-related protein 4	Larimichthys crocea	31-38
34556193-8	2021	Beyond that, PA might increase angptl4 expression partly via the insulin signaling.	Protactinium	13-15	LOC104932842	Larimichthys crocea	65-72
34321379-5	2021	Analysis of the association between these promoter genotypes and the immune phenotypes revealed that the immune-selected promoter-type in RNASEL was associated with increased PA and was inherited recessively.	Protactinium	175-177	ribonuclease L	Sus scrofa	138-144
34575281-11	2021	We recommend using intraoperative AoA-guided GA to reduce the presence of OCR, and the addition of PA using COX-3 inhibitors to reduce the rate of PONV.	Protactinium	99-101	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	108-113
34309160-5	2021	The simultaneously high PA signal and fluorescence brightness of TPA-TQ3 NPs enable precise image-guided surgery.	Protactinium	24-26	plasminogen activator, tissue type	Homo sapiens	65-68
34502788-6	2021	A comparative assessment of the bivariate models versus their conventional counterparts is experimentally performed for the modeling of two PAs driven by a 30 MHz 5G New Radio signal: a class AB PA and a class J PA.	Protactinium	140-143	filamin C	Homo sapiens	192-197
34566700-5	2021	Twelve relevant pa-pers were identified using four different cell types (C2C12, primary mouse satellite cells, primary chick myoblasts, and primary human myoblasts) and a range of myogenic markers (myoD, myogenin, creatine kinase, myosin heavy chain, and myotube size).	Protactinium	16-18	myogenic differentiation 1	Homo sapiens	198-202
34926792-5	2021	The PAs released LXR in response to physiological levels of ROS and reducing agents and could be co-assembled with plaque-targeting PAs to form nanofibers.	Protactinium	4-7	nuclear receptor subfamily 1, group H, member 3	Mus musculus	17-20
34926792-7	2021	Further, the ApoA1-LXR PA nanofibers targeted plaque within an atherosclerotic mouse model in vivo and activated ATP-binding cassette A1 (ABCA1) expression as well as LXR alone with reduced liver toxicity.	Protactinium	23-25	apolipoprotein A-I	Mus musculus	13-18
34926792-7	2021	Further, the ApoA1-LXR PA nanofibers targeted plaque within an atherosclerotic mouse model in vivo and activated ATP-binding cassette A1 (ABCA1) expression as well as LXR alone with reduced liver toxicity.	Protactinium	23-25	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	113-136
34926792-7	2021	Further, the ApoA1-LXR PA nanofibers targeted plaque within an atherosclerotic mouse model in vivo and activated ATP-binding cassette A1 (ABCA1) expression as well as LXR alone with reduced liver toxicity.	Protactinium	23-25	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	138-143
34926792-7	2021	Further, the ApoA1-LXR PA nanofibers targeted plaque within an atherosclerotic mouse model in vivo and activated ATP-binding cassette A1 (ABCA1) expression as well as LXR alone with reduced liver toxicity.	Protactinium	23-25	nuclear receptor subfamily 1, group H, member 3	Mus musculus	167-170
34167638-8	2021	The results suggested that Oridonin caused stomatal closure by affecting GPA1 and promoting PLDalpha1 to produce PA, and further accumulating H2O2 to upregulate gene OST1.	Protactinium	113-115	phospholipase D alpha 1	Arabidopsis thaliana	92-101
34406744-6	2021	The probe demonstrated a ratiometric PA limit of detection of 148 pM miR-21, sequence specificity against one- and two-base mutations, and selectivity over other microRNAs.	Protactinium	37-39	microRNA 21	Homo sapiens	69-75
34502984-4	2021	Results indicated that the PA of ER was higher than that of BOZ.	Protactinium	27-29	epiregulin	Homo sapiens	33-35
34157861-8	2021	Overexpression of NFYA, a transcriptional-enhancer of sGCbeta1, was performed by PA delivery of adeno-associated-virus 6 (AAV6).	Protactinium	81-83	nuclear transcription factor Y subunit alpha	Homo sapiens	18-22
34167292-6	2021	By comparing the PA signal intensity changes at 680 and 760 nm, the photoacoustic signal intensity ratios were shown to be enhanced by 3-5 times after incubation with MMP-2.	Protactinium	17-19	matrix metallopeptidase 2	Mus musculus	167-172
34471643-6	2021	We built endothelial lipotoxicity in vitro and found that LOX-1 was upregulated after PA stimulation, during which ER stress played an important role.	Protactinium	86-88	oxidized low density lipoprotein receptor 1	Homo sapiens	58-63
34406744-7	2021	It was further tested in live human ovarian cancer (SKOV3) and noncancerous (HEK 293T) cells to exemplify in situ PA activation based on differences in endogenous miR-21 regulation (p = 0.0002).	Protactinium	114-116	microRNA 21	Homo sapiens	163-169
34406744-9	2021	The probe"s miR-21-specific activation and its ability to maintain contrast in biologically relevant absorbing and scattering media support its consideration for live-cell PA microscopy and potential cancer diagnostics.	Protactinium	172-174	microRNA 21	Homo sapiens	12-18
34354208-3	2021	In this present study, we synthesized IR783 conjugated chitosan-polypyrrole nanocomposites (IR-CS-PPy NCs) as a theragnostic agent used for FL/PA dual-modal imaging.	Protactinium	143-145	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	140-142
34380042-3	2021	In this study, we show that high CD45 PA in MBCs enhances BCR signaling and is essential for their effective ASC differentiation.	Protactinium	38-40	protein tyrosine phosphatase receptor type C	Homo sapiens	33-37
34380042-3	2021	In this study, we show that high CD45 PA in MBCs enhances BCR signaling and is essential for their effective ASC differentiation.	Protactinium	38-40	PYD and CARD domain containing	Homo sapiens	109-112
34380042-4	2021	Mechanistically, Th signals upregulate CD45 PA through intensifying the surface binding of a CD45 ligand, Galectin-1.	Protactinium	44-46	protein tyrosine phosphatase receptor type C	Homo sapiens	39-43
34380042-4	2021	Mechanistically, Th signals upregulate CD45 PA through intensifying the surface binding of a CD45 ligand, Galectin-1.	Protactinium	44-46	protein tyrosine phosphatase receptor type C	Homo sapiens	93-97
34380042-4	2021	Mechanistically, Th signals upregulate CD45 PA through intensifying the surface binding of a CD45 ligand, Galectin-1.	Protactinium	44-46	galectin 1	Homo sapiens	106-116
34380042-5	2021	CD45 PA works as a sensor of T cell help and defines high-affinity germinal center (GC) plasma cell (PC) precursors characterized by IRF4 expression in vivo.	Protactinium	5-7	protein tyrosine phosphatase receptor type C	Homo sapiens	0-4
34380042-5	2021	CD45 PA works as a sensor of T cell help and defines high-affinity germinal center (GC) plasma cell (PC) precursors characterized by IRF4 expression in vivo.	Protactinium	5-7	interferon regulatory factor 4	Homo sapiens	133-137
34060603-11	2021	However, women with a history of PA had decreased SHBG levels and thus, increased bioavailability of circulating androgens.	Protactinium	33-35	sex hormone binding globulin	Homo sapiens	50-54
34403221-10	2021	We also discovered that RSAD2 and SMC4 were associated with immune cell infiltration in the PA microenvironment.	Protactinium	92-94	radical S-adenosyl methionine domain containing 2	Homo sapiens	24-29
34403221-10	2021	We also discovered that RSAD2 and SMC4 were associated with immune cell infiltration in the PA microenvironment.	Protactinium	92-94	structural maintenance of chromosomes 4	Homo sapiens	34-38
34403221-14	2021	Moreover, ELISAs indicated that serum ISG15 could be a potential novel diagnostic biomarker for PA.	Protactinium	96-98	ISG15 ubiquitin like modifier	Homo sapiens	38-43
34382907-4	2022	Herein, we found that PA treatment or direct stimulation of STING1 promoted, whereas STING1 deficiency impaired, MTORC1 activation, suggesting that STING1 is involved in PA-induced MTORC1 activation.	Protactinium	22-24	origin recognition complex subunit 1	Homo sapiens	113-119
34382907-4	2022	Herein, we found that PA treatment or direct stimulation of STING1 promoted, whereas STING1 deficiency impaired, MTORC1 activation, suggesting that STING1 is involved in PA-induced MTORC1 activation.	Protactinium	22-24	origin recognition complex subunit 1	Homo sapiens	181-187
34382907-4	2022	Herein, we found that PA treatment or direct stimulation of STING1 promoted, whereas STING1 deficiency impaired, MTORC1 activation, suggesting that STING1 is involved in PA-induced MTORC1 activation.	Protactinium	170-172	origin recognition complex subunit 1	Homo sapiens	113-119
34382907-4	2022	Herein, we found that PA treatment or direct stimulation of STING1 promoted, whereas STING1 deficiency impaired, MTORC1 activation, suggesting that STING1 is involved in PA-induced MTORC1 activation.	Protactinium	170-172	origin recognition complex subunit 1	Homo sapiens	181-187
34382907-5	2022	Mechanistic studies revealed that STING1 interacted with several components of the MTORC1 complex and played an important role in the complex formation of MTORC1 under PA treatment.	Protactinium	168-170	origin recognition complex subunit 1	Homo sapiens	83-89
34382907-5	2022	Mechanistic studies revealed that STING1 interacted with several components of the MTORC1 complex and played an important role in the complex formation of MTORC1 under PA treatment.	Protactinium	168-170	origin recognition complex subunit 1	Homo sapiens	155-161
34325115-2	2021	Even those prone to internalizing symptoms show varied proclivities to PA; social anxiety (SA), for instance, unlike other types of anxiety, shows a strong negative association with PA that cannot be explained by diminished reward sensitivity.	Protactinium	71-73	acyl-CoA synthetase medium chain family member 3	Homo sapiens	91-93
34161154-4	2021	Quantitative RT-PCR revealed that the endothelium-denuded intralobar PA of rats expressed Slc12a gene family-encoded Na-K-2Cl cotransporter 1 (NKCC1), K-Cl cotransporters (KCC) 1, 3 and 4, and Slc4a gene family-encoded Na+-independent and Na +-dependent Cl-/HCO3- exchangers.	Protactinium	69-71	solute carrier family 12 member 2	Rattus norvegicus	117-141
34161154-4	2021	Quantitative RT-PCR revealed that the endothelium-denuded intralobar PA of rats expressed Slc12a gene family-encoded Na-K-2Cl cotransporter 1 (NKCC1), K-Cl cotransporters (KCC) 1, 3 and 4, and Slc4a gene family-encoded Na+-independent and Na +-dependent Cl-/HCO3- exchangers.	Protactinium	69-71	solute carrier family 12 member 2	Rattus norvegicus	143-148
34161154-4	2021	Quantitative RT-PCR revealed that the endothelium-denuded intralobar PA of rats expressed Slc12a gene family-encoded Na-K-2Cl cotransporter 1 (NKCC1), K-Cl cotransporters (KCC) 1, 3 and 4, and Slc4a gene family-encoded Na+-independent and Na +-dependent Cl-/HCO3- exchangers.	Protactinium	69-71	solute carrier family 12 member 7	Rattus norvegicus	151-187
34394397-2	2021	PG2 or PA applied to skin of hairless mice after UVB-irradiation alleviated UVB-induced effects observed in untreated skin, such as increased transepidermal water loss (TEWL), increased epidermal thickness, and decreased stratum corneum water content without affecting body weight.	Protactinium	7-9	lysine demethylase and nuclear receptor corepressor	Mus musculus	29-37
34325115-2	2021	Even those prone to internalizing symptoms show varied proclivities to PA; social anxiety (SA), for instance, unlike other types of anxiety, shows a strong negative association with PA that cannot be explained by diminished reward sensitivity.	Protactinium	182-184	acyl-CoA synthetase medium chain family member 3	Homo sapiens	91-93
34190396-3	2021	The results confirmed that hepatocyte senescence occurred in HFD-fed Golden hamsters and PA-treated LO2 cells as manifested by increased levels of senescence marker SA-beta-gal, p16 and p21, heterochromatin marker H3K9me3, DNA damage marker gamma-H2AX and decreased activity of telomerase.	Protactinium	89-91	cyclin dependent kinase inhibitor 2A	Homo sapiens	178-181
34190396-3	2021	The results confirmed that hepatocyte senescence occurred in HFD-fed Golden hamsters and PA-treated LO2 cells as manifested by increased levels of senescence marker SA-beta-gal, p16 and p21, heterochromatin marker H3K9me3, DNA damage marker gamma-H2AX and decreased activity of telomerase.	Protactinium	89-91	H3 histone pseudogene 16	Homo sapiens	186-189
34190396-5	2021	Of importance, depression of lncRNA MAYA (MAYA) reduced iron overload and cellular senescence via promotion of YAP in PA-treated hepatocytes.	Protactinium	118-120	Yes1 associated transcriptional regulator	Homo sapiens	111-114
34212709-9	2021	Conclusions H-MSCs prevent PA development by suppressing the prolonged release of IL-6 at proliferation phase.	Protactinium	27-29	interleukin 6	Rattus norvegicus	82-86
34368604-4	2021	This review highlights recent advances on Pc/Nc-based PA agents and their extended use for multiplexed biomedical imaging, multimodal diagnostic imaging, and image-guided phototherapy.	Protactinium	54-56	pyruvate carboxylase	Homo sapiens	42-44
34357360-6	2021	We found two putative metabolites ((phosphatidylserine PS (16:0/16:1) and phosphatidic acid PA (18:1/18:0)) as having statistically significant increased levels in plasma samples of MDD1 patients compared to healthy subjects.	Protactinium	92-94	MDD1	Homo sapiens	182-186
34393775-8	2021	In scopolamine-treated mice, PA increased the concentrations of neurotransmitters in the hippocampus, activated the brain-derived neurotrophic factor (BDNF)/extracellular signal-regulated kinase (ERK)/cAMP response element binding protein (CREB) signaling pathway, and increased the expression of p90 ribosomal S6 kinase (p90RSK) and postsynaptic density (PSD)95 proteins.	Protactinium	29-31	brain derived neurotrophic factor	Mus musculus	116-149
34393775-8	2021	In scopolamine-treated mice, PA increased the concentrations of neurotransmitters in the hippocampus, activated the brain-derived neurotrophic factor (BDNF)/extracellular signal-regulated kinase (ERK)/cAMP response element binding protein (CREB) signaling pathway, and increased the expression of p90 ribosomal S6 kinase (p90RSK) and postsynaptic density (PSD)95 proteins.	Protactinium	29-31	brain derived neurotrophic factor	Mus musculus	151-155
34393775-8	2021	In scopolamine-treated mice, PA increased the concentrations of neurotransmitters in the hippocampus, activated the brain-derived neurotrophic factor (BDNF)/extracellular signal-regulated kinase (ERK)/cAMP response element binding protein (CREB) signaling pathway, and increased the expression of p90 ribosomal S6 kinase (p90RSK) and postsynaptic density (PSD)95 proteins.	Protactinium	29-31	mitogen-activated protein kinase 1	Mus musculus	196-199
34393775-8	2021	In scopolamine-treated mice, PA increased the concentrations of neurotransmitters in the hippocampus, activated the brain-derived neurotrophic factor (BDNF)/extracellular signal-regulated kinase (ERK)/cAMP response element binding protein (CREB) signaling pathway, and increased the expression of p90 ribosomal S6 kinase (p90RSK) and postsynaptic density (PSD)95 proteins.	Protactinium	29-31	cAMP responsive element binding protein 1	Mus musculus	240-244
34393775-8	2021	In scopolamine-treated mice, PA increased the concentrations of neurotransmitters in the hippocampus, activated the brain-derived neurotrophic factor (BDNF)/extracellular signal-regulated kinase (ERK)/cAMP response element binding protein (CREB) signaling pathway, and increased the expression of p90 ribosomal S6 kinase (p90RSK) and postsynaptic density (PSD)95 proteins.	Protactinium	29-31	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	297-320
34393775-8	2021	In scopolamine-treated mice, PA increased the concentrations of neurotransmitters in the hippocampus, activated the brain-derived neurotrophic factor (BDNF)/extracellular signal-regulated kinase (ERK)/cAMP response element binding protein (CREB) signaling pathway, and increased the expression of p90 ribosomal S6 kinase (p90RSK) and postsynaptic density (PSD)95 proteins.	Protactinium	29-31	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	322-328
34361433-0	2021	Selective Laser Melting of PA 2200 for Hip Implant Applications: Finite Element Analysis, Process Optimization, and Morphological and Mechanical Characterization.	Protactinium	27-29	hedgehog interacting protein	Homo sapiens	39-42
34304848-8	2022	CONCLUSIONS: PA using normocellular, fresh parathyroid donor tissue that is ABO-compatible, with induction and, at minimum, short-term maintenance IS presents a potentially safe and effective therapeutic option for permanent hypoparathyroidism in patients tolerating IS.	Protactinium	13-15	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	76-79
34335468-8	2021	Gene silencing of JunD reversed the lipotoxic effects induced by PA on beta-cells.	Protactinium	65-67	JunD proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	18-22
34255223-1	2021	The first atmospheric PAHs levels and associated inhalation cancer risk were assessed over southwest Buenos Aires region by deploying PUF disk PAS samplers.	Protactinium	143-146	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	134-137
34181407-8	2021	Cell imaging showed that HCy-Cit-Val or HCy-Gly-Leu-Phe-Gly could image endogenous CTB in lysosome with 6.8-fold or 5.1-fold enhancement of the FL signal and 5.8-fold or 3.4-fold enhancement of the PA signal compared to their inhibitor contrast groups.	Protactinium	198-200	cathepsin B	Homo sapiens	83-86
34160212-5	2021	Both in vitro and in vivo experiments demonstrated that such Au-RRVR nanoparticles could be simultaneously induced by furin and acidic pH to form large aggregates within tumorous tissue resulting in improved tumor accumulation and retention, which can further activate the PA and PTT effect of AuNPs for sensitive imaging and efficient therapy of tumors.	Protactinium	273-275	furin, paired basic amino acid cleaving enzyme	Homo sapiens	118-123
34217271-1	2021	BACKGROUND: Aryl hydrocarbon receptor nuclear translocator like 2 (ARNTL2) is a member of the PAS superfamily.	Protactinium	94-97	aryl hydrocarbon receptor nuclear translocator like 2	Homo sapiens	12-65
34217271-1	2021	BACKGROUND: Aryl hydrocarbon receptor nuclear translocator like 2 (ARNTL2) is a member of the PAS superfamily.	Protactinium	94-97	aryl hydrocarbon receptor nuclear translocator like 2	Homo sapiens	67-73
34277112-10	2021	LTF was elevated in PA-treated skin tissues and TNF-alpha and IFN-gamma-induced HaCaT cells.	Protactinium	20-22	lactotransferrin	Homo sapiens	0-3
34061473-4	2021	Here, PA nanofibers that target the angiotensin I-converting enzyme and the receptor for advanced glycation end-products (RAGE) are developed, as both proteins are overexpressed in the lung with pulmonary hypertension.	Protactinium	6-8	advanced glycosylation end product-specific receptor	Mus musculus	76-120
34061473-4	2021	Here, PA nanofibers that target the angiotensin I-converting enzyme and the receptor for advanced glycation end-products (RAGE) are developed, as both proteins are overexpressed in the lung with pulmonary hypertension.	Protactinium	6-8	advanced glycosylation end product-specific receptor	Mus musculus	122-126
34765322-4	2021	Individuals with greater net increases in PA (AUC) following binge eating at baseline exhibited better treatment response in ICAT-BED at end-of-treatment and follow-up.	Protactinium	42-44	catenin beta interacting protein 1	Homo sapiens	125-129
34277112-13	2021	Moreover, anti-LTF antibody treatment alleviated AD development in PA-induced AD model.	Protactinium	67-69	lactotransferrin	Homo sapiens	15-18
34160442-1	2021	BACKGROUND: Recent observations raised concern that the intravenous recombinant tissue plasminogen activator (rt-PA) may result in damage to stroke patients caused by small artery occlusion (SAO).	Protactinium	112-115	chromosome 20 open reading frame 181	Homo sapiens	80-108
34113940-7	2021	Both in vitro and in vivo experiments demonstrate that the Fe3+@Au1Ag24@PbP nanoplatform presented excellent PA/PT imaging-guided synergetic PTT/PDT/ferroptosis effects toward tumor cells and tumors.	Protactinium	109-111	polycystin 1, transient receptor potential channel interacting	Homo sapiens	72-75
34130460-6	2021	In this work, we developed the first turn-on PA probe (MTR-CO) to visualize the CO level in the lipopolysaccharide (LPS)-induced acute inflammation murine model through PA imaging technology.	Protactinium	45-47	telomerase RNA component	Mus musculus	55-58
34130460-6	2021	In this work, we developed the first turn-on PA probe (MTR-CO) to visualize the CO level in the lipopolysaccharide (LPS)-induced acute inflammation murine model through PA imaging technology.	Protactinium	169-171	telomerase RNA component	Mus musculus	55-58
34130460-7	2021	MTR-CO is composed of a near-infrared absorption cyanine-like dye (MTR-OH) and allyl formate, showing a 10.2-fold PA signal enhancement at 690 nm upon activation by CO.	Protactinium	114-116	telomerase RNA component	Mus musculus	0-3
34130460-7	2021	MTR-CO is composed of a near-infrared absorption cyanine-like dye (MTR-OH) and allyl formate, showing a 10.2-fold PA signal enhancement at 690 nm upon activation by CO.	Protactinium	114-116	telomerase RNA component	Mus musculus	67-70
34130460-9	2021	MTR-CO was then applied for PA imaging of CO in cells and for monitoring the development of acute inflammation in the murine model by tracking the changes of the CO level.	Protactinium	28-30	telomerase RNA component	Mus musculus	0-3
34109188-10	2021	We also review the literature of PA, mostly the RA-like pattern, and the association between PA and ACPA positivity.	Protactinium	93-95	proteinase 3	Homo sapiens	100-104
34061908-7	2021	Modelling revealed that due to a fitness advantage for the PA P653L mutant, reassortment with the wild-type virus to gain wild-type PB1 segment in vivo resulted in the loss of the PB1 resistance mutation K229R.	Protactinium	59-61	polybromo 1	Homo sapiens	132-135
34061908-7	2021	Modelling revealed that due to a fitness advantage for the PA P653L mutant, reassortment with the wild-type virus to gain wild-type PB1 segment in vivo resulted in the loss of the PB1 resistance mutation K229R.	Protactinium	59-61	polybromo 1	Homo sapiens	180-183
34136519-8	2021	Furthermore, whereas PA and LA did not differently modulate the levels of mitochondrial electron transport chain complex proteins, PA induced mitochondrial fragmentation (37%; P < 0.001), decreased MFN-2 (38%; P < 0.05), and caused a drop in mitochondrial membrane potential (11%; P < 0.01) compared to control, with this effect being absent in LA-treated cells.	Protactinium	131-133	mitofusin 2	Homo sapiens	198-203
34353484-1	2021	In this chapter, we discuss the need for the development of enzyme-activatable probes in the field of tumor-targeted photoacoustic (PA) imaging, then we give a brief description of the innovation of designing alkaline phosphatase (ALP)-activatable probes for PA imaging.	Protactinium	259-261	alkaline phosphatase, placental	Homo sapiens	209-229
34353484-1	2021	In this chapter, we discuss the need for the development of enzyme-activatable probes in the field of tumor-targeted photoacoustic (PA) imaging, then we give a brief description of the innovation of designing alkaline phosphatase (ALP)-activatable probes for PA imaging.	Protactinium	259-261	alkaline phosphatase, placental	Homo sapiens	231-234
34353484-3	2021	With this tool, 1P could form nanoparticles 1-NPs under the catalysis of ALP and thus could be used to enhance PA imaging both in vitro and in vivo.	Protactinium	111-113	alkaline phosphatase, placental	Homo sapiens	73-76
34353488-3	2021	In this chapter, we present the synthesis and application of a tumor targeting and caspase-3 activatable PA probe (1-RGD) for real-time and noninvasive imaging of tumor apoptosis.	Protactinium	105-107	caspase 3	Homo sapiens	83-92
34353488-4	2021	1-RGD can be efficiently delivered into tumor tissues and recognized by caspase-3, which triggered efficient proteolysis of DEVD substrate and subsequent intramolecular macrocyclization, followed by in situ self-assembly into nanoparticles, leading to prolonged retention in apoptotic tumors and enhanced PA signals.	Protactinium	305-307	caspase 3	Homo sapiens	72-81
34084717-3	2021	The PA effect was not obvious in amelanotic melanoma, but was seen in melanotic melanoma by PA imaging (PAI) and histopathological correlation in cases of primary melanotic melanoma accompanied by metastatic lymph nodes, including the coexistence of amelanotic melanoma and melanotic melanoma.	Protactinium	4-6	serpin family E member 1	Homo sapiens	104-107
34084717-3	2021	The PA effect was not obvious in amelanotic melanoma, but was seen in melanotic melanoma by PA imaging (PAI) and histopathological correlation in cases of primary melanotic melanoma accompanied by metastatic lymph nodes, including the coexistence of amelanotic melanoma and melanotic melanoma.	Protactinium	92-94	serpin family E member 1	Homo sapiens	104-107
35616304-7	2022	Both cardiorespiratory exercise and resistance exercise elicited a significant (p<0.05) mobilization of highly-differentiated (CD45RA+ CD62L-; CD57+ CD45RA+ CD62L-) CD8+ T-cells into the circulation post-exercise in both PA and PI groups.	Protactinium	221-223	beta-1,3-glucuronyltransferase 1	Homo sapiens	143-147
35178660-2	2022	The objective of the present study is to evaluate the effectiveness of PA on muscle atrophy and to find its active ingredients using dexamethasone-induced muscle ring finger protein-1 (MuRF1) mRNA expression in murine myoblast C2C12 cells.	Protactinium	71-73	tripartite motif-containing 63	Mus musculus	155-183
35178660-2	2022	The objective of the present study is to evaluate the effectiveness of PA on muscle atrophy and to find its active ingredients using dexamethasone-induced muscle ring finger protein-1 (MuRF1) mRNA expression in murine myoblast C2C12 cells.	Protactinium	71-73	tripartite motif-containing 63	Mus musculus	185-190
35178660-3	2022	Dexamethasone-induced MuRF1 expression was significantly suppressed by methanol-soluble part of boiling water extract of PA in a concentration-dependent manner with its IC50 value of 1.5 mg/ml.	Protactinium	121-123	tripartite motif-containing 63	Mus musculus	22-27
35533489-6	2022	In this study, we found, for the first time, that oleic acid/palmitic acid (OA/PA)-induced lipid accumulation was largely abrogated by DDX17 overexpression in both HepG2 (a human hepatocellular carcinoma line) and Hep1-6 (a murine hepatocellular carcinoma line) cells, and this effect was due to a marked reduction in cellular triglyceride (TG) content.	Protactinium	79-81	DEAD-box helicase 17	Homo sapiens	135-140
35533489-6	2022	In this study, we found, for the first time, that oleic acid/palmitic acid (OA/PA)-induced lipid accumulation was largely abrogated by DDX17 overexpression in both HepG2 (a human hepatocellular carcinoma line) and Hep1-6 (a murine hepatocellular carcinoma line) cells, and this effect was due to a marked reduction in cellular triglyceride (TG) content.	Protactinium	79-81	DNL-type zinc finger	Homo sapiens	214-220
35616304-7	2022	Both cardiorespiratory exercise and resistance exercise elicited a significant (p<0.05) mobilization of highly-differentiated (CD45RA+ CD62L-; CD57+ CD45RA+ CD62L-) CD8+ T-cells into the circulation post-exercise in both PA and PI groups.	Protactinium	221-223	CD8a molecule	Homo sapiens	165-168
35507501-6	2022	To further improve the practical performance, we combined UiO-66-TBPE with the polymer polyacrylate (PA) to obtain a flexible hybrid membrane with fast detection performance for styrene vapor within the 30 s. The deeper sensing mechanism of p-xylene and styrene inducing different fluorescence enhancement and fluorescence quenching is explained by a combination of modern characterization techniques and computer simulation.	Protactinium	101-103	Fas activated serine/threonine kinase	Homo sapiens	147-151
35504018-7	2022	We found that three formulations of the PA nanofibers were able to localize to AAA tissue, but the MMP-2 targeting PA substantially outperformed the other nanofibers.	Protactinium	115-117	matrix metallopeptidase 2	Rattus norvegicus	99-104
35500300-5	2022	Among the many transition metals studied, Fe is accommodated by the hydrogel the most due to the favorable affinity of the PA groups in the hydrogel for Fe.	Protactinium	123-125	general transcription factor IIE subunit 1	Homo sapiens	42-44
35500300-5	2022	Among the many transition metals studied, Fe is accommodated by the hydrogel the most due to the favorable affinity of the PA groups in the hydrogel for Fe.	Protactinium	123-125	general transcription factor IIE subunit 1	Homo sapiens	153-155
35543128-13	2022	CONCLUSIONS: RNF213 variants were confirmed to be associated with PA in moyamoya disease.	Protactinium	66-68	ring finger protein 213	Homo sapiens	13-19
35504018-8	2022	Additionally, we demonstrated that the MMP-2 targeting PA nanofibers had an optimal dose of 5 mg (~12 mg/kg).	Protactinium	55-57	matrix metallopeptidase 2	Rattus norvegicus	39-44
35151910-6	2022	METHODS: Here, we developed 2 quantifications methods to explore BRCA1 and RAD51C promoter methylation in a series of 121 Formalin Fixed-Paraffin-Embedded (FFPE) specimens from resected PA without neoadjuvant treatment.	Protactinium	186-188	BRCA1 DNA repair associated	Homo sapiens	65-70
35243699-5	2022	The in vivo PA imaging and photothermal therapy abilities are activated by acidic tumor microenvironment and self-augmented by the reaction between GOx and glucose.	Protactinium	12-14	hydroxyacid oxidase 1	Homo sapiens	148-151
35243699-8	2022	In addition, the in vivo PA imaging with PANITG reveals the tumor pH level which is correlated to the efficiency of the photothermal therapy and to the catalytic activity of GOx at each stage, enabling real-time activatable CDx.	Protactinium	25-27	hydroxyacid oxidase 1	Homo sapiens	174-177
35318857-7	2022	Furthermore, Piezo1 in the remodeled PA from rats with experimental PH was upregulated in comparison to PA from control rats.	Protactinium	37-39	piezo-type mechanosensitive ion channel component 1	Rattus norvegicus	13-19
35151910-6	2022	METHODS: Here, we developed 2 quantifications methods to explore BRCA1 and RAD51C promoter methylation in a series of 121 Formalin Fixed-Paraffin-Embedded (FFPE) specimens from resected PA without neoadjuvant treatment.	Protactinium	186-188	RAD51 paralog C	Homo sapiens	75-81
35440123-4	2022	APL-16-5 binds to both the E3 ligase TRIM25 and IAV polymerase subunit PA, leading to TRIM25 ubiquitination of PA and subsequent degradation of PA in the proteasome.	Protactinium	111-113	tripartite motif containing 25	Homo sapiens	37-43
35472164-6	2022	We identify exposed collagen as the central trigger arresting platelets and initiating subsequent PA in a CypD- and TMEM16F-dependent manner both in vivo and in vitro.	Protactinium	98-100	anoctamin 6	Mus musculus	116-123
35472164-7	2022	Platelet PA promotes binding of the prothrombinase complex to the platelet membrane, greatly enhancing thrombin activity resulting in fibrin formation.	Protactinium	9-11	coagulation factor II	Mus musculus	103-111
35472164-10	2022	Platelet-specific genetic loss of either CypD or TMEM16F as well as combined blockade of platelet GPIIBIIIA and GPVI reduce platelet PA in vivo and aggravate pulmonary inflammatory hemorrhage.	Protactinium	133-135	anoctamin 6	Mus musculus	49-56
35472164-10	2022	Platelet-specific genetic loss of either CypD or TMEM16F as well as combined blockade of platelet GPIIBIIIA and GPVI reduce platelet PA in vivo and aggravate pulmonary inflammatory hemorrhage.	Protactinium	133-135	integrin alpha 2b	Mus musculus	98-107
35472164-10	2022	Platelet-specific genetic loss of either CypD or TMEM16F as well as combined blockade of platelet GPIIBIIIA and GPVI reduce platelet PA in vivo and aggravate pulmonary inflammatory hemorrhage.	Protactinium	133-135	glycoprotein 6 (platelet)	Mus musculus	112-116
35440123-4	2022	APL-16-5 binds to both the E3 ligase TRIM25 and IAV polymerase subunit PA, leading to TRIM25 ubiquitination of PA and subsequent degradation of PA in the proteasome.	Protactinium	111-113	tripartite motif containing 25	Homo sapiens	86-92
35440123-4	2022	APL-16-5 binds to both the E3 ligase TRIM25 and IAV polymerase subunit PA, leading to TRIM25 ubiquitination of PA and subsequent degradation of PA in the proteasome.	Protactinium	144-146	tripartite motif containing 25	Homo sapiens	37-43
35395852-10	2022	Contraction of PA in response to prostaglandin-F2alpha and endothelin-1 were significantly reduced in the +/44insG rats.	Protactinium	15-17	endothelin 1	Rattus norvegicus	59-71
35302343-8	2022	Additionally, the relationships between peptide block location and lipid block size provide further information on the chemical structure-function relationships of PA micelles for the delivery of VIP as well as potentially for other peptides more broadly.	Protactinium	164-166	vasoactive intestinal peptide	Homo sapiens	196-199
35469222-6	2022	Furthermore, we established the NAFLD cell model with LO2 cells induced using PA; ELISA showed that the levels of TG, ALT, and AST were significantly improved by indoximod.	Protactinium	78-80	solute carrier family 17 member 5	Homo sapiens	127-130
35464376-8	2022	Results indicated an enhancing effect of PA on IgM, interleukins 2 and 4, interferon-gamma, and IgG subclass responses.	Protactinium	41-43	interleukin 2	Homo sapiens	52-72
35464376-8	2022	Results indicated an enhancing effect of PA on IgM, interleukins 2 and 4, interferon-gamma, and IgG subclass responses.	Protactinium	41-43	interferon gamma	Homo sapiens	74-90
35395852-12	2022	CONCLUSIONS: The present study demonstrates that the Bmpr2 mutation promotes dedifferentiation of PA smooth muscle cells, late PVD and RV myocardial fibrosis and adversely impacts both the natural and post-treatment courses of MCT-PH in rats with significant effects only in the late stages and warrants preclinical studies using this new genetic model to optimize treatment outcomes of heritable PAH.	Protactinium	98-100	bone morphogenetic protein receptor type 2	Rattus norvegicus	53-58
35433254-6	2022	To address this problem, we proposed a method called time-reversed photoacoustic wave guided time-reversed ultrasonically encoded (TRPA-TRUE) optical focusing by integrating accurate ultrasonic focusing through acoustically heterogeneous medium guided by time-reversing PA signals, and the ultrasound modulation of diffused coherent light with optical phase conjugation (OPC), achieving dynamic focusing of light into scattering medium.	Protactinium	270-272	tryptase gamma 1	Homo sapiens	131-135
35422858-13	2022	In addition, we further discovered that quercetin could increase ACC phosphorylation and CPT1alpha expression in PA-induced HepG2 cells.	Protactinium	113-115	carnitine palmitoyltransferase 1A	Homo sapiens	89-98
35366945-6	2022	LPS-stimulated neutrophils show a significantly decreased intracellular accumulation of galectin-3 in the presence of PA functionalization compared to Control (unmodified PLCA scaffolds).	Protactinium	118-120	galectin 3	Rattus norvegicus	88-98
35373347-10	2022	As a ceramide precursor, PA induces intracellular ceramide generation through TLR4 signaling, which could be abolished by an inhibitor of ceramide synthesis.	Protactinium	25-27	toll-like receptor 4	Rattus norvegicus	78-82
35373347-11	2022	Furthermore, mechanistic investigations demonstrated that pharmacological or genetic inhibition of TLR4 attenuated PA-induced cell death and the corresponding ceramide production.	Protactinium	115-117	toll-like receptor 4	Rattus norvegicus	99-103
35387554-4	2022	The accumulation of circ-MYBL2 and miR-19a in PA was detected by RT-qPCR.	Protactinium	46-48	MYB proto-oncogene like 2	Homo sapiens	25-30
35387554-4	2022	The accumulation of circ-MYBL2 and miR-19a in PA was detected by RT-qPCR.	Protactinium	46-48	microRNA 19a	Homo sapiens	35-42
35067649-4	2022	We thus investigated the association between PA and circulating interleukin-6 (IL-6) and moderation of that association by sleep in a sample of women with TMD and sleep difficulties.	Protactinium	45-47	interleukin 6	Homo sapiens	64-77
35141910-9	2022	On the PA sites 12R-LOX was particularly lower in the Albino Africans compared with the Black African and Caucasian women.	Protactinium	7-9	arachidonate 12-lipoxygenase, 12R type	Homo sapiens	16-23
35168091-6	2022	PA are created by modeling the pharmaceutical experiment about DRP and the thread of their criticality.	Protactinium	0-2	utrophin	Homo sapiens	63-66
35496324-9	2022	In ABT+PA, but not BT or BT+PA, lower grit related to higher weight loss at 12 and 24 months, session attendance, and perceived intervention effectiveness.	Protactinium	7-9	Rho GTPase activating protein 32	Homo sapiens	38-42
35067649-4	2022	We thus investigated the association between PA and circulating interleukin-6 (IL-6) and moderation of that association by sleep in a sample of women with TMD and sleep difficulties.	Protactinium	45-47	interleukin 6	Homo sapiens	79-83
35067649-9	2022	Surprisingly, when sleep was poor, PA predicted greater IL-6.	Protactinium	35-37	interleukin 6	Homo sapiens	56-60
35067649-10	2022	CONCLUSIONS: The potential salutary effects of PA on resting IL-6 erode when sleep is poor, underscoring the importance of considering sleep in conceptual and intervention models of TMD.	Protactinium	47-49	interleukin 6	Homo sapiens	61-65
35266590-11	2022	Additionally, a correlation between CB1 mediated-signaling in the NBM and freezing in PA was found, suggesting that the endocannabinoid system might be responsible for modulating fear response induced by aversive memories.	Protactinium	86-88	cannabinoid receptor 1	Rattus norvegicus	36-39
35408631-1	2022	Perindopril arginine (PA) as an angiotensin-converting enzyme (ACE) inhibitor is widely used in cardiovascular diseases, especially in systemic hypertension and heart failure.	Protactinium	22-24	angiotensin I converting enzyme	Homo sapiens	32-61
35408631-1	2022	Perindopril arginine (PA) as an angiotensin-converting enzyme (ACE) inhibitor is widely used in cardiovascular diseases, especially in systemic hypertension and heart failure.	Protactinium	22-24	angiotensin I converting enzyme	Homo sapiens	63-66
35294003-3	2022	In Arabidopsis thaliana, AtTT19 is necessary for both anthocyanin and PA accumulation.	Protactinium	70-72	glutathione S-transferase phi 12	Arabidopsis thaliana	25-31
35152093-2	2022	Recently, we first reported phanginin A (PA, 1), a natural cassane diterpenoid isolated from the seeds of Caesalpinia sappan, exhibited potent anti-diabetic effect through activation of SIK1 and increasing PDE4 activity to inhibit hepatic gluconeogenesis pathway by suppressing the cAMP/PKA/CREB pathway in the liver.	Protactinium	41-43	salt inducible kinase 1	Mus musculus	186-190
35152093-2	2022	Recently, we first reported phanginin A (PA, 1), a natural cassane diterpenoid isolated from the seeds of Caesalpinia sappan, exhibited potent anti-diabetic effect through activation of SIK1 and increasing PDE4 activity to inhibit hepatic gluconeogenesis pathway by suppressing the cAMP/PKA/CREB pathway in the liver.	Protactinium	41-43	cAMP responsive element binding protein 1	Homo sapiens	291-295
35454090-6	2022	(4) The present review provides a novel and complete scheme for the biosynthesis of Pas, including glycine, glutamate, proline and others as PA precursors, and provides a hypothesis that the agmatine pathway may rescue putrescine production when ODC knockout seems to be lethal (solving the apparent contradiction in the literature).	Protactinium	84-87	ornithine decarboxylase 1	Homo sapiens	246-249
35277519-4	2022	The combination of nanozyme and GOx can induce the PA signal variation of endogenous molecules.	Protactinium	51-53	hydroxyacid oxidase 1	Homo sapiens	32-35
35365489-9	2022	In vitro, TMZ reduced the oxidative stress reaction, increased the ratios of p-AKT/AKT and p-IRS1/IRS1, and attenuated the insulin stimulation of PA-induced glucose uptake.	Protactinium	146-148	insulin	Homo sapiens	123-130
34542211-5	2022	Localization of the PA-tag was confirmed in neural stem cells marked with Pax6 in the embryonic brain.	Protactinium	20-22	paired box 6	Mus musculus	74-78
35212873-2	2022	In anthrax intoxication, PA interacts with capillary morphogenesis gene 2 (CMG2) and tumor endothelial marker 8 (TEM8).	Protactinium	25-27	ANTXR cell adhesion molecule 2	Homo sapiens	75-79
34999396-6	2022	Additionally, excessive reactive oxygen species (ROS) generation was also strongly down-regulated by LIEN in cells upon PA stimulation through enhancing nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation.	Protactinium	120-122	nuclear factor, erythroid derived 2, like 2	Mus musculus	153-196
34999396-6	2022	Additionally, excessive reactive oxygen species (ROS) generation was also strongly down-regulated by LIEN in cells upon PA stimulation through enhancing nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation.	Protactinium	120-122	nuclear factor, erythroid derived 2, like 2	Mus musculus	198-202
34999396-7	2022	Moreover, PA-triggered inflammatory response was markedly restrained by LIEN via the blockage of TGF-beta-activating kinase 1/nuclear factor-kappaB (TAK1/NF-kappaB) signaling.	Protactinium	10-12	mitogen-activated protein kinase kinase kinase 7	Mus musculus	149-153
34999396-7	2022	Moreover, PA-triggered inflammatory response was markedly restrained by LIEN via the blockage of TGF-beta-activating kinase 1/nuclear factor-kappaB (TAK1/NF-kappaB) signaling.	Protactinium	10-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	154-163
35267550-12	2022	Although pretreatment with IFN-alpha was associated with a shortened median PFS of 81 months (43-118) after PA therapy, this tendency of inferior PFS did not result in inferior OS.	Protactinium	108-110	interferon alpha 1	Homo sapiens	27-36
35175041-2	2022	In particular, tissues that carry blood and water produce the lowest PA background in the wavelength range of 1050 to 1150 nm.	Protactinium	69-71	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Homo sapiens	123-125
35175041-6	2022	This conversion extended the conjugate system of the molecule and shifted the absorption peak from 520 to 1065 nm, which resulted in a strong PA signal after irradiation with a 1065 nm laser.	Protactinium	142-144	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Homo sapiens	111-113
35175041-6	2022	This conversion extended the conjugate system of the molecule and shifted the absorption peak from 520 to 1065 nm, which resulted in a strong PA signal after irradiation with a 1065 nm laser.	Protactinium	142-144	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Homo sapiens	182-184
35175041-7	2022	At a detection limit of 0.6 nM, a good linear relationship within the range of 5-1000 nM was obtained for the PA signal intensity versus the concentration of  OH.	Protactinium	110-112	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Homo sapiens	28-30
35175041-7	2022	At a detection limit of 0.6 nM, a good linear relationship within the range of 5-1000 nM was obtained for the PA signal intensity versus the concentration of  OH.	Protactinium	110-112	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Homo sapiens	86-88
35212873-2	2022	In anthrax intoxication, PA interacts with capillary morphogenesis gene 2 (CMG2) and tumor endothelial marker 8 (TEM8).	Protactinium	25-27	ANTXR cell adhesion molecule 1	Homo sapiens	113-117
35212873-3	2022	Here, we show that CMG2 mediates the antiangiogenic effects of PA and is required for growth-factor-induced chemotaxis.	Protactinium	63-65	ANTXR cell adhesion molecule 2	Homo sapiens	19-23
35212873-5	2022	Furthermore, the antiangiogenic effect of PA was abolished when the CMG2, but not the TEM8, gene was disrupted.	Protactinium	42-44	anthrax toxin receptor 2	Mus musculus	68-72
35212873-7	2022	Ex vivo experiments demonstrated that CMG2 (but not TEM8) is required for PA activity in human dermal microvascular endothelial cell (HMVEC-d) network formation assays.	Protactinium	74-76	ANTXR cell adhesion molecule 2	Homo sapiens	38-42
35212873-8	2022	Remarkably, blocking CMG2-ligand binding with PA or CRISPR knockout abolishes endothelial cell chemotaxis but not chemokinesis in microfluidic migration assays.	Protactinium	46-48	ANTXR cell adhesion molecule 2	Homo sapiens	21-25
34549301-3	2022	Therefore, we aimed to investigate the possible inhibitory effect of PA on renal Wnt/beta-catenin signalling in CKD.	Protactinium	69-71	Wnt family member 1	Rattus norvegicus	81-84
35222033-9	2022	Inhibition of miR-21 expression or Fenofibrate (PPARalpha agonist) administration prevented the decrease of PPARalpha in renal tubular epithelial cells under high glucose (HG) and high fat (Palmitic acid, PA) conditions, alleviating lipid metabolism disorders and reducing mitochondrial dynamics and inflammation.	Protactinium	205-207	microRNA 21a	Mus musculus	14-20
35222033-9	2022	Inhibition of miR-21 expression or Fenofibrate (PPARalpha agonist) administration prevented the decrease of PPARalpha in renal tubular epithelial cells under high glucose (HG) and high fat (Palmitic acid, PA) conditions, alleviating lipid metabolism disorders and reducing mitochondrial dynamics and inflammation.	Protactinium	205-207	peroxisome proliferator activated receptor alpha	Mus musculus	48-57
35222033-9	2022	Inhibition of miR-21 expression or Fenofibrate (PPARalpha agonist) administration prevented the decrease of PPARalpha in renal tubular epithelial cells under high glucose (HG) and high fat (Palmitic acid, PA) conditions, alleviating lipid metabolism disorders and reducing mitochondrial dynamics and inflammation.	Protactinium	205-207	peroxisome proliferator activated receptor alpha	Mus musculus	108-117
35506099-9	2022	The PA pulsatility was lower than that expected based on observations in humans: sPAP matched ~120%mPAP only and PA pulse pressure was markedly lower than mPAP.	Protactinium	4-6	PDZK1 interacting protein 1	Homo sapiens	81-85
34549301-3	2022	Therefore, we aimed to investigate the possible inhibitory effect of PA on renal Wnt/beta-catenin signalling in CKD.	Protactinium	69-71	catenin beta 1	Rattus norvegicus	85-97
34549301-10	2022	CONCLUSIONS: These results suggest a new therapeutic benefit of PA in ameliorating CKD in rats through its up-regulatory effect on renal klotho thereby preventing Wnt/beta-catenin reactivation and RAS gene expression.	Protactinium	64-66	Klotho	Rattus norvegicus	137-143
35182103-7	2022	Moreover, in vivo test demonstrated that oral administration of insulin-loaded HCP exerts strong and continuous hyperthermia effect (with PA of 13.8%).	Protactinium	138-140	insulin	Homo sapiens	64-71
35182103-7	2022	Moreover, in vivo test demonstrated that oral administration of insulin-loaded HCP exerts strong and continuous hyperthermia effect (with PA of 13.8%).	Protactinium	138-140	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	79-82
35151259-2	2022	The protocol of extracapsular resection(ER), which considers the pseudocapsule as the PA boundary for surgical removal, has also been introduced gradually.	Protactinium	86-88	epiregulin	Homo sapiens	40-42
35151259-7	2022	Although the meta-analysis showed no significant difference in complete resection, a sensitivity analysis revealed that ER was more conducive to total PA resection than IR.	Protactinium	151-153	epiregulin	Homo sapiens	120-122
34978755-9	2022	Chemical or molecular inhibition of PKM2 restores the normal PKM2/PKM1 ratio, reduces PH, RVSP and RVH, and regresses adverse PA remodeling.	Protactinium	126-128	pyruvate kinase M1/2	Rattus norvegicus	36-40
35022664-13	2022	TRANSLATIONAL PERSPECTIVE: In heart failure (HF) related (Group 2) PH, despite remodeling of pulmonary veins (PV) and arteries (PA), therapies targeting PA biology altered in Group 1 PH have not shown consistent benefit.	Protactinium	153-155	phenylalanine hydroxylase	Homo sapiens	183-185
34549301-10	2022	CONCLUSIONS: These results suggest a new therapeutic benefit of PA in ameliorating CKD in rats through its up-regulatory effect on renal klotho thereby preventing Wnt/beta-catenin reactivation and RAS gene expression.	Protactinium	64-66	Wnt family member 1	Rattus norvegicus	163-166
34549301-10	2022	CONCLUSIONS: These results suggest a new therapeutic benefit of PA in ameliorating CKD in rats through its up-regulatory effect on renal klotho thereby preventing Wnt/beta-catenin reactivation and RAS gene expression.	Protactinium	64-66	catenin beta 1	Rattus norvegicus	167-179
2514093-8	1989	Kinetic analysis demonstrated that the procaryote-produced PAI-1 had an inhibitory activity towards all three forms of PA that resembled that of natural PAI-1 with association rate constants of approximately 10(7) M-1 s-1.	Protactinium	59-61	serpin family E member 1	Homo sapiens	153-158
35178989-1	2022	The present study investigated the pharmaceutical effect and underlying mechanism of Zexie Decoction(ZXD) on nonalcoholic fatty liver disease(NAFLD) in vitro and in vivo via the LKB1/AMPK/PGC-1alpha pathway based on palmitic acid(PA)-induced lipid accumulation model and high-fat diet(HFD)-induced NAFLD model in mice.	Protactinium	230-232	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	188-198
35178989-2	2022	As revealed by the MTT assay, ZXD had no effect on HepG2 activity, but dose-dependently down-regulated alanine aminotransferase(ALT) and aspartate aminotransferase(AST) in the liver cell medium induced by PA, and decreased the plasma levels of ALT and AST, and total cholesterol(TC) and triglyceride(TG) levels in the liver.	Protactinium	205-207	glutamic pyruvic transaminase, soluble	Mus musculus	128-131
35178989-2	2022	As revealed by the MTT assay, ZXD had no effect on HepG2 activity, but dose-dependently down-regulated alanine aminotransferase(ALT) and aspartate aminotransferase(AST) in the liver cell medium induced by PA, and decreased the plasma levels of ALT and AST, and total cholesterol(TC) and triglyceride(TG) levels in the liver.	Protactinium	205-207	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	164-167
2512375-9	1989	PAs released from sympathetic neurons and PC12 cells interact with 3 different binding sites on the cell surface: (1) an inhibitor of serine proteases (including uPA and tPA) is bound to the surface via a heparinase-sensitive site; (2) a uPA-selective binding site is present in patches on the bottom surface of PC12 cells; and (3) a tPA-selective binding site with high affinity (KD = 23 +/- 10 nM) and high capacity (340,000 +/- 130,000 sites/neuron) for 125I-tPA is homogeneously distributed over the entire surface.	Protactinium	0-3	plasminogen activator, urokinase	Rattus norvegicus	162-165
2614195-8	1989	The number of tumor cells in mice treated with E2 and P was less than in mice given P alone because of a secretive function seen in the appearance of PAS positive granules in the glandular epithelium and degenerative change such as swelling.	Protactinium	150-153	ATPase, H+ transporting, lysosomal V1 subunit E1	Mus musculus	47-55
2687298-4	1989	An assay for PSF in rat serum was devised using PA from perirenal fat of 3-month-old Fischer 344 rats grown first to confluence in FCS for 8 days and then for the next 3 days in test serum, followed by measurement of triglyceride (TG) and glycerol-3-phosphate dehydrogenase (GPDH).	Protactinium	48-50	interleukin 3	Mus musculus	13-16
2512375-9	1989	PAs released from sympathetic neurons and PC12 cells interact with 3 different binding sites on the cell surface: (1) an inhibitor of serine proteases (including uPA and tPA) is bound to the surface via a heparinase-sensitive site; (2) a uPA-selective binding site is present in patches on the bottom surface of PC12 cells; and (3) a tPA-selective binding site with high affinity (KD = 23 +/- 10 nM) and high capacity (340,000 +/- 130,000 sites/neuron) for 125I-tPA is homogeneously distributed over the entire surface.	Protactinium	0-3	plasminogen activator, tissue type	Rattus norvegicus	170-173
2512375-9	1989	PAs released from sympathetic neurons and PC12 cells interact with 3 different binding sites on the cell surface: (1) an inhibitor of serine proteases (including uPA and tPA) is bound to the surface via a heparinase-sensitive site; (2) a uPA-selective binding site is present in patches on the bottom surface of PC12 cells; and (3) a tPA-selective binding site with high affinity (KD = 23 +/- 10 nM) and high capacity (340,000 +/- 130,000 sites/neuron) for 125I-tPA is homogeneously distributed over the entire surface.	Protactinium	0-3	plasminogen activator, urokinase	Rattus norvegicus	238-241
2512375-9	1989	PAs released from sympathetic neurons and PC12 cells interact with 3 different binding sites on the cell surface: (1) an inhibitor of serine proteases (including uPA and tPA) is bound to the surface via a heparinase-sensitive site; (2) a uPA-selective binding site is present in patches on the bottom surface of PC12 cells; and (3) a tPA-selective binding site with high affinity (KD = 23 +/- 10 nM) and high capacity (340,000 +/- 130,000 sites/neuron) for 125I-tPA is homogeneously distributed over the entire surface.	Protactinium	0-3	plasminogen activator, tissue type	Rattus norvegicus	334-337
2512375-9	1989	PAs released from sympathetic neurons and PC12 cells interact with 3 different binding sites on the cell surface: (1) an inhibitor of serine proteases (including uPA and tPA) is bound to the surface via a heparinase-sensitive site; (2) a uPA-selective binding site is present in patches on the bottom surface of PC12 cells; and (3) a tPA-selective binding site with high affinity (KD = 23 +/- 10 nM) and high capacity (340,000 +/- 130,000 sites/neuron) for 125I-tPA is homogeneously distributed over the entire surface.	Protactinium	0-3	plasminogen activator, tissue type	Rattus norvegicus	334-337
2551068-4	1989	The addition of tranexamic acid to the mixture of sct-PA and K4 inhibited the rate of the conversion of sct-PA by plasmin.	Protactinium	54-56	plasminogen	Homo sapiens	114-121
2559867-8	1989	Our results suggest that nerve edema and increased blood-nerve barrier PA are secondary to polyol production and can be prevented by inhibiting aldose reductase.	Protactinium	71-73	aldo-keto reductase family 1 member B1	Rattus norvegicus	144-160
2594021-4	1989	Of 830 hepatic cirrhosises in adult age, in eight cases PAS positive, diastase-resistant AAT immunreactive globules occurred in periportal hepatocytes, suggesting AAT deficiency; however, the AAT level and fenotype of these patients were not known.	Protactinium	56-59	serpin family A member 1	Homo sapiens	163-166
2594021-5	1989	Examination of possibility of AAT deficiency should be performed in every case, where the cause of liver disease is unsolved; this examination is especially indicated by the presence of typical PAS positive, diastase-resistant, AAT immunreactive globules in hepatocytes.	Protactinium	194-197	serpin family A member 1	Homo sapiens	30-33
2551068-3	1989	The addition of the fragments of plasminogen such as kringle 1 to 3 (K1-3), and K4 resulted in the facilitation of the conversion of sct-PA to tct-PA by plasmin.	Protactinium	136-139	keratin 1	Homo sapiens	69-73
2551068-3	1989	The addition of the fragments of plasminogen such as kringle 1 to 3 (K1-3), and K4 resulted in the facilitation of the conversion of sct-PA to tct-PA by plasmin.	Protactinium	136-139	plasminogen	Homo sapiens	33-40
2551068-5	1989	These results suggest that binding of lysine binding sites of plasmin or plasminogen with sct-PA enhanced its conversion to tct-PA by plasmin, and that there is a site on a t-PA molecule to bind to plasminogen or plasmin.	Protactinium	93-96	plasminogen	Homo sapiens	62-69
2551068-5	1989	These results suggest that binding of lysine binding sites of plasmin or plasminogen with sct-PA enhanced its conversion to tct-PA by plasmin, and that there is a site on a t-PA molecule to bind to plasminogen or plasmin.	Protactinium	93-96	plasminogen	Homo sapiens	73-80
2551068-5	1989	These results suggest that binding of lysine binding sites of plasmin or plasminogen with sct-PA enhanced its conversion to tct-PA by plasmin, and that there is a site on a t-PA molecule to bind to plasminogen or plasmin.	Protactinium	93-96	plasminogen	Homo sapiens	73-80
2502553-4	1989	The serum GH response to GHRH during NaCl infusion was significantly lower in the TPN subjects than in the PA subjects.	Protactinium	107-109	growth hormone 1	Homo sapiens	10-12
2588960-8	1989	Significant relationships were observed between T1/2 of 125I-labeled fibrinogen and the following: plasma levels of vWF: Ag both before and after the venous occlusion, PA activities after the occlusion, PA antigen before the occlusion, and the net decrease in PA activities and the net increase in PA antigen as a result of the occlusion.	Protactinium	168-170	fibrinogen beta chain	Homo sapiens	69-79
2588960-8	1989	Significant relationships were observed between T1/2 of 125I-labeled fibrinogen and the following: plasma levels of vWF: Ag both before and after the venous occlusion, PA activities after the occlusion, PA antigen before the occlusion, and the net decrease in PA activities and the net increase in PA antigen as a result of the occlusion.	Protactinium	203-205	fibrinogen beta chain	Homo sapiens	69-79
2588960-8	1989	Significant relationships were observed between T1/2 of 125I-labeled fibrinogen and the following: plasma levels of vWF: Ag both before and after the venous occlusion, PA activities after the occlusion, PA antigen before the occlusion, and the net decrease in PA activities and the net increase in PA antigen as a result of the occlusion.	Protactinium	203-205	fibrinogen beta chain	Homo sapiens	69-79
2588960-8	1989	Significant relationships were observed between T1/2 of 125I-labeled fibrinogen and the following: plasma levels of vWF: Ag both before and after the venous occlusion, PA activities after the occlusion, PA antigen before the occlusion, and the net decrease in PA activities and the net increase in PA antigen as a result of the occlusion.	Protactinium	203-205	fibrinogen beta chain	Homo sapiens	69-79
2588960-9	1989	Significant relationships were also observed between j3x of fibrinogen and the following: plasma levels of vWF: Ag both before and after the venous occlusion, vWF: RCo after the occlusion, PA activities after the occlusion, PA antigen before the occlusion, and the net decrease in PA activities resulting from the occlusion.	Protactinium	189-191	fibrinogen beta chain	Homo sapiens	60-70
2588960-9	1989	Significant relationships were also observed between j3x of fibrinogen and the following: plasma levels of vWF: Ag both before and after the venous occlusion, vWF: RCo after the occlusion, PA activities after the occlusion, PA antigen before the occlusion, and the net decrease in PA activities resulting from the occlusion.	Protactinium	224-226	fibrinogen beta chain	Homo sapiens	60-70
2588960-9	1989	Significant relationships were also observed between j3x of fibrinogen and the following: plasma levels of vWF: Ag both before and after the venous occlusion, vWF: RCo after the occlusion, PA activities after the occlusion, PA antigen before the occlusion, and the net decrease in PA activities resulting from the occlusion.	Protactinium	224-226	fibrinogen beta chain	Homo sapiens	60-70
2793680-6	1989	Alveolar pressure (PA) was higher on MEFV than on PEFV maneuvers in asthmatic subjects; comparisons between PA (on PEFV and MEFV maneuvers) in normal subjects varied at different lung volumes.	Protactinium	19-21	MEFV innate immuity regulator, pyrin	Homo sapiens	37-41
2513300-4	1989	The serological specificities of the IF-negative/PA-positive specimens were tested by using a newly developed PA inhibition (PAI) test.	Protactinium	110-112	serpin family E member 1	Homo sapiens	125-128
2513300-6	1989	Sixty of the 104 specimens collected randomly from the IF-negative/PA-positive donors were PAI-positive.	Protactinium	67-69	serpin family E member 1	Homo sapiens	91-94
2505772-7	1989	By comparing the 3H/32P ratios of PA and PEt to that of PC, it is concluded that PA and PEt are formed exclusively by a PLD that catalyzes both hydrolysis and transphosphatidylation between PC and ethanol.	Protactinium	34-36	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	120-123
2505772-7	1989	By comparing the 3H/32P ratios of PA and PEt to that of PC, it is concluded that PA and PEt are formed exclusively by a PLD that catalyzes both hydrolysis and transphosphatidylation between PC and ethanol.	Protactinium	81-83	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	120-123
2502553-4	1989	The serum GH response to GHRH during NaCl infusion was significantly lower in the TPN subjects than in the PA subjects.	Protactinium	107-109	growth hormone releasing hormone	Homo sapiens	25-29
2502553-5	1989	During the Met-hGH infusion, the serum GH response to GHRH in the PA subjects was significantly lower than that after the NaCl infusion, whereas in the TPN subjects the response was similar to that during the NaCl infusion.	Protactinium	66-68	growth hormone 1	Homo sapiens	16-18
2502553-5	1989	During the Met-hGH infusion, the serum GH response to GHRH in the PA subjects was significantly lower than that after the NaCl infusion, whereas in the TPN subjects the response was similar to that during the NaCl infusion.	Protactinium	66-68	growth hormone releasing hormone	Homo sapiens	54-58
2502553-6	1989	The mean integrated areas under the GH response-time curve after GHRH treatment were 3963 +/- 2086 min/micrograms.L following NaCl infusion and 413 +/- 64 min/micrograms.L following Met-hGH infusion in PA subjects; they were 1127 +/- 500 min/micrograms.L following NaCl infusion and 1456 +/- 682 min/micrograms.L during Met-hGH infusion in the TPN subjects.	Protactinium	202-204	growth hormone 1	Homo sapiens	36-38
2502553-6	1989	The mean integrated areas under the GH response-time curve after GHRH treatment were 3963 +/- 2086 min/micrograms.L following NaCl infusion and 413 +/- 64 min/micrograms.L following Met-hGH infusion in PA subjects; they were 1127 +/- 500 min/micrograms.L following NaCl infusion and 1456 +/- 682 min/micrograms.L during Met-hGH infusion in the TPN subjects.	Protactinium	202-204	growth hormone releasing hormone	Homo sapiens	65-69
2546796-4	1989	The potentiation by adrenaline of thrombin-induced PLC activation measured as [32P]PA formation and final platelet responses was, however, not blocked by EIPA, even at low concentrations of thrombin.	Protactinium	83-85	coagulation factor II, thrombin	Homo sapiens	34-42
2753160-6	1989	Whereas fMLP induced a maximum rise in PA and AAG at 30-45 s, these products began to appear only after 1 min upon cell incubation with PMA.	Protactinium	39-41	formyl peptide receptor 1	Homo sapiens	8-12
2811869-3	1989	Antibodies formed in response to a synthetic PAF analog coupled to a protein carrier were detected with two types of solid phases: PAF non-covalently adsorbed onto NC and the PAF analog covalently linked to PA.	Protactinium	45-47	PCNA clamp associated factor	Homo sapiens	131-134
2811869-3	1989	Antibodies formed in response to a synthetic PAF analog coupled to a protein carrier were detected with two types of solid phases: PAF non-covalently adsorbed onto NC and the PAF analog covalently linked to PA.	Protactinium	45-47	PCNA clamp associated factor	Homo sapiens	131-134
2508258-5	1989	After 90 min, in plasma samples containing anti-rt-PA-IgG to inhibit in vitro effects, fibrinogen was decreased to 54%, plasminogen to 52%, alpha 2-antiplasmin to 25%, alpha 2-macroglobulin to 90% and antithrombin III to 85% of initial values.	Protactinium	51-53	fibrinogen beta chain	Homo sapiens	87-97
2527866-4	1989	Both CF sera derived from PA-positive patients and PA supernatant interfered with the appearance of interleukin 2 (IL-2) receptors and with the functional enhancement caused by exogenously added IL-2.	Protactinium	26-28	interleukin 2	Homo sapiens	100-113
2527866-4	1989	Both CF sera derived from PA-positive patients and PA supernatant interfered with the appearance of interleukin 2 (IL-2) receptors and with the functional enhancement caused by exogenously added IL-2.	Protactinium	26-28	interleukin 2	Homo sapiens	115-119
2527866-4	1989	Both CF sera derived from PA-positive patients and PA supernatant interfered with the appearance of interleukin 2 (IL-2) receptors and with the functional enhancement caused by exogenously added IL-2.	Protactinium	26-28	interleukin 2	Homo sapiens	195-199
2527866-4	1989	Both CF sera derived from PA-positive patients and PA supernatant interfered with the appearance of interleukin 2 (IL-2) receptors and with the functional enhancement caused by exogenously added IL-2.	Protactinium	51-53	interleukin 2	Homo sapiens	100-113
2527866-4	1989	Both CF sera derived from PA-positive patients and PA supernatant interfered with the appearance of interleukin 2 (IL-2) receptors and with the functional enhancement caused by exogenously added IL-2.	Protactinium	51-53	interleukin 2	Homo sapiens	115-119
2527866-4	1989	Both CF sera derived from PA-positive patients and PA supernatant interfered with the appearance of interleukin 2 (IL-2) receptors and with the functional enhancement caused by exogenously added IL-2.	Protactinium	51-53	interleukin 2	Homo sapiens	195-199
2741339-4	1989	Examination of the ability of paired combinations of the P proteins to associate indicated that PB1 contained independent binding sites for PB2 and PA, and so probably formed the backbone of the complex.	Protactinium	148-150	polybromo 1 L homeolog	Xenopus laevis	96-99
2742883-6	1989	PA-DPH binds to rat hepatic fatty acid binding protein (hFABP) and bovine serum albumin at PA-DPH/protein molar ratios of 1.5:1 and at least 6:1, respectively.	Protactinium	0-2	fatty acid binding protein 3	Homo sapiens	56-61
2508258-5	1989	After 90 min, in plasma samples containing anti-rt-PA-IgG to inhibit in vitro effects, fibrinogen was decreased to 54%, plasminogen to 52%, alpha 2-antiplasmin to 25%, alpha 2-macroglobulin to 90% and antithrombin III to 85% of initial values.	Protactinium	51-53	serpin family C member 1	Homo sapiens	201-217
2469454-4	1989	A high degree of glycosylation of MSA molecule was shown by its poor staining with Coomassie blue but good staining in a PAS-silver stain.	Protactinium	121-124	thyroid peroxidase	Homo sapiens	34-37
2787094-8	1989	The diagnosis of alpha-1-antitrypsin deficiency was made on the basis of low values in the serum and on the basis of liver biopso and findings of typical PAS positive inclusions in the endoplasmic reticulum of hepatocytes.	Protactinium	154-157	serpin family A member 1	Homo sapiens	17-36
2707846-2	1989	Acid mucin was differentiated from neutral mucin by the alcian blue/PAS technique and sulphomucin by the high iron diamine/alcian blue technique.	Protactinium	68-71	LOC100508689	Homo sapiens	5-10
2770729-3	1989	The further increase in CPA induces the corresponding increase in theta PA up to the value which provides ZPA theta PA greater than 0.76, and is accompanied by drastic decrease of macromolecule"s dimensions and partial DNA condensation as well.	Protactinium	25-27	zona pellucida glycoprotein 2	Homo sapiens	106-109
2770729-3	1989	The further increase in CPA induces the corresponding increase in theta PA up to the value which provides ZPA theta PA greater than 0.76, and is accompanied by drastic decrease of macromolecule"s dimensions and partial DNA condensation as well.	Protactinium	72-74	carboxypeptidase A1	Homo sapiens	24-27
2770729-3	1989	The further increase in CPA induces the corresponding increase in theta PA up to the value which provides ZPA theta PA greater than 0.76, and is accompanied by drastic decrease of macromolecule"s dimensions and partial DNA condensation as well.	Protactinium	72-74	zona pellucida glycoprotein 2	Homo sapiens	106-109
2563345-9	1989	Mucin histochemistry showed PAS-positive cells also strongly stained by LA lectin in the heterotopic tissue, differentiating the rectal epithelium that remained unstained.	Protactinium	28-31	LOC100508689	Homo sapiens	0-5
2922705-7	1989	This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG.	Protactinium	5-7	plasminogen	Homo sapiens	102-105
2922705-7	1989	This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG.	Protactinium	5-7	plasminogen	Homo sapiens	170-173
2922705-7	1989	This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG.	Protactinium	5-7	plasminogen	Homo sapiens	170-173
2922705-7	1989	This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG.	Protactinium	5-7	plasminogen	Homo sapiens	170-173
2922705-7	1989	This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG.	Protactinium	119-121	plasminogen	Homo sapiens	102-105
2922705-7	1989	This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG.	Protactinium	119-121	plasminogen	Homo sapiens	170-173
2922705-7	1989	This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG.	Protactinium	119-121	plasminogen	Homo sapiens	170-173
2922705-7	1989	This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG.	Protactinium	119-121	plasminogen	Homo sapiens	170-173
3139763-2	1988	Mononuclear phagocytes are known to produce both urokinase-type plasminogen activator (u-PA) and a specific PA inhibitor, PAI-2.	Protactinium	89-91	plasminogen activator, urokinase	Homo sapiens	49-85
2475921-5	1989	In the children with PA, the alpha 2-MG levels were significantly lower than predicted based on age alone and were similar to the predicted values based on log10 [D-S] levels.	Protactinium	21-23	alpha-2-macroglobulin	Homo sapiens	29-39
2612439-2	1989	The pHi values were obtained from the chemical shift differences between the phosphoarginine PA resonance and the inorganic phosphate Pi resonance.	Protactinium	93-95	glucose-6-phosphate isomerase	Homo sapiens	4-7
3139763-14	1988	We conclude that agonist-specific differentiation of U937 cells modulates the expression of PA and PAI activities by altering the proportionate biosynthesis of u-PA and PAI-2 proteins.	Protactinium	92-94	serpin family B member 2	Homo sapiens	169-174
3139763-14	1988	We conclude that agonist-specific differentiation of U937 cells modulates the expression of PA and PAI activities by altering the proportionate biosynthesis of u-PA and PAI-2 proteins.	Protactinium	92-94	plasminogen activator, urokinase	Homo sapiens	160-164
3144525-6	1988	In vitro, clindamycin prevented spontaneous mutation of PA-96 to the stably-derepressed state for beta-lactamase overproduction and also enhanced reversion of derepressed cells of PA-48 to the ceftazidime-susceptible parental phenotype by approximately 2 log10 cfu/ml.	Protactinium	56-58	Beta lactamase	Pseudomonas aeruginosa	98-112
3168161-4	1988	The spin-labeled positionally isomeric (n,m)PA- and AP(n,m)-type esters carry straight aliphatic acyl chains of different overall lengths N (number of C atoms).	Protactinium	44-46	spindlin 1	Mus musculus	4-8
3140468-3	1988	The Sip gene which controls the incubation periods of experimental scrapie in Cheviot sheep has two alleles; sA which shortens and pA which lengthens the incubation periods of most strains of scrapie after the first experimental injection in sheep (the A group of strains).	Protactinium	131-133	major prion protein	Ovis aries	4-7
2845924-5	1988	The thrombin-induced hydrolysis of inositol phospholipids by phospholipase C, which was measured as the formation of [32P]PA, was potentiated by adrenaline, as was the increase in the levels of [32P]PIP2 and [32P]PIP.	Protactinium	122-124	coagulation factor II, thrombin	Homo sapiens	4-12
2839365-4	1988	When rhodopsin deactivation is accelerated (in the presence of NH2OH), PA-signal recovery is also accelerated.	Protactinium	71-73	rhodopsin	Bos taurus	5-14
3165977-12	1988	These results constitute the first direct evidence for receptor-linked activation of PLD, leading to the generation of PA and PEt in an intact cell system.	Protactinium	119-121	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	85-88
3140468-4	1988	The CH1641 isolate differs from them in that the alleles of Sip act in the opposite way, with incubation being shorter in the pA homozygotes.	Protactinium	126-128	major prion protein	Ovis aries	60-63
3142078-10	1988	Free PA-inhibitor was virtually absent from arterial blood after DDAVP, but appeared in hepatic vein blood, indicating either production of the inhibitor by the liver or dissociation of a circulating complex of t-PA and its inhibitor in the liver.	Protactinium	5-7	plasminogen activator, tissue type	Homo sapiens	211-215
2460964-3	1988	Studies with metabolic inhibitors and direct measurements of PA-specific mRNAs show that ECGF-mediated production of PA by human lung fibroblasts is dependent on de novo protein and RNA synthesis.	Protactinium	61-63	fibroblast growth factor 1	Homo sapiens	89-93
2460964-3	1988	Studies with metabolic inhibitors and direct measurements of PA-specific mRNAs show that ECGF-mediated production of PA by human lung fibroblasts is dependent on de novo protein and RNA synthesis.	Protactinium	117-119	fibroblast growth factor 1	Homo sapiens	89-93
3132861-7	1988	This PA activity on the cell surface was not stimulated by addition of CNBr fibrinogen fragments but could be partially inhibited by activated bovine PAI and antibodies against human t-PA and urokinase PA, respectively.	Protactinium	5-7	serpin family E member 1	Bos taurus	150-153
2460964-5	1988	The results raise the possibility that endogenous ECGF or related polypeptides (and heparin) may act to regulate PA synthesis by lung fibroblasts and possibly other responsive target cells in vivo.	Protactinium	113-115	fibroblast growth factor 1	Homo sapiens	50-54
2971392-6	1988	In one such case involving liposomes composed of PA/PS/PE/phosphatidylcholine (PC) (10:15:65:10), synexin reduced the fusion rate constant by 50%.	Protactinium	49-51	annexin A7	Homo sapiens	98-105
3384087-4	1988	Treatment of [3H]myristic acid-labeled cells with either phorbol diesters, sn-1,2-dioctanoylglycerol, or vasopressin elicited the formation of labeled phosphatidate (PA) and DG.	Protactinium	166-168	arginine vasopressin	Rattus norvegicus	105-116
3132861-7	1988	This PA activity on the cell surface was not stimulated by addition of CNBr fibrinogen fragments but could be partially inhibited by activated bovine PAI and antibodies against human t-PA and urokinase PA, respectively.	Protactinium	5-7	plasminogen activator, tissue type	Homo sapiens	183-187
3368667-9	1988	The following results were obtained: 1) component Pa (or Na-Pa) of AEMLR has significant lateralization, 2) the generation site of Pa may be in the subcortical thalamic projection of the contralateral lobe, 3) component Po (or No-Po) is a true neurogenic response but is frequently enhanced by the post-auricular reflex, 4) the contralateral inferior colliculus is very important for the generation of Po, 5) the auditory system (hearing) may have contralateral AEMLR dominancy.	Protactinium	50-52	NSF attachment protein alpha	Homo sapiens	57-62
2967334-4	1988	PA extracted from normal human epidermis is only partially inhibited by DFP, suggesting that precursor uPA is also present in vivo.	Protactinium	0-2	plasminogen activator, urokinase	Homo sapiens	103-106
2464917-8	1988	The positive rate in patients with prostatic carcinoma of low stage was increased by the additional measurement of PA or gamma-Sm to PAP or that of gamma-Sm to PA.	Protactinium	133-135	kallikrein related peptidase 3	Homo sapiens	121-129
3125172-16	1988	In vitro studies on the binding of hybrid PAs to fibrin showed that hybrid B, like t-PA, possesses affinity toward fibrin, while hybrid A shows lower binding.	Protactinium	42-45	plasminogen activator, tissue	Mus musculus	83-87
2962626-1	1987	To study the organization of the plasminogen activator/plasminogen-plasmin (PA/PG-P) system in human epidermis we raised monoclonal antibodies with specificity for human plasminogen and plasmin (PG-P).	Protactinium	76-78	plasminogen	Homo sapiens	33-44
3131318-7	1988	In addition, we found that alpha-lactalbumin stimulated the galactosyltransferase activity towards PA-acceptor.	Protactinium	99-101	lactalbumin alpha	Homo sapiens	27-44
3422154-7	1988	In contrast, [3H]PA arises from both PLD and diglyceride kinase activities.	Protactinium	17-19	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	37-40
3422154-8	1988	Furthermore, PEt synthesis closely parallels PA formation and both are inhibited by an fMLP receptor antagonist, suggesting that both PA and PEt are derived from agonist-stimulated PLD action.	Protactinium	134-136	formyl peptide receptor 1	Homo sapiens	87-100
3422154-8	1988	Furthermore, PEt synthesis closely parallels PA formation and both are inhibited by an fMLP receptor antagonist, suggesting that both PA and PEt are derived from agonist-stimulated PLD action.	Protactinium	134-136	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	181-184
3422154-2	1988	Stimulation of these labeled cells with the chemotactic peptide, N-formyl-Met-Leu-Phe (fMLP), induces rapid generation of [3H]phosphatidic acid (PA) and slower formation of [3H]diglyceride, suggesting hydrolysis of alkyl-PC by PLD.	Protactinium	145-147	formyl peptide receptor 1	Homo sapiens	65-85
3422154-2	1988	Stimulation of these labeled cells with the chemotactic peptide, N-formyl-Met-Leu-Phe (fMLP), induces rapid generation of [3H]phosphatidic acid (PA) and slower formation of [3H]diglyceride, suggesting hydrolysis of alkyl-PC by PLD.	Protactinium	145-147	formyl peptide receptor 1	Homo sapiens	87-91
3263411-3	1988	Somatostatin (SLI), PGE2, and PAS-stained mucus in the corpus were significantly reduced in SMR rats in comparison to SMR + EGF and control rats.	Protactinium	30-33	Scm-like with four mbt domains 1	Mus musculus	92-95
3133765-5	1988	The formation of complexes between PA and PAI completely blocks or decreases PA activity.	Protactinium	35-37	serpin family E member 1	Rattus norvegicus	42-45
2962626-1	1987	To study the organization of the plasminogen activator/plasminogen-plasmin (PA/PG-P) system in human epidermis we raised monoclonal antibodies with specificity for human plasminogen and plasmin (PG-P).	Protactinium	76-78	plasminogen	Homo sapiens	55-66
2962626-1	1987	To study the organization of the plasminogen activator/plasminogen-plasmin (PA/PG-P) system in human epidermis we raised monoclonal antibodies with specificity for human plasminogen and plasmin (PG-P).	Protactinium	76-78	plasminogen	Homo sapiens	170-193
3310318-8	1987	After 15 days of treatment, in group M a significant decrease in PA Inhibition (5.51 +/- 1.4, versus 9.48 +/- 2.1 p less than 0.05) in plasma insulin (18.5 +/- 0.1, versus 24.5 +/- 3.5, p less than 0.05) and plasma triglyceride (1.08 +/- 0.1, versus 1.47 +/- 0.3 p less than 0.05) and an increase in EFA (6.50 +/- 0.28, versus 5.25 +/- 0.35 p less than 0.05) were observed.	Protactinium	65-67	insulin	Homo sapiens	142-149
3501347-8	1987	The data suggest that small amounts of PA-inhibitor is released on venous occlusion, but at the same time an inactivation takes place, most likely due to the formation of enzymatically inactive complex with simultaneously released t-PA.	Protactinium	39-41	plasminogen activator, tissue type	Homo sapiens	231-235
3479996-7	1987	PAS staining was observed in 7% of cord Bsp-1+ cells and of 55% CML Bsp-1+ cells.	Protactinium	0-3	binder of sperm protein homolog 1	Homo sapiens	40-45
3479996-7	1987	PAS staining was observed in 7% of cord Bsp-1+ cells and of 55% CML Bsp-1+ cells.	Protactinium	0-3	binder of sperm protein homolog 1	Homo sapiens	68-73
2446484-2	1987	The incidence of abnormal values of PA in untreated prostatic cancer, was 50, 50, 80, and 100% for stage A1, C (pN0, NX), D1 and D2 cancers, respectively.	Protactinium	36-38	leiomodin 1	Homo sapiens	122-131
2953727-4	1987	These PMN proteins, like bovine liver synexin, promoted aggregation of isolated PMN specific granules in the presence of Ca2+ and increased the overall rate of Ca2+-induced fusion of liposomes composed of phosphatidate (PA)/phosphatidylethanolamine (PE) (1:3) and phosphatidylserine/PE (1:3), but decreased the rate of spermine-induced fusion of PA/PE (1:3) liposomes.	Protactinium	220-222	annexin A7	Bos taurus	38-45
2953727-4	1987	These PMN proteins, like bovine liver synexin, promoted aggregation of isolated PMN specific granules in the presence of Ca2+ and increased the overall rate of Ca2+-induced fusion of liposomes composed of phosphatidate (PA)/phosphatidylethanolamine (PE) (1:3) and phosphatidylserine/PE (1:3), but decreased the rate of spermine-induced fusion of PA/PE (1:3) liposomes.	Protactinium	346-348	annexin A7	Bos taurus	38-45
2953727-5	1987	Using fluorescent lipid probes, rapid fusion of PA/PE liposomes with PMN specific granules (50% maximum signal within a few minutes) was observed when 1 mM Ca2+ was added in the presence of both synexin and free arachidonic acid.	Protactinium	48-50	annexin A7	Homo sapiens	195-202
3629560-5	1987	PAS-stained SDS-PAGE of her whole platelets showed markedly decreased GP IIb and IIIa.	Protactinium	0-3	integrin subunit alpha 2b	Homo sapiens	70-76
3115843-4	1987	In a population of 49 non-diabetic obese women (differing from a control group of normal weight by lower EFA and higher level, of PA Inhibitor activity, plasma insulin and triglyceride), the PA Inhibitor activity was positively correlated with BMI, insulin and triglyceride.	Protactinium	191-193	insulin	Homo sapiens	249-256
3110994-4	1987	Our results show that tissue-type-PA antigen (t-PA-antigen) and PA-inhibition were both significantly increased irrespective of the presence or absence of tumor metastasis (p less than 0.001 compared to age matched healthy controls.	Protactinium	34-36	plasminogen activator, tissue type	Homo sapiens	46-50
3116975-9	1987	In contrast, early thrombin-induced lipid metabolism, when monitored as changes in 32P-phosphatidic acid (PA), was significantly higher in SHR than WKY and the extent of the difference was independent of the extracellular calcium concentration.	Protactinium	106-108	coagulation factor II	Rattus norvegicus	19-27
3302737-7	1987	75% of PAS positive ALL cases were positive for TdT as well.	Protactinium	7-10	deoxynucleotidyltransferase, terminal	Mus musculus	48-51
3496679-7	1987	At 0.1 unit/ml thrombin also an increase in PA inhibitor activity was found.	Protactinium	44-46	coagulation factor II, thrombin	Homo sapiens	15-23
3496679-8	1987	At high concentrations of thrombin a decrease of PA inhibitor activity was found, due to the conversion of the active 46 kD PA inhibitor-1 into a 42 kD product without PA inhibitor activity.	Protactinium	49-51	coagulation factor II, thrombin	Homo sapiens	26-34
3102144-1	1987	A mathematic model of the systemic fibrinogenolysis that accompanies coronary thrombolysis with recombinant tissue plasminogen activator (rt-PA) has been devised.	Protactinium	141-143	chromosome 20 open reading frame 181	Homo sapiens	108-136
2431875-2	1987	In patients with unilateral temporal lobe lesions, the amplitude of Pa and hence that of the Na-Pa complex was reduced over the involved hemisphere but remained intact over the contralateral hemisphere.	Protactinium	68-70	NSF attachment protein alpha	Homo sapiens	93-98
3582742-7	1987	Of importance was the finding that recombinant tissue plasminogen activator (rt-PA) and hepatitis B surface antigen (HBsAg) vaccine failed to induce tumors in either normal or immunosuppressed rats.	Protactinium	80-82	plasminogen activator, tissue type	Rattus norvegicus	47-75
2468750-7	1987	These findings suggest that PA analogs (and/or their metabolites) increased brain tryptophan (and hence 5-HT synthesis) by directly inhibiting liver TP activity.	Protactinium	28-30	tryptophan 2,3-dioxygenase	Rattus norvegicus	149-151
3604167-3	1987	PAS staining and mobility on SDS gels identified this component as glycophorin C.	Protactinium	0-3	glycophorin C (Gerbich blood group)	Homo sapiens	67-80
3103601-7	1986	PA-inhibitor derived from the t-PA-PA-inhibitor complex showed an Mr approx.	Protactinium	0-2	plasminogen activator, tissue type	Homo sapiens	30-34
3563959-1	1986	Arginine-vasopressin (AVP) in the presence of Mg2+ but not in the absence of bivalent cations led to accumulation of [32P]-phosphatidic acid [( 32P]-PA) in human blood platelets.	Protactinium	147-151	arginine vasopressin	Homo sapiens	9-20
3563959-1	1986	Arginine-vasopressin (AVP) in the presence of Mg2+ but not in the absence of bivalent cations led to accumulation of [32P]-phosphatidic acid [( 32P]-PA) in human blood platelets.	Protactinium	147-151	mucin 7, secreted	Homo sapiens	46-49
3491081-8	1986	TGF beta also decreased the amounts of urokinase-type and tissue-type PAs accumulated in the conditioned medium, as detected by zymography.	Protactinium	70-73	transforming growth factor beta 1	Homo sapiens	0-8
3542231-5	1986	Interleukin 2 production was depressed only in C57BL/6 and C3H/Pas mice.	Protactinium	63-66	interleukin 2	Mus musculus	0-13
3730298-4	1986	Normal platelets activated with thrombin or calcium ionophore A23187, also had levels of surface PA-IgG close to total PA-IgG.	Protactinium	97-99	coagulation factor II, thrombin	Homo sapiens	32-40
3730298-4	1986	Normal platelets activated with thrombin or calcium ionophore A23187, also had levels of surface PA-IgG close to total PA-IgG.	Protactinium	119-121	coagulation factor II, thrombin	Homo sapiens	32-40
3730298-7	1986	Platelets treated at 2 degrees C with soluble heat-aggregated IgG, which binds to the Fc gamma receptor, showed increased surface PA-IgG, but, after incubation at 37 degrees C, although [14C]serotonin was released, PA-IgG levels were no longer increased.	Protactinium	130-132	Fc gamma receptor Ia	Homo sapiens	86-103
3730298-7	1986	Platelets treated at 2 degrees C with soluble heat-aggregated IgG, which binds to the Fc gamma receptor, showed increased surface PA-IgG, but, after incubation at 37 degrees C, although [14C]serotonin was released, PA-IgG levels were no longer increased.	Protactinium	215-217	Fc gamma receptor Ia	Homo sapiens	86-103
3730298-8	1986	Thus since platelet activation, including that mediated by IgG binding to the Fc gamma receptor, causes PA-IgG release, levels of both surface-located and total PA-IgG may be affected by platelet activation, either in vivo, or in vitro during sample preparation and assay.	Protactinium	104-106	Fc gamma receptor Ia	Homo sapiens	78-95
2424742-4	1986	Differences in Pa amplitude and latency were not due exclusively to changes in auditory thresholds, since they were not duplicated by changes in stimulus intensity, and persisted when MAEPs from selected young and old subjects were compared at similar SPL levels.	Protactinium	15-17	sphingosine-1-phosphate lyase 1	Homo sapiens	252-255
3931291-2	1985	To a series of plasma samples with various concentrations of naturally occurring PA-inhibitor purified t-PA was added to a final concentration, which in pooled normal plasma is sufficient to induce clot lysis within a few hours.	Protactinium	81-83	plasminogen activator, tissue type	Homo sapiens	103-107
3086473-5	1986	Moreover, PA-inhibitor-rich plasma inhibited in a very similar way in vitro thrombolysis by one-chain or two-chain t-PA incorporated into the clot.	Protactinium	10-12	plasminogen activator, tissue type	Homo sapiens	115-119
3086473-6	1986	Injection of one-chain or two-chain t-PA into rabbits with increased levels of PA-inhibitor, induced by endotoxin, resulted in very rapid inhibition of t-PA activity.	Protactinium	38-40	plasminogen activator, tissue type	Homo sapiens	152-156
3086473-10	1986	It is concluded that PA-inhibitor neutralizes one-chain and two-chain molecular forms of t-PA in plasma at very similar rates, both in vitro and in vivo.	Protactinium	21-23	plasminogen activator, tissue type	Homo sapiens	89-93
3092390-2	1986	Since the concentration of t-PA Ag depends on both free t-PA and t-PA complexed with inhibitors, mainly plasminogen activator inhibitor (PA inhibitor), we have investigated the relationship between the plasma concentration of PA inhibitor and age in 20 elderly and 20 young individuals.	Protactinium	29-31	plasminogen activator, tissue type	Homo sapiens	56-60
3092390-2	1986	Since the concentration of t-PA Ag depends on both free t-PA and t-PA complexed with inhibitors, mainly plasminogen activator inhibitor (PA inhibitor), we have investigated the relationship between the plasma concentration of PA inhibitor and age in 20 elderly and 20 young individuals.	Protactinium	29-31	plasminogen activator, tissue type	Homo sapiens	56-60
3092390-2	1986	Since the concentration of t-PA Ag depends on both free t-PA and t-PA complexed with inhibitors, mainly plasminogen activator inhibitor (PA inhibitor), we have investigated the relationship between the plasma concentration of PA inhibitor and age in 20 elderly and 20 young individuals.	Protactinium	58-60	plasminogen activator, tissue type	Homo sapiens	27-31
3705196-2	1986	The tumor consisted almost entirely of signet-ring cells containing mucin, which was strongly positive with PAS, with and without diastase pre-treatment, and Alcian blue stain at pH 2.5.	Protactinium	108-111	LOC100508689	Homo sapiens	68-73
3085533-2	1986	The method is based on (1) the high-affinity binding (Kp = 1.4 +/- 2 nM) of tPA to a solid-phase fibrin network constructed by thrombin proteolysis of fibrinogen covalently coupled to polyglutaraldehyde-activated polyvinyl chloride microtiter plates, and (2) the subsequent development of PA activity by the fibrin-tPA complex and its measurement with a coupled assay using a chromogenic substrate highly selective for plasmin.	Protactinium	77-79	coagulation factor II, thrombin	Homo sapiens	127-135
3088264-2	1986	When rats were ventilated to produce physiological Pa, CO2 levels (35-40 mmHg) responses to boluses of angiotensin II were greater with increasing Pa, O2 over the Pa, O2 range of 65-460 mmHg.	Protactinium	51-53	angiotensinogen	Rattus norvegicus	103-117
3088264-2	1986	When rats were ventilated to produce physiological Pa, CO2 levels (35-40 mmHg) responses to boluses of angiotensin II were greater with increasing Pa, O2 over the Pa, O2 range of 65-460 mmHg.	Protactinium	147-149	angiotensinogen	Rattus norvegicus	103-117
3088264-2	1986	When rats were ventilated to produce physiological Pa, CO2 levels (35-40 mmHg) responses to boluses of angiotensin II were greater with increasing Pa, O2 over the Pa, O2 range of 65-460 mmHg.	Protactinium	147-149	angiotensinogen	Rattus norvegicus	103-117
3088264-4	1986	All variations in response to angiotensin II were attributable to changes in Pa, O2.	Protactinium	77-79	angiotensinogen	Rattus norvegicus	30-44
3085266-1	1986	We have compared the ability of a plasminogen activator inhibitor (PA-inhibitor) in human plasma, to form complexes with radioiodinated tissue-type plasminogen activator (t-PA) and high molecular weight urokinase (HMr-UK).	Protactinium	67-69	plasminogen activator, tissue type	Homo sapiens	136-169
3085266-1	1986	We have compared the ability of a plasminogen activator inhibitor (PA-inhibitor) in human plasma, to form complexes with radioiodinated tissue-type plasminogen activator (t-PA) and high molecular weight urokinase (HMr-UK).	Protactinium	67-69	plasminogen activator, tissue type	Homo sapiens	171-175
3085266-2	1986	Addition of 125I-t-PA (final concentration 10 IU/ml) or of 125I-HMr-UK (2 IU/ml) to a plasma containing 33 U/ml of PA-inhibitor resulted in the rapid formation of a 110,000 Mr complex of 125I-t-PA or a 95,000 Mr complex of 125I-HMr-UK with PA-inhibitor.	Protactinium	115-117	plasminogen activator, tissue type	Homo sapiens	192-196
3085266-4	1986	Preincubation of the plasma with unlabelled t-PA, HMr-UK or LMr-UK at higher concentrations prevented the subsequent formation of complexes between radiolabelled PAs and the PA-inhibitor.	Protactinium	162-165	plasminogen activator, tissue type	Homo sapiens	44-48
2935348-6	1986	The mean serum DHEA-S was significantly higher in the PA children than in the controls, but there was a broad range of concentrations (10-143 micrograms/dl), with values in 10 of 24 cases falling within the control range for age.	Protactinium	54-56	sulfotransferase family 2A member 1	Homo sapiens	15-21
3912161-5	1985	When infused iv at a rate of 10 pmol/kg X min (maximum non-pressor dose) for 120 min, both Ile8-ANG II and Sar1-, Ile8-ANG II lowered PRA and increased PA gradually, but 100 mg oral captopril given immediately before these infusions caused no significant increase in PRA or no significant decrease in PA but again a decrease in PRA and an increase in PA.	Protactinium	152-154	angiotensinogen	Homo sapiens	96-102
3912161-5	1985	When infused iv at a rate of 10 pmol/kg X min (maximum non-pressor dose) for 120 min, both Ile8-ANG II and Sar1-, Ile8-ANG II lowered PRA and increased PA gradually, but 100 mg oral captopril given immediately before these infusions caused no significant increase in PRA or no significant decrease in PA but again a decrease in PRA and an increase in PA.	Protactinium	152-154	secretion associated Ras related GTPase 1A	Homo sapiens	107-111
3912161-5	1985	When infused iv at a rate of 10 pmol/kg X min (maximum non-pressor dose) for 120 min, both Ile8-ANG II and Sar1-, Ile8-ANG II lowered PRA and increased PA gradually, but 100 mg oral captopril given immediately before these infusions caused no significant increase in PRA or no significant decrease in PA but again a decrease in PRA and an increase in PA.	Protactinium	152-154	angiotensinogen	Homo sapiens	119-125
2940723-7	1986	Moreover, complexes of UK or t-PA with plasmatic PA-inhibitor or with the PA-inhibitor(s) from platelets bound to immobilized antibodies against bovine endothelial cell-derived PA-inhibitor.	Protactinium	49-51	plasminogen activator, tissue type	Homo sapiens	29-33
2940723-7	1986	Moreover, complexes of UK or t-PA with plasmatic PA-inhibitor or with the PA-inhibitor(s) from platelets bound to immobilized antibodies against bovine endothelial cell-derived PA-inhibitor.	Protactinium	49-51	plasminogen activator, tissue type	Homo sapiens	29-33
3085276-6	1986	Tissue-PA was mainly detected in the endothelial cells, but not in the muscular layer of the inferior mesenteric artery when immunochemical technique was used with polyclonal t-PA antibody.	Protactinium	6-9	plasminogen activator, tissue type	Homo sapiens	175-179
3702206-6	1986	PA-treated animals received either saline, dimethyl sulfoxide, superoxide dismutase, or catalase over 30 min prior to and 30 min following PA administration.	Protactinium	0-2	catalase	Rattus norvegicus	88-96
3511021-5	1986	Fluctuating interventions increased PVR more than did static trials at comparable levels of PA.	Protactinium	92-94	PVR cell adhesion molecule	Homo sapiens	36-39
3511021-6	1986	Substantially less PA was needed to double ipsilateral PVR by fluctuating than by static interventions (16 vs. 26 mmHg, respectively).	Protactinium	19-21	PVR cell adhesion molecule	Homo sapiens	55-58
3511021-7	1986	These data indicate that, in the intact animal with reactive pulmonary vasculature, both PA and the waveform of airway pressure applied can influence PVR.	Protactinium	89-91	PVR cell adhesion molecule	Homo sapiens	150-153
2982895-8	1985	The mean 17-OHP response to ACTH in girls with PA was significantly higher than that in girls and women whose pubertal development was normal.	Protactinium	47-49	proopiomelanocortin	Homo sapiens	28-32
3156142-5	1985	The increments in PRA and PA above basal significantly (P less than 0.05) increased (3.1 +/- 1.2 ng/ml X h and 12.2 +/- 5.3 ng/dl, respectively; P less than 0.05) at the end of the beta-endorphin infusion.	Protactinium	26-28	proopiomelanocortin	Homo sapiens	181-195
3842197-4	1985	The PA relaxation was associated with the release of immunoreactive VIP, both before and after this blockade.	Protactinium	4-6	VIP peptides	Cavia porcellus	68-71
3975572-5	1985	An elevated TC2 was found in a small number of patients with folate deficiency and with PA.	Protactinium	88-90	transcobalamin 2	Homo sapiens	12-15
4057130-3	1985	While heart rate correlated directly with the subject"s score on the Hard Driving and Competitive Factor (H), diastolic blood pressure response to PA was inversely related to the subject"s Type A and factor H scores.	Protactinium	147-149	complement factor H	Homo sapiens	189-208
2415838-4	1985	Our results showed a lack of correlation between ER and PA as well as between concentrations of PgR and PA in the tumors.	Protactinium	104-106	progesterone receptor	Homo sapiens	96-99
6094562-2	1984	At 37 degrees C, the efflux of PA was linear and no saturation was reached up to an HDL3 protein concentration in the medium of 800 micrograms/ml.	Protactinium	31-33	HDL3	Homo sapiens	84-88
6094562-3	1984	In turn, at 4 degrees C, maximal PA release was reached at a concentration below 600 micrograms/ml of HDL3 protein/ml in the medium.	Protactinium	33-35	HDL3	Homo sapiens	102-106
6094562-4	1984	Canine HDL, which contains apo-A-I, but not apo-A-II, was as effective as human HDL3 in promoting the release of PA from PMN.	Protactinium	113-115	apolipoprotein A1	Canis lupus familiaris	27-34
6094562-4	1984	Canine HDL, which contains apo-A-I, but not apo-A-II, was as effective as human HDL3 in promoting the release of PA from PMN.	Protactinium	113-115	HDL3	Homo sapiens	80-84
6094562-8	1984	When human HDL3 was incubated with PMN at 4 or 37 degrees C and then subjected to ultracentrifugation at d 1.21 g/ml, most of the PA that was initially associated with this lipoprotein was recovered in the bottom of the tube.	Protactinium	130-132	HDL3	Homo sapiens	11-15
6229640-5	1984	Two of them, designated PR1 and PR2, are directed towards the tet repressor gene and the third, called PA, initiates transcription of the tet resistance gene.	Protactinium	103-105	transmembrane protein 37	Homo sapiens	24-27
6427766-8	1984	It was confirmed by using two-dimensional gel electrophoresis that PA toxin resistance in hybrid cells was caused by the presence of EF-2 resistant to ADP-ribosylation by fragment A of diphtheria toxin.	Protactinium	67-69	eukaryotic translation elongation factor 2	Homo sapiens	133-137
6738801-12	1984	The cytoplasm in the majority of cells contained abundant mucin positive to PAS staining.	Protactinium	76-79	LOC100508689	Homo sapiens	58-63
6436474-4	1984	Increases in VE during transient and steady-state conditions may be described by the equation: VE = 6.76 delta PA, CO2/delta te -3.50, a relationship which is consistent with a feed-forward control system.	Protactinium	111-113	complement C2	Homo sapiens	115-133
6436482-19	1984	From arterial sampling in three of the patients it was found that when PET,CO2 rose, the corresponding change in Pa,CO2 was less.	Protactinium	113-115	complement C2	Homo sapiens	71-78
6482661-2	1984	The apparent PA-CA2+ dissociation constant is 3 X 10(-3), i.e., in the range of extracellular Ca2+ concentration.	Protactinium	13-15	carbonic anhydrase 2	Homo sapiens	16-19
6482661-2	1984	The apparent PA-CA2+ dissociation constant is 3 X 10(-3), i.e., in the range of extracellular Ca2+ concentration.	Protactinium	13-15	carbonic anhydrase 2	Homo sapiens	94-97
6089583-7	1984	We conclude that PA response to intracerebroventricular ANG II is mediated primarily through the renin-angiotensin system in the salt-depleted state; however, in the salt-replete state, ACTH assumes a more important role.	Protactinium	17-19	renin	Canis lupus familiaris	97-102
6087605-8	1984	Periodate-borohydride/saponification/PAS stain also indicated that the mucin produced by the carcinoma had the nature of rectal mucosal origin.	Protactinium	37-40	LOC100508689	Homo sapiens	71-76
6713694-2	1984	PAS positive material, presumably thyroglobulin, was found in the interstitial network between follicles.	Protactinium	0-3	thyroglobulin	Homo sapiens	34-47
6320866-6	1984	With as little as 5 mol % egg PA in egg PC, Cd2+ induces phase separation up to about 25 degrees C. The phase behavior of egg PA/spin-labeled PC in the presence of Cd2+ was very similar to that of egg PA/egg PC in the 10-35 degrees C temperature range.	Protactinium	30-32	CD2 molecule	Homo sapiens	44-47
6610261-1	1984	PAS staining, immunohistochemical examination and electron microscopy revealed presence of alpha-1-antitrypsin (AAT) globules in the hepatocytes of a HBsAg and anti-HBc seropositive female patient diseased of liver cirrhosis.	Protactinium	0-3	serpin family A member 1	Homo sapiens	91-110
6610261-1	1984	PAS staining, immunohistochemical examination and electron microscopy revealed presence of alpha-1-antitrypsin (AAT) globules in the hepatocytes of a HBsAg and anti-HBc seropositive female patient diseased of liver cirrhosis.	Protactinium	0-3	serpin family A member 1	Homo sapiens	112-115
6654177-6	1983	The 19 patients with positive PA nodes had significantly worse survival and FFR when compared with the other groups.	Protactinium	30-32	VPS51 subunit of GARP complex	Homo sapiens	76-79
6194317-5	1983	Mucosubstances of CEA-producing gastric cancer were positive for A-B, HID, AL-PAS and CPS III-1; those of CEA non-producing gastric cancer were positive for PAS and CPS III-s, but negative for A-B, HID and A1-PAS.	Protactinium	78-81	CEA cell adhesion molecule 3	Homo sapiens	18-21
6418883-6	1983	In each subject delta PA, CO2/delta t was less than would have been obtained at normal lung volume.	Protactinium	22-24	complement C2	Homo sapiens	26-35
6653856-5	1983	Glycogen lymphocyte content was determined by calculation of the PAS-positive Index of the lymphocytes (PIL) according to Skrabalo.	Protactinium	65-68	serpin family A member 2 (gene/pseudogene)	Homo sapiens	104-107
6354522-8	1983	On the low sodium intake, the enhanced PA response to MCP probably reflects both a direct adrenal effect and an indirect effect mediated via activation of the renin-angiotensin system.	Protactinium	39-41	renin	Homo sapiens	159-164
6819422-3	1982	The incorporation of radioactivity into PA and PI is increased as early as in 2 and 5 min after TRH addition, respectively, and reaches 40 and 140% above control, respectively, at 20 min.	Protactinium	40-42	thyrotropin releasing hormone	Rattus norvegicus	96-99
6832299-2	1983	However, expression of PA at certain periods, when PgR was undetectable suggests, that the extent of availability of both estradiol and progesterone at target sites may act as controlling factors in synthesis of one protein over another.	Protactinium	23-25	progesterone receptor	Rattus norvegicus	51-54
6343215-4	1983	The results further indicate that K can induce an enhancement of the activity of renin-angiotensin-aldosterone system with an higher PRA and PA response to stimulatory action of M.	Protactinium	141-143	renin	Homo sapiens	81-86
6824774-1	1983	The effects of the antituberculous drugs, isoniazide, phthivazide, streptomycin and PAS, on the isoform content of rat liver microsomal cytochrome P-450 was studied by electrophoresis in acrylamide concentration gradient (5-15%) in the presence of sodium dodecyl sulphate.	Protactinium	84-87	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	136-152
6189238-5	1983	Purified human thrombin also enhanced PA release in a dose-dependent fashion (1.5-12 U).	Protactinium	38-40	coagulation factor II, thrombin	Homo sapiens	15-23
7140484-11	1982	PA contained moderate to large number of PML via aspiration.	Protactinium	0-2	PML nuclear body scaffold	Homo sapiens	41-44
6290130-1	1982	Interruption of the renin-aldosterone system with angiotensin-converting enzyme inhibitors (CEI) should result in a low aldosterone secretion, but most investigators have measured aldosterone production only indirectly by plasma aldosterone (PA) levels or urinary metabolites.	Protactinium	242-244	renin	Homo sapiens	20-25
7179222-7	1982	Direct ADP injections into the flow device showed that at low [ADP] (less than 1 microM), maximal values for both PA and TA were reached when step-wise increases in G reached less than or approximately 30 sec-1, with TA decreasing at higher G; these values were only some 10-20% of maximal values achieved with high (ADP] (greater than or approximately 4 microM), when PA was again maximal at G greater than or approximately 30 sec-1, but TA expressed as a rate of aggregation continued to increase with G up to 150 sec-1.	Protactinium	114-116	secretory blood group 1, pseudogene	Homo sapiens	205-210
7179222-7	1982	Direct ADP injections into the flow device showed that at low [ADP] (less than 1 microM), maximal values for both PA and TA were reached when step-wise increases in G reached less than or approximately 30 sec-1, with TA decreasing at higher G; these values were only some 10-20% of maximal values achieved with high (ADP] (greater than or approximately 4 microM), when PA was again maximal at G greater than or approximately 30 sec-1, but TA expressed as a rate of aggregation continued to increase with G up to 150 sec-1.	Protactinium	114-116	secretory blood group 1, pseudogene	Homo sapiens	428-433
7179222-7	1982	Direct ADP injections into the flow device showed that at low [ADP] (less than 1 microM), maximal values for both PA and TA were reached when step-wise increases in G reached less than or approximately 30 sec-1, with TA decreasing at higher G; these values were only some 10-20% of maximal values achieved with high (ADP] (greater than or approximately 4 microM), when PA was again maximal at G greater than or approximately 30 sec-1, but TA expressed as a rate of aggregation continued to increase with G up to 150 sec-1.	Protactinium	114-116	secretory blood group 1, pseudogene	Homo sapiens	428-433
6752473-19	1982	The renin-angiotensin system also seems to contribute to elevation of SVR, to maintain effective arterial pressure by enhanced sympathetic activity, and the renin-angiotensin system seems to be a main determinant of PA in CHF.	Protactinium	216-218	renin	Homo sapiens	4-9
6752473-19	1982	The renin-angiotensin system also seems to contribute to elevation of SVR, to maintain effective arterial pressure by enhanced sympathetic activity, and the renin-angiotensin system seems to be a main determinant of PA in CHF.	Protactinium	216-218	renin	Homo sapiens	157-162
6279498-6	1982	PA responses to ACTH and MCP were similar in both groups, but the hypertensives displayed greater (p less than 0.01) PA responses to AII.	Protactinium	0-2	proopiomelanocortin	Homo sapiens	16-20
6290965-1	1982	Sections of various adenocarcinomas and malignant mesotheliomas were tested for carcinoembryonic antigen (CEA) localized in tissues by the immunoperoxidase technique; epithelial mucin was demonstrated with the PAS technique.	Protactinium	210-213	LOC100508689	Homo sapiens	178-183
7042000-7	1982	PA-IgG levels were higher in the group of patients with elevated PA-C3 levels than in those with normal values.	Protactinium	0-2	proteasome assembly chaperone 3	Homo sapiens	65-70
7044409-4	1982	However, the response of PA to isopressor angiotensin II infusions was comparable before and shortly after treatment with L-dopa in 16 pregnant subjects.	Protactinium	25-27	angiotensinogen	Homo sapiens	42-56
6279498-7	1982	BEC suppressed PA responses to AII (p less than 0.01) and to high dose ACTH (p less than 0.05) to a similar extent in both groups.	Protactinium	15-17	angiotensinogen	Homo sapiens	31-34
6750191-2	1982	Various hormones such as plasma catecholamines, PA, DOC, B, cortisol 18-OH-DOC, 18-OH-B, ACTH, AVP and PRL tended to be high in the high renin group and tended to be low in the low renin group.	Protactinium	48-50	renin	Homo sapiens	137-142
6210439-7	1982	The intracellular PA inhibitor was found to be 50--60 kilodaltons by gel chromatography, to be of anionic charge at pH 7.4 and to inhibit urokinase esterolytic and proteolytic activity but not preformed plasmin.	Protactinium	18-20	plasminogen	Homo sapiens	203-210
6269709-9	1981	beta-endorphin inhibited PA formation and this effect was abolished by C-terminal shortening to gamma-endorphin.	Protactinium	25-27	proopiomelanocortin	Homo sapiens	0-14
6175250-6	1982	The mucin-producing cells retained their AB/PAS-reactive secretory granules.	Protactinium	44-47	LOC100508689	Homo sapiens	4-9
6175250-8	1982	These observations suggest that mucin-producing cells are capable of retaining their AB/PAS-reactive secretory products in primary culture and that basal cells are capable of differentiating into mucin-producing cells in vitro.	Protactinium	88-91	LOC100508689	Homo sapiens	32-37
6283838-3	1982	The PA is due to an enzyme distinct from myeloperoxidase (MPO), since monocytes from a patient with MPO deficiency develop the same PA as that of normal monocytes after adherence.	Protactinium	4-6	myeloperoxidase	Homo sapiens	58-61
7181677-9	1982	FSC, systolic BP and insulin treatment are major RF for PA in male NIDDM patients.	Protactinium	56-58	insulin	Homo sapiens	21-28
7047005-2	1982	The PA response to sodium restriction in relation to changes in plasma renin activity (PRA) was estimated by the ratio of PA increment to PRA increment after sodium restriction (delta PA/delta PRA).	Protactinium	4-6	renin	Homo sapiens	71-76
7061282-8	1982	Reduction in Pf below PA was larger at higher Ptp, consistent with increased tau with lung inflation.	Protactinium	22-24	protein tyrosine phosphatase non-receptor type 13	Canis lupus familiaris	46-49
6269709-11	1981	It is concluded that the structure-activity relationship on TPI/PA formation correlates with a similar relationship obtained on excessive grooming behavior in vivo.	Protactinium	64-66	triosephosphate isomerase 1	Homo sapiens	60-63
6169273-1	1981	The presence of PAS-positive, diastase-resistant inclusions in the cytoplasm of the hepatocytes is characteristic of alpha-1-antitrypsin deficiency.	Protactinium	16-19	serpin family A member 1	Homo sapiens	117-136
6169273-6	1981	It is concluded that, in patients with liver disease, the presence of PAS-positive, diastase-resistant inclusions--even containing alpha-1-antitrypsin--in the cytoplasm of the hepatocytes does not permit the hepatic lesions to be ascribed to alpha-1-antitrypsin deficiency.	Protactinium	70-73	adrenoceptor alpha 1D	Homo sapiens	131-138
7040751-6	1981	PA responses to furosemide had significant positive correlation with those to angiotensin II.	Protactinium	0-2	angiotensinogen	Homo sapiens	78-92
7029031-13	1981	These results suggest that the dopaminergic system in the brain regulates renin secretion, thereby changing PA.	Protactinium	108-110	renin	Rattus norvegicus	74-79
7016959-3	1981	THe PA response to graded AII infusions was determined by the increment of PA above the basal level after each dose of AII.	Protactinium	4-6	angiotensinogen	Homo sapiens	26-29
7016959-3	1981	THe PA response to graded AII infusions was determined by the increment of PA above the basal level after each dose of AII.	Protactinium	4-6	angiotensinogen	Homo sapiens	119-122
7397569-2	1980	PA, the product of cerebrovascular permeability (P) to 14C-sucrose and of cerebral capillary surface area (A), is very low in mature rats that have been maintained either on an 8% or 25% casein diet, and equals about 8 X 10(-6) sec-1 in both groups.	Protactinium	0-2	secretory blood group 1	Rattus norvegicus	228-233
7014072-11	1981	Correlation coefficients between decrease in mean ABP and either precaptopril PA or decrease in PA were not significant.	Protactinium	78-80	amine oxidase copper containing 1	Homo sapiens	50-53
7014072-11	1981	Correlation coefficients between decrease in mean ABP and either precaptopril PA or decrease in PA were not significant.	Protactinium	96-98	amine oxidase copper containing 1	Homo sapiens	50-53
7014743-9	1981	Reduced platelet survival times were also seen with HLA A- and HLA B-matched donor platelets when donor-recipient incompatibility was demonstrated by the PA-IgG assay.	Protactinium	154-156	major histocompatibility complex, class I, A	Homo sapiens	52-57
7014743-9	1981	Reduced platelet survival times were also seen with HLA A- and HLA B-matched donor platelets when donor-recipient incompatibility was demonstrated by the PA-IgG assay.	Protactinium	154-156	major histocompatibility complex, class I, B	Homo sapiens	63-68
6264356-5	1981	A significant increase in PA is observed also during the insulin test, but the percent increase is lower than that under ACTH stimulation.	Protactinium	26-28	insulin	Homo sapiens	57-64
7451995-10	1981	PSAP was characterized as a polydisperse PAS-positive staining material composed primarily of substances(s) with an apparent m.w.	Protactinium	41-44	prosaposin	Homo sapiens	0-4
7440698-13	1980	During the daytime, the influence of ACTH on PA remains apparent in the group with APA.	Protactinium	45-47	proopiomelanocortin	Homo sapiens	37-41
7440698-14	1980	However, the renin-angiotensin system seems to play a predominant role in the control of PA during the daytime in patients with IHA.	Protactinium	89-91	renin	Homo sapiens	13-18
6997021-7	1980	Infusion of the angiotensin II antagonist, saralasin (10 micrograms/kg min-1), begun 30 min before MCP, depressed basal levels of PA slightly but did not significantly alter the PA response to MCP.	Protactinium	130-132	angiotensinogen	Rattus norvegicus	16-30
7007404-3	1981	An iv infusion of 200 ng/kg.min des-Asp1-,Ileu8-angiotensin II (AIIIA) for 2 h caused a significant decrease in PRA and a slight but significant increase in PA, but caused no change in BP in the normal men.	Protactinium	157-159	beta-secretase 2	Homo sapiens	36-40
7007404-3	1981	An iv infusion of 200 ng/kg.min des-Asp1-,Ileu8-angiotensin II (AIIIA) for 2 h caused a significant decrease in PRA and a slight but significant increase in PA, but caused no change in BP in the normal men.	Protactinium	157-159	angiotensinogen	Homo sapiens	48-62
6252224-7	1980	BEC produced a significiant (P &lt; 0.025) suppression of the PA response to graded angiotensin II infusions but did not alter the PA response to graded ACTH.	Protactinium	62-64	angiotensinogen	Homo sapiens	84-98
6252224-10	1980	The finding that BEC suppressed PA responses to angiotensin II and posture but not to ACTH would imply that dopamine selectively exerts its effect or adrenal angiotensin II-mediated aldosterone secretion.	Protactinium	32-34	angiotensinogen	Homo sapiens	48-62
7000394-6	1980	The responses of PA to various stimulations, such as ACTH, angiotensin II, potassium and frusemide, were equally suppressed.	Protactinium	17-19	proopiomelanocortin	Homo sapiens	53-57
7000394-6	1980	The responses of PA to various stimulations, such as ACTH, angiotensin II, potassium and frusemide, were equally suppressed.	Protactinium	17-19	angiotensinogen	Homo sapiens	59-73
6456387-3	1980	As the PA is antigenic, because it produces a blastification (TTL positive), we can say that it acts as antigen provoking immunologic mechanisms which help to explain the inflammatory processes at the pilo-sebaceous follicle in the AV.	Protactinium	7-9	tubulin tyrosine ligase	Homo sapiens	62-65
6247440-4	1980	These three peptides as well as intact HBsAg were found to have almost identical amino acid compositions and carbohydrate was detected in p27 and p68 by PAS staining.	Protactinium	153-156	GATA zinc finger domain containing 2B	Homo sapiens	146-149
7359282-6	1980	Thus, platelets appear to be important in the pathogenesis of PHN complicating PAS.	Protactinium	79-82	carbamoyl-phosphate synthase 1	Homo sapiens	62-65
553903-3	1979	The minor, although highly significant, changes which were recognized in the PAS pattern of beta-thalassemia patients compared with normal controls concerned the PAS-4 region and a shoulder trailing band PAS-2, which both increased in staining intensity relatively to the main sialocomponent PAS-1.	Protactinium	77-80	glycophorin C (Gerbich blood group)	Homo sapiens	204-209
397972-7	1979	PA correlated directly with PRA and inversely with GF or CPAH in most groups.	Protactinium	0-2	carboxypeptidase A6	Homo sapiens	57-61
6992265-4	1980	In the CTD-group, low PA was only found in 4 cases of SLE-like syndromes, all having evidence of vasculitis.	Protactinium	22-24	CTD	Homo sapiens	7-10
524251-2	1979	PA (product of permeability and capillary surface area) increases from a mean of 3.3 X 10(-5) sec-1 in brains of control rats to as much as 28 X 10(-5) sec-1 at the cerebral hemisphere ipsilateral to carotid infusion.	Protactinium	0-2	secretory blood group 1	Rattus norvegicus	94-99
524251-2	1979	PA (product of permeability and capillary surface area) increases from a mean of 3.3 X 10(-5) sec-1 in brains of control rats to as much as 28 X 10(-5) sec-1 at the cerebral hemisphere ipsilateral to carotid infusion.	Protactinium	0-2	secretory blood group 1	Rattus norvegicus	152-157
449010-6	1979	A very high correlation between concurrent PRC and PA (r = 0.92, P less than 0.001) was found in normal subjects at rest and under acute stimulation of renin release.	Protactinium	51-53	renin	Homo sapiens	152-157
468613-4	1979	For Pa of 25 cmH2O, mean Px in five lobes was -2 cmH2O at Ptp of 2 cmH2O and decreased almost linearly to -9 cmH2O at Ptp of 25 cmH2O.	Protactinium	4-6	protein tyrosine phosphatase non-receptor type 13	Canis lupus familiaris	58-61
468613-5	1979	Reducing Pa from 25 to 10 cmH2O resulted in a mean decrease in Px of 1 cmH2O at Ptp of 2 cmH2O and 2 cmH2O at Ptp of 25 cmH2O.	Protactinium	9-11	protein tyrosine phosphatase non-receptor type 13	Canis lupus familiaris	80-83
468613-5	1979	Reducing Pa from 25 to 10 cmH2O resulted in a mean decrease in Px of 1 cmH2O at Ptp of 2 cmH2O and 2 cmH2O at Ptp of 25 cmH2O.	Protactinium	9-11	protein tyrosine phosphatase non-receptor type 13	Canis lupus familiaris	110-113
438469-4	1979	PA in 3-mo-old rats averaged 7.53 x 10(-6) sec-1 in 14 cerebral regions, and was not significantly elevated in 28-mo-old rats except possibly at white matter.	Protactinium	0-2	secretory blood group 1	Rattus norvegicus	43-48
474620-4	1979	Biochemical reactions of the cells of these patients indicate presence of tyrosinase in the melanosomes.and show that the substance accumulated in cultured fibroblasts and in the bone marrow histiocytes is a PAS and Oil-red-O positive material but is Oil-red-O negative after extraction; it has the typical reactions of melanin withe the Masson and Fontana stain, but cannot be considered typical melanin, since without stain it is colorless.	Protactinium	208-211	tyrosinase	Homo sapiens	74-84
220171-2	1979	After suppression of prolactin, statistically signific1nt circadian rhythms in PC and PA have been detected with a moderate decrease of PA concentration, while the PC level remained unalterated.	Protactinium	86-88	prolactin	Homo sapiens	21-30
533513-5	1979	Furthermore, our findings, showing an inverse relationship between LAP activity and the PAS positivity of the secretion products, suggest the hypothesis that the presence of this exopeptidase could induce qualitative modifications of one or more secreted glycoprotein.	Protactinium	88-91	leucine aminopeptidase 3	Rattus norvegicus	67-70
176034-6	1976	Yet when both endogenous renin and ACTH secretion were blocked, PA rose much less after ethacrynic acid.	Protactinium	64-66	renin	Homo sapiens	25-30
400714-7	1978	The angiotensin II analog, saralasin, also increased PA slightly in five studies.	Protactinium	53-55	angiotensinogen	Homo sapiens	4-18
357001-2	1978	The LHbeta antiserum reacts with a cell that is PAS-positive, occurs singly and is randomly distributed throughout the pars distalis.	Protactinium	48-51	lutropin subunit beta	Macaca mulatta	4-10
147932-4	1978	Serum prolactin concentrations in the patients with PA were not increased over those of the age-matched (less than 8 years) prepubertal girls.	Protactinium	52-54	prolactin	Homo sapiens	6-15
638150-3	1978	Pure glycophorin A has a tendency to form multiple bands on SDS gels at positions of higher apparent molecular weight than the PAS 1 and PAS 2 bands previously seen.	Protactinium	127-130	glycophorin A (MNS blood group)	Homo sapiens	5-18
874910-10	1977	Morphologically it was found that in resting glands PAS-positive saliva was displaced from the ductal system when the outflow cannula was raised, but it was preserved in the lumina under similar conditions when the myoepithelial cells were being stimulated by phenylephrine or bradykinin.7.	Protactinium	52-55	kininogen 1	Canis lupus familiaris	277-287
849256-7	1977	When the Pa type is Pa 0, the SAPX phenotype is SAPX 1.	Protactinium	9-11	lactoperoxidase	Homo sapiens	30-34
175830-2	1976	When analyzed by dodecyl sulfate acrylamide electrophoresis this molecule forms two PAS-stainable bands (PAS-U and PAS-2) which are reversibly interconvertible.	Protactinium	84-87	glycophorin A (MNS blood group)	Homo sapiens	115-120
945156-2	1976	Moreover, the response of PA to angiotensin-II infusion was studied in 6 cases of normotensive acromegaly.	Protactinium	26-28	angiotensinogen	Homo sapiens	32-46
945156-6	1976	The response of PA to angiotensin-II fusion was significantly suppressed in normotensive acromegaly as compared to the normal subjects in spite of normal levels of PRA except for 1 case.	Protactinium	16-18	angiotensinogen	Homo sapiens	22-36
945156-8	1976	The low PA and suppressed response of PA toangiotensin-II infusion may suggest the defective action of angiotensin-II infusion on the adrenal gland.	Protactinium	38-40	angiotensinogen	Homo sapiens	43-57
750607-1	1978	Previous studies from this laboratory have demonstrated that the redistribution of blood volume and concomitant central hypervolemia induced by water immersion to the neck (NI), produces a prompt and profound suppression of plasma renin activity (PRA) and plasma aldosterone concentration (PA) without concomitant alterations in serum sodium and potassium concentrations.	Protactinium	290-292	renin	Homo sapiens	231-236
750607-10	1978	The present findings support the role of the renin-angiotensin system as the prepotent mediator of volume-induced changes in PA.	Protactinium	125-127	renin	Homo sapiens	45-50
744535-2	1978	showed the possibility of using KOH/PAS effect (visualisation of C7 and C8O-acylated sialic acids characteristic to colon mucin) for differential diagnosis of metastatic colorectal cancer.	Protactinium	36-39	LOC100508689	Homo sapiens	122-127
744535-3	1978	Our investigations revealed, however, KOH/PAS positive mucin prevailing in some cases of gallbladder, pancreatic and gastric cancer.	Protactinium	42-45	LOC100508689	Homo sapiens	55-60
862382-1	1977	PA should be suspected in any hypertensive patient with evidence of renin suppression and should be confirmed by demonstration of inappropriate and excessive aldosterone production.	Protactinium	0-2	renin	Homo sapiens	68-73
188760-4	1977	In addition, EF-2 activity was almost totally absent in livers of mice which had been injected 24 h earlier with PA toxin.	Protactinium	113-115	eukaryotic translation elongation factor 2	Mus musculus	13-17
188760-10	1977	Furthermore, PA toxin inactivates EF-2 in intoxicated mice to an extent which would ultimately result in death.	Protactinium	13-15	eukaryotic translation elongation factor 2	Mus musculus	34-38
153992-3	1977	As the PA is antigenic, because it produces a blastification (TTL positive), we can say that it acts as antigen provoking immunologic mechanisms with help to explain the inflammatory process at the pilosebaceous follicle in the AV.	Protactinium	7-9	tubulin tyrosine ligase	Homo sapiens	62-65
184893-2	1976	After TRH administration, enzyme modifications (myeloperoxydase, alkaline phosphatase) and metabolism changes (PAS, Sudan black) happen in vivo within the neutrophil, showing a functional activation of that blood cell.	Protactinium	111-114	thyrotropin releasing hormone	Homo sapiens	6-9
61050-5	1976	Out of the 8 granular PAS-positive cases 4 patients (50%) went into complete (M1, P1), and 1 reached partial remission (M2, P1-2).	Protactinium	22-25	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	124-128
989596-0	1976	Characterization of LAS proteins by PAS staining and surface-tension measurements.	Protactinium	36-39	lipoic acid synthetase	Homo sapiens	20-23
56986-7	1976	The intra- and extracellular distribution of alpha-fetoprotein, in general, appeared to coincide with that of the PAS-positive hyaline globules in the tumor.	Protactinium	114-117	alpha fetoprotein	Homo sapiens	45-62
176034-8	1976	The data presented indicate that multiple factors influencing PA after acute volume depletion could be dissected out and that renin, ACTH and a decrease of the MCR each contribute to the elevation of PA.	Protactinium	200-202	renin	Homo sapiens	126-131
176034-8	1976	The data presented indicate that multiple factors influencing PA after acute volume depletion could be dissected out and that renin, ACTH and a decrease of the MCR each contribute to the elevation of PA.	Protactinium	200-202	proopiomelanocortin	Homo sapiens	133-137
1165475-3	1975	The former two enzymes are distinct from the C3b-dependent C3 convertase in that they utilize native C3 instead of C3b and PA in an apparently uncleaved form.	Protactinium	123-125	complement C3	Homo sapiens	45-48
1084-2	1975	This purified FABP represents two protein bands that bind PGA on polyacrylamide disc gel electrophoreis, elutes from DEAE-cellulose in 0.001 M phosphate buffer, stains positive with PAS, Elutes from concanavalin A Sepharose affinity columns with methyl alpha-mannoside, and shows three major peaks (pl =6.8, 7.5, 8.2) by isotric focusing.	Protactinium	182-185	folate receptor alpha	Homo sapiens	14-18
168714-9	1975	Our results indicate that in normal supine man the influence of ACTH and renin on PA may vary with different sodium intakes.	Protactinium	82-84	proopiomelanocortin	Homo sapiens	64-68
168714-9	1975	Our results indicate that in normal supine man the influence of ACTH and renin on PA may vary with different sodium intakes.	Protactinium	82-84	renin	Homo sapiens	73-78
168714-10	1975	Under normal sodium intake ACTH seems to be the dominant factor controlling PA, whereas under sodium restriction changes in PA are mediated through the renin angiotensin system.	Protactinium	76-78	proopiomelanocortin	Homo sapiens	27-31
168714-10	1975	Under normal sodium intake ACTH seems to be the dominant factor controlling PA, whereas under sodium restriction changes in PA are mediated through the renin angiotensin system.	Protactinium	124-126	renin	Homo sapiens	152-157
1159066-9	1975	Furthermore, the current studies confirm the importance of the renin-angiotensin axis in the control of volume-related changes in PA in normal man.	Protactinium	130-132	renin	Homo sapiens	63-68
808068-5	1975	The cells of one patient with lymphoblastic leukaemia were negative for beta-gluc. A coarsely granular PAS reaction was noted in 5 cases of lymphoblastic leukaemia including the one with negative beta-glu, reaction.	Protactinium	103-106	glucuronidase beta	Homo sapiens	72-82
13884647-0	1961	[Is resistance break-through possible after INH and PAS long-term therapy in pulmonary tuberculosis by the use of INHA-PAS?	Protactinium	52-55	inhibin subunit alpha	Homo sapiens	114-118
808174-5	1975	The other hand, the only one PAS stained band of native tyrosinase T1 was splitted into the three slower-moving bands.	Protactinium	29-32	tyrosinase	Homo sapiens	56-66
4112031-0	1972	PAS-positive hyalin change in ACTH-MSH cells of man.	Protactinium	0-3	proopiomelanocortin	Homo sapiens	30-34
5010779-0	1972	[Peculiarities of PAS and tubazid metabolism in tuberculous patients treated with nerobol and ATP].	Protactinium	18-21	ATPase phospholipid transporting 8A2	Homo sapiens	94-98
1089082-2	1975	The partial deficiency of alpha-1-antitrypsin and the diagnosis of cirrhosis were suspected one year prior to death because a needle biopsy of liver showed PAS positive, diastase resistant cytoplasmic bodies within hepatocytes.	Protactinium	156-159	serpin family A member 1	Homo sapiens	26-45
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	18-20	complement C2	Homo sapiens	21-24
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	18-20	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	18-20	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	21-24
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	21-24
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	21-24
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	21-24
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	29-32
5056668-6	1972	This fraction is (Pa(CO2)/Pa(CO2))(2), where Pa(CO2) and Pa(CO2) are the mean partial pressures of expired alveolar and of arterial CO(2); in the other equation this fraction is [Pe(CO2)/Pa(CO2) (Vt - Vd(an) - Vd(m))](2) where Pe(CO2) is mixed expired Pco(2) and Vd(an) is anatomical dead space.	Protactinium	26-28	complement C2	Homo sapiens	29-32
5056668-7	1972	The second equation requires an estimated Vd(an) and is applicable when Pa(CO2) is not measured or does not plateau (as in exercise).	Protactinium	72-74	complement C2	Homo sapiens	75-78
13825626-0	1960	Effect of peracetic acid on the enzymatic digestion of various mucopolysaccharides: reversal of the PAS staining reaction of mucin.	Protactinium	100-103	LOC100508689	Homo sapiens	125-130
13615506-0	1958	[Case of successful use of ACTH in hypersensitivity to PAS].	Protactinium	55-58	proopiomelanocortin	Homo sapiens	27-31
18137830-0	1949	[Considerations on the behavior of blood and CSF concentrations in children subjected to the introduction of PAS by various routes].	Protactinium	109-112	colony stimulating factor 2	Homo sapiens	45-48
13235249-0	1954	[The compound drug INHA-PAS in the treatment of pulmonary tuberculosis].	Protactinium	24-27	inhibin subunit alpha	Homo sapiens	19-23
14349763-0	1954	Changes in plasma proconvertin and prothrombin during PAS therapy.	Protactinium	54-57	coagulation factor II, thrombin	Homo sapiens	35-46
13055031-0	1953	[Prothrombin index during PAS therapy].	Protactinium	26-29	coagulation factor II, thrombin	Homo sapiens	1-12
33933962-5	2021	During gelation, the aggregation of myosin head was weakened and cross-linking of myosin tail and PA molecules was enhanced by hydrophobic interactions.	Protactinium	98-100	myosin, heavy chain 7B, cardiac muscle, beta	Gallus gallus	82-88
33945875-5	2021	A strong correlation was observed between the content (mumol/mg DNA) of PE containing arachidonic acid (20:4) and PA (r2 = 0.9168).	Protactinium	114-116	prolyl endopeptidase	Rattus norvegicus	72-74
33657484-2	2021	First of all, the optimal conditions for lipase-catalyzed G7-PA synthesis, which were 0.2 of the G7/PA molar ratio, 33.5 U of immobilized CALB per 1 g of PA in 10% DMSO, were determined by response surface methodology.	Protactinium	61-63	calbindin 1	Homo sapiens	138-142
34055120-11	2021	Subjects with moderate to severe LBP showed a significant increase in adiposity markers, lower PA, muscle performance, malnutrition, and lower Ca and vitamin D intake compared to normal controls.	Protactinium	95-97	lipopolysaccharide binding protein	Homo sapiens	33-36
33753221-5	2021	The myogenic response of the PA was abolished in SS and was restored in SS.BN5 and SS.Cyp4a1 rats.	Protactinium	29-31	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	86-92
34031970-6	2021	Then, side carboxyl groups are introduced by a thio-ene "click" chemical reaction, followed with CA4 conjugation through the Yamaguchi-reaction, resulting in the target copolymer, mPEG-b-P(PA-alt-GCA4).	Protactinium	189-191	carbonic anhydrase 4	Mus musculus	97-100
33607166-11	2021	galanin, galanin infusion into the dorsal hippocampus alone impaired PA retention and failed to attenuate the 8-OH-DPAT-mediated PA impairment.	Protactinium	69-71	galanin and GMAP prepropeptide	Mus musculus	9-16
34012255-5	2021	Results: We found that the gene expression of polypyrimidine tract-binding protein1 (PTBP1) was increased significantly in a time-dependent manner in rats PA tissues and PASMCs after hypoxia.	Protactinium	155-157	polypyrimidine tract binding protein 1	Rattus norvegicus	46-83
34012255-5	2021	Results: We found that the gene expression of polypyrimidine tract-binding protein1 (PTBP1) was increased significantly in a time-dependent manner in rats PA tissues and PASMCs after hypoxia.	Protactinium	155-157	polypyrimidine tract binding protein 1	Rattus norvegicus	85-90
33607166-8	2021	galanin significantly attenuated the PA impairment caused by 5-HT1A receptor activation in mice.	Protactinium	37-39	galanin and GMAP prepropeptide	Mus musculus	0-7
33607166-8	2021	galanin significantly attenuated the PA impairment caused by 5-HT1A receptor activation in mice.	Protactinium	37-39	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	61-76
33545536-6	2021	Multivariate linear regression models showed that PA quartile 1 was significantly associated with length of hospital stay (beta, SE) in both crude and adjusted models-respectively, beta (SE) = 6.199 (1.625), P <= 0.001, and beta = 2.193 (1.355), P = 0.033.	Protactinium	50-52	ATPase H+ transporting V0 subunit a2	Homo sapiens	224-232
32770172-9	2021	In either HSMCs or AML12 hepatocytes, BBR (5 muM) abolished palmitate acid (PA)-induced increase of CypD protein levels.	Protactinium	76-78	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	100-104
33484224-11	2021	The expression of eNOS and the concentration of NO was lower in the NA group than that in other groups (P <0.05); it was lower in the VLA group than that in the LA group (P <0.05), and lower in LA group than that in PA group (P <0.05).	Protactinium	216-218	nitric oxide synthase 3	Rattus norvegicus	18-22
33099886-1	2021	BACKGROUND: Baloxavir marboxil (BXM) is an approved drug that selectively targets cap-dependent endonuclease on PA subunit in the RNA polymerase complex of influenza A and B viruses.	Protactinium	112-114	influenza a and b	None	156-173
33952498-10	2021	CONCLUSION: PIT-1 accurately classifies GH-secreting PAs.	Protactinium	53-56	POU class 1 homeobox 1	Homo sapiens	12-17
33952498-10	2021	CONCLUSION: PIT-1 accurately classifies GH-secreting PAs.	Protactinium	53-56	growth hormone 1	Homo sapiens	40-42
33780908-9	2021	In addi-tion, Western blot showed that DUSP1 expression was reduced in the DSCs of pa-tients with RM, along with JNK overactivation and decreased IGFBP1 expression.	Protactinium	83-85	dual specificity phosphatase 1	Homo sapiens	39-44
33831690-12	2021	In vitro study revealed PA significantly induced hepatotoxicity by inhibition of L-02 cell growth, abnormally elevation of ALT and AST.	Protactinium	24-26	glutamic pyruvic transaminase, soluble	Mus musculus	123-126
33831690-12	2021	In vitro study revealed PA significantly induced hepatotoxicity by inhibition of L-02 cell growth, abnormally elevation of ALT and AST.	Protactinium	24-26	solute carrier family 17 member 5	Homo sapiens	131-134
33831690-14	2021	In vivo study confirmed PA could induce liver injury in mice with observation of the body weight loss, increasing of serum ALT and AST, and the histopathological changes in liver tissues.	Protactinium	24-26	glutamic pyruvic transaminase, soluble	Mus musculus	123-126
33831690-14	2021	In vivo study confirmed PA could induce liver injury in mice with observation of the body weight loss, increasing of serum ALT and AST, and the histopathological changes in liver tissues.	Protactinium	24-26	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	131-134
33780908-9	2021	In addi-tion, Western blot showed that DUSP1 expression was reduced in the DSCs of pa-tients with RM, along with JNK overactivation and decreased IGFBP1 expression.	Protactinium	83-85	mitogen-activated protein kinase 8	Homo sapiens	113-116
33780908-9	2021	In addi-tion, Western blot showed that DUSP1 expression was reduced in the DSCs of pa-tients with RM, along with JNK overactivation and decreased IGFBP1 expression.	Protactinium	83-85	insulin like growth factor binding protein 1	Homo sapiens	146-152
33975149-9	2021	RESULTS: Controlling for negative affect, body mass index, age, and sex, PA significantly moderated the associations between sleep condition and stimulated monocyte production of IL-6 (b = -1.03, t = -2.02, p = .048) and its co-expression with TNF (b = -0.93, t = -2.00, p = .049), such that inflammatory responses were blunted among those high in PA with increases principally among those low in PA.	Protactinium	348-350	interleukin 6	Homo sapiens	179-183
33934094-11	2021	CONCLUSIONS: In contrast to our hypothesis, feeding a newly composed infant formula based on a fat blend with 25% of PA in the sn-2 position of triacylglycerols and supplemented with a prebiotic could not decrease insoluble FA soap excretion compared with a standard product; in this respect, breastfeeding is obviously the best choice.	Protactinium	117-119	FAT atypical cadherin 1	Homo sapiens	95-98
33953586-16	2021	Moreover, ASIV restored apoptotic protein (Bax and Bcl-2) expression in PA-treated LO2 cells.	Protactinium	72-74	BCL2 associated X, apoptosis regulator	Homo sapiens	43-46
33953586-16	2021	Moreover, ASIV restored apoptotic protein (Bax and Bcl-2) expression in PA-treated LO2 cells.	Protactinium	72-74	BCL2 apoptosis regulator	Homo sapiens	51-56
33975149-9	2021	RESULTS: Controlling for negative affect, body mass index, age, and sex, PA significantly moderated the associations between sleep condition and stimulated monocyte production of IL-6 (b = -1.03, t = -2.02, p = .048) and its co-expression with TNF (b = -0.93, t = -2.00, p = .049), such that inflammatory responses were blunted among those high in PA with increases principally among those low in PA.	Protactinium	348-350	interleukin 6	Homo sapiens	179-183
33975149-9	2021	RESULTS: Controlling for negative affect, body mass index, age, and sex, PA significantly moderated the associations between sleep condition and stimulated monocyte production of IL-6 (b = -1.03, t = -2.02, p = .048) and its co-expression with TNF (b = -0.93, t = -2.00, p = .049), such that inflammatory responses were blunted among those high in PA with increases principally among those low in PA.	Protactinium	73-75	interleukin 6	Homo sapiens	179-183
33556399-8	2021	CS/PA coating on fabric could form the IFR system which acts through both condensed phase action by the catalysis dehydration reaction to forming stable char and gas phase action by the blowing effect.	Protactinium	3-5	citrate synthase	Homo sapiens	0-2
33975149-9	2021	RESULTS: Controlling for negative affect, body mass index, age, and sex, PA significantly moderated the associations between sleep condition and stimulated monocyte production of IL-6 (b = -1.03, t = -2.02, p = .048) and its co-expression with TNF (b = -0.93, t = -2.00, p = .049), such that inflammatory responses were blunted among those high in PA with increases principally among those low in PA.	Protactinium	73-75	tumor necrosis factor	Homo sapiens	244-247
33853954-7	2022	Furthermore, we found that some of the residues affecting A/Viet Nam/1203/2004 H5N1 PA-X host shutoff activity also affect PA polymerase activity in a minigenome assay.	Protactinium	84-86	SH3 and cysteine rich domain 3	Homo sapiens	65-68
33556473-6	2021	In adolescence PA sheep had decreased hepatic expression and circulating concentrations of FGF21.	Protactinium	15-17	fibroblast growth factor 21	Ovis aries	91-96
33903591-5	2021	In addition, knockdown of PXDN reversed PA-induced downregulated forkhead box-1 (FoxO1) and reduced FoxO1 phosphorylation, whereas did not affect AKT phosphorylation.	Protactinium	40-42	peroxidasin	Homo sapiens	26-30
33903591-5	2021	In addition, knockdown of PXDN reversed PA-induced downregulated forkhead box-1 (FoxO1) and reduced FoxO1 phosphorylation, whereas did not affect AKT phosphorylation.	Protactinium	40-42	forkhead box O1	Homo sapiens	81-86
33903591-5	2021	In addition, knockdown of PXDN reversed PA-induced downregulated forkhead box-1 (FoxO1) and reduced FoxO1 phosphorylation, whereas did not affect AKT phosphorylation.	Protactinium	40-42	forkhead box O1	Homo sapiens	100-105
33903591-6	2021	Not consistent with the effects of si-PXDN, double-silence of PXDN and FoxO1 significantly increased cell death, suppressed autophagic flux and declined the level of FoxO1 and PXDN, while the expression of LC3-II was unchanged under PA stimulation.	Protactinium	233-235	peroxidasin	Homo sapiens	62-66
33903591-6	2021	Not consistent with the effects of si-PXDN, double-silence of PXDN and FoxO1 significantly increased cell death, suppressed autophagic flux and declined the level of FoxO1 and PXDN, while the expression of LC3-II was unchanged under PA stimulation.	Protactinium	233-235	forkhead box O1	Homo sapiens	71-76
33903591-6	2021	Not consistent with the effects of si-PXDN, double-silence of PXDN and FoxO1 significantly increased cell death, suppressed autophagic flux and declined the level of FoxO1 and PXDN, while the expression of LC3-II was unchanged under PA stimulation.	Protactinium	233-235	peroxidasin	Homo sapiens	62-66
33903591-7	2021	Furthermore, inhibition of FoxO1 in PA-untreated cells induced cell death, inhibited autophagic flux, and inhibited FoxO1 and PXDN expression.	Protactinium	36-38	forkhead box O1	Homo sapiens	27-32
33903591-7	2021	Furthermore, inhibition of FoxO1 in PA-untreated cells induced cell death, inhibited autophagic flux, and inhibited FoxO1 and PXDN expression.	Protactinium	36-38	forkhead box O1	Homo sapiens	116-121
33903591-7	2021	Furthermore, inhibition of FoxO1 in PA-untreated cells induced cell death, inhibited autophagic flux, and inhibited FoxO1 and PXDN expression.	Protactinium	36-38	peroxidasin	Homo sapiens	126-130
33903591-8	2021	Thus, we come to conclusion that PXDN plays a key role in PA-induced cell death by impairing autophagic flux through inhibiting FoxO1, and FoxO1 may also affect the expression of PXDN.	Protactinium	58-60	peroxidasin	Homo sapiens	33-37
33903591-8	2021	Thus, we come to conclusion that PXDN plays a key role in PA-induced cell death by impairing autophagic flux through inhibiting FoxO1, and FoxO1 may also affect the expression of PXDN.	Protactinium	58-60	forkhead box O1	Homo sapiens	128-133
33889948-8	2021	Attenuation of the TGR5 receptor precluded the positive effect of TUDCA supplementation on development of PA and fertilized embryos cultured under standard conditions, and PA embryos cultured with excess glucose.	Protactinium	106-108	G protein-coupled bile acid receptor 1	Homo sapiens	19-23
33889948-9	2021	Moreover, attenuation of TUDCA/TGR5 signaling induced ER and oxidative stress as well as cell survival genes, but decreased expression of pluripotency genes in PA embryos cultured under excess glucose conditions.	Protactinium	160-162	G protein-coupled bile acid receptor 1	Homo sapiens	31-35
33890331-6	2021	The methylation levels of H3K9me3 and the expression patterns of Suv39h1 and Suv39h2 were similar (P<0.05), and both of them displayed higher levels in Debao procine SCNT embryos compared with that in PA embryos.	Protactinium	201-203	suppressor of variegation 3-9 2	Mus musculus	77-84
33846537-8	2021	These results suggest that the mGluR2-PA tag helps actuate trafficking to the axon terminal, thereby providing abundant possibilities for optogenetic experiments.	Protactinium	38-40	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	31-37
33999775-8	2021	Current findings obtained during waking suggest that enhanced alpha2 power may serve as a direct-objective measure of the subjective reduction of tonic pain in response to PA treatment.	Protactinium	172-174	glycoprotein hormone subunit alpha 2	Homo sapiens	62-68
32654099-5	2021	It was also confirmed that PA pre-treatment inhibited the expression of HIF-1alpha, thereby downregulating the hypoxia-associated gene/protein expressions such as GLUT-1, VEGF, ANG and FGF.	Protactinium	27-29	hypoxia inducible factor 1 subunit alpha	Homo sapiens	72-82
32654099-5	2021	It was also confirmed that PA pre-treatment inhibited the expression of HIF-1alpha, thereby downregulating the hypoxia-associated gene/protein expressions such as GLUT-1, VEGF, ANG and FGF.	Protactinium	27-29	vascular endothelial growth factor A	Homo sapiens	171-175
32654099-5	2021	It was also confirmed that PA pre-treatment inhibited the expression of HIF-1alpha, thereby downregulating the hypoxia-associated gene/protein expressions such as GLUT-1, VEGF, ANG and FGF.	Protactinium	27-29	angiogenin	Homo sapiens	177-180
33837678-2	2021	For PA imaging (PAI), non-ideal signal detection deteriorates image quality, and quantitative PAI (QPAI) remains challenging due to the unknown light fluence spectra in deep tissue.	Protactinium	4-6	serpin family E member 1	Homo sapiens	16-19
33736642-8	2021	HDAC3 silencing decreased ROS production, inflammation, and damage-associated tube formation in HG-PA-treated HUVECs.	Protactinium	99-101	histone deacetylase 3	Mus musculus	0-5
33689376-3	2021	In the chlorophyll pair [PAPB], the electronic coupling between PA and PB is large (85 meV) for the highest occupied molecular orbital, forming the electronically coupled dimer [PAPB] and serving as an initial electron donor.	Protactinium	25-27	GLI family zinc finger 3	Homo sapiens	178-182
33689376-4	2021	In contrast, the coupling for the lowest unoccupied molecular orbital is small (15 meV), leading to charge transfer from PB to PA upon the [PAPB] excitation.	Protactinium	127-129	GLI family zinc finger 3	Homo sapiens	140-144
33658485-7	2021	In vitro experiments showed that in the human normal hepatocyte cell line LO2 and primary hepatocytes isolated from mice, overexpression of WBP2 reduced fat deposition, and knocking out or knocking down WBP2 aggravated PA-induced fat deposition.	Protactinium	219-221	WW domain binding protein 2	Mus musculus	140-144
33305425-4	2021	After systemic administration, SPNP passively targets the tumor and in-situ reacts with granzyme B to release the dye-labeled peptide, leading to decreased NIRF and PA signals from the dye but unchanged signals from the polymer.	Protactinium	165-167	granzyme B	Homo sapiens	88-98
33305425-5	2021	Such ratiometric NIRF and PA signals of SPNP correlate well with the expression level of granzyme B and intratumoral population of CTLs.	Protactinium	26-28	granzyme B	Homo sapiens	89-99
33658485-7	2021	In vitro experiments showed that in the human normal hepatocyte cell line LO2 and primary hepatocytes isolated from mice, overexpression of WBP2 reduced fat deposition, and knocking out or knocking down WBP2 aggravated PA-induced fat deposition.	Protactinium	219-221	WW domain binding protein 2	Mus musculus	203-207
33609094-10	2021	CONCLUSIONS: PA can ensure 4F-PCC is dosed appropriately without affecting patient outcomes.	Protactinium	13-15	crystallin gamma D	Homo sapiens	30-33
31257022-9	2021	Thirty-two percent had positive HLA-B27 and it was associated with axial PA subtypes.	Protactinium	73-75	major histocompatibility complex, class I, B	Homo sapiens	32-39
33430700-9	2021	In conclusion, our study showed that PA could destroy differentiative capacity of C2C12 myoblasts by affecting the expression of Pax7, MyoD and MyoG, and OA could improve this impairment through PI3K /Akt signaling pathway.	Protactinium	37-39	paired box 7	Mus musculus	129-133
33430700-9	2021	In conclusion, our study showed that PA could destroy differentiative capacity of C2C12 myoblasts by affecting the expression of Pax7, MyoD and MyoG, and OA could improve this impairment through PI3K /Akt signaling pathway.	Protactinium	37-39	myogenin	Mus musculus	144-148
33430700-9	2021	In conclusion, our study showed that PA could destroy differentiative capacity of C2C12 myoblasts by affecting the expression of Pax7, MyoD and MyoG, and OA could improve this impairment through PI3K /Akt signaling pathway.	Protactinium	37-39	thymoma viral proto-oncogene 1	Mus musculus	201-204
33508938-6	2021	Cu2+ can efficiently coordinate with the chelator PNIPAM and lead to aggregation of the nanoprobe, resulting in the absorption red-shift and increased PA performance of the nanoprobe in the NIR-II window.	Protactinium	53-55	immunoglobulin kappa variable 1-35	Mus musculus	0-3
33300065-3	2021	The established anti-TROP2 mAb, TrMab-6 (mouse IgG2b, kappa), detected TROP2 on PA-tagged TROP2-overexpressing Chinese hamster ovary-K1 (CHO/TROP2-PA) and breast cancer cell lines, including MCF7 and BT-474 using flow cytometry.	Protactinium	80-82	tumor associated calcium signal transducer 2	Homo sapiens	21-26
33679636-8	2021	IAV with the PA-I38T mutation shows resistance against BXA, but is still susceptible toward ATR-002.	Protactinium	13-15	ATR serine/threonine kinase	Homo sapiens	92-95
33565061-7	2021	In PA-MSCs, expression level of Twist1 and TGF-beta3 was the highest and FGF2 was the lowest.	Protactinium	3-5	twist family bHLH transcription factor 1	Homo sapiens	32-38
33565061-7	2021	In PA-MSCs, expression level of Twist1 and TGF-beta3 was the highest and FGF2 was the lowest.	Protactinium	3-5	transforming growth factor beta 3	Homo sapiens	43-52
33565061-7	2021	In PA-MSCs, expression level of Twist1 and TGF-beta3 was the highest and FGF2 was the lowest.	Protactinium	3-5	fibroblast growth factor 2	Homo sapiens	73-77
33565061-11	2021	The regulatory effect of Twist1, SIRT1, FGF2 and TGF-beta3 genes on PA-MSCs, UC-MSCs and DP-MSCs are different.	Protactinium	68-70	twist family bHLH transcription factor 1	Homo sapiens	25-31
33565061-11	2021	The regulatory effect of Twist1, SIRT1, FGF2 and TGF-beta3 genes on PA-MSCs, UC-MSCs and DP-MSCs are different.	Protactinium	68-70	sirtuin 1	Homo sapiens	33-38
33565061-11	2021	The regulatory effect of Twist1, SIRT1, FGF2 and TGF-beta3 genes on PA-MSCs, UC-MSCs and DP-MSCs are different.	Protactinium	68-70	fibroblast growth factor 2	Homo sapiens	40-44
33565061-11	2021	The regulatory effect of Twist1, SIRT1, FGF2 and TGF-beta3 genes on PA-MSCs, UC-MSCs and DP-MSCs are different.	Protactinium	68-70	transforming growth factor beta 3	Homo sapiens	49-58
33562386-5	2021	The membrane exhibits high CO2 permeance of 3.451 x 10-7 mol m-2 s-1 Pa-1 and CO2/CH4 selectivity of 62 at 298 K and 0.15 MPa feed gas pressure.	Protactinium	69-71	gastrin	Homo sapiens	131-134
32614657-9	2021	The modified recombinant protein comprising the PA immunogenic domains 3 and 4 (rPA3 + 4) was stable during storage at 4 and 25 C. rPA3 + 4 interacts with antibodies to rPA83 both individually and as a part of a complex with SPs.	Protactinium	48-50	replication protein A3	Rattus norvegicus	80-84
32614657-9	2021	The modified recombinant protein comprising the PA immunogenic domains 3 and 4 (rPA3 + 4) was stable during storage at 4 and 25 C. rPA3 + 4 interacts with antibodies to rPA83 both individually and as a part of a complex with SPs.	Protactinium	48-50	replication protein A3	Rattus norvegicus	131-135
33300065-3	2021	The established anti-TROP2 mAb, TrMab-6 (mouse IgG2b, kappa), detected TROP2 on PA-tagged TROP2-overexpressing Chinese hamster ovary-K1 (CHO/TROP2-PA) and breast cancer cell lines, including MCF7 and BT-474 using flow cytometry.	Protactinium	80-82	tumor associated calcium signal transducer 2	Homo sapiens	71-76
33300065-3	2021	The established anti-TROP2 mAb, TrMab-6 (mouse IgG2b, kappa), detected TROP2 on PA-tagged TROP2-overexpressing Chinese hamster ovary-K1 (CHO/TROP2-PA) and breast cancer cell lines, including MCF7 and BT-474 using flow cytometry.	Protactinium	80-82	tumor associated calcium signal transducer 2	Homo sapiens	71-76
33300065-3	2021	The established anti-TROP2 mAb, TrMab-6 (mouse IgG2b, kappa), detected TROP2 on PA-tagged TROP2-overexpressing Chinese hamster ovary-K1 (CHO/TROP2-PA) and breast cancer cell lines, including MCF7 and BT-474 using flow cytometry.	Protactinium	80-82	tumor associated calcium signal transducer 2	Homo sapiens	71-76
33491973-11	2021	While the only factor significantly associated with PA for interns was resident cooperation, time in operating room and clinical autonomy were significantly associated with PA for PGY2/3.	Protactinium	52-54	ATP binding cassette subfamily B member 4	Homo sapiens	180-186
33491973-11	2021	While the only factor significantly associated with PA for interns was resident cooperation, time in operating room and clinical autonomy were significantly associated with PA for PGY2/3.	Protactinium	173-175	ATP binding cassette subfamily B member 4	Homo sapiens	180-186
33345355-13	2021	The presence of PA was the independent predictor of activation loss in ipsilateral SM1(P < 0.05).	Protactinium	16-18	SM1	Homo sapiens	83-86
33552096-12	2020	The results in this present paper indicated that tobacco NtAn1 genes regulate both PAs and lipid accumulation in the process of seed development and that targeted mutagenesis of NtAn1 genes could generate a yellow-seeded tobacco variety with high lipid and protein content.	Protactinium	83-86	annexin D1-like	Nicotiana tabacum	57-62
33447908-7	2021	NF-kappaB (P65) mRNA expression and the phosphorylation of p65 were increased in Mn-treated BV2 cell, and suppressed by PAS-Na, analogous to the effect of JSH-23 pretreatment.	Protactinium	120-123	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-9
33447908-7	2021	NF-kappaB (P65) mRNA expression and the phosphorylation of p65 were increased in Mn-treated BV2 cell, and suppressed by PAS-Na, analogous to the effect of JSH-23 pretreatment.	Protactinium	120-123	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	11-14
33447908-7	2021	NF-kappaB (P65) mRNA expression and the phosphorylation of p65 were increased in Mn-treated BV2 cell, and suppressed by PAS-Na, analogous to the effect of JSH-23 pretreatment.	Protactinium	120-123	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	59-62
33439763-6	2021	HSP70 acutely increased only in the PA group (p=0.024, ES=1.20).	Protactinium	36-38	heat shock protein family A (Hsp70) member 4	Homo sapiens	0-5
33613155-6	2021	Objective: The present study aimed to investigate the effect and potential mechanism of action of PA on basal and insulin stimulated glucose uptake in C2C12 myotubes.	Protactinium	98-100	insulin	Homo sapiens	114-121
33613155-10	2021	Results: We found that PA significantly promoted glucose uptake and GLUT4 translocation to the plasma membrane.	Protactinium	23-25	solute carrier family 2 member 4	Homo sapiens	68-73
33613155-11	2021	PA had no effect on the insulin-dependent pathway involving insulin receptor substrate 1 (Tyr632) and protein kinase B (PKB/Akt), but increased phosphorylation of AMPK and Akt substrate of 160 kDa (AS160).	Protactinium	0-2	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	163-167
33613155-11	2021	PA had no effect on the insulin-dependent pathway involving insulin receptor substrate 1 (Tyr632) and protein kinase B (PKB/Akt), but increased phosphorylation of AMPK and Akt substrate of 160 kDa (AS160).	Protactinium	0-2	TBC1 domain family member 4	Homo sapiens	172-196
33613155-12	2021	Compound C (an AMPK inhibitor) blocked PA-induced AMPK activation and reversed PA-induced GLUT4 translocation, indicating that PA promotes glucose uptake via the AMPK pathway in vitro.	Protactinium	39-41	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	15-19
33613155-12	2021	Compound C (an AMPK inhibitor) blocked PA-induced AMPK activation and reversed PA-induced GLUT4 translocation, indicating that PA promotes glucose uptake via the AMPK pathway in vitro.	Protactinium	39-41	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	50-54
33613155-12	2021	Compound C (an AMPK inhibitor) blocked PA-induced AMPK activation and reversed PA-induced GLUT4 translocation, indicating that PA promotes glucose uptake via the AMPK pathway in vitro.	Protactinium	39-41	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	50-54
33613155-12	2021	Compound C (an AMPK inhibitor) blocked PA-induced AMPK activation and reversed PA-induced GLUT4 translocation, indicating that PA promotes glucose uptake via the AMPK pathway in vitro.	Protactinium	79-81	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	15-19
33613155-12	2021	Compound C (an AMPK inhibitor) blocked PA-induced AMPK activation and reversed PA-induced GLUT4 translocation, indicating that PA promotes glucose uptake via the AMPK pathway in vitro.	Protactinium	79-81	solute carrier family 2 member 4	Homo sapiens	90-95
33613155-12	2021	Compound C (an AMPK inhibitor) blocked PA-induced AMPK activation and reversed PA-induced GLUT4 translocation, indicating that PA promotes glucose uptake via the AMPK pathway in vitro.	Protactinium	79-81	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	15-19
33613155-12	2021	Compound C (an AMPK inhibitor) blocked PA-induced AMPK activation and reversed PA-induced GLUT4 translocation, indicating that PA promotes glucose uptake via the AMPK pathway in vitro.	Protactinium	79-81	solute carrier family 2 member 4	Homo sapiens	90-95
33613155-13	2021	Moreover, PA significantly promoted insulin-stimulated glucose uptake in myotubes.	Protactinium	10-12	insulin	Homo sapiens	36-43
33613155-14	2021	Under insulin stimulation, PA did not affect the insulin-dependent pathway, but still activated AMPK.	Protactinium	27-29	insulin	Homo sapiens	6-13
33613155-14	2021	Under insulin stimulation, PA did not affect the insulin-dependent pathway, but still activated AMPK.	Protactinium	27-29	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	96-100
33613155-15	2021	Conclusion: PA, an odd-chain SFA, significantly stimulates glucose uptake via the AMPK-AS160 pathway and exhibits an insulin-sensitizing effect in myotubes.	Protactinium	12-14	insulin	Homo sapiens	117-124
33171314-3	2021	We show that the surface of silica nanoparticles allows the clustering of RGDS bioactive signals leading to improved adhesion and spreading of fibroblast cells on composite hydrogels at an epitope concentration much lower than in PA-only based matrices.	Protactinium	230-232	ral guanine nucleotide dissociation stimulator	Homo sapiens	74-78
33171314-4	2021	Most importantly, by combining the two integrin-binding sequences RGDS and PHSRN on nanoparticle surfaces, we improved cell adhesion on the PA nanofiber/particle composite hydrogels, which is attributed to synergistic interactions known to be effective only for peptide intermolecular distance of ca.	Protactinium	140-142	ral guanine nucleotide dissociation stimulator	Homo sapiens	66-70
33827406-6	2021	The lower availability of nutrients in the presence of phytates is not due to action of phytates, but is caused by PA anions (IP6-3), which bind positively charged metal ions, amino acids, and proteins.	Protactinium	115-117	centrosomal protein 78	Homo sapiens	126-131
33080042-8	2021	CONCLUSION: In BLM-treated rats, an early-onset and persistent suppression of the BMP9/BMPR2/SMAD signaling pathway might be a trigger to induce the severe loss of PA endothelium and subsequent PA vascular remodeling, contributing to the development of PH.	Protactinium	164-166	growth differentiation factor 2	Homo sapiens	82-86
33080042-8	2021	CONCLUSION: In BLM-treated rats, an early-onset and persistent suppression of the BMP9/BMPR2/SMAD signaling pathway might be a trigger to induce the severe loss of PA endothelium and subsequent PA vascular remodeling, contributing to the development of PH.	Protactinium	164-166	bone morphogenetic protein receptor type 2	Rattus norvegicus	87-92
33289578-6	2021	The use of new digital health interventions and telehealth communication tools, such as smart insulin pens, is now creating opportunities for health care professionals to have a more complete understanding of the PA of drugs, which allows for more personalized prescribing practices.	Protactinium	213-215	insulin	Homo sapiens	94-101
33241870-3	2021	The protein ankyrin repeat domain 17 (Ankrd17), a positive regulator of inflammatory responses via the retinoic acid-inducible gene-I (RIG-I)-like receptor (RLR) signaling pathway, was identified as a specific PA-X binding partner that preferred PA-X to the PA protein.	Protactinium	210-212	ankyrin repeat domain 17	Homo sapiens	12-36
33241870-3	2021	The protein ankyrin repeat domain 17 (Ankrd17), a positive regulator of inflammatory responses via the retinoic acid-inducible gene-I (RIG-I)-like receptor (RLR) signaling pathway, was identified as a specific PA-X binding partner that preferred PA-X to the PA protein.	Protactinium	210-212	ankyrin repeat domain 17	Homo sapiens	38-45
33241870-3	2021	The protein ankyrin repeat domain 17 (Ankrd17), a positive regulator of inflammatory responses via the retinoic acid-inducible gene-I (RIG-I)-like receptor (RLR) signaling pathway, was identified as a specific PA-X binding partner that preferred PA-X to the PA protein.	Protactinium	210-212	DExH-box helicase 58	Homo sapiens	157-160
33241870-4	2021	The N-terminal ankyrin repeats of Ankrd17 are the key domain for the interaction with PA-X rather of PA, which is required for the function of Ankrd17 in elevating the host immune response.	Protactinium	86-88	ankyrin repeat domain 17	Homo sapiens	34-41
33241870-4	2021	The N-terminal ankyrin repeats of Ankrd17 are the key domain for the interaction with PA-X rather of PA, which is required for the function of Ankrd17 in elevating the host immune response.	Protactinium	86-88	ankyrin repeat domain 17	Homo sapiens	143-150
33241870-6	2021	Our data therefore reveal a novel function for PA-X in the regulation of innate immune pathways via the interaction between PA-X and Ankrd17.	Protactinium	47-49	ankyrin repeat domain 17	Homo sapiens	133-140
33276216-2	2021	Despite a very similar clinical presentation among subtypes, the differential diagnosis is limited by the difficulty to identify bradykinin-mediated PA and the lack of specific biomarkers.	Protactinium	149-151	kininogen 1	Homo sapiens	129-139
33334374-1	2020	BACKGROUND: The aqueous solution behavior of thermosensitive PEG-PA block copolymers as well as secondary structure of PA is expected to significantly change through modification of the hydrophobic PA by long chain alkyl (C18) groups with different configurations.	Protactinium	65-67	Bardet-Biedl syndrome 9	Homo sapiens	222-225
33334374-1	2020	BACKGROUND: The aqueous solution behavior of thermosensitive PEG-PA block copolymers as well as secondary structure of PA is expected to significantly change through modification of the hydrophobic PA by long chain alkyl (C18) groups with different configurations.	Protactinium	119-121	Bardet-Biedl syndrome 9	Homo sapiens	222-225
33334374-3	2020	RESULTS: Due to the nature of a hydrophilic PEG block and a hydrophobic PA or C18-modified PA, PEG-PA, oleoyl group-conjugated PEG-PA (PEG-PAO), and stearoyl group-conjugated PEG-PA (PEG-PAS) block copolymers form micelles in water.	Protactinium	91-93	Bardet-Biedl syndrome 9	Homo sapiens	78-81
33218491-9	2020	Via binding with a different pair of PA and PB, this suspension sensor array has successfully typed and quantified cancer-associated miRNAs of miR-21, miR-155, miR-335, and miR-122 in buffer and serum conditions.	Protactinium	37-39	microRNA 21	Homo sapiens	143-149
33218491-9	2020	Via binding with a different pair of PA and PB, this suspension sensor array has successfully typed and quantified cancer-associated miRNAs of miR-21, miR-155, miR-335, and miR-122 in buffer and serum conditions.	Protactinium	37-39	microRNA 122	Homo sapiens	173-180
33290100-5	2020	RESULTS: The serum CK levels were significantly higher in the DAA group than in the PA group on postoperative days 1, 4, 7, 10, and 14.	Protactinium	84-86	cytidine/uridine monophosphate kinase 1	Homo sapiens	19-21
33290100-6	2020	On postoperative day 4 and 7, the percentage of patients whose serum CK levels were above the normal range was 46.8% and 8.5% in the PA group and 95.2% and 45.5% in the DAA group.	Protactinium	133-135	cytidine/uridine monophosphate kinase 1	Homo sapiens	69-71
32865200-11	2020	Activities of 17beta-hydroxysteroid-dehydrogenase and of 17,20-lyase were higher in girls with PA.	Protactinium	95-97	hydroxysteroid 17-beta dehydrogenase 13	Homo sapiens	14-49
33075707-1	2020	OBJECTIVES: While the intravenous recombinant tissue plasminogen activator (rt-PA) therapy for acute ischemic stroke patients with cancer is recommended when survival of >= 6 months is expected, the risk factors for death and stroke recurrence within 6 months after stroke are not well known.	Protactinium	78-81	chromosome 20 open reading frame 181	Homo sapiens	46-74
33260345-8	2020	EGFR mutations were detected in PA-TNA with 83% sensitivity and 100% specificity.	Protactinium	32-34	epidermal growth factor receptor	Homo sapiens	0-4
33315023-6	2020	The results of the PAS assay showed that FABP7 knockout in vivo aggravated lipopolysaccharide (LPS)-induced AKI.	Protactinium	19-22	fatty acid binding protein 7	Homo sapiens	41-46
33257471-8	2021	RESULTS: KLF16 expression was decreased in patients with NAFLD, mice models and oleic acid and palmitic acid (OA and PA) cochallenged hepatocytes.	Protactinium	117-119	Kruppel like factor 16	Homo sapiens	9-14
32717421-10	2020	Furthermore, overexpression of miR-21 improved the impaired mitochondrial biogenesis and decreased the cardiomyocyte apoptosis induced by HG/PA, while inhibition of miR-21 exerted the opposite effects.	Protactinium	141-143	microRNA 21	Homo sapiens	31-37
33203418-4	2020	We hypothesized that PAS-Na might act through NLRP3.	Protactinium	21-25	NLR family, pyrin domain containing 3	Mus musculus	46-51
33511018-3	2021	Here, a FePSe3-based theranostic agent, FePSe3@APP@CCM, loaded with anti-PD-1 peptide (APP) as the inner component and CT26 cancer cell membrane (CCM) as the outer shell is reported, which acts as a multifunctional agent for MR and PA imaging and photothermal and immunotherapy against cancer.	Protactinium	232-234	programmed cell death 1	Mus musculus	73-77
33240683-7	2020	Notably, AMPK inhibitor Compound C (CC) blocked the regulative effects, while AMPK activator AICAR mimicked the effects of SGs in PA-treated insulin-resistant HepG2 cells.	Protactinium	130-132	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	78-82
33240683-7	2020	Notably, AMPK inhibitor Compound C (CC) blocked the regulative effects, while AMPK activator AICAR mimicked the effects of SGs in PA-treated insulin-resistant HepG2 cells.	Protactinium	130-132	insulin	Homo sapiens	141-148
33224099-3	2020	Hypothesis: We hypothesize that individual patient plasmin potential, as measured by in vitro response to recombinant tissue-type plasminogen activator (rt-PA), is a biomarker of rt-PA response, and that patients with greater plasmin response are more likely to recanalize early.	Protactinium	155-158	plasminogen	Homo sapiens	51-58
32679485-4	2020	The strength of the enhanced PA signal for TEX and CL-20 was of the order of 65.38 and 1.77 times, respectively.	Protactinium	29-31	epithelial membrane protein 1	Homo sapiens	51-56
32991800-7	2020	Results suggest that PA neurotoxicity molecular mechanism is mediated, in part, through distortion of JAK/STAT pathway.	Protactinium	21-23	signal transducer and activator of transcription 1	Mus musculus	106-110
32991800-8	2020	PA selectively activated STAT1 pathway, independently of IFN-gamma pathway, in vitro in Schwann cells and in vivo in Swiss albino mice sciatic nerves.	Protactinium	0-2	signal transducer and activator of transcription 1	Mus musculus	25-30
33176851-6	2020	RESULTS: When the risk for the Never-PA group was set as the benchmark (ref = 1), the Maintenance-PA group had the lowest incidence of dementia of the Alzheimer type (DAT) compared to the other groups (HR = 0.82, 95% CI 0.79-0.86).	Protactinium	98-100	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	72-79
33176851-6	2020	RESULTS: When the risk for the Never-PA group was set as the benchmark (ref = 1), the Maintenance-PA group had the lowest incidence of dementia of the Alzheimer type (DAT) compared to the other groups (HR = 0.82, 95% CI 0.79-0.86).	Protactinium	98-100	solute carrier family 6 member 3	Homo sapiens	167-170
33125846-4	2020	High glucose and palmitic acid (HG/PA)-induced apoptosis and autophagy impairment could be attenuated by CD-1 in INS-1 cells as well as primary cultured murine islets.	Protactinium	35-37	CD1d1 molecule	Rattus norvegicus	105-109
33125846-6	2020	Moreover, it was shown that the effects of CD-1 on activation of Keap1/Nrf2 antioxidant signaling pathway and the amelioration of inflammation, endoplasmic reticulum stress, and apoptosis were through autophagy induction in HG/PA-treated INS-1 cells.	Protactinium	227-229	CD1d1 molecule	Rattus norvegicus	43-47
33182770-5	2020	Apoptosis protein array and immunoblotting analysis revealed that PA downregulated the pro-survival proteins, including cIAP1, cIAP2, and survivin, leading to cell death of both attached and suspended cells.	Protactinium	66-68	baculoviral IAP repeat-containing 3	Mus musculus	120-125
33182770-5	2020	Apoptosis protein array and immunoblotting analysis revealed that PA downregulated the pro-survival proteins, including cIAP1, cIAP2, and survivin, leading to cell death of both attached and suspended cells.	Protactinium	66-68	baculoviral IAP repeat-containing 3	Mus musculus	127-132
33182770-5	2020	Apoptosis protein array and immunoblotting analysis revealed that PA downregulated the pro-survival proteins, including cIAP1, cIAP2, and survivin, leading to cell death of both attached and suspended cells.	Protactinium	66-68	baculoviral IAP repeat-containing 5	Mus musculus	138-146
33182770-6	2020	Interestingly, PA decreased the levels of proteins associated with anoikis resistance, including p21, cyclin D1, p-STAT3, and HO-1.	Protactinium	15-17	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	97-100
33182770-6	2020	Interestingly, PA decreased the levels of proteins associated with anoikis resistance, including p21, cyclin D1, p-STAT3, and HO-1.	Protactinium	15-17	cyclin D1	Mus musculus	102-111
33182770-6	2020	Interestingly, PA decreased the levels of proteins associated with anoikis resistance, including p21, cyclin D1, p-STAT3, and HO-1.	Protactinium	15-17	signal transducer and activator of transcription 3	Mus musculus	115-120
33182770-6	2020	Interestingly, PA decreased the levels of proteins associated with anoikis resistance, including p21, cyclin D1, p-STAT3, and HO-1.	Protactinium	15-17	heme oxygenase 1	Mus musculus	126-130
33182770-7	2020	Ectopic expression of active STAT3 attenuated PA-induced anoikis sensitivity.	Protactinium	46-48	signal transducer and activator of transcription 3	Mus musculus	29-34
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	9-11	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	123-132
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	9-11	microtubule-associated protein 1 light chain 3 beta	Mus musculus	147-151
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	168-170	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	123-132
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	168-170	microtubule-associated protein 1 light chain 3 beta	Mus musculus	147-151
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	168-170	microtubule-associated protein 1 light chain 3 beta	Mus musculus	159-163
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	168-170	nucleoporin 62	Mus musculus	193-196
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	168-170	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	123-132
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	168-170	microtubule-associated protein 1 light chain 3 beta	Mus musculus	147-151
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	168-170	microtubule-associated protein 1 light chain 3 beta	Mus musculus	159-163
33182770-8	2020	Although PA activated ER stress and autophagy, as determined by increases in the levels of characteristic markers, such as IRE1alpha, p-elF2alpha, LC3B I, and LC3B II, PA treatment resulted in p62 accumulation, which could be due to PA-induced defects in autophagy flux.	Protactinium	168-170	nucleoporin 62	Mus musculus	193-196
33204402-6	2020	CA upregulated AMPK phosphorylation, the nuclear protein level of Nrf2, and downregulated NFkappaB protein level both in HFD mice and PA-treated HepG2 cells.	Protactinium	134-136	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	90-98
33204402-7	2020	Notably, AMPK inhibitor compound C blocked the regulation of Nrf2 and NFkappaB, as well as ROS overproduction mediated by CA in PA-treated HepG2 cells, while AMPK activator AICAR mimicked the effects of CA.	Protactinium	128-130	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	9-13
33204402-8	2020	Similarly, Nrf2 inhibitor ML385 partly blocked the regulation of antioxidative genes and ROS overproduction by CA in PA-treated HepG2 cells.	Protactinium	117-119	NFE2 like bZIP transcription factor 2	Homo sapiens	11-15
33224099-3	2020	Hypothesis: We hypothesize that individual patient plasmin potential, as measured by in vitro response to recombinant tissue-type plasminogen activator (rt-PA), is a biomarker of rt-PA response, and that patients with greater plasmin response are more likely to recanalize early.	Protactinium	155-158	plasminogen activator, tissue type	Homo sapiens	118-151
33224099-3	2020	Hypothesis: We hypothesize that individual patient plasmin potential, as measured by in vitro response to recombinant tissue-type plasminogen activator (rt-PA), is a biomarker of rt-PA response, and that patients with greater plasmin response are more likely to recanalize early.	Protactinium	155-158	plasminogen	Homo sapiens	130-137
32798647-7	2020	Subsequently, using a high-throughput micronucleus assay, we demonstrated that PAs induced concentration-dependent increases in micronuclei and G2/M phase cell cycle arrest in three CYP3A variant-expressing TK6 cell lines.	Protactinium	79-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	182-187
33051821-7	2020	So we assessed the effects of JAB1 knockdown in palmitate acid (PA) treated HepG2 cells.	Protactinium	64-66	COP9 signalosome subunit 5	Homo sapiens	30-34
32771443-7	2020	MATERIALS AND METHODS: On the basis of the available literature and our institutional experience, we present an algorithm for management of post-traumatic maxillofacial PAs.	Protactinium	169-172	solute carrier family 35 member G1	Homo sapiens	140-144
33051821-8	2020	Importantly, JAB1 siRNA blocked the effect of PA-induced activation of ERK1/2.	Protactinium	46-48	COP9 signalosome subunit 5	Homo sapiens	13-17
32780555-1	2020	BACKGROUND: Upregulation of the plasminogen activation system, including urokinase plasminogen activator (uPA), has been observed in many malignancies, suggesting that co-opting the PA system is a common method by which tumor cells accomplish extracellular matrix proteolysis.	Protactinium	107-109	plasminogen activator, urokinase	Mus musculus	73-104
33051821-8	2020	Importantly, JAB1 siRNA blocked the effect of PA-induced activation of ERK1/2.	Protactinium	46-48	mitogen-activated protein kinase 3	Homo sapiens	71-77
33051821-10	2020	All these data implicated that JAB1 knockdown might alleviate PA-induced IR through ERK pathway in hepatocytes.	Protactinium	62-64	COP9 signalosome subunit 5	Homo sapiens	31-35
33051821-10	2020	All these data implicated that JAB1 knockdown might alleviate PA-induced IR through ERK pathway in hepatocytes.	Protactinium	62-64	mitogen-activated protein kinase 1	Homo sapiens	84-87
33123317-4	2020	This study is aimed at exploring the effects of CFTR on palmitate- (PA-) induced endothelial dysfunction and its underlying mechanisms.	Protactinium	68-70	CF transmembrane conductance regulator	Homo sapiens	48-52
33097026-9	2020	Compared with PA intervention, the ICERs were $10,335.2 ($1478.6) and 4626.3 ($661.8) for CNP and NE respectively.	Protactinium	14-16	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	90-93
33087718-2	2020	We herein report an enzyme replacement approach to treat PA using a combination of two messenger RNAs (mRNAs) (dual mRNAs) encoding both human PCCA (hPCCA) and PCCB (hPCCB) encapsulated in biodegradable lipid nanoparticles (LNPs) to produce functional PCC enzyme in liver.	Protactinium	57-59	propionyl-CoA carboxylase subunit alpha	Homo sapiens	143-147
33087718-2	2020	We herein report an enzyme replacement approach to treat PA using a combination of two messenger RNAs (mRNAs) (dual mRNAs) encoding both human PCCA (hPCCA) and PCCB (hPCCB) encapsulated in biodegradable lipid nanoparticles (LNPs) to produce functional PCC enzyme in liver.	Protactinium	57-59	propionyl-CoA carboxylase subunit beta	Homo sapiens	160-164
33087718-2	2020	We herein report an enzyme replacement approach to treat PA using a combination of two messenger RNAs (mRNAs) (dual mRNAs) encoding both human PCCA (hPCCA) and PCCB (hPCCB) encapsulated in biodegradable lipid nanoparticles (LNPs) to produce functional PCC enzyme in liver.	Protactinium	57-59	propionyl-CoA carboxylase subunit beta	Homo sapiens	166-171
33123317-6	2020	Simultaneously, PA decreased CFTR protein expression.	Protactinium	16-18	CF transmembrane conductance regulator	Homo sapiens	29-33
33123317-7	2020	CFTR agonist Forskolin upregulated CFTR protein expression and protected against PA-induced endothelial dysfunction, while CFTR knockdown exacerbated endothelial dysfunction induced by PA and blunted the protective effects of Forskolin.	Protactinium	81-83	CF transmembrane conductance regulator	Homo sapiens	0-4
33123317-7	2020	CFTR agonist Forskolin upregulated CFTR protein expression and protected against PA-induced endothelial dysfunction, while CFTR knockdown exacerbated endothelial dysfunction induced by PA and blunted the protective effects of Forskolin.	Protactinium	185-187	CF transmembrane conductance regulator	Homo sapiens	0-4
33123317-11	2020	Our findings illustrate that CFTR upregulation protects against PA-induced endothelial dysfunction by improving autophagic flux and underlying mechanisms are involved in enhancing autophagic signaling mediated by the Atg16L-Atg12-Atg5 complex, cathepsin B, and cathepsin D.	Protactinium	64-66	CF transmembrane conductance regulator	Homo sapiens	29-33
33123317-11	2020	Our findings illustrate that CFTR upregulation protects against PA-induced endothelial dysfunction by improving autophagic flux and underlying mechanisms are involved in enhancing autophagic signaling mediated by the Atg16L-Atg12-Atg5 complex, cathepsin B, and cathepsin D.	Protactinium	64-66	autophagy related 16 like 1	Homo sapiens	217-223
33123317-11	2020	Our findings illustrate that CFTR upregulation protects against PA-induced endothelial dysfunction by improving autophagic flux and underlying mechanisms are involved in enhancing autophagic signaling mediated by the Atg16L-Atg12-Atg5 complex, cathepsin B, and cathepsin D.	Protactinium	64-66	autophagy related 12	Homo sapiens	224-229
33123317-11	2020	Our findings illustrate that CFTR upregulation protects against PA-induced endothelial dysfunction by improving autophagic flux and underlying mechanisms are involved in enhancing autophagic signaling mediated by the Atg16L-Atg12-Atg5 complex, cathepsin B, and cathepsin D.	Protactinium	64-66	autophagy related 5	Homo sapiens	230-234
33123317-11	2020	Our findings illustrate that CFTR upregulation protects against PA-induced endothelial dysfunction by improving autophagic flux and underlying mechanisms are involved in enhancing autophagic signaling mediated by the Atg16L-Atg12-Atg5 complex, cathepsin B, and cathepsin D.	Protactinium	64-66	cathepsin B	Homo sapiens	244-255
33123317-11	2020	Our findings illustrate that CFTR upregulation protects against PA-induced endothelial dysfunction by improving autophagic flux and underlying mechanisms are involved in enhancing autophagic signaling mediated by the Atg16L-Atg12-Atg5 complex, cathepsin B, and cathepsin D.	Protactinium	64-66	cathepsin D	Homo sapiens	261-272
32495128-8	2020	After HCT116 cells were treated with palmitate acid (PA) and/or TNF-alpha for 24 h, the combination of PA and TNF-alpha increased ROS production, promoted mitochondrial dysfunction, and activated the pro-apoptotic pathway, but these effects were markedly attenuated by a ROS inhibitor.	Protactinium	53-55	tumor necrosis factor	Homo sapiens	110-119
32910855-0	2020	Fast and Sensitive Detection of Oligosaccharides Using Desalting Pa-per Spray Mass Spectrometry (DPS-MS).	Protactinium	65-67	Fas activated serine/threonine kinase	Homo sapiens	0-4
32951426-2	2020	Under the excitation of ligand absorption bands, 1 exhibits the NIR luminescence of Yb(III) and displays high luminescence sensitivity and selectivity to Co(II), Cu(II), and 2,4,6-trinitrophenol (PA) at the parts per million level.	Protactinium	196-198	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	154-160
32755726-10	2020	In PA treated HepG2 cells during development of hepatic steatosis PPARgamma was significantly up-regulated concomitant with down-regulation of miR-3666.	Protactinium	3-5	peroxisome proliferator activated receptor gamma	Homo sapiens	66-75
32755726-10	2020	In PA treated HepG2 cells during development of hepatic steatosis PPARgamma was significantly up-regulated concomitant with down-regulation of miR-3666.	Protactinium	3-5	microRNA 3666	Homo sapiens	143-151
33020779-3	2020	To address this issue, three atomistic models of PA (pure polyamide membrane), PA-CNT1 (polyamide nanocomposite membrane with an embedded carbon nanotube oriented vertical to the membrane surface) and PA-CNT2 (polyamide nanocomposite with an embedded carbon nanotube oriented parallel to the membrane surface) were constructed respectively in this work.	Protactinium	79-81	solute carrier family 28 member 1	Homo sapiens	82-86
33020779-3	2020	To address this issue, three atomistic models of PA (pure polyamide membrane), PA-CNT1 (polyamide nanocomposite membrane with an embedded carbon nanotube oriented vertical to the membrane surface) and PA-CNT2 (polyamide nanocomposite with an embedded carbon nanotube oriented parallel to the membrane surface) were constructed respectively in this work.	Protactinium	79-81	solute carrier family 28 member 1	Homo sapiens	82-86
33020779-5	2020	The EMD simulations revealed a better stacking of the PA matrix due to the addition of the CNT and this impact was more significant in PA-CNT1 than in PA-CNT2.	Protactinium	54-56	solute carrier family 28 member 1	Homo sapiens	138-142
33020779-5	2020	The EMD simulations revealed a better stacking of the PA matrix due to the addition of the CNT and this impact was more significant in PA-CNT1 than in PA-CNT2.	Protactinium	54-56	solute carrier family 28 member 2	Homo sapiens	154-158
33020779-5	2020	The EMD simulations revealed a better stacking of the PA matrix due to the addition of the CNT and this impact was more significant in PA-CNT1 than in PA-CNT2.	Protactinium	135-137	solute carrier family 28 member 1	Homo sapiens	138-142
33020779-5	2020	The EMD simulations revealed a better stacking of the PA matrix due to the addition of the CNT and this impact was more significant in PA-CNT1 than in PA-CNT2.	Protactinium	135-137	solute carrier family 28 member 1	Homo sapiens	138-142
33020779-8	2020	The partially covered CNT might not help to increase water flux in PA-CNT1 while guided water molecules and the smaller polymer region afftected by the CNT contributed to a relatively high flux in PA-CNT2.	Protactinium	197-199	solute carrier family 28 member 2	Homo sapiens	200-204
33082910-3	2020	The study is aimed at investigating the role of tubulin polymerization-promoting protein family member 3 (TPPP3) in palmitic acid- (PA-) induced endothelial injury.	Protactinium	132-134	tubulin polymerization promoting protein family member 3	Homo sapiens	48-104
33082910-3	2020	The study is aimed at investigating the role of tubulin polymerization-promoting protein family member 3 (TPPP3) in palmitic acid- (PA-) induced endothelial injury.	Protactinium	132-134	tubulin polymerization promoting protein family member 3	Homo sapiens	106-111
33082910-5	2020	TPPP3 silencing inhibited PA overload-induced apoptosis and production of ROS, along with the alteration of apoptosis-related key proteins such as BCL-2 and Bax.	Protactinium	26-28	tubulin polymerization promoting protein family member 3	Homo sapiens	0-5
33082910-8	2020	Collectively, these results demonstrated that TPPP3 could promote PA-induced oxidative damage in HUVECs via a VDAC1-dependent pathway, suggesting that TPPP3 might be considered as a potential therapeutic target in vascular disease.	Protactinium	66-68	tubulin polymerization promoting protein family member 3	Homo sapiens	46-51
33082910-8	2020	Collectively, these results demonstrated that TPPP3 could promote PA-induced oxidative damage in HUVECs via a VDAC1-dependent pathway, suggesting that TPPP3 might be considered as a potential therapeutic target in vascular disease.	Protactinium	66-68	voltage dependent anion channel 1	Homo sapiens	110-115
33082910-8	2020	Collectively, these results demonstrated that TPPP3 could promote PA-induced oxidative damage in HUVECs via a VDAC1-dependent pathway, suggesting that TPPP3 might be considered as a potential therapeutic target in vascular disease.	Protactinium	66-68	tubulin polymerization promoting protein family member 3	Homo sapiens	151-156
32495128-8	2020	After HCT116 cells were treated with palmitate acid (PA) and/or TNF-alpha for 24 h, the combination of PA and TNF-alpha increased ROS production, promoted mitochondrial dysfunction, and activated the pro-apoptotic pathway, but these effects were markedly attenuated by a ROS inhibitor.	Protactinium	103-105	tumor necrosis factor	Homo sapiens	64-73
32970940-9	2020	Real-time-PCR quantitative analysis revealed that miR-34a was significantly upregulated in the liver tissues of the HFD mice and in the PA-treated BNL CL.2 cells.	Protactinium	136-138	microRNA 34a	Mus musculus	50-57
32679213-7	2020	In an cellular uptake study, Tra-Lipo-IONPs were taken up by HER2-positive tumor cells and HER2-specific MR/PA dual imaging was achieved.	Protactinium	108-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
32679213-9	2020	In conclusion, we demonstrated the usefulness of Lipo-IONPs as platforms for sensitive MR/PA dual imaging and the possibility of HER2-specific tumor MR/PA imaging using Tra-Lipo-IONPs.	Protactinium	152-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
32278738-9	2020	Besides, we found that gCTRP9 increased the ratio of LC3II/I and the expression of ATG5 which was vital to the formation of autophagosomes and decreased the level of P62, suggesting enhanced autophagic flux in the absence or presence of PA.	Protactinium	237-239	autophagy related 5	Rattus norvegicus	83-87
32967670-6	2020	RESULTS: The results showed that PA flower ethanolic extract significantly reduced blood glucose, HBA1c%, MDA, TGs, Tc, VLDL, LDL-c, TNF-alpha, and IL-6 levels in a dose-dependent manner.	Protactinium	33-35	hemoglobin alpha, adult chain 1	Rattus norvegicus	98-102
32565512-8	2020	KL-6 was also found to be significantly correlated with oxygenation index and oxygen partial pressure difference of alveolar artery (PA-aDO2) (Both P < 0.01).	Protactinium	133-135	mucin 1, cell surface associated	Homo sapiens	0-4
32967670-6	2020	RESULTS: The results showed that PA flower ethanolic extract significantly reduced blood glucose, HBA1c%, MDA, TGs, Tc, VLDL, LDL-c, TNF-alpha, and IL-6 levels in a dose-dependent manner.	Protactinium	33-35	tumor necrosis factor	Rattus norvegicus	133-142
32967670-6	2020	RESULTS: The results showed that PA flower ethanolic extract significantly reduced blood glucose, HBA1c%, MDA, TGs, Tc, VLDL, LDL-c, TNF-alpha, and IL-6 levels in a dose-dependent manner.	Protactinium	33-35	interleukin 6	Rattus norvegicus	148-152
32967670-8	2020	Treatment of diabetic rats with PA flower increased insulin, HDL-c, GSH, catalase, and SOD levels.	Protactinium	32-34	catalase	Rattus norvegicus	73-81
32973207-7	2020	Moreover, quantitative expression analysis of OPG and RANKL revealed altered levels in mechanically stimulated PA-treated HPdLF.	Protactinium	111-113	basic transcription factor 3 pseudogene 11	Homo sapiens	46-49
32973207-7	2020	Moreover, quantitative expression analysis of OPG and RANKL revealed altered levels in mechanically stimulated PA-treated HPdLF.	Protactinium	111-113	TNF superfamily member 11	Homo sapiens	54-59
33013197-12	2020	Additionally, TLR4/AP-1 siRNA transfection mitigated palmitic acid- (PA-) induced inflammation in RAW264.7 cells and metabolic abnormalities in cocultured AML hepatocytes.	Protactinium	69-71	toll-like receptor 4	Mus musculus	14-18
33013197-12	2020	Additionally, TLR4/AP-1 siRNA transfection mitigated palmitic acid- (PA-) induced inflammation in RAW264.7 cells and metabolic abnormalities in cocultured AML hepatocytes.	Protactinium	69-71	jun proto-oncogene	Mus musculus	19-23
33013197-13	2020	Herein, we propose that TLR4-AP1 signaling pathway activation plays a crucial role in high fat- or PA-induced metabolic inflammation and insulin resistance in hepatocytes.	Protactinium	99-101	toll-like receptor 4	Mus musculus	24-28
33013197-13	2020	Herein, we propose that TLR4-AP1 signaling pathway activation plays a crucial role in high fat- or PA-induced metabolic inflammation and insulin resistance in hepatocytes.	Protactinium	99-101	jun proto-oncogene	Mus musculus	29-32
32439405-4	2020	AIM OF THE STUDY: In the present study, we investigated whether GJG, PA, and neoline could inhibit Nav1.7 voltage-gated sodium channel (VGSC) current and whether neoline could ameliorate mechanical hyperalgesia in diabetic mice.	Protactinium	69-71	sodium channel, voltage-gated, type IX, alpha	Mus musculus	99-105
32439405-8	2020	Powdered PA also inhibited Nav1.7 VGSC peak current.	Protactinium	9-11	sodium channel, voltage-gated, type IX, alpha	Mus musculus	27-33
32439405-11	2020	CONCLUSION: These results suggest that neoline might be a novel active ingredient of GJG and PA that is one of responsible ingredients for ameliorating mechanical hyperalgesia in diabetes via the inhibition of Nav1.7 VGSC current at least.	Protactinium	93-95	sodium channel, voltage-gated, type IX, alpha	Mus musculus	210-216
32774516-8	2020	Results: In NRC, serum and morphogens strongly stimulated PS and PA and the reestablishment of cell-cell contacts (CCC).	Protactinium	65-67	nuclear receptor coactivator 6	Rattus norvegicus	12-15
32904446-5	2020	When combined with the checkpoint-blockade using anti-cytotoxic T-lymphocyte antigen-4, the generated immunological responses will further promote the infiltrating CD8 and CD4 T-cells to increase the CD8/Foxp3 T-cell ratio to inhibit the growth of distant tumors beyond the direct impact range of the PA therapy.	Protactinium	301-303	CD8a molecule	Homo sapiens	164-167
32904446-5	2020	When combined with the checkpoint-blockade using anti-cytotoxic T-lymphocyte antigen-4, the generated immunological responses will further promote the infiltrating CD8 and CD4 T-cells to increase the CD8/Foxp3 T-cell ratio to inhibit the growth of distant tumors beyond the direct impact range of the PA therapy.	Protactinium	301-303	CD4 molecule	Homo sapiens	172-175
32904446-5	2020	When combined with the checkpoint-blockade using anti-cytotoxic T-lymphocyte antigen-4, the generated immunological responses will further promote the infiltrating CD8 and CD4 T-cells to increase the CD8/Foxp3 T-cell ratio to inhibit the growth of distant tumors beyond the direct impact range of the PA therapy.	Protactinium	301-303	CD8a molecule	Homo sapiens	200-203
32904446-5	2020	When combined with the checkpoint-blockade using anti-cytotoxic T-lymphocyte antigen-4, the generated immunological responses will further promote the infiltrating CD8 and CD4 T-cells to increase the CD8/Foxp3 T-cell ratio to inhibit the growth of distant tumors beyond the direct impact range of the PA therapy.	Protactinium	301-303	forkhead box P3	Homo sapiens	204-209
32825354-0	2020	A New Type of Composite Membrane PVA-NaY/PA-6 for Separation of Industrially Valuable Mixture Ethanol/Ethyl Tert-Butyl Ether by Pervaporation.	Protactinium	41-43	telomerase reverse transcriptase	Homo sapiens	108-112
32764635-3	2020	We first inserted the PA tag into the plexin-semaphorin-integrin (PSI) domain of beta7 chain, which reacted with an anti-PA tag antibody (NZ-1) in an Mn2+-dependent manner.	Protactinium	22-24	immunoglobulin kappa variable 2D-24 (non-functional)	Homo sapiens	81-86
32764635-3	2020	We first inserted the PA tag into the plexin-semaphorin-integrin (PSI) domain of beta7 chain, which reacted with an anti-PA tag antibody (NZ-1) in an Mn2+-dependent manner.	Protactinium	121-123	immunoglobulin kappa variable 2D-24 (non-functional)	Homo sapiens	81-86
32999836-4	2020	The charge reversal polymer NGR-poly(ethylene glycol)-poly(l-lysine)-dimethylmaleic anhydride (NGR-PEG-PLL-DMA, ND) in PA/PI-ND promotes the pH-triggered charge reversal from negative to positive and size reduction from about 180 to 10 nm in an acidic tumor microenvironment, which greatly enhances cellular uptake and tumor tissue deep penetration.	Protactinium	119-121	reticulon 4 receptor	Homo sapiens	28-31
32999836-4	2020	The charge reversal polymer NGR-poly(ethylene glycol)-poly(l-lysine)-dimethylmaleic anhydride (NGR-PEG-PLL-DMA, ND) in PA/PI-ND promotes the pH-triggered charge reversal from negative to positive and size reduction from about 180 to 10 nm in an acidic tumor microenvironment, which greatly enhances cellular uptake and tumor tissue deep penetration.	Protactinium	119-121	reticulon 4 receptor	Homo sapiens	95-98
32752316-7	2020	TDH-PAI reduces the cost and complexity of the nonlinear PA system, which provides an efficient way for achieving a high-contrast PA imaging.	Protactinium	4-6	L-threonine dehydrogenase (pseudogene)	Homo sapiens	0-3
32752316-7	2020	TDH-PAI reduces the cost and complexity of the nonlinear PA system, which provides an efficient way for achieving a high-contrast PA imaging.	Protactinium	57-59	L-threonine dehydrogenase (pseudogene)	Homo sapiens	0-3
32768968-7	2020	PA reduced the relative mRNA expression of PAR-2, TNF-alpha, IL-4 and IL-13 in the cells.	Protactinium	0-2	pulmonary adenoma resistance 2	Mus musculus	43-48
32768968-7	2020	PA reduced the relative mRNA expression of PAR-2, TNF-alpha, IL-4 and IL-13 in the cells.	Protactinium	0-2	tumor necrosis factor	Mus musculus	50-59
32768968-7	2020	PA reduced the relative mRNA expression of PAR-2, TNF-alpha, IL-4 and IL-13 in the cells.	Protactinium	0-2	interleukin 4	Mus musculus	61-65
32768968-7	2020	PA reduced the relative mRNA expression of PAR-2, TNF-alpha, IL-4 and IL-13 in the cells.	Protactinium	0-2	interleukin 13	Mus musculus	70-75
32768968-8	2020	In dorsal skin of Nc/Nga mice applied with DNCB, PA dose-dependently attenuated erythema, hemorrhage, edema, excoriation, dryness and scratching behavior and PA-H improved the clinical symptoms similar to the positive-control.	Protactinium	49-51	reticulon 4	Mus musculus	21-24
32768968-10	2020	PA dose-dependently reduced serum IgE and TNF-alpha concentrations and the mRNA expression of TNF-alpha, IL-4, and IL-13 in dorsal skin.	Protactinium	0-2	tumor necrosis factor	Mus musculus	42-51
32768968-10	2020	PA dose-dependently reduced serum IgE and TNF-alpha concentrations and the mRNA expression of TNF-alpha, IL-4, and IL-13 in dorsal skin.	Protactinium	0-2	tumor necrosis factor	Mus musculus	94-103
32768968-10	2020	PA dose-dependently reduced serum IgE and TNF-alpha concentrations and the mRNA expression of TNF-alpha, IL-4, and IL-13 in dorsal skin.	Protactinium	0-2	interleukin 4	Mus musculus	105-109
32768968-10	2020	PA dose-dependently reduced serum IgE and TNF-alpha concentrations and the mRNA expression of TNF-alpha, IL-4, and IL-13 in dorsal skin.	Protactinium	0-2	interleukin 13	Mus musculus	115-120
32867156-4	2020	The postprandial fat oxidation rate AUC of the PA trial was significantly higher than that of the ST trial (p = 0.009); (4) Conclusions: The results of this study indicated that nonexercise energy expenditure decrease the postprandial TG concentration and increase the fat oxidation the next day.	Protactinium	47-49	FAT atypical cadherin 1	Homo sapiens	17-20
32733053-7	2020	Particularly, HDAC1 and HDAC8 were consistently increased in IPAH-PAs and IPAH-PAAFs, whereas HDAC2 and HDAC8 showed predominant localization with ACTA2-expressing cells in extensively remodeled IPAH-PAs.	Protactinium	66-69	histone deacetylase 1	Danio rerio	14-19
32733053-7	2020	Particularly, HDAC1 and HDAC8 were consistently increased in IPAH-PAs and IPAH-PAAFs, whereas HDAC2 and HDAC8 showed predominant localization with ACTA2-expressing cells in extensively remodeled IPAH-PAs.	Protactinium	66-69	histone deacetylase 8	Danio rerio	24-29
32709035-10	2020	Conclusions: Our results suggest the presence of molecular stages of PA, defined according to the over-expression (first stage) or under-expression (second stage) of the HMOX1, SOD1, IL-6, and IFNgamma genes in abnormal skin tissue.	Protactinium	69-71	heme oxygenase 1	Homo sapiens	170-175
32709035-10	2020	Conclusions: Our results suggest the presence of molecular stages of PA, defined according to the over-expression (first stage) or under-expression (second stage) of the HMOX1, SOD1, IL-6, and IFNgamma genes in abnormal skin tissue.	Protactinium	69-71	superoxide dismutase 1	Homo sapiens	177-181
32709035-10	2020	Conclusions: Our results suggest the presence of molecular stages of PA, defined according to the over-expression (first stage) or under-expression (second stage) of the HMOX1, SOD1, IL-6, and IFNgamma genes in abnormal skin tissue.	Protactinium	69-71	interleukin 6	Homo sapiens	183-187
32709035-10	2020	Conclusions: Our results suggest the presence of molecular stages of PA, defined according to the over-expression (first stage) or under-expression (second stage) of the HMOX1, SOD1, IL-6, and IFNgamma genes in abnormal skin tissue.	Protactinium	69-71	interferon gamma	Homo sapiens	193-201
32660602-15	2020	CONCLUSION: PA and QS improved PAH possibly by affecting the expression of PARP1 and miR-204 and their downstream targets, HIF1a and NFATc2.	Protactinium	12-14	poly (ADP-ribose) polymerase 1	Rattus norvegicus	75-80
32660602-15	2020	CONCLUSION: PA and QS improved PAH possibly by affecting the expression of PARP1 and miR-204 and their downstream targets, HIF1a and NFATc2.	Protactinium	12-14	microRNA 204	Rattus norvegicus	85-92
32660602-15	2020	CONCLUSION: PA and QS improved PAH possibly by affecting the expression of PARP1 and miR-204 and their downstream targets, HIF1a and NFATc2.	Protactinium	12-14	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	123-128
32660602-15	2020	CONCLUSION: PA and QS improved PAH possibly by affecting the expression of PARP1 and miR-204 and their downstream targets, HIF1a and NFATc2.	Protactinium	12-14	nuclear factor of activated T-cells 2	Rattus norvegicus	133-139
31222631-7	2020	RESULTS: After covarying for age, gender, body mass index, chronic pain status, salivary flow rate, and NA, higher PA was associated with lower salivary CRP (beta = - 0.02, 95% CI (- 0.03, - 0.00) sr2 = .06, p = .01) but not IL-6; removing NA from this model did not change results.	Protactinium	115-117	C-reactive protein	Homo sapiens	153-156
32664151-11	2020	CONCLUSION: Our findings indicated that XPC Lys939Gln variant might contribute to increased PA susceptibility, especially for Asian patients.	Protactinium	92-94	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	40-43
32215982-3	2020	The objective of this study is to identify the role of Txnip in geniposide preventing the apoptosis of pancreatic beta cells induced by high glucose and palmitate (HG/PA).	Protactinium	167-169	thioredoxin interacting protein	Rattus norvegicus	55-60
32215982-4	2020	The results revealed that geniposide attenuated HG/PA-induced cell apoptosis and the expression of Bax and caspase-3, while increasing mitochondrial membrane potential and the anti-apoptotic protein levels of heme-oxygenase-1 (HO-1) and Bcl-2 in INS-1 rat pancreatic beta cells.	Protactinium	51-53	BCL2 associated X, apoptosis regulator	Rattus norvegicus	99-102
32215982-4	2020	The results revealed that geniposide attenuated HG/PA-induced cell apoptosis and the expression of Bax and caspase-3, while increasing mitochondrial membrane potential and the anti-apoptotic protein levels of heme-oxygenase-1 (HO-1) and Bcl-2 in INS-1 rat pancreatic beta cells.	Protactinium	51-53	caspase 3	Rattus norvegicus	107-116
32215982-4	2020	The results revealed that geniposide attenuated HG/PA-induced cell apoptosis and the expression of Bax and caspase-3, while increasing mitochondrial membrane potential and the anti-apoptotic protein levels of heme-oxygenase-1 (HO-1) and Bcl-2 in INS-1 rat pancreatic beta cells.	Protactinium	51-53	heme oxygenase 1	Rattus norvegicus	227-231
32215982-4	2020	The results revealed that geniposide attenuated HG/PA-induced cell apoptosis and the expression of Bax and caspase-3, while increasing mitochondrial membrane potential and the anti-apoptotic protein levels of heme-oxygenase-1 (HO-1) and Bcl-2 in INS-1 rat pancreatic beta cells.	Protactinium	51-53	BCL2, apoptosis regulator	Rattus norvegicus	237-242
32215982-6	2020	Furthermore, geniposide enhanced the adoptive unfolded protein response by increasing the phosphorylation of PERK/eIF2alpha and IRE1alpha in HG/PA-treated INS-1 cells.	Protactinium	144-146	eukaryotic translation initiation factor 2A	Rattus norvegicus	114-123
32469498-3	2020	Eight TF-targeting sequences were identified, synthesized into PA molecules, co-assembled with non-targeted backbone PA at various weight percentages, and characterized via circular dichroism spectroscopy, transmission electron microscopy, and X-ray scattering.	Protactinium	63-65	coagulation factor III, tissue factor	Rattus norvegicus	6-8
32469498-3	2020	Eight TF-targeting sequences were identified, synthesized into PA molecules, co-assembled with non-targeted backbone PA at various weight percentages, and characterized via circular dichroism spectroscopy, transmission electron microscopy, and X-ray scattering.	Protactinium	117-119	coagulation factor III, tissue factor	Rattus norvegicus	6-8
32555693-8	2020	Adding pA to two lots of A431 cell lysates with high and low pTyr-EGFR allowed normalization and quantification of the latter by expressing results as density ratios for both 1D and 2D WB.	Protactinium	7-9	epidermal growth factor receptor	Homo sapiens	66-70
32497050-8	2020	These data suggest that the CYP11A1-CD4+Tcell-IL-13 axis in activated CD4+ T cells from PA children is associated with development of PA reactions.	Protactinium	88-90	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	28-35
32497050-8	2020	These data suggest that the CYP11A1-CD4+Tcell-IL-13 axis in activated CD4+ T cells from PA children is associated with development of PA reactions.	Protactinium	88-90	CD4 molecule	Homo sapiens	36-39
32497050-8	2020	These data suggest that the CYP11A1-CD4+Tcell-IL-13 axis in activated CD4+ T cells from PA children is associated with development of PA reactions.	Protactinium	88-90	interleukin 13	Homo sapiens	46-51
32497050-8	2020	These data suggest that the CYP11A1-CD4+Tcell-IL-13 axis in activated CD4+ T cells from PA children is associated with development of PA reactions.	Protactinium	88-90	CD4 molecule	Homo sapiens	70-73
32658408-9	2020	RESULTS: The results demonstrated that miR-424 expression was remarkably increased in tissues and serum of pa-tients with melanoma.	Protactinium	107-109	microRNA 424	Homo sapiens	39-46
32894459-5	2020	Cytokine production under the influence of PA was different only in case of TNF-alpha in all study groups.	Protactinium	43-45	tumor necrosis factor	Homo sapiens	76-85
32599914-4	2020	We discovered for the first time that the high concentration alkyl-silica NPs in organic solvent isopar-G can limit the diffusion of MPD molecules at the interface, therefore shaping the intrinsic thickness and microstructures of the PA layer.	Protactinium	234-236	mevalonate diphosphate decarboxylase	Homo sapiens	133-136
32641992-9	2020	Furthermore, the PDA nanocore in the PDA@hm@CQ@GOx could be also used for PA imaging.	Protactinium	74-76	hydroxyacid oxidase 1	Homo sapiens	47-50
31222631-7	2020	RESULTS: After covarying for age, gender, body mass index, chronic pain status, salivary flow rate, and NA, higher PA was associated with lower salivary CRP (beta = - 0.02, 95% CI (- 0.03, - 0.00) sr2 = .06, p = .01) but not IL-6; removing NA from this model did not change results.	Protactinium	115-117	interleukin 6	Homo sapiens	225-229
31222631-10	2020	CONCLUSIONS: Findings suggest that higher PA may be associated with lower salivary CRP in young adults, even after accounting for NA and demographic characteristics.	Protactinium	42-44	C-reactive protein	Homo sapiens	83-86
32088243-10	2020	Moreover, we demonstrate that SB interacted with rs3811791 of UCP1 was associated with T2DM, and PA interacted with rs3811791 of UCP1 was associated with the level of HOMA-IR, HDL-C, and TG.	Protactinium	97-99	uncoupling protein 1	Homo sapiens	129-133
32253043-14	2020	The PA increased energy-corrected milk and milk fat yield but had no effect on milk protein yield compared with MIX.	Protactinium	4-6	Weaning weight-maternal milk	Bos taurus	34-38
32253043-14	2020	The PA increased energy-corrected milk and milk fat yield but had no effect on milk protein yield compared with MIX.	Protactinium	4-6	Weaning weight-maternal milk	Bos taurus	43-47
32253043-14	2020	The PA increased energy-corrected milk and milk fat yield but had no effect on milk protein yield compared with MIX.	Protactinium	4-6	Weaning weight-maternal milk	Bos taurus	43-47
32253043-15	2020	Our results indicate that dairy cows producing around 45 kg of milk respond better to a FA supplement enriched in C16:0 compared with a supplement containing both C16:0 and C18:0, which is likely due in part to PA increasing FA and neutral detergent fiber digestibility compared with MIX.	Protactinium	211-213	Weaning weight-maternal milk	Bos taurus	63-67
32173525-4	2020	We also found PA treatment resulted in the activation of mitophagy by increasing co-localization of GFP-LC3 with mitochondria and enhancing the formation of mitophagosome, stabilization of PINK1 and mitochondrial translocation of Parkin, which indicated that PINK1/Parkin pathway was involved in PA-induced mitophagy in podocytes.	Protactinium	14-16	PTEN induced kinase 1	Rattus norvegicus	189-194
32173525-4	2020	We also found PA treatment resulted in the activation of mitophagy by increasing co-localization of GFP-LC3 with mitochondria and enhancing the formation of mitophagosome, stabilization of PINK1 and mitochondrial translocation of Parkin, which indicated that PINK1/Parkin pathway was involved in PA-induced mitophagy in podocytes.	Protactinium	14-16	PTEN induced kinase 1	Rattus norvegicus	259-264
32173525-7	2020	Taken together, our results suggest that PINK1/Parkin mediated mitophagy plays a protective role in PA-induced podocytes apoptosis through reducing mitochondrial ROS production and that enhancing mitophagy provides a potential therapeutic strategy for kidney diseases with hyperlipidemia, such as DN.	Protactinium	100-102	PTEN induced kinase 1	Rattus norvegicus	41-46
32406216-4	2020	AIM: The aim of this study is to derive an effective PA absorption spectrum of collagen to select the optimal wavelength for high-sensitive PA imaging (PAI).	Protactinium	53-55	serpin family E member 1	Homo sapiens	152-155
32184022-2	2020	We previously found that DGKalpha produces palmitic acid (16:0)-containing PA species, such as 16:0/16:0- and 16:0/18:0-PA, in melanoma cells under serum-starved (nonproliferative) conditions.	Protactinium	75-77	diacylglycerol kinase alpha	Homo sapiens	25-33
32184022-2	2020	We previously found that DGKalpha produces palmitic acid (16:0)-containing PA species, such as 16:0/16:0- and 16:0/18:0-PA, in melanoma cells under serum-starved (nonproliferative) conditions.	Protactinium	120-122	diacylglycerol kinase alpha	Homo sapiens	25-33
32184022-3	2020	In the present study, we identified the PA species generated by DGKalpha in T cells under serum-starved (nonproliferative) conditions.	Protactinium	40-42	diacylglycerol kinase alpha	Homo sapiens	64-72
32184022-7	2020	These results indicate that DGKalpha generates different PA species in starved melanoma cells (palmitic acid-containing PA species) and T cells (palmitic acid- and/or palmitoleic acid (16:1)-containing PA species).	Protactinium	57-59	diacylglycerol kinase alpha	Homo sapiens	28-36
32184022-7	2020	These results indicate that DGKalpha generates different PA species in starved melanoma cells (palmitic acid-containing PA species) and T cells (palmitic acid- and/or palmitoleic acid (16:1)-containing PA species).	Protactinium	120-122	diacylglycerol kinase alpha	Homo sapiens	28-36
32184022-7	2020	These results indicate that DGKalpha generates different PA species in starved melanoma cells (palmitic acid-containing PA species) and T cells (palmitic acid- and/or palmitoleic acid (16:1)-containing PA species).	Protactinium	120-122	diacylglycerol kinase alpha	Homo sapiens	28-36
32184022-8	2020	Therefore, the differences in the PA molecular species may account for the opposing functions of DGKalpha in melanoma and T cells.	Protactinium	34-36	diacylglycerol kinase alpha	Homo sapiens	97-105
32154705-6	2020	To this end, we designed and synthesized the first PA probe of Zn2+, namely, CR-1 for in situ ratiometric imaging of Zn2+ in deep tissue in vivo.	Protactinium	51-53	complement receptor 2	Mus musculus	77-81
32406216-4	2020	AIM: The aim of this study is to derive an effective PA absorption spectrum of collagen to select the optimal wavelength for high-sensitive PA imaging (PAI).	Protactinium	140-142	serpin family E member 1	Homo sapiens	152-155
32406216-9	2020	Thereby, the PA signal increased by up to five times compared with the wavelength commonly used in collagen PAI.	Protactinium	13-15	serpin family E member 1	Homo sapiens	108-111
32341757-4	2020	BCH significantly inhibited para-211At-PA uptake in C6 glioma (12.2 +- 0.8%), U-87MG (27.6 +- 1.1%), and GL261 (12.6 +- 2.0%) cells compared to baseline, suggesting an uptake contribution by system L amino acid transporters.	Protactinium	39-41	chimerin 2	Mus musculus	0-3
32307923-6	2020	By intravenous administration, BTII-DUPA SPN demonstrates selective accumulation and retention in the PSMA-positive tumor, allowing noninvasive PA detection of PSMA overexpressing prostate tumors in vivo.	Protactinium	38-40	DEAF1 transcription factor	Homo sapiens	41-44
32307923-6	2020	By intravenous administration, BTII-DUPA SPN demonstrates selective accumulation and retention in the PSMA-positive tumor, allowing noninvasive PA detection of PSMA overexpressing prostate tumors in vivo.	Protactinium	38-40	folate hydrolase 1	Homo sapiens	102-106
32307923-6	2020	By intravenous administration, BTII-DUPA SPN demonstrates selective accumulation and retention in the PSMA-positive tumor, allowing noninvasive PA detection of PSMA overexpressing prostate tumors in vivo.	Protactinium	38-40	folate hydrolase 1	Homo sapiens	160-164
32178513-8	2020	Both PA and G-PA changed CD4+ and CD8+ T cells percentages in some lymphoid tissues; however, this did not impact cytokines production by splenocyte cultures evidenced by the stimulation of Th1, Th2, and Th17 cells.	Protactinium	5-7	CD4 antigen	Mus musculus	25-28
32181656-7	2020	Deficiency of SIRT1 eliminated the therapeutic effect of ginsenoside Rg2 on lipid accumulation and overproduction of reactive oxygen species (ROS) in OA&PA-induced mice primary hepatocytes.	Protactinium	153-155	sirtuin 1	Mus musculus	14-19
31884344-7	2020	Notably, we demonstrate that these effects of PA are mediated through inhitibing the phosphorylation of p38 and activation of the IkappaBalpha/nuclear factor-kappaB (NF-kappaB) pathway.	Protactinium	46-48	mitogen-activated protein kinase 14	Homo sapiens	104-107
32337269-8	2020	Overexpression of PLD1 and its downstream product PA could ameliorate Cd-induced apoptosis.	Protactinium	50-52	phospholipase D1	Rattus norvegicus	18-22
32337269-11	2020	In conclusion, our results indicated that PLD1 and its downstream PA were strongly implicated in Cd-induced chronic kidney impairment and could be a novel player in the defense against Cd-induced nephrotoxicity.	Protactinium	66-68	phospholipase D1	Rattus norvegicus	42-46
32108476-6	2020	Silica nanolayers were successfully synthesized on these acid-treated CNFs via PA coating because the acidic functional groups catalyzed the hydrolysis of TEOS accumulated on the CNF surfaces.	Protactinium	79-81	NPHS1 adhesion molecule, nephrin	Homo sapiens	70-73
32029476-3	2020	Here, we report that sesquiterpene lactone parthenolide (PTL) inhibits USP7 activity, assessed with deubiquitinating enzyme activity assays, including fluorogenic Ub-AMC/Ub-Rho110, Ub-VME/PA labeling, and Di-Ub hydrolysis assays.	Protactinium	188-190	ubiquitin specific peptidase 7	Homo sapiens	71-75
31758944-6	2020	Furthermore, our analyses suggested that IP3R2-LacZ positive PA smooth muscle layers gradually elongate from the central PA to the peripheral PAs from E13.5 to E18.5, supporting the distal angiogenesis theory for the development of PA, whereas IP3R2-LacZ was rarely expressed in smooth muscle cells in the pulmonary trunk.	Protactinium	142-145	inositol 1,4,5-triphosphate receptor 2	Mus musculus	41-46
31173066-9	2020	Importantly, CXCL12 neutralization with either chalcone 4 or LIT-927 inhibited the migration of PA-SMCs and pericytes in vitro with a better efficacy than AMD3100.	Protactinium	96-98	C-X-C motif chemokine ligand 12	Rattus norvegicus	13-19
31980286-2	2020	OBJECTIVE: The purpose of this study was to determine whether a simple equation using EtO2 and FiO2 at time of induction could reliably estimate minimal PaO2 in ED patients undergoing RSI.	Protactinium	153-157	CBFA2/RUNX1 partner transcriptional co-repressor 3	Homo sapiens	86-90
31980286-10	2020	CONCLUSIONS: Among ED patients undergoing RSI, the use of a gas analyzer to measure EtO2 and FiO2 can provide a reliable measure of the minimal PaO2 at the time of induction during the RSI phase of preoxygenation.	Protactinium	144-148	CBFA2/RUNX1 partner transcriptional co-repressor 3	Homo sapiens	84-88
31566904-4	2020	SLI was defined by moderate hypoxaemia (Berlin classification; PaO2 /FiO2  &lt; 200 mm Hg) and abnormalities on CXR.	Protactinium	63-67	SHC adaptor protein 2	Homo sapiens	0-3
32109873-1	2020	OBJECTIVE: Prior profiling of the human pituitary adenoma (PA) DNA methylome showed the potassium channel subunit-encoding gene KCNAB2 to be highly differentially methylated between nonfunctional PAs (NFPAs) and growth hormone (GH)-secreting PAs, with greater KCNAB2 methylation detected in secretory PAs.	Protactinium	196-199	potassium voltage-gated channel subfamily A regulatory beta subunit 2	Homo sapiens	128-134
32109873-1	2020	OBJECTIVE: Prior profiling of the human pituitary adenoma (PA) DNA methylome showed the potassium channel subunit-encoding gene KCNAB2 to be highly differentially methylated between nonfunctional PAs (NFPAs) and growth hormone (GH)-secreting PAs, with greater KCNAB2 methylation detected in secretory PAs.	Protactinium	203-206	potassium voltage-gated channel subfamily A regulatory beta subunit 2	Homo sapiens	128-134
32109873-1	2020	OBJECTIVE: Prior profiling of the human pituitary adenoma (PA) DNA methylome showed the potassium channel subunit-encoding gene KCNAB2 to be highly differentially methylated between nonfunctional PAs (NFPAs) and growth hormone (GH)-secreting PAs, with greater KCNAB2 methylation detected in secretory PAs.	Protactinium	203-206	potassium voltage-gated channel subfamily A regulatory beta subunit 2	Homo sapiens	128-134
32109873-5	2020	METHODS: Previously generated RNA-seq data were reanalyzed to compare KCNAB2 expression levels in human NFPAs and GH-secreting PAs.	Protactinium	106-109	potassium voltage-gated channel subfamily A regulatory beta subunit 2	Homo sapiens	70-76
32101164-4	2020	However, we find that CRY1 is recruited with much higher affinity to the PAS domain core of CLOCK:BMAL1, allowing it to serve as a stronger repressor that lengthens circadian period.	Protactinium	73-76	cryptochrome circadian regulator 1	Homo sapiens	22-26
32101164-4	2020	However, we find that CRY1 is recruited with much higher affinity to the PAS domain core of CLOCK:BMAL1, allowing it to serve as a stronger repressor that lengthens circadian period.	Protactinium	73-76	clock circadian regulator	Homo sapiens	92-103
32734173-6	2020	Real time polymerase chain reaction (RT-PCR) data showed that the DPSCs cultured in 235 Pa matrices demonstrated an increased expression of endothelial markers after 28 days, and the effect was enhanced upon VEGF incorporation.	Protactinium	88-90	vascular endothelial growth factor A	Homo sapiens	208-212
31758944-7	2020	Crossing IP3R-LacZ mice with mice hypomorphic for Tbx1 alleles revealed that PTA of Tbx1 mutants may result from agenesis or hypoplasia of the pulmonary trunk; thus, the left and right central to peripheral PAs connect directly to the dorsal side of the truncus arteriosus in these mutants.	Protactinium	207-210	T-box 1	Mus musculus	84-88
32089647-12	2020	Conclusion: Taken together, our findings disclose that AE could alleviate HFD/PA-induced cardiac inflammation via inhibition of the TLR4/NF-kappaB signaling pathway.	Protactinium	78-80	toll-like receptor 4	Rattus norvegicus	132-136
30923071-9	2020	High-PA FSNs increased paracellular permeability, decreased occludin and increased phosphorylated myosin light chain (pMLC) expression.	Protactinium	5-7	occludin	Homo sapiens	60-68
32110174-12	2020	Moreover, Sirt1 knockdown abolished these ameliorative effects of PSPC on apoptosis and P53 acetylation and protein expression in PA-treated L02 cells.	Protactinium	130-132	sirtuin 1	Homo sapiens	10-15
32110174-12	2020	Moreover, Sirt1 knockdown abolished these ameliorative effects of PSPC on apoptosis and P53 acetylation and protein expression in PA-treated L02 cells.	Protactinium	130-132	tumor protein p53	Homo sapiens	88-91
32399392-5	2020	Here, we examined the role of EET-dependent TRPV4 activation in the 5-HT-mediated PA contraction.	Protactinium	82-84	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	44-49
32381880-6	2020	However, our findings suggested that an additional laparoscopic surgery could be one of the curative and safe treatment options for selected pa- tients with GCC.	Protactinium	53-55	guanylate cyclase 2C	Homo sapiens	157-160
32563939-12	2020	Metrnl may be one possible mediator of the beneficial effects of PA on insulin sensitivity in healthy humans.	Protactinium	65-67	meteorin like, glial cell differentiation regulator	Homo sapiens	0-6
32563939-12	2020	Metrnl may be one possible mediator of the beneficial effects of PA on insulin sensitivity in healthy humans.	Protactinium	65-67	insulin	Homo sapiens	71-78
30923071-12	2020	Patients with high-PA IBS had lower occludin expression, wider TJs on biopsies and reduced microbial diversity than patients with low PA. Mice humanised with high-PA IBS microbiota had greater in vivo permeability than those with low-PA microbiota.	Protactinium	19-21	occludin	Homo sapiens	36-44
32658989-11	2020	The length scale of spread for PA-GFP-Tubulin increased in mutant embryos containing short plasma membrane furrows and a disrupted tubulin cytoskeleton.	Protactinium	31-33	gamma-Tubulin at 23C	Drosophila melanogaster	38-45
33530089-9	2020	While lipids did not differ, median insulin and HOMA-IR were higher but not statistically different in PA and PP.	Protactinium	103-105	insulin	Homo sapiens	36-43
32658989-11	2020	The length scale of spread for PA-GFP-Tubulin increased in mutant embryos containing short plasma membrane furrows and a disrupted tubulin cytoskeleton.	Protactinium	31-33	gamma-Tubulin at 23C	Drosophila melanogaster	131-138
33100082-8	2020	Receiver operating characteristic (ROC) analysis of SIPA revealed that increased production of IL-18 in the IBC-NST biopsy samples after exposure to PAs may block the PA-driven, cytokine-mediated differentiation of moderately differentiated into highly differentiated tumour cells.	Protactinium	54-56	interleukin 18	Homo sapiens	95-100
32658989-13	2020	Taken together, these data show that PA-GFP-Tubulin spread is restricted by its incorporation in the microtubule network and intact plasma membrane furrows.	Protactinium	37-39	gamma-Tubulin at 23C	Drosophila melanogaster	44-51
31478148-1	2020	Treatment with recombinant tissue plasminogen activator (rt-PA) is the most effective therapeutic option against brain ischemic stroke at the present time.	Protactinium	59-62	chromosome 20 open reading frame 181	Homo sapiens	27-55
32107157-11	2020	EVALUATION: An average of 24% of PAs processed by PAC3 were completed by ePA.	Protactinium	33-36	proteasome assembly chaperone 3	Homo sapiens	50-54
32107157-17	2020	The ePA process also increased efficiency, allowing PAC3 to centrally manage PAs for additional clinics, thereby decreasing the workload in the clinic.	Protactinium	77-80	proteasome assembly chaperone 3	Homo sapiens	52-56
31460824-4	2020	In addition, endothelial cells were induced with PA +25OHCH (800 muM/L+10 mug/mL).	Protactinium	49-51	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	69-73
31460824-14	2020	Mixture of PA +25OHCH caused decrease of VE-cadherin mRNA expression as compared with fasting serum (P &lt; 0.01).	Protactinium	11-13	cadherin 5	Homo sapiens	41-52
31460824-16	2020	Postprandial serum and PA +25OHCH caused increase of IL-33, MCP-1, ICAM-1, IL-32, VEGF, and CX3C-chemokine mRNA expression as compared with fasting serum (P &lt; 0.05).	Protactinium	23-25	interleukin 33	Homo sapiens	53-58
31460824-16	2020	Postprandial serum and PA +25OHCH caused increase of IL-33, MCP-1, ICAM-1, IL-32, VEGF, and CX3C-chemokine mRNA expression as compared with fasting serum (P &lt; 0.05).	Protactinium	23-25	C-C motif chemokine ligand 2	Homo sapiens	60-65
31460824-16	2020	Postprandial serum and PA +25OHCH caused increase of IL-33, MCP-1, ICAM-1, IL-32, VEGF, and CX3C-chemokine mRNA expression as compared with fasting serum (P &lt; 0.05).	Protactinium	23-25	intercellular adhesion molecule 1	Homo sapiens	67-73
31460824-16	2020	Postprandial serum and PA +25OHCH caused increase of IL-33, MCP-1, ICAM-1, IL-32, VEGF, and CX3C-chemokine mRNA expression as compared with fasting serum (P &lt; 0.05).	Protactinium	23-25	interleukin 32	Homo sapiens	75-80
31460824-16	2020	Postprandial serum and PA +25OHCH caused increase of IL-33, MCP-1, ICAM-1, IL-32, VEGF, and CX3C-chemokine mRNA expression as compared with fasting serum (P &lt; 0.05).	Protactinium	23-25	vascular endothelial growth factor A	Homo sapiens	82-86
33304996-5	2019	Coassembly of the DR5-targeting PA and a pegylated PA creates a supramolecular nanoscale construct with enhanced binding affinity to DR5 relative to a monomeric targeting PA, and was found to be cytotoxic in vitro.	Protactinium	32-34	TNF receptor superfamily member 10b	Homo sapiens	18-21
31295033-6	2020	Immunofluorescence assay also showed that PAS could reduce phosphorylation of IGF-1R (Tyr1165/1166).	Protactinium	42-45	insulin like growth factor 1 receptor	Homo sapiens	78-84
31830262-8	2019	ROCK1 and TGM2 genes were up-regulated in PAs and TMAs from the FFC/STZ group.	Protactinium	42-45	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	0-5
31830262-8	2019	ROCK1 and TGM2 genes were up-regulated in PAs and TMAs from the FFC/STZ group.	Protactinium	42-45	transglutaminase 2	Homo sapiens	10-14
31830262-11	2019	ROCK1 and TGM2 proteins were immunolocalized in the media of PAs and TMAs, and their fluorescence levels were increased in the FFC/STZ group.	Protactinium	61-64	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	0-5
31830262-11	2019	ROCK1 and TGM2 proteins were immunolocalized in the media of PAs and TMAs, and their fluorescence levels were increased in the FFC/STZ group.	Protactinium	61-64	transglutaminase 2	Homo sapiens	10-14
33304996-5	2019	Coassembly of the DR5-targeting PA and a pegylated PA creates a supramolecular nanoscale construct with enhanced binding affinity to DR5 relative to a monomeric targeting PA, and was found to be cytotoxic in vitro.	Protactinium	32-34	TNF receptor superfamily member 10b	Homo sapiens	133-136
33304996-5	2019	Coassembly of the DR5-targeting PA and a pegylated PA creates a supramolecular nanoscale construct with enhanced binding affinity to DR5 relative to a monomeric targeting PA, and was found to be cytotoxic in vitro.	Protactinium	51-53	TNF receptor superfamily member 10b	Homo sapiens	133-136
33304996-5	2019	Coassembly of the DR5-targeting PA and a pegylated PA creates a supramolecular nanoscale construct with enhanced binding affinity to DR5 relative to a monomeric targeting PA, and was found to be cytotoxic in vitro.	Protactinium	51-53	TNF receptor superfamily member 10b	Homo sapiens	133-136
31717842-9	2019	Moreover, PA also regulated the NAFLD signaling pathway.	Protactinium	10-12	TSC complex subunit 2	Mus musculus	32-37
30767565-5	2019	Gal-3 has been identified as a regulator of numerous changes in cell behavior that contributes to aberrant PA remodeling, including cell proliferation, inflammation, and fibrosis, but its role in PAH has remained poorly understood until recently.	Protactinium	107-109	galectin 3	Homo sapiens	0-5
31376347-5	2019	Birds fed the PA or PG diets had increased (P < 0.05) hepatic total SOD, glutathione peroxidase, and glutathione-S-transferase than in chickens given PO alone.	Protactinium	14-16	glutathione S-transferase alpha 3	Gallus gallus	101-126
31717842-11	2019	Taken together, our results demonstrate that PA can improve the liver function of NAFLD mice, regulating blood lipids, reducing liver-fat accumulation, and regulating lipid metabolism.	Protactinium	45-47	TSC complex subunit 2	Mus musculus	82-87
31491074-10	2019	The in silico molecular docking and dynamics simulation studies of lead compounds affirmed their consensual binding interactions with PAS-AChE and aspartate dyad of BACE-1.	Protactinium	134-137	acetylcholinesterase	Rattus norvegicus	138-142
31378757-4	2019	PA embryos showed higher IFNT mRNA expression than in vitro fertilization (IVF) embryos.	Protactinium	0-2	interferon tau-2	Bos taurus	25-29
31556998-7	2019	Because oxo exchange occurs via conversion of an actinyl(V) hydrate, AnO2(H2O)+, to an actinide(V) hydroxide, AnO(OH)2+, it reflects the propensity for actinyl(V) hydrolysis: PaO2+ hydrolyzes and oxo-exchanges most easily, despite the fact that it has the highest BDE of all AnO2+.	Protactinium	175-179	anoctamin 2	Homo sapiens	69-73
31491074-10	2019	The in silico molecular docking and dynamics simulation studies of lead compounds affirmed their consensual binding interactions with PAS-AChE and aspartate dyad of BACE-1.	Protactinium	134-137	beta-secretase 1	Homo sapiens	165-171
31187430-0	2019	The Long-Term Impairment in Redox Homeostasis Observed in the Hippocampus of Rats Subjected to Global Perinatal Asphyxia (PA) Implies Changes in Glutathione-Dependent Antioxidant Enzymes and TIGAR-Dependent Shift Towards the Pentose Phosphate Pathways: Effect of Nicotinamide.	Protactinium	122-124	TP53 induced glycolysis regulatory phosphatase	Rattus norvegicus	191-196
31617496-7	2019	Among patients with anti-MDA5 antibody with RP-ILD, non-survivors were older and revealed lower PaO2 at first visit relative to survivors.	Protactinium	96-100	interferon induced with helicase C domain 1	Homo sapiens	25-29
31476900-7	2019	Disruptions of the SOD2 gene reproduced PPHN phenotypes, manifested by elevated right ventricular systolic pressure, PA-endothelial cells apoptosis, and PA-smooth muscle cells proliferation.	Protactinium	117-119	superoxide dismutase 2	Homo sapiens	19-23
31476900-13	2019	Consequently, mitochondrial H2O2 formation is impaired, leading to XIAP (X-linked inhibitor of apoptosis) overexpression that suppresses caspase activity in PA-smooth muscle cells, allowing them to survive and proliferate, contributing to PA remodeling.	Protactinium	157-159	X-linked inhibitor of apoptosis	Homo sapiens	67-71
31476900-13	2019	Consequently, mitochondrial H2O2 formation is impaired, leading to XIAP (X-linked inhibitor of apoptosis) overexpression that suppresses caspase activity in PA-smooth muscle cells, allowing them to survive and proliferate, contributing to PA remodeling.	Protactinium	157-159	X-linked inhibitor of apoptosis	Homo sapiens	73-104
31476900-14	2019	In-vivo, ola1-/- downregulated SOD2 expression, induced distal-PA remodeling, and right ventricular hypertrophy.	Protactinium	63-65	Obg like ATPase 1	Homo sapiens	9-13
31319179-2	2019	In vitro experiments showed that encapsulation of PELA into PA (PA-PELA) significantly enhanced its stimulatory capacity on dendritic cells as evidenced by increased levels of the cell surface costimulatory molecules, CD80/CD86.	Protactinium	60-62	CD80 antigen	Mus musculus	218-222
31319179-2	2019	In vitro experiments showed that encapsulation of PELA into PA (PA-PELA) significantly enhanced its stimulatory capacity on dendritic cells as evidenced by increased levels of the cell surface costimulatory molecules, CD80/CD86.	Protactinium	60-62	CD86 antigen	Mus musculus	223-227
31187430-10	2019	The present study demonstrates that the long-term impaired redox homeostasis observed in the hippocampus of rats subjected to global PA implies changes in GR, GPx, and catalase, and a shift towards PPP, as indicated by an increase of TIGAR levels at P14.	Protactinium	133-135	glutathione-disulfide reductase	Rattus norvegicus	155-157
31187430-10	2019	The present study demonstrates that the long-term impaired redox homeostasis observed in the hippocampus of rats subjected to global PA implies changes in GR, GPx, and catalase, and a shift towards PPP, as indicated by an increase of TIGAR levels at P14.	Protactinium	133-135	catalase	Rattus norvegicus	168-176
31187430-10	2019	The present study demonstrates that the long-term impaired redox homeostasis observed in the hippocampus of rats subjected to global PA implies changes in GR, GPx, and catalase, and a shift towards PPP, as indicated by an increase of TIGAR levels at P14.	Protactinium	133-135	TP53 induced glycolysis regulatory phosphatase	Rattus norvegicus	234-239
31737170-9	2019	The upregulation of LEGLTBC attenuated HG/PA-induced INS-1 cell injury through the promotion of SIRT1-mediated suppression of ROS accumulation and apoptosis.	Protactinium	42-44	sirtuin 1	Rattus norvegicus	96-101
31187430-8	2019	It was found that global PA produced (i) a sustained increase of GSSG levels and GSSG/GSH ratio at P1 and P14; (ii) a decrease of GR, GPx, and catalase activity at P1 and P14; (iii) a decrease at P1, followed by an increase at P14 of TIGAR levels; (iv) an increase of calpain activity at P14; and (v) an increase of XRCC1 levels, but only at P1.	Protactinium	25-27	perforin 1	Rattus norvegicus	99-109
31187430-10	2019	The present study demonstrates that the long-term impaired redox homeostasis observed in the hippocampus of rats subjected to global PA implies changes in GR, GPx, and catalase, and a shift towards PPP, as indicated by an increase of TIGAR levels at P14.	Protactinium	133-135	SUB1 regulator of transcription	Rattus norvegicus	250-253
31187430-8	2019	It was found that global PA produced (i) a sustained increase of GSSG levels and GSSG/GSH ratio at P1 and P14; (ii) a decrease of GR, GPx, and catalase activity at P1 and P14; (iii) a decrease at P1, followed by an increase at P14 of TIGAR levels; (iv) an increase of calpain activity at P14; and (v) an increase of XRCC1 levels, but only at P1.	Protactinium	25-27	glutathione-disulfide reductase	Rattus norvegicus	130-132
31187430-8	2019	It was found that global PA produced (i) a sustained increase of GSSG levels and GSSG/GSH ratio at P1 and P14; (ii) a decrease of GR, GPx, and catalase activity at P1 and P14; (iii) a decrease at P1, followed by an increase at P14 of TIGAR levels; (iv) an increase of calpain activity at P14; and (v) an increase of XRCC1 levels, but only at P1.	Protactinium	25-27	catalase	Rattus norvegicus	143-151
31187430-8	2019	It was found that global PA produced (i) a sustained increase of GSSG levels and GSSG/GSH ratio at P1 and P14; (ii) a decrease of GR, GPx, and catalase activity at P1 and P14; (iii) a decrease at P1, followed by an increase at P14 of TIGAR levels; (iv) an increase of calpain activity at P14; and (v) an increase of XRCC1 levels, but only at P1.	Protactinium	25-27	perforin 1	Rattus norvegicus	164-174
31187430-8	2019	It was found that global PA produced (i) a sustained increase of GSSG levels and GSSG/GSH ratio at P1 and P14; (ii) a decrease of GR, GPx, and catalase activity at P1 and P14; (iii) a decrease at P1, followed by an increase at P14 of TIGAR levels; (iv) an increase of calpain activity at P14; and (v) an increase of XRCC1 levels, but only at P1.	Protactinium	25-27	SUB1 regulator of transcription	Rattus norvegicus	106-109
31187430-8	2019	It was found that global PA produced (i) a sustained increase of GSSG levels and GSSG/GSH ratio at P1 and P14; (ii) a decrease of GR, GPx, and catalase activity at P1 and P14; (iii) a decrease at P1, followed by an increase at P14 of TIGAR levels; (iv) an increase of calpain activity at P14; and (v) an increase of XRCC1 levels, but only at P1.	Protactinium	25-27	TP53 induced glycolysis regulatory phosphatase	Rattus norvegicus	234-239
31187430-8	2019	It was found that global PA produced (i) a sustained increase of GSSG levels and GSSG/GSH ratio at P1 and P14; (ii) a decrease of GR, GPx, and catalase activity at P1 and P14; (iii) a decrease at P1, followed by an increase at P14 of TIGAR levels; (iv) an increase of calpain activity at P14; and (v) an increase of XRCC1 levels, but only at P1.	Protactinium	25-27	SUB1 regulator of transcription	Rattus norvegicus	171-174
31187430-8	2019	It was found that global PA produced (i) a sustained increase of GSSG levels and GSSG/GSH ratio at P1 and P14; (ii) a decrease of GR, GPx, and catalase activity at P1 and P14; (iii) a decrease at P1, followed by an increase at P14 of TIGAR levels; (iv) an increase of calpain activity at P14; and (v) an increase of XRCC1 levels, but only at P1.	Protactinium	25-27	X-ray repair cross complementing 1	Rattus norvegicus	316-321
31009107-8	2019	We then found the increasing HIF1a expression and decreasing PTEN expression in the mice on HFD and in PA-treated HepG2 cells.	Protactinium	103-105	hypoxia inducible factor 1, alpha subunit	Mus musculus	29-34
31558691-1	2019	<strong>BACKGROUND</strong> PAS domain containing repressor 1 (PASD1), the cancer-testis antigen (CTA), has been reported to be aberrantly expressed in various cancer tissues and cancer cell lines; however, normal PASD1 expression can be detected in normal tissue, excluding testicular tissue.	Protactinium	28-31	PAS domain containing repressor 1	Homo sapiens	63-68
31558691-1	2019	<strong>BACKGROUND</strong> PAS domain containing repressor 1 (PASD1), the cancer-testis antigen (CTA), has been reported to be aberrantly expressed in various cancer tissues and cancer cell lines; however, normal PASD1 expression can be detected in normal tissue, excluding testicular tissue.	Protactinium	28-31	PAS domain containing repressor 1	Homo sapiens	214-219
31490124-2	2019	Kv10.1 or Eag1 also has three intracellular domains: PAS, C-linker, and CNBHD.	Protactinium	53-56	potassium voltage-gated channel subfamily H member 1	Homo sapiens	0-6
31490124-2	2019	Kv10.1 or Eag1 also has three intracellular domains: PAS, C-linker, and CNBHD.	Protactinium	53-56	potassium voltage-gated channel subfamily H member 1	Homo sapiens	10-14
31309679-2	2019	In this work, we developed a series of activatable photoacoustic (PA) probes with low molecular weights (less than 438 Da), RPS1-RPS4, which can specifically chelate with Cu2+ to form radicals with turn-on PA signals in the near-infrared (NIR) region.	Protactinium	66-68	ribosomal protein S4, X-linked	Mus musculus	129-133
31309679-2	2019	In this work, we developed a series of activatable photoacoustic (PA) probes with low molecular weights (less than 438 Da), RPS1-RPS4, which can specifically chelate with Cu2+ to form radicals with turn-on PA signals in the near-infrared (NIR) region.	Protactinium	66-68	immunoglobulin kappa variable 1-35	Mus musculus	171-174
31309679-5	2019	Owing to the low molecular weight and amphiphilic structure, RPS1 could effectively cross the blood-brain barrier (BBB) and thus allowed us, for the first time, to visualize Cu2+ in vivo via PA imaging in the brains of AD mice.	Protactinium	191-193	immunoglobulin kappa variable 1-35	Mus musculus	174-177
31378570-8	2019	Thus, this work demonstrates that PAs are effective in inhibiting E2F1 TF activity which results in a temporal reduction in BC-CML cell number.	Protactinium	34-37	E2F transcription factor 1	Homo sapiens	66-70
31009107-8	2019	We then found the increasing HIF1a expression and decreasing PTEN expression in the mice on HFD and in PA-treated HepG2 cells.	Protactinium	103-105	phosphatase and tensin homolog	Mus musculus	61-65
30721555-2	2019	This is associated with impaired TRPV4-mediated PA dilation; therefore, we tested the hypothesis that TRPV4 channels are important regulators of cerebral perfusion, PA structure and dilation, and cognition.	Protactinium	48-50	transient receptor potential cation channel, subfamily V, member 4	Rattus norvegicus	33-38
30325468-8	2019	Feeding PA supplemented diets downregulated the expression of CD40LG (P < 0.001), IFNG, and IL6 (P < 0.05).	Protactinium	8-10	CD40 ligand	Homo sapiens	62-68
30325468-8	2019	Feeding PA supplemented diets downregulated the expression of CD40LG (P < 0.001), IFNG, and IL6 (P < 0.05).	Protactinium	8-10	interferon gamma	Homo sapiens	82-86
30325468-8	2019	Feeding PA supplemented diets downregulated the expression of CD40LG (P < 0.001), IFNG, and IL6 (P < 0.05).	Protactinium	8-10	interleukin 6	Homo sapiens	92-95
30325468-9	2019	There was a cereal type x PA interaction (P < 0.05), as expression of IFNB was downregulated in the birds fed PA supplemented MC but not WC.	Protactinium	26-28	interferon beta 1	Homo sapiens	70-74
30325468-9	2019	There was a cereal type x PA interaction (P < 0.05), as expression of IFNB was downregulated in the birds fed PA supplemented MC but not WC.	Protactinium	110-112	interferon beta 1	Homo sapiens	70-74
30325468-10	2019	However, expression of IL12B was downregulated in birds fed PA supplemented WC but there was no significant (P > 0.05) change in expression levels in birds fed MC diets.	Protactinium	60-62	interleukin 12B	Homo sapiens	23-28
31408950-4	2019	This study shows that these PA nanostructures are quickly incorporated into cells, are able to specifically bind BCL-2 proteins, are stable at physiologic temperatures and pH, and induce dose-dependent apoptosis in cells.	Protactinium	28-30	BCL2 apoptosis regulator	Homo sapiens	113-118
31043333-10	2019	RESULTS: Cell proliferation using the RGDS-PA gel was significantly higher than that observed in other gels.	Protactinium	43-45	ral guanine nucleotide dissociation stimulator	Homo sapiens	38-42
31043333-11	2019	The RGDS-PA gel significantly enhanced re-epithelialization during the burn wound healing process between days 7 and 28.	Protactinium	9-11	ral guanine nucleotide dissociation stimulator	Homo sapiens	4-8
31456912-6	2019	For the PAs, the average positivity of C-myc was 4.6%; the average proliferation index of Ki-67 was 3.2%; pan-cytokeratin was positive in ductal cells, and vimentin was positive in myoepithelial cells.	Protactinium	8-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	39-44
30721555-2	2019	This is associated with impaired TRPV4-mediated PA dilation; therefore, we tested the hypothesis that TRPV4 channels are important regulators of cerebral perfusion, PA structure and dilation, and cognition.	Protactinium	165-167	transient receptor potential cation channel, subfamily V, member 4	Rattus norvegicus	102-107
31173931-9	2019	Optimization of SHH PA delivery is essential for clinical translation to ED patients, and the PA vehicle has wide applicability as an in vivo delivery tool.	Protactinium	20-22	sonic hedgehog signaling molecule	Homo sapiens	16-19
31307185-1	2019	BACKGROUND: HbA1c concentration is an indicator of the development of long-term complications in diabetic pa-tients.	Protactinium	106-108	hemoglobin subunit alpha 1	Homo sapiens	12-16
31528825-6	2019	However, prevalence of insulin resistance (IR; P = 0.014) and acanthosis nigricans (P = 0.010) was higher in the PA group.	Protactinium	113-115	insulin	Homo sapiens	23-30
31299041-12	2019	Increased miR-381 combined with Ci and Pa suppressed the proliferation and enhanced the anti-tumor effects of Ci and Pa at tolerated concentrations in vitro.	Protactinium	117-119	microRNA 381	Mus musculus	10-17
31077472-2	2019	We illustrate with real clinical test results of UV protection ability of sunscreen for SPF and PA. With approximately 2200 individual clinical results for both SPF and PA level detection, individually, we were able to see that active ingredient information can provide accurate SPF and PA prediction rates through machine learning.	Protactinium	169-171	SEC14 like lipid binding 2	Homo sapiens	88-91
31188932-7	2019	The results demonstrated that m6A expression decreased in the 2-cell stage, whereas it increased in the 8-cell stage of PA embryos.	Protactinium	120-122	methyltransferase like 3	Mus musculus	30-33
31193041-5	2019	CCl4 induced deleterious hepatic effects as revealed by the liver function biomarkers (AST, ALT, ALP and total protein), antioxidant indicators (GSH and CAT) and histopathological effects, demonstrated by H &amp; E, Gordon and Sweet, Masson"s trichrome, PAS staining techniques as well as by quantificational analyses of the liver micrographs, using image-J.	Protactinium	254-257	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
31934069-11	2019	LncRNA XIST and miR-204 inhibitors significantly decreased the PaO2/FiO2 ratio, whereas miR-204 and silencing of IRF2 significantly increased the PaO2/FiO2 ratio in LPS-induced ARDS.	Protactinium	63-67	inactive X specific transcripts	Mus musculus	7-11
31934069-11	2019	LncRNA XIST and miR-204 inhibitors significantly decreased the PaO2/FiO2 ratio, whereas miR-204 and silencing of IRF2 significantly increased the PaO2/FiO2 ratio in LPS-induced ARDS.	Protactinium	63-67	microRNA 204	Mus musculus	16-23
31934069-11	2019	LncRNA XIST and miR-204 inhibitors significantly decreased the PaO2/FiO2 ratio, whereas miR-204 and silencing of IRF2 significantly increased the PaO2/FiO2 ratio in LPS-induced ARDS.	Protactinium	146-150	microRNA 204	Mus musculus	88-95
31934069-11	2019	LncRNA XIST and miR-204 inhibitors significantly decreased the PaO2/FiO2 ratio, whereas miR-204 and silencing of IRF2 significantly increased the PaO2/FiO2 ratio in LPS-induced ARDS.	Protactinium	146-150	interferon regulatory factor 2	Mus musculus	113-117
30921741-4	2019	Moreover, both kinetic analysis of AChE inhibition and molecular modeling study revealed that 7c showed a mixed-type inhibition, binding simultaneously to CAS and PAS of AChE.	Protactinium	163-166	acetylcholinesterase (Cartwright blood group)	Homo sapiens	35-39
30921741-4	2019	Moreover, both kinetic analysis of AChE inhibition and molecular modeling study revealed that 7c showed a mixed-type inhibition, binding simultaneously to CAS and PAS of AChE.	Protactinium	163-166	acetylcholinesterase (Cartwright blood group)	Homo sapiens	170-174
31109603-18	2019	And serum levels of IL-1beta and TNF-alpha were significantly reduced by 33.9% and 14.7% respectively in PAS-Na prevention group.	Protactinium	105-108	interleukin 1 alpha	Rattus norvegicus	20-28
31109603-18	2019	And serum levels of IL-1beta and TNF-alpha were significantly reduced by 33.9% and 14.7% respectively in PAS-Na prevention group.	Protactinium	105-108	tumor necrosis factor	Rattus norvegicus	33-42
31137903-8	2019	TRX consumes 5 mW on RX and 6 mW on the TX when PA is 0-dBm.	Protactinium	48-50	thioredoxin	Homo sapiens	0-3
30834697-0	2019	Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas a cause du BNP?	Protactinium	92-95	natriuretic peptide B	Homo sapiens	107-110
30724100-7	2019	Gal-3 inhibitors attenuated and reversed PA remodeling and fibrosis, as well as hemodynamic indices in monocrotaline (MCT)-treated rats in vivo.	Protactinium	41-43	galectin 3	Rattus norvegicus	0-5
30724100-9	2019	In conclusion, our results suggest that elevated Gal-3 levels contribute to inappropriate PA remodeling in PH by enhancing multiple profibrotic mechanisms.	Protactinium	90-92	galectin 3	Rattus norvegicus	49-54
30831131-7	2019	Inhibition of the RhoA/ROCK signaling pathway prevented the development of hypoxic pulmonary hypertension (HPH), as evidenced by significantly reduced PA remodeling and pulmonary vasoconstriction.	Protactinium	151-153	ras homolog family member A	Mus musculus	18-22
31118974-6	2019	We also found that SAB reversed HG- or PA-induced oxidative stress, apoptosis cell cytokines production, and expression of thioredoxin-interacting protein (TXNIP).	Protactinium	39-41	SH3 domain binding protein 5	Homo sapiens	19-22
31118974-6	2019	We also found that SAB reversed HG- or PA-induced oxidative stress, apoptosis cell cytokines production, and expression of thioredoxin-interacting protein (TXNIP).	Protactinium	39-41	thioredoxin interacting protein	Homo sapiens	123-154
31118974-6	2019	We also found that SAB reversed HG- or PA-induced oxidative stress, apoptosis cell cytokines production, and expression of thioredoxin-interacting protein (TXNIP).	Protactinium	39-41	thioredoxin interacting protein	Homo sapiens	156-161
31118974-7	2019	Moreover, SAB increased HG- or PA-induced expression of Sirtuin 1 (Sirt1), a nicotinamide adenine dinucleotide- (NAD+-) dependent histone deacetylase.	Protactinium	31-33	SH3 domain binding protein 5	Homo sapiens	10-13
31118974-7	2019	Moreover, SAB increased HG- or PA-induced expression of Sirtuin 1 (Sirt1), a nicotinamide adenine dinucleotide- (NAD+-) dependent histone deacetylase.	Protactinium	31-33	sirtuin 1	Homo sapiens	56-65
31118974-7	2019	Moreover, SAB increased HG- or PA-induced expression of Sirtuin 1 (Sirt1), a nicotinamide adenine dinucleotide- (NAD+-) dependent histone deacetylase.	Protactinium	31-33	sirtuin 1	Homo sapiens	67-72
31118974-9	2019	In conclusion, the results suggested that SAB could attenuate HUVEC cells damage treated with HG or PA via Sirt1 and might be a potential therapy agent for the diabetic cardiopathy treatment.	Protactinium	100-102	SH3 domain binding protein 5	Homo sapiens	42-45
31118974-9	2019	In conclusion, the results suggested that SAB could attenuate HUVEC cells damage treated with HG or PA via Sirt1 and might be a potential therapy agent for the diabetic cardiopathy treatment.	Protactinium	100-102	sirtuin 1	Homo sapiens	107-112
30831131-7	2019	Inhibition of the RhoA/ROCK signaling pathway prevented the development of hypoxic pulmonary hypertension (HPH), as evidenced by significantly reduced PA remodeling and pulmonary vasoconstriction.	Protactinium	151-153	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	23-27
30532074-3	2019	Mechanistically, DGKalpha-activated Akt/NF-kappaB signaling via stimulating PA production to reduce cAMP level and PTEN activity, and specifically, independently of its kinase function, through direct interaction with the FERM domain of FAK to relieve the auto-inhibitory effect of FERM domain on FAK.	Protactinium	76-78	nuclear factor kappa B subunit 1	Homo sapiens	40-49
30949771-5	2019	A concurrent report also found a different CLCN2 mutation (p.Gly24Asp) in a single severely affected patient from a cohort of 12 with early-onset PA for a prevalence of 8.3%.	Protactinium	146-148	chloride voltage-gated channel 2	Homo sapiens	43-48
30688393-4	2019	It is selectively recognized by active caspase-3 to trigger peptide substrate cleavage and biocompatible macrocyclization-mediated self-assembly, leading to an amplified PA imaging signal and prolonged retention in apoptotic tumor cells.	Protactinium	170-172	caspase 3	Mus musculus	39-48
30688393-5	2019	Strong, high-resolution PA images are obtained in chemotherapy-induced apoptotic tumors in living mice after intravenous administration with 1-RGD, facilitating sensitive reporting of caspase-3 activity and distribution within tumor tissues.	Protactinium	24-26	caspase 3	Mus musculus	184-193
30532074-3	2019	Mechanistically, DGKalpha-activated Akt/NF-kappaB signaling via stimulating PA production to reduce cAMP level and PTEN activity, and specifically, independently of its kinase function, through direct interaction with the FERM domain of FAK to relieve the auto-inhibitory effect of FERM domain on FAK.	Protactinium	76-78	diacylglycerol kinase alpha	Homo sapiens	17-25
30688393-1	2019	Photoacoustic (PA) imaging shows promise in the sensitive detection of caspase-3 activated in early tumor apoptosis in response to chemotherapy; smart PA probes are thus in high demand.	Protactinium	15-17	caspase 3	Mus musculus	71-80
30732813-5	2019	With only 3.66 vol% GONS, the oxygen permeability coefficient of CNF film decreased by about 4 x 104 times, from 5.5 x 10-13 to 1.4 x 10-17  cm3 cm cm-2 s-1  Pa-1.	Protactinium	158-160	NPHS1 adhesion molecule, nephrin	Homo sapiens	65-68
30666745-0	2019	Application of the NZ-1 Fab as a crystallization chaperone for PA tag-inserted target proteins.	Protactinium	63-65	FA complementation group B	Homo sapiens	24-27
30532074-3	2019	Mechanistically, DGKalpha-activated Akt/NF-kappaB signaling via stimulating PA production to reduce cAMP level and PTEN activity, and specifically, independently of its kinase function, through direct interaction with the FERM domain of FAK to relieve the auto-inhibitory effect of FERM domain on FAK.	Protactinium	76-78	AKT serine/threonine kinase 1	Homo sapiens	36-39
30666745-6	2019	We, therefore, explored the application of NZ-1 Fab as a crystallization chaperone that complexes with a target protein displaying a PA tag.	Protactinium	133-135	FA complementation group B	Homo sapiens	48-51
30666745-7	2019	Specifically, we inserted the PA tag into the beta-hairpins of the PDZ tandem fragment of a bacterial Site-2 protease.	Protactinium	30-32	membrane bound transcription factor peptidase, site 2	Homo sapiens	102-117
30666745-8	2019	We crystallized the PA-inserted PDZ tandem mutants with the NZ-1 Fab and solved the co-crystal structure to analyze their interaction modes.	Protactinium	20-22	FA complementation group B	Homo sapiens	65-68
30666745-11	2019	The present work also suggests that beta-hairpins are suitable sites for the PA insertion because the PA tag contains a Pro-Gly sequence with a propensity for a beta-turn conformation.	Protactinium	77-79	amyloid beta precursor protein	Homo sapiens	159-165
30666745-11	2019	The present work also suggests that beta-hairpins are suitable sites for the PA insertion because the PA tag contains a Pro-Gly sequence with a propensity for a beta-turn conformation.	Protactinium	102-104	amyloid beta precursor protein	Homo sapiens	159-165
30882834-4	2019	Upon dephosphorylation, the probes are activated and they provide a red-shifted strong absorption and emission in the NIR window and thus enable NIR FL and PA imaging of ALP activity in tumor tissues.	Protactinium	156-158	alkaline phosphatase, placental	Homo sapiens	170-173
30682387-9	2019	Both p38alpha inhibition and siRNA-mediated silencing attenuated H2O2- or 0.45-0.75 mM PA-mediated augmentation of DHEA production with relatively stable 17OHP levels, indicating that activated p38alpha mediates oxidative stress-induced 17,20-lyase activation and androgen synthesis stimulation, which may underlie hyperandrogenism in PCOS.	Protactinium	87-89	mitogen-activated protein kinase 14	Homo sapiens	5-13
30948929-6	2019	Results: Here we demonstrated that PA could promote the nuclear transport of FABP5, which then increased the nuclear protein levels of SP1.	Protactinium	35-37	fatty acid binding protein 5	Homo sapiens	77-82
31114257-4	2019	While a number of these proteins have been identified and investigated, the functions of PA0847, a PAS and GGDEF domain-containing protein from Pseudomonas aeruginosa PAO1, remain unclear.	Protactinium	99-102	hypothetical protein	Pseudomonas aeruginosa PAO1	89-95
31114257-8	2019	Both in-vitro and in-vivo studies showed that PA0847 is an active diguanylate cyclase (DGC), whose activity depends on the neighboring PAS domain.	Protactinium	135-138	hypothetical protein	Pseudomonas aeruginosa PAO1	46-52
30682387-9	2019	Both p38alpha inhibition and siRNA-mediated silencing attenuated H2O2- or 0.45-0.75 mM PA-mediated augmentation of DHEA production with relatively stable 17OHP levels, indicating that activated p38alpha mediates oxidative stress-induced 17,20-lyase activation and androgen synthesis stimulation, which may underlie hyperandrogenism in PCOS.	Protactinium	87-89	mitogen-activated protein kinase 14	Homo sapiens	194-202
30566905-11	2019	Concentrations increased above the two-fold upper limit of normal were mostly observed in PA for serum DHEAS (&gt;20-fold in the single case of adrenocortical carcinoma) and in CAH for serum androstenedione.	Protactinium	90-92	sulfotransferase family 2A member 1	Homo sapiens	103-108
30845941-13	2019	CONCLUSIONS: Cigarette smoke caused PA remodeling in PH rats related to RASEF hypermethylation.	Protactinium	36-38	RAS and EF hand domain containing	Rattus norvegicus	72-77
30633255-11	2019	As PA had the most stable fibre formation, it was chosen as a template to further incorporate stromal cell-derived factor-1 (SDF-1) and granulocyte colony-stimulating factor (G-CSF), and stimulate higher hMSC infiltration.	Protactinium	3-5	C-X-C motif chemokine ligand 12	Homo sapiens	94-123
31094293-4	2019	Results showed that autistic trait profiles were related to faux pas detection ability in the FPT but not the FPTa.	Protactinium	65-68	farnesyltransferase, CAAX box, alpha	Homo sapiens	94-97
30452878-4	2019	Exposure of beta-cells to palmitatic acid (PA), a saturated free fatty acid, resulted in a nearly 2-fold increase in SK2 expression, which paralleled the induction of cell death in a similar dose- and time-dependent fashion.	Protactinium	43-45	sphingosine kinase 2	Mus musculus	117-120
30452878-5	2019	Silencing SK2 expression by its specific small interfering RNAs significantly inhibited PA-induced cell death and caspase-3 activation, whereas overexpression of SK2 promoted lipotoxicity in beta-cells.	Protactinium	88-90	sphingosine kinase 2	Mus musculus	10-13
30452878-6	2019	Mechanistically, upon exposure to PA, endogenous SK2 was shuttled from the nucleus to the cytoplasm, where it interacted with B-cell lymphoma-extra-large (Bcl-xL), leading to mitochondrial apoptotic pathway activation and cell death.	Protactinium	34-36	sphingosine kinase 2	Mus musculus	49-52
30452878-6	2019	Mechanistically, upon exposure to PA, endogenous SK2 was shuttled from the nucleus to the cytoplasm, where it interacted with B-cell lymphoma-extra-large (Bcl-xL), leading to mitochondrial apoptotic pathway activation and cell death.	Protactinium	34-36	BCL2-like 1	Mus musculus	155-161
30506941-5	2019	Chronic hypertension was induced in mice by 28-day angiotensin II (Ang II) infusion; PA resting tone and myogenic responses increased significantly.	Protactinium	85-87	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	51-65
30506941-5	2019	Chronic hypertension was induced in mice by 28-day angiotensin II (Ang II) infusion; PA resting tone and myogenic responses increased significantly.	Protactinium	85-87	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	67-73
30506941-10	2019	In addition, pharmacological TRPV4 channel blockade or genetic deletion abrogated enhanced hypertension-induced increases in PA tone.	Protactinium	125-127	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	29-34
30633255-11	2019	As PA had the most stable fibre formation, it was chosen as a template to further incorporate stromal cell-derived factor-1 (SDF-1) and granulocyte colony-stimulating factor (G-CSF), and stimulate higher hMSC infiltration.	Protactinium	3-5	C-X-C motif chemokine ligand 12	Homo sapiens	125-130
30633255-11	2019	As PA had the most stable fibre formation, it was chosen as a template to further incorporate stromal cell-derived factor-1 (SDF-1) and granulocyte colony-stimulating factor (G-CSF), and stimulate higher hMSC infiltration.	Protactinium	3-5	colony stimulating factor 3	Homo sapiens	136-173
30633255-11	2019	As PA had the most stable fibre formation, it was chosen as a template to further incorporate stromal cell-derived factor-1 (SDF-1) and granulocyte colony-stimulating factor (G-CSF), and stimulate higher hMSC infiltration.	Protactinium	3-5	colony stimulating factor 3	Homo sapiens	175-180
30518648-3	2019	Here, we demonstrate that HDAC6 acts as a negative regulator of IAV infection by destabilizing PA. HDAC6 binds to and deacetylates PA, thereby promoting the proteasomal degradation of PA.	Protactinium	95-97	histone deacetylase 6	Homo sapiens	26-31
30765854-5	2019	We present a combinatorial PIT approach for targeting BC expressing EGFR and HER2, using PA- labeled panitumumab (pan) and trastuzumab (tra), respectively.	Protactinium	89-91	epidermal growth factor receptor	Homo sapiens	68-72
30765854-5	2019	We present a combinatorial PIT approach for targeting BC expressing EGFR and HER2, using PA- labeled panitumumab (pan) and trastuzumab (tra), respectively.	Protactinium	89-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
30809524-7	2019	Utilizing a human papillomavirus transgenic mouse model that develops cutaneous SCC in response to ultraviolet irradiation we identified tumor uptake of PA in vivo.	Protactinium	153-155	serpin family B member 3	Homo sapiens	80-83
30809524-11	2019	These results suggest that PA could be systemically administered for rapid identification of cutaneous SCC, with potential for further therapeutic development.	Protactinium	27-29	serpin family B member 3	Homo sapiens	103-106
30689382-7	2019	Moreover, taking the PA signal at 730 nm as an internal reference, the PA signal at 680 nm allowed quantitative detection of MMP-2 expression in breast cancer in vivo.	Protactinium	71-73	matrix metallopeptidase 2	Homo sapiens	125-130
30518648-3	2019	Here, we demonstrate that HDAC6 acts as a negative regulator of IAV infection by destabilizing PA. HDAC6 binds to and deacetylates PA, thereby promoting the proteasomal degradation of PA.	Protactinium	95-97	histone deacetylase 6	Homo sapiens	99-104
30518648-3	2019	Here, we demonstrate that HDAC6 acts as a negative regulator of IAV infection by destabilizing PA. HDAC6 binds to and deacetylates PA, thereby promoting the proteasomal degradation of PA.	Protactinium	131-133	histone deacetylase 6	Homo sapiens	26-31
30518648-3	2019	Here, we demonstrate that HDAC6 acts as a negative regulator of IAV infection by destabilizing PA. HDAC6 binds to and deacetylates PA, thereby promoting the proteasomal degradation of PA.	Protactinium	131-133	histone deacetylase 6	Homo sapiens	99-104
30518648-4	2019	Based on mass spectrometric analysis, Lys(664) of PA can be deacetylated by HDAC6, and the residue is crucial for PA protein stability.	Protactinium	50-52	histone deacetylase 6	Homo sapiens	76-81
30518648-4	2019	Based on mass spectrometric analysis, Lys(664) of PA can be deacetylated by HDAC6, and the residue is crucial for PA protein stability.	Protactinium	114-116	histone deacetylase 6	Homo sapiens	76-81
30556205-7	2019	The applications of PA contrast agents as biosensors (in the sensing of metal ions, pH, enzymes, temperature, hypoxia, reactive oxygen species, and reactive nitrogen species) and in bioimaging (lymph nodes, vasculature, tumors, and brain tissue) are discussed in detail.	Protactinium	20-22	phenylalanine hydroxylase	Homo sapiens	84-86
30307055-6	2019	PAs located in the submandibular gland demonstrated CTNNB1-PLAG1 fusion at a significantly higher rate than other fusions (P = 0.0109).	Protactinium	0-3	catenin beta 1	Homo sapiens	52-58
30620448-5	2019	By adjusting the molar ratios and processing conditions, the Ac2-26 PA can be co-assembled with a PA containing an apolipoprotein A1-mimetic peptide to create a targeted, therapeutic nanofiber (ApoA1-Ac226 PA).	Protactinium	68-70	adenylate cyclase 2	Homo sapiens	61-64
30620448-5	2019	By adjusting the molar ratios and processing conditions, the Ac2-26 PA can be co-assembled with a PA containing an apolipoprotein A1-mimetic peptide to create a targeted, therapeutic nanofiber (ApoA1-Ac226 PA).	Protactinium	68-70	apolipoprotein A1	Homo sapiens	115-132
30620448-5	2019	By adjusting the molar ratios and processing conditions, the Ac2-26 PA can be co-assembled with a PA containing an apolipoprotein A1-mimetic peptide to create a targeted, therapeutic nanofiber (ApoA1-Ac226 PA).	Protactinium	68-70	apolipoprotein A1	Homo sapiens	194-199
30594305-3	2019	In this study, we found that the PA mediated ER-stress activation could induce M1-type polarization in macrophages, and this phenotype polarization could be inhibited by ER-stress inhibitor 4-PBA as well as GSK2656157, an inhibitor of PERK.	Protactinium	33-35	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	235-239
30307055-6	2019	PAs located in the submandibular gland demonstrated CTNNB1-PLAG1 fusion at a significantly higher rate than other fusions (P = 0.0109).	Protactinium	0-3	PLAG1 zinc finger	Homo sapiens	59-64
30061152-6	2019	Pah1 is PA-specific and is the only PA phosphatase responsible for lipid synthesis at the nuclear/endoplasmic reticulum membrane.	Protactinium	8-10	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	0-4
30621469-7	2019	Methods: In this study, for the first time, a triple chimeric protein called ELP was modeled by fusing three different domains of anthrax toxic antigens, the N-terminal domains of EF and LF, and the C-terminal domain of PA as a high immunogenic antigen using Modeller 9.19 software.	Protactinium	220-222	diazepam binding inhibitor-like 5	Mus musculus	77-80
30595411-3	2019	In this study, we explored the potentiality of the IKVAV-functionalized PA hydrogel to provide a permissive environment for cell migration and growth as well as sustained release of BDNF at the lesion after severe compression injury model.	Protactinium	72-74	brain derived neurotrophic factor	Homo sapiens	182-186
30061152-7	2019	App1, Dpp1, and Lpp1, respectively, are localized to cortical actin patches and the vacuole and Golgi membranes; they utilize several lipid phosphate substrates, including PA, lyso-PA, and diacylglycerol pyrophosphate.	Protactinium	172-174	phosphatidate phosphatase APP1	Saccharomyces cerevisiae S288C	0-4
30809553-4	2019	The model was used to quantify PA-induced lipid accumulation in the two cell lines treated with various concentrations of mangiferin simultaneously for 24 h. We found that mangiferin significantly increased insulin-stimulated glucose uptake, via phosphorylation of protein kinase B (P-AKT), glucose transporter 2 (GLUT2), and glucose transporter 4 (GLUT4) protein expressions, and markedly decreased glucose content, respectively, in HepG2 and C2C12 cells induced by PA.	Protactinium	31-33	insulin	Homo sapiens	207-214
30061152-7	2019	App1, Dpp1, and Lpp1, respectively, are localized to cortical actin patches and the vacuole and Golgi membranes; they utilize several lipid phosphate substrates, including PA, lyso-PA, and diacylglycerol pyrophosphate.	Protactinium	172-174	bifunctional diacylglycerol diphosphate phosphatase/phosphatidate phosphatase	Saccharomyces cerevisiae S288C	6-10
30061152-7	2019	App1, Dpp1, and Lpp1, respectively, are localized to cortical actin patches and the vacuole and Golgi membranes; they utilize several lipid phosphate substrates, including PA, lyso-PA, and diacylglycerol pyrophosphate.	Protactinium	172-174	phosphatidate phosphatase LPP1	Saccharomyces cerevisiae S288C	16-20
30255933-7	2019	PA decreased the density of calbindin neurons in layer II of the Anterior Insular Cortex, while deep hypothermia reversed this effect.	Protactinium	0-2	calbindin 1	Rattus norvegicus	28-37
30645025-3	2019	The absorbance band of LET-2 shifts from 625 to 715 nm after the interaction with Cu2+ , thus producing strong PA signal output at 715 nm (PA715 ) as an indicator.	Protactinium	111-113	immunoglobulin kappa variable 1-35	Mus musculus	82-85
30704522-4	2019	Our preliminary study indicated that patients with PA at novel sites near antecubital veins had higher serum concentrations of parathyroid hormone (PTH).	Protactinium	51-53	parathyroid hormone	Homo sapiens	127-146
30745907-8	2019	In conclusion, three rare novel CNVs were identified only in PA-VSD: 16p11.2 del (PPP4C), 5q35.3 del (FLT4) and 5p13.1 del (RICTOR), implicating novel candidate genes of interest for PA-VSD.	Protactinium	61-63	protein phosphatase 4 catalytic subunit	Homo sapiens	82-87
30745907-8	2019	In conclusion, three rare novel CNVs were identified only in PA-VSD: 16p11.2 del (PPP4C), 5q35.3 del (FLT4) and 5p13.1 del (RICTOR), implicating novel candidate genes of interest for PA-VSD.	Protactinium	61-63	fms related receptor tyrosine kinase 4	Homo sapiens	102-106
30809553-4	2019	The model was used to quantify PA-induced lipid accumulation in the two cell lines treated with various concentrations of mangiferin simultaneously for 24 h. We found that mangiferin significantly increased insulin-stimulated glucose uptake, via phosphorylation of protein kinase B (P-AKT), glucose transporter 2 (GLUT2), and glucose transporter 4 (GLUT4) protein expressions, and markedly decreased glucose content, respectively, in HepG2 and C2C12 cells induced by PA.	Protactinium	31-33	protein tyrosine kinase 2 beta	Homo sapiens	265-281
30745907-8	2019	In conclusion, three rare novel CNVs were identified only in PA-VSD: 16p11.2 del (PPP4C), 5q35.3 del (FLT4) and 5p13.1 del (RICTOR), implicating novel candidate genes of interest for PA-VSD.	Protactinium	61-63	RPTOR independent companion of MTOR complex 2	Homo sapiens	124-130
30809553-4	2019	The model was used to quantify PA-induced lipid accumulation in the two cell lines treated with various concentrations of mangiferin simultaneously for 24 h. We found that mangiferin significantly increased insulin-stimulated glucose uptake, via phosphorylation of protein kinase B (P-AKT), glucose transporter 2 (GLUT2), and glucose transporter 4 (GLUT4) protein expressions, and markedly decreased glucose content, respectively, in HepG2 and C2C12 cells induced by PA.	Protactinium	31-33	solute carrier family 2 member 2	Homo sapiens	291-312
30745907-8	2019	In conclusion, three rare novel CNVs were identified only in PA-VSD: 16p11.2 del (PPP4C), 5q35.3 del (FLT4) and 5p13.1 del (RICTOR), implicating novel candidate genes of interest for PA-VSD.	Protactinium	183-185	protein phosphatase 4 catalytic subunit	Homo sapiens	82-87
30809553-4	2019	The model was used to quantify PA-induced lipid accumulation in the two cell lines treated with various concentrations of mangiferin simultaneously for 24 h. We found that mangiferin significantly increased insulin-stimulated glucose uptake, via phosphorylation of protein kinase B (P-AKT), glucose transporter 2 (GLUT2), and glucose transporter 4 (GLUT4) protein expressions, and markedly decreased glucose content, respectively, in HepG2 and C2C12 cells induced by PA.	Protactinium	31-33	solute carrier family 2 member 2	Homo sapiens	314-319
30745907-8	2019	In conclusion, three rare novel CNVs were identified only in PA-VSD: 16p11.2 del (PPP4C), 5q35.3 del (FLT4) and 5p13.1 del (RICTOR), implicating novel candidate genes of interest for PA-VSD.	Protactinium	183-185	RPTOR independent companion of MTOR complex 2	Homo sapiens	124-130
30809553-4	2019	The model was used to quantify PA-induced lipid accumulation in the two cell lines treated with various concentrations of mangiferin simultaneously for 24 h. We found that mangiferin significantly increased insulin-stimulated glucose uptake, via phosphorylation of protein kinase B (P-AKT), glucose transporter 2 (GLUT2), and glucose transporter 4 (GLUT4) protein expressions, and markedly decreased glucose content, respectively, in HepG2 and C2C12 cells induced by PA.	Protactinium	31-33	solute carrier family 2 member 4	Homo sapiens	326-347
30809553-4	2019	The model was used to quantify PA-induced lipid accumulation in the two cell lines treated with various concentrations of mangiferin simultaneously for 24 h. We found that mangiferin significantly increased insulin-stimulated glucose uptake, via phosphorylation of protein kinase B (P-AKT), glucose transporter 2 (GLUT2), and glucose transporter 4 (GLUT4) protein expressions, and markedly decreased glucose content, respectively, in HepG2 and C2C12 cells induced by PA.	Protactinium	31-33	solute carrier family 2 member 4	Homo sapiens	349-354
30809553-4	2019	The model was used to quantify PA-induced lipid accumulation in the two cell lines treated with various concentrations of mangiferin simultaneously for 24 h. We found that mangiferin significantly increased insulin-stimulated glucose uptake, via phosphorylation of protein kinase B (P-AKT), glucose transporter 2 (GLUT2), and glucose transporter 4 (GLUT4) protein expressions, and markedly decreased glucose content, respectively, in HepG2 and C2C12 cells induced by PA.	Protactinium	467-469	insulin	Homo sapiens	207-214
31016108-5	2019	It is also demonstrated that A1094@RGD-HBc, with an enhanced absorption in the NIR II window, displays ninefold PA signal amplification in vivo, allowing for precise PAI of the brain gliomas at a depth up to 5.9 mm.	Protactinium	112-114	keratin 88, pseudogene	Homo sapiens	39-42
30723473-8	2019	Upon stimulation with palmitate acid (PA), bone marrow-derived macrophages (BMDMs) derived from Spred2 KO mice secreted higher levels of TNFalpha and MCP-1 than those from WT mice with enhanced ERK activation.	Protactinium	38-40	sprouty-related EVH1 domain containing 2	Mus musculus	96-102
30723473-8	2019	Upon stimulation with palmitate acid (PA), bone marrow-derived macrophages (BMDMs) derived from Spred2 KO mice secreted higher levels of TNFalpha and MCP-1 than those from WT mice with enhanced ERK activation.	Protactinium	38-40	tumor necrosis factor	Mus musculus	137-145
30723473-8	2019	Upon stimulation with palmitate acid (PA), bone marrow-derived macrophages (BMDMs) derived from Spred2 KO mice secreted higher levels of TNFalpha and MCP-1 than those from WT mice with enhanced ERK activation.	Protactinium	38-40	chemokine (C-C motif) ligand 2	Mus musculus	150-155
30723473-8	2019	Upon stimulation with palmitate acid (PA), bone marrow-derived macrophages (BMDMs) derived from Spred2 KO mice secreted higher levels of TNFalpha and MCP-1 than those from WT mice with enhanced ERK activation.	Protactinium	38-40	mitogen-activated protein kinase 1	Mus musculus	194-197
30723473-9	2019	U0126, a MEK inhibitor, reduced the PA-induced cytokine response.	Protactinium	36-38	midkine	Mus musculus	9-12
30442987-2	2019	The oral delivery of most PAs is hindered by their poor bioavailability, which is largely caused by P-glycoprotein (P-gp)-mediated drug efflux.	Protactinium	26-29	phosphoglycolate phosphatase	Mus musculus	100-114
30565613-1	2019	A Cd(ii)-based metal-organic framework (MOF) {[Cd(PA)(4,4"-bpy)2](H2O)}n (where, PA = pamoic acid, and bpy = bipyridine) has been demonstrated to have trifunctional properties, namely as (i) an efficient and selective adsorbent for dyes, (ii) a visible-light-active photocatalyst for the degradation of dyes and (iii) a photocatalyst for Cr(vi) reduction.	Protactinium	50-52	lysine acetyltransferase 8	Homo sapiens	15-44
30525573-8	2019	In conclusion, phloretin attenuates PA-induced oxidative stress in HUVECs via the AMPK/Nrf2 antioxidative pathway.	Protactinium	36-38	NFE2 like bZIP transcription factor 2	Homo sapiens	87-91
30527635-9	2019	Finally, a strong correlation, r(17) = 0.92, p &lt; 0.001, was observed between the cycle-to-cycle variability in PA1 and the LyE calculated for PP1, supporting the notion that PA variability and LyE share some of the information they provide about movement control.	Protactinium	114-116	inorganic pyrophosphatase 1	Homo sapiens	145-148
30442987-2	2019	The oral delivery of most PAs is hindered by their poor bioavailability, which is largely caused by P-glycoprotein (P-gp)-mediated drug efflux.	Protactinium	26-29	phosphoglycolate phosphatase	Mus musculus	116-120
30539695-6	2019	Here we will discuss recent evidence that bridges the gap between basic research in the field of the PA system and the bedside of ischemic stroke patients, indicating that uPA and uPAR are potential targets for the development of therapeutic strategies to promote neurological recovery among ischemic stroke survivors.	Protactinium	101-103	plasminogen activator, urokinase	Homo sapiens	172-175
30539695-6	2019	Here we will discuss recent evidence that bridges the gap between basic research in the field of the PA system and the bedside of ischemic stroke patients, indicating that uPA and uPAR are potential targets for the development of therapeutic strategies to promote neurological recovery among ischemic stroke survivors.	Protactinium	101-103	plasminogen activator, urokinase receptor	Homo sapiens	180-184
31274955-4	2019	An exemplary sample based on P84 crosslinked by BuDA for 6 h exhibits a H2 permeability of 47 Barrers (1 Barrer = 3.35 x 10-16 mol m/m2 s Pa) and H2/CO2 selectivity of 14 at 100  C, which is on the Robeson"s upper bound, indicating their potential for practical applications.	Protactinium	138-140	THO complex 1	Homo sapiens	29-32
30217538-2	2018	We examined how different indicators of NA and PA predicted concentrations of C-reactive protein (CRP) and seven peripheral inflammatory cytokines (IL-1beta, IL-6, TNF-alpha, IL-8, IL-4, IL-10, and IFN-gamma) that were examined in the form of an inflammatory composite.	Protactinium	47-49	C-reactive protein	Homo sapiens	78-96
30662369-8	2018	In mature adipocytes, we found that KLF4 played an important anti-inflammatory role; moreover, PA can promote the development of inflammation by inhibiting KLF4 expression; TLR9 has a positive regulation function on KLF4 expression, but unrelated to PA.	Protactinium	95-97	Kruppel like factor 4	Rattus norvegicus	156-160
30662369-8	2018	In mature adipocytes, we found that KLF4 played an important anti-inflammatory role; moreover, PA can promote the development of inflammation by inhibiting KLF4 expression; TLR9 has a positive regulation function on KLF4 expression, but unrelated to PA.	Protactinium	95-97	Kruppel like factor 4	Rattus norvegicus	156-160
30265746-8	2018	Compared with storage in SSP+, storage in PAS-5 or PAS-G resulted in better preservation of platelet adenosine triphosphate and hypotonic shock response, lower annexin V binding, and improved mitochondrial membrane potential.	Protactinium	42-45	annexin A5	Homo sapiens	160-169
30567381-7	2018	Similarly docking studies predicted interaction of the most active compounds with both CAS and PAS of either AChE or BChE with mixed type of enzyme inhibition confirmed by kinetic studies.	Protactinium	95-98	acetylcholinesterase (Cartwright blood group)	Homo sapiens	109-113
30567381-7	2018	Similarly docking studies predicted interaction of the most active compounds with both CAS and PAS of either AChE or BChE with mixed type of enzyme inhibition confirmed by kinetic studies.	Protactinium	95-98	butyrylcholinesterase	Homo sapiens	117-121
30481463-2	2018	However, to the best of our knowledge, using an alkaline phosphatase (ALP)-activatable probe for the enhanced PA imaging of tumors has not been reported.	Protactinium	110-112	alkaline phosphatase, placental	Homo sapiens	48-68
30481463-2	2018	However, to the best of our knowledge, using an alkaline phosphatase (ALP)-activatable probe for the enhanced PA imaging of tumors has not been reported.	Protactinium	110-112	alkaline phosphatase, placental	Homo sapiens	70-73
30481463-3	2018	In this work, we rationally designed a NIR probe IR775-Phe-Phe-Tyr(H2PO3)-OH (1P) for PA imaging ALP activity in vitro and in tumor.	Protactinium	86-88	alkaline phosphatase, placental	Homo sapiens	97-100
30481463-6	2018	In vivo tumor PA imaging results indicated that, compared to that in the ALP inhibitor-treated control group, PA contrast in the experimental group enhanced 2.3 folds at 4 h after 1P injection.	Protactinium	14-16	alkaline phosphatase, placental	Homo sapiens	73-76
30481463-6	2018	In vivo tumor PA imaging results indicated that, compared to that in the ALP inhibitor-treated control group, PA contrast in the experimental group enhanced 2.3 folds at 4 h after 1P injection.	Protactinium	110-112	alkaline phosphatase, placental	Homo sapiens	73-76
30544746-11	2018	The baseline serum NEDD9 levels were significantly higher in patients with PA than in the control group (p = 0.03).	Protactinium	75-77	neural precursor cell expressed, developmentally down-regulated 9	Homo sapiens	19-24
29786894-8	2018	Low PA was associated with worse nutrition status evaluated by body mass index, serum albumin level, transferrin, and fat-free mass.	Protactinium	4-6	albumin	Homo sapiens	86-93
29786894-8	2018	Low PA was associated with worse nutrition status evaluated by body mass index, serum albumin level, transferrin, and fat-free mass.	Protactinium	4-6	transferrin	Homo sapiens	101-112
30290311-5	2018	Experiments with PA-mutant and -chimeric viruses confirmed that the avian PA segment conferred BST-2 downregulation and antagonism.	Protactinium	17-19	bone marrow stromal cell antigen 2	Homo sapiens	95-100
30290311-5	2018	Experiments with PA-mutant and -chimeric viruses confirmed that the avian PA segment conferred BST-2 downregulation and antagonism.	Protactinium	74-76	bone marrow stromal cell antigen 2	Homo sapiens	95-100
30290311-6	2018	These results indicate a species-specific ability of PA from low pathogenic avian viruses to mitigate human BST-2 antiviral activity, suggesting that BST-2 is unlikely to be a general cross-species barrier to transmission of such viruses to humans.	Protactinium	53-55	bone marrow stromal cell antigen 2	Homo sapiens	108-113
30290311-6	2018	These results indicate a species-specific ability of PA from low pathogenic avian viruses to mitigate human BST-2 antiviral activity, suggesting that BST-2 is unlikely to be a general cross-species barrier to transmission of such viruses to humans.	Protactinium	53-55	bone marrow stromal cell antigen 2	Homo sapiens	150-155
30224439-2	2018	This signaling pathway regulates the consumption of acetate, which in turn alters the relative virulence of interactions with arthropods, including Drosophila melanogaster CrbS is a histidine kinase that links a transporter-like domain to its signaling apparatus via putative STAC and PAS domains.	Protactinium	285-288	crumbs	Drosophila melanogaster	172-176
30217538-2	2018	We examined how different indicators of NA and PA predicted concentrations of C-reactive protein (CRP) and seven peripheral inflammatory cytokines (IL-1beta, IL-6, TNF-alpha, IL-8, IL-4, IL-10, and IFN-gamma) that were examined in the form of an inflammatory composite.	Protactinium	47-49	C-reactive protein	Homo sapiens	98-101
30019185-13	2018	In in vitro experiments, PA stimulation could increase the expressions of CTSB and NLRP3 inflammasome in KCs, and CTSB inhibition downregulated the expression of NLRP3 inflammasome in KCs, when challenged by PA.	Protactinium	25-27	cathepsin B	Mus musculus	74-78
30056577-12	2018	Mean insulin concentration was higher and mean glucose and FGIR were lower in PA group and also dyslipidemia ratio was 5.3 times higher in PA than controls (p = 0.040).	Protactinium	78-80	insulin	Homo sapiens	5-12
30056577-13	2018	In PA group, overweight/obese subjects had still higher BMI at second evaluation and also higher fasting glucose, insulin, HOMA-IR.	Protactinium	3-5	insulin	Homo sapiens	114-121
29857026-2	2018	AIM: The primary aim was to compare the proportion of PA-OprD among P. aeruginosa samples before and after an incidental relocation of the ICU.	Protactinium	54-56	opioid receptor delta 1	Homo sapiens	57-61
29857026-10	2018	The proportion of PA-OprD strains decreased significantly from 31% to 7.7% after the relocation of the ICU (P = 0.004).	Protactinium	18-20	opioid receptor delta 1	Homo sapiens	21-25
29857026-14	2018	The polyclonal character of PA-OprD strains isolated from patients and the absence of tap-water-to-patient contamination highlight the complexity of the environmental impact on the endogenous colonization/infection with P. aeruginosa.	Protactinium	28-30	opioid receptor delta 1	Homo sapiens	31-35
30019185-13	2018	In in vitro experiments, PA stimulation could increase the expressions of CTSB and NLRP3 inflammasome in KCs, and CTSB inhibition downregulated the expression of NLRP3 inflammasome in KCs, when challenged by PA.	Protactinium	25-27	NLR family, pyrin domain containing 3	Mus musculus	83-88
30019185-13	2018	In in vitro experiments, PA stimulation could increase the expressions of CTSB and NLRP3 inflammasome in KCs, and CTSB inhibition downregulated the expression of NLRP3 inflammasome in KCs, when challenged by PA.	Protactinium	208-210	cathepsin B	Mus musculus	114-118
30019185-13	2018	In in vitro experiments, PA stimulation could increase the expressions of CTSB and NLRP3 inflammasome in KCs, and CTSB inhibition downregulated the expression of NLRP3 inflammasome in KCs, when challenged by PA.	Protactinium	208-210	NLR family, pyrin domain containing 3	Mus musculus	162-167
30405515-10	2018	Patients studied before and after ERT showed a dramatic decrease of PAS-positive vacuolated lymphocytes number (p = 0.016).	Protactinium	68-71	E74 like ETS transcription factor 3	Homo sapiens	34-37
30304687-5	2018	By integrating the cryptochrome 2-cryptochrome-interacting basic helix-loop-helix 1 (Cry2-CIB1) light-inducible binding switch, expression of the gene of interest is tightly regulated under the control of light illumination and drug application in our PA-Tet-OFF/ON system.	Protactinium	252-254	cryptochrome circadian regulator 2	Homo sapiens	85-89
30201607-1	2018	The Nem1-Spo7 protein phosphatase plays a role in lipid synthesis by controlling the membrane localization of Pah1, the diacylglycerol-producing phosphatidate (PA) phosphatase that is crucial for the synthesis of triacylglycerol in the yeast Saccharomyces cerevisiae By dephosphorylating Pah1, Nem1-Spo7 facilitates its translocation to the nuclear/endoplasmic reticulum membrane for catalytic activity.	Protactinium	160-162	Nem1-Spo7 phosphatase catalytic subunit NEM1	Saccharomyces cerevisiae S288C	4-8
30201607-1	2018	The Nem1-Spo7 protein phosphatase plays a role in lipid synthesis by controlling the membrane localization of Pah1, the diacylglycerol-producing phosphatidate (PA) phosphatase that is crucial for the synthesis of triacylglycerol in the yeast Saccharomyces cerevisiae By dephosphorylating Pah1, Nem1-Spo7 facilitates its translocation to the nuclear/endoplasmic reticulum membrane for catalytic activity.	Protactinium	160-162	Nem1-Spo7 phosphatase regulatory subunit SPO7	Saccharomyces cerevisiae S288C	9-13
30201607-1	2018	The Nem1-Spo7 protein phosphatase plays a role in lipid synthesis by controlling the membrane localization of Pah1, the diacylglycerol-producing phosphatidate (PA) phosphatase that is crucial for the synthesis of triacylglycerol in the yeast Saccharomyces cerevisiae By dephosphorylating Pah1, Nem1-Spo7 facilitates its translocation to the nuclear/endoplasmic reticulum membrane for catalytic activity.	Protactinium	160-162	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	110-114
30201607-1	2018	The Nem1-Spo7 protein phosphatase plays a role in lipid synthesis by controlling the membrane localization of Pah1, the diacylglycerol-producing phosphatidate (PA) phosphatase that is crucial for the synthesis of triacylglycerol in the yeast Saccharomyces cerevisiae By dephosphorylating Pah1, Nem1-Spo7 facilitates its translocation to the nuclear/endoplasmic reticulum membrane for catalytic activity.	Protactinium	160-162	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	288-292
30201607-1	2018	The Nem1-Spo7 protein phosphatase plays a role in lipid synthesis by controlling the membrane localization of Pah1, the diacylglycerol-producing phosphatidate (PA) phosphatase that is crucial for the synthesis of triacylglycerol in the yeast Saccharomyces cerevisiae By dephosphorylating Pah1, Nem1-Spo7 facilitates its translocation to the nuclear/endoplasmic reticulum membrane for catalytic activity.	Protactinium	160-162	Nem1-Spo7 phosphatase catalytic subunit NEM1	Saccharomyces cerevisiae S288C	294-298
30201607-1	2018	The Nem1-Spo7 protein phosphatase plays a role in lipid synthesis by controlling the membrane localization of Pah1, the diacylglycerol-producing phosphatidate (PA) phosphatase that is crucial for the synthesis of triacylglycerol in the yeast Saccharomyces cerevisiae By dephosphorylating Pah1, Nem1-Spo7 facilitates its translocation to the nuclear/endoplasmic reticulum membrane for catalytic activity.	Protactinium	160-162	Nem1-Spo7 phosphatase regulatory subunit SPO7	Saccharomyces cerevisiae S288C	299-303
30211565-8	2018	Our findings suggest that the BDNF mimetic PA nanostructure creates a highly bioactive matrix that could serve as a biomaterial therapy in injured regions of the CNS.	Protactinium	43-45	brain derived neurotrophic factor	Homo sapiens	30-34
30304687-5	2018	By integrating the cryptochrome 2-cryptochrome-interacting basic helix-loop-helix 1 (Cry2-CIB1) light-inducible binding switch, expression of the gene of interest is tightly regulated under the control of light illumination and drug application in our PA-Tet-OFF/ON system.	Protactinium	252-254	calcium and integrin binding 1	Homo sapiens	90-94
30037776-9	2018	SHH is a critical regulator of neurite formation in peripheral neurons under uninjured and regenerative conditions, and SHH PA treatment at the time of injury/prostatectomy provides an exploitable avenue for intervention to prevent ED.	Protactinium	124-126	sonic hedgehog signaling molecule	Homo sapiens	120-123
29974255-2	2018	In a previous study, we reported that nucleolin (NCL) is a novel PA-interacting host protein.	Protactinium	65-67	nucleolin	Homo sapiens	38-47
29974255-2	2018	In a previous study, we reported that nucleolin (NCL) is a novel PA-interacting host protein.	Protactinium	65-67	nucleolin	Homo sapiens	49-52
30098330-6	2018	SIRT5 overexpression significantly alleviated apoptosis under the High-PA-G condition, accompanied by suppressed Caspase 3 activity and reduced malondialdehyde levels.	Protactinium	71-73	sirtuin 5	Mus musculus	0-5
30098330-7	2018	SIRT5 overexpression also improved beta cell secretory capacity in response to glucose under the High-PA-G condition, suggesting its protective role in beta cell function.	Protactinium	102-104	sirtuin 5	Mus musculus	0-5
30098330-8	2018	Furthermore, SIRT5 overexpression reversed the decreasing trend of anti-apoptotic factors BCL-2 and BCL-XL expression under High-PA-G condition.	Protactinium	129-131	sirtuin 5	Mus musculus	13-18
30098330-8	2018	Furthermore, SIRT5 overexpression reversed the decreasing trend of anti-apoptotic factors BCL-2 and BCL-XL expression under High-PA-G condition.	Protactinium	129-131	B cell leukemia/lymphoma 2	Mus musculus	90-95
30098330-8	2018	Furthermore, SIRT5 overexpression reversed the decreasing trend of anti-apoptotic factors BCL-2 and BCL-XL expression under High-PA-G condition.	Protactinium	129-131	BCL2-like 1	Mus musculus	100-106
30233722-8	2018	PAS showed HIF-1alpha-/- + STZ mice had damaged kidney tissues, with more renal fibrosis and apparent glomerular hypertrophy.	Protactinium	0-3	hypoxia inducible factor 1, alpha subunit	Mus musculus	11-21
29940163-8	2018	CONCLUSIONS: In incident idiopathic PAH, PA stiffness was related to mPAP and heart rate, and this finding outperformed the potential influences of age and sex.	Protactinium	36-38	phospholipid phosphatase 1	Mus musculus	69-73
29653029-4	2018	Differences in contrast between PSMA+ and isogenic control tumors were observed upon PA imaging, with PSMA+ tumors showing higher contrast in average of 66.07-fold with 5 mice at the 24-hour postinjection time points.	Protactinium	85-87	folate hydrolase 1	Homo sapiens	32-36
29959728-5	2018	It was found that global PA produced a regionally specific and sustained increase in GSSG/GSH ratio, a regionally specific decrease in tissue reducing capacity and a regionally and time specific decrease of catalase activity and increase of cleaved caspase-3 levels.	Protactinium	25-27	catalase	Rattus norvegicus	207-215
29959728-6	2018	The present study provides evidence for regionally impaired redox homeostasis in the brain of rats subjected to global PA, an effect observed up to P14, mainly affecting mesencephalon and hippocampus, suggesting a sustained oxidative stress after the posthypoxia period.	Protactinium	119-121	S100 calcium binding protein A9	Rattus norvegicus	148-151
29928916-7	2018	Compared with the serious hydrolysis in the free PLD (35.3% yield of PA), the side reaction was minimized in this work.	Protactinium	69-71	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	49-52
29653029-6	2018	Spectroscopic PA imaging is a new molecular imaging modality with sufficient sensitivity for targeting PSMA in vivo, demonstrating the potential applications for other saturable targets relevant to cancer and other disorders.	Protactinium	14-16	folate hydrolase 1	Homo sapiens	103-107
29875249-5	2018	In this study, we show that a PA subunit lacking the PA51-72-loop assembles into a heterotrimeric polymerase with PB1 and PB2.	Protactinium	30-32	polybromo 1	Homo sapiens	114-117
29961324-3	2018	The PA nanoprobes (Au-H1/PEG and Au-H2/PEG) were constructed by linking poly(ethylene glycol) (PEG) and two hairpin DNA strands (H1 and H2, respectively) to the surface of gold nanoparticles (AuNPs).	Protactinium	4-6	progestagen associated endometrial protein	Homo sapiens	19-28
29961324-3	2018	The PA nanoprobes (Au-H1/PEG and Au-H2/PEG) were constructed by linking poly(ethylene glycol) (PEG) and two hairpin DNA strands (H1 and H2, respectively) to the surface of gold nanoparticles (AuNPs).	Protactinium	4-6	progestagen associated endometrial protein	Homo sapiens	33-42
29961324-4	2018	In the presence of miR-155, the PA nanoprobes self-assembled into Au aggregates via HCR between H1, H2, and miR-155.	Protactinium	32-34	microRNA 155	Homo sapiens	19-26
29961324-4	2018	In the presence of miR-155, the PA nanoprobes self-assembled into Au aggregates via HCR between H1, H2, and miR-155.	Protactinium	32-34	microRNA 155	Homo sapiens	108-115
29961324-10	2018	By virtue of these advantages, the PA nanoprobes may provide a powerful platform for in situ detection of miR-155 and thus real-time monitoring of tumorigenesis and drug response in breast cancer.	Protactinium	35-37	microRNA 155	Homo sapiens	106-113
29543503-7	2018	We demonstrate [CGRP]-dependent hyperpolarization of ECs for the first time while validating freshly isolated PA endothelial tubes as an experimental model.	Protactinium	110-112	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	16-20
30147118-9	2018	We consider these findings in conjunction with previous research investigating PA methods and concluded that R-PA tends to offer somewhat stronger results.	Protactinium	79-81	replication protein A1	Homo sapiens	109-113
29215735-5	2018	GAA activity, measured on dried blood spot (DBS) in all patients inversely correlated with number of PAS-positive lymphocytes.	Protactinium	101-104	alpha glucosidase	Homo sapiens	0-3
29215735-9	2018	ROC curve assessment of PAS-positive lymphocytes disclosed 100% of sensitivity and 94% of specificity in recognizing both compound heterozygous and heterozygous GAA carriers.	Protactinium	24-27	alpha glucosidase	Homo sapiens	161-164
29899096-7	2018	Using reverse genetics, we discovered fitness was restored in virus rPB2-MA9/PA-D479N by a combination of PA-D479N and PB2-E158G amino acid mutations and PB2 noncoding mutations C1161T and C1977T.	Protactinium	77-79	RNA polymerase II subunit B	Rattus norvegicus	68-72
29899096-7	2018	Using reverse genetics, we discovered fitness was restored in virus rPB2-MA9/PA-D479N by a combination of PA-D479N and PB2-E158G amino acid mutations and PB2 noncoding mutations C1161T and C1977T.	Protactinium	77-79	RNA polymerase II subunit B	Rattus norvegicus	69-72
29899096-7	2018	Using reverse genetics, we discovered fitness was restored in virus rPB2-MA9/PA-D479N by a combination of PA-D479N and PB2-E158G amino acid mutations and PB2 noncoding mutations C1161T and C1977T.	Protactinium	77-79	RNA polymerase II subunit B	Rattus norvegicus	119-122
30012999-6	2018	Rheological behavior of LA-RG was found to be a pseudoplastic flow with thixotropy with viscosity of approximately 0.007 Pas.	Protactinium	121-124	Rho guanine nucleotide exchange factor 12	Bos taurus	24-29
29664418-7	2018	Consequently, tip-mediated mechanical forces can provide an effective means of altering nanofiber integrity and visualizing the self-recovery of PA assemblies.	Protactinium	145-147	TOR signaling pathway regulator	Homo sapiens	14-17
29770392-4	2018	A high-affinity NGF-binding sequence was identified by phage display and combined with a beta-sheet forming motif to produce a self-assembling PA molecule.	Protactinium	143-145	nerve growth factor	Rattus norvegicus	16-19
30119490-2	2018	For the back-to-back case, PA on an ASE-loaded signal yielded a receiver sensitivity penalty of   14.5 dB at the ITU-T G.975.1.I3 FEC threshold of 3.5 x 10-3, relative to matched-filter reception theory.	Protactinium	27-29	arylsulfatase L	Homo sapiens	36-39
29799029-4	2018	While tenascin-C mimetic PA nanofibers significantly increased the length and number of neurites produced by PC12 cells on 2D cell culture, more extensive neurite outgrowth was observed in the 3D gel environment.	Protactinium	25-27	tenascin C	Rattus norvegicus	6-16
29718758-3	2018	Hence, we hypothesized that activation of either one, or both JNK isoforms regulates PA remodeling in PH.	Protactinium	85-87	mitogen-activated protein kinase 8	Homo sapiens	62-65
28990416-4	2018	In addition, PA subjects showed lower levels of urinary isoprostanes, a marker of reactive oxygen species (ROS) production, and lower serum levels of sNox2-dp, a validated assay to measure Nox2 activity, one of the most important enzymes producing ROS in the blood cells.	Protactinium	13-15	cytochrome b-245 beta chain	Homo sapiens	151-155
29718758-11	2018	Our findings suggest that JNK2 participates in PA remodeling (but likely not in vasoconstriction) in murine hypoxic PH and that modulating JNK2 actions might quell vascular abnormalities and limit the course of PH.	Protactinium	47-49	mitogen-activated protein kinase 9	Mus musculus	26-30
30109002-3	2018	Here, we report the design, synthesis and binding of a peptidic-aminoglycoside (PA) based chemical library against pre-miR21 that led to the identification of a group of small molecules that bind to pre-miR21 with high affinities and antagonize miR-21 maturation and function, thereby reversing EMT.	Protactinium	80-82	microRNA 21	Homo sapiens	119-124
30109002-3	2018	Here, we report the design, synthesis and binding of a peptidic-aminoglycoside (PA) based chemical library against pre-miR21 that led to the identification of a group of small molecules that bind to pre-miR21 with high affinities and antagonize miR-21 maturation and function, thereby reversing EMT.	Protactinium	80-82	microRNA 21	Homo sapiens	203-208
30109002-3	2018	Here, we report the design, synthesis and binding of a peptidic-aminoglycoside (PA) based chemical library against pre-miR21 that led to the identification of a group of small molecules that bind to pre-miR21 with high affinities and antagonize miR-21 maturation and function, thereby reversing EMT.	Protactinium	80-82	microRNA 21	Homo sapiens	245-251
29622593-4	2018	However, the mechanism of TRPM8-induced PA relaxation is unclear.	Protactinium	40-42	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	26-31
29447981-3	2018	Mechanistic analysis also showed that ethyl acetate extracts of aerial parts and fruit of PA (PAG-EA and PAF-EA) enhanced glucose transporter 4 expression and function as well as enhanced insulin sensitivity by inhibiting the expression of cytochrome P450-2E1 (CYP2E1) mRNA and protein.	Protactinium	90-92	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	261-267
29938208-9	2018	PA size was independently associated with mPAP (p &lt; 0.001) and BSA (p = 0.001), but not with forced vital capacity % predicted (p = 0.597), Transfer factor of the lungs for carbon monoxide (TLCO) % predicted (p = 0.321) or the presence of ILD on CT (p = 0.905).	Protactinium	0-2	phospholipid phosphatase 1	Mus musculus	42-46
29164820-3	2018	METHODS &amp; RESULTS: HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFalpha, IL1beta and IL6).	Protactinium	63-65	superoxide dismutase 1	Homo sapiens	138-142
29164820-3	2018	METHODS &amp; RESULTS: HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFalpha, IL1beta and IL6).	Protactinium	63-65	superoxide dismutase 2	Homo sapiens	144-148
29164820-3	2018	METHODS &amp; RESULTS: HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFalpha, IL1beta and IL6).	Protactinium	63-65	catalase	Homo sapiens	177-185
29164820-3	2018	METHODS &amp; RESULTS: HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFalpha, IL1beta and IL6).	Protactinium	63-65	tumor necrosis factor	Homo sapiens	237-245
29164820-3	2018	METHODS &amp; RESULTS: HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFalpha, IL1beta and IL6).	Protactinium	63-65	interleukin 1 beta	Homo sapiens	247-254
29164820-3	2018	METHODS &amp; RESULTS: HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFalpha, IL1beta and IL6).	Protactinium	63-65	interleukin 6	Homo sapiens	259-262
29440315-5	2018	METHODS AND RESULTS: JAK2 expression was increased in pulmonary arteries (PAs) from IPF (n=10; 1.93-fold; P=0.0011) and IPF+PH (n=9; 2.65-fold; P&lt;0.0001) compared with PA from control subjects (n=10).	Protactinium	74-76	Janus kinase 2	Homo sapiens	21-25
29768216-5	2018	Co-localization studies revealed the enrichment of pA+ RNA foci with "pA-tail exosome targeting (PAXT) connection" components MTR4, ZFC3H1, and PABPN1 but no overlap with known nuclear structures such as Cajal bodies, speckles, paraspeckles, or nucleoli.	Protactinium	51-54	Mtr4 exosome RNA helicase	Homo sapiens	126-130
29768216-5	2018	Co-localization studies revealed the enrichment of pA+ RNA foci with "pA-tail exosome targeting (PAXT) connection" components MTR4, ZFC3H1, and PABPN1 but no overlap with known nuclear structures such as Cajal bodies, speckles, paraspeckles, or nucleoli.	Protactinium	51-54	zinc finger C3H1-type containing	Homo sapiens	132-138
29768216-5	2018	Co-localization studies revealed the enrichment of pA+ RNA foci with "pA-tail exosome targeting (PAXT) connection" components MTR4, ZFC3H1, and PABPN1 but no overlap with known nuclear structures such as Cajal bodies, speckles, paraspeckles, or nucleoli.	Protactinium	51-54	poly(A) binding protein nuclear 1	Homo sapiens	144-150
29563290-6	2018	PB1-F2 binds to HCLS1-associated protein X1 (HAX-1), a recently identified host restriction factor of the PA subunit of IAV polymerase complexes.	Protactinium	106-108	submaxillary gland androgen regulated protein 3A	Homo sapiens	0-3
29563290-6	2018	PB1-F2 binds to HCLS1-associated protein X1 (HAX-1), a recently identified host restriction factor of the PA subunit of IAV polymerase complexes.	Protactinium	106-108	HCLS1 associated protein X-1	Homo sapiens	16-43
29563290-6	2018	PB1-F2 binds to HCLS1-associated protein X1 (HAX-1), a recently identified host restriction factor of the PA subunit of IAV polymerase complexes.	Protactinium	106-108	HCLS1 associated protein X-1	Homo sapiens	45-50
29563290-8	2018	We also showed HAX-1 sensitivity for PAs of A/Brevig Mission/1/1918 (H1N1) and A/Shanghai/1/2013 (H7N9), two avian-origin zoonotic IAV.	Protactinium	37-40	HCLS1 associated protein X-1	Homo sapiens	15-20
29625202-4	2018	Using this strategy combined with cryo-EM 3D reconstruction, we were able to visualize the characteristic NZ-1 Fab density attached to the PA tag inserted into a surface-exposed loop in the middle of the sequence of CCT6 subunit present in the Saccharomyces cerevisiae group II chaperonin TRiC/CCT.	Protactinium	139-141	chaperonin-containing T-complex subunit CCT6	Saccharomyces cerevisiae S288C	216-220
30182050-9	2018	In IL10-/- mice, increased PA caused a consistent impairment of the intestinal barrier associated with inflammatory activation in the large intestinal tissue.	Protactinium	27-29	interleukin 10	Mus musculus	3-7
30182050-10	2018	In the long term, the vancomycin/metronidazole-induced lasting increase in PA aggravated colitis development in IL10-/- mice.	Protactinium	75-77	interleukin 10	Mus musculus	112-116
29440315-8	2018	JAK2 inhibition induced small PA relaxation in precision-cut lung slice experiments.	Protactinium	30-32	Janus kinase 2	Homo sapiens	0-4
29440315-13	2018	CONCLUSIONS: JAK2 participates in PA remodelling and tension and may be an attractive target to treat IPF associated to PH.	Protactinium	34-36	Janus kinase 2	Homo sapiens	13-17
29247621-11	2018	CONCLUSIONS: We have concluded that all cases of PA that present with histologic overlap with basal cell carcinoma, especially those from incisional biopsies, those that appear significantly infiltrative, and those that appear ulcerated and/or demonstrate recurrence should be evaluated with Ber-EP4 to rule out IOBCC.	Protactinium	49-51	prostaglandin E receptor 4	Homo sapiens	296-299
29867845-6	2018	Comparative analysis of the interactome of PA, PA-N155, and PA-N182 identified UBA52 as a conserved host factor that interacted with all three viral proteins.	Protactinium	43-45	ubiquitin A-52 residue ribosomal protein fusion product 1	Homo sapiens	79-84
28933316-9	2018	Using the newly developed PA-Akt probe, endogenous Akt was activated easily, transiently, and repeatedly.	Protactinium	26-28	AKT serine/threonine kinase 1	Homo sapiens	29-32
30603202-6	2018	In addition, we focus on the role of the PA imaging modality on real-time SLN identification and biopsy guidance.	Protactinium	41-43	sarcolipin	Homo sapiens	74-77
30603202-7	2018	In particular, PA-based hybrid imaging methods for precise SLN identification and efficient biopsy guidance are introduced, and their unique features, advantages, and disadvantages are discussed.	Protactinium	15-17	sarcolipin	Homo sapiens	59-62
28933316-9	2018	Using the newly developed PA-Akt probe, endogenous Akt was activated easily, transiently, and repeatedly.	Protactinium	26-28	AKT serine/threonine kinase 1	Homo sapiens	51-54
29686616-2	2018	In previous studies we have observed that the expression of different neurodegenerative markers increases in CA1 hippocampal area of 4-months-old male rats born by cesarean section and exposed for 19 min to PA.	Protactinium	207-209	carbonic anhydrase 1	Rattus norvegicus	109-112
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Protactinium	50-52	estrogen receptor 1	Homo sapiens	92-120
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Protactinium	50-52	insulin like growth factor 1 receptor	Homo sapiens	162-168
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Protactinium	50-52	AKT serine/threonine kinase 1	Homo sapiens	237-240
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Protactinium	50-52	glycogen synthase kinase 3 beta	Homo sapiens	241-272
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Protactinium	50-52	catenin beta 1	Homo sapiens	273-285
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Protactinium	50-52	BCL2 apoptosis regulator	Homo sapiens	323-328
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Protactinium	50-52	BCL2 associated X, apoptosis regulator	Homo sapiens	329-332
29686616-6	2018	Taking together, our data suggest that the interaction between ERalpha and IGF-IR, with the subsequent downstream activation, underlies the beneficial effects of estradiol observed in late treatment of PA.	Protactinium	202-204	estrogen receptor 1	Homo sapiens	63-70
29686616-6	2018	Taking together, our data suggest that the interaction between ERalpha and IGF-IR, with the subsequent downstream activation, underlies the beneficial effects of estradiol observed in late treatment of PA.	Protactinium	202-204	insulin like growth factor 1 receptor	Homo sapiens	75-81
29363240-14	2018	Our data showed that removal of extracellular magnesium suppressed vasoreactivity of PAs to both ET-1 and ACh.	Protactinium	85-88	endothelin 1	Mus musculus	97-101
29377789-1	2018	1,2-Dehydro-pyrrolizidine alkaloids (PA) and their N-oxides (PANO) exhibit acute and chronic toxic effects on the liver and other organs and therefore are a hazard for animal and human health.	Protactinium	37-39	proapoptotic nucleolar protein 1	Homo sapiens	61-65
29363240-15	2018	A high concentration of magnesium (4.8 mm) inhibited ET-1-induced vasoconstriction in endothelium-intact or endothelium-disrupted PAs of normoxic and CH-treated mice, and enhanced the ACh-induced production of NO in PAs of normoxic mice.	Protactinium	130-133	endothelin 1	Mus musculus	53-57
29422440-6	2018	The presence of alpha-amylase resistant PAS-positive material in skeletal muscle biopsy of patients with slowly progressive limb girdle muscle weakness should prompt the search for GYG1 mutations.	Protactinium	40-43	glycogenin 1	Homo sapiens	181-185
27723266-3	2018	In this study, we investigated the effects of TGF-beta1 on PA system of dental pulp cells and its signalling pathways.	Protactinium	59-61	transforming growth factor beta 1	Homo sapiens	46-55
29632531-3	2018	The lead PIC1 derivative, PA-dPEG24, was able to dose-dependently inhibit complement activation initiated by multiple types of immune complexes (IC), including C1-anti-C1q IC, limiting the generation of pro-inflammatory complement effectors, including C5a and membrane attack complex (sC5b-9).	Protactinium	26-28	small ubiquitin like modifier 1	Homo sapiens	9-13
29662433-10	2018	After 1 month of the PA insult, we observed neuronal nucleus degeneration in CA1 using electron microscopy.	Protactinium	21-23	carbonic anhydrase 1	Rattus norvegicus	77-80
29632531-3	2018	The lead PIC1 derivative, PA-dPEG24, was able to dose-dependently inhibit complement activation initiated by multiple types of immune complexes (IC), including C1-anti-C1q IC, limiting the generation of pro-inflammatory complement effectors, including C5a and membrane attack complex (sC5b-9).	Protactinium	26-28	complement C5a receptor 1	Homo sapiens	252-255
29092071-5	2018	AhR consists of the N-terminal bHLH domain containing NLS and NES, the middle PAS domain and the C-terminal transactivation domain.	Protactinium	78-81	aryl hydrocarbon receptor	Homo sapiens	0-3
29174667-3	2018	With the introduction of target PSA, the FA value was obviously decreased on account of the specific recognition between PSA and PA which resulted in the detachment of PA from the surface of MOG.	Protactinium	129-131	myelin oligodendrocyte glycoprotein	Homo sapiens	191-194
29164305-6	2018	Combining these observations with our structural investigations using a homology model of the AHR-PAS B domain, we suggest a dual role of histidine 291: (1) a major role for shaping the ligand binding site including direct interactions with ligands and, (2) an essential role for the conformational dynamics of a PAS B loop, which most likely influences the association of the AHR with the AHR nuclear translocator through interference with their protein-protein interface.	Protactinium	98-101	aryl hydrocarbon receptor	Homo sapiens	94-97
29092071-10	2018	We found that not only the PAS domain but also the bHLH domain bound to HSP90.	Protactinium	27-30	heat shock protein 90 alpha family class A member 1	Homo sapiens	72-77
29520135-15	2018	Multiple logistic analyses have indicated that bronchiectasis is an independent risk factor for high PA:A ratios in COPD patients (OR =3.707; 95% CI =1.888-7.278; P&lt;0.001).	Protactinium	101-103	COPD	Homo sapiens	116-120
29221641-9	2018	In outcome-models including further well-established histo-pathological factors, p53-expression dichotomized at 20% independently impacted DP (HR = 4.13; P = 0.004) and CSM (HR = 3.74; P = 0.033), while no significant PA gain was achieved.	Protactinium	218-220	tumor protein p53	Homo sapiens	81-84
29489822-9	2018	Among quaternary structure oscillations revealed by Molecular Dynamics simulations, the hinge-bending motion of the ARNT PAS-B domain around the flexible PAS-A/PAS-B linker supports a general model for ARNT dimerization in different heterodimers.	Protactinium	121-124	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	116-120
29489822-9	2018	Among quaternary structure oscillations revealed by Molecular Dynamics simulations, the hinge-bending motion of the ARNT PAS-B domain around the flexible PAS-A/PAS-B linker supports a general model for ARNT dimerization in different heterodimers.	Protactinium	121-124	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	202-206
29489822-9	2018	Among quaternary structure oscillations revealed by Molecular Dynamics simulations, the hinge-bending motion of the ARNT PAS-B domain around the flexible PAS-A/PAS-B linker supports a general model for ARNT dimerization in different heterodimers.	Protactinium	154-157	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	116-120
29489822-9	2018	Among quaternary structure oscillations revealed by Molecular Dynamics simulations, the hinge-bending motion of the ARNT PAS-B domain around the flexible PAS-A/PAS-B linker supports a general model for ARNT dimerization in different heterodimers.	Protactinium	154-157	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	202-206
29291794-4	2018	Under the action of UDG, the uracil base in the PA probe could be removed to generate an apyrimidinic (AP) site.	Protactinium	48-50	uracil DNA glycosylase	Homo sapiens	20-23
29170031-6	2018	We confirmed that the purified PA-tagged integrin ectodomain fragments can form a stable complex with NZ-1 Fab.	Protactinium	31-33	FA complementation group B	Homo sapiens	107-110
29278874-2	2018	METHODS: CD34-PAS staining was carried out to observe VM formation, and immunohistochemistry was used to determine the expression levels of Beclin-1, HIF-1alpha, VEGF and MMP2 in 105 patients with primary glioma.	Protactinium	14-17	CD34 molecule	Homo sapiens	9-13
28815778-7	2018	With PAS stain, we found that PGCs (primordial germ cells) was significantly decreased after inhibiting MAPK8.	Protactinium	5-8	mitogen-activated protein kinase 8	Gallus gallus	104-109
28079009-5	2018	A recently identified novel transacetylase activity of CRT adds a new dimension to its multi-faceted involvement in cancer by virtue of polyphenolic acetates (PA): CRT transacetylase (CRTase) system which results in hyperacetylation of target proteins, thereby mimicking the effects of Histone deacetylase inhibitors (HDACi).	Protactinium	159-161	calreticulin	Homo sapiens	55-58
28079009-5	2018	A recently identified novel transacetylase activity of CRT adds a new dimension to its multi-faceted involvement in cancer by virtue of polyphenolic acetates (PA): CRT transacetylase (CRTase) system which results in hyperacetylation of target proteins, thereby mimicking the effects of Histone deacetylase inhibitors (HDACi).	Protactinium	159-161	calreticulin	Homo sapiens	164-167
29263147-5	2018	In PA cells, Phe increased (P &lt; 0.05) the alpha-amylase secretion and mRNA expression, the phosphorylation of ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4EBP1).	Protactinium	3-5	alpha amylase	Bos taurus	45-58
28844085-5	2018	PA induces overactivation of a number of sentinel proteins, including hypoxia-induced factor-1alpha (HIF-1alpha) and the genome-protecting poly(ADP-ribose) polymerase-1 (PARP-1).	Protactinium	0-2	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	101-111
28844085-5	2018	PA induces overactivation of a number of sentinel proteins, including hypoxia-induced factor-1alpha (HIF-1alpha) and the genome-protecting poly(ADP-ribose) polymerase-1 (PARP-1).	Protactinium	0-2	poly (ADP-ribose) polymerase 1	Rattus norvegicus	139-168
28844085-5	2018	PA induces overactivation of a number of sentinel proteins, including hypoxia-induced factor-1alpha (HIF-1alpha) and the genome-protecting poly(ADP-ribose) polymerase-1 (PARP-1).	Protactinium	0-2	poly (ADP-ribose) polymerase 1	Rattus norvegicus	170-176
30372679-5	2018	RESULTS: In healthy subjects, ccPAS - 5 protocol induced the expected long-lasting increase of MEP amplitude compatible with LTP-like cortical plasticity while PAS +5 protocol induced the opposite effect.	Protactinium	32-35	neurolysin	Homo sapiens	95-98
29263145-1	2018	Objective: The present study aimed to investigate the efficacy and safety of Reteplase (rPA) and Alteplase (rt-PA) in the treatment of hyper-acute cerebral infarction (CI).Methods: Six hundred and eleven patients with hyper-acute CI selected from September 2014 to September 2016 were assigned into the aspirin, rt-PA, rPA, rt-PA + aspirin, and rPA + aspirin groups based on their willingness.	Protactinium	89-91	plasminogen activator, tissue type	Homo sapiens	77-86
29260827-5	2018	Because of their good dispersibility, Cu-Ag2S/PVP NPs passively accumulate within tumors via the enhanced permeability and retention effect, which can be confirmed by PA imaging, photothermal performance, and biodistribution in vivo.	Protactinium	167-169	angiotensin II receptor type 1	Homo sapiens	41-45
29274782-1	2018	The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor and member of the basic helix-loop-helix-PAS family.	Protactinium	120-123	aryl hydrocarbon receptor	Homo sapiens	4-29
29274782-1	2018	The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor and member of the basic helix-loop-helix-PAS family.	Protactinium	120-123	aryl hydrocarbon receptor	Homo sapiens	31-34
29152826-0	2018	Synthesis and Reactivity of Nickel-Stabilised mu2 :eta2 ,eta2 -P2 , As2 and PAs Units.	Protactinium	76-79	adaptor related protein complex 1 subunit mu 2	Homo sapiens	46-49
29326146-7	2018	Between 82% and 97% of individuals were enrolled in plans implementing PA for PCSK9is (depending on insurance segment), and one third to two thirds of these enrollees faced PAs restricting PCSK9i prescribing to a specialist.	Protactinium	173-176	proprotein convertase subtilisin/kexin type 9	Homo sapiens	189-194
29679319-8	2018	The enzyme responsiveness of PA assemblies is described with respect to their degradation by MMP-2.	Protactinium	29-31	matrix metallopeptidase 2	Homo sapiens	93-98
30023598-4	2017	To this end, we report efficient intracellular delivery of beta-gal via arginase-responsive dextran sulfate/poly-l-arginine polymer capsules (DS/PA capsules).	Protactinium	145-147	galactosidase, beta 1	Mus musculus	59-67
29949806-6	2018	RESULTS: Compared to controls, the relatively hyperandrogenic PA females exhibited ~100% increase (p = 0.037) in LH pulse frequency, positive correlation of LH pulse amplitude (p = 0.017) with androstenedione, ~100% greater increase (p = 0.034) in acute (0-10 min) LH responses to exogenous GnRH, and an absence (p = 0.008) of modest LH elevation following acute progesterone receptor blockade suggestive of diminished progesterone negative feedback.	Protactinium	62-64	gonadotropin releasing hormone 1	Macaca mulatta	291-295
28834646-8	2018	Hypoxia induces an elevation of PA level both in Wt and pldzeta1, while the PA level is unchanged in pldzeta2.	Protactinium	32-34	phospholipase D P1	Arabidopsis thaliana	56-64
28834646-9	2018	Thus, it is likely that AtPLDzeta2 is involved in PA production by a calcium signaling pathway, while AtPLDzeta1 is more important in ROS signaling.	Protactinium	50-52	phospholipase D P2	Arabidopsis thaliana	24-34
30134248-9	2018	Also, PA associated with maternal HFD induces miR124 upregulation and miR132 downregulation relative to PA only.	Protactinium	6-8	microRNA 132	Rattus norvegicus	70-76
29297305-8	2017	Our PA/CPA models complied with 89 known NS3 protease inhibitors.	Protactinium	4-6	KRAS proto-oncogene, GTPase	Homo sapiens	41-44
29274231-3	2017	A core CPSF complex comprising CPSF160, WDR33, CPSF30 and Fip1 is sufficient for AAUAAA motif recognition, yet the molecular interactions underpinning its assembly and mechanism of PAS recognition are not understood.	Protactinium	181-184	factor interacting with PAPOLA and CPSF1	Homo sapiens	58-62
29203888-3	2017	Despite the availability of an X-ray structure of the PAS-B domain/ Leu794-Gly814-STAT6 complex, the mechanistic details of this interaction are still poorly understood.	Protactinium	54-57	signal transducer and activator of transcription 6	Homo sapiens	82-87
29024093-3	2017	Computations of actinide dioxide cations AnO2+ for An=Pa to Lr reveal an unexpected minimum for D[O-(CmO+ )].	Protactinium	54-56	anoctamin 2	Homo sapiens	41-45
29028325-6	2017	Using thrombin as a model, a relationship was established between the thrombin concentrations and the PA ratio, with a dynamic range of 0-1000 nM and a limit of detection of 112 nM.	Protactinium	102-104	coagulation factor II	Mus musculus	6-14
29028325-6	2017	Using thrombin as a model, a relationship was established between the thrombin concentrations and the PA ratio, with a dynamic range of 0-1000 nM and a limit of detection of 112 nM.	Protactinium	102-104	coagulation factor II	Mus musculus	70-78
29028325-7	2017	Finally, in vivo PA imaging studies showed that the PA ratio increased significantly 45 min after injection of thrombin but not with injection of PBS as a vehicle control, demonstrating the first aptamer-based activatable PA probe for advanced molecular imaging in living mice.	Protactinium	17-19	coagulation factor II	Mus musculus	111-119
29028325-7	2017	Finally, in vivo PA imaging studies showed that the PA ratio increased significantly 45 min after injection of thrombin but not with injection of PBS as a vehicle control, demonstrating the first aptamer-based activatable PA probe for advanced molecular imaging in living mice.	Protactinium	52-54	coagulation factor II	Mus musculus	111-119
29028325-7	2017	Finally, in vivo PA imaging studies showed that the PA ratio increased significantly 45 min after injection of thrombin but not with injection of PBS as a vehicle control, demonstrating the first aptamer-based activatable PA probe for advanced molecular imaging in living mice.	Protactinium	52-54	coagulation factor II	Mus musculus	111-119
29568455-3	2017	The obtained PDA/mCaP H-JNPs were further selectively functionalized with indocyanine green (ICG) and methoxy-poly(ethylene glycol)thiol (PEG-SH) on PDA domains to achieve a superior photoacoustic (PA) imaging capability and stability, while the other mCaP sides with hollow cavities served as storage spaces and passages for the anti-cancer drug, doxorubicin (DOX).	Protactinium	198-200	non-SMC condensin I complex, subunit H	Mus musculus	17-23
29113763-4	2017	In silico docking performed on the beta5 and beta1 subunits bearing the respective ChT-L and PA catalytic sites showed features common to poses associated with active compounds.	Protactinium	93-95	adaptor related protein complex 5 subunit beta 1	Homo sapiens	35-50
29568455-4	2017	The resultant PEG-ICG-PDA/mCaP H-JNPs possess excellent biocompatibility, a competent drug loading capability, high photothermal conversion efficiency, strong near-infrared (NIR) absorbance, and pH/NIR dual-responsive properties, enabling the H-JNPs to be applied for PA imaging-guided synergistic cancer chemo-phototherapy in vitro and in vivo.	Protactinium	268-270	non-SMC condensin I complex, subunit H	Mus musculus	26-32
29102248-11	2017	Finally, the Pnoc knockout mice exhibited enhanced PA retention latencies compared to the wild type mice.	Protactinium	51-53	prepronociceptin	Mus musculus	13-17
27761944-5	2017	Moreover, PGC-1alpha (p &lt; 0.01) and MEF2c (p &lt; 0.05) mRNA levels were higher in the piglets from the LA treatment group than in those from the PA treatment group.	Protactinium	149-151	myocyte enhancer factor 2C	Homo sapiens	39-44
28782183-7	2017	Following the P. gingivalis infection, PU and PA significantly promoted HGF proliferation and metabolic activity.	Protactinium	46-48	hepatocyte growth factor	Homo sapiens	72-75
28825193-12	2017	p-SMAD2/3 was strongly expressed in SA and DP but sparsely localized in PA.	Protactinium	72-74	SMAD family member 2	Mus musculus	2-9
28975490-6	2017	PA made a significant contribution to HRR-1 as well (p &lt; .05).	Protactinium	0-2	nuclear receptor subfamily 1 group H member 4	Homo sapiens	38-43
29158525-6	2017	PLGA-GO group with PA pretreatment showed promising outcomes in terms of the expression of ALP, OPN, and calcium content, thus enhanced the repair of bone defect.	Protactinium	19-21	secreted phosphoprotein 1	Rattus norvegicus	96-99
28772134-6	2017	RESULTS: The majority of MECs, ACCs and PLGAs showed high CXCR4 and CXCR7 expression, whereas most PAs showed high CXCR4 but low CXCR7 expression.	Protactinium	99-102	C-X-C motif chemokine receptor 4	Homo sapiens	115-120
28972000-6	2017	We constructed an extracellular matrix-mimicking PA nanomatrix gel (PA-RGDS) by incorporating the cell adhesive ligand Arg-Gly-Asp-Ser (RGDS) and a matrix metalloproteinase-2-degradable sequence.	Protactinium	49-51	ral guanine nucleotide dissociation stimulator	Homo sapiens	71-75
28972000-6	2017	We constructed an extracellular matrix-mimicking PA nanomatrix gel (PA-RGDS) by incorporating the cell adhesive ligand Arg-Gly-Asp-Ser (RGDS) and a matrix metalloproteinase-2-degradable sequence.	Protactinium	49-51	ral guanine nucleotide dissociation stimulator	Homo sapiens	136-140
28972000-6	2017	We constructed an extracellular matrix-mimicking PA nanomatrix gel (PA-RGDS) by incorporating the cell adhesive ligand Arg-Gly-Asp-Ser (RGDS) and a matrix metalloproteinase-2-degradable sequence.	Protactinium	49-51	matrix metallopeptidase 2	Homo sapiens	148-174
28972000-13	2017	Furthermore, this study demonstrated that a biocompatible PA-RGDS nanomatrix gel substantially improved long-term survival of hPSC-ECs in an ischemic environment and improved neovascularization effects of hPSC-ECs via prolonged and unique angiogenic and vessel-forming properties.	Protactinium	58-60	ral guanine nucleotide dissociation stimulator	Homo sapiens	61-65
29118420-7	2017	In muscles from TFEB-treated mice we observed reduced PAS staining and improved ultrastructure, with reduced number and increased translucency of lysosomes, while total glycogen content remained unchanged.	Protactinium	54-57	transcription factor EB	Mus musculus	16-20
28772134-6	2017	RESULTS: The majority of MECs, ACCs and PLGAs showed high CXCR4 and CXCR7 expression, whereas most PAs showed high CXCR4 but low CXCR7 expression.	Protactinium	99-102	atypical chemokine receptor 3	Homo sapiens	129-134
28739531-6	2017	PA also induced the production of oxidant species (OS), and OS prevention nullified the capacity of PA to increase H/R damage and ASK1/JNK stimulation.	Protactinium	100-102	mitogen-activated protein kinase kinase kinase 5	Mus musculus	130-134
27707769-7	2017	Our novel findings suggest that cortical structures activated by PA and AP stimuli are differentially active during precision and power grip.	Protactinium	65-67	glutamate receptor interacting protein 1	Homo sapiens	136-140
28739531-6	2017	PA also induced the production of oxidant species (OS), and OS prevention nullified the capacity of PA to increase H/R damage and ASK1/JNK stimulation.	Protactinium	100-102	mitogen-activated protein kinase 8	Mus musculus	135-138
28739531-8	2017	In KC, PA directly activated ER stress, ASK1 and p38 MAPK and increased H/R damage.	Protactinium	7-9	mitogen-activated protein kinase kinase kinase 5	Mus musculus	40-44
28739531-8	2017	In KC, PA directly activated ER stress, ASK1 and p38 MAPK and increased H/R damage.	Protactinium	7-9	mitogen-activated protein kinase 14	Mus musculus	49-57
29285471-10	2017	Chi-square test found differences between PAs and Ca-ex-PAs regarding BRCA1/2 mutations in ductal cells and myoepithelial cells (P = 0.007, 0.000), respectively.	Protactinium	42-45	BRCA1 DNA repair associated	Homo sapiens	70-77
28776262-9	2017	Vaspin significantly attenuated MCT-induced rise in PA pressure, while it had no influence on impairment of relaxing function in IPA.	Protactinium	52-54	serpin family A member 12	Rattus norvegicus	0-6
27785753-7	2017	Cells were pretreated with melatonin (10 muM) for 1 h followed by with and without PA (100 muM) for 24 h. In the present study, our data has confirmed that PA markedly increased both intracellular reactive oxygen species and reactive nitrogen species levels.	Protactinium	156-158	latexin	Homo sapiens	41-44
27785753-7	2017	Cells were pretreated with melatonin (10 muM) for 1 h followed by with and without PA (100 muM) for 24 h. In the present study, our data has confirmed that PA markedly increased both intracellular reactive oxygen species and reactive nitrogen species levels.	Protactinium	156-158	latexin	Homo sapiens	91-94
28892609-5	2017	The CP3 NPs show a high PA signal to background ratio of 47 in U87 tumor-bearing mice, which is superior to other reported PA/PTT theranostic agents.	Protactinium	24-26	peroxiredoxin 6	Mus musculus	4-7
28797883-4	2017	Molecular modeling and kinetic studies revealed that compound 7f was a mixed-type inhibitor, which bond simultaneously to CAS and PAS of AChE, and it was also a competitive inhibitor, which occupied the active site of MAO-B.	Protactinium	130-133	acetylcholinesterase	Rattus norvegicus	137-141
28892609-5	2017	The CP3 NPs show a high PA signal to background ratio of 47 in U87 tumor-bearing mice, which is superior to other reported PA/PTT theranostic agents.	Protactinium	123-125	peroxiredoxin 6	Mus musculus	4-7
28880555-1	2017	The proton affinity (PA) on the oxygen atom in silanol and siloxane derivatives is enhanced by the formation of tetrel bonds with small Lewis bases [B   R3SiOH, B   R3SiOSiR3, B   R3SiOSiR3   B; B = H2O, CO, NH3, HCN, H2S; R = H, Me], as shown by MP2/jul-cc-pVTZ calculations.	Protactinium	21-23	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	213-216
28872298-7	2017	The selectivity of the SPME method toward mRNA was enhanced by functionalizing the PA sorbent with oligo dT20 using carbodiimide-based amide linker chemistry.	Protactinium	83-85	thioredoxin peroxidase 1	Drosophila melanogaster	105-109
28872298-8	2017	The oligo dT20-modified PA sorbent coating demonstrated superior extraction performance than the native PA sorbent coating with quantification cycle (Cq) values 33.74 +- 0.24 and 39, respectively.	Protactinium	24-26	thioredoxin peroxidase 1	Drosophila melanogaster	10-14
29041191-2	2017	The double dressed PA-four-wave mixing (PA-FWM) is the superposition of one PA-FWM process, two different PA-six-wave mixing (PA-SWM) processes (PA-SWM1 and PA-SWM2 with external dressing field 776nm and 795nm, respectively) and one PA-EWM process.	Protactinium	19-21	anaphase promoting complex subunit 13	Homo sapiens	148-152
29041191-2	2017	The double dressed PA-four-wave mixing (PA-FWM) is the superposition of one PA-FWM process, two different PA-six-wave mixing (PA-SWM) processes (PA-SWM1 and PA-SWM2 with external dressing field 776nm and 795nm, respectively) and one PA-EWM process.	Protactinium	40-42	anaphase promoting complex subunit 13	Homo sapiens	148-152
28802581-5	2017	Furthermore, PKM2 overexpression enhanced the effects of PA on the lipid accumulation, the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) and hepatic glucose uptake.	Protactinium	57-59	pyruvate kinase M1/2	Homo sapiens	13-17
28802581-6	2017	Intriguingly, PA-induced insulin resistance was suppressed following by the ablation of PKM2 in HepG2 cells.	Protactinium	14-16	insulin	Homo sapiens	25-32
28802581-6	2017	Intriguingly, PA-induced insulin resistance was suppressed following by the ablation of PKM2 in HepG2 cells.	Protactinium	14-16	pyruvate kinase M1/2	Homo sapiens	88-92
28880555-1	2017	The proton affinity (PA) on the oxygen atom in silanol and siloxane derivatives is enhanced by the formation of tetrel bonds with small Lewis bases [B   R3SiOH, B   R3SiOSiR3, B   R3SiOSiR3   B; B = H2O, CO, NH3, HCN, H2S; R = H, Me], as shown by MP2/jul-cc-pVTZ calculations.	Protactinium	21-23	tryptase pseudogene 1	Homo sapiens	247-250
28689116-7	2017	Based on this aggregation-induced "turn-on" PA signals, we noninvasively determine the ATG4B activity for monitoring autophagy of tumor in vivo.	Protactinium	44-46	autophagy related 4B, cysteine peptidase	Mus musculus	87-92
28771332-6	2017	To address these problems, we have constructed a PA platform consisting of cathepsin-B cleavable PAs in which a selective p53-based inhibitory peptide is cleaved from its lipid tail within endosomes, allowing for intracellular peptide accumulation and extracellular recycling of the lipid moiety.	Protactinium	49-51	cathepsin B	Homo sapiens	75-86
28662411-4	2017	PA was intra-tracheally administrated to ATF3 knock-out (KO) mice to establish ALI model.	Protactinium	0-2	activating transcription factor 3	Mus musculus	41-45
28662411-7	2017	Peritoneal macrophages were isolated from ATF3 KO mice and stimulated by PA.	Protactinium	73-75	activating transcription factor 3	Mus musculus	42-46
28662411-8	2017	PA increased the expression of ATF3 in the lung tissues in ATF3 wild type (WT) mice.	Protactinium	0-2	activating transcription factor 3	Mus musculus	31-35
28662411-8	2017	PA increased the expression of ATF3 in the lung tissues in ATF3 wild type (WT) mice.	Protactinium	0-2	activating transcription factor 3	Mus musculus	59-63
28662411-9	2017	ATF3 deficiency significantly increased the concentration of TNFalpha, IL-6 and IL-1beta in the supernatant of peritoneal macrophages, lung tissue and BALF after PA stimulation and also enhanced the activity of NF-kappaB.	Protactinium	162-164	activating transcription factor 3	Mus musculus	0-4
28662411-11	2017	The lung injury score and mortality were higher in ATF3 KO mice treated with PA.	Protactinium	77-79	activating transcription factor 3	Mus musculus	51-55
28662411-12	2017	Moreover, ATF3 was demonstrated to bind to LBP These finding suggest ATF3 protect mice against ALI induced by PA partly due to the binding to LBP.	Protactinium	110-112	activating transcription factor 3	Mus musculus	10-14
28662411-12	2017	Moreover, ATF3 was demonstrated to bind to LBP These finding suggest ATF3 protect mice against ALI induced by PA partly due to the binding to LBP.	Protactinium	110-112	lipopolysaccharide binding protein	Mus musculus	43-46
28662411-12	2017	Moreover, ATF3 was demonstrated to bind to LBP These finding suggest ATF3 protect mice against ALI induced by PA partly due to the binding to LBP.	Protactinium	110-112	activating transcription factor 3	Mus musculus	69-73
28662411-12	2017	Moreover, ATF3 was demonstrated to bind to LBP These finding suggest ATF3 protect mice against ALI induced by PA partly due to the binding to LBP.	Protactinium	110-112	lipopolysaccharide binding protein	Mus musculus	142-145
28708509-10	2017	The present study suggests that supplementation of GDF8 during IVM synergistically improved the developmental potential of IVF- and PA-derived porcine embryos by reducing the intracellular ROS level in oocytes by altering the transcription of specific genes and increasing the phosphorylation of p38 MAPK during IVM.	Protactinium	132-134	myostatin	Homo sapiens	51-55
28951368-5	2017	RESULTS: beta-catenin expression was significantly higher in LSTs than in Pas (P&lt;0.05).	Protactinium	74-77	catenin beta 1	Homo sapiens	9-21
28683158-1	2017	A one-dimensional nanostructure with sp3 -hybridized carbon atoms, namely, poly[5]asterane (PA), is predicted by means of electronic structure calculations and reactive molecular dynamics simulations.	Protactinium	92-94	Sp3 transcription factor	Homo sapiens	37-40
28771332-6	2017	To address these problems, we have constructed a PA platform consisting of cathepsin-B cleavable PAs in which a selective p53-based inhibitory peptide is cleaved from its lipid tail within endosomes, allowing for intracellular peptide accumulation and extracellular recycling of the lipid moiety.	Protactinium	49-51	tumor protein p53	Homo sapiens	122-125
31289747-7	2017	More insulin-producing beta cells were observed when islets were PA-encapsulated than control islets with the differentiated U937 cells for 7 days compared to the bare islets.	Protactinium	65-67	insulin	Homo sapiens	5-12
31289747-10	2017	The PA-encapsulated islets showed greater insulin secretion response to glucose stimulation than the bare islets with the differentiated U937 cells after 3 and 7 days.	Protactinium	4-6	insulin	Homo sapiens	42-49
29088723-9	2017	We provide evidence that ATGs transcripts from distal PAS retain in the nucleus and thus have reduced translation efficiency in cells with reduced PABPN1.	Protactinium	54-57	poly(A) binding protein nuclear 1	Homo sapiens	147-153
28955326-5	2017	In addition, PA inhibited IFN-beta induction by RIG-I, melanoma differentiation-associated gene 5, mitochondria antiviral signaling protein, TANK-binding kinase 1, inhibitor of nuclear factor kappa-B kinase-epsilon (IKKepsilon), and IRF3 overexpression.	Protactinium	13-15	interferon beta 1	Homo sapiens	26-34
28955326-5	2017	In addition, PA inhibited IFN-beta induction by RIG-I, melanoma differentiation-associated gene 5, mitochondria antiviral signaling protein, TANK-binding kinase 1, inhibitor of nuclear factor kappa-B kinase-epsilon (IKKepsilon), and IRF3 overexpression.	Protactinium	13-15	DExD/H-box helicase 58	Homo sapiens	48-53
28955326-5	2017	In addition, PA inhibited IFN-beta induction by RIG-I, melanoma differentiation-associated gene 5, mitochondria antiviral signaling protein, TANK-binding kinase 1, inhibitor of nuclear factor kappa-B kinase-epsilon (IKKepsilon), and IRF3 overexpression.	Protactinium	13-15	interferon induced with helicase C domain 1	Homo sapiens	55-139
28955326-5	2017	In addition, PA inhibited IFN-beta induction by RIG-I, melanoma differentiation-associated gene 5, mitochondria antiviral signaling protein, TANK-binding kinase 1, inhibitor of nuclear factor kappa-B kinase-epsilon (IKKepsilon), and IRF3 overexpression.	Protactinium	13-15	TANK binding kinase 1	Homo sapiens	141-214
28955326-5	2017	In addition, PA inhibited IFN-beta induction by RIG-I, melanoma differentiation-associated gene 5, mitochondria antiviral signaling protein, TANK-binding kinase 1, inhibitor of nuclear factor kappa-B kinase-epsilon (IKKepsilon), and IRF3 overexpression.	Protactinium	13-15	inhibitor of nuclear factor kappa B kinase subunit epsilon	Homo sapiens	216-226
28955326-5	2017	In addition, PA inhibited IFN-beta induction by RIG-I, melanoma differentiation-associated gene 5, mitochondria antiviral signaling protein, TANK-binding kinase 1, inhibitor of nuclear factor kappa-B kinase-epsilon (IKKepsilon), and IRF3 overexpression.	Protactinium	13-15	interferon regulatory factor 3	Homo sapiens	233-237
28955326-6	2017	Furthermore, PA interacted with IRF3 to block its activation.	Protactinium	13-15	interferon regulatory factor 3	Homo sapiens	32-36
28955326-7	2017	The N-terminal endonuclease activity of PA was responsible for its interaction with IRF3 and inhibition of the IFN-beta signaling pathway.	Protactinium	40-42	interferon regulatory factor 3	Homo sapiens	84-88
28955326-7	2017	The N-terminal endonuclease activity of PA was responsible for its interaction with IRF3 and inhibition of the IFN-beta signaling pathway.	Protactinium	40-42	interferon beta 1	Homo sapiens	111-119
28989649-4	2017	These dyes exhibit intense NIR absorption, a lack of fluorescence emission, and PA sensitivity in concentrations below 3 nmol mL-1.	Protactinium	80-82	L1 cell adhesion molecule	Mus musculus	126-130
28741111-4	2017	The binding of the aptamer to the target PSA could induce a rigid aptamer conformation, resulting in the release of the PA away from the surface of SiO2 NPs.	Protactinium	120-122	kallikrein related peptidase 3	Homo sapiens	41-44
28570763-2	2017	The structural arrangement of the enzyme, which features a narrow gorge that separates the catalytic and peripheral anionic subsites (CAS and PAS, respectively), inspired the development of bivalent ligands that are able to bind and block the catalytic activity of the CAS as well as the role of the PAS in beta amyloid (Abeta) fibrillogenesis.	Protactinium	142-145	BCAR1 scaffold protein, Cas family member	Homo sapiens	269-272
28570763-2	2017	The structural arrangement of the enzyme, which features a narrow gorge that separates the catalytic and peripheral anionic subsites (CAS and PAS, respectively), inspired the development of bivalent ligands that are able to bind and block the catalytic activity of the CAS as well as the role of the PAS in beta amyloid (Abeta) fibrillogenesis.	Protactinium	300-303	BCAR1 scaffold protein, Cas family member	Homo sapiens	134-137
28570763-2	2017	The structural arrangement of the enzyme, which features a narrow gorge that separates the catalytic and peripheral anionic subsites (CAS and PAS, respectively), inspired the development of bivalent ligands that are able to bind and block the catalytic activity of the CAS as well as the role of the PAS in beta amyloid (Abeta) fibrillogenesis.	Protactinium	300-303	BCAR1 scaffold protein, Cas family member	Homo sapiens	269-272
28699213-7	2017	A kinetic study revealed them to be mixed-type inhibitors, binding with both the CAS and PAS sites of AChE.	Protactinium	89-92	acetylcholinesterase (Cartwright blood group)	Homo sapiens	102-106
28819200-8	2017	Fibronectin and type I collagen mRNA and protein expressions increased significantly in the kidneys of diabetic mice: PA administration abrogated these increases significantly.	Protactinium	118-120	fibronectin 1	Mus musculus	0-11
28793052-0	2017	Cordyceps sinensis promotes immune regulation and enhances bacteriostatic activity of PA-824 via IL-10 in Mycobacterium tuberculosis disease.	Protactinium	86-88	interleukin 10	Mus musculus	97-102
28649092-2	2017	The aim of this study was to use a high-throughput screening method to identify molecular pathways that may be playing a significant and consistent role in PA. RNA profiling using microarrays on eight local PAs identified the aryl hydrocarbon receptor (AHR) signalling pathway as a key canonical pathway downregulated in all PA types.	Protactinium	207-210	aryl hydrocarbon receptor	Rattus norvegicus	226-251
28649092-2	2017	The aim of this study was to use a high-throughput screening method to identify molecular pathways that may be playing a significant and consistent role in PA. RNA profiling using microarrays on eight local PAs identified the aryl hydrocarbon receptor (AHR) signalling pathway as a key canonical pathway downregulated in all PA types.	Protactinium	207-210	aryl hydrocarbon receptor	Rattus norvegicus	253-256
28711067-10	2017	RESULTS: PA-6 docking in the V93I/D172N double mutant homology model of KIR2.1 demonstrated that mutations and drug-binding site are &gt;30 A apart.	Protactinium	9-11	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	72-78
29056948-7	2017	Analysis by subgroups of medications showed cardiac therapy medications (C01), beta blocking agents (C07), and renin-angiotensin system agents (C09) were associated with lower PAS-Cog scores (better cognition) and lower dementia diagnosis probability.	Protactinium	176-179	renin	Homo sapiens	111-116
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Protactinium	41-43	actin alpha 2, smooth muscle, aorta	Mus musculus	140-165
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Protactinium	41-43	actin alpha 2, smooth muscle, aorta	Mus musculus	167-176
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Protactinium	41-43	interleukin 6	Mus musculus	219-232
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Protactinium	41-43	interleukin 6	Mus musculus	234-238
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Protactinium	41-43	tumor necrosis factor	Mus musculus	244-271
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Protactinium	41-43	tumor necrosis factor	Mus musculus	273-282
28674407-5	2017	We found that HDAC6 is significantly up-regulated in lungs, distal PAs, and isolated PASMCs from PAH patients and animal models.	Protactinium	67-70	histone deacetylase 6	Homo sapiens	14-19
28606467-3	2017	The term "PAS", abbreviation for "per-Arnt-sim" was first coined in 1991.	Protactinium	10-13	aryl hydrocarbon receptor nuclear translocator	Mus musculus	38-42
27700191-9	2017	But the frequency of cases with low PTH level in cases undergoing PA was higher than that of the control cases.	Protactinium	66-68	parathyroid hormone	Homo sapiens	36-39
28622865-2	2017	PA-X protein is a newly discovered protein produced from the PA gene by ribosomal frameshifting and the effects of PA-X on the 1918 H1N1, the pandemic 2009 H1N1, the highly pathogenic avian H5N1 and the avian H9N2 influenza viruses have been reported.	Protactinium	0-2	paxillin	Mus musculus	115-119
27792249-6	2017	As expected, BRAF mutations were detected in the aforementioned low-grade gliomas: in 4/27 PAs, 2/3 PXAs, 4/8 GGs, and 1/6 DNTs.	Protactinium	91-94	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	13-17
28024967-6	2017	More extensive PA was associated with older age, lower prostate-specific antigen, larger prostate volume, and higher prevalence of acute and chronic inflammations (all P &lt; .05).	Protactinium	15-17	kallikrein related peptidase 3	Homo sapiens	55-80
28427239-2	2017	RESULTS: Up-regulation of Foxo3a restored autophagy flux and dampened the activation of the NLRP3 inflammasome in KCs stimulated with PA and LPS.	Protactinium	134-136	forkhead box O3	Mus musculus	26-32
28427239-2	2017	RESULTS: Up-regulation of Foxo3a restored autophagy flux and dampened the activation of the NLRP3 inflammasome in KCs stimulated with PA and LPS.	Protactinium	134-136	NLR family, pyrin domain containing 3	Mus musculus	92-97
28427239-4	2017	Additionally, mRNA levels of Bim were significantly changed with the alteration of Foxo3a in KCs under PA and LPS stimulation among foxo3a targeted genes.	Protactinium	103-105	forkhead box O3	Mus musculus	83-89
28427239-8	2017	Additionally, various target genes of Foxo3a were measured in KCs pretreated with an agonist (Iturin A) or inhibitor (SC97) of Foxo3a after KCs stimulation with PA and LPS in order to hunt for targets of Foxo3a.	Protactinium	161-163	forkhead box O3	Mus musculus	38-44
28503168-7	2017	Moreover, two cellular proteins (nucleolin and eukaryotic translation elongation factor 1-alpha 1) identified both in this study and others were further validated to interact with PA using co-immunoprecipitation and co-localization assays.	Protactinium	180-182	nucleolin	Homo sapiens	33-42
28503168-7	2017	Moreover, two cellular proteins (nucleolin and eukaryotic translation elongation factor 1-alpha 1) identified both in this study and others were further validated to interact with PA using co-immunoprecipitation and co-localization assays.	Protactinium	180-182	eukaryotic translation elongation factor 1 alpha 1	Homo sapiens	47-97
28390436-9	2017	Also, the NDRG2 expression was significantly higher in prolactinoma (PRL hypersecretion) than in in other diagnoses of PAs (p &lt; 0.05).	Protactinium	119-122	NDRG family member 2	Homo sapiens	10-15
28289017-7	2017	In mice, chronic hypoxia caused a 25-fold increase in plasma levels of TAFIa with increased plasma levels of thrombin and TM, which led to thrombus formation in PA, vascular remodeling, and pulmonary hypertension.	Protactinium	161-163	coagulation factor II	Mus musculus	109-117
28087305-9	2017	The baseline serum IL-18 levels were significantly higher in patients with PA than in the control group (p &lt; 0.001).	Protactinium	75-77	interleukin 18	Homo sapiens	19-24
28087305-13	2017	CONCLUSION: Serum levels of IL-18 can be a good diagnostic and predictive marker; especially for predicting the response to gemcitabine based CTx in patients with PA but it has no prognostic role.	Protactinium	163-165	interleukin 18	Homo sapiens	28-33
27832527-3	2017	In particular, through multilinear regression of ion counts on predicted chemometric data, we find that log10(MS ion counts) = -4.824 + c 1 PA + c 2 SA, where PA is the aqueous proton affinity of the molecule computed at the SMD(aq)/M06-L/MIDI!//M06-L/MIDI!	Protactinium	140-142	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	136-139
27444965-2	2017	We hypothesized that greater PA would buffer against the influence of perceived psychological stress (PPS) on systemic inflammation, operationalized as C-reactive protein (CRP, mg/L).	Protactinium	29-31	C-reactive protein	Homo sapiens	152-170
27444965-2	2017	We hypothesized that greater PA would buffer against the influence of perceived psychological stress (PPS) on systemic inflammation, operationalized as C-reactive protein (CRP, mg/L).	Protactinium	29-31	C-reactive protein	Homo sapiens	172-175
27444965-3	2017	Specifically, we predicted that PA would moderate the relationship between PPS and CRP.	Protactinium	32-34	C-reactive protein	Homo sapiens	83-86
27444965-6	2017	Using a moderated hierarchical regression analysis, PPS and PA significantly interacted to predict levels of CRP (p&lt;0.05).	Protactinium	60-62	C-reactive protein	Homo sapiens	109-112
27444965-7	2017	Examination of the simple slopes revealed a disordinal interaction between PPS and PA, such that higher PA was protective against elevated CRP levels, but only when individuals also reported greater levels of PPS.	Protactinium	83-85	C-reactive protein	Homo sapiens	139-142
27444965-7	2017	Examination of the simple slopes revealed a disordinal interaction between PPS and PA, such that higher PA was protective against elevated CRP levels, but only when individuals also reported greater levels of PPS.	Protactinium	104-106	C-reactive protein	Homo sapiens	139-142
27444965-9	2017	Findings also provide caution of future assumptions that relationships among PA, PPS, and physical health markers, such as CRP, are always positive (e.g., PA) or negative (e.g., PPS) in nature.	Protactinium	77-79	C-reactive protein	Homo sapiens	123-126
27566296-9	2017	When patients were grouped according to resting coupling efficiency, those with poorer eta exhibited stiffer proximal PAs at rest, a lower maximum exercise level, and more limited CPA reduction at maximum exercise.	Protactinium	118-121	endothelin receptor type A	Homo sapiens	87-90
28143926-4	2017	Here we show that CRY1 binds directly to the PAS domain core of CLOCK:BMAL1, driven primarily by interaction with the CLOCK PAS-B domain.	Protactinium	45-48	cryptochrome circadian regulator 1	Homo sapiens	18-22
28143926-4	2017	Here we show that CRY1 binds directly to the PAS domain core of CLOCK:BMAL1, driven primarily by interaction with the CLOCK PAS-B domain.	Protactinium	45-48	clock circadian regulator	Homo sapiens	64-75
28143926-4	2017	Here we show that CRY1 binds directly to the PAS domain core of CLOCK:BMAL1, driven primarily by interaction with the CLOCK PAS-B domain.	Protactinium	45-48	clock circadian regulator	Homo sapiens	64-69
28143926-6	2017	CRY1 docks onto the transcription factor alongside the PAS domains, extending above the DNA-binding bHLH domain.	Protactinium	55-58	cryptochrome circadian regulator 1	Homo sapiens	0-4
28167279-6	2017	We activated NLRP3 inflammasome in human MSCs via lipopolysaccharide and palmitic acid (LPS/PA) treatment for self-renewal maintenance, adipogenic differentiation or osteogenic differentiation.	Protactinium	92-94	NLR family pyrin domain containing 3	Homo sapiens	13-18
28167279-7	2017	LPS/PA treatment significantly increased NLRP3 expression, decreased SIRT1 expression and promoted caspase-1 activity in MSCs.	Protactinium	4-6	NLR family pyrin domain containing 3	Homo sapiens	41-46
28167279-7	2017	LPS/PA treatment significantly increased NLRP3 expression, decreased SIRT1 expression and promoted caspase-1 activity in MSCs.	Protactinium	4-6	sirtuin 1	Homo sapiens	69-74
28167279-7	2017	LPS/PA treatment significantly increased NLRP3 expression, decreased SIRT1 expression and promoted caspase-1 activity in MSCs.	Protactinium	4-6	caspase 1	Homo sapiens	99-108
28167279-9	2017	Moreover, inhibition of caspase-1 activity repressed adipogenic differentiation and partially improved osteogenic differentiation of MSCs with LPS/PA treatment.	Protactinium	147-149	caspase 1	Homo sapiens	24-33
28092730-4	2017	RESULTS: The data showed that serum AGR2 level was significantly higher in the serum of PA patients (250.10+-79.14ng/ml) than the patients with other sellar lesions (220.84+-79.62ng/ml, P=0.017) and normal people (163.67+-50.38ng/ml, P &lt;0.001).	Protactinium	88-90	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	36-40
28379594-20	2017	PA + EtOH-treated cells increased TNF-alpha levels in media compared to EtOH alone [86+-8 vs. 53+-5 pg/mL in cells exposed to 100 mmol/L EtOH (p&lt;0.05) and 218+-14 vs. 179+-8 pg/mL in cells exposed to 2x100 mmol/L EtOH (p&lt;0.05)].	Protactinium	0-2	tumor necrosis factor	Homo sapiens	34-43
28106206-5	2017	In addition, the desired PT effect also makes MoO3-x QDs an exogenous PA contrast agent for in vivo live-imaging to depict tumors.	Protactinium	70-72	modifier of obesity 3	Mus musculus	46-50
27832527-3	2017	In particular, through multilinear regression of ion counts on predicted chemometric data, we find that log10(MS ion counts) = -4.824 + c 1 PA + c 2 SA, where PA is the aqueous proton affinity of the molecule computed at the SMD(aq)/M06-L/MIDI!//M06-L/MIDI!	Protactinium	140-142	complement C2	Homo sapiens	145-148
27664540-3	2017	In this study, four UPR-related genes (GRP78/BiP, ATF6alpha, XBP1 and CHO) were isolated characterized from large yellow croaker (Larimichthys crocea), and their expression in response to dietary lipid sources (various fatty acids) such as fish oil (FO), palmic acid (PA), olive oil (OO), sunflower oil (SO), and perilla oil (PO), were examined following feeding.	Protactinium	268-270	LOW QUALITY PROTEIN: X-box-binding protein 1	Larimichthys crocea	61-65
27987663-1	2017	An electrochemical sensor for determining dopamine was developed by modifying phytic acid/graphene oxide (PA/GO) nanocomposites onto a glassy carbon electrode (GCE).	Protactinium	106-108	aminomethyltransferase	Homo sapiens	160-163
28138556-7	2017	PA revealed changes in miR-mRNA interactions predictive of decreased apoptosis and myocardial cell death.	Protactinium	0-2	myosin regulatory light chain interacting protein	Homo sapiens	23-26
30695511-2	2017	Approximately 30% of pa- tients with cytogenetically normal acute myeloid leukemia (CN-AML) harbor FLT3 mutations.	Protactinium	21-23	fms related receptor tyrosine kinase 3	Homo sapiens	99-103
28102700-2	2017	The aryl hydrocarbon receptor (AhR) shares structural homology to clock genes, containing both PAS domains and basic helix-loop helix structural motifs, allowing for interaction with components of the primary circadian feedback loop.	Protactinium	95-98	aryl-hydrocarbon receptor	Mus musculus	4-29
28102700-2	2017	The aryl hydrocarbon receptor (AhR) shares structural homology to clock genes, containing both PAS domains and basic helix-loop helix structural motifs, allowing for interaction with components of the primary circadian feedback loop.	Protactinium	95-98	aryl-hydrocarbon receptor	Mus musculus	31-34
28341047-4	2017	Overall, PA treatments increased milk fat content (4.25 vs. 3.99%), milk fat yield (1.48 vs. 1.39kg/d), 3.5% fat-corrected milk (39.2 vs. 37.7kg/d), and improved feed efficiency (fat-corrected milk:dry matter intake; 1.51 vs. 1.42) compared with control.	Protactinium	9-11	FAT atypical cadherin 1	Bos taurus	38-41
28341047-4	2017	Overall, PA treatments increased milk fat content (4.25 vs. 3.99%), milk fat yield (1.48 vs. 1.39kg/d), 3.5% fat-corrected milk (39.2 vs. 37.7kg/d), and improved feed efficiency (fat-corrected milk:dry matter intake; 1.51 vs. 1.42) compared with control.	Protactinium	9-11	FAT atypical cadherin 1	Bos taurus	73-76
28341047-4	2017	Overall, PA treatments increased milk fat content (4.25 vs. 3.99%), milk fat yield (1.48 vs. 1.39kg/d), 3.5% fat-corrected milk (39.2 vs. 37.7kg/d), and improved feed efficiency (fat-corrected milk:dry matter intake; 1.51 vs. 1.42) compared with control.	Protactinium	9-11	FAT atypical cadherin 1	Bos taurus	73-76
28341047-4	2017	Overall, PA treatments increased milk fat content (4.25 vs. 3.99%), milk fat yield (1.48 vs. 1.39kg/d), 3.5% fat-corrected milk (39.2 vs. 37.7kg/d), and improved feed efficiency (fat-corrected milk:dry matter intake; 1.51 vs. 1.42) compared with control.	Protactinium	9-11	FAT atypical cadherin 1	Bos taurus	73-76
28341047-12	2017	Results demonstrate that PA increased milk fat content and yield, and feed efficiency.	Protactinium	25-27	FAT atypical cadherin 1	Bos taurus	43-46
30695518-1	2017	During the exploration of factors that interfere with the erythropoietin (EPO) -EPO receptor (EPOR) interaction in anemia, a novel inhibitory factor of EPO, anti-EPOR antibody, has been detected in anemic pa- tients with immune-mediated diseases.	Protactinium	205-207	erythropoietin	Homo sapiens	58-72
30695518-1	2017	During the exploration of factors that interfere with the erythropoietin (EPO) -EPO receptor (EPOR) interaction in anemia, a novel inhibitory factor of EPO, anti-EPOR antibody, has been detected in anemic pa- tients with immune-mediated diseases.	Protactinium	205-207	erythropoietin	Homo sapiens	74-77
30695518-1	2017	During the exploration of factors that interfere with the erythropoietin (EPO) -EPO receptor (EPOR) interaction in anemia, a novel inhibitory factor of EPO, anti-EPOR antibody, has been detected in anemic pa- tients with immune-mediated diseases.	Protactinium	205-207	erythropoietin	Homo sapiens	80-83
30695518-1	2017	During the exploration of factors that interfere with the erythropoietin (EPO) -EPO receptor (EPOR) interaction in anemia, a novel inhibitory factor of EPO, anti-EPOR antibody, has been detected in anemic pa- tients with immune-mediated diseases.	Protactinium	205-207	erythropoietin receptor	Homo sapiens	94-98
30695518-1	2017	During the exploration of factors that interfere with the erythropoietin (EPO) -EPO receptor (EPOR) interaction in anemia, a novel inhibitory factor of EPO, anti-EPOR antibody, has been detected in anemic pa- tients with immune-mediated diseases.	Protactinium	205-207	erythropoietin	Homo sapiens	80-83
30695518-1	2017	During the exploration of factors that interfere with the erythropoietin (EPO) -EPO receptor (EPOR) interaction in anemia, a novel inhibitory factor of EPO, anti-EPOR antibody, has been detected in anemic pa- tients with immune-mediated diseases.	Protactinium	205-207	erythropoietin receptor	Homo sapiens	162-166
28096669-8	2017	Moreover, osteogenic transcriptional response of osteoblasts was induced by nanocoating in terms of gene induction of Runx2, Alpl, Bglap, and Col1a1 in a time-dependent manner - of note - to the highest extent under the PA-coating condition.	Protactinium	220-222	runt related transcription factor 2	Mus musculus	118-123
27071708-6	2016	DNA translocations with cyclin D1 overexpression occur in PAs (8%).	Protactinium	58-61	cyclin D1	Homo sapiens	24-33
27936114-6	2016	Furthermore, apoptosis-induction induced by Cur in PA cells was associated with morphological changes including cell shrinkage, cytoplasmic blebbing, irregularity in shape and the externalization of cell membrane phosphatidylserine, which was preceded by an increase in intracellular reactive oxygen species (ROS) generation and caspase 3/7 activation.	Protactinium	51-53	caspase 3	Homo sapiens	329-338
27475756-6	2016	TAS2R38 genotype was related to energy intake from sweet tasting foods: Children with PP and PA genotype consumed an average 83 kJ/d (95% CI 21 to 146; p = 0.009) more sweet tasting foods than children with AA genotype and a mean 56 kJ/d (95% CI 15 to 98; p = 0.007) more energy from energy dense sweet products.	Protactinium	93-95	taste 2 receptor member 38	Homo sapiens	0-7
27071708-12	2016	In addition, hypermethylation has been observed for the same genes in PAs and PCs (e.g. SFRP1, CDKN2A and WT1).	Protactinium	70-73	secreted frizzled related protein 1	Homo sapiens	88-93
27071708-12	2016	In addition, hypermethylation has been observed for the same genes in PAs and PCs (e.g. SFRP1, CDKN2A and WT1).	Protactinium	70-73	cyclin dependent kinase inhibitor 2A	Homo sapiens	95-101
27050249-9	2016	In both PAs-treated groups, Bax and Caspase-3 expression were decreased compared to I/R group, while the Bcl-2 expression increased (p &lt; .05), which was similarly the case for serum SOD activity demonstrated significant enhance (p &lt; .05) and decline in MDA levels in comparison with I/R group (both p &lt; .05).	Protactinium	8-11	BCL2 associated X, apoptosis regulator	Rattus norvegicus	28-31
27071708-12	2016	In addition, hypermethylation has been observed for the same genes in PAs and PCs (e.g. SFRP1, CDKN2A and WT1).	Protactinium	70-73	WT1 transcription factor	Homo sapiens	106-109
27050249-9	2016	In both PAs-treated groups, Bax and Caspase-3 expression were decreased compared to I/R group, while the Bcl-2 expression increased (p &lt; .05), which was similarly the case for serum SOD activity demonstrated significant enhance (p &lt; .05) and decline in MDA levels in comparison with I/R group (both p &lt; .05).	Protactinium	8-11	caspase 3	Rattus norvegicus	36-45
27788491-11	2016	PA-MSHA-mediated inhibition of EGFR signaling and activation of the caspase pathway may play an important role in the induction of apoptosis in pancreatic cancer cells.	Protactinium	0-2	epidermal growth factor receptor	Homo sapiens	31-35
27050249-9	2016	In both PAs-treated groups, Bax and Caspase-3 expression were decreased compared to I/R group, while the Bcl-2 expression increased (p &lt; .05), which was similarly the case for serum SOD activity demonstrated significant enhance (p &lt; .05) and decline in MDA levels in comparison with I/R group (both p &lt; .05).	Protactinium	8-11	BCL2, apoptosis regulator	Rattus norvegicus	105-110
27071708-5	2016	Recurrent mutations in the MEN1 gene have been confirmed by the whole-exome sequencing in 35% of PAs, suggesting that non-protein-coding genes, regulatory elements or epigenetic derangements may also have roles in the majority of PAs.	Protactinium	97-100	menin 1	Homo sapiens	27-31
27644134-7	2016	In addition, both PA- and SCNT-derived blastocysts from the 40 muM Cx-treated group showed significantly increased mRNA expression of Bcl2 and Oct4 and decreased Caspase3 expression level (p &lt; .05), when compared with the control group.	Protactinium	18-20	BCL2 apoptosis regulator	Homo sapiens	134-138
27644134-7	2016	In addition, both PA- and SCNT-derived blastocysts from the 40 muM Cx-treated group showed significantly increased mRNA expression of Bcl2 and Oct4 and decreased Caspase3 expression level (p &lt; .05), when compared with the control group.	Protactinium	18-20	POU class 5 homeobox 1	Homo sapiens	143-147
27644134-7	2016	In addition, both PA- and SCNT-derived blastocysts from the 40 muM Cx-treated group showed significantly increased mRNA expression of Bcl2 and Oct4 and decreased Caspase3 expression level (p &lt; .05), when compared with the control group.	Protactinium	18-20	caspase 3	Homo sapiens	162-170
27644134-8	2016	PA-derived blastocysts from the 40 muM Cx-treated group also exhibited significantly decreased expression of Bax (p &lt; .05).	Protactinium	0-2	BCL2 associated X, apoptosis regulator	Homo sapiens	109-112
27046632-2	2016	A transcription factor complex consisting of TT2, TT8 and TTG1 controls expression of PA biosynthetic genes, just as similar TTG1-dependent complexes have been shown to control flavonoid pigment pathway gene expression in general.	Protactinium	86-88	Duplicated homeodomain-like superfamily protein	Arabidopsis thaliana	45-48
27726346-2	2016	Structural studies of a probe 1 and PA (1 PA) complex revealed that the adduct formed by the deprotonation of PA by the -NMe2 group along with weak interactions is responsible for the selective detection of PA over other polynitrated organic compounds.	Protactinium	36-38	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	121-125
27726346-2	2016	Structural studies of a probe 1 and PA (1 PA) complex revealed that the adduct formed by the deprotonation of PA by the -NMe2 group along with weak interactions is responsible for the selective detection of PA over other polynitrated organic compounds.	Protactinium	42-44	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	121-125
27046632-4	2016	TTG2 mutants lack the pigmentation found in wild-type seeds, but produce other flavonoid compounds, such as anthocyanins in the shoot, suggesting that TTG2 regulates genes in the PA biosynthetic branch of the flavonoid pathway.	Protactinium	179-181	WRKY family transcription factor family protein	Arabidopsis thaliana	0-4
27046632-4	2016	TTG2 mutants lack the pigmentation found in wild-type seeds, but produce other flavonoid compounds, such as anthocyanins in the shoot, suggesting that TTG2 regulates genes in the PA biosynthetic branch of the flavonoid pathway.	Protactinium	179-181	WRKY family transcription factor family protein	Arabidopsis thaliana	151-155
27149112-14	2016	In the PAH Sugen/hypoxia rat model, molecular RUNX2 inhibition reduces PA remodeling and prevents calcification, thus improving pulmonary hemodynamic parameters and right ventricular function.	Protactinium	7-9	RUNX family transcription factor 2	Rattus norvegicus	46-51
27149112-15	2016	CONCLUSIONS: RUNX2 plays a pivotal role in the pathogenesis of PAH, contributing to the development of proliferative and calcified PA lesions.	Protactinium	63-65	RUNX family transcription factor 2	Homo sapiens	13-18
27046632-5	2016	We analyzed the expression of PA biosynthetic genes within the developing seeds of ttg2-1 and wild-type plants for potential TTG2 regulatory targets.	Protactinium	30-32	WRKY family transcription factor family protein	Arabidopsis thaliana	83-87
27046632-2	2016	A transcription factor complex consisting of TT2, TT8 and TTG1 controls expression of PA biosynthetic genes, just as similar TTG1-dependent complexes have been shown to control flavonoid pigment pathway gene expression in general.	Protactinium	86-88	basic helix-loop-helix (bHLH) DNA-binding superfamily protein	Arabidopsis thaliana	50-53
27046632-2	2016	A transcription factor complex consisting of TT2, TT8 and TTG1 controls expression of PA biosynthetic genes, just as similar TTG1-dependent complexes have been shown to control flavonoid pigment pathway gene expression in general.	Protactinium	86-88	Transducin/WD40 repeat-like superfamily protein	Arabidopsis thaliana	58-62
27689880-6	2016	PAS staining, showed remarkably intense magenta color, remarkable increase of HSP70 and decrease of Bax proteins in rats pre-treated with plant extracts compared to the ulcer control group.	Protactinium	0-3	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	78-83
27785418-3	2016	This study was conducted to investigate the serum levels of omentin in patients with PA and the relationship with tumor progression and known prognostic parameters.	Protactinium	85-87	intelectin 1	Homo sapiens	60-67
27785418-12	2016	The baseline serum omentin levels were significantly higher in patients with PA than in the control group (p &lt; 0.001).	Protactinium	77-79	intelectin 1	Homo sapiens	19-26
27785418-15	2016	CONCLUSION: Serum levels of omentin may have a good diagnostic role in patients with PA.	Protactinium	85-87	intelectin 1	Homo sapiens	28-35
27229374-6	2016	Pa ESP associated with kinetochore microtubules in metaphase and then with anaphase spindle midzone.	Protactinium	0-2	epithiospecifier protein	Arabidopsis thaliana	3-6
27229374-9	2016	Furthermore, whilst Pa ESP can rescue the chromatid nondisjunction phenotype of Arabidopsis ESP mutants, it cannot rescue anisotropic cell expansion.	Protactinium	20-22	epithiospecifier protein	Arabidopsis thaliana	23-26
27229374-9	2016	Furthermore, whilst Pa ESP can rescue the chromatid nondisjunction phenotype of Arabidopsis ESP mutants, it cannot rescue anisotropic cell expansion.	Protactinium	20-22	epithiospecifier protein	Arabidopsis thaliana	92-95
27473265-7	2016	Thirty-seven PAs (92.5%), 15 residual PAs (71%), and 14 CXPAs (35%) were positive for PLAG1.	Protactinium	13-16	PLAG1 zinc finger	Homo sapiens	86-91
27345614-11	2016	Changes in metalloproteinases (MMP-9), cell proliferation and apoptosis are the main actors in the remodeling process occurring after transposition of the PA into systemic regimens.	Protactinium	155-157	matrix metallopeptidase 9	Homo sapiens	31-36
27702549-9	2016	While Fenofibrate, abrogated PA-induced TxNIP expression and ROS generation in skeletal muscle cells, Saroglitazar, a dual PPARalpha/gamma-agonist, not only inhibited PA-induced TXNIP expression but also led to greater improvement in glucose uptake.	Protactinium	29-31	thioredoxin interacting protein	Homo sapiens	40-45
27702549-9	2016	While Fenofibrate, abrogated PA-induced TxNIP expression and ROS generation in skeletal muscle cells, Saroglitazar, a dual PPARalpha/gamma-agonist, not only inhibited PA-induced TXNIP expression but also led to greater improvement in glucose uptake.	Protactinium	29-31	thioredoxin interacting protein	Homo sapiens	178-183
27555325-5	2016	To obtain PA variants that selectively bind to CMG2, here we performed phage display selections using magnetic beads having bound CMG2.	Protactinium	10-12	anthrax toxin receptor 2	Mus musculus	47-51
27555325-5	2016	To obtain PA variants that selectively bind to CMG2, here we performed phage display selections using magnetic beads having bound CMG2.	Protactinium	10-12	anthrax toxin receptor 2	Mus musculus	130-134
27555325-6	2016	We found that PA residue isoleucine 656 plays a critical role in PA binding to TEM8 but has a much lesser effect on PA binding to CMG2.	Protactinium	14-16	anthrax toxin receptor 1	Mus musculus	79-83
27555325-6	2016	We found that PA residue isoleucine 656 plays a critical role in PA binding to TEM8 but has a much lesser effect on PA binding to CMG2.	Protactinium	14-16	anthrax toxin receptor 2	Mus musculus	130-134
27555325-6	2016	We found that PA residue isoleucine 656 plays a critical role in PA binding to TEM8 but has a much lesser effect on PA binding to CMG2.	Protactinium	65-67	anthrax toxin receptor 1	Mus musculus	79-83
27555325-6	2016	We found that PA residue isoleucine 656 plays a critical role in PA binding to TEM8 but has a much lesser effect on PA binding to CMG2.	Protactinium	65-67	anthrax toxin receptor 1	Mus musculus	79-83
27555325-7	2016	We further characterized the role of residue 656 in distinguishing PA binding to CMG2 versus TEM8 by substituting it with the other 19 amino acids.	Protactinium	67-69	anthrax toxin receptor 2	Mus musculus	81-85
27555325-8	2016	Of the resulting variants, PA I656Q and PA I656V had significantly reduced activity on TEM8-expressing CHO cells but maintained their activity on CMG2-expressing CHO cells.	Protactinium	27-29	anthrax toxin receptor 1	Mus musculus	87-91
27555325-8	2016	Of the resulting variants, PA I656Q and PA I656V had significantly reduced activity on TEM8-expressing CHO cells but maintained their activity on CMG2-expressing CHO cells.	Protactinium	27-29	anthrax toxin receptor 2	Mus musculus	146-150
27555325-9	2016	The preference of these PA mutants for CMG2 over TEM8 was further demonstrated using mouse embryonic fibroblast cells and mice deficient in the CMG2 and/or the TEM8 receptors.	Protactinium	24-26	anthrax toxin receptor 2	Mus musculus	39-43
27555325-9	2016	The preference of these PA mutants for CMG2 over TEM8 was further demonstrated using mouse embryonic fibroblast cells and mice deficient in the CMG2 and/or the TEM8 receptors.	Protactinium	24-26	anthrax toxin receptor 1	Mus musculus	49-53
27555325-9	2016	The preference of these PA mutants for CMG2 over TEM8 was further demonstrated using mouse embryonic fibroblast cells and mice deficient in the CMG2 and/or the TEM8 receptors.	Protactinium	24-26	anthrax toxin receptor 2	Mus musculus	144-148
27555325-9	2016	The preference of these PA mutants for CMG2 over TEM8 was further demonstrated using mouse embryonic fibroblast cells and mice deficient in the CMG2 and/or the TEM8 receptors.	Protactinium	24-26	anthrax toxin receptor 1	Mus musculus	160-164
27689880-6	2016	PAS staining, showed remarkably intense magenta color, remarkable increase of HSP70 and decrease of Bax proteins in rats pre-treated with plant extracts compared to the ulcer control group.	Protactinium	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	100-103
27219053-5	2016	R. trigyna LDOX can complement the Arabidopsis LDOX mutant transparent testa11 (tt11-11), which has reduced proanthocyanin (PA) and anthocyanin levels in seeds, to accumulate these two compounds.	Protactinium	124-126	leucoanthocyanidin dioxygenase	Arabidopsis thaliana	11-15
27219053-5	2016	R. trigyna LDOX can complement the Arabidopsis LDOX mutant transparent testa11 (tt11-11), which has reduced proanthocyanin (PA) and anthocyanin levels in seeds, to accumulate these two compounds.	Protactinium	124-126	leucoanthocyanidin dioxygenase	Arabidopsis thaliana	47-51
27311393-9	2016	Our results suggest that the increase in caveolae and Cav-1 expression in PH contributes to the enhanced agonist-induced contraction of PA via modulation of SOCE and ROCE; and targeting caveolae/Cav-1 in PASMCs may provide a novel therapeutic strategy for the treatment of PH.	Protactinium	136-138	caveolin 1	Rattus norvegicus	54-59
27311393-9	2016	Our results suggest that the increase in caveolae and Cav-1 expression in PH contributes to the enhanced agonist-induced contraction of PA via modulation of SOCE and ROCE; and targeting caveolae/Cav-1 in PASMCs may provide a novel therapeutic strategy for the treatment of PH.	Protactinium	136-138	caveolin 1	Rattus norvegicus	195-200
27516763-6	2016	Supplementation of salt affected seedlings with exogenous PAs enhanced the contents of glutathione and ascorbate, increased activities of antioxidant enzymes (dehydroascorbate reductase, glutathione reductase, catalase, and glutathione peroxidase) and glyoxalase enzyme (glyoxalase II), which reduced salt-induced oxidative stress and MG toxicity, respectively.	Protactinium	58-61	catalase	Vigna radiata	210-218
27329673-3	2016	A substrate of intestinal alkaline phosphatase (IAP), 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid sodium (PA), was thereafter incorporated into SEDDS.	Protactinium	109-111	alkaline phosphatase, intestinal	Homo sapiens	15-46
27329673-3	2016	A substrate of intestinal alkaline phosphatase (IAP), 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid sodium (PA), was thereafter incorporated into SEDDS.	Protactinium	109-111	alkaline phosphatase, intestinal	Homo sapiens	48-51
27389560-6	2016	The KIAA1549-BRAF fusion gene was detected only in 8 out of 11 PAs (73%) and in 3 out of 9 gangliogliomas (33%) (P=0.003).	Protactinium	63-66	KIAA1549	Homo sapiens	4-12
27389560-6	2016	The KIAA1549-BRAF fusion gene was detected only in 8 out of 11 PAs (73%) and in 3 out of 9 gangliogliomas (33%) (P=0.003).	Protactinium	63-66	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	13-17
27289459-8	2016	Moreover, we also found that PA nuclear accumulation of the PA-X-null viruses accelerated in MDCK cells.	Protactinium	29-31	paxillin	Mus musculus	60-64
27512990-6	2016	Compared with the HCs, V1, V2, and MT+ in the PAs exhibited decreased FC with the V1, V2, MT+, fusiform, BA37, and increased FC primarily in the bilateral temporal lobe (especially BA20,21,22), prefrontal cortex, PCC, insular, angular gyrus, ACC, pre-SMA, SMG, hippocampal formation, caudate and putamen.	Protactinium	46-49	survival of motor neuron 1, telomeric	Homo sapiens	251-254
27491388-12	2016	The blockage of CF6 might be applied as a novel therapeutic approach for PAH and PA remodeling.	Protactinium	73-75	ATP synthase peripheral stalk subunit F6	Rattus norvegicus	16-19
26935863-5	2016	This study revealed that in the mEPM and PA tests, type-2 diabetes-induced mice exhibited significant impairment of learning and memory which were ameliorated by GLP-1 receptor agonist exenatide.	Protactinium	41-43	glucagon-like peptide 1 receptor	Mus musculus	162-176
27297630-8	2016	FA pretreatment markedly inverted the PA-induced expression of TLR4 and downstream inflammatory genes, activated ER stress, improved beta-oxidation and insulin signaling in differentiated myotube cells.	Protactinium	38-40	toll-like receptor 4	Rattus norvegicus	63-67
27063496-3	2016	The tenascin-C mimetic PA (TN-C PA) was found to self-assemble into supramolecular nanofibers and was incorporated through co-assembly into PA gels formed by highly aligned nanofibers.	Protactinium	23-25	tenascin C	Homo sapiens	4-14
27191496-4	2016	In this study, we reported that MSCs pre-stimulated with the combination of TNF-alpha and IFN-gamma promote PA cells invasion.	Protactinium	108-110	tumor necrosis factor	Mus musculus	76-85
27191496-4	2016	In this study, we reported that MSCs pre-stimulated with the combination of TNF-alpha and IFN-gamma promote PA cells invasion.	Protactinium	108-110	interferon gamma	Mus musculus	90-99
27191496-6	2016	We observed MSCs pre-stimulated with the combination of TNF-alpha and IFN-gamma promoted PA cells invasion in vitro and in vivo.	Protactinium	89-91	tumor necrosis factor	Mus musculus	56-65
27191496-6	2016	We observed MSCs pre-stimulated with the combination of TNF-alpha and IFN-gamma promoted PA cells invasion in vitro and in vivo.	Protactinium	89-91	interferon gamma	Mus musculus	70-79
27191496-9	2016	MSCs promoting EMT-mediated PA cells invasion could be reversed by short interfering RNA of TGF-beta1.	Protactinium	28-30	transforming growth factor, beta 1	Mus musculus	92-101
27061586-10	2016	The P-like pA+ biotype strains did not synthesize fibrinolysin, lacked the sak gene, and showed susceptibility to methicillin.	Protactinium	11-14	polo like kinase 4	Homo sapiens	75-78
27685911-3	2016	Our aim was to investigate the serum levels of leptin in patients with PA, the relationship of leptin with tumor progression and known prognostic parameters and its diagnostic, predictive and prognostic role.	Protactinium	71-73	leptin	Homo sapiens	47-53
27685911-13	2016	The baseline serum leptin levels were significantly higher in patients with PA than in the control group (p=0.02).	Protactinium	76-78	leptin	Homo sapiens	19-25
27364353-16	2016	CONCLUSIONS: The results of this study suggest that PA boosted by immunization with A91 after moderate SC-injury can exert its benefits even at chronic stages, as shown by long-term production of BDNF and NT-3 and a substantial improvement in motor recovery.	Protactinium	52-54	brain-derived neurotrophic factor	Rattus norvegicus	196-200
27364353-16	2016	CONCLUSIONS: The results of this study suggest that PA boosted by immunization with A91 after moderate SC-injury can exert its benefits even at chronic stages, as shown by long-term production of BDNF and NT-3 and a substantial improvement in motor recovery.	Protactinium	52-54	neurotrophin 3	Rattus norvegicus	205-209
27347562-5	2016	Pulmonary artery smooth muscle cells (PASMC) grown on substrates with the stiffness of remodeled PAs showed increased proliferation, decreased apoptosis, exaggerated contraction, enhanced matrix deposition, and reduced COX-2-derived prostanoid production compared with cells grown on substrates approximating normal PA stiffness.	Protactinium	97-100	prostaglandin-endoperoxide synthase 2	Homo sapiens	219-224
27347562-5	2016	Pulmonary artery smooth muscle cells (PASMC) grown on substrates with the stiffness of remodeled PAs showed increased proliferation, decreased apoptosis, exaggerated contraction, enhanced matrix deposition, and reduced COX-2-derived prostanoid production compared with cells grown on substrates approximating normal PA stiffness.	Protactinium	38-40	prostaglandin-endoperoxide synthase 2	Homo sapiens	219-224
26257338-12	2016	Real-time polymerase chain reaction analysis revealed stronger expression of Runx2, Osx, OC, Bsp and Cap mRNAs in the PA-CM-treated PDL cells and cementoblasts than those in the control cells.	Protactinium	118-120	runt related transcription factor 2	Canis lupus familiaris	77-82
26882287-8	2016	Only 12% of PAs were found to be positive for MYB or KIT.	Protactinium	12-15	MYB proto-oncogene, transcription factor	Homo sapiens	46-49
26882287-8	2016	Only 12% of PAs were found to be positive for MYB or KIT.	Protactinium	12-15	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	53-56
26882287-10	2016	CONCLUSIONS: An immunohistochemical panel of MYB, KIT, PLAG1, and HMGA2 on fine-needle aspiration cell blocks is useful in distinguishing ACCs and PAs from each other and other salivary gland neoplasms.	Protactinium	147-150	MYB proto-oncogene, transcription factor	Homo sapiens	45-48
26882287-10	2016	CONCLUSIONS: An immunohistochemical panel of MYB, KIT, PLAG1, and HMGA2 on fine-needle aspiration cell blocks is useful in distinguishing ACCs and PAs from each other and other salivary gland neoplasms.	Protactinium	147-150	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	50-53
26882287-10	2016	CONCLUSIONS: An immunohistochemical panel of MYB, KIT, PLAG1, and HMGA2 on fine-needle aspiration cell blocks is useful in distinguishing ACCs and PAs from each other and other salivary gland neoplasms.	Protactinium	147-150	PLAG1 zinc finger	Homo sapiens	55-60
26882287-10	2016	CONCLUSIONS: An immunohistochemical panel of MYB, KIT, PLAG1, and HMGA2 on fine-needle aspiration cell blocks is useful in distinguishing ACCs and PAs from each other and other salivary gland neoplasms.	Protactinium	147-150	high mobility group AT-hook 2	Homo sapiens	66-71
27153104-9	2016	The additional PAS domains in the CLOCK and BMAL1 proteins affect insignificantly the interactions of the CLOCK and BMAL1 proteins with the DNA molecule due to the flexible and long loop linkers located at the middle of the PAS and bHLH domains.	Protactinium	15-18	clock circadian regulator	Homo sapiens	34-39
27293999-3	2016	Previously, we have shown that L1 reactivation in several human cell lines is dependent upon the activation of aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor member of the PAS superfamily of proteins.	Protactinium	198-201	aryl hydrocarbon receptor	Homo sapiens	111-136
27293999-3	2016	Previously, we have shown that L1 reactivation in several human cell lines is dependent upon the activation of aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor member of the PAS superfamily of proteins.	Protactinium	198-201	aryl hydrocarbon receptor	Homo sapiens	138-141
26956376-13	2016	The restorative effect of CEEV was accompanied by a significant increase in mucin content (PAS staining) and by a reduction in oxidative stress and inflammatory parameters at the site of the ulcer.	Protactinium	91-94	solute carrier family 13 member 2	Rattus norvegicus	76-81
27153104-9	2016	The additional PAS domains in the CLOCK and BMAL1 proteins affect insignificantly the interactions of the CLOCK and BMAL1 proteins with the DNA molecule due to the flexible and long loop linkers located at the middle of the PAS and bHLH domains.	Protactinium	15-18	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	44-49
27153104-9	2016	The additional PAS domains in the CLOCK and BMAL1 proteins affect insignificantly the interactions of the CLOCK and BMAL1 proteins with the DNA molecule due to the flexible and long loop linkers located at the middle of the PAS and bHLH domains.	Protactinium	15-18	clock circadian regulator	Homo sapiens	106-111
27153104-9	2016	The additional PAS domains in the CLOCK and BMAL1 proteins affect insignificantly the interactions of the CLOCK and BMAL1 proteins with the DNA molecule due to the flexible and long loop linkers located at the middle of the PAS and bHLH domains.	Protactinium	15-18	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	116-121
27153104-9	2016	The additional PAS domains in the CLOCK and BMAL1 proteins affect insignificantly the interactions of the CLOCK and BMAL1 proteins with the DNA molecule due to the flexible and long loop linkers located at the middle of the PAS and bHLH domains.	Protactinium	224-227	clock circadian regulator	Homo sapiens	34-39
27153104-9	2016	The additional PAS domains in the CLOCK and BMAL1 proteins affect insignificantly the interactions of the CLOCK and BMAL1 proteins with the DNA molecule due to the flexible and long loop linkers located at the middle of the PAS and bHLH domains.	Protactinium	224-227	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	44-49
27153104-9	2016	The additional PAS domains in the CLOCK and BMAL1 proteins affect insignificantly the interactions of the CLOCK and BMAL1 proteins with the DNA molecule due to the flexible and long loop linkers located at the middle of the PAS and bHLH domains.	Protactinium	224-227	clock circadian regulator	Homo sapiens	106-111
26646710-7	2016	RESULTS: Platelets in PA concentrates had significantly more (P = 0 009, n &gt;= 8) bound VWF compared to AF platelets, but differences in VWF concentration, VWF collagen binding, activated VWF or GPIbalpha expression were not found.	Protactinium	22-24	von Willebrand factor	Homo sapiens	90-93
26781944-7	2016	Further, PA, the product of PLD2 enzymatic reaction, has profound effects on its own and it further regulates the transcription factors.	Protactinium	9-11	phospholipase D2	Homo sapiens	28-32
26926794-11	2016	Our data suggest that H2O2 produced through PA catabolism by ZmPAO1 plays an important role in tumor development during the maize-U.	Protactinium	44-46	polyamine oxidase 1	Zea mays	61-67
26646710-7	2016	RESULTS: Platelets in PA concentrates had significantly more (P = 0 009, n &gt;= 8) bound VWF compared to AF platelets, but differences in VWF concentration, VWF collagen binding, activated VWF or GPIbalpha expression were not found.	Protactinium	22-24	glycoprotein Ib platelet subunit alpha	Homo sapiens	197-206
26646710-9	2016	On day 6, however, significantly less VWF adhesion (P = 0 009, n &gt;= 6) was found for PA platelets compared to AF, indicating accelerated storage lesion in PA products.	Protactinium	88-90	von Willebrand factor	Homo sapiens	38-41
26646710-10	2016	In a model that mimicks PA formation by chemically induced binding of VWF to platelets, we found that degranulation, phosphatidylserine expression and metabolism did not differ with paired controls at any time during subsequent storage.	Protactinium	24-26	von Willebrand factor	Homo sapiens	70-73
29615583-5	2016	Our results reveal the presence of sequence elements embedded in the medaka hoxa2a and psihoxa2b upstream enhancer regions (UERs) that mediate expression in r4 and the PAs (hoxa2a r4/CNCC element) or in r3-7 and the PAs psihoxa2b r3-7/CNCC element), respectively.	Protactinium	168-171	homeobox protein Hox-A2a	Oryzias latipes	76-82
27014908-7	2016	We observed that c-Src and EGFR forms a complex, and following PA stimulation, it is the successive phosphorylation, not formation, of the c-Src/EGFR complex that results in the subsequent cascade activation.	Protactinium	63-65	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	17-22
27014908-7	2016	We observed that c-Src and EGFR forms a complex, and following PA stimulation, it is the successive phosphorylation, not formation, of the c-Src/EGFR complex that results in the subsequent cascade activation.	Protactinium	63-65	epidermal growth factor receptor	Rattus norvegicus	27-31
27231631-2	2016	Anti-EGFR-GNs provided a significant enhancement in the PA signal in MDA-MB-231 tumor and the axillary LN metastases relative to MCF-7 tumor and non-LN metastases.	Protactinium	56-58	epidermal growth factor receptor	Homo sapiens	5-9
26809801-4	2016	In addition, PA treatment significantly decreased the production of IL-6 (a marker of inflamed tissue) in the toxin A-induced mouse enteritis model.	Protactinium	13-15	interleukin 6	Mus musculus	68-72
26947607-5	2016	Both the inhibition kinetic analysis and molecular modeling study revealed that these compounds showed mixed-type inhibition, binding simultaneously to the CAS and PAS of AChE.	Protactinium	164-167	acetylcholinesterase (Cartwright blood group)	Homo sapiens	171-175
29615583-5	2016	Our results reveal the presence of sequence elements embedded in the medaka hoxa2a and psihoxa2b upstream enhancer regions (UERs) that mediate expression in r4 and the PAs (hoxa2a r4/CNCC element) or in r3-7 and the PAs psihoxa2b r3-7/CNCC element), respectively.	Protactinium	168-171	homeobox protein Hox-A2a	Oryzias latipes	173-179
29615583-5	2016	Our results reveal the presence of sequence elements embedded in the medaka hoxa2a and psihoxa2b upstream enhancer regions (UERs) that mediate expression in r4 and the PAs (hoxa2a r4/CNCC element) or in r3-7 and the PAs psihoxa2b r3-7/CNCC element), respectively.	Protactinium	216-219	homeobox protein Hox-A2a	Oryzias latipes	76-82
26776147-9	2016	These studies show that SHH PA treatment reduces collagen under regenerative post-prostatectomy conditions, indicating broad application for ED prevention in prostatectomy, diabetic and aging patients and in other peripheral nerve injuries.	Protactinium	28-30	sonic hedgehog signaling molecule	Homo sapiens	24-27
26866974-11	2016	GAPDH antibody interacts with proteins that only bind to DGPP and PA.	Protactinium	66-68	LOC548217	Hordeum vulgare	0-5
26828018-6	2016	Protein complexes including the minichromosome maintenance complex (MCM), 26S proteasome and the coat protein I (COPI) complex associated with PA in chicken cells, indicating the essential roles of these functional protein complexes during the course of IAV infection.	Protactinium	143-145	minichromosome maintenance complex component 7	Homo sapiens	68-71
26828018-7	2016	Gene Ontology and pathway enrichment analysis both showed strong enrichment of PA interacting proteins in the category of DNA replication, covering genes such as PCNA, MCM2, MCM3, MCM4, MCM5 and MCM7.	Protactinium	79-81	proliferating cell nuclear antigen	Homo sapiens	162-166
26828018-7	2016	Gene Ontology and pathway enrichment analysis both showed strong enrichment of PA interacting proteins in the category of DNA replication, covering genes such as PCNA, MCM2, MCM3, MCM4, MCM5 and MCM7.	Protactinium	79-81	minichromosome maintenance complex component 2	Homo sapiens	168-172
26828018-7	2016	Gene Ontology and pathway enrichment analysis both showed strong enrichment of PA interacting proteins in the category of DNA replication, covering genes such as PCNA, MCM2, MCM3, MCM4, MCM5 and MCM7.	Protactinium	79-81	minichromosome maintenance complex component 3	Homo sapiens	174-178
26828018-7	2016	Gene Ontology and pathway enrichment analysis both showed strong enrichment of PA interacting proteins in the category of DNA replication, covering genes such as PCNA, MCM2, MCM3, MCM4, MCM5 and MCM7.	Protactinium	79-81	minichromosome maintenance complex component 4	Homo sapiens	180-184
26828018-7	2016	Gene Ontology and pathway enrichment analysis both showed strong enrichment of PA interacting proteins in the category of DNA replication, covering genes such as PCNA, MCM2, MCM3, MCM4, MCM5 and MCM7.	Protactinium	79-81	minichromosome maintenance complex component 5	Homo sapiens	186-190
26828018-7	2016	Gene Ontology and pathway enrichment analysis both showed strong enrichment of PA interacting proteins in the category of DNA replication, covering genes such as PCNA, MCM2, MCM3, MCM4, MCM5 and MCM7.	Protactinium	79-81	minichromosome maintenance complex component 7	Homo sapiens	195-199
26860184-4	2016	Herein, we developed a CD44 targeted photoacoustic (PA) nanophototherapy agent by conjugating Indocyanine Green (ICG) to hyaluronic acid nanoparticles (HANPs) encapsulated with single-walled carbon nanotubes (SWCNTs), resulting in a theranostic nanocomplex of ICG-HANP/SWCNTs (IHANPT).	Protactinium	52-54	CD44 antigen	Mus musculus	23-27
26776147-15	2016	These results suggest that SHH treatment by PA has translational potential to suppress collagen induction and remodelling, an irreversible component of ED development.	Protactinium	44-46	sonic hedgehog signaling molecule	Homo sapiens	27-30
26718241-6	2016	Data from our pharmacologic and genetic approaches suggest that AR activation-mediated vasodilation in the PA is mediated by both the A2AAR and A2BAR, whereas neither the A1AR nor A3AR play a role in vascular tone regulation of the PA.	Protactinium	107-109	adenosine A2a receptor	Mus musculus	134-139
26637231-15	2016	The baseline serum IL-17 levels were significantly higher in patients with PA than in the control group (p = 0.001).	Protactinium	75-77	interleukin 17A	Homo sapiens	19-24
26718241-6	2016	Data from our pharmacologic and genetic approaches suggest that AR activation-mediated vasodilation in the PA is mediated by both the A2AAR and A2BAR, whereas neither the A1AR nor A3AR play a role in vascular tone regulation of the PA.	Protactinium	107-109	adenosine A2b receptor	Mus musculus	144-149
26702100-7	2016	Importantly, inhibition of mTORC1 signaling by rapamycin treatment aggravated the neurodegenerative phenotype in a TDP-43-depleted Drosophila model, whereas activation of mTORC1 signaling by PA treatment ameliorated the neurodegenerative phenotype.	Protactinium	191-193	CREB regulated transcription coactivator 1	Mus musculus	171-177
27420317-5	2016	The questions dealt with the reliability of the questionnaires in assessing physical activity in children, choices of the cut-off points for considering levels of physical activity as moderate or intense, and the association of leptin with PA levels.	Protactinium	240-242	leptin	Homo sapiens	228-234
26907386-11	2016	IL-6 mRNA was higher in the labouring PA group.	Protactinium	38-40	interleukin 6	Rattus norvegicus	0-4
26907386-13	2016	At birth, IL-10 mRNA increased in the PA group; however, IL-10 protein decreased in both the PA and the FA group.	Protactinium	38-40	interleukin 10	Rattus norvegicus	10-15
26907386-13	2016	At birth, IL-10 mRNA increased in the PA group; however, IL-10 protein decreased in both the PA and the FA group.	Protactinium	93-95	interleukin 10	Rattus norvegicus	57-62
26323261-7	2016	Expression of Cav-1 was correlated with Ki67 labeling index in PAs, but not in malignant tumors.	Protactinium	63-66	caveolin 1	Homo sapiens	14-19
26792748-2	2016	The PA linker (residues 197 to 256) can be altered by nucleotide substitutions to engineer temperature-sensitive (ts), attenuated mutants that display a defect in the transport of the PA-PB1 complex to the nucleus at a restrictive temperature.	Protactinium	4-6	polybromo 1	Homo sapiens	187-190
26626506-8	2016	The effects of PA upon fibroblasts were dependent upon ALK receptor function.	Protactinium	15-17	ALK receptor tyrosine kinase	Homo sapiens	55-58
26189033-7	2016	Significant positive correlations were found between faux pas detection and the MCCB domains of Attention/Vigilance and Working Memory in CHR participants when controlling for age and years of education.	Protactinium	58-61	methylcrotonyl-CoA carboxylase subunit 2	Homo sapiens	80-84
26700464-5	2016	Three TF-binding sequences were identified (EGR, RLM, and RTL), covalently incorporated into the PA backbone, and shown to self-assemble into nanofibers by cryo-transmission electron microscopy.	Protactinium	97-99	coagulation factor III, tissue factor	Homo sapiens	6-8
26700464-11	2016	In summary, these studies demonstrate successful binding of peptides to TF in vitro and successful homing of a TF-targeted PA nanofiber to the site of hemorrhage with an associated decrease in blood loss in vivo.	Protactinium	123-125	coagulation factor III, tissue factor	Homo sapiens	111-113
27463119-4	2016	PLAG1 IHC expression has been reported to be positive in most PAs.	Protactinium	62-65	PLAG1 zinc finger	Homo sapiens	0-5
26522130-3	2016	The objective of the study was to evaluate the expression of FSCN1 in 312 PAs cases, and to analyze its association with clinicopathologic features and invasion of PAs, thus serving as a promoter of cancer invasion.	Protactinium	74-77	fascin actin-bundling protein 1	Rattus norvegicus	61-66
26727491-6	2016	In order to understand structural and ligand binding features we compared the stability and dynamics of the promiscuous AhR PAS-B to other PAS domains exhibiting specific interactions or no ligand binding function.	Protactinium	124-127	aryl hydrocarbon receptor	Homo sapiens	120-123
27463119-12	2016	Hence, PLAG1 is a modest marker for PAs in FNAs.	Protactinium	36-39	PLAG1 zinc finger	Homo sapiens	7-12
27843479-5	2016	Moreover, PCE treatment recovered the expression of autophagy marker genes such as beclin-1 and p62, which was decreased by PA treatment.	Protactinium	124-126	beclin 1	Rattus norvegicus	83-91
27843479-5	2016	Moreover, PCE treatment recovered the expression of autophagy marker genes such as beclin-1 and p62, which was decreased by PA treatment.	Protactinium	124-126	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	96-99
27843479-3	2016	PCE significantly increased cell viability in PA-treated PC12 cells and showed antiapoptotic effects, as evidenced by decreased expression of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, and bax protein as well as increased expression of bcl-2 protein.	Protactinium	46-48	BCL2 associated X, apoptosis regulator	Rattus norvegicus	202-205
26383537-8	2015	PA, but not sulindac, suppressed levels of Wnt pathway effector beta-catenin (a critical regulator of CSC proliferation) and its downstream proteins (c-Myc and cyclin D1) and elevated Bax and cytochrome c, proteins-mediating mitochondrial apoptosis.	Protactinium	0-2	cytochrome c	Solanum tuberosum	192-204
27843479-3	2016	PCE significantly increased cell viability in PA-treated PC12 cells and showed antiapoptotic effects, as evidenced by decreased expression of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, and bax protein as well as increased expression of bcl-2 protein.	Protactinium	46-48	BCL2, apoptosis regulator	Rattus norvegicus	249-254
26964390-2	2016	In ECD, central nervous system (CNS) and orbital lesions are frequent, and more than half of ECD pa tients carry the V600E mutation of the protooncogene BRAF.	Protactinium	97-99	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	153-157
26526811-3	2015	It has also been found that HIF2alpha C-terminal PAS domains can form complexes with inactive benzoxadiazole antagonists.	Protactinium	49-52	endothelial PAS domain protein 1	Homo sapiens	28-37
26332891-1	2015	Ingestion of a high-fat diet composed mainly of the saturated fatty acid, palmitic (PA), and the unsaturated fatty acid, oleic (OA), stimulates transcription in the brain of the opioid neuropeptide, enkephalin (ENK), which promotes intake of substances of abuse.	Protactinium	84-86	pyroglutamylated RFamide peptide	Rattus norvegicus	185-197
26332891-4	2015	In the second set of experiments, PA treatment of hypothalamic and forebrain neurons had no effect on PPARdelta protein while stimulating ENK mRNA and protein, whereas OA increased both mRNA and protein levels of PPARdelta in forebrain neurons while having no effect on ENK mRNA and increasing ENK levels.	Protactinium	34-36	proenkephalin	Rattus norvegicus	138-141
26332891-5	2015	These findings show that PA has a strong, stimulatory effect on ENK and weak effect on PPARdelta protein, whereas OA has a strong stimulatory effect on PPARdelta and weak effect on ENK, consistent with the inhibitory effect of PPARdelta on ENK.	Protactinium	25-27	proenkephalin	Rattus norvegicus	64-67
27299133-1	2016	INTRODUCTION: Infantile Systemic Hyalinosis (ISH) is a rare and fatal genetic disorder with mutations in Capillary morphogenesis gene-2 CMG2 / Human anthrax toxin receptor gene-2 ANTXR2 resulting in spindle cell proliferation, altered collagen metabolism with extensive deposition of amorphous eosinophilic PAS positive hyaline material in the connective tissues of various organs.	Protactinium	307-310	ANTXR cell adhesion molecule 2	Homo sapiens	179-185
25925675-10	2016	When used on PA data obtained from a 12-day-old mouse embryo, the DAS + SCF processing improved visualization of neurovasculature.	Protactinium	13-15	kit ligand	Mus musculus	72-75
26637296-4	2015	RESULTS: Seipin prevents a localized accumulation of phosphatidic acid (PA puncta) at ER-droplet junctions.	Protactinium	72-74	BSCL2 lipid droplet biogenesis associated, seipin	Homo sapiens	9-15
26637296-8	2015	Suppression of PA puncta requires the first 14 amino acids of Sei1p (Nterm), a domain that is also important for initiation of droplet assembly.	Protactinium	15-17	SERTA domain containing 1	Homo sapiens	62-67
26637296-9	2015	Consistent with recent evidence that Ldb16p and Sei1p form a functional unit, the PA puncta phenotype in the ldb16Delta sei1Delta strain was rescued by human seipin.	Protactinium	82-84	SERTA domain containing 1	Homo sapiens	48-53
26637296-9	2015	Consistent with recent evidence that Ldb16p and Sei1p form a functional unit, the PA puncta phenotype in the ldb16Delta sei1Delta strain was rescued by human seipin.	Protactinium	82-84	BSCL2 lipid droplet biogenesis associated, seipin	Homo sapiens	158-164
26637296-10	2015	Moreover, PA puncta in the sei1Delta strain expressing Sei1p(DeltaNterm) was suppressed by overexpression of Ldb16p, suggesting a functional interaction of Nterm with this protein.	Protactinium	10-12	SERTA domain containing 1	Homo sapiens	55-60
26888838-9	2015	The electrophysiological analysis indicated that SCN5A-V411M significantly increased the peak current density ((230.8 +- 27.6)pA/pF vs. (101.2 +- 10.9)pA/pF, n=10, P&lt;0.01) and the late sodium current ((156.6 +- 13.6)pA/pF vs. (95.9 +- 7.9)pA/pF, n=12, P&lt;0.01) of sodium channel compared to wide type.	Protactinium	126-128	sodium voltage-gated channel alpha subunit 5	Homo sapiens	49-54
26506981-2	2015	Henry"s constant values range from 13.8 x 10(5) Pa for n-butane in [C5C1im][Ntf2] at 303 K to 64.5 x 10(5) Pa for isobutane in [(2mC3)C1im][Ntf2] at 343 K. The difference in solubility between the two gases can be explained by a more negative enthalpy of solvation for n-butane.	Protactinium	48-50	nuclear transport factor 2	Homo sapiens	76-80
26593397-6	2015	The YfiB-YfiR complex reveals a conserved interaction surface on YfiR that overlaps with residues predicted to interact with the periplasmic PAS domain of YfiN.	Protactinium	141-144	hypothetical protein	Pseudomonas aeruginosa PAO1	4-8
26593397-6	2015	The YfiB-YfiR complex reveals a conserved interaction surface on YfiR that overlaps with residues predicted to interact with the periplasmic PAS domain of YfiN.	Protactinium	141-144	hypothetical protein	Pseudomonas aeruginosa PAO1	9-13
26593397-6	2015	The YfiB-YfiR complex reveals a conserved interaction surface on YfiR that overlaps with residues predicted to interact with the periplasmic PAS domain of YfiN.	Protactinium	141-144	hypothetical protein	Pseudomonas aeruginosa PAO1	65-69
26454504-4	2015	Kinetic and molecular modeling studies suggested that compound 9d was mixed-type inhibitor, binding simultaneously to CAS and PAS of AChE.	Protactinium	126-129	acetylcholinesterase (Cartwright blood group)	Homo sapiens	133-137
26503718-12	2015	Open-state stabilization in Elk1 requires the N-terminal eag domain (PAS domain + Cap), and PIP2-dependent stabilization is enhanced by a conserved basic residue (K5) in the Cap.	Protactinium	69-72	ETS transcription factor ELK1	Homo sapiens	28-32
26503718-12	2015	Open-state stabilization in Elk1 requires the N-terminal eag domain (PAS domain + Cap), and PIP2-dependent stabilization is enhanced by a conserved basic residue (K5) in the Cap.	Protactinium	69-72	potassium voltage-gated channel subfamily H member 1	Homo sapiens	57-60
26238078-6	2015	We propose 20-nm anti-HER2 scFv-conjugated IONPs (SNP20) as a novel PA contrast agent.	Protactinium	68-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26
26238078-6	2015	We propose 20-nm anti-HER2 scFv-conjugated IONPs (SNP20) as a novel PA contrast agent.	Protactinium	68-70	immunglobulin heavy chain variable region	Homo sapiens	27-31
26238078-8	2015	These data indicate that SNP20 is a potential PA contrast agent for imaging of HER2-expressing tumors.	Protactinium	46-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83
25981612-13	2015	CONCLUSIONS: PVR for PA can be performed safely.	Protactinium	21-23	PVR cell adhesion molecule	Homo sapiens	13-16
25646352-8	2015	The positive effect of PPT-S was stronger for those higher in PA (OR = 6.69, 95% CI = 1.16, 38.47, p = .03).	Protactinium	62-64	tachykinin precursor 1	Homo sapiens	23-26
26438221-7	2015	When compared to other insects" orthologues, L. longipalpis CLOCK shows a high degree of conservation in the functional domains bHLH and PAS, but a much shorter glutamine-rich (poly-Q) C-terminal region.	Protactinium	137-140	Clock	Drosophila melanogaster	60-65
26722256-2	2015	Western blotting was performed to confirm the expression profile of AGR2 in different subtypes of PAs.	Protactinium	98-101	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	68-72
26722256-4	2015	Although AGR2 expression occurred more frequently in PAs secreting growth hormone (GH; 62.5%), adrenocorticotropic hormone (ACTH; 80.0%) and follicle-stimulating hormone (FSH; 75.0%),the positive expression rate of AGR2 showed no statistically significant differences between PA subtypes (P&gt;0.05).	Protactinium	53-56	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	9-13
26722256-4	2015	Although AGR2 expression occurred more frequently in PAs secreting growth hormone (GH; 62.5%), adrenocorticotropic hormone (ACTH; 80.0%) and follicle-stimulating hormone (FSH; 75.0%),the positive expression rate of AGR2 showed no statistically significant differences between PA subtypes (P&gt;0.05).	Protactinium	53-56	growth hormone 1	Homo sapiens	67-81
26722256-7	2015	In conclusion, the current study detected the expression of AGR2 in different subtypes of PAs for the first time.	Protactinium	90-93	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	60-64
26722256-9	2015	AGR2 may be a target for the study of PA aggressiveness, and a potential index for the diagnosis or prognosis of PAs.	Protactinium	113-116	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	0-4
26269581-5	2015	We show that the conserved phosphatidate (PA) phosphatase Pah1, which generates diacylglycerol from PA, targets a nuclear membrane subdomain that is in contact with growing lipid droplets and mediates TAG synthesis.	Protactinium	42-44	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	58-62
26269581-5	2015	We show that the conserved phosphatidate (PA) phosphatase Pah1, which generates diacylglycerol from PA, targets a nuclear membrane subdomain that is in contact with growing lipid droplets and mediates TAG synthesis.	Protactinium	100-102	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	58-62
26301632-8	2015	In addition, Over-expression of PRDX1 enhanced PA-induced insulin resistance in HepG2 cells.	Protactinium	47-49	peroxiredoxin 1	Homo sapiens	32-37
26301632-8	2015	In addition, Over-expression of PRDX1 enhanced PA-induced insulin resistance in HepG2 cells.	Protactinium	47-49	insulin	Homo sapiens	58-65
26407865-6	2015	Noteworthy, the migration capacity of PA-MSCs of second passage was significantly improved after stimulation with FGF-2 (P &lt; 0.02), PDGF-BB (P &lt; 0.006), MCP-1 (P &lt; 0.002) and IL-6 (P &lt; 0.03), whereas only TGF-beta enhanced significantly migration process of PA-MSCs of P4 12 h after the treatment (P &lt; 0.02).	Protactinium	38-40	fibroblast growth factor 2	Homo sapiens	114-119
26681867-2	2015	In this paper, we present a case of PA in a 44-year-old male affecting the right retromolar trigone area along with its immunohistochemical profile using CK19 and Ber-EP4 markers.	Protactinium	36-38	keratin 19	Homo sapiens	154-158
26423353-4	2015	We have generated a computational model of CRY2-Akt activation that allows us to use PA-Akt to control the activity quantitatively.	Protactinium	85-87	cryptochrome 2	Arabidopsis thaliana	43-47
26407865-6	2015	Noteworthy, the migration capacity of PA-MSCs of second passage was significantly improved after stimulation with FGF-2 (P &lt; 0.02), PDGF-BB (P &lt; 0.006), MCP-1 (P &lt; 0.002) and IL-6 (P &lt; 0.03), whereas only TGF-beta enhanced significantly migration process of PA-MSCs of P4 12 h after the treatment (P &lt; 0.02).	Protactinium	38-40	C-C motif chemokine ligand 2	Homo sapiens	159-164
26407865-6	2015	Noteworthy, the migration capacity of PA-MSCs of second passage was significantly improved after stimulation with FGF-2 (P &lt; 0.02), PDGF-BB (P &lt; 0.006), MCP-1 (P &lt; 0.002) and IL-6 (P &lt; 0.03), whereas only TGF-beta enhanced significantly migration process of PA-MSCs of P4 12 h after the treatment (P &lt; 0.02).	Protactinium	38-40	interleukin 6	Homo sapiens	184-188
26407865-6	2015	Noteworthy, the migration capacity of PA-MSCs of second passage was significantly improved after stimulation with FGF-2 (P &lt; 0.02), PDGF-BB (P &lt; 0.006), MCP-1 (P &lt; 0.002) and IL-6 (P &lt; 0.03), whereas only TGF-beta enhanced significantly migration process of PA-MSCs of P4 12 h after the treatment (P &lt; 0.02).	Protactinium	38-40	transforming growth factor beta 1	Homo sapiens	217-225
25724441-9	2015	Mice that received high and medium dose of PA-MSHA had significantly higher serum levels of IFN-gamma and TNF-alpha (days 21 and 28), and higher levels of CD4(+) /CD8(+) cells (days 21 and 28).	Protactinium	43-45	interferon gamma	Mus musculus	92-101
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	Protactinium	16-18	insulin	Homo sapiens	33-40
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	Protactinium	16-18	AKT serine/threonine kinase 1	Homo sapiens	134-137
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	Protactinium	16-18	glycogen synthase kinase 3 beta	Homo sapiens	143-174
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	Protactinium	16-18	glycogen synthase kinase 3 beta	Homo sapiens	176-184
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	Protactinium	16-18	insulin	Homo sapiens	196-203
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	Protactinium	16-18	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	236-241
26084306-6	2015	We provide evidence that miR-223 is downregulated in human PAH lungs, distal PAs, and isolated PASMCs.	Protactinium	77-80	microRNA 223	Homo sapiens	25-32
26209484-10	2015	Electron microscopy of ACE-sealed PA vessels demonstrated adventitial sealing with partial preservation of the collagen bundles and media with a sealed matrix of melted collagen.	Protactinium	34-36	angiotensin I converting enzyme	Homo sapiens	23-26
26209484-11	2015	CONCLUSIONS: PA branches sealed using the HARMONIC ACE+ in a simulated ex vivo model were able to sustain high intraluminal pressures.	Protactinium	13-15	angiotensin I converting enzyme	Homo sapiens	51-54
25724441-9	2015	Mice that received high and medium dose of PA-MSHA had significantly higher serum levels of IFN-gamma and TNF-alpha (days 21 and 28), and higher levels of CD4(+) /CD8(+) cells (days 21 and 28).	Protactinium	43-45	tumor necrosis factor	Mus musculus	106-115
25724441-9	2015	Mice that received high and medium dose of PA-MSHA had significantly higher serum levels of IFN-gamma and TNF-alpha (days 21 and 28), and higher levels of CD4(+) /CD8(+) cells (days 21 and 28).	Protactinium	43-45	CD4 antigen	Mus musculus	155-158
26202921-10	2015	MAIN RESULTS AND THE ROLE OF CHANCE: The long chain saturated fatty acids, stearic and palmitic (PA), stimulated the synthesis as well as the release of TNF-alpha, IL-6 and IL-8 by trophoblast cells (2- to 6-fold, P &lt; 0.001).	Protactinium	97-99	tumor necrosis factor	Homo sapiens	153-162
26202921-10	2015	MAIN RESULTS AND THE ROLE OF CHANCE: The long chain saturated fatty acids, stearic and palmitic (PA), stimulated the synthesis as well as the release of TNF-alpha, IL-6 and IL-8 by trophoblast cells (2- to 6-fold, P &lt; 0.001).	Protactinium	97-99	interleukin 6	Homo sapiens	164-168
26202921-10	2015	MAIN RESULTS AND THE ROLE OF CHANCE: The long chain saturated fatty acids, stearic and palmitic (PA), stimulated the synthesis as well as the release of TNF-alpha, IL-6 and IL-8 by trophoblast cells (2- to 6-fold, P &lt; 0.001).	Protactinium	97-99	C-X-C motif chemokine ligand 8	Homo sapiens	173-177
26202921-13	2015	LIMITATIONS, REASONS FOR CAUTION: TNF-alpha protein level was close to the limit of detection in the culture medium even when cells were cultured with PA.	Protactinium	151-153	tumor necrosis factor	Homo sapiens	34-43
26136104-6	2015	The results revealed that treatment with YCG063 significantly inhibited the levels of IL-6, IL-8, MCP-1 and ICAM-1 in the PA-LPS-stimulated ARPE-19 cells.	Protactinium	122-124	C-C motif chemokine ligand 2	Homo sapiens	98-103
26136104-6	2015	The results revealed that treatment with YCG063 significantly inhibited the levels of IL-6, IL-8, MCP-1 and ICAM-1 in the PA-LPS-stimulated ARPE-19 cells.	Protactinium	122-124	intercellular adhesion molecule 1	Homo sapiens	108-114
26224795-7	2015	METHODS AND RESULTS: BRD4 is upregulated in lungs, distal PAs, and PASMCs of patients with PAH compared with controls.	Protactinium	58-61	bromodomain containing 4	Homo sapiens	21-25
26321697-4	2015	The KIAA1549-BRAF fusion gene has been found in approximately 70% of PAs, but is reportedly rare in PMAs.	Protactinium	69-72	KIAA1549	Homo sapiens	4-12
26321697-4	2015	The KIAA1549-BRAF fusion gene has been found in approximately 70% of PAs, but is reportedly rare in PMAs.	Protactinium	69-72	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	13-17
26321697-17	2015	In summary, no BRAF V600E mutations were found in PMSAs, but KIAA1549-BRAF fusion was identified in IPT, particularly in the PA component.	Protactinium	125-127	KIAA1549	Homo sapiens	61-69
26321697-17	2015	In summary, no BRAF V600E mutations were found in PMSAs, but KIAA1549-BRAF fusion was identified in IPT, particularly in the PA component.	Protactinium	125-127	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	70-74
26321697-17	2015	In summary, no BRAF V600E mutations were found in PMSAs, but KIAA1549-BRAF fusion was identified in IPT, particularly in the PA component.	Protactinium	125-127	tRNA isopentenyltransferase 1	Homo sapiens	100-103
26168727-3	2015	In vitro PA imaging studies demonstrated that Pan-EG4-ICG yielded high EGFR-specific PA signals in EGFR-positive cells.	Protactinium	9-11	epidermal growth factor receptor	Mus musculus	71-75
26168727-3	2015	In vitro PA imaging studies demonstrated that Pan-EG4-ICG yielded high EGFR-specific PA signals in EGFR-positive cells.	Protactinium	85-87	epidermal growth factor receptor	Mus musculus	71-75
26168727-3	2015	In vitro PA imaging studies demonstrated that Pan-EG4-ICG yielded high EGFR-specific PA signals in EGFR-positive cells.	Protactinium	85-87	epidermal growth factor receptor	Mus musculus	99-103
26168727-7	2015	Co-injection of excess Pan resulted in a 35% inhibition of this PA signal, indicating the EGFR-specific accumulation.	Protactinium	64-66	epidermal growth factor receptor	Mus musculus	90-94
26226049-3	2015	To provide artificial routes to target misregulated HIF activity, we identified small molecule antagonists of the HIF-2 transcription factor that bind an internal cavity within the C-terminal PAS domain of the HIF-2alpha subunit.	Protactinium	192-195	endothelial PAS domain protein 1	Homo sapiens	210-220
26072115-10	2015	Therefore, binding of PAS inhibitors at the main door of AChE remain ineffective against AAA activity.	Protactinium	22-25	acetylcholinesterase (Cartwright blood group)	Homo sapiens	57-61
26345861-1	2015	We determined the alleles of ten single nucleotide poly-morphisms (SNPs) in the APOA5/A4/C3/A1 gene cluster and in APOB in Han Chinese from Xinjiang Shihezi, China using MALDI-TOF mass spectrometry, and explored the correlation between these SNPs and dyslipidemia through a case-control study design with 250 pa-tients and 250 normal controls.	Protactinium	309-311	apolipoprotein A5	Homo sapiens	80-85
25918143-1	2015	Amino acid residues in the N-terminal of the PA subunit (PAN) of the influenza A virus polymerase play critical roles in endonuclease activity, protein stability, and viral RNA (vRNA) promoter binding.	Protactinium	45-47	adenosine deaminase 2	Homo sapiens	57-60
25963985-7	2015	The covariate effects associated with efavirenz, gender, and NAT1*3, NAT1*14, and NAT2*5 alleles corresponded to 25, 37, -17, -48, and -27% changes, respectively, in oral clearance of PAS.	Protactinium	184-187	N-acetyltransferase 1	Homo sapiens	61-65
25963985-12	2015	We confirm that the slow phenotype conferred by the NAT1*14 and NAT1*3 alleles resulted in higher PAS exposure but found no evidence of increased activity of the NAT1*10 allele.	Protactinium	98-101	N-acetyltransferase 1	Homo sapiens	64-68
25963985-7	2015	The covariate effects associated with efavirenz, gender, and NAT1*3, NAT1*14, and NAT2*5 alleles corresponded to 25, 37, -17, -48, and -27% changes, respectively, in oral clearance of PAS.	Protactinium	184-187	N-acetyltransferase 1	Homo sapiens	69-73
25963985-12	2015	We confirm that the slow phenotype conferred by the NAT1*14 and NAT1*3 alleles resulted in higher PAS exposure but found no evidence of increased activity of the NAT1*10 allele.	Protactinium	98-101	N-acetyltransferase 1	Homo sapiens	64-68
25963985-7	2015	The covariate effects associated with efavirenz, gender, and NAT1*3, NAT1*14, and NAT2*5 alleles corresponded to 25, 37, -17, -48, and -27% changes, respectively, in oral clearance of PAS.	Protactinium	184-187	N-acetyltransferase 2	Homo sapiens	82-86
25963985-12	2015	We confirm that the slow phenotype conferred by the NAT1*14 and NAT1*3 alleles resulted in higher PAS exposure but found no evidence of increased activity of the NAT1*10 allele.	Protactinium	98-101	N-acetyltransferase 1	Homo sapiens	52-56
25988279-3	2015	PA (amino acid micro-nutrient) was used as a ligand which facilitated carrier mediated transport (CMT) via l-amino acid transporter i.e. LAT1 to traverse BBB.	Protactinium	0-2	solute carrier family 7 member 5	Homo sapiens	137-141
25824146-5	2015	Likewise, in mice, exposure to CH increased BMP4 expression in distal PA for ~80%, which was absent in HIF-1alpha heterozygous mutant mice.	Protactinium	70-72	bone morphogenetic protein 4	Mus musculus	44-48
25824146-6	2015	Comparing with wild-type littermates, BMP4 heterozygous mutant mice exposed to CH displayed lower BMP4 and TRPC levels in PA, decreased basal [Ca(2+)]i in PASMCs, and attenuated CHPH.	Protactinium	122-124	bone morphogenetic protein 4	Mus musculus	38-42
25988279-4	2015	PA was coupled to SLN via amide linkage using carbodiimide chemistry and coupling was confirmed by comparative infrared spectroscopic analysis.	Protactinium	0-2	sarcolipin	Homo sapiens	18-21
25701423-9	2015	When applied to full lipid extracts from rat primary cardiomyocytes treated with peroxynitrite donor SIN-1, ten PL-bound oxoLPP were unambiguously identified by LC-MS, including two PC-, two PE-, one PG-, two PS-, and three PA-derived species.	Protactinium	224-226	MAPK associated protein 1	Homo sapiens	101-106
25988279-7	2015	In vivo studies showed 2-3-folds and 7-8-folds accumulation of PA-SLN in brain as compared to SLN and EFV, respectively.	Protactinium	63-65	sarcolipin	Homo sapiens	66-69
25855727-0	2015	Temperature-Sensitive Mutants in the Influenza A Virus RNA Polymerase: Alterations in the PA Linker Reduce Nuclear Targeting of the PB1-PA Dimer and Result in Viral Attenuation.	Protactinium	90-92	polybromo 1	Homo sapiens	132-135
26058015-8	2015	Behavioral tests revealed that MCPs facilitated long-term learning and memory of the pups with PA through reducing oxidative damage and acetylcholinesterase (AChE) activity in the brain, and increasing hippocampus phosphorylated cAMP-response element binding protein (p-CREB) and brain derived neurotrophic factor (BDNF) expression.	Protactinium	95-97	acetylcholinesterase	Rattus norvegicus	136-156
26058015-8	2015	Behavioral tests revealed that MCPs facilitated long-term learning and memory of the pups with PA through reducing oxidative damage and acetylcholinesterase (AChE) activity in the brain, and increasing hippocampus phosphorylated cAMP-response element binding protein (p-CREB) and brain derived neurotrophic factor (BDNF) expression.	Protactinium	95-97	acetylcholinesterase	Rattus norvegicus	158-162
25818119-10	2015	Therefore, nasal immunization of mice with Bacillus anthracis protective antigen (PA) adsorbed on Chi-C48/80 NP elicited high levels of serum anti-PA neutralizing antibodies and a more balanced Th1/Th2 profile than C48/80 in solution or Chi/Alg-C48/80 NP.	Protactinium	82-84	negative elongation factor complex member C/D, Th1l	Mus musculus	194-197
25818119-10	2015	Therefore, nasal immunization of mice with Bacillus anthracis protective antigen (PA) adsorbed on Chi-C48/80 NP elicited high levels of serum anti-PA neutralizing antibodies and a more balanced Th1/Th2 profile than C48/80 in solution or Chi/Alg-C48/80 NP.	Protactinium	82-84	heart and neural crest derivatives expressed 2	Mus musculus	198-201
26166073-4	2015	A selective nuclear expression of Bmi-1 was found exclusively in the malignant component of 8 cases (6 luminal type and 2 myoepithelial type), including intraductal carcinoma areas, except for 1 case in which scarce cells of the remnant PA were positive.	Protactinium	237-239	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	34-39
25855727-0	2015	Temperature-Sensitive Mutants in the Influenza A Virus RNA Polymerase: Alterations in the PA Linker Reduce Nuclear Targeting of the PB1-PA Dimer and Result in Viral Attenuation.	Protactinium	136-138	polybromo 1	Homo sapiens	132-135
25855727-3	2015	We investigated the structure and function of the PA linker (residues 197 to 256), located between its N-terminal endonuclease domain and its C-terminal structured domain that binds PB1, the polymerase core.	Protactinium	50-52	polybromo 1	Homo sapiens	182-185
25732140-8	2015	PA produced hypophosphorylation of the GR at Ser-232 without affecting expression of total protein.	Protactinium	0-2	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	39-41
25835215-4	2015	Using a global PA rat model, we report here evidence that hypoxia increases PARP-1 activity, triggering a signalling cascade leading to nuclear translocation of the NF-kappaB subunit p65, modulating the expression of IL-1beta and TNF-alpha, pro-inflammatory molecules, increasing apoptotic-like cell death in mesencephalon of neonate rats, monitored with Western blots, qPCR, TUNEL and ELISA.	Protactinium	15-17	poly (ADP-ribose) polymerase 1	Rattus norvegicus	76-82
25481255-7	2015	The detection rate for two CYP21A2 mutations was higher in girls with PA than in adult females with hyperandrogenemia in our studied population.	Protactinium	70-72	cytochrome P450 family 21 subfamily A member 2	Homo sapiens	27-34
25481255-9	2015	CONCLUSIONS: In girls with PA, the frequency of the underlying CYP21A2 genetic defects is similar to that observed in other populations.	Protactinium	27-29	cytochrome P450 family 21 subfamily A member 2	Homo sapiens	63-70
25575510-2	2015	It has been previously reported that unconventional repeat-associated non-ATG (RAN) translation of GGGGCC GGCCCC repeats produces five types of dipeptide-repeat proteins (referred to as RAN proteins): poly-glycine-alanine (GA), poly-glycine-proline (GP), poly-glycine-arginine (GR), poly-proline-arginine (PR) and poly-proline-alanine (PA).	Protactinium	336-338	RAN, member RAS oncogene family	Homo sapiens	79-82
25575510-2	2015	It has been previously reported that unconventional repeat-associated non-ATG (RAN) translation of GGGGCC GGCCCC repeats produces five types of dipeptide-repeat proteins (referred to as RAN proteins): poly-glycine-alanine (GA), poly-glycine-proline (GP), poly-glycine-arginine (GR), poly-proline-arginine (PR) and poly-proline-alanine (PA).	Protactinium	336-338	RAN, member RAS oncogene family	Homo sapiens	186-189
25835215-4	2015	Using a global PA rat model, we report here evidence that hypoxia increases PARP-1 activity, triggering a signalling cascade leading to nuclear translocation of the NF-kappaB subunit p65, modulating the expression of IL-1beta and TNF-alpha, pro-inflammatory molecules, increasing apoptotic-like cell death in mesencephalon of neonate rats, monitored with Western blots, qPCR, TUNEL and ELISA.	Protactinium	15-17	synaptotagmin 1	Rattus norvegicus	183-186
25835215-4	2015	Using a global PA rat model, we report here evidence that hypoxia increases PARP-1 activity, triggering a signalling cascade leading to nuclear translocation of the NF-kappaB subunit p65, modulating the expression of IL-1beta and TNF-alpha, pro-inflammatory molecules, increasing apoptotic-like cell death in mesencephalon of neonate rats, monitored with Western blots, qPCR, TUNEL and ELISA.	Protactinium	15-17	interleukin 1 beta	Rattus norvegicus	217-225
25835215-8	2015	), 1 h post delivery, prevented the effect of PA on PARP-1 activity, p65 translocation, pro-inflammatory cytokine expression and apoptotic-like cell death.	Protactinium	46-48	poly (ADP-ribose) polymerase 1	Rattus norvegicus	52-58
25835215-8	2015	), 1 h post delivery, prevented the effect of PA on PARP-1 activity, p65 translocation, pro-inflammatory cytokine expression and apoptotic-like cell death.	Protactinium	46-48	synaptotagmin 1	Rattus norvegicus	69-72
25835215-9	2015	The present study demonstrates that PA leads to PARP-1 overactivation, increasing the expression of pro-inflammatory cytokines and cell death in mesencephalon, effects prevented by systemic neonatal nicotinamide administration, supporting the idea that PARP-1 inhibition represents a therapeutic target against the effects of PA.	Protactinium	36-38	poly (ADP-ribose) polymerase 1	Rattus norvegicus	48-54
25835215-9	2015	The present study demonstrates that PA leads to PARP-1 overactivation, increasing the expression of pro-inflammatory cytokines and cell death in mesencephalon, effects prevented by systemic neonatal nicotinamide administration, supporting the idea that PARP-1 inhibition represents a therapeutic target against the effects of PA.	Protactinium	36-38	poly (ADP-ribose) polymerase 1	Rattus norvegicus	253-259
25754290-13	2015	Finally, PA were disintegrated by plasmin-mediated thrombolysis but not by integrin alphaIIb beta3 inhibition.	Protactinium	9-11	plasminogen	Homo sapiens	34-41
25694392-6	2015	The proton affinity of silicon trimer is determined as PA(Si3) = 830 +- 4 kJ/mol at 298 K. The metal cation affinities are also predicted to be LiCA(Si3) = 108 +- 8 kJ/mol, NaCA(Si3) = 79 +- 8 kJ/mol and KCA(Si3) = 44 +- 8 kJ/mol.	Protactinium	55-57	nascent polypeptide associated complex subunit alpha	Homo sapiens	173-177
25768656-9	2015	This study represents the first report that the 7-GS-DHP adduct can be a potential reactive metabolite of PAs leading to DNA adduct formation.	Protactinium	106-109	dihydropyrimidinase	Homo sapiens	53-56
25923736-4	2015	Here, we found that PKB-mediated phosphorylation of Thr649 on AS160/TBC1D4 represented one of the major PAS-binding signals in the heart in response to insulin.	Protactinium	104-107	thymoma viral proto-oncogene 1	Mus musculus	20-23
25923736-4	2015	Here, we found that PKB-mediated phosphorylation of Thr649 on AS160/TBC1D4 represented one of the major PAS-binding signals in the heart in response to insulin.	Protactinium	104-107	TBC1 domain family, member 4	Mus musculus	62-67
25923736-4	2015	Here, we found that PKB-mediated phosphorylation of Thr649 on AS160/TBC1D4 represented one of the major PAS-binding signals in the heart in response to insulin.	Protactinium	104-107	TBC1 domain family, member 4	Mus musculus	68-74
25999786-4	2015	In endothelium-denuded PA rings, KMUP-1 (1 muM) dose-dependently reduced 5-HT (100 muM) mediated contractile responses.	Protactinium	23-25	latexin	Homo sapiens	43-46
27047156-12	2015	PA was found to be highest in the milk of healthy group of cows, but decreased significantly (p&lt;0.05) in subclinically infected cows.	Protactinium	0-2	Weaning weight-maternal milk	Bos taurus	34-38
27047156-14	2015	PA of milk was also found to be significantly lower in the milk of healthy cows when compared to that of blood neutrophils.	Protactinium	0-2	Weaning weight-maternal milk	Bos taurus	6-10
27047156-14	2015	PA of milk was also found to be significantly lower in the milk of healthy cows when compared to that of blood neutrophils.	Protactinium	0-2	Weaning weight-maternal milk	Bos taurus	59-63
25863249-3	2015	Mice with EC deletion of BMPR2 develop hypoxia-induced pulmonary hypertension that, in contrast to non-transgenic littermates, does not reverse upon reoxygenation and is associated with reduced PA microvessels and lung EC p53, PGC1alpha and TFAM, regulators of mitochondrial biogenesis, and mitochondrial DNA.	Protactinium	194-196	bone morphogenetic protein receptor, type II (serine/threonine kinase)	Mus musculus	25-30
25140386-7	2015	Compared with identical doses of scuPA alone or with IgG, treatment with scuPA and anti-PAI-1 mAbs generated higher PF uPA amidolytic and PA activities, faster formation of alphaM/uPA complexes, and slower uPA inactivation.	Protactinium	36-38	plasminogen activator inhibitor 1	Oryctolagus cuniculus	88-93
25140386-7	2015	Compared with identical doses of scuPA alone or with IgG, treatment with scuPA and anti-PAI-1 mAbs generated higher PF uPA amidolytic and PA activities, faster formation of alphaM/uPA complexes, and slower uPA inactivation.	Protactinium	36-38	urokinase-type plasminogen activator	Oryctolagus cuniculus	75-78
25140386-7	2015	Compared with identical doses of scuPA alone or with IgG, treatment with scuPA and anti-PAI-1 mAbs generated higher PF uPA amidolytic and PA activities, faster formation of alphaM/uPA complexes, and slower uPA inactivation.	Protactinium	36-38	urokinase-type plasminogen activator	Oryctolagus cuniculus	75-78
25684318-7	2015	The CB1 receptor antagonist improved the scores on the PA acquisition and retention tests.	Protactinium	55-57	cannabinoid receptor 1	Rattus norvegicus	4-7
25817463-5	2015	Vbeta6(+) PA-specific Treg cells expressed CCR4 and CCR5 on their surface.	Protactinium	10-12	chemokine (C-C motif) receptor 4	Mus musculus	43-47
25817463-5	2015	Vbeta6(+) PA-specific Treg cells expressed CCR4 and CCR5 on their surface.	Protactinium	10-12	chemokine (C-C motif) receptor 5	Mus musculus	52-56
26622209-8	2015	The HD2 of the echo signal received by the transducer using a PA with the linearizer (-24.8 dB) was lower than that obtained for the PA alone (-16.6 dB).	Protactinium	62-64	histone deacetylase 2	Homo sapiens	4-7
25382612-3	2015	We detected the KIAA1549:BRAF fusion gene in five of 34 non-PA tumors (14.7%), that is, one glioblastoma, one anaplastic astrocytoma, one anaplastic pleomorphic xanthoastrocytoma, 1 ependymoma, and 1 Atypical Teratoid Rhabdoid Tumor.	Protactinium	60-62	KIAA1549	Homo sapiens	16-24
25382612-3	2015	We detected the KIAA1549:BRAF fusion gene in five of 34 non-PA tumors (14.7%), that is, one glioblastoma, one anaplastic astrocytoma, one anaplastic pleomorphic xanthoastrocytoma, 1 ependymoma, and 1 Atypical Teratoid Rhabdoid Tumor.	Protactinium	60-62	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	25-29
25684318-9	2015	The CB1 receptor antagonist partly decreased the glutamatergic receptor antagonist effects on PA learning and memory.	Protactinium	94-96	cannabinoid receptor 1	Rattus norvegicus	4-7
25917039-5	2015	An in vitro insulin resistant model in L6 myotubes was established by 500 micromol/L of palmitate acid (PA).	Protactinium	104-106	insulin	Homo sapiens	12-19
25664856-5	2015	In a murine PAH model, Ep3 deletion in SMCs, but not endothelial cells, retarded PA medial thickness.	Protactinium	12-14	prostaglandin E receptor 3 (subtype EP3)	Mus musculus	23-26
25645812-8	2015	In addition, PA inhibited the expression of ATP-binding cassette transporters G5/8 (ABCG5/8) and liver X receptor (LXR) in liver, and reduced cholesterol transport from the hepatocytes to the gallbladder.	Protactinium	13-15	ATP binding cassette subfamily G member 5	Mus musculus	84-91
25645812-8	2015	In addition, PA inhibited the expression of ATP-binding cassette transporters G5/8 (ABCG5/8) and liver X receptor (LXR) in liver, and reduced cholesterol transport from the hepatocytes to the gallbladder.	Protactinium	13-15	nuclear receptor subfamily 1, group H, member 3	Mus musculus	97-113
25645812-8	2015	In addition, PA inhibited the expression of ATP-binding cassette transporters G5/8 (ABCG5/8) and liver X receptor (LXR) in liver, and reduced cholesterol transport from the hepatocytes to the gallbladder.	Protactinium	13-15	nuclear receptor subfamily 1, group H, member 3	Mus musculus	115-118
25598283-7	2015	In addition, the results of BSP showed that the hypermethylation of exon 1c of MEST-1C was observed in PA samples.	Protactinium	103-105	mesoderm specific transcript	Homo sapiens	79-83
25917039-16	2015	And it plays a key role in PA-induced insulin resistance of skeletal muscle.	Protactinium	27-29	insulin	Homo sapiens	38-45
25917039-8	2015	RESULTS: SREBP-1c protein expression increased significantly after 1-hour exposure to PA.	Protactinium	86-88	sterol regulatory element binding transcription factor 1	Homo sapiens	9-17
25917039-9	2015	The protein levels of p-IRS-1(Tyr608/612),IRS-1 and p-AKt (Ser473) decreased significantly after a 6-hour incubation of PA.	Protactinium	120-122	insulin receptor substrate 1	Homo sapiens	24-29
25917039-9	2015	The protein levels of p-IRS-1(Tyr608/612),IRS-1 and p-AKt (Ser473) decreased significantly after a 6-hour incubation of PA.	Protactinium	120-122	insulin receptor substrate 1	Homo sapiens	42-47
25917039-9	2015	The protein levels of p-IRS-1(Tyr608/612),IRS-1 and p-AKt (Ser473) decreased significantly after a 6-hour incubation of PA.	Protactinium	120-122	AKT serine/threonine kinase 1	Homo sapiens	54-57
25723091-4	2015	PA images demonstrated that INDs accumulate in tumors and completely delineated the entire tumor within 10 h. HER2 targeting significantly enhanced imaging of HER2-positive tumors.	Protactinium	0-2	erb-b2 receptor tyrosine kinase 2	Mus musculus	110-114
24112413-2	2015	The objective of this study is to determine the prognostic significance of epidermal growth factor receptor (EGFR) expression (membrane and cytoplasmic) in resected PA and its correlation with lymph node metastasis and survival.	Protactinium	165-167	epidermal growth factor receptor	Homo sapiens	75-107
24112413-2	2015	The objective of this study is to determine the prognostic significance of epidermal growth factor receptor (EGFR) expression (membrane and cytoplasmic) in resected PA and its correlation with lymph node metastasis and survival.	Protactinium	165-167	epidermal growth factor receptor	Homo sapiens	109-113
25776488-7	2015	Combination with PA and IR also increased the production of ROS, which subsequently induced phosphorylation of p38, suppressed phosphorylation of ERK, and activated caspase-3, -8, and -9.	Protactinium	17-19	mitogen-activated protein kinase 14	Homo sapiens	111-114
25776488-7	2015	Combination with PA and IR also increased the production of ROS, which subsequently induced phosphorylation of p38, suppressed phosphorylation of ERK, and activated caspase-3, -8, and -9.	Protactinium	17-19	mitogen-activated protein kinase 1	Homo sapiens	146-149
25776488-7	2015	Combination with PA and IR also increased the production of ROS, which subsequently induced phosphorylation of p38, suppressed phosphorylation of ERK, and activated caspase-3, -8, and -9.	Protactinium	17-19	caspase 3	Homo sapiens	165-186
25776488-10	2015	Collectively, these results indicate that PA functions as a radiosensitizer by enhancing apoptosis through activation of a ROS/p38/caspase pathway and suppression of ERK.	Protactinium	42-44	mitogen-activated protein kinase 14	Homo sapiens	127-130
25776488-10	2015	Collectively, these results indicate that PA functions as a radiosensitizer by enhancing apoptosis through activation of a ROS/p38/caspase pathway and suppression of ERK.	Protactinium	42-44	mitogen-activated protein kinase 1	Homo sapiens	166-169
26045757-12	2015	Moreover, PAL administration significantly decreased the mRNA and proteins expression of Bcl-2 as well as increased the mRNA expression of BAX and the protein expression of caspase-3 and caspase-8 as compare to those of control group, but APS treatment could reverse PA-induced HCMs apoptosis.	Protactinium	10-12	BCL2 apoptosis regulator	Homo sapiens	89-94
26045757-12	2015	Moreover, PAL administration significantly decreased the mRNA and proteins expression of Bcl-2 as well as increased the mRNA expression of BAX and the protein expression of caspase-3 and caspase-8 as compare to those of control group, but APS treatment could reverse PA-induced HCMs apoptosis.	Protactinium	10-12	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
26045757-12	2015	Moreover, PAL administration significantly decreased the mRNA and proteins expression of Bcl-2 as well as increased the mRNA expression of BAX and the protein expression of caspase-3 and caspase-8 as compare to those of control group, but APS treatment could reverse PA-induced HCMs apoptosis.	Protactinium	10-12	caspase 3	Homo sapiens	173-182
26045757-12	2015	Moreover, PAL administration significantly decreased the mRNA and proteins expression of Bcl-2 as well as increased the mRNA expression of BAX and the protein expression of caspase-3 and caspase-8 as compare to those of control group, but APS treatment could reverse PA-induced HCMs apoptosis.	Protactinium	10-12	caspase 8	Homo sapiens	187-196
25575134-4	2015	We found that Notch pathway members were overexpressed at the mRNA (NOTCH1, NOTCH2, HEY1, HEY2) and protein (HES1) levels in PAs at various anatomic sites compared with non-neoplastic brain samples.	Protactinium	125-128	notch receptor 1	Homo sapiens	14-19
25545365-5	2015	Cardiac Na(+) current (INa) density was reduced by Wnt3a (-20 +- 4 vs. control -59 +- 7 pA pF(-1) , at -30 mV) or CHIR (-22 +- 5 pA pF(-1) ), without changes in steady-state activation, inactivation or repriming kinetics.	Protactinium	88-90	Wnt family member 3A	Rattus norvegicus	51-56
25510732-10	2015	RESULTS: Our data showed that JLDG could significantly reduce PA-induced intracellular lipid accumulation in NIT-1 pancreatic beta cells.	Protactinium	62-64	nitrilase 1	Mus musculus	109-114
25510732-15	2015	CONCLUSIONS: The results suggest that JLDG could reduce intracellular lipid accumulation and enhance the autophagy in NIT-1 pancreatic beta cells cultured with PA.	Protactinium	160-162	nitrilase 1	Mus musculus	118-123
25590691-4	2015	Moreover, the active component of CKS, platyconic acid A (PA), suppressed PMA-induced MUC5AC mRNA expression (from 2.1 +- 0.2 to 1.1 +- 0.1) by inhibiting NF-kappaB activation (from 2.3 +- 0.2 to 1.2 +- 0.1) via Akt (from 3.7 +- 0.3 to 2.1 +- 0.2) (p &lt; 0.01) in A549 cells.	Protactinium	58-60	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	86-92
25590691-4	2015	Moreover, the active component of CKS, platyconic acid A (PA), suppressed PMA-induced MUC5AC mRNA expression (from 2.1 +- 0.2 to 1.1 +- 0.1) by inhibiting NF-kappaB activation (from 2.3 +- 0.2 to 1.2 +- 0.1) via Akt (from 3.7 +- 0.3 to 2.1 +- 0.2) (p &lt; 0.01) in A549 cells.	Protactinium	58-60	thymoma viral proto-oncogene 1	Mus musculus	212-215
24237326-5	2015	The results showed that contents of ginsenosides Rg1 and Rb1 in Nao-Qing microemulsion was 8475.13 +- 54.61 mug/ml and 6633.42 +- 527.27 mug/ml, respectively, and that the particle size, pH and viscosity of the microemulsion were 19.9 +- 5.07 nm, 6.1 and 3.056 x 10(-3 )Pas, respectively.	Protactinium	270-273	RB transcriptional corepressor 1	Rattus norvegicus	57-60
27047094-5	2015	RESULTS: Significantly (p&lt;0.05) higher SCC, PA was found in milk of CM cows as compared to SCM and control cows.	Protactinium	47-49	SCC	Bos taurus	42-45
25510732-3	2015	To determine the main components in JLDG and to explore the effect of JLDG on autophagy and lipid accumulation in NIT-1 pancreatic beta cells exposed to politic acid (PA) through AMP activated protein kinase (AMPK) signaling pathway.	Protactinium	167-169	nitrilase 1	Mus musculus	114-119
25510732-3	2015	To determine the main components in JLDG and to explore the effect of JLDG on autophagy and lipid accumulation in NIT-1 pancreatic beta cells exposed to politic acid (PA) through AMP activated protein kinase (AMPK) signaling pathway.	Protactinium	167-169	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	209-213
25510732-5	2015	Intracellular lipid accumulation in NIT-1 cells was induced by culturing with medium containing PA.	Protactinium	96-98	nitrilase 1	Mus musculus	36-41
25575134-4	2015	We found that Notch pathway members were overexpressed at the mRNA (NOTCH1, NOTCH2, HEY1, HEY2) and protein (HES1) levels in PAs at various anatomic sites compared with non-neoplastic brain samples.	Protactinium	125-128	notch receptor 1	Homo sapiens	68-74
25575134-4	2015	We found that Notch pathway members were overexpressed at the mRNA (NOTCH1, NOTCH2, HEY1, HEY2) and protein (HES1) levels in PAs at various anatomic sites compared with non-neoplastic brain samples.	Protactinium	125-128	notch receptor 2	Homo sapiens	76-82
25575134-4	2015	We found that Notch pathway members were overexpressed at the mRNA (NOTCH1, NOTCH2, HEY1, HEY2) and protein (HES1) levels in PAs at various anatomic sites compared with non-neoplastic brain samples.	Protactinium	125-128	hes related family bHLH transcription factor with YRPW motif 1	Homo sapiens	84-88
25575134-4	2015	We found that Notch pathway members were overexpressed at the mRNA (NOTCH1, NOTCH2, HEY1, HEY2) and protein (HES1) levels in PAs at various anatomic sites compared with non-neoplastic brain samples.	Protactinium	125-128	hes related family bHLH transcription factor with YRPW motif 2	Homo sapiens	90-94
25575134-4	2015	We found that Notch pathway members were overexpressed at the mRNA (NOTCH1, NOTCH2, HEY1, HEY2) and protein (HES1) levels in PAs at various anatomic sites compared with non-neoplastic brain samples.	Protactinium	125-128	hes family bHLH transcription factor 1	Homo sapiens	109-113
25569796-6	2015	RESULTS: S100B salivary levels were significantly (P&lt;0.001) higher in newborns with PA than in normal infants.	Protactinium	87-89	S100 calcium binding protein B	Homo sapiens	9-14
24753455-2	2015	Here, the use of PA nanofibers with binding affinity for the bone promoting growth factor BMP-2 to create a gel scaffold for osteogenesis is reported.	Protactinium	17-19	myotrophin	Rattus norvegicus	76-89
24753455-2	2015	Here, the use of PA nanofibers with binding affinity for the bone promoting growth factor BMP-2 to create a gel scaffold for osteogenesis is reported.	Protactinium	17-19	bone morphogenetic protein 2	Rattus norvegicus	90-95
24753455-4	2015	The efficacy of the bioactive PA system to promote BMP-2-induced osteogenesis in vivo is investigated in a rat posterolateral lumbar intertransverse spinal fusion model.	Protactinium	30-32	bone morphogenetic protein 2	Rattus norvegicus	51-56
24753455-5	2015	PA nanofiber gels displaying BMP-2-binding segments exhibit superior spinal fusion rates relative to controls, effectively decreasing the required therapeutic dose of BMP-2 by 10-fold.	Protactinium	0-2	bone morphogenetic protein 2	Rattus norvegicus	29-34
25636094-1	2015	OBJECTIVE: To analyze PCCA and PCCB gene mutations in 10 Chinese patients with propionic acidemia(PA).	Protactinium	98-100	propionyl-CoA carboxylase subunit alpha	Homo sapiens	22-26
25636094-1	2015	OBJECTIVE: To analyze PCCA and PCCB gene mutations in 10 Chinese patients with propionic acidemia(PA).	Protactinium	98-100	propionyl-CoA carboxylase subunit beta	Homo sapiens	31-35
25918522-7	2015	The CRP level in PA group was significantly higher than that in non-PA.	Protactinium	17-19	C-reactive protein	Homo sapiens	4-7
25462245-6	2015	The docking study of compound 7h with AChE enzyme revealed that the (R)-enantiomer binds preferably to CAS while the (S)-enantiomer prone to be a PAS binder.	Protactinium	146-149	acetylcholinesterase (Cartwright blood group)	Homo sapiens	38-42
25547104-2	2015	Our investigations, for the first time, established the role of calreticulin transacetylase (CRTAase) in catalyzing the acetylation of nitric oxide synthase (NOS) by Pas leading to robust activation of NOS.	Protactinium	166-169	nitric oxide synthase 2	Homo sapiens	135-156
24753455-5	2015	PA nanofiber gels displaying BMP-2-binding segments exhibit superior spinal fusion rates relative to controls, effectively decreasing the required therapeutic dose of BMP-2 by 10-fold.	Protactinium	0-2	bone morphogenetic protein 2	Rattus norvegicus	167-172
25791507-6	2015	RESULTS: Ginsenoside Rb1 elicited concentration-dependent relaxation of ET-1-induced PA contraction.	Protactinium	85-87	RB transcriptional corepressor 1	Rattus norvegicus	21-24
25791507-6	2015	RESULTS: Ginsenoside Rb1 elicited concentration-dependent relaxation of ET-1-induced PA contraction.	Protactinium	85-87	endothelin 1	Rattus norvegicus	72-76
25791507-8	2015	Ginsenoside Rb1 suppressed cyclopiazonic acid (CPA)-induced PA contraction, and CPA-activated cation entry and Ca(2+) transient in PASMCs.	Protactinium	48-50	RB transcriptional corepressor 1	Rattus norvegicus	12-15
25918522-7	2015	The CRP level in PA group was significantly higher than that in non-PA.	Protactinium	68-70	C-reactive protein	Homo sapiens	4-7
25439740-7	2015	PLAG1 or HMGA2 rearrangements were identified in 6 (67%) of 9 hypocellular myxoid PAs and in 2 (29%) of 7 cellular PAs.	Protactinium	82-85	PLAG1 zinc finger	Homo sapiens	0-5
25439740-7	2015	PLAG1 or HMGA2 rearrangements were identified in 6 (67%) of 9 hypocellular myxoid PAs and in 2 (29%) of 7 cellular PAs.	Protactinium	82-85	high mobility group AT-hook 2	Homo sapiens	9-14
25439740-11	2015	Interestingly, rearrangements of PLAG1/HMGA2 were identified in most hypocellular PAs but only in a small subset of cellular PAs.	Protactinium	82-85	PLAG1 zinc finger	Homo sapiens	33-38
26513727-9	2015	CONCLUSIONS: MeS was seen only in obese subjects whether or not they had PA.	Protactinium	73-75	MKS transition zone complex subunit 1	Homo sapiens	13-16
25439740-11	2015	Interestingly, rearrangements of PLAG1/HMGA2 were identified in most hypocellular PAs but only in a small subset of cellular PAs.	Protactinium	82-85	high mobility group AT-hook 2	Homo sapiens	39-44
26397899-9	2015	Protein levels for c-terminal binding protein 1 (CtBP1), a regulator of PA biosynthesis, were reduced in striatal synaptosomes from HD mice compared to wild-type at 6 and 12 months.	Protactinium	72-74	C-terminal binding protein 1	Mus musculus	19-47
25454812-11	2015	PA treated mice also showed a marked inhibition of inducible nitric oxide synthase and MMP-9 expression.	Protactinium	0-2	matrix metallopeptidase 9	Mus musculus	87-92
26397899-9	2015	Protein levels for c-terminal binding protein 1 (CtBP1), a regulator of PA biosynthesis, were reduced in striatal synaptosomes from HD mice compared to wild-type at 6 and 12 months.	Protactinium	72-74	C-terminal binding protein 1	Mus musculus	49-54
24981554-3	2015	METHODS: We conducted a systematic review of studies that used IV recombinant tissue plasminogen activator (rt-PA) therapy in China and the USA published between January 1950 and April 2012.	Protactinium	111-113	chromosome 20 open reading frame 181	Homo sapiens	78-106
24957188-8	2015	In addition, RUNX3 expression was significantly decreased after Pa-PDT in KFs, and KFs with downregulation of RUNX3 showed significantly increased cell viability after Pa-PDT.	Protactinium	64-66	RUNX family transcription factor 3	Homo sapiens	13-18
24957188-8	2015	In addition, RUNX3 expression was significantly decreased after Pa-PDT in KFs, and KFs with downregulation of RUNX3 showed significantly increased cell viability after Pa-PDT.	Protactinium	168-170	RUNX family transcription factor 3	Homo sapiens	110-115
26633920-9	2015	Interestingly, anti-LCSFA IgG neutralized PA-induced IL-1beta secretion by dendritic cells.	Protactinium	42-44	interleukin 1 beta	Homo sapiens	53-61
25475986-1	2014	Phosphatidate phosphatase-1 (PAP1) enzymes (yeast Pah1p/Smp2p, mammalian lipin1-3) have a key role in lipid homeostasis by controlling the relative proportions of its substrate phosphatidate (PA) and its product diacylglycerol (DAG).	Protactinium	29-31	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	50-55
27019861-3	2015	In our recent research paper published in the Journal of Molecular Medicine, we found that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) activation could attenuate the PH pathogenesis by suppressing the elevated distal PA pressure and vascular remodeling.	Protactinium	167-169	peroxisome proliferator activated receptor gamma	Homo sapiens	116-164
24562316-10	2015	AURKA and urinary cytology showed similar overall PA for UBC detection (74.4 vs. 72.1 %, p = 0.588).	Protactinium	50-52	aurora kinase A	Homo sapiens	0-5
25521508-5	2014	Using phenotypic, genetic, biochemical and transcriptomic approaches, we have focused specifically on the role of STK in PA biosynthesis.	Protactinium	121-123	K-box region and MADS-box transcription factor family protein	Arabidopsis thaliana	114-117
25496273-2	2014	Our investigations, for the first time, established the role of calreticulin transacetylase (CRTAase) in catalyzing the acetylation of nitric oxide synthase (NOS) by Pas leading to robust activation of NOS.	Protactinium	166-169	nitric oxide synthase 2	Homo sapiens	135-156
25475986-1	2014	Phosphatidate phosphatase-1 (PAP1) enzymes (yeast Pah1p/Smp2p, mammalian lipin1-3) have a key role in lipid homeostasis by controlling the relative proportions of its substrate phosphatidate (PA) and its product diacylglycerol (DAG).	Protactinium	29-31	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	56-61
25475986-1	2014	Phosphatidate phosphatase-1 (PAP1) enzymes (yeast Pah1p/Smp2p, mammalian lipin1-3) have a key role in lipid homeostasis by controlling the relative proportions of its substrate phosphatidate (PA) and its product diacylglycerol (DAG).	Protactinium	29-31	lipin 1	Homo sapiens	73-81
25253355-11	2014	We found that DnaJA1 associates with both PB2 and PA subunits and translocates into the nucleus along with the nuclear import of the PB1-PA dimer during influenza virus replication.	Protactinium	50-52	DnaJ heat shock protein family (Hsp40) member A1	Homo sapiens	14-20
25253355-11	2014	We found that DnaJA1 associates with both PB2 and PA subunits and translocates into the nucleus along with the nuclear import of the PB1-PA dimer during influenza virus replication.	Protactinium	137-139	DnaJ heat shock protein family (Hsp40) member A1	Homo sapiens	14-20
25253355-11	2014	We found that DnaJA1 associates with both PB2 and PA subunits and translocates into the nucleus along with the nuclear import of the PB1-PA dimer during influenza virus replication.	Protactinium	137-139	polybromo 1	Homo sapiens	133-136
24894514-6	2014	Mucin content was tested by PAS methodology.	Protactinium	28-31	LOC100508689	Homo sapiens	0-5
25293377-4	2014	AtVSR1 harbors three complex-type N-glycans, which are located in the N-terminal "PA domain", the central region and the C-terminal epidermal growth factor repeat domain, respectively.	Protactinium	82-84	vacuolar sorting receptor homolog 1	Arabidopsis thaliana	0-6
25380285-5	2014	Parallel studies using ex vivo DCs expanded from human peripheral blood and activated under the same conditions as the murine DC, demonstrated that human DCs had a PA dose-related significant increase in the markers CD40, CD80 and CCR7 and that the increases in CD40 and CD80 were maintained when the other activating components, CpG and HK B. anthracis were added to the rPA in culture.	Protactinium	164-166	CD40 molecule	Homo sapiens	216-220
25380285-5	2014	Parallel studies using ex vivo DCs expanded from human peripheral blood and activated under the same conditions as the murine DC, demonstrated that human DCs had a PA dose-related significant increase in the markers CD40, CD80 and CCR7 and that the increases in CD40 and CD80 were maintained when the other activating components, CpG and HK B. anthracis were added to the rPA in culture.	Protactinium	164-166	CD80 molecule	Homo sapiens	222-226
25380285-5	2014	Parallel studies using ex vivo DCs expanded from human peripheral blood and activated under the same conditions as the murine DC, demonstrated that human DCs had a PA dose-related significant increase in the markers CD40, CD80 and CCR7 and that the increases in CD40 and CD80 were maintained when the other activating components, CpG and HK B. anthracis were added to the rPA in culture.	Protactinium	164-166	C-C motif chemokine receptor 7	Homo sapiens	231-235
25380285-5	2014	Parallel studies using ex vivo DCs expanded from human peripheral blood and activated under the same conditions as the murine DC, demonstrated that human DCs had a PA dose-related significant increase in the markers CD40, CD80 and CCR7 and that the increases in CD40 and CD80 were maintained when the other activating components, CpG and HK B. anthracis were added to the rPA in culture.	Protactinium	164-166	CD40 molecule	Homo sapiens	262-266
25380285-5	2014	Parallel studies using ex vivo DCs expanded from human peripheral blood and activated under the same conditions as the murine DC, demonstrated that human DCs had a PA dose-related significant increase in the markers CD40, CD80 and CCR7 and that the increases in CD40 and CD80 were maintained when the other activating components, CpG and HK B. anthracis were added to the rPA in culture.	Protactinium	164-166	CD80 molecule	Homo sapiens	271-275
25250705-6	2014	In a separate case, we show disruption of key interactions in the MAPK signaling pathway after PA-mediated delivery of an affibody binder that targets hRaf-1.	Protactinium	95-97	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	151-157
25066317-3	2014	In our study we evaluated 51 PAs for BRAF duplication and BRAF V600E point mutation.	Protactinium	29-32	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	37-41
25214240-9	2014	The PA catabolic pathway was also altered in PC3 cells causing the generation of reactive oxygen species (ROS) and intracellular PA pool decrease.	Protactinium	4-6	chromobox 8	Homo sapiens	45-48
25214240-9	2014	The PA catabolic pathway was also altered in PC3 cells causing the generation of reactive oxygen species (ROS) and intracellular PA pool decrease.	Protactinium	129-131	chromobox 8	Homo sapiens	45-48
25422985-10	2014	In contrast, C3aRA treatment improved renal function and morphology, reduced CREA, UACR and the intensity of PAS and collagen I staining in the kidney of T2DM rats, and decreased C3a, p-IKBalpha, IL-6, TGF-beta, p-Smad3 and collagen I expressions in HRGECs and T2DM rats.	Protactinium	109-112	complement C3	Homo sapiens	13-16
25370305-3	2014	Interesting, the PA signal is enhanced with increase of SQ in the nanoconfined bilayer region, which is attributed to the formation of SQ-based H-aggregates and enhanced thermal conversion efficiency (eta).	Protactinium	17-19	endothelin receptor type A	Homo sapiens	201-204
25210842-3	2014	We cultured rat neonatal CMs in PA-RGDS for 7 days and found that more than 90% of the CMs survived.	Protactinium	32-34	ral guanine nucleotide dissociation stimulator	Mus musculus	35-39
25185133-8	2014	Notably, TNF-alpha short hairpin small-interfering RNA prevented the cold-induced increases in TNF-alpha, interleukin-6, and phosphodiesterase-1C protein expression, abolished lung macrophage infiltration, and attenuated PH (26.28+-1.6 mm Hg), PA remodeling, and right ventricle hypertrophy.	Protactinium	244-246	tumor necrosis factor	Homo sapiens	9-18
25185133-12	2014	AAV delivery of TNF-alpha short hairpin small-interfering RNA may be an effective therapeutic approach for cold-induced PH and PA remodeling.	Protactinium	127-129	tumor necrosis factor	Homo sapiens	16-25
25082152-7	2014	Such a PLD-based autophagy mechanism would involve two positive inputs: the generation of PA to help the initiation of the autophagosome and a protein-protein interaction between PLD and PKC that leads to enhanced PA.	Protactinium	90-92	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	7-10
25082152-7	2014	Such a PLD-based autophagy mechanism would involve two positive inputs: the generation of PA to help the initiation of the autophagosome and a protein-protein interaction between PLD and PKC that leads to enhanced PA.	Protactinium	214-216	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	7-10
25082152-7	2014	Such a PLD-based autophagy mechanism would involve two positive inputs: the generation of PA to help the initiation of the autophagosome and a protein-protein interaction between PLD and PKC that leads to enhanced PA.	Protactinium	214-216	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	179-182
25082152-7	2014	Such a PLD-based autophagy mechanism would involve two positive inputs: the generation of PA to help the initiation of the autophagosome and a protein-protein interaction between PLD and PKC that leads to enhanced PA.	Protactinium	214-216	protein kinase C beta	Homo sapiens	187-190
25515809-3	2014	RESULTS: Histopathological analysis showed the epithelium with scattered PAS-positive goblet cells was positive for CEA and CK7.	Protactinium	73-76	CEA cell adhesion molecule 3	Homo sapiens	116-119
25515809-3	2014	RESULTS: Histopathological analysis showed the epithelium with scattered PAS-positive goblet cells was positive for CEA and CK7.	Protactinium	73-76	keratin 7	Homo sapiens	124-127
25353171-12	2014	CONCLUSIONS: By analyzing 26 aged mouse strains we found that some strains developed an intracapillary PAS and apoE-positive lesion and identified a small haplotype block on Chr 1 within the Esrrg gene to be associated with these lipoprotein deposits.	Protactinium	103-106	estrogen-related receptor gamma	Mus musculus	191-196
25210842-5	2014	Histologic examination and flow cytometry analysis of digested heart tissues showed approximately 3-fold higher engraftment in the mice that received CMs with PA-RGDS compared to those without PA-RGDS.	Protactinium	159-161	ral guanine nucleotide dissociation stimulator	Mus musculus	162-166
25210842-8	2014	However, from 3 weeks, higher cardiac function was maintained only in the CM+PA-RGDS group; this was sustained for 12 weeks.	Protactinium	77-79	ral guanine nucleotide dissociation stimulator	Mus musculus	80-84
25210842-9	2014	Confocal microscopic examination of the cardiac tissues harvested at 14 weeks demonstrated sustained engraftment and integration of mESC-CMs into host myocardium in the CM+PA-RGDS group only.	Protactinium	172-174	ral guanine nucleotide dissociation stimulator	Mus musculus	175-179
25210842-10	2014	This study for the first time demonstrated that PA-RGDS encapsulation can enhance survival of mESC-derived CMs and improve cardiac function post-MI.	Protactinium	48-50	ral guanine nucleotide dissociation stimulator	Mus musculus	51-55
25550806-1	2014	OBJECTIVE: This study was performed to investigate PTX3-mediated iNOS expression and IKK/IkappaB/NF-kappaB activation in PA-induced atherosclerotic HUVECs injury model.	Protactinium	121-123	pentraxin 3	Homo sapiens	51-55
25550806-1	2014	OBJECTIVE: This study was performed to investigate PTX3-mediated iNOS expression and IKK/IkappaB/NF-kappaB activation in PA-induced atherosclerotic HUVECs injury model.	Protactinium	121-123	nuclear factor kappa B subunit 1	Homo sapiens	97-106
25550800-9	2014	PA also induced upregulation expression of HIF1a-AS1.	Protactinium	0-2	HIF1A antisense RNA 1	Homo sapiens	43-52
25550806-7	2014	PA also induced upregulation expression of PTX3.	Protactinium	0-2	pentraxin 3	Homo sapiens	43-47
25550800-10	2014	We also found that transfection of cells with HIF1a-AS1 siRNA decreased the expression of caspase3 and caspase8 and increased the expression of Bcl2, and protected PA-induced cell apoptosis in VSMCs.	Protactinium	164-166	HIF1A antisense RNA 1	Homo sapiens	46-55
25550806-8	2014	TPCA-1, an inhibitor of IKK-2, could suppress the expression of PTX3 and phospho-IkappaB-alpha in PA-induced endothelial dysfunction cell model.	Protactinium	98-100	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	24-29
25143401-10	2014	Finally, Vps21 localizes to PAS.	Protactinium	28-31	Rab family GTPase VPS21	Saccharomyces cerevisiae S288C	9-14
25550806-8	2014	TPCA-1, an inhibitor of IKK-2, could suppress the expression of PTX3 and phospho-IkappaB-alpha in PA-induced endothelial dysfunction cell model.	Protactinium	98-100	pentraxin 3	Homo sapiens	64-68
25550806-9	2014	We also found that transfection of cells with PTX3 siRNA reduced the expression of iNOS and NO, and protected PA-induced cell apoptosis in HUVECs.	Protactinium	110-112	pentraxin 3	Homo sapiens	46-50
25485104-8	2014	The osteoblast differentiation marker, alkaline phosphatase, peaked in activity 4-12 days earlier on the QHREDGS-immobilized PA-coated Ti plates than on the unimmobilized, DGQESHR (scrambled)- and RGDS-immobilized surfaces.	Protactinium	125-127	ral guanine nucleotide dissociation stimulator	Homo sapiens	197-201
25442282-2	2014	The chemical structure of (+)-PA is similar to a known fatty acid synthase (FASN) inhibitor C75.	Protactinium	26-32	fatty acid synthase	Homo sapiens	55-74
25442282-2	2014	The chemical structure of (+)-PA is similar to a known fatty acid synthase (FASN) inhibitor C75.	Protactinium	26-32	fatty acid synthase	Homo sapiens	76-80
25442282-3	2014	AIMS: To test whether the anti-proliferative activity of (+)-PA is associated with effects on FASN and HER2 (human epidermal growth factor receptor 2) and major signalling pathways.	Protactinium	57-63	fatty acid synthase	Homo sapiens	94-98
25442282-3	2014	AIMS: To test whether the anti-proliferative activity of (+)-PA is associated with effects on FASN and HER2 (human epidermal growth factor receptor 2) and major signalling pathways.	Protactinium	57-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
25442282-3	2014	AIMS: To test whether the anti-proliferative activity of (+)-PA is associated with effects on FASN and HER2 (human epidermal growth factor receptor 2) and major signalling pathways.	Protactinium	57-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-149
25442282-10	2014	RESULTS: Treatment with (+)-PA increased FASN expression in SK-BR-3 cells, which overexpress FASN and HER2, implying a compensatory response to inhibition of FASN activity.	Protactinium	24-30	fatty acid synthase	Homo sapiens	41-45
25442282-10	2014	RESULTS: Treatment with (+)-PA increased FASN expression in SK-BR-3 cells, which overexpress FASN and HER2, implying a compensatory response to inhibition of FASN activity.	Protactinium	24-30	fatty acid synthase	Homo sapiens	93-97
25442282-10	2014	RESULTS: Treatment with (+)-PA increased FASN expression in SK-BR-3 cells, which overexpress FASN and HER2, implying a compensatory response to inhibition of FASN activity.	Protactinium	24-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
25442282-10	2014	RESULTS: Treatment with (+)-PA increased FASN expression in SK-BR-3 cells, which overexpress FASN and HER2, implying a compensatory response to inhibition of FASN activity.	Protactinium	24-30	fatty acid synthase	Homo sapiens	93-97
25442282-15	2014	CONCLUSION: Results suggest that the primary effect of (+)-PA is inhibition of FASN activity.	Protactinium	55-61	fatty acid synthase	Homo sapiens	79-83
25442282-16	2014	Synergistic effects with lapatinib were seen only in SK-BR-3 cells, and not T-47D cells, further supporting the notion that (+)-PA acts by inhibiting FASN with secondary effects on HER2 expression and signalling.	Protactinium	124-130	fatty acid synthase	Homo sapiens	150-154
25442282-16	2014	Synergistic effects with lapatinib were seen only in SK-BR-3 cells, and not T-47D cells, further supporting the notion that (+)-PA acts by inhibiting FASN with secondary effects on HER2 expression and signalling.	Protactinium	124-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-185
25442282-17	2014	(+)-PA could therefore be a suitable agent for further testing, alone or in combination treatment against HER2-overexpressing breast cancer.	Protactinium	0-6	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
25070091-1	2014	The objectives of this study were to characterize any drug-drug interaction between the antimalarial Pyramax (pyronaridine-artesunate [PA]) and the CYP2D6 probe substrate metoprolol and to assess the safety of 60-day or 90-day PA redosing, particularly with regard to liver biochemistry parameters.	Protactinium	135-137	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	148-154
25070091-5	2014	The coadministration of metoprolol and PA was associated with an average 47.93% (90% confidence interval [CI], 30.52, 67.66) increase in the maximum concentration of metoprolol and a 25.60% (90% CI, 15.78, 36.25) increase in the metoprolol area under the concentration-time curve from time zero to the last quantifiable concentration obtained (AUC0-t); these increases most likely resulted from pyronaridine-mediated CYP2D6 inhibition.	Protactinium	39-41	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	417-423
24554201-3	2014	Nevertheless, the most important causative factors seem to be NF1 gene inactivation, in cases related to neurofibromatosis type 1, and BRAF gene overexpression in sporadic PAs, both resulting in MAPK/Erk pathway upregulation.	Protactinium	172-175	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	135-139
25275504-8	2014	The expression of HDAC1,2,3,4,7 and Nur77 increased in PA samples at levels significantly higher than those observed in the CP group (p = 0.0160; 0.0114; 0.0227; 0.0440; 0.0136; 0.0004, respectively).	Protactinium	55-57	histone deacetylase 1	Homo sapiens	18-23
25275504-8	2014	The expression of HDAC1,2,3,4,7 and Nur77 increased in PA samples at levels significantly higher than those observed in the CP group (p = 0.0160; 0.0114; 0.0227; 0.0440; 0.0136; 0.0004, respectively).	Protactinium	55-57	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-41
24554201-3	2014	Nevertheless, the most important causative factors seem to be NF1 gene inactivation, in cases related to neurofibromatosis type 1, and BRAF gene overexpression in sporadic PAs, both resulting in MAPK/Erk pathway upregulation.	Protactinium	172-175	mitogen-activated protein kinase 1	Homo sapiens	195-199
25101992-2	2014	To enhance the efficacy of CMG2-Fc against anthrax toxin, we attempted to engineer a CMG2-Fc with an improved affinity for PA.	Protactinium	123-125	ANTXR cell adhesion molecule 2	Homo sapiens	27-31
24952321-9	2014	CONCLUSIONS: Peg-the-Mole is a new computerized PA procedure that can be easily standardized and successfully used to induce significant after-effects.	Protactinium	48-50	progestagen associated endometrial protein	Homo sapiens	13-16
24957823-3	2014	Cytochrome P450 (CYP) 3A, which can be induced or inhibited by ARV and antituberculosis drugs, is a minor (~20%) metabolic pathway for PA-824.	Protactinium	135-137	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-24
25191833-3	2014	Here, we prepared a human serum albumin (HSA) conjugated with indocyanine green (ICG) as a PA contrast agent allowing enhanced permeability and retention effect for sensitive tumor imaging.	Protactinium	91-93	albumin	Mus musculus	26-39
24869798-8	2014	However, PA degradation was significantly inhibited in hypoxia + GABA treated roots by significantly decreasing gene expression and activity of diamine oxidase (DAO) and polyamine oxidase (PAO).	Protactinium	9-11	amine oxidase copper containing 1	Homo sapiens	144-159
24869798-8	2014	However, PA degradation was significantly inhibited in hypoxia + GABA treated roots by significantly decreasing gene expression and activity of diamine oxidase (DAO) and polyamine oxidase (PAO).	Protactinium	9-11	amine oxidase copper containing 1	Homo sapiens	161-164
24869798-8	2014	However, PA degradation was significantly inhibited in hypoxia + GABA treated roots by significantly decreasing gene expression and activity of diamine oxidase (DAO) and polyamine oxidase (PAO).	Protactinium	9-11	polyamine oxidase	Homo sapiens	170-187
24846011-7	2014	The docking models implied that these two compounds bound to PAS domain of HERG channels and inhibited its function.	Protactinium	61-64	potassium voltage-gated channel subfamily H member 2	Homo sapiens	75-79
25349783-6	2014	We constructed and purified the PAS domain from AhR.	Protactinium	32-35	aryl hydrocarbon receptor	Homo sapiens	48-51
25101992-2	2014	To enhance the efficacy of CMG2-Fc against anthrax toxin, we attempted to engineer a CMG2-Fc with an improved affinity for PA.	Protactinium	123-125	ANTXR cell adhesion molecule 2	Homo sapiens	85-89
25101992-3	2014	Using the automatic design algorithm FoldX and visual inspection, we devised two CMG2-Fc variants that introduce mutations in the CMG2 binding interface and improve the computationally assessed binding affinity for PA.	Protactinium	215-217	ANTXR cell adhesion molecule 2	Homo sapiens	81-85
25101992-3	2014	Using the automatic design algorithm FoldX and visual inspection, we devised two CMG2-Fc variants that introduce mutations in the CMG2 binding interface and improve the computationally assessed binding affinity for PA.	Protactinium	215-217	ANTXR cell adhesion molecule 2	Homo sapiens	130-134
25101992-5	2014	This study shows that the computational design of the PA binding interface of CMG2 to obtain CMG2-Fc variants with improving anti-toxin abilities is viable.	Protactinium	54-56	ANTXR cell adhesion molecule 2	Homo sapiens	78-82
25101992-5	2014	This study shows that the computational design of the PA binding interface of CMG2 to obtain CMG2-Fc variants with improving anti-toxin abilities is viable.	Protactinium	54-56	ANTXR cell adhesion molecule 2	Homo sapiens	93-97
25089892-3	2014	The first crystal structures of the C-terminal domain of PA (PA-CTD) in the absence of PB1-derived peptides show a number of structural changes relative to the previously reported PB1-peptide bound structures.	Protactinium	57-59	polybromo 1	Homo sapiens	87-90
25098415-8	2014	Injection into an injured spinal cord of PAs expressing two other epitopes known to interact with beta1-integrin, a Tenascin C epitope and the fibronectin epitope RGD, improved functional recovery comparable to the effects of IKVAV-PA.	Protactinium	41-44	integrin subunit beta 1	Homo sapiens	98-112
25098415-8	2014	Injection into an injured spinal cord of PAs expressing two other epitopes known to interact with beta1-integrin, a Tenascin C epitope and the fibronectin epitope RGD, improved functional recovery comparable to the effects of IKVAV-PA.	Protactinium	41-44	tenascin C	Homo sapiens	116-126
25098415-8	2014	Injection into an injured spinal cord of PAs expressing two other epitopes known to interact with beta1-integrin, a Tenascin C epitope and the fibronectin epitope RGD, improved functional recovery comparable to the effects of IKVAV-PA.	Protactinium	41-44	fibronectin 1	Homo sapiens	143-154
25089892-3	2014	The first crystal structures of the C-terminal domain of PA (PA-CTD) in the absence of PB1-derived peptides show a number of structural changes relative to the previously reported PB1-peptide bound structures.	Protactinium	57-59	polybromo 1	Homo sapiens	180-183
24947524-7	2014	Small-molecule inhibitors of Nox4 reduced adventitial reactive oxygen species generation and vascular remodeling as well as ameliorating right ventricular hypertrophy and noninvasive indices of PA stiffness in monocrotaline-treated rats as determined by morphometric analysis and high-resolution digital ultrasound.	Protactinium	194-196	NADPH oxidase 4	Rattus norvegicus	29-33
24948832-1	2014	In Arabidopsis (Arabidopsis thaliana), the major MYB protein regulating proanthocyanidin (PA) biosynthesis is TT2, named for the transparent testa phenotype of tt2 mutant seeds that lack PAs in their coats.	Protactinium	187-190	Duplicated homeodomain-like superfamily protein	Arabidopsis thaliana	110-113
24894645-2	2014	The arginine grafted bio-reducible poly (cystamine bisacrylamide-diaminohexane, CBA-DAH) polymer (ABP) conjugated poly (amido amine) (PAMAM), PAM-ABP (PA) was designed previously as an efficient gene delivery carrier.	Protactinium	134-136	amine oxidase copper containing 1	Homo sapiens	98-101
24894645-7	2014	To confirm the therapeutic effect, the VEGF siRNA expressing plasmid was constructed and then delivered into cancer cells using PA-PEG1k-RGD.	Protactinium	128-130	vascular endothelial growth factor A	Homo sapiens	39-43
24832193-5	2014	RESULTS: At baseline, circulating CD14+CD16+ monocyte percentage, C-reactive protein, and cholesterol were higher in PI vs. PA.	Protactinium	124-126	CD14 molecule	Homo sapiens	34-38
24832193-5	2014	RESULTS: At baseline, circulating CD14+CD16+ monocyte percentage, C-reactive protein, and cholesterol were higher in PI vs. PA.	Protactinium	124-126	Fc gamma receptor IIIa	Homo sapiens	39-43
24423642-4	2014	In an attempt to treat EAMG with an 18aa peptide derived from the PA system inhibitor (PAI-1), designed to tether out the endogenous inhibitor, a significant suppression of disease severity was demonstrated.	Protactinium	66-68	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	87-92
24948832-1	2014	In Arabidopsis (Arabidopsis thaliana), the major MYB protein regulating proanthocyanidin (PA) biosynthesis is TT2, named for the transparent testa phenotype of tt2 mutant seeds that lack PAs in their coats.	Protactinium	187-190	Duplicated homeodomain-like superfamily protein	Arabidopsis thaliana	160-163
24941128-6	2014	The docking study of compound 4r with AChE enzyme showed that both CAS and PAS are occupied by the ligand.	Protactinium	75-78	acetylcholinesterase	Rattus norvegicus	38-42
25010614-13	2014	The latency of Na, Pa, and Nb waves was significantly longer and the amplitude of Pa wave was significantly lower in group P3, P4, and P5 than in group NS and I.	Protactinium	82-84	protein disulfide isomerase family A, member 6	Rattus norvegicus	127-137
24867821-6	2014	We have found that the ChT-L activity is dramatically reduced in the presence of T-L and PA substrates.	Protactinium	89-91	chymotrypsin like	Homo sapiens	23-28
24752531-7	2014	Anyway, biological data obtained by flow cytometry analysis indicate that the five PAs have a different binding ability towards the CCK-2 receptors, with higher binding properties shown by PA containing PEG with MW of 2000 Dalton.	Protactinium	83-85	cholecystokinin	Homo sapiens	132-135
24964096-3	2014	Treatment with estradiol in physiological ranges for 2 weeks caused a concentration-dependent increase in the number of PAS-positive cells (confirmed to be goblet cells by MUC5AC immunostaining) in ALI cultures, and this action was attenuated by estrogen receptor beta (ER-beta) antagonist.	Protactinium	120-123	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	172-178
24970916-0	2014	Influence of F(IO2) on Pa(CO2) during noninvasive ventilation in patients with COPD: what will be constant over time?	Protactinium	23-25	complement C2	Homo sapiens	26-29
24964096-3	2014	Treatment with estradiol in physiological ranges for 2 weeks caused a concentration-dependent increase in the number of PAS-positive cells (confirmed to be goblet cells by MUC5AC immunostaining) in ALI cultures, and this action was attenuated by estrogen receptor beta (ER-beta) antagonist.	Protactinium	120-123	estrogen receptor 2	Homo sapiens	246-268
24964096-3	2014	Treatment with estradiol in physiological ranges for 2 weeks caused a concentration-dependent increase in the number of PAS-positive cells (confirmed to be goblet cells by MUC5AC immunostaining) in ALI cultures, and this action was attenuated by estrogen receptor beta (ER-beta) antagonist.	Protactinium	120-123	estrogen receptor 2	Homo sapiens	270-277
24926305-2	2014	Recent findings suggest that current smokers may present higher recanalization rates after intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA).	Protactinium	171-173	chromosome 20 open reading frame 181	Homo sapiens	138-166
25330661-8	2014	RESULTS: The SK2 current density was (-2.92 +/- 0.35) pA/pF in SR group (n = 6) vs (-6.83 +/- 0.19) pA/pF in AF group at -130 mV (n = 3, P &lt; 0.05).	Protactinium	54-56	sphingosine kinase 2	Homo sapiens	13-16
24446351-6	2014	Meanwhile, miR-190 antisense oligos can partially reverse the effects of miR-190 on PASMCs and PAs.	Protactinium	95-98	microRNA 190a	Homo sapiens	11-18
24446351-6	2014	Meanwhile, miR-190 antisense oligos can partially reverse the effects of miR-190 on PASMCs and PAs.	Protactinium	95-98	microRNA 190a	Homo sapiens	73-80
24835346-11	2014	In vitro, KMUP-1 inhibited ET-1-induced PA constriction and ET-1-dependent/independent RhoA activation of PASMCs.	Protactinium	40-42	endothelin 1	Rattus norvegicus	27-31
24835346-12	2014	In summary, KMUP-1 attenuates ET-1-induced/ET-1-mediated PA constriction, and could thus aid in the treatment of PAH caused by MCT.	Protactinium	57-59	endothelin 1	Rattus norvegicus	30-34
24835346-12	2014	In summary, KMUP-1 attenuates ET-1-induced/ET-1-mediated PA constriction, and could thus aid in the treatment of PAH caused by MCT.	Protactinium	57-59	endothelin 1	Rattus norvegicus	43-47
24841847-9	2014	Graded prolongation of PA-PDI interval was observed across 3 groups of patients divided according to the tertile values of PCF.	Protactinium	23-25	peptidyl arginine deiminase 1	Homo sapiens	26-29
24237181-14	2014	In AGA-born girls with PA, decreasing insulin sensitivity is strongly and independently associated with an increase in MOV.	Protactinium	23-25	insulin	Homo sapiens	38-45
24623801-7	2014	More importantly, PA-MSHA-induced DCs were essential for PA-MSHA to enhance activation, expansion, and interferon (IFN)-gamma secretion of TLR4-mediated T cells, which play a role in the antitumor effect of PA-MSHA.	Protactinium	18-20	interferon gamma	Mus musculus	103-125
24583145-7	2014	In addition, CKLF1 plasmid (100mug) injection and electroporation led to the asthmatic change in the lung in mice as shown by HE and PAS staining.	Protactinium	133-136	CKLF-like MARVEL transmembrane domain containing 2A	Mus musculus	13-18
25328295-6	2014	RESULTS: The immunoreactivity for c-kit was found in all cases of AdCC, PLGA and MEC and majority of PAs.	Protactinium	101-104	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	34-39
24623801-7	2014	More importantly, PA-MSHA-induced DCs were essential for PA-MSHA to enhance activation, expansion, and interferon (IFN)-gamma secretion of TLR4-mediated T cells, which play a role in the antitumor effect of PA-MSHA.	Protactinium	18-20	toll-like receptor 4	Mus musculus	139-143
24369117-2	2014	In response to activation of the cAMP signaling cascade nuclear DGK activity is rapidly increased, facilitating PA-mediated, SF1-dependent transcription of genes required for cortisol and dehydroepiandrosterone (DHEA) biosynthesis.	Protactinium	112-114	diacylglycerol kinase beta	Homo sapiens	64-67
24646624-9	2014	Within the PA group, the proportion of successful results was significantly higher in the decompression subgroup than in the fusion group according to 6-month posttreatment NRS leg and ODI scores.	Protactinium	11-13	sphingolipid transporter 1 (putative)	Homo sapiens	173-176
24721726-3	2014	We have previously shown that PA biosynthesis (occurring exclusively in seeds) involves the transcriptional activity of four different ternary protein complexes composed of different R2R3-MYB and bHLH factors together with TRANSPARENT TESTA GLABRA 1 (TTG1), a WD repeat containing protein.	Protactinium	30-32	Transducin/WD40 repeat-like superfamily protein	Arabidopsis thaliana	223-249
24721726-3	2014	We have previously shown that PA biosynthesis (occurring exclusively in seeds) involves the transcriptional activity of four different ternary protein complexes composed of different R2R3-MYB and bHLH factors together with TRANSPARENT TESTA GLABRA 1 (TTG1), a WD repeat containing protein.	Protactinium	30-32	Transducin/WD40 repeat-like superfamily protein	Arabidopsis thaliana	251-255
24369117-7	2014	DGKtheta knockdown cells exhibited a reduced capacity to metabolize PA, with a down-regulation of lipin and phospholipase D (PLD) isoforms.	Protactinium	68-70	diacylglycerol kinase theta	Homo sapiens	0-8
24468654-13	2014	Immunohistochemical analysis revealed frequent overexpression of the translocation target gene PLAG1 in PAs and in 1 Ca-ex-PA.	Protactinium	104-107	PLAG1 zinc finger	Homo sapiens	95-100
24468654-14	2014	In contrast, overexpression of HMGA2 was observed in only a small subset of PAs.	Protactinium	76-79	high mobility group AT-hook 2	Homo sapiens	31-36
24369117-2	2014	In response to activation of the cAMP signaling cascade nuclear DGK activity is rapidly increased, facilitating PA-mediated, SF1-dependent transcription of genes required for cortisol and dehydroepiandrosterone (DHEA) biosynthesis.	Protactinium	112-114	splicing factor 1	Homo sapiens	125-128
24387786-0	2014	Tumour-associated mutations of PA-TM-RING ubiquitin ligases RNF167/RNF13 identify the PA domain as a determinant for endosomal localization.	Protactinium	31-33	ring finger protein 167	Homo sapiens	60-66
24387786-0	2014	Tumour-associated mutations of PA-TM-RING ubiquitin ligases RNF167/RNF13 identify the PA domain as a determinant for endosomal localization.	Protactinium	31-33	ring finger protein 13	Homo sapiens	67-72
24440642-5	2014	RESULTS: HMOX1 transfection induced cytoplasmic vacuolation and the accumulation of PAS+ inclusions in cultured astroglia.	Protactinium	84-88	heme oxygenase 1	Mus musculus	9-14
24302647-9	2014	In contrast, all PAs (N = 20 of 20) were negative for MYB (P &lt; .0001).	Protactinium	17-20	MYB proto-oncogene, transcription factor	Homo sapiens	54-57
24653686-2	2014	Located in the dorsal midline thalamus, the Pa is heavily innervated by serotonin, norepinephrine, dopamine (DA), corticotropin-releasing hormone, and orexins (ORX), and is the only thalamic nucleus connected to the group of structures comprising the amygdala, bed nucleus of the stria terminalis (BNST), nucleus accumbens (NAcc), and infralimbic/subgenual anterior cingulate cortex (sgACC).	Protactinium	44-46	corticotropin releasing hormone	Homo sapiens	114-145
24480903-9	2014	There was no statistically significant correlation between CK-MB and BSID-II score (P&gt;0.05).Serum cTnI concentrations and duration of inotropic support were significantly greater with increasing severity of PA.	Protactinium	210-212	troponin I3, cardiac type	Homo sapiens	101-105
24868229-4	2014	Immunohistochemical comparisons showed that the PA was strongly positive for ameloblastin, KL1, p63, carcinoembryonic antigen, focal adhesion kinase, and cathepsin K, and slightly positive for amelogenin, Krox-25, E-cadherin, and PTCH1, whereas the OBCC was not.	Protactinium	48-50	ameloblastin	Homo sapiens	77-89
24868229-4	2014	Immunohistochemical comparisons showed that the PA was strongly positive for ameloblastin, KL1, p63, carcinoembryonic antigen, focal adhesion kinase, and cathepsin K, and slightly positive for amelogenin, Krox-25, E-cadherin, and PTCH1, whereas the OBCC was not.	Protactinium	48-50	KIT ligand	Homo sapiens	91-94
24868229-4	2014	Immunohistochemical comparisons showed that the PA was strongly positive for ameloblastin, KL1, p63, carcinoembryonic antigen, focal adhesion kinase, and cathepsin K, and slightly positive for amelogenin, Krox-25, E-cadherin, and PTCH1, whereas the OBCC was not.	Protactinium	48-50	tumor protein p63	Homo sapiens	96-99
24868229-4	2014	Immunohistochemical comparisons showed that the PA was strongly positive for ameloblastin, KL1, p63, carcinoembryonic antigen, focal adhesion kinase, and cathepsin K, and slightly positive for amelogenin, Krox-25, E-cadherin, and PTCH1, whereas the OBCC was not.	Protactinium	48-50	cathepsin K	Homo sapiens	154-165
24868229-4	2014	Immunohistochemical comparisons showed that the PA was strongly positive for ameloblastin, KL1, p63, carcinoembryonic antigen, focal adhesion kinase, and cathepsin K, and slightly positive for amelogenin, Krox-25, E-cadherin, and PTCH1, whereas the OBCC was not.	Protactinium	48-50	cadherin 1	Homo sapiens	214-224
24868229-4	2014	Immunohistochemical comparisons showed that the PA was strongly positive for ameloblastin, KL1, p63, carcinoembryonic antigen, focal adhesion kinase, and cathepsin K, and slightly positive for amelogenin, Krox-25, E-cadherin, and PTCH1, whereas the OBCC was not.	Protactinium	48-50	patched 1	Homo sapiens	230-235
24478261-1	2014	Self-assembly of PAs composed of palmitic acid and several repeated heptad peptide sequences, C15H31CO-(IEEYTKK)(n)-NH2 (n = 1-4, represented by PA1-PA4), was investigated systematically.	Protactinium	17-20	PAXIP1 associated glutamate rich protein 1	Homo sapiens	145-152
24532452-4	2014	Indeed, this phenotype resembled those of tt10 mutant seeds defective in the laccase-like enzyme TT10/LAC15, which is involved in the oxidative polymerization of flavonoids such as the proantocyanidins (PAs) (i.e. epicatechin monomers and PA oligomers) and flavonol glycosides.	Protactinium	203-205	Laccase/Diphenol oxidase family protein	Arabidopsis thaliana	42-46
24532452-4	2014	Indeed, this phenotype resembled those of tt10 mutant seeds defective in the laccase-like enzyme TT10/LAC15, which is involved in the oxidative polymerization of flavonoids such as the proantocyanidins (PAs) (i.e. epicatechin monomers and PA oligomers) and flavonol glycosides.	Protactinium	203-205	Laccase/Diphenol oxidase family protein	Arabidopsis thaliana	97-101
24532452-4	2014	Indeed, this phenotype resembled those of tt10 mutant seeds defective in the laccase-like enzyme TT10/LAC15, which is involved in the oxidative polymerization of flavonoids such as the proantocyanidins (PAs) (i.e. epicatechin monomers and PA oligomers) and flavonol glycosides.	Protactinium	203-205	Laccase/Diphenol oxidase family protein	Arabidopsis thaliana	102-107
24532452-7	2014	Functional complementation of the nrt2.7-2 mutant by overexpression of a full-length NRT2.7 cDNA clearly demonstrated the link between the nrt2.7 mutation and the PA phenotype.	Protactinium	163-165	nitrate transporter 2:1	Arabidopsis thaliana	34-38
24532452-7	2014	Functional complementation of the nrt2.7-2 mutant by overexpression of a full-length NRT2.7 cDNA clearly demonstrated the link between the nrt2.7 mutation and the PA phenotype.	Protactinium	163-165	nitrate transporter 2:1	Arabidopsis thaliana	85-89
24532452-7	2014	Functional complementation of the nrt2.7-2 mutant by overexpression of a full-length NRT2.7 cDNA clearly demonstrated the link between the nrt2.7 mutation and the PA phenotype.	Protactinium	163-165	nitrate transporter 2:1	Arabidopsis thaliana	139-143
24532452-8	2014	However, the PA-related phenotype of nrt2.7-2 seeds was not strictly correlated to the nitrate content of seeds.	Protactinium	13-15	nitrate transporter 2:1	Arabidopsis thaliana	37-41
24532452-10	2014	All together, the results highlight a hitherto-unknown function of NRT2.7 in PA accumulation/oxidation.	Protactinium	77-79	nitrate transporter 2:1	Arabidopsis thaliana	67-71
24333689-5	2014	JNK inhibitor or chemical chaperone was protective against both PAA/Eto- and HG/PA-induced cell death.	Protactinium	64-66	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
24581246-8	2014	Acrolein was pro-inflammatory for the PNEC cultures (30 muM exposure for 4 h inducing a 2.0 fold increase in IL-8 release) and also increased IL-8 release after stimulation with PA LPS.	Protactinium	178-180	C-X-C motif chemokine ligand 8	Homo sapiens	142-146
24550275-6	2014	The majority of residues in active ERK2 fit to a single conformational exchange process, with kex   300 s(-1) (kAB   240 s(-1)/kBA   60 s(-1)) and pA/pB   20%/80%, suggesting global domain motions involving interconversion between two states.	Protactinium	147-149	mitogen-activated protein kinase 1	Homo sapiens	35-39
24484680-5	2014	RESULTS: In a linear mixed-effect model adjusted for baseline demographic and clinical parameters, each pg/mL increase in IL-6 over time was associated with a decrease in PA levels of 0.001 /2-y (P = 0.003 for IL-6 x time interaction).	Protactinium	171-173	interleukin 6	Homo sapiens	122-126
24484680-6	2014	PA remained associated with the rate of change in IL-6 even after controlling for extracellular water and fat mass.	Protactinium	0-2	interleukin 6	Homo sapiens	50-54
24484680-7	2014	Changes in PA over time were associated with inverse linear changes in IL-6 (adjusted r = -0.32; P = 0.005) and consequently with mortality risk.	Protactinium	11-13	interleukin 6	Homo sapiens	71-75
24550275-7	2014	A mutant of ERK2, engineered to enhance conformational mobility at the hinge region linking the N- and C-terminal domains, also induced two-state conformational exchange throughout the kinase core, with exchange properties of kex   500 s(-1) (kAB   15 s(-1)/kBA   485 s(-1)) and pA/pB   97%/3%.	Protactinium	279-281	mitogen-activated protein kinase 1	Homo sapiens	12-16
24521082-4	2014	Furthermore, AA rescued significantly PA-impaired glucose uptake and -signal transduction of Akt in response to insulin.Based on the observations that polyunsaturated AA generated competently cellular droplets at low concentration within the cytosol of myotubes compared with other monounsaturated fatty acids, and AA-driven lipid droplets were also enhanced in the presence of PA, we hypothesized that incorporation of harmful PA into inert triglyceride (TG) may be responsible for the protective effects of AA against PA-induced lipotoxicity.	Protactinium	38-40	AKT serine/threonine kinase 1	Homo sapiens	93-96
24170349-6	2014	Also, knockdown of LC3 expression led to accumulation of PA proteins and reduction of pluripotency in hESCs.	Protactinium	57-59	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	19-22
24425876-3	2014	In the absence of AGPAT2, the liver can synthesize PAs by activating diacylglycerol kinase or phospholipase D, both of which were elevated in the livers of Agpat2(-/-) mice.	Protactinium	51-54	1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)	Mus musculus	156-162
24425876-4	2014	We found that PAs C16:0/18:1 and C18:1/20:4 enhanced HGP in primary WT hepatocytes, an effect that was further enhanced in primary hepatocytes from Agpat2(-/-) mice.	Protactinium	14-17	1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)	Mus musculus	148-154
24437929-2	2014	(NH4)2PaF7, K2PaF7, Rb2PaF7, and Cs2PaF7 were found to crystallize in the monoclinic space group P21/c for the ammonium compound and C2/c for the K(+)-, Rb(+)-, and Cs(+)-containing compounds, with nine-coordinate Pa forming infinite chains through fluorine bridges.	Protactinium	6-8	H3 histone pseudogene 16	Homo sapiens	97-102
24672947-12	2014	Compared with the model group, mRNA expression of Smad2 and Smad3 obviously increased in the low dose PA group and the high dose PA group at week 2, 4, and 6, showing statistical difference (P &lt; 0.05).	Protactinium	102-104	SMAD family member 2	Rattus norvegicus	50-55
24672947-12	2014	Compared with the model group, mRNA expression of Smad2 and Smad3 obviously increased in the low dose PA group and the high dose PA group at week 2, 4, and 6, showing statistical difference (P &lt; 0.05).	Protactinium	102-104	SMAD family member 3	Rattus norvegicus	60-65
24672947-12	2014	Compared with the model group, mRNA expression of Smad2 and Smad3 obviously increased in the low dose PA group and the high dose PA group at week 2, 4, and 6, showing statistical difference (P &lt; 0.05).	Protactinium	129-131	SMAD family member 2	Rattus norvegicus	50-55
24672947-12	2014	Compared with the model group, mRNA expression of Smad2 and Smad3 obviously increased in the low dose PA group and the high dose PA group at week 2, 4, and 6, showing statistical difference (P &lt; 0.05).	Protactinium	129-131	SMAD family member 3	Rattus norvegicus	60-65
24672947-13	2014	Compared with the same group at week 4 after gastrogavage, mRNA expression of Smad2 and Smad3 obviously decreased in the low dose PA group and the high dose PA group at week 6, showing statistical difference (P &lt; 0.05).	Protactinium	130-132	SMAD family member 2	Rattus norvegicus	78-83
24672947-13	2014	Compared with the same group at week 4 after gastrogavage, mRNA expression of Smad2 and Smad3 obviously decreased in the low dose PA group and the high dose PA group at week 6, showing statistical difference (P &lt; 0.05).	Protactinium	130-132	SMAD family member 3	Rattus norvegicus	88-93
24672947-13	2014	Compared with the same group at week 4 after gastrogavage, mRNA expression of Smad2 and Smad3 obviously decreased in the low dose PA group and the high dose PA group at week 6, showing statistical difference (P &lt; 0.05).	Protactinium	157-159	SMAD family member 2	Rattus norvegicus	78-83
24672947-13	2014	Compared with the same group at week 4 after gastrogavage, mRNA expression of Smad2 and Smad3 obviously decreased in the low dose PA group and the high dose PA group at week 6, showing statistical difference (P &lt; 0.05).	Protactinium	157-159	SMAD family member 3	Rattus norvegicus	88-93
24672947-14	2014	Compared with the model group, protein expression of Smad2 and Smad3 obviously increased in the chondrocytes of the low dose PA group and the high dose PA group at week 2 and 4, showing statistical difference (P &lt; 0.01).	Protactinium	125-127	SMAD family member 2	Rattus norvegicus	53-58
24672947-14	2014	Compared with the model group, protein expression of Smad2 and Smad3 obviously increased in the chondrocytes of the low dose PA group and the high dose PA group at week 2 and 4, showing statistical difference (P &lt; 0.01).	Protactinium	125-127	SMAD family member 3	Rattus norvegicus	63-68
24672947-14	2014	Compared with the model group, protein expression of Smad2 and Smad3 obviously increased in the chondrocytes of the low dose PA group and the high dose PA group at week 2 and 4, showing statistical difference (P &lt; 0.01).	Protactinium	152-154	SMAD family member 2	Rattus norvegicus	53-58
24672947-14	2014	Compared with the model group, protein expression of Smad2 and Smad3 obviously increased in the chondrocytes of the low dose PA group and the high dose PA group at week 2 and 4, showing statistical difference (P &lt; 0.01).	Protactinium	152-154	SMAD family member 3	Rattus norvegicus	63-68
24672947-15	2014	Compared with the same group at week 2 after gastrogavage, protein expression of Smad2 and Smad3 obviously increased in the low dose PA group and the high dose PA group at week 4, showing statistical difference (P &lt; 0.01).	Protactinium	133-135	SMAD family member 2	Rattus norvegicus	81-86
24672947-15	2014	Compared with the same group at week 2 after gastrogavage, protein expression of Smad2 and Smad3 obviously increased in the low dose PA group and the high dose PA group at week 4, showing statistical difference (P &lt; 0.01).	Protactinium	133-135	SMAD family member 3	Rattus norvegicus	91-96
24672947-15	2014	Compared with the same group at week 2 after gastrogavage, protein expression of Smad2 and Smad3 obviously increased in the low dose PA group and the high dose PA group at week 4, showing statistical difference (P &lt; 0.01).	Protactinium	160-162	SMAD family member 2	Rattus norvegicus	81-86
24672947-15	2014	Compared with the same group at week 2 after gastrogavage, protein expression of Smad2 and Smad3 obviously increased in the low dose PA group and the high dose PA group at week 4, showing statistical difference (P &lt; 0.01).	Protactinium	160-162	SMAD family member 3	Rattus norvegicus	91-96
24672947-16	2014	Compared with the same group at week 4 after gastrogavage, protein expression of Smad2 and Smad3 obviously decreased in the low dose PA group and the high dose PA group at week 6, showing statistical difference (P &lt; 0.01).	Protactinium	133-135	SMAD family member 2	Rattus norvegicus	81-86
24672947-16	2014	Compared with the same group at week 4 after gastrogavage, protein expression of Smad2 and Smad3 obviously decreased in the low dose PA group and the high dose PA group at week 6, showing statistical difference (P &lt; 0.01).	Protactinium	133-135	SMAD family member 3	Rattus norvegicus	91-96
24672947-16	2014	Compared with the same group at week 4 after gastrogavage, protein expression of Smad2 and Smad3 obviously decreased in the low dose PA group and the high dose PA group at week 6, showing statistical difference (P &lt; 0.01).	Protactinium	160-162	SMAD family member 2	Rattus norvegicus	81-86
24672947-16	2014	Compared with the same group at week 4 after gastrogavage, protein expression of Smad2 and Smad3 obviously decreased in the low dose PA group and the high dose PA group at week 6, showing statistical difference (P &lt; 0.01).	Protactinium	160-162	SMAD family member 3	Rattus norvegicus	91-96
24665572-5	2014	RESULTS: In the group of full-term neonates with PA significantly higher levels of cardiac tropon-inI (p = 0.000), CK-MB fraction (p = 0.000), brain natriuretic peptide (p = 0.003) and C-reactive protein (p = 0.017) were found, compared to the group of healthy full-term newborns.	Protactinium	49-51	C-reactive protein	Homo sapiens	185-203
25651714-5	2014	RESULTS: The results indicate a lower expression of IL-17A, IL-17E, and IL-17F in PMNs and B lymphocytes of pa- tients with B-cell chronic lymphocytic leukemia compared to cells of healthy subjects.	Protactinium	108-110	interleukin 17A	Homo sapiens	52-58
25243135-8	2014	However, transplants receiving the BDNF-containing PA gel demonstrated significantly higher numbers of HNPCs and neuronal differentiation.	Protactinium	51-53	brain derived neurotrophic factor	Homo sapiens	35-39
25651714-5	2014	RESULTS: The results indicate a lower expression of IL-17A, IL-17E, and IL-17F in PMNs and B lymphocytes of pa- tients with B-cell chronic lymphocytic leukemia compared to cells of healthy subjects.	Protactinium	108-110	interleukin 25	Homo sapiens	60-66
25651714-5	2014	RESULTS: The results indicate a lower expression of IL-17A, IL-17E, and IL-17F in PMNs and B lymphocytes of pa- tients with B-cell chronic lymphocytic leukemia compared to cells of healthy subjects.	Protactinium	108-110	interleukin 17F	Homo sapiens	72-78
24470023-5	2014	We will describe here the detailed protocol and show some examples of how PA can reveal impairments or enhancements in memory consolidation following loss or gain of function genetic manipulations of the Ras-ERK pathway.	Protactinium	74-76	mitogen-activated protein kinase 1	Mus musculus	208-211
24734256-6	2014	(2) Western blot analysis of the activation of MAPKs during GLU+PA-induced INS-1 cell apoptosis showed that phosphorylation of P38 increased gradually and reached a peak at 96 h, which coincided with PARP-1 cleavage.	Protactinium	64-66	insulin 1	Rattus norvegicus	75-80
24734256-6	2014	(2) Western blot analysis of the activation of MAPKs during GLU+PA-induced INS-1 cell apoptosis showed that phosphorylation of P38 increased gradually and reached a peak at 96 h, which coincided with PARP-1 cleavage.	Protactinium	64-66	mitogen activated protein kinase 14	Rattus norvegicus	127-130
24734256-6	2014	(2) Western blot analysis of the activation of MAPKs during GLU+PA-induced INS-1 cell apoptosis showed that phosphorylation of P38 increased gradually and reached a peak at 96 h, which coincided with PARP-1 cleavage.	Protactinium	64-66	poly (ADP-ribose) polymerase 1	Rattus norvegicus	200-206
24734256-7	2014	A transient increase of ERK activation was followed by a rapid decline at 96 h, whereas JNK phosphorylation status remained unchanged in response to GLU+PA.	Protactinium	153-155	mitogen-activated protein kinase 8	Rattus norvegicus	88-91
24734256-9	2014	(4) Inhibition of P38, but not JNK or ERK, blocked GLU+PA-induced INS-1 cell apoptosis.	Protactinium	55-57	mitogen activated protein kinase 14	Rattus norvegicus	18-21
24734256-9	2014	(4) Inhibition of P38, but not JNK or ERK, blocked GLU+PA-induced INS-1 cell apoptosis.	Protactinium	55-57	insulin 1	Rattus norvegicus	66-71
24080545-2	2014	Previously, we have identified several PA virulence factors that are important for resistance to the surfactant protein-A (SP-A), a pulmonary innate immunity protein that mediates bacterial opsonization and membrane permeabilization.	Protactinium	39-41	surfactant associated protein A1	Mus musculus	123-127
24080545-3	2014	In this study, we demonstrate that the type IV pilus (Tfp) is important in the resistance of PA to the antibacterial effects of SP-A.	Protactinium	93-95	tripartite motif-containing 39	Mus musculus	54-57
24080545-3	2014	In this study, we demonstrate that the type IV pilus (Tfp) is important in the resistance of PA to the antibacterial effects of SP-A.	Protactinium	93-95	surfactant associated protein A1	Mus musculus	128-132
24734256-5	2014	RESULTS: (1) Live cell imaging studies showed that treatment with GLU+PA for 72 h induced significant cell death, concomitant with PARP-1 cleavage and caspase-3 activation, which peaked at 96 h of treatment.	Protactinium	70-72	poly (ADP-ribose) polymerase 1	Rattus norvegicus	131-137
24734256-5	2014	RESULTS: (1) Live cell imaging studies showed that treatment with GLU+PA for 72 h induced significant cell death, concomitant with PARP-1 cleavage and caspase-3 activation, which peaked at 96 h of treatment.	Protactinium	70-72	caspase 3	Rattus norvegicus	151-160
25602706-3	2014	We previously identified TDP-43 as a binder of the downstream element (DSE) of the beta-Adducin (Add2) brain-specific polyadenylation site (A4 PAS), suggesting its involvement in pre-mRNA 3" end processing.	Protactinium	143-146	TAR DNA binding protein	Homo sapiens	25-31
24435979-5	2014	Exogenous applications of PAs positively modulate GUS expression, thus alleviating the negative effect of AtPAO2 uORF, while treatments with MGBG inhibitor show an opposite effect.	Protactinium	26-29	polyamine oxidase 2	Arabidopsis thaliana	106-112
25602706-3	2014	We previously identified TDP-43 as a binder of the downstream element (DSE) of the beta-Adducin (Add2) brain-specific polyadenylation site (A4 PAS), suggesting its involvement in pre-mRNA 3" end processing.	Protactinium	143-146	adducin 2	Homo sapiens	83-95
25602706-3	2014	We previously identified TDP-43 as a binder of the downstream element (DSE) of the beta-Adducin (Add2) brain-specific polyadenylation site (A4 PAS), suggesting its involvement in pre-mRNA 3" end processing.	Protactinium	143-146	adducin 2	Homo sapiens	97-101
24403254-7	2013	Western blot analysis revealed that MsMab-1 reacts with PA tag combined recombinant proteins of IDH2-R172S.	Protactinium	56-58	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	96-100
24233153-8	2014	The differences in VEGF-D expression between non-recurrent, primary-to-recur, and recurrent PAs were not significant (p&gt;0.05).	Protactinium	92-95	vascular endothelial growth factor D	Homo sapiens	19-25
24047466-8	2013	Sirt3(-/-) mice housed in chronic hypoxia (10% O2; 30 d) developed PH, PA wall remodeling, and right ventricular hypertrophy that was indistinguishable from Sirt3(+/+) littermates.	Protactinium	71-73	sirtuin 3	Mus musculus	0-5
24077947-10	2013	Moreover, after 2 wk of hypoxia, Kv1.5 expression in resistance PAs decreased significantly in the IUGR group.	Protactinium	64-67	potassium voltage-gated channel subfamily A member 5	Rattus norvegicus	33-38
25379522-7	2014	Both PON and ARE activity increased at the bout of ME in PA subjects and only ARE activity in S subjects.	Protactinium	57-59	paraoxonase 1	Homo sapiens	5-8
24335964-4	2013	We focus on in vivo photoacoustic (PA) flow cytometry (PAFC) of CTCs using label-free or targeted detection, photoswitchable nanoparticles with ultrasharp PA resonances, magnetic trapping with fiber-magnetic-PA probes, optical clearance, real-time spectral identification, nonlinear signal amplification, and the integration with PAFC in vitro.	Protactinium	35-37	PAFC	Homo sapiens	55-59
24215132-3	2013	Here, four PA derivatives containing arginine and lysine conjugated with fatty acyl groups with different chain lengths, namely, PA1: R-K(C14)-R, PA2: R-K(C16)-R, PA3: K(C14)-R-K(C14), and PA4: K(C16)-R-K(C16), where C16 = palmitic acid and C14 = myristic acid, were synthesized through Fmoc chemistry.	Protactinium	11-13	PAXIP1 associated glutamate rich protein 1	Homo sapiens	129-132
23901080-0	2013	Caspase-1 deficient mice are more susceptible to influenza A virus infection with PA variation.	Protactinium	82-84	caspase 1	Mus musculus	0-9
24287489-2	2013	We have measured HCN in the headspace of various PA culture types, planktonic and biofilm, significant numbers of genetically identified PA strains together with studies of HCN in the mouth-exhaled and nose-exhaled breath of healthy children and adults and those with CF.	Protactinium	49-51	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	17-20
24287489-3	2013	The major findings are: (i) virtually all strains of PA release HCN when cultured in vitro, as shown by the investigation of more than 150 genetically differentiated strains, both mucoid and non-mucoid.	Protactinium	53-55	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	64-67
24287489-6	2013	(iii) HCN is present in both mouth-exhaled and nose-exhaled breath of patients with CF, suggesting the presence of PA in the lower airways as indicated by clinical microbiological cultures.	Protactinium	115-117	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	6-9
24057326-11	2013	These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiologic and histologic features, including those at extracerebellar sites, (b) BRAF V600E mutation is uncommon in extracerebellar PAs, and (c) TP53 mutation analysis remains a valuable tool in identifying childhood gliomas that will likely behave in a malignant fashion.	Protactinium	69-72	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	31-35
24283275-4	2013	A further bioactivity-guided approach led to the isolation of ent-pimara-8(14),15-dien-19-oic acid, (PA), one of the major compounds of A. cordata, which suppressed the GPAT1 activity with IC50 value of 60.5 muM.	Protactinium	101-103	glycerol-3-phosphate acyltransferase, mitochondrial	Homo sapiens	169-174
24057326-11	2013	These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiologic and histologic features, including those at extracerebellar sites, (b) BRAF V600E mutation is uncommon in extracerebellar PAs, and (c) TP53 mutation analysis remains a valuable tool in identifying childhood gliomas that will likely behave in a malignant fashion.	Protactinium	69-72	KIAA1549	Homo sapiens	36-44
24057326-11	2013	These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiologic and histologic features, including those at extracerebellar sites, (b) BRAF V600E mutation is uncommon in extracerebellar PAs, and (c) TP53 mutation analysis remains a valuable tool in identifying childhood gliomas that will likely behave in a malignant fashion.	Protactinium	69-72	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	176-180
24057326-11	2013	These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiologic and histologic features, including those at extracerebellar sites, (b) BRAF V600E mutation is uncommon in extracerebellar PAs, and (c) TP53 mutation analysis remains a valuable tool in identifying childhood gliomas that will likely behave in a malignant fashion.	Protactinium	69-72	tumor protein p53	Homo sapiens	240-244
23597848-5	2013	We performed PA imaging of albumin in three regions in the rats, burn and nonburn regions and their boundary, and the imaging showed that albumin started to leak out of the vessels in the boundary and diffused within the burned tissue.	Protactinium	13-15	albumin	Rattus norvegicus	27-34
24100927-12	2013	In conclusion, these data supports the notion that D3Rs might modulate CREB phosphorylation after acquisition of PA, probably via activation of ERK signaling.	Protactinium	113-115	cAMP responsive element binding protein 1	Mus musculus	71-75
24100927-5	2013	Therefore, in this study we assessed whether phosphorylation levels of several MAPKs, Akt and CREB were differentially affected by PA in both wild-type (WT) and D 3 (-/-) mice hippocampi.	Protactinium	131-133	cAMP responsive element binding protein 1	Mus musculus	94-98
23597848-5	2013	We performed PA imaging of albumin in three regions in the rats, burn and nonburn regions and their boundary, and the imaging showed that albumin started to leak out of the vessels in the boundary and diffused within the burned tissue.	Protactinium	13-15	albumin	Rattus norvegicus	138-145
23597848-7	2013	In the burn and boundary regions, albumin-originating PA signal increased in two phases: immediately after making burns and from 24 to 72 h after burn.	Protactinium	54-56	albumin	Rattus norvegicus	34-41
24049102-0	2013	Pas de quatre: an interaction of HLA-B*27:05 and KIR3DL2 homodimers in spondyloarthropathies.	Protactinium	0-3	major histocompatibility complex, class I, B	Homo sapiens	33-38
24135596-5	2013	The residual phytase activities along the GIT had increased (P &lt; 0.01) with the addition of TCDP, PA, and PB to the NC diets.	Protactinium	101-103	phytase	Zea mays	13-20
24049102-0	2013	Pas de quatre: an interaction of HLA-B*27:05 and KIR3DL2 homodimers in spondyloarthropathies.	Protactinium	0-3	killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2	Homo sapiens	49-56
23804201-6	2013	In human embryonic kidney (HEK-293) cells stably expressing TREK-1, outward currents at 80 mV increased from 91.0 +- 23.8 to 247.5 +- 73.3 pA/pF and from 34.8 +- 8.9 to 218.6 +- 45.0 pA/pF with application of AA and NaHCO3, respectively.	Protactinium	139-141	potassium two pore domain channel subfamily K member 2	Homo sapiens	60-66
24088244-4	2013	However, DACs featuring less hindered N-aryl substituents facilitated proton transfer, and the measured PA values were found to be consistent with density functional theory calculations (B3LYP/6-31+G(d)).	Protactinium	104-106	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	189-192
23761402-9	2013	Preventing RS and maintaining redox homeostasis in the TG:Nrf2-def mice ameliorated PA, leading to decreased ubiquitination of proteins.	Protactinium	84-86	nuclear factor, erythroid derived 2, like 2	Mus musculus	58-62
23761402-9	2013	Preventing RS and maintaining redox homeostasis in the TG:Nrf2-def mice ameliorated PA, leading to decreased ubiquitination of proteins.	Protactinium	84-86	UTP25 small subunit processome component	Mus musculus	63-66
23560455-8	2013	Both activity and expression of MDR1 and P-gp were reduced by Pa-PDT treatment and such reductions were attenuated by alpha-tocopherol, the scavenger of reactive oxygen species (ROS), suggesting that the effect of Pa-PDT was mediated by the generation of intracellular ROS.	Protactinium	62-64	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
23560455-8	2013	Both activity and expression of MDR1 and P-gp were reduced by Pa-PDT treatment and such reductions were attenuated by alpha-tocopherol, the scavenger of reactive oxygen species (ROS), suggesting that the effect of Pa-PDT was mediated by the generation of intracellular ROS.	Protactinium	62-64	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
23560455-8	2013	Both activity and expression of MDR1 and P-gp were reduced by Pa-PDT treatment and such reductions were attenuated by alpha-tocopherol, the scavenger of reactive oxygen species (ROS), suggesting that the effect of Pa-PDT was mediated by the generation of intracellular ROS.	Protactinium	214-216	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
25620857-3	2013	Because of the specific binding of the ligand conjugated NDs to the HER2-overexpressing murine breast cancer cells (4T1.2 neu), the tumor tissues are significantly delineated from the surrounding normal tissue at wavelength of 820 nm under the PA imaging modality.	Protactinium	244-246	erb-b2 receptor tyrosine kinase 2	Mus musculus	68-72
23349144-6	2013	These analyses revealed that the formation of PA SAMs accelerate the deposition of poorly crystallized HA, in an alkyl chain length-dependent manner.	Protactinium	46-48	methionine adenosyltransferase 1A	Homo sapiens	49-53
24427695-10	2013	When MMP-9/TIMP1 rates of all groups were compared, there were significant difference between Group A and D (pA-D = 0.005) and between Group A and E, also between Group C and E. Our study is the first study to evaluate the effects of different corticosteroid treatment modalities on MMP-9 and TIMP-1 in nasal polyps and concluded that corticosteroid did not do a significant impact on this pathway.	Protactinium	109-111	matrix metallopeptidase 9	Homo sapiens	5-10
23836950-7	2013	FUT6 was more immunoexpressed in PA cases than the FUT3 (p&lt;0.0001) as well as in BPH cases but in a not significant way (p=0.0661).	Protactinium	33-35	fucosyltransferase 6	Homo sapiens	0-4
23562377-6	2013	However, sirtinol as an inhibitor of NAD-dependant deacetylase or knockdown of SIRT3 or SIRT4 significantly reduced the HG/PA-induced death.	Protactinium	123-125	sirtuin 3	Rattus norvegicus	79-84
23562377-6	2013	However, sirtinol as an inhibitor of NAD-dependant deacetylase or knockdown of SIRT3 or SIRT4 significantly reduced the HG/PA-induced death.	Protactinium	123-125	sirtuin 4	Rattus norvegicus	88-93
23670046-5	2013	We showed that the Atg13 HORMA domain is required for autophagy and for recruitment of the phosphatidylinositol (PtdIns) 3-kinase subunit Atg14, but is not required for Atg1 interaction or Atg13 recruitment to the PAS.	Protactinium	214-217	serine/threonine protein kinase regulatory subunit ATG13	Saccharomyces cerevisiae S288C	19-24
23670046-5	2013	We showed that the Atg13 HORMA domain is required for autophagy and for recruitment of the phosphatidylinositol (PtdIns) 3-kinase subunit Atg14, but is not required for Atg1 interaction or Atg13 recruitment to the PAS.	Protactinium	214-217	serine/threonine protein kinase ATG1	Saccharomyces cerevisiae S288C	19-23
23637044-7	2013	rPA, but not rLF, was the dominant factor in determining potency of serum samples containing anti-PA antibodies only or an excess of anti-PA relative to anti-rLF antibodies.	Protactinium	1-3	RLF zinc finger	Rattus norvegicus	158-161
23859847-6	2013	We demonstrate that this probe reports furin and furin-like activity in cells and tumor models by generating a significantly higher PA signal relative to furin-deficient and nontarget controls.	Protactinium	132-134	furin, paired basic amino acid cleaving enzyme	Homo sapiens	39-44
23859847-6	2013	We demonstrate that this probe reports furin and furin-like activity in cells and tumor models by generating a significantly higher PA signal relative to furin-deficient and nontarget controls.	Protactinium	132-134	furin, paired basic amino acid cleaving enzyme	Homo sapiens	49-54
23859847-6	2013	We demonstrate that this probe reports furin and furin-like activity in cells and tumor models by generating a significantly higher PA signal relative to furin-deficient and nontarget controls.	Protactinium	132-134	furin, paired basic amino acid cleaving enzyme	Homo sapiens	49-54
23600676-5	2013	All PAs were positive for CD24 and CD44 by immunohistochemistry: neoplastic luminal structures were positive for CD24; modified myoepithelial cells were positive for CD44.	Protactinium	4-7	CD24 molecule	Homo sapiens	26-30
23600676-5	2013	All PAs were positive for CD24 and CD44 by immunohistochemistry: neoplastic luminal structures were positive for CD24; modified myoepithelial cells were positive for CD44.	Protactinium	4-7	CD44 molecule (Indian blood group)	Homo sapiens	35-39
23691121-5	2013	Nox inhibitors diphenyleneiodonium chloride (DPI) and Duox1 siRNA were used to investigate whether Duox1 is involved in PA-LPS-induced MUC5AC and Clca3 expression both in vitro and in vivo.	Protactinium	120-122	dual oxidase 1	Mus musculus	99-104
23570516-12	2013	This study outlines a strategy for designing novel derivatives of 4APB with potentially better AChE inhibitory activities through interaction at the PAS and AS sites.	Protactinium	149-152	acetylcholinesterase (Cartwright blood group)	Homo sapiens	95-99
23704878-1	2013	In a transcriptomic screen of Manduca sexta-induced N-acyltransferases in leaves of Nicotiana attenuata, we identified an N-acyltransferase gene sharing a high similarity with the tobacco lignin-biosynthetic hydroxycinnamoyl-CoA:shikimate/quinate hydroxycinnamoyl transferase (HCT) gene whose expression is controlled by MYB8, a transcription factor that regulates the production of phenylpropanoid polyamine conjugates (phenolamides, PAs).	Protactinium	435-438	shikimate O-hydroxycinnamoyltransferase	Nicotiana tabacum	247-275
23704878-1	2013	In a transcriptomic screen of Manduca sexta-induced N-acyltransferases in leaves of Nicotiana attenuata, we identified an N-acyltransferase gene sharing a high similarity with the tobacco lignin-biosynthetic hydroxycinnamoyl-CoA:shikimate/quinate hydroxycinnamoyl transferase (HCT) gene whose expression is controlled by MYB8, a transcription factor that regulates the production of phenylpropanoid polyamine conjugates (phenolamides, PAs).	Protactinium	435-438	shikimate O-hydroxycinnamoyltransferase	Nicotiana tabacum	277-280
23691121-3	2013	Our aim was to clarify whether Duox1 was also involved in the PA-LPS-induced MUC5AC and calcium dependent chloride channel 3(Clca3), another recognized marker of goblet cell hyperplasia and mucus hyper-production.	Protactinium	62-64	dual oxidase 1	Mus musculus	31-36
23691121-5	2013	Nox inhibitors diphenyleneiodonium chloride (DPI) and Duox1 siRNA were used to investigate whether Duox1 is involved in PA-LPS-induced MUC5AC and Clca3 expression both in vitro and in vivo.	Protactinium	120-122	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	135-141
23691121-3	2013	Our aim was to clarify whether Duox1 was also involved in the PA-LPS-induced MUC5AC and calcium dependent chloride channel 3(Clca3), another recognized marker of goblet cell hyperplasia and mucus hyper-production.	Protactinium	62-64	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	77-83
23691121-8	2013	Knockdown of Duox1 markedly inhibited PA-LPS-induced MUC5AC expression via a ROS-TGF-alpha cascade in A549 cells.	Protactinium	38-40	dual oxidase 1	Mus musculus	13-18
23691121-3	2013	Our aim was to clarify whether Duox1 was also involved in the PA-LPS-induced MUC5AC and calcium dependent chloride channel 3(Clca3), another recognized marker of goblet cell hyperplasia and mucus hyper-production.	Protactinium	62-64	chloride channel accessory 1	Mus musculus	125-130
23691121-8	2013	Knockdown of Duox1 markedly inhibited PA-LPS-induced MUC5AC expression via a ROS-TGF-alpha cascade in A549 cells.	Protactinium	38-40	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	53-59
23691121-8	2013	Knockdown of Duox1 markedly inhibited PA-LPS-induced MUC5AC expression via a ROS-TGF-alpha cascade in A549 cells.	Protactinium	38-40	transforming growth factor alpha	Mus musculus	81-90
23691121-10	2013	CONCLUSIONS: We demonstrate for the first time that PA-LPS-induced MUC5AC and Clca3 expression is partly through Duox1, and provide supportive evidence for Duox1 as a potential target in treatments of mucin over-production diseases.	Protactinium	52-54	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	67-73
23691121-10	2013	CONCLUSIONS: We demonstrate for the first time that PA-LPS-induced MUC5AC and Clca3 expression is partly through Duox1, and provide supportive evidence for Duox1 as a potential target in treatments of mucin over-production diseases.	Protactinium	52-54	chloride channel accessory 1	Mus musculus	78-83
23691121-10	2013	CONCLUSIONS: We demonstrate for the first time that PA-LPS-induced MUC5AC and Clca3 expression is partly through Duox1, and provide supportive evidence for Duox1 as a potential target in treatments of mucin over-production diseases.	Protactinium	52-54	dual oxidase 1	Mus musculus	113-118
23691121-10	2013	CONCLUSIONS: We demonstrate for the first time that PA-LPS-induced MUC5AC and Clca3 expression is partly through Duox1, and provide supportive evidence for Duox1 as a potential target in treatments of mucin over-production diseases.	Protactinium	52-54	dual oxidase 1	Mus musculus	156-161
23827295-9	2013	CRP also showed the highest sensitivity (100%) and negative predictive value (100%) for PA.	Protactinium	88-90	C-reactive protein	Homo sapiens	0-3
23418776-2	2013	In the present study we analysed, using a site-directed cysteine and disulfide chemistry approach, whether the eag/PAS (Per/Arnt/Sim) and proximal domains at the HERG N-terminus exert a role in controlling the access of the N-terminal flexible tail to its binding site in the channel core for interaction with the gating machinery.	Protactinium	115-118	potassium voltage-gated channel subfamily H member 2	Homo sapiens	162-166
23458975-5	2013	In the present study, we have identified t-PA as the principal PA, which is responsible for the conversion of PG to plasmin.	Protactinium	43-45	plasminogen	Bos taurus	116-123
23216877-6	2013	In contrast, VSMCs in PAs express functional RyR and BK channels, but under physiological conditions, these channels do not oppose pressure-induced vasoconstriction.	Protactinium	22-25	ryanodine receptor 1	Homo sapiens	45-48
23471892-8	2013	In addition, VEGF expression was immunolocalized in cells of the ganglion cell layer of the IR and this expression significantly increased in the PA group from PND15 on.	Protactinium	146-148	vascular endothelial growth factor A	Rattus norvegicus	13-17
23626779-5	2013	We demonstrate the advantages of PA-GFP expressing mice by the correlation of in vivo firing rates of individual neurons with their expression levels of the immediate early gene c-fos.	Protactinium	33-35	FBJ osteosarcoma oncogene	Mus musculus	178-183
23730366-1	2013	BACKGROUND: The aim is to correlate pulmonary arterial (PA) remodeling estimated by PA fibrosis in PA hypertension (PAH) with clinical follow-up.	Protactinium	56-58	phenylalanine hydroxylase	Homo sapiens	116-119
23827295-12	2013	CONCLUSIONS: CRP provides the highest diagnostic accuracy for PA.	Protactinium	62-64	C-reactive protein	Homo sapiens	13-16
23621018-6	2013	In vivo, the pharmacological activity PA% of series OACS-insulin micelles ranged from 7.7%-16.8%.	Protactinium	38-40	insulin	Homo sapiens	57-64
23601336-8	2013	PA among adults was associated with higher income and education, older age, presence of chronic conditions, and living within 100 miles of four specific CTSA locations.	Protactinium	0-2	cathepsin A	Homo sapiens	153-157
23480702-6	2013	The expression levels of Bak, caspase-3 and Bcl-xL were low in the H and EA groups and increased in the PA group (P &lt; 0.01).	Protactinium	104-106	BCL2 antagonist/killer 1	Homo sapiens	25-28
23445486-6	2013	Mean values for prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and d-dimer obtained on the first day were significantly higher in the PA group compared to healthy controls (P &lt;= .001 for all comparisons), whereas platelet count, levels of fibrinogen, factors II, V, VII, IX, X, and XI were significantly lower (P &lt;= .005 for all comparisons).	Protactinium	194-196	fibrinogen beta chain	Homo sapiens	302-312
23480702-6	2013	The expression levels of Bak, caspase-3 and Bcl-xL were low in the H and EA groups and increased in the PA group (P &lt; 0.01).	Protactinium	104-106	BCL2 like 1	Homo sapiens	44-50
23480702-6	2013	The expression levels of Bak, caspase-3 and Bcl-xL were low in the H and EA groups and increased in the PA group (P &lt; 0.01).	Protactinium	104-106	caspase 3	Homo sapiens	30-39
23335564-2	2013	App1p, which catalyzes the conversion of phosphatidate (PA) to diacylglycerol, is unique among Mg(2+)-dependent PAP enzymes in that its reaction is not involved with de novo lipid synthesis.	Protactinium	56-58	phosphatidate phosphatase APP1	Saccharomyces cerevisiae S288C	0-5
23232596-3	2013	The results show that, under irradiation at 254 nm and independently of the presence of oxygen, the predominant reaction pathway is a photo-Fries rearrangement (PFR), yielding the PA isomer 2"-amino-5"-hydroxyacetophenone (PAI).	Protactinium	180-182	serpin family E member 1	Homo sapiens	223-226
23255810-8	2013	These results demonstrated that the PA gene mainly determines the pathogenicity discrepancy between CK10 and GS10 in mice.	Protactinium	36-38	keratin 10	Mus musculus	100-104
23255810-9	2013	We further determined that arginine (R) at position 353 of the PA gene contributes to the high virulence of CK10 in mice.	Protactinium	63-65	keratin 10	Mus musculus	108-112
23255810-10	2013	The reciprocal substitution at position 353 in PA or the exchange of the entire PA gene largely caused the transfer of viral phenotypes, including virus replication, polymerase activity, and manipulation of the innate response, between CK10 and GS10.	Protactinium	47-49	keratin 10	Mus musculus	236-240
23255810-10	2013	The reciprocal substitution at position 353 in PA or the exchange of the entire PA gene largely caused the transfer of viral phenotypes, including virus replication, polymerase activity, and manipulation of the innate response, between CK10 and GS10.	Protactinium	80-82	keratin 10	Mus musculus	236-240
23242790-3	2013	Here in this study, we hypothesized that during acquisition of PA conditioning the expression of NF1 and APP genes could be influenced by D(3)Rs.	Protactinium	63-65	neurofibromin 1	Mus musculus	97-100
23242790-6	2013	In conclusion, the present finding show for the first time that both D(3)R and NF1 genes are upregulated following PA conditioning and suggest that hippocampal D(3)Rs might be relevant to NF1 transcriptional regulation in the hippocampus.	Protactinium	115-117	neurofibromin 1	Mus musculus	79-82
23242790-6	2013	In conclusion, the present finding show for the first time that both D(3)R and NF1 genes are upregulated following PA conditioning and suggest that hippocampal D(3)Rs might be relevant to NF1 transcriptional regulation in the hippocampus.	Protactinium	115-117	neurofibromin 1	Mus musculus	188-191
23364426-11	2013	These alterations in PA reactivity were reversed by SOD/CAT pretreatment.	Protactinium	21-23	superoxide dismutase 1	Rattus norvegicus	52-55
23433102-8	2013	Transient increases in alanine aminotransferase and aspartate aminotransferase were observed with PA but did not lead to any clinical sequelae.	Protactinium	98-100	glutamic--pyruvic transaminase	Homo sapiens	23-47
23161031-3	2013	Resequencing and reannotation revealed that in the N-terminal part, ArcS possesses a periplasmic CaChe-sensing domain bracketed by two transmembrane domains and, moreover, that ArcS has two cytoplasmic PAS-sensing domains and two receiver domains, compared to a single one of each in ArcB.	Protactinium	202-205	SO_RS02740	Shewanella oneidensis MR-1	68-72
23161031-3	2013	Resequencing and reannotation revealed that in the N-terminal part, ArcS possesses a periplasmic CaChe-sensing domain bracketed by two transmembrane domains and, moreover, that ArcS has two cytoplasmic PAS-sensing domains and two receiver domains, compared to a single one of each in ArcB.	Protactinium	202-205	SO_RS02740	Shewanella oneidensis MR-1	177-181
23422577-13	2013	The percentage of subjects with low PA level or below of the P25 was 25.9% for males and 26.3% for females.	Protactinium	36-38	tubulin polymerization promoting protein	Homo sapiens	61-64
23175803-2	2013	Na(+) current density (pA/pF) was significantly greater in VP neurons than in OT neurons.	Protactinium	23-25	arginine vasopressin	Rattus norvegicus	59-61
23317295-7	2013	RESULTS: The Insulin Resistant (IR) group had higher energy, carbohydrate and protein intakes (p &lt; 0.05) and lower PA levels than Insulin Sensitive (IS) group (P &lt; 0.001), but there were no differences in RER or RER:FQ between groups.	Protactinium	118-120	insulin	Homo sapiens	13-20
22777489-6	2013	RESULTS: Comparing the PA and N-PA group, the first presented lower: total body mass (-13%), body mass index (-16%), fat mass (kg -39%, FM% -30%), CRP (-23%), serum insulin (-61%), homeostasis model assessment (HOMA, -35%) and serum leptin (-62%; P&lt;0.05).	Protactinium	23-25	C-reactive protein	Homo sapiens	147-150
22777489-6	2013	RESULTS: Comparing the PA and N-PA group, the first presented lower: total body mass (-13%), body mass index (-16%), fat mass (kg -39%, FM% -30%), CRP (-23%), serum insulin (-61%), homeostasis model assessment (HOMA, -35%) and serum leptin (-62%; P&lt;0.05).	Protactinium	23-25	insulin	Homo sapiens	165-172
22777489-6	2013	RESULTS: Comparing the PA and N-PA group, the first presented lower: total body mass (-13%), body mass index (-16%), fat mass (kg -39%, FM% -30%), CRP (-23%), serum insulin (-61%), homeostasis model assessment (HOMA, -35%) and serum leptin (-62%; P&lt;0.05).	Protactinium	23-25	leptin	Homo sapiens	233-239
23351591-12	2013	Two hours after birth, all proinflammatory cytokines and pSTAT3/STAT3 levels decreased in pups that experienced FA and/or PA.	Protactinium	122-124	signal transducer and activator of transcription 3	Rattus norvegicus	58-63
23261454-6	2013	Furthermore, direct treatment of dioctanoyl phosphatidic acid (diC(8)PA) into cells also induced ABCA1 mRNA and protein indicating that PLD2-mediated PA involve in the TLR2-stimulated ABCA1 expression.	Protactinium	69-71	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	97-102
23261454-6	2013	Furthermore, direct treatment of dioctanoyl phosphatidic acid (diC(8)PA) into cells also induced ABCA1 mRNA and protein indicating that PLD2-mediated PA involve in the TLR2-stimulated ABCA1 expression.	Protactinium	69-71	phospholipase D2	Mus musculus	136-140
23261454-6	2013	Furthermore, direct treatment of dioctanoyl phosphatidic acid (diC(8)PA) into cells also induced ABCA1 mRNA and protein indicating that PLD2-mediated PA involve in the TLR2-stimulated ABCA1 expression.	Protactinium	69-71	toll-like receptor 2	Mus musculus	168-172
23261454-6	2013	Furthermore, direct treatment of dioctanoyl phosphatidic acid (diC(8)PA) into cells also induced ABCA1 mRNA and protein indicating that PLD2-mediated PA involve in the TLR2-stimulated ABCA1 expression.	Protactinium	69-71	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	184-189
23525442-10	2013	In vivo, RAGE inhibition in monocrotaline- and Sugen-induced PAH demonstrates therapeutic effects characterized by PA pressure and right ventricular hypertrophy decrease (control rats have an mPAP around 15 mm Hg, PAH rats have an mPAP &gt;40 mm Hg, and with RAGE inhibition, mPAP decreases to 20 and 28 mm Hg, respectively, in MCT and Sugen models).	Protactinium	61-63	advanced glycosylation end product-specific receptor	Rattus norvegicus	9-13
23525442-10	2013	In vivo, RAGE inhibition in monocrotaline- and Sugen-induced PAH demonstrates therapeutic effects characterized by PA pressure and right ventricular hypertrophy decrease (control rats have an mPAP around 15 mm Hg, PAH rats have an mPAP &gt;40 mm Hg, and with RAGE inhibition, mPAP decreases to 20 and 28 mm Hg, respectively, in MCT and Sugen models).	Protactinium	61-63	phospholipid phosphatase 1	Mus musculus	231-235
23525442-10	2013	In vivo, RAGE inhibition in monocrotaline- and Sugen-induced PAH demonstrates therapeutic effects characterized by PA pressure and right ventricular hypertrophy decrease (control rats have an mPAP around 15 mm Hg, PAH rats have an mPAP &gt;40 mm Hg, and with RAGE inhibition, mPAP decreases to 20 and 28 mm Hg, respectively, in MCT and Sugen models).	Protactinium	61-63	advanced glycosylation end product-specific receptor	Rattus norvegicus	259-263
23525442-10	2013	In vivo, RAGE inhibition in monocrotaline- and Sugen-induced PAH demonstrates therapeutic effects characterized by PA pressure and right ventricular hypertrophy decrease (control rats have an mPAP around 15 mm Hg, PAH rats have an mPAP &gt;40 mm Hg, and with RAGE inhibition, mPAP decreases to 20 and 28 mm Hg, respectively, in MCT and Sugen models).	Protactinium	61-63	phospholipid phosphatase 1	Mus musculus	231-235
24611289-6	2013	The homogeneous tapes formed by PA 1-PA 3 or PA 2-PA 3 mixtures presented a structure similar to that observed for the corresponding pure PA 1 or PA 2 nanotapes.	Protactinium	32-34	PAXIP1 associated glutamate rich protein 1	Homo sapiens	138-142
23107823-13	2013	PA 25 and PA 250 reduced mice relative liver weight and caused mild hepatic hydropic degeneration as well as a decrease in alanine aminotransferase (ALT) serum level.	Protactinium	0-2	glutamic pyruvic transaminase, soluble	Mus musculus	123-147
23107823-13	2013	PA 25 and PA 250 reduced mice relative liver weight and caused mild hepatic hydropic degeneration as well as a decrease in alanine aminotransferase (ALT) serum level.	Protactinium	0-2	glutamic pyruvic transaminase, soluble	Mus musculus	149-152
23107823-13	2013	PA 25 and PA 250 reduced mice relative liver weight and caused mild hepatic hydropic degeneration as well as a decrease in alanine aminotransferase (ALT) serum level.	Protactinium	10-12	glutamic pyruvic transaminase, soluble	Mus musculus	123-147
23107823-13	2013	PA 25 and PA 250 reduced mice relative liver weight and caused mild hepatic hydropic degeneration as well as a decrease in alanine aminotransferase (ALT) serum level.	Protactinium	10-12	glutamic pyruvic transaminase, soluble	Mus musculus	149-152
22986624-5	2013	RESULTS: Reports of CSA (CSA+ group) were associated with reports of perpetration of severe dating PA (PA+ group), but the relation of these reports to laboratory-assessed patterns of cortisol changes following the stressor was opposite.	Protactinium	99-101	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	20-35
23055567-4	2013	We focused our study on one of the new PA-interacting proteins, HAX1, a protein with antiapoptotic function.	Protactinium	39-41	HCLS1 associated protein X-1	Homo sapiens	64-68
23055567-5	2013	By using glutathione S-transferase pulldown and coimmunoprecipitation assays, we demonstrate that HAX1 specifically interacts with PA in vitro and in vivo and that HAX1 interacts with the nuclear localization signal domain of PA.	Protactinium	131-133	HCLS1 associated protein X-1	Homo sapiens	98-102
23055567-5	2013	By using glutathione S-transferase pulldown and coimmunoprecipitation assays, we demonstrate that HAX1 specifically interacts with PA in vitro and in vivo and that HAX1 interacts with the nuclear localization signal domain of PA.	Protactinium	226-228	HCLS1 associated protein X-1	Homo sapiens	164-168
23055567-6	2013	Nuclear accumulation of PA was increased in HAX1-knockdown cells, and this phenotype could be reversed by reexpression of HAX1, indicating that HAX1 can impede nuclear transport of PA.	Protactinium	24-26	HCLS1 associated protein X-1	Homo sapiens	44-48
23055567-6	2013	Nuclear accumulation of PA was increased in HAX1-knockdown cells, and this phenotype could be reversed by reexpression of HAX1, indicating that HAX1 can impede nuclear transport of PA.	Protactinium	24-26	HCLS1 associated protein X-1	Homo sapiens	122-126
23055567-6	2013	Nuclear accumulation of PA was increased in HAX1-knockdown cells, and this phenotype could be reversed by reexpression of HAX1, indicating that HAX1 can impede nuclear transport of PA.	Protactinium	24-26	HCLS1 associated protein X-1	Homo sapiens	122-126
23055567-6	2013	Nuclear accumulation of PA was increased in HAX1-knockdown cells, and this phenotype could be reversed by reexpression of HAX1, indicating that HAX1 can impede nuclear transport of PA.	Protactinium	181-183	HCLS1 associated protein X-1	Homo sapiens	44-48
23055567-6	2013	Nuclear accumulation of PA was increased in HAX1-knockdown cells, and this phenotype could be reversed by reexpression of HAX1, indicating that HAX1 can impede nuclear transport of PA.	Protactinium	181-183	HCLS1 associated protein X-1	Homo sapiens	122-126
23055567-6	2013	Nuclear accumulation of PA was increased in HAX1-knockdown cells, and this phenotype could be reversed by reexpression of HAX1, indicating that HAX1 can impede nuclear transport of PA.	Protactinium	181-183	HCLS1 associated protein X-1	Homo sapiens	122-126
22906481-6	2013	PA also inhibited ABO incompatibility in vitro and demonstrated in vivo complement suppression up to 24h post-injection.	Protactinium	0-2	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Rattus norvegicus	18-21
23874216-9	2013	Thus, the conserved intronic pA of the CstF-77 gene may function as a sensor for cellular C/P and splicing activities, controlling the homeostasis of CstF-77 and C/P activity and impacting cell proliferation and differentiation.	Protactinium	29-31	cleavage stimulation factor subunit 3	Homo sapiens	39-46
23874216-9	2013	Thus, the conserved intronic pA of the CstF-77 gene may function as a sensor for cellular C/P and splicing activities, controlling the homeostasis of CstF-77 and C/P activity and impacting cell proliferation and differentiation.	Protactinium	29-31	cleavage stimulation factor subunit 3	Homo sapiens	150-157
23592988-6	2013	In contrast, a current licensed Pa, administered with alum as the adjuvant, induced Th2 and Th17 cells, but weak Th1 responses.	Protactinium	32-34	heart and neural crest derivatives expressed 2	Mus musculus	84-87
23592988-8	2013	Pa generated strong antibody and Th2 responses, but was fully protective in IL-4-defective mice, suggesting that Th2 cells were dispensable.	Protactinium	0-2	heart and neural crest derivatives expressed 2	Mus musculus	33-36
23592988-8	2013	Pa generated strong antibody and Th2 responses, but was fully protective in IL-4-defective mice, suggesting that Th2 cells were dispensable.	Protactinium	0-2	interleukin 4	Mus musculus	76-80
23026370-4	2012	We screened a representative library supplied from Korean Chemical Bank for prevention of high glucose/palmitate (HG/PA)-induced viability reduction of INS-1 beta cells and were able to identify a new small molecule (DW1182v) with a function to protect HG/PA-induced glucolipotoxicity.	Protactinium	117-119	insulin 1	Rattus norvegicus	152-157
23034390-8	2012	In conclusion, augmented Cl(Ca)/TMEM16A channel activity is a major contributor to the changes in electromechanical coupling of PA in this model of PH.	Protactinium	128-130	anoctamin 1	Rattus norvegicus	32-39
23011394-6	2012	PA endothelial cells isolated from Apc(Min/+) demonstrated reduced survival and angiogenic responses along with a profound reduction in adhesion to laminin.	Protactinium	0-2	APC regulator of WNT signaling pathway	Homo sapiens	35-38
23011394-8	2012	We found that PA endothelial cells from lungs of patients with idiopathic PH have reduced APC expression, decreased adhesion to laminin, and impaired vascular tube formation.	Protactinium	14-16	APC regulator of WNT signaling pathway	Homo sapiens	90-93
23011394-10	2012	CONCLUSIONS: We show that APC is integral to PA endothelial cells adhesion and survival and is reduced in PA endothelial cells from PH patient lungs.	Protactinium	45-47	APC regulator of WNT signaling pathway	Homo sapiens	26-29
23153342-5	2012	The placement of the photolabile group on the peptide backbone enabled efficient removal of the ECM-derived cell adhesion epitope RGDS from PA molecules upon exposure to light (half-life of photolysis ~1.9 min) without affecting the nanofiber assembly.	Protactinium	140-142	ral guanine nucleotide dissociation stimulator	Homo sapiens	130-134
23153342-6	2012	Fibroblasts cultured on RGDS-presenting PA nanofiber substrates demonstrated increased cell spreading and more mature focal adhesions compared with unfunctionalized and control (RGES-presenting) surfaces, as determined by immunostaining and cell morphological analysis.	Protactinium	40-42	ral guanine nucleotide dissociation stimulator	Homo sapiens	24-28
23153342-7	2012	Furthermore, we observed an arrest in fibroblast spreading on substrates containing a cleavable RGDS epitope when the culture was exposed to light; in contrast, this dynamic shift in cell response was absent when the RGDS epitope was attached to the PA molecule by a light-insensitive control linker.	Protactinium	250-252	ral guanine nucleotide dissociation stimulator	Homo sapiens	217-221
23064346-4	2012	The tripartite hybrid kinase ArcB possesses a transmembrane, a PAS, a primary transmitter (H1), a receiver (D1), and a phosphotransfer (H2) domain.	Protactinium	63-66	hypothetical protein	Escherichia coli	29-33
24082328-5	2012	The PA-treated MCAo rats showed greatly decreased neuronal death, glial proliferation, and S100B proteins in the penumbra area of the cortex and in the ischemic core area of the cortex, but BDNF did not changed.	Protactinium	4-6	S100 calcium binding protein B	Rattus norvegicus	91-96
22975802-6	2012	The neuron number in hippocampal CA3 and DG of the Pa group was significantly increased by therapeutic acupuncture compared with the Pc group.	Protactinium	51-53	carbonic anhydrase 3	Mus musculus	33-36
22736150-12	2012	Our case illustrates that: (1) although rare, in the salivary glands SCC may arise from lower grade neoplasms including PAs; (2) SCC ex PA may metastasize as pure SCC even if the primary SCC component was focal; (3) adequate sampling of PAs is crucial to prevent missing a rare SCC that must be treated with chemotherapy.	Protactinium	120-123	serpin family B member 3	Homo sapiens	69-72
23247621-6	2012	Compared to pa-tients without NE patients with NE showed higher HbA1c values, higher scores on the disinhibition and the perceived hunger scale, lower scores on the quality of life scale and higher depression scores.	Protactinium	3-5	hemoglobin subunit alpha 1	Homo sapiens	64-68
22930413-10	2012	A positive correlation was established between PA performance and systemic IGF-1 (r = 0.46, P &lt; 0.05).	Protactinium	47-49	insulin-like growth factor 1	Rattus norvegicus	75-80
22736150-12	2012	Our case illustrates that: (1) although rare, in the salivary glands SCC may arise from lower grade neoplasms including PAs; (2) SCC ex PA may metastasize as pure SCC even if the primary SCC component was focal; (3) adequate sampling of PAs is crucial to prevent missing a rare SCC that must be treated with chemotherapy.	Protactinium	237-240	serpin family B member 3	Homo sapiens	129-132
22736150-12	2012	Our case illustrates that: (1) although rare, in the salivary glands SCC may arise from lower grade neoplasms including PAs; (2) SCC ex PA may metastasize as pure SCC even if the primary SCC component was focal; (3) adequate sampling of PAs is crucial to prevent missing a rare SCC that must be treated with chemotherapy.	Protactinium	237-240	serpin family B member 3	Homo sapiens	129-132
22736150-12	2012	Our case illustrates that: (1) although rare, in the salivary glands SCC may arise from lower grade neoplasms including PAs; (2) SCC ex PA may metastasize as pure SCC even if the primary SCC component was focal; (3) adequate sampling of PAs is crucial to prevent missing a rare SCC that must be treated with chemotherapy.	Protactinium	237-240	serpin family B member 3	Homo sapiens	129-132
22736150-12	2012	Our case illustrates that: (1) although rare, in the salivary glands SCC may arise from lower grade neoplasms including PAs; (2) SCC ex PA may metastasize as pure SCC even if the primary SCC component was focal; (3) adequate sampling of PAs is crucial to prevent missing a rare SCC that must be treated with chemotherapy.	Protactinium	237-240	serpin family B member 3	Homo sapiens	129-132
22762791-7	2012	We also show that PA formed by distinct phospholipases D (PLD) is involved in pathways both upstream and downstream of NOX-mediated ROS generation and identify NtPLDdelta as a PLD isoform acting in the ROS response pathway.	Protactinium	18-20	respiratory burst oxidase homolog protein A-like	Nicotiana tabacum	119-122
22713857-10	2012	We extend the original eight-state model to a 12-state model in order to illustrate this competition, and perform a similar reduction to that of Li and Rinzel in the first modeling study we are aware of considering PA effect on an IP(3) receptor.	Protactinium	215-217	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	231-245
24082328-5	2012	The PA-treated MCAo rats showed greatly decreased neuronal death, glial proliferation, and S100B proteins in the penumbra area of the cortex and in the ischemic core area of the cortex, but BDNF did not changed.	Protactinium	4-6	brain-derived neurotrophic factor	Rattus norvegicus	190-194
22928971-8	2012	Cleaved PA embryos showed higher expression of cyclin A, cyclin B, cyclin E, and CDK2 and lower expression of CDC2 when compared with that from the IVP group.	Protactinium	8-10	cyclin A2	Bos taurus	47-55
22928971-8	2012	Cleaved PA embryos showed higher expression of cyclin A, cyclin B, cyclin E, and CDK2 and lower expression of CDC2 when compared with that from the IVP group.	Protactinium	8-10	cyclin dependent kinase 2	Bos taurus	81-85
22928971-8	2012	Cleaved PA embryos showed higher expression of cyclin A, cyclin B, cyclin E, and CDK2 and lower expression of CDC2 when compared with that from the IVP group.	Protactinium	8-10	cyclin dependent kinase 1	Bos taurus	110-114
23028143-5	2012	Thus, in accordance with recent findings, U1 snRNP can shield premature pA sites.	Protactinium	72-74	RNA, U1 small nuclear 1	Homo sapiens	42-50
23008384-2	2012	Intravenous recombinant tissue plasminogen activator (rt-PA), the only established revascularization therapy approved by the US Food &amp; Drug Administration for AIS, may be less effective for large artery occlusion.	Protactinium	57-59	chromosome 20 open reading frame 181	Homo sapiens	24-52
23213315-4	2012	In this study we investigated the role of the PA as inhibitor of caspase-1, which converts prointerleukin-1beta (proIL-1beta) to active IL-1beta and is activated by inflammasome involved in the inflammatory process.	Protactinium	46-48	interleukin 1 beta	Mus musculus	116-124
23213315-5	2012	We tested the effect of PA on the production of pro-inflammatory cytokines, IL-1beta in murine macrophage cell line, RAW264.7.	Protactinium	24-26	interleukin 1 beta	Mus musculus	76-84
23213315-6	2012	PA inhibited lipopolysaccharide (LPS)-induced IL-1beta production by macrophages at a dose dependent manner.	Protactinium	0-2	interleukin 1 beta	Mus musculus	46-54
23101643-3	2012	In contrast, above VT(1), CO(2) is washed-out from the alkaline reserve due to the combined effect of the fall in PA(CO2) (because of hyperventilation) and in pH, and this helps maintaining acid-base balance.	Protactinium	114-116	complement C2	Homo sapiens	117-120
22440242-9	2012	Based on ALP expression, the presence of phosphoserine residues in PA nanofibers seems to favor osteogenic differentiation.	Protactinium	67-69	alkaline phosphatase, placental	Homo sapiens	9-12
22229392-9	2012	C57Bl6 mice exposed to 90%-100% O(2) for 45 min+-mechanical ventilation had increased PA PDE5 activity (206+-39% and 235+-75%, respectively).	Protactinium	86-88	phosphodiesterase 5A, cGMP-specific	Mus musculus	89-93
21395954-1	2012	PAP is a rare alveolointerstitial lung disorder characterized histologically by the intra-alveolar accumulation of eosinophilic and PAS-positive material.	Protactinium	132-135	regenerating family member 3 alpha	Homo sapiens	0-3
22809229-4	2012	The effects of PA on the activity of histone demethylase, the Drosophila melanogaster lifespan and gene expression in Drosophila S2 cells were investigated.	Protactinium	15-17	Suppressor of variegation 3-3	Drosophila melanogaster	37-56
22809229-5	2012	RESULTS: PA inhibited the activity of Jumonji domain-containing protein 2A (JMJD2A) histone demethylase in a dose-dependent manner with a half-maximal inhibitory concentration (IC50) of 11.6 muM.	Protactinium	9-11	Suppressor of variegation 3-3	Drosophila melanogaster	84-103
22809229-8	2012	In Drosophila S2 cells, the eukaryotic translation initiation factor 4E binding protein (4E-BP) was up-regulated by PA exposure.	Protactinium	116-118	thor	Drosophila melanogaster	28-87
22809229-8	2012	In Drosophila S2 cells, the eukaryotic translation initiation factor 4E binding protein (4E-BP) was up-regulated by PA exposure.	Protactinium	116-118	thor	Drosophila melanogaster	89-94
22300412-4	2012	We present a case of PA as a complication of underlying psoriasis, which developed during tumour necrosis factor (TNF)-alpha inhibitor therapy for Crohn disease.	Protactinium	21-23	tumor necrosis factor	Homo sapiens	90-124
22502813-6	2012	PA treatment impaired the Ach induced EDV which was significantly attenuated by pretreatment with adiponectin.	Protactinium	0-2	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	98-109
22426782-7	2012	Significant associations with PA phenotypes were found for Ace, Gln223ARrg, MC4R and DRD2 genes.	Protactinium	30-32	angiotensin I converting enzyme	Homo sapiens	59-62
22426782-7	2012	Significant associations with PA phenotypes were found for Ace, Gln223ARrg, MC4R and DRD2 genes.	Protactinium	30-32	melanocortin 4 receptor	Homo sapiens	76-80
22426782-7	2012	Significant associations with PA phenotypes were found for Ace, Gln223ARrg, MC4R and DRD2 genes.	Protactinium	30-32	dopamine receptor D2	Homo sapiens	85-89
22528165-12	2012	The mean (standard deviation) changes in CRP levels from baseline at 48 hr in Groups AA, PA, and PP were 141.0 (72.4), 153.5 (42.2), and 111.2 (84.6), respectively.	Protactinium	89-91	C-reactive protein	Homo sapiens	41-44
22311271-12	2012	The present results support the idea that the long-term effects induced by PA imply PARP-1 over-activation.	Protactinium	75-77	poly (ADP-ribose) polymerase 1	Rattus norvegicus	84-90
22716651-7	2012	Neuropsychiatric and acute diagnoses and patients with a long-stay status were associated with more APN/PA visits.	Protactinium	104-106	alanyl aminopeptidase, membrane	Homo sapiens	100-103
22731784-8	2012	PAS staining for mucus showed that there was a significant positive correlation between CLCA1 protein expression and mucus production (r = 0.67, p = 0.001).	Protactinium	0-3	chloride channel accessory 1	Homo sapiens	88-93
22425791-4	2012	We demonstrate that hmAb p6C01 is neutralizing by preventing furin cleavage of PA in a dose-dependent manner, but the mechanism of p6F01 is unclear.	Protactinium	79-81	furin, paired basic amino acid cleaving enzyme	Homo sapiens	61-66
22728857-7	2012	RESULTS: Mean ADC/CSF for PA and PMA was 0.53+-0.10 and 0.69+-0.10 (p&lt;0.01).	Protactinium	26-28	laminin subunit gamma 2	Homo sapiens	18-21
22728857-8	2012	Mean T2/CSF for PA and PMA was 0.78+-0.19 and 0.93+-0.09 (p&lt;0.01).	Protactinium	16-18	laminin subunit gamma 2	Homo sapiens	5-11
22591394-8	2012	Lauryl-GALA was tolerated well by SJSA-1 osteocarcinoma cells and enhanced cell internalization of the PA was observed.	Protactinium	103-105	galactosidase alpha	Homo sapiens	7-11
22487201-9	2012	As compared to cell transplantation and gel only, BDNF content in the PA gel increased cell survival and neuronal differentiation.	Protactinium	70-72	brain-derived neurotrophic factor	Rattus norvegicus	50-54
22169970-6	2012	In MVID cases, Rab11 showed diffuse apical cytoplasmic staining of surface enterocytes in a pattern similar to PAS and CD10, which was absent in all the 20 control cases.	Protactinium	111-114	RAB11A, member RAS oncogene family	Homo sapiens	15-20
22320360-7	2012	The results showed that n-HA/PA composites had great bioactivity, demonstrating significant BMSC proliferation, active alkaline phosphatase secretion, and stimulating the expression of osteogenic proteins (bone morphogenetic protein 2 [BMP2], osteoprotegerin [OPG], osteopontin [OPN], collagen type I [Col I], and osteocalcin [OCN]), in comparison to the control (polyethylene).	Protactinium	29-31	bone morphogenetic protein 2	Oryctolagus cuniculus	206-234
22311232-1	2012	BACKGROUND: Angioedema is an underappreciated and potentially life-threatening complication of intravenous (IV) recombinant tissue plasminogen activator (rt-PA).	Protactinium	157-159	chromosome 20 open reading frame 181	Homo sapiens	124-152
22612917-3	2012	Milk fat content was higher for PAS-, averaging 5.05 compared with 4.10 +- 0.17% for the mean of other treatments, and was significantly depressed with microalgae supplementation (3.97 vs. 4.69 +- 0.17%).	Protactinium	32-35	Weaning weight-maternal milk	Bos taurus	0-4
22612917-6	2012	Feeding the rumen-protected microalgae increased the DHA content of milk more than 4-fold (0.06 to 0.26 g/100g of FA) with the PAS treatment.	Protactinium	127-130	Weaning weight-maternal milk	Bos taurus	68-72
22612917-7	2012	The conjugated linoleic acid content of milk was highest for PAS+ compared with the other treatments (4.18 vs. 3.41 g/100g of FA).	Protactinium	61-65	Weaning weight-maternal milk	Bos taurus	40-44
22320360-7	2012	The results showed that n-HA/PA composites had great bioactivity, demonstrating significant BMSC proliferation, active alkaline phosphatase secretion, and stimulating the expression of osteogenic proteins (bone morphogenetic protein 2 [BMP2], osteoprotegerin [OPG], osteopontin [OPN], collagen type I [Col I], and osteocalcin [OCN]), in comparison to the control (polyethylene).	Protactinium	29-31	bone morphogenetic protein 2	Oryctolagus cuniculus	236-240
22320360-7	2012	The results showed that n-HA/PA composites had great bioactivity, demonstrating significant BMSC proliferation, active alkaline phosphatase secretion, and stimulating the expression of osteogenic proteins (bone morphogenetic protein 2 [BMP2], osteoprotegerin [OPG], osteopontin [OPN], collagen type I [Col I], and osteocalcin [OCN]), in comparison to the control (polyethylene).	Protactinium	29-31	tumor necrosis factor receptor superfamily member 11B	Oryctolagus cuniculus	243-258
22320360-7	2012	The results showed that n-HA/PA composites had great bioactivity, demonstrating significant BMSC proliferation, active alkaline phosphatase secretion, and stimulating the expression of osteogenic proteins (bone morphogenetic protein 2 [BMP2], osteoprotegerin [OPG], osteopontin [OPN], collagen type I [Col I], and osteocalcin [OCN]), in comparison to the control (polyethylene).	Protactinium	29-31	tumor necrosis factor receptor superfamily member 11B	Oryctolagus cuniculus	260-263
22320360-7	2012	The results showed that n-HA/PA composites had great bioactivity, demonstrating significant BMSC proliferation, active alkaline phosphatase secretion, and stimulating the expression of osteogenic proteins (bone morphogenetic protein 2 [BMP2], osteoprotegerin [OPG], osteopontin [OPN], collagen type I [Col I], and osteocalcin [OCN]), in comparison to the control (polyethylene).	Protactinium	29-31	osteopontin	Oryctolagus cuniculus	266-277
22320360-7	2012	The results showed that n-HA/PA composites had great bioactivity, demonstrating significant BMSC proliferation, active alkaline phosphatase secretion, and stimulating the expression of osteogenic proteins (bone morphogenetic protein 2 [BMP2], osteoprotegerin [OPG], osteopontin [OPN], collagen type I [Col I], and osteocalcin [OCN]), in comparison to the control (polyethylene).	Protactinium	29-31	osteopontin	Oryctolagus cuniculus	279-282
22320360-7	2012	The results showed that n-HA/PA composites had great bioactivity, demonstrating significant BMSC proliferation, active alkaline phosphatase secretion, and stimulating the expression of osteogenic proteins (bone morphogenetic protein 2 [BMP2], osteoprotegerin [OPG], osteopontin [OPN], collagen type I [Col I], and osteocalcin [OCN]), in comparison to the control (polyethylene).	Protactinium	29-31	osteocalcin	Oryctolagus cuniculus	314-325
22310694-2	2012	However, KCNH1 channels also show some amino-acid sequence similarity to cyclic-nucleotide-regulated channels: they harbor an N-terminal PAS domain, a C-terminal cyclic nucleotide binding homology domain (cNBHD), and N- and C-terminal binding sites for calmodulin.	Protactinium	137-140	potassium voltage-gated channel subfamily H member 1	Homo sapiens	9-14
22507985-8	2012	The numbers of bacteria in tissues of EA1-immunized mice were significantly decreased compared to those in the control and PA alone-immunized mice.	Protactinium	123-125	erythrocyte antigen 1	Mus musculus	38-41
22507985-10	2012	These results suggest that EA1 is a novel candidate for anthrax vaccine and provides a more effective protection when used in combination with PA.	Protactinium	143-145	erythrocyte antigen 1	Mus musculus	27-30
22643124-3	2012	Although the levels of the different forms of Abeta in prefrontal cortex from patients with AD tended to be higher than those from patients with PA, the authors found extensive overlap between the two groups and suggest that PA is likely to represent a prodromal stage of AD.	Protactinium	225-227	amyloid beta precursor protein	Homo sapiens	46-51
22621179-3	2012	PA may represent either a prodromal phase of AD, a benign form of Abeta accumulation, or inherent individual resistance to the toxic effects of Abeta accumulation.	Protactinium	0-2	amyloid beta precursor protein	Homo sapiens	66-71
22621179-3	2012	PA may represent either a prodromal phase of AD, a benign form of Abeta accumulation, or inherent individual resistance to the toxic effects of Abeta accumulation.	Protactinium	0-2	amyloid beta precursor protein	Homo sapiens	144-149
22342354-5	2012	This GLP-1-mimetic PA self-assembles into one-dimensional nanofibers that stabilize the active secondary structure of GLP-1 and can be cross-linked by calcium ions to form a macroscopic gel capable of cell encapsulation and three-dimensional culture.	Protactinium	19-21	glucagon	Rattus norvegicus	5-10
22342354-5	2012	This GLP-1-mimetic PA self-assembles into one-dimensional nanofibers that stabilize the active secondary structure of GLP-1 and can be cross-linked by calcium ions to form a macroscopic gel capable of cell encapsulation and three-dimensional culture.	Protactinium	19-21	glucagon	Rattus norvegicus	118-123
22342354-6	2012	The GLP-1-mimetic PA nanofibers were found to stimulate insulin secretion from rat insulinoma (RINm5f) cells to a significantly greater extent than the mimetic peptide alone and to a level equivalent to that of the clinically used agonist exendin-4.	Protactinium	18-20	glucagon	Rattus norvegicus	4-9
22342354-7	2012	The activity of the GLP-1-mimetic PA is glucose-dependent, lipid-raft dependent and partially PKA-dependent consistent with native GLP-1.	Protactinium	34-36	glucagon	Rattus norvegicus	20-25
22342354-7	2012	The activity of the GLP-1-mimetic PA is glucose-dependent, lipid-raft dependent and partially PKA-dependent consistent with native GLP-1.	Protactinium	34-36	glucagon	Rattus norvegicus	131-136
22342354-8	2012	The GLP-1-mimetic PA also completely abrogates inflammatory cytokine-induced cell death to the level of untreated controls.	Protactinium	18-20	glucagon	Rattus norvegicus	4-9
22342354-9	2012	When used as a PA gel to encapsulate RINm5f cells, the GLP-1-mimetic PA stimulates insulin secretion and proliferation in a cytokine-resistant manner that is significantly greater than a non-bioactive PA gel containing exendin-4.	Protactinium	15-17	glucagon	Rattus norvegicus	55-60
22342354-9	2012	When used as a PA gel to encapsulate RINm5f cells, the GLP-1-mimetic PA stimulates insulin secretion and proliferation in a cytokine-resistant manner that is significantly greater than a non-bioactive PA gel containing exendin-4.	Protactinium	69-71	glucagon	Rattus norvegicus	55-60
22342354-9	2012	When used as a PA gel to encapsulate RINm5f cells, the GLP-1-mimetic PA stimulates insulin secretion and proliferation in a cytokine-resistant manner that is significantly greater than a non-bioactive PA gel containing exendin-4.	Protactinium	69-71	glucagon	Rattus norvegicus	55-60
22342354-10	2012	Due to its self-assembling property and bioactivity, the GLP-1-mimetic PA can be incorporated into previously developed islet cell transplantation protocols with the potential for significant enhancement of beta-cell viability and function.	Protactinium	71-73	glucagon	Rattus norvegicus	57-62
22314193-9	2012	Puerarin attenuated PA-induced phosphorylation of insulin receptor substrate-1 (IRS-1) at S307 and effectively ameliorated insulin-mediated tyrosine phosphorylation of IRS-1.	Protactinium	20-22	insulin receptor substrate 1	Rattus norvegicus	50-78
22314193-9	2012	Puerarin attenuated PA-induced phosphorylation of insulin receptor substrate-1 (IRS-1) at S307 and effectively ameliorated insulin-mediated tyrosine phosphorylation of IRS-1.	Protactinium	20-22	insulin receptor substrate 1	Rattus norvegicus	80-85
22622905-9	2012	RESULTS: At 2 weeks after PA, significant improvement was observed in NRS back, NRS leg, and ODI compared with pretreatment.	Protactinium	26-28	sphingolipid transporter 1 (putative)	Homo sapiens	70-73
22486195-4	2012	HER2 amplification was more prevalent in extracapsular CXPAs (9/18 cases; 50%) than intracapsular CXPAs (1/5 cases; 20%), intraductal CXPAs (2/8 cases; 25%), or atypical PAs (0/7 case; 0%).	Protactinium	57-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
22668626-6	2012	The p63 expression levels were notably decreased in M-noninvasive CXPAs and WI CXPAs compared with PAs (P = .007).	Protactinium	68-71	tumor protein p63	Homo sapiens	4-7
22285412-9	2012	The variable patterns of interactions between the substrate models and PA domains of tomato SBT3 and soybean protease C1 illustrate a crucial role for the PA domain in molecular recognition of their substrates.	Protactinium	71-73	subtilisin-like protease	Solanum lycopersicum	92-96
22325937-5	2012	We showed that, although PB1 interacts with both PA and PB2 individually, nuclear localization of PB1 is enhanced only when co-expressed with PA.	Protactinium	49-51	polybromo 1	Homo sapiens	25-28
22325937-5	2012	We showed that, although PB1 interacts with both PA and PB2 individually, nuclear localization of PB1 is enhanced only when co-expressed with PA.	Protactinium	142-144	polybromo 1	Homo sapiens	98-101
22325937-6	2012	Interestingly, one of the anti-PA mAbs reacted much more strongly with PA when co-expressed with PB1.	Protactinium	31-33	polybromo 1	Homo sapiens	97-100
22325937-6	2012	Interestingly, one of the anti-PA mAbs reacted much more strongly with PA when co-expressed with PB1.	Protactinium	71-73	polybromo 1	Homo sapiens	97-100
22325937-7	2012	These results suggest that PA-PB1 interactions induce a conformational change in PA, which could be required for its nuclear translocation.	Protactinium	27-29	polybromo 1	Homo sapiens	30-33
22285412-9	2012	The variable patterns of interactions between the substrate models and PA domains of tomato SBT3 and soybean protease C1 illustrate a crucial role for the PA domain in molecular recognition of their substrates.	Protactinium	155-157	subtilisin-like protease	Solanum lycopersicum	92-96
22265674-10	2012	CONCLUSIONS: The novel flow device found that PA and TV were significantly reduced under high shear stress in vWD patients compared to normal controls.	Protactinium	46-48	von Willebrand factor	Homo sapiens	110-113
21996662-12	2012	Adiponectin deficiency is associated with exaggerated leukocyte and PA in cerebral microcirculation of mice with CLP via modulation of E-selectin expression.	Protactinium	68-70	adiponectin, C1Q and collagen domain containing	Mus musculus	0-11
22131441-7	2012	Treatment with BCH blocked HG-induced GSIS inhibition and the HG/PA-induced reduction in insulin gene expression in INS-1 cells.	Protactinium	65-67	chimerin 2	Mus musculus	15-18
22131441-8	2012	In addition, BCH significantly reduced HG/PA-induced INS-1 cell death and phospho-JNK level.	Protactinium	42-44	chimerin 2	Mus musculus	13-16
22431751-5	2012	Distinct point mutations targeting the predicted BAR-like PA domain differentially disrupted patch assembly, dynein anchoring, and mitochondrial attachment functions of Num1.	Protactinium	58-60	Num1p	Saccharomyces cerevisiae S288C	169-173
22245004-1	2012	Neuronal PAS domain protein 2 (NPAS2), which is a CO-dependent transcription factor, consists of a basic helix-loop-helix domain (bHLH), and two heme-containing PAS domains (PAS-A and PAS-B).	Protactinium	9-12	neuronal PAS domain protein 2	Homo sapiens	31-36
22108550-4	2012	METHODS: We performed a docking simulation targeting the interface of PA interacting with PB1 using a drug database including ~4000 compounds.	Protactinium	70-72	polybromo 1	Homo sapiens	90-93
22561494-13	2012	After the amputation, the expression of GFAP was significantly higher in the PA group (P&lt;0.05).	Protactinium	77-79	glial fibrillary acidic protein	Rattus norvegicus	40-44
22264757-1	2012	Calreticulin transacetylase (CRTAase) is known to catalyze the transfer of acetyl group from polyphenolic acetates (PA) to certain receptor proteins (RP), thus modulating their activity.	Protactinium	116-118	calreticulin	Homo sapiens	0-12
22378922-0	2012	CD4+ T cells and HIV: A paradoxical Pas de Deux.	Protactinium	36-39	CD4 molecule	Homo sapiens	0-3
23119115-13	2012	It has been reported that approximately 70% of PAs demonstrate ALK gene rearrangement when SRCs comprised &gt;10% of the tumor cells.	Protactinium	47-50	ALK receptor tyrosine kinase	Homo sapiens	63-66
22447138-3	2012	FH-III is a severe variety of PA resistant to pharmacotherapy and recently demonstrated to be caused by mutations in the gene encoding the potassium channel KCNJ5.	Protactinium	30-32	potassium inwardly rectifying channel subfamily J member 5	Homo sapiens	157-162
22490477-12	2012	Sufentanil consumption and plasma interleukin-8 levels at 2 and 12 hours postoperatively were significantly lower in the PA group than the C group (P &lt; 0.05).	Protactinium	121-123	C-X-C motif chemokine ligand 8	Homo sapiens	34-47
21926266-9	2012	Contractile PA myocytes exhibit marked Rho-dependent APM in hypoxia, with increased active RhoA and LIMK phosphorylation.	Protactinium	12-14	ras homolog family member A	Sus scrofa	91-95
22100620-3	2012	In our previous reports, we have conclusively established the Calreticulin Transacetylase (CRTAase) catalyzed activation of neuronal nitric oxide synthase (nNOS) and tumor necrosis factor-alpha (TNF-alpha) induced nitric oxide synthase (iNOS) by PA.	Protactinium	246-248	tumor necrosis factor	Homo sapiens	166-193
21500184-11	2012	CONCLUSION: Compared with transplantation to the OM, transplantation of rat metanephroi to the PA results in better renin production, whereas the transplantation site does not affect EPO production.	Protactinium	95-97	renin	Rattus norvegicus	116-121
22100620-3	2012	In our previous reports, we have conclusively established the Calreticulin Transacetylase (CRTAase) catalyzed activation of neuronal nitric oxide synthase (nNOS) and tumor necrosis factor-alpha (TNF-alpha) induced nitric oxide synthase (iNOS) by PA.	Protactinium	246-248	nitric oxide synthase 1	Homo sapiens	124-154
22100620-3	2012	In our previous reports, we have conclusively established the Calreticulin Transacetylase (CRTAase) catalyzed activation of neuronal nitric oxide synthase (nNOS) and tumor necrosis factor-alpha (TNF-alpha) induced nitric oxide synthase (iNOS) by PA.	Protactinium	246-248	tumor necrosis factor	Homo sapiens	195-204
22100620-3	2012	In our previous reports, we have conclusively established the Calreticulin Transacetylase (CRTAase) catalyzed activation of neuronal nitric oxide synthase (nNOS) and tumor necrosis factor-alpha (TNF-alpha) induced nitric oxide synthase (iNOS) by PA.	Protactinium	246-248	nitric oxide synthase 1	Homo sapiens	156-160
22100620-3	2012	In our previous reports, we have conclusively established the Calreticulin Transacetylase (CRTAase) catalyzed activation of neuronal nitric oxide synthase (nNOS) and tumor necrosis factor-alpha (TNF-alpha) induced nitric oxide synthase (iNOS) by PA.	Protactinium	246-248	nitric oxide synthase 2	Homo sapiens	237-241
22100620-8	2012	The differential specificities of CRTAase to PA were found to positively correlate with increased production of NO upon incubation of PRP with PA and l-arginine.	Protactinium	45-47	complement component 4 binding protein alpha	Homo sapiens	134-137
22100620-8	2012	The differential specificities of CRTAase to PA were found to positively correlate with increased production of NO upon incubation of PRP with PA and l-arginine.	Protactinium	143-145	complement component 4 binding protein alpha	Homo sapiens	134-137
22100620-10	2012	The real-time RT-PCR profile of NOS isoforms confirmed the preponderance of eNOS over iNOS in human platelets on treatment with PA.	Protactinium	128-130	nitric oxide synthase 2	Homo sapiens	86-90
21858873-10	2012	On the other hand, MAP-2 immunostaining was decreased after PA, being NF-200 expression unmodified.	Protactinium	60-62	microtubule-associated protein 2	Rattus norvegicus	19-24
22309046-4	2012	The %PA induced by 5 microM thrombin receptor-activating peptide (TRAP) was also assessed for 10 neonates and 21 infants/toddlers enrolled in PICOLO and compared with 11 adult samples.	Protactinium	5-7	TRAP	Homo sapiens	28-64
22309046-4	2012	The %PA induced by 5 microM thrombin receptor-activating peptide (TRAP) was also assessed for 10 neonates and 21 infants/toddlers enrolled in PICOLO and compared with 11 adult samples.	Protactinium	5-7	TRAP	Homo sapiens	66-70
22309046-9	2012	In conclusion, ADP- and TRAP-induced %PA is lower in pediatric cardiac patients than normal adults, but highly variable in both.	Protactinium	38-40	TRAP	Homo sapiens	24-28
23284721-7	2012	Intrinsic fluorescence intensity of the CaCDPK1 protein was quenched on adding PA and PC.	Protactinium	79-81	calcium-dependent protein kinase 21-like	Cicer arietinum	40-47
23284721-10	2012	The stimulation by PA and PC suggests regulation of CaCDPK1 by these phospholipids during stress response.	Protactinium	19-21	calcium-dependent protein kinase 21-like	Cicer arietinum	52-59
22077993-5	2011	It was hypothesized the biphasic hydrogel would induce osteogenic differentiation of human mesenchymal stem cells (hMSCs) and improve bone healing as mediated by RGDS ligand signaling within PA nanofibers and embedded HA mineralization source.	Protactinium	191-193	ral guanine nucleotide dissociation stimulator	Homo sapiens	162-166
22077993-10	2011	The combination of RGDS ligand signaling and HA nanoparticles within the biphasic PA nanomatrix hydrogel demonstrated the most effective osteoinduction and comparative bone healing response.	Protactinium	82-84	ral guanine nucleotide dissociation stimulator	Homo sapiens	19-23
22044068-8	2011	Furthermore, a pronounced maximum in SFG intensity of the C(60) band is observed for SAMs, which are deposited from solutions with ~75% C(60)C(18)-PA and ~25% FC(12)-PA.	Protactinium	145-149	methionine adenosyltransferase 1A	Homo sapiens	85-89
22044068-8	2011	Furthermore, a pronounced maximum in SFG intensity of the C(60) band is observed for SAMs, which are deposited from solutions with ~75% C(60)C(18)-PA and ~25% FC(12)-PA.	Protactinium	164-168	methionine adenosyltransferase 1A	Homo sapiens	85-89
21945665-4	2011	PD and PD2 increased the antigen specific IgG, IgG1, IgG2a, and IgG2b antibody titers, while PA and PGD only induce the IgG and IgG1 antibody responses in the immunized mice.	Protactinium	93-95	LOC105243590	Mus musculus	128-132
21978102-9	2011	The individual S1-PAS-induced changes in S1 and M1 excitability showed no correlation.	Protactinium	18-21	myoregulin	Homo sapiens	48-50
21668567-11	2011	Further studies are necessary to evaluate the usefulness of PA-PDI intervals in diagnosing PAF in addition to the current methods and tools.	Protactinium	60-62	prolyl 4-hydroxylase subunit beta	Homo sapiens	63-66
21957294-8	2011	The use of PA(SC35M/WSN) chimeras revealed that the reduced affinity of the SC35M PB1-PA dimer was mediated by the N-terminal 277 amino acids of PA.	Protactinium	11-13	polybromo 1	Homo sapiens	82-85
21957294-8	2011	The use of PA(SC35M/WSN) chimeras revealed that the reduced affinity of the SC35M PB1-PA dimer was mediated by the N-terminal 277 amino acids of PA.	Protactinium	86-88	polybromo 1	Homo sapiens	82-85
22117833-2	2011	Next, we wanted to determine the number of mucinous BACs using histochemical staining with Alcian Blue PAS.	Protactinium	103-106	solute carrier family 27 member 5	Homo sapiens	52-56
21799125-10	2011	The increased PA contractility induced by 100% O(2) was reversed by scavenging superoxide anions with superoxide dismutase and catalase.	Protactinium	14-16	catalase	Ovis aries	127-135
22126385-6	2011	Histochemically, these mucin materials were PAS-positive and diastase-resistant.	Protactinium	44-47	LOC100508689	Homo sapiens	23-28
21978102-12	2011	Potentially, this extends the opportunities of therapeutic PAS applications because M1-PAS "non-responders" may well respond to S1-PAS.	Protactinium	59-62	myoregulin	Homo sapiens	84-86
21715506-6	2011	These proteins mediate molecular transport across the mitochondrial membrane or regulate membrane potential and may in concert with the identified mitochondrion-associated apoptosis inducing factor (AIFM1) have roles in the induction of apoptosis upon association with PA.	Protactinium	269-271	apoptosis inducing factor mitochondria associated 1	Homo sapiens	199-204
22335902-8	2011	RESULTS: CD34-PAS staining showed that endothelium-dependent vessels (CD34(+), PAS(+)), VM vessels (CD34(-), PAS(+)), and the MVs (CD34(+), PAS(-)) could be seen in the transplantated tumors.	Protactinium	14-17	CD34 molecule	Homo sapiens	9-13
21658887-5	2011	RESULTS: Seventy-five ulcers with 86 associated incompetent perforating veins were treated with PA in 45 patients with CEAP 6 recalcitrant venous ulcers.	Protactinium	96-98	biogenesis of lysosomal organelles complex 1 subunit 2	Homo sapiens	119-123
21849283-8	2011	CONCLUSIONS: Although the changes of RNP activity did not exactly reflect to mice virulence, we consistently observed that the PA gene of H1N1(pdm) results in increased polymerase activity, better replication in mice, and lower LD50.	Protactinium	127-129	RNA binding region (RNP1, RRM) containing 3	Homo sapiens	37-40
21763677-4	2011	We found an association exists between the percentage of PAs with neointimal lesions and elastin fragmentation in S100A4 mice 6 months after viral infection.	Protactinium	57-60	elastin	Mus musculus	89-96
21854254-3	2011	We examined whether there is an association between saliva PSA and serum PSA in patients with PA using enzyme-linked immunosorbent assay.	Protactinium	94-96	kallikrein related peptidase 3	Homo sapiens	59-62
21854254-3	2011	We examined whether there is an association between saliva PSA and serum PSA in patients with PA using enzyme-linked immunosorbent assay.	Protactinium	94-96	kallikrein related peptidase 3	Homo sapiens	73-76
21854254-7	2011	This result suggests that saliva PSA is associated with blood PSA in patients with recurrent or metastatic PA and may, therefore, be a useful PA biomarker.	Protactinium	107-109	kallikrein related peptidase 3	Homo sapiens	33-36
21854254-7	2011	This result suggests that saliva PSA is associated with blood PSA in patients with recurrent or metastatic PA and may, therefore, be a useful PA biomarker.	Protactinium	107-109	kallikrein related peptidase 3	Homo sapiens	62-65
21854254-7	2011	This result suggests that saliva PSA is associated with blood PSA in patients with recurrent or metastatic PA and may, therefore, be a useful PA biomarker.	Protactinium	142-144	kallikrein related peptidase 3	Homo sapiens	33-36
21645548-7	2011	The PA-PB1 interaction was also disrupted by single amino acid mutations in the N-terminal domain of PB1 that is responsible for binding PA.	Protactinium	4-6	polybromo 1	Homo sapiens	7-10
21645548-7	2011	The PA-PB1 interaction was also disrupted by single amino acid mutations in the N-terminal domain of PB1 that is responsible for binding PA.	Protactinium	4-6	polybromo 1	Homo sapiens	101-104
21708942-1	2011	The PAH1-encoded phosphatidate (PA) phosphatase in Saccharomyces cerevisiae is a pivotal enzyme that produces diacylglycerol for the synthesis of triacylglycerol (TAG) and simultaneously controls the level of PA used for phospholipid synthesis.	Protactinium	32-34	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	4-8
21423207-5	2011	Using the peptide aptamer (PA) strategy, we isolated PAs that specifically interact with Hsp27 and not with the other members of the small heat shock protein family.	Protactinium	53-56	heat shock protein family B (small) member 1	Homo sapiens	89-94
21423207-6	2011	In mammalian cell cultures, PAs expression perturbed the dimerization and oligomerization of Hsp27, and acted as negative regulators of the anti-apoptotic and cytoprotective activities of this protein.	Protactinium	28-31	heat shock protein family B (small) member 1	Homo sapiens	93-98
21423207-8	2011	Our data suggest that PAs could provide a potential tool to develop strategies for the discovery of Hsp27 chemical inhibitors.	Protactinium	22-25	heat shock protein family B (small) member 1	Homo sapiens	100-105
22152386-5	2011	RESULTS: PAS staining assay revealed that BMP2 and BMP9 enhanced glycogen storage in hepatic progenitor cells most obviously at day 7.	Protactinium	9-12	bone morphogenetic protein 2	Homo sapiens	42-46
22152386-5	2011	RESULTS: PAS staining assay revealed that BMP2 and BMP9 enhanced glycogen storage in hepatic progenitor cells most obviously at day 7.	Protactinium	9-12	growth differentiation factor 2	Homo sapiens	51-55
21708942-8	2011	Deletion of the DGK1-encoded diacylglycerol kinase, which counteracts PA phosphatase in controlling PA content, suppressed the defect in lipid droplet formation in the pah1Delta mutant.	Protactinium	70-72	diacylglycerol kinase	Saccharomyces cerevisiae S288C	16-20
21477081-4	2011	In this study we show that TT1 is not only required for correct expression of PA-specific genes in the seed coat, but also affects CHS, encoding the first enzyme of flavonoid biosynthesis.	Protactinium	78-80	C2H2 and C2HC zinc fingers superfamily protein	Arabidopsis thaliana	27-30
21833358-7	2011	The system provides greater penetration depth than previous combined PA/OCT devices due to the longer wavelength of the OCT beam (1050 nm rather than 829-870 nm) and by operating in the tomographic rather than the optical resolution mode of photoacoustic imaging.	Protactinium	69-71	plexin A2	Homo sapiens	120-123
21477081-6	2011	We demonstrate that TT1 can interact with the R2R3 MYB protein TT2 and that ectopic expression of TT2 can partially restore the lack in PA production in tt1.	Protactinium	136-138	Duplicated homeodomain-like superfamily protein	Arabidopsis thaliana	98-101
21602393-10	2011	The modeled structure for the SO3389 PAS domains was highly similar to the crystal structures of FAD-binding PAS domains that are known O2/redox sensors.	Protactinium	37-40	bifunctional diguanylate cyclase/phosphodiesterase	Shewanella oneidensis MR-1	30-36
21610151-5	2011	RESULTS: Our results indicate that PAs are senescent as evidenced by marked senescence-associated acidic beta-galactosidase activity, low KI-67 index, and induction of p16(INK4a) but not p53 in the majority of 52 PA samples (46 of 52; 88.5%).	Protactinium	35-38	cyclin dependent kinase inhibitor 2A	Homo sapiens	168-171
21610151-5	2011	RESULTS: Our results indicate that PAs are senescent as evidenced by marked senescence-associated acidic beta-galactosidase activity, low KI-67 index, and induction of p16(INK4a) but not p53 in the majority of 52 PA samples (46 of 52; 88.5%).	Protactinium	35-38	cyclin dependent kinase inhibitor 2A	Homo sapiens	172-177
21610151-10	2011	We show that it is triggered in PAs through p16(INK4a) pathway induction following aberrant MAPK activation.	Protactinium	32-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	44-47
21610151-10	2011	We show that it is triggered in PAs through p16(INK4a) pathway induction following aberrant MAPK activation.	Protactinium	32-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	48-53
21657246-8	2011	The unmodified PA:PVP membranes drastically increased the level of TNF-alpha; however, the concentration of IL-1beta and IL-6 remained almost the same.	Protactinium	15-17	tumor necrosis factor	Homo sapiens	67-76
21602393-10	2011	The modeled structure for the SO3389 PAS domains was highly similar to the crystal structures of FAD-binding PAS domains that are known O2/redox sensors.	Protactinium	109-112	bifunctional diguanylate cyclase/phosphodiesterase	Shewanella oneidensis MR-1	30-36
21653594-8	2011	We conclude that MIB-1 labeling remains the best predictor of PFS in pediatric PAs.	Protactinium	79-82	MIB E3 ubiquitin protein ligase 1	Homo sapiens	17-22
21700047-10	2011	Milk production averaged 13.5 kg/d and was greater at high than at low PA (+1.4 kg/d) and in supplemented than unsupplemented treatments (+5.2 kg/d).	Protactinium	71-73	Weaning weight-maternal milk	Bos taurus	0-4
21397736-6	2011	When Sp(O2) was decreased to 85% via manipulation of the FI(O2) (inspired fraction of oxygen) Pa(O2), decreased to 6.1 (5.9-6.2) kPa.	Protactinium	94-96	immunoglobulin kappa variable 1D-39	Homo sapiens	5-10
21605745-5	2011	The major MFGM proteins were hydrolyzed at different rates by the pepsin in the SGF; butyrophilin was more resistant than xanthine oxidase, PAS 6, or PAS 7.	Protactinium	140-143	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	10-14
21605745-5	2011	The major MFGM proteins were hydrolyzed at different rates by the pepsin in the SGF; butyrophilin was more resistant than xanthine oxidase, PAS 6, or PAS 7.	Protactinium	150-153	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	10-14
21512126-4	2011	Structural insights from NMR spectroscopy illustrate how this PAS domain simultaneously mediates interactions with HIF-alpha and TACC3.	Protactinium	62-65	transforming acidic coiled-coil containing protein 3	Homo sapiens	129-134
21515352-3	2011	MATERIALS AND METHODS: Anti-proliferative activity of ethyl acetate extracts of P. angulata (PA extracts), was determined against human oral squamous carcinoma (HSC-3) and human umbilical vein endothelial cells (HUVECs) by trypan blue exclusion method.	Protactinium	93-95	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	161-166
21515352-5	2011	RESULTS: We demonstrated that at sub-cytotoxic concentrations of PA extracts (5-15 mug/mL) markedly inhibited the migration and invasion of highly metastatic HSC-3 cells as shown by wound-healing repair assay and trans-well assay.	Protactinium	65-67	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	158-163
21515352-6	2011	Gelatin zymography assay showed that PA extracts suppressed the activity of matrix metalloproteinase (MMP)-9 and -2, and urokinase plasminogen activator (u-PA) in HSC-3 cells.	Protactinium	37-39	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	163-168
21515352-7	2011	In addition, Western blot analysis confirmed that PA extracts significantly decreased MMP-2 and u-PA protein expression in HSC-3 cells.	Protactinium	50-52	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	123-128
21337363-6	2011	A significantly increased activity of both constitutive NO synthase (nNOS, Ca(2+)-dependent) and inducible NO synthase (iNOS, Ca(2+)-independent) was observed in PA retinas from 21 days old up to 60 days old with respect to age-matched CTL, with a significant increase along the time course in the PA. nNOS was immunolocalized at amacrine, horizontal, and ganglion cells of the PA group, with a significant increase in relative optical density (R.O.D.	Protactinium	162-164	nitric oxide synthase 1	Rattus norvegicus	69-73
21337363-6	2011	A significantly increased activity of both constitutive NO synthase (nNOS, Ca(2+)-dependent) and inducible NO synthase (iNOS, Ca(2+)-independent) was observed in PA retinas from 21 days old up to 60 days old with respect to age-matched CTL, with a significant increase along the time course in the PA. nNOS was immunolocalized at amacrine, horizontal, and ganglion cells of the PA group, with a significant increase in relative optical density (R.O.D.	Protactinium	162-164	nitric oxide synthase 2	Rattus norvegicus	97-118
21337363-6	2011	A significantly increased activity of both constitutive NO synthase (nNOS, Ca(2+)-dependent) and inducible NO synthase (iNOS, Ca(2+)-independent) was observed in PA retinas from 21 days old up to 60 days old with respect to age-matched CTL, with a significant increase along the time course in the PA. nNOS was immunolocalized at amacrine, horizontal, and ganglion cells of the PA group, with a significant increase in relative optical density (R.O.D.	Protactinium	162-164	nitric oxide synthase 2	Rattus norvegicus	120-124
21337363-6	2011	A significantly increased activity of both constitutive NO synthase (nNOS, Ca(2+)-dependent) and inducible NO synthase (iNOS, Ca(2+)-independent) was observed in PA retinas from 21 days old up to 60 days old with respect to age-matched CTL, with a significant increase along the time course in the PA. nNOS was immunolocalized at amacrine, horizontal, and ganglion cells of the PA group, with a significant increase in relative optical density (R.O.D.	Protactinium	162-164	nitric oxide synthase 1	Rattus norvegicus	302-306
21337363-8	2011	iNOS immunoreactivity was observed in the inner nuclear layer and in the internal Muller cell processes of PA, with a significant increase in R.O.D.	Protactinium	107-109	nitric oxide synthase 2	Rattus norvegicus	0-4
21337363-9	2011	and colocalizing with GFAP in the 60-day-old PA group.	Protactinium	45-47	glial fibrillary acidic protein	Rattus norvegicus	22-26
21245039-0	2011	Identification of residues in the N-terminal PAS domains important for dimerization of Arnt and AhR.	Protactinium	45-48	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	87-91
21245039-0	2011	Identification of residues in the N-terminal PAS domains important for dimerization of Arnt and AhR.	Protactinium	45-48	aryl hydrocarbon receptor	Homo sapiens	96-99
21245039-3	2011	Using a new bacterial two-hybrid system that selects for loss of protein interactions, we have identified 22 amino acids in the N-terminal PAS domain of Arnt that are involved in heterodimerization with aryl hydrocarbon receptor (AhR).	Protactinium	139-142	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	153-157
21245039-3	2011	Using a new bacterial two-hybrid system that selects for loss of protein interactions, we have identified 22 amino acids in the N-terminal PAS domain of Arnt that are involved in heterodimerization with aryl hydrocarbon receptor (AhR).	Protactinium	139-142	aryl hydrocarbon receptor	Homo sapiens	203-228
21245039-3	2011	Using a new bacterial two-hybrid system that selects for loss of protein interactions, we have identified 22 amino acids in the N-terminal PAS domain of Arnt that are involved in heterodimerization with aryl hydrocarbon receptor (AhR).	Protactinium	139-142	aryl hydrocarbon receptor	Homo sapiens	230-233
21245039-5	2011	Arnt uses the same face of the N-terminal PAS domain for homo- and heterodimerization and mutational analysis of AhR demonstrated that the equivalent region is used by AhR when dimerizing with Arnt.	Protactinium	42-45	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	0-4
21245039-5	2011	Arnt uses the same face of the N-terminal PAS domain for homo- and heterodimerization and mutational analysis of AhR demonstrated that the equivalent region is used by AhR when dimerizing with Arnt.	Protactinium	42-45	aryl hydrocarbon receptor	Homo sapiens	168-171
21245039-5	2011	Arnt uses the same face of the N-terminal PAS domain for homo- and heterodimerization and mutational analysis of AhR demonstrated that the equivalent region is used by AhR when dimerizing with Arnt.	Protactinium	42-45	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	193-197
21245039-6	2011	These interfaces differ from the PAS beta-scaffold surfaces used for dimerization between the C-terminal PAS domains of hypoxia inducible factor-2alpha and Arnt, commonly used for PAS domain interactions.	Protactinium	33-36	endothelial PAS domain protein 1	Homo sapiens	120-151
21245039-6	2011	These interfaces differ from the PAS beta-scaffold surfaces used for dimerization between the C-terminal PAS domains of hypoxia inducible factor-2alpha and Arnt, commonly used for PAS domain interactions.	Protactinium	33-36	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	156-160
21245039-6	2011	These interfaces differ from the PAS beta-scaffold surfaces used for dimerization between the C-terminal PAS domains of hypoxia inducible factor-2alpha and Arnt, commonly used for PAS domain interactions.	Protactinium	105-108	endothelial PAS domain protein 1	Homo sapiens	120-151
21245039-6	2011	These interfaces differ from the PAS beta-scaffold surfaces used for dimerization between the C-terminal PAS domains of hypoxia inducible factor-2alpha and Arnt, commonly used for PAS domain interactions.	Protactinium	105-108	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	156-160
21496174-0	2011	Patient with syncope and LQTS carrying a mutation in the PAS domain of the hERG1 channel.	Protactinium	57-60	potassium voltage-gated channel subfamily H member 2	Homo sapiens	75-80
21496174-6	2011	Identifying mutations in the PAS domain or other domains of the hERG1 channel and understanding their effect may provide more focused and mutation-specific risk assessment in this population.	Protactinium	29-32	potassium voltage-gated channel subfamily H member 2	Homo sapiens	64-69
20887817-1	2011	Mouse period homolog 2 (mPer2), an important transcriptional regulatory factor associated with circadian rhythms, is composed of two N-terminal PAS (PAS-A and PAS-B) domains and a C-terminal domain.	Protactinium	144-147	period circadian clock 2	Mus musculus	24-29
20711762-3	2011	In addition, hERG has an N-terminal PAS (Per, Arnt and Sim) domain and a C-terminal cyclic nucleotide binding domain (cNBD).	Protactinium	36-39	ETS transcription factor ERG	Homo sapiens	13-17
21276437-6	2011	RESULTS: 4HNE-PAs levels were increased in MeCP2- and CDKL5-related RTT but not in FOXG1-related RTT.	Protactinium	14-17	methyl-CpG binding protein 2	Homo sapiens	43-48
21276437-6	2011	RESULTS: 4HNE-PAs levels were increased in MeCP2- and CDKL5-related RTT but not in FOXG1-related RTT.	Protactinium	14-17	cyclin dependent kinase like 5	Homo sapiens	54-59
21213024-8	2011	Both polymers opened tight junctions reversibly, and insulin transport through monolayers increased when QPa or Pa was used.	Protactinium	106-108	insulin	Homo sapiens	53-60
21317706-6	2011	S100P overexpression was significantly more prevalent in CXPAs (27 cases; 87.1%) than in atypical PAs (2 cases; 28.6%) and conventional PAs (1 case; 4.8%) (P&lt;0.05).	Protactinium	98-101	S100 calcium binding protein P	Homo sapiens	0-5
21127288-7	2011	Notably, in VICs grown on collagen-coated PA gels with physiological stiffnesses, TGF-beta1-induced beta-catenin nuclear translocation and myofibroblast differentiation occurred only on matrices with fibrosa-like stiffness, but not ventricularis-like stiffness.	Protactinium	42-44	transforming growth factor beta 1	Sus scrofa	82-91
21127288-7	2011	Notably, in VICs grown on collagen-coated PA gels with physiological stiffnesses, TGF-beta1-induced beta-catenin nuclear translocation and myofibroblast differentiation occurred only on matrices with fibrosa-like stiffness, but not ventricularis-like stiffness.	Protactinium	42-44	catenin beta 1	Sus scrofa	100-112
21412469-5	2011	Averaged PA signal intensity from the stimulated cells was about 3 folds higher (~10 dB) compared to the un-stimulated cells for both ICAM-1 and E-selectin.	Protactinium	9-11	intercellular adhesion molecule 1	Homo sapiens	134-140
21412469-5	2011	Averaged PA signal intensity from the stimulated cells was about 3 folds higher (~10 dB) compared to the un-stimulated cells for both ICAM-1 and E-selectin.	Protactinium	9-11	selectin E	Homo sapiens	145-155
21135188-2	2011	We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between PA and PB1 using peptides derived from the extreme N terminus of PB1 (amino acids [aa] 1 to 15), comprising the PA-binding domain of PB1.	Protactinium	108-110	polybromo 1	Homo sapiens	173-176
21135188-2	2011	We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between PA and PB1 using peptides derived from the extreme N terminus of PB1 (amino acids [aa] 1 to 15), comprising the PA-binding domain of PB1.	Protactinium	108-110	polybromo 1	Homo sapiens	173-176
21135188-2	2011	We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between PA and PB1 using peptides derived from the extreme N terminus of PB1 (amino acids [aa] 1 to 15), comprising the PA-binding domain of PB1.	Protactinium	220-222	polybromo 1	Homo sapiens	115-118
21135188-2	2011	We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between PA and PB1 using peptides derived from the extreme N terminus of PB1 (amino acids [aa] 1 to 15), comprising the PA-binding domain of PB1.	Protactinium	220-222	polybromo 1	Homo sapiens	173-176
21135188-2	2011	We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between PA and PB1 using peptides derived from the extreme N terminus of PB1 (amino acids [aa] 1 to 15), comprising the PA-binding domain of PB1.	Protactinium	220-222	polybromo 1	Homo sapiens	173-176
21135188-7	2011	Thus, the feasibility to enhance the PA-binding affinity presents an intriguing possibility to increase antiviral activity of the PB1-derived peptide and one step forward in the development of an antiviral drug against influenza A viruses.	Protactinium	37-39	polybromo 1	Homo sapiens	130-133
21481311-14	2011	(2)The overexpression of ADRP gene could prevent apoptosis of cells caused by PA, which indicated that ADRP might play a protective role in H9c2 cells.	Protactinium	78-80	perilipin 2	Rattus norvegicus	25-29
21481311-14	2011	(2)The overexpression of ADRP gene could prevent apoptosis of cells caused by PA, which indicated that ADRP might play a protective role in H9c2 cells.	Protactinium	78-80	perilipin 2	Rattus norvegicus	103-107
21317706-5	2011	HER2 expression, p53 expression, and the Ki-67 labeling index were higher in CXPAs than in atypical PAs and conventional PAs, whereas the AR expression level was relatively high even in atypical PAs.	Protactinium	79-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
21317706-6	2011	S100P overexpression was significantly more prevalent in CXPAs (27 cases; 87.1%) than in atypical PAs (2 cases; 28.6%) and conventional PAs (1 case; 4.8%) (P&lt;0.05).	Protactinium	59-62	S100 calcium binding protein P	Homo sapiens	0-5
21156203-4	2011	Using statistical model selection and testing, we show that for human genome data, one-piece PC (PC1) is often in a statistical tie with two-piece PA model (PA2).	Protactinium	147-149	polycystin 1, transient receptor potential channel interacting	Homo sapiens	93-95
21156203-4	2011	Using statistical model selection and testing, we show that for human genome data, one-piece PC (PC1) is often in a statistical tie with two-piece PA model (PA2).	Protactinium	147-149	polycystin 1, transient receptor potential channel interacting	Homo sapiens	97-100
21221730-0	2011	Detection of synthetic RGDS(PO3H2)PA peptide adsorption using a titanium surface plasmon resonance biosensor.	Protactinium	34-36	ral guanine nucleotide dissociation stimulator	Homo sapiens	23-27
20887817-8	2011	Marked pH-dependent spectral changes were observed, in contrast to the spectrum of the Fe(III) bound PAS-A domain of mPer2, which appeared pH-resistant.	Protactinium	101-104	period circadian clock 2	Mus musculus	117-122
20709140-11	2011	PA also increases the activities of ERK, mTOR, myc and sphingosine kinase-1 (SK-1), which provide individual signals for cells division, survival, chemo-resistance and angiogenesis.	Protactinium	0-2	Eph receptor B2	Mus musculus	36-39
20965146-5	2011	In particular, the mitochondrial tricarboxylate carrier inhibitor, benzene tricarboxylate (BTA), also showed a strong protective effect on the HG/PA-induced INS-1 cell death.	Protactinium	146-148	solute carrier family 25 member 1	Rattus norvegicus	19-55
22156465-6	2011	Mucin was demonstrated by mucicarmine, Alcian Blue/PAS, and Alcian Blue (pH 2.5).	Protactinium	51-54	LOC100508689	Homo sapiens	0-5
20971506-4	2011	We performed localization studies, inhibition of SHH signaling in the CN, and treatment of crushed CNs with SHH protein via linear PA gels, which are an innovative extended release method of delivery.	Protactinium	131-133	sonic hedgehog signaling molecule	Homo sapiens	108-111
21276224-9	2011	In addition, a 3 nucleotide deletion leading to the loss of a serine residue at position 93 was found in the SEG/Pas Wap gene.	Protactinium	113-116	whey acidic protein	Mus musculus	117-120
21241149-11	2011	Overall, the theoretical results are quite consistent with the experimental observations (e.g., at 25  C the alpha-helix content of the apo state of AA c(555) is almost equal to that of the holo state while almost all helices are collapsed in the apo states of PA c(551), PH c(552), and HT c(552)).	Protactinium	261-263	glycine-N-acyltransferase	Homo sapiens	149-153
20956592-10	2011	Significantly, CMG2-Fc effectively neutralized, in vitro, LeTx-containing mutant forms of PA that were not neutralized by anti-PA monoclonal antibodies.	Protactinium	90-92	ANTXR cell adhesion molecule 2	Homo sapiens	15-19
20709140-11	2011	PA also increases the activities of ERK, mTOR, myc and sphingosine kinase-1 (SK-1), which provide individual signals for cells division, survival, chemo-resistance and angiogenesis.	Protactinium	0-2	mechanistic target of rapamycin kinase	Mus musculus	41-45
20709140-11	2011	PA also increases the activities of ERK, mTOR, myc and sphingosine kinase-1 (SK-1), which provide individual signals for cells division, survival, chemo-resistance and angiogenesis.	Protactinium	0-2	myelocytomatosis oncogene	Mus musculus	47-50
20709140-11	2011	PA also increases the activities of ERK, mTOR, myc and sphingosine kinase-1 (SK-1), which provide individual signals for cells division, survival, chemo-resistance and angiogenesis.	Protactinium	0-2	sphingosine kinase 1	Mus musculus	55-81
21314207-7	2011	Histochemical reaction for NIS in the pituitaries at 48 hours after iodide administration showed a dose related increase beginning from 4 mug/100 g (from 1.8+-0.7 to 12.9+-1.0 % PA, respectively to the dose of iodide), while such increase in the thyroids started from 8 mug/100g (from 3.7+-1.2 to 9.1+-2.0 % PA).	Protactinium	308-310	solute carrier family 5 member 5	Rattus norvegicus	27-30
20807324-15	2011	CONCLUSIONS: PA technology is effective in delivering SHH protein to the penis and SHH is effective in suppressing CN injury-induced apoptosis.	Protactinium	13-15	sonic hedgehog signaling molecule	Rattus norvegicus	54-57
21314207-7	2011	Histochemical reaction for NIS in the pituitaries at 48 hours after iodide administration showed a dose related increase beginning from 4 mug/100 g (from 1.8+-0.7 to 12.9+-1.0 % PA, respectively to the dose of iodide), while such increase in the thyroids started from 8 mug/100g (from 3.7+-1.2 to 9.1+-2.0 % PA).	Protactinium	178-180	solute carrier family 5 member 5	Rattus norvegicus	27-30
21858226-2	2011	In the current study we examined the role of Th1 and Th2 type responses in NKT-mediated enhancement of antibody responses to PA.	Protactinium	125-127	negative elongation factor complex member C/D, Th1l	Mus musculus	45-48
22046423-9	2011	Moreover, co-silencing both novel PKC theta and epsilon isoforms in myoblasts by RNA interference, but not their individual silencing, prevented the inflammatory response and restored insulin sensitivity to CM-PA-treated myoblasts.	Protactinium	210-212	insulin	Homo sapiens	184-191
22132111-5	2011	Specifically, 70% of PA underwent early antrum (EA) differentiation and supported in culture oocyte global DNA methylation, telomere elongation, TERT and Dnmt3a redistribution thus mimicking the physiological events that involve the oocyte during the transition from secondary to tertiary follicle.	Protactinium	21-23	telomerase reverse transcriptase	Ovis aries	145-149
22132111-5	2011	Specifically, 70% of PA underwent early antrum (EA) differentiation and supported in culture oocyte global DNA methylation, telomere elongation, TERT and Dnmt3a redistribution thus mimicking the physiological events that involve the oocyte during the transition from secondary to tertiary follicle.	Protactinium	21-23	DNA (cytosine-5)-methyltransferase 3A	Ovis aries	154-160
21858226-3	2011	First, the contribution of IL-4 and IFNgamma to the production of PA-specific toxin-neutralizing Abs was examined.	Protactinium	66-68	interleukin 4	Mus musculus	27-31
21858226-4	2011	By immunizing C57Bl/6 controls IL-4(-/-) mice and IFNgamma(-/-) mice and performing passive serum transfer experiments, it was observed that sera containing PA-specific IgG1, IgG2b and IgG2c neutralized toxin in vitro and conferred protection in vivo.	Protactinium	157-159	interleukin 4	Mus musculus	31-35
21858226-4	2011	By immunizing C57Bl/6 controls IL-4(-/-) mice and IFNgamma(-/-) mice and performing passive serum transfer experiments, it was observed that sera containing PA-specific IgG1, IgG2b and IgG2c neutralized toxin in vitro and conferred protection in vivo.	Protactinium	157-159	interferon gamma	Mus musculus	50-58
21858226-4	2011	By immunizing C57Bl/6 controls IL-4(-/-) mice and IFNgamma(-/-) mice and performing passive serum transfer experiments, it was observed that sera containing PA-specific IgG1, IgG2b and IgG2c neutralized toxin in vitro and conferred protection in vivo.	Protactinium	157-159	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	169-173
21858226-9	2011	Neutralizing PA-specific IgG1 responses were modestly enhanced by OCH in C57Bl/6 mice.	Protactinium	13-15	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	25-29
21858226-9	2011	Neutralizing PA-specific IgG1 responses were modestly enhanced by OCH in C57Bl/6 mice.	Protactinium	13-15	ochre	Mus musculus	66-69
21829615-5	2011	PA applied at the time of highest TEM8 expression reduced vascular density and disrupted hierarchical branching as revealed by quantitative morphometric analysis of the vascular tree after 48h.	Protactinium	0-2	ANTXR cell adhesion molecule 1	Homo sapiens	34-38
21829615-8	2011	Consistent with this model, PA increased beta catenin levels acutely in CAM blood vessels in vivo and in TEM8 transfected primary human endothelial cells in vitro.	Protactinium	28-30	catenin beta 1	Homo sapiens	41-53
21829615-8	2011	Consistent with this model, PA increased beta catenin levels acutely in CAM blood vessels in vivo and in TEM8 transfected primary human endothelial cells in vitro.	Protactinium	28-30	ANTXR cell adhesion molecule 1	Homo sapiens	105-109
21829615-10	2011	This agonistic function is supported by findings in the CAM, where the increase in TEM8 expression from day 10 to day 12 and PA application correlated with Axin 2 induction, a universal reporter gene for canonical Wnt signaling.	Protactinium	125-127	Wnt family member 3A	Homo sapiens	214-217
21701685-14	2011	Basal 24 h post-RE and insulin-stimulated PAS-AS160/TBC1D4 phosphorylation was greater for EX and EX+PRO.	Protactinium	42-45	TBC1 domain family member 4	Homo sapiens	52-58
21829615-6	2011	PA-dependent reduced branching phenotype was partially mimicked by Wnt3a application and ameliorated by the Wnt antagonist, Dikkopf-1.	Protactinium	0-2	Wnt family member 3A	Homo sapiens	67-72
21829615-6	2011	PA-dependent reduced branching phenotype was partially mimicked by Wnt3a application and ameliorated by the Wnt antagonist, Dikkopf-1.	Protactinium	0-2	Wnt family member 3A	Homo sapiens	67-70
20444210-6	2010	KAN4 was localized to the nucleus and could specifically bind with promoters of early and late flavonoid biosynthetic genes and PA regulatory genes.	Protactinium	128-130	Homeodomain-like superfamily protein	Arabidopsis thaliana	0-4
21674060-3	2011	Inhibition of PA binding to its receptors, tumor endothelium marker-8 (TEM8) and capillary morphogenesis protein-2 (CMG2) can effectively block anthrax intoxication, which is particularly valuable when the toxin has already been overproduced at the late stage of anthrax infection, thus rendering antibiotics ineffectual.	Protactinium	14-16	ANTXR cell adhesion molecule 2	Homo sapiens	116-120
20845497-1	2010	This study was to evaluate enhanced bone formation by bone morphogenetic protein-7 (BMP-7) transduced MSCs on nano-hydroxyapatite/polyamide (n-HA/PA) composite scaffolds for bone tissue engineering in repair of mandibular defect.	Protactinium	146-148	bone morphogenetic protein 7	Oryctolagus cuniculus	54-82
20845497-1	2010	This study was to evaluate enhanced bone formation by bone morphogenetic protein-7 (BMP-7) transduced MSCs on nano-hydroxyapatite/polyamide (n-HA/PA) composite scaffolds for bone tissue engineering in repair of mandibular defect.	Protactinium	146-148	bone morphogenetic protein 7	Oryctolagus cuniculus	84-89
20889682-4	2010	In addition, we report new polymorphisms in the coding sequence of Fadd and demonstrate that the interaction between Fas and Fadd is significantly stronger if Fas and Fadd are of SEG/Pas origin compared with the C57BL/6J system.	Protactinium	183-186	Fas (TNFRSF6)-associated via death domain	Mus musculus	67-71
20889682-4	2010	In addition, we report new polymorphisms in the coding sequence of Fadd and demonstrate that the interaction between Fas and Fadd is significantly stronger if Fas and Fadd are of SEG/Pas origin compared with the C57BL/6J system.	Protactinium	183-186	Fas (TNFRSF6)-associated via death domain	Mus musculus	125-129
20889682-4	2010	In addition, we report new polymorphisms in the coding sequence of Fadd and demonstrate that the interaction between Fas and Fadd is significantly stronger if Fas and Fadd are of SEG/Pas origin compared with the C57BL/6J system.	Protactinium	183-186	Fas (TNFRSF6)-associated via death domain	Mus musculus	125-129
20444210-10	2010	These results confirm that KAN4 is a regulatory protein which modulates the content of flavonols and PA in Arabidopsis seeds.	Protactinium	101-103	Homeodomain-like superfamily protein	Arabidopsis thaliana	27-31
20109516-11	2010	Based on the observation that the autoacetylated CR was a stable intermediate in the CRTAase catalyzed protein acetylation by PA, a putative mechanism was proposed.	Protactinium	126-128	calreticulin	Homo sapiens	49-51
20952056-5	2010	Our results show that in PA the amount of uterine natural killer (uNK) cells is significantly reduced (0.2 uNK cell/standardised area) as compared to CP (9.8 uNK cell/standardised area, p &lt; 0.001) whereas the number of trophoblast cells and the expression of HLA-G by trophoblast are similar in the decidua of PA and CP.	Protactinium	25-27	major histocompatibility complex, class I, G	Homo sapiens	262-267
20694540-2	2010	The aim of this study, therefore, is to investigate the signal transduction of VIP in the relaxation of isolated rat PA rings.	Protactinium	117-119	vasoactive intestinal peptide	Rattus norvegicus	79-82
20694540-6	2010	Inhibition of the endothelial nitric oxide synthase (eNOS) by NG-nitro-L-arginine methyl ester diminished the VIP-induced vasodilatation of PA rings.	Protactinium	140-142	vasoactive intestinal peptide	Rattus norvegicus	110-113
21030928-0	2010	Redo CABG for ACS via the left thoracotomy using the PAS-port system to the descending thoracic aorta: a case report.	Protactinium	53-56	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	14-17
20606076-6	2010	At a fixed concentration of 0.5 mM, PA markedly inhibited acetylcholine-stimulated insulin release, the rise of intracellular Ca(2+), and enhancement of cAMP production but did not influence the effects of GLP-1 on these parameters of islet cell function.	Protactinium	36-38	zinc finger, GATA-like protein 1	Mus musculus	206-211
22654787-8	2010	In the PA group, TNF-alpha concentration was not associated with metabolic-endocrine features, but high IL-6 was associated with lower birth weight.	Protactinium	7-9	tumor necrosis factor	Homo sapiens	17-26
22654787-10	2010	In conclusion, PA was associated with increased serum TNF-alpha concentrations which, unexpectedly, were not connected with BMI or insulin resistance.	Protactinium	15-17	tumor necrosis factor	Homo sapiens	54-63
20797910-5	2010	Lung tissues of Nrf2(-/-) mice after DEP exposure showed inflammatory cell infiltrates, and increased PAS staining-positive mucus cell hyperplasia.	Protactinium	102-105	nuclear factor, erythroid derived 2, like 2	Mus musculus	16-20
20876142-4	2010	Here we show that recruitment of the yeast lipin (Pah1p) is regulated by PA levels onto the nuclear/endoplasmic reticulum (ER) membrane.	Protactinium	73-75	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	50-55
20538018-5	2010	The PA infection group showed significantly higher mean levels of both IgG and IgA class antibodies than the PA colonization group, non-PA infection group and healthy controls (each, p&lt;0.0001).	Protactinium	4-6	CD79a molecule	Homo sapiens	79-82
20538018-6	2010	In receiver operating characteristic (ROC) curves analysis to differentiate between total PA infections and the PA colonization group, the area under curve (AUC) of the IgA antibody (0.848) was significantly larger than the AUC of the IgG antibody (0.677) (p=0.019).	Protactinium	90-92	CD79a molecule	Homo sapiens	169-172
20055685-13	2010	The HMGA2 staining in 50% of PAs suggests that it may be more frequently involved in PAs than previously thought based on cytogenetic studies, at least in children.	Protactinium	29-32	high mobility group AT-hook 2	Homo sapiens	4-9
20055685-13	2010	The HMGA2 staining in 50% of PAs suggests that it may be more frequently involved in PAs than previously thought based on cytogenetic studies, at least in children.	Protactinium	85-88	high mobility group AT-hook 2	Homo sapiens	4-9
20206165-5	2010	Animals subjected to PA and treated with vehicle showed an increased astrogliosis, focal swelling and fragmented appearance of MAP-2 immunoreactive dendrites, decreased MAP-2 immunoreactivity and decreased phosphorylation of high and medium molecular weight neurofilaments in the hippocampus, compared to control animals.	Protactinium	21-23	microtubule-associated protein 2	Rattus norvegicus	127-132
20666392-4	2010	CLOCK comprises two PAS domains, each with a heme binding site.	Protactinium	20-23	clock circadian regulator	Homo sapiens	0-5
20712259-15	2010	CONCLUSION: Obese women with a low PA tertile have high fat mass with a secondary high level of glucose, HOMA, IL-6 and leptin.	Protactinium	35-37	interleukin 6	Homo sapiens	111-115
20619377-4	2010	Newborn mice primed with a single dose of Ty21a(PA) exhibited high frequencies of mucosal IgA-secreting B cells and IFN-gamma-secreting T cells during the neonatal period, none of which was detected in newborns immunized with a single dose of PA-alum.	Protactinium	48-50	interferon gamma	Mus musculus	116-125
20694142-9	2010	CONCLUSIONS: We found that Slc1p utilized fatty acid (FA) 18:1 and FA 14:0 as substrates to synthesize corresponding PAs; moreover, it was probably the only acyltransferase responsible for acylation of saturated short-chain fatty acyls (12:0 and 10:0) in S. cerevisiae.	Protactinium	117-120	1-acylglycerol-3-phosphate O-acyltransferase SLC1	Saccharomyces cerevisiae S288C	27-32
20002660-7	2010	RESULTS: Mean itch intensity was significantly lower in VA (35.7 +/- 6.4) compared to NA (45.9 +/- 7.8) and PA (40.4 +/- 5.8) regarding the direct effect; and significantly lower in VA (34.3 +/- 7.1) and PA (37.8 +/- 5.6) compared to NA (44.6 +/- 6.2) regarding the preventive effect.	Protactinium	204-206	itchy E3 ubiquitin protein ligase	Homo sapiens	14-18
20943061-5	2010	The expression of the components of the PA system, including uPA, its type-1 and type-2 inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), was examined by Western blot in fibroblasts from patients affected by limited and diffuse forms of SSc.	Protactinium	40-42	serpin family E member 1	Homo sapiens	100-105
20943061-5	2010	The expression of the components of the PA system, including uPA, its type-1 and type-2 inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), was examined by Western blot in fibroblasts from patients affected by limited and diffuse forms of SSc.	Protactinium	40-42	serpin family B member 2	Homo sapiens	110-115
20943061-5	2010	The expression of the components of the PA system, including uPA, its type-1 and type-2 inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), was examined by Western blot in fibroblasts from patients affected by limited and diffuse forms of SSc.	Protactinium	40-42	plasminogen activator, urokinase receptor	Homo sapiens	135-139
20206165-5	2010	Animals subjected to PA and treated with vehicle showed an increased astrogliosis, focal swelling and fragmented appearance of MAP-2 immunoreactive dendrites, decreased MAP-2 immunoreactivity and decreased phosphorylation of high and medium molecular weight neurofilaments in the hippocampus, compared to control animals.	Protactinium	21-23	microtubule-associated protein 2	Rattus norvegicus	169-174
20363752-6	2010	Consequently, FluB PB1 harboring the PA-binding domain of FluA (PB1-AB) failed to assemble with PA and PB2 into an active polymerase complex.	Protactinium	37-39	submaxillary gland androgen regulated protein 3A	Homo sapiens	19-22
20363752-2	2010	Inefficient polymerase assembly of the three polymerase subunits may contribute to this incompatibility, especially because the known protein-protein interaction domains, including the PA-binding domain of PB1, are highly conserved for each virus type.	Protactinium	185-187	submaxillary gland androgen regulated protein 3A	Homo sapiens	206-209
20363752-6	2010	Consequently, FluB PB1 harboring the PA-binding domain of FluA (PB1-AB) failed to assemble with PA and PB2 into an active polymerase complex.	Protactinium	37-39	submaxillary gland androgen regulated protein 3A	Homo sapiens	64-67
20363752-4	2010	Consistent with these findings, surface plasmon resonance spectroscopy measurements revealed that PA of FluA exhibits impaired affinity to biotinylated PB1-B(1-25) peptides.	Protactinium	98-100	submaxillary gland androgen regulated protein 3A	Homo sapiens	152-155
20363752-6	2010	Consequently, FluB PB1 harboring the PA-binding domain of FluA (PB1-AB) failed to assemble with PA and PB2 into an active polymerase complex.	Protactinium	96-98	submaxillary gland androgen regulated protein 3A	Homo sapiens	19-22
20228837-8	2010	In conclusion, this study showed that the involvement of the mannose-mediated EGFR pathway has a critical function in the preclinical rationale for the development of PA-MSHA for the treatment of human breast cancer.	Protactinium	167-169	epidermal growth factor receptor	Homo sapiens	78-82
20147842-3	2010	Platelet-derived growth factor (PDGF) produced in the hypoxic PA wall promotes CREB proteasomal degradation in SMCs via phosphatidylinositol-3-kinase/Akt signaling, which promotes phosphorylation of CREB at 2 casein kinase 2 (CK2) sites.	Protactinium	62-64	cAMP responsive element binding protein 1	Rattus norvegicus	79-83
20303989-11	2010	PA relaxation in response to the ROCK inhibitor Y27632 (0.1 microM) was much higher in MCT-treated rats than in control rats.	Protactinium	0-2	Rho-associated coiled-coil containing protein kinase 2	Rattus norvegicus	33-37
20044755-6	2010	Neither 1p, 9p, and 10q nor 19q showed significant association with outcome in PAs, although p16 deletion was more common in PAs of the midbrain, brainstem, and spinal cord.	Protactinium	125-128	cyclin dependent kinase inhibitor 2A	Homo sapiens	93-96
22993559-6	2010	beta-catenin immunoreactivity was positive in 14 PAs (73.3%) and 14 malignant salivary gland tumors (82.4%).	Protactinium	49-52	catenin beta 1	Homo sapiens	0-12
22993559-7	2010	Four (28.6%) of the 14 beta-catenin-positive PAs showed clear beta-catenin immunoreactivity at the plasma membrane (membrane type), while 10 (71.4%) showed diffuse immunoreactivity in the cytoplasm and nucleus but not at the plasma membrane (non-membrane type).	Protactinium	45-48	catenin beta 1	Homo sapiens	23-35
22993559-7	2010	Four (28.6%) of the 14 beta-catenin-positive PAs showed clear beta-catenin immunoreactivity at the plasma membrane (membrane type), while 10 (71.4%) showed diffuse immunoreactivity in the cytoplasm and nucleus but not at the plasma membrane (non-membrane type).	Protactinium	45-48	catenin beta 1	Homo sapiens	62-74
22993559-10	2010	PAs with non-membrane-type beta-catenin expression showed a significantly higher Ki67 labeling index than PAs with negative or membrane-type expression.	Protactinium	0-3	catenin beta 1	Homo sapiens	27-39
22993559-11	2010	Additionally, PAs that were REG Ialpha-positive showed a significantly higher Ki67 labeling index than those that were negative.	Protactinium	14-17	regenerating family member 1 alpha	Homo sapiens	28-31
20147842-12	2010	CONCLUSION: We conclude that thiazolidinediones prevent PA remodeling in part by suppressing upregulation of CK2 and loss of CREB in PA SMCs.	Protactinium	56-58	casein kinase 2 beta	Rattus norvegicus	109-112
20123711-4	2010	We therefore tested the hypothesis that activation of NKT cells with the CD1d ligand (alpha-galactosylceramide [alpha-GC]) at the time of immunization improves PA-specific Ab responses.	Protactinium	160-162	CD1d1 antigen	Mus musculus	73-77
20459507-6	2010	There was also a significant correlation between the amplitudes of the first PA signal peaks and densities of CD31-positive cells evaluated from histology with immunohistochemical staining (R=0.859, p&lt;0.05).	Protactinium	77-79	platelet and endothelial cell adhesion molecule 1	Rattus norvegicus	110-114
20123711-6	2010	In CD1d(-/-) mice deficient in type I and type II NKT cells the anti-PA Ab response was diminished.	Protactinium	69-71	CD1d1 antigen	Mus musculus	3-7
19952305-5	2010	Over 40% of labeled anti-GPA scFv/PA injected in mice bound to RBC, which markedly prolonged its intravascular circulation and fibrinolytic activity compared with its nontargeted PA counterpart, anti-GPA scFv/PA, but not its nontargeted PA analog, prevented thrombotic occlusion in FeCl(3) models of vascular injury.	Protactinium	26-28	immunglobulin heavy chain variable region	Homo sapiens	29-33
20110350-3	2010	Using photoactivation, we measured the movement of PA-GFP-TPX2 in the mitotic spindle.	Protactinium	51-53	TPX2 microtubule nucleation factor	Homo sapiens	58-62
20196107-6	2010	In this order of potency, the PDE inhibitors Sildenafil (PDE5) &gt; EHNA (PDE2) &gt; Rolipram (PDE4) &gt; Cilostamide (PDE3) all dilated isolated third generation PA after pre-constriction with the thromboxane analog U46619.	Protactinium	163-165	phosphodiesterase 2A	Rattus norvegicus	30-33
20074245-6	2010	For cranial defect implantation, the serum alkaline phosphatase level was remarkably higher in nAg-HA-TiO(2)/PA group than that in e-PTFE group.	Protactinium	109-111	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	95-98
20074245-9	2010	CONCLUSION: nAg-HA-TiO(2)/PA membranes demonstrated better biocompatibility and similar osteoinductive activity compared with e-PTFE membranes.	Protactinium	26-28	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	12-15
20074245-10	2010	nAg-HA-TiO(2)/PA composite membranes provided a good prospect for further research and development in anti-bacterial GBR membrane.	Protactinium	14-16	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	0-3
19857911-6	2010	However, transcript levels of PM-H(+)-ATPase CsHA2 and V-ATPase subunit A and c in roots treated with 50 microM PAs were similar to those in the control.	Protactinium	112-115	plasma membrane ATPase 4	Cucumis sativus	45-50
19952305-5	2010	Over 40% of labeled anti-GPA scFv/PA injected in mice bound to RBC, which markedly prolonged its intravascular circulation and fibrinolytic activity compared with its nontargeted PA counterpart, anti-GPA scFv/PA, but not its nontargeted PA analog, prevented thrombotic occlusion in FeCl(3) models of vascular injury.	Protactinium	34-36	immunglobulin heavy chain variable region	Homo sapiens	204-208
20032469-12	2010	Our data suggest that WNT-5a is necessary to maintain osteogenic potential of MSC and that inhibition of WNT-5a signaling therefore plays a role in their determination into PA in humans.	Protactinium	173-175	Wnt family member 5A	Homo sapiens	105-111
19690090-4	2009	In the present study, we chemically synthesized Galbeta1-4Fuc and Galbeta1-3Fuc labeled with 2-aminopyridine (PA) and demonstrated that LEC-6 interacts with PA-Galbeta1-4Fuc more strongly than PA-Galbeta1-3Fuc by frontal affinity chromatography (FAC).	Protactinium	110-112	Galectin	Caenorhabditis elegans	136-141
20039074-2	2010	The purpose of this study is to investigate PA, after adjusting for sex and age (standardized phase angle; SPA) as a prognostic factor for survival in cancer patients.	Protactinium	44-46	surfactant protein A2	Homo sapiens	107-110
20039074-10	2010	CONCLUSIONS: The present study demonstrates that PA, used as SPA, is an independent prognostic indicator in this group of cancer patients receiving chemotherapy treatment even after adjustment for other prognostic variables.	Protactinium	49-51	surfactant protein A2	Homo sapiens	61-64
19889962-9	2010	day(-1)) inhibited mRNA and protein expression of TRPC1 and TRPC6 in PA from chronically hypoxic (10% O2 for 21 days) rats, which was associated with decreased right ventricular pressure and right ventricular hypertrophy.	Protactinium	69-71	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	50-55
19889962-9	2010	day(-1)) inhibited mRNA and protein expression of TRPC1 and TRPC6 in PA from chronically hypoxic (10% O2 for 21 days) rats, which was associated with decreased right ventricular pressure and right ventricular hypertrophy.	Protactinium	69-71	transient receptor potential cation channel, subfamily C, member 6	Rattus norvegicus	60-65
20133666-4	2010	Growth factor release studies showed that passive release of TGFbeta-1 was slower from PA gels containing the growth factor binding sites.	Protactinium	87-89	transforming growth factor beta 1	Homo sapiens	61-70
20453465-5	2010	RESULTS: Girls with PA had lower serum AMH concentrations than their controls (2.65 vs. 3.43 ng/ml, p = 0.035).	Protactinium	20-22	anti-Mullerian hormone	Homo sapiens	39-42
19703971-4	2009	As expected, 1-F1 blocked PA"s ability to associate with CMG-2 in an in vitro solid-phase binding assay, and it protected murine macrophage cells from intoxication with LT. 2-B12 recognized a 12-mer peptide corresponding to residues 716 to 727, an epitope located immediately adjacent to the core 14B7 binding site and a stretch of amino acids not previously identified as a target of neutralizing antibodies.	Protactinium	26-28	anthrax toxin receptor 2	Mus musculus	57-62
19740899-5	2009	RESULTS: Serum AMH levels in early-treated PA females declined with age to levels that were significantly lower than those of normal (P &lt; or = 0.05) and late-treated PA females (P &lt; or = 0.025) by late-reproductive life.	Protactinium	43-45	anti-Mullerian hormone	Macaca mulatta	15-18
20063724-2	2009	Results showed that the PUF PAS mostly absorbed the 3-4 ring PAHs, which accounted for 91.22%-96.37% comparing to total concentration.	Protactinium	28-31	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	24-27
20063724-8	2009	The results of the study demonstrated the capability of PUF PAS to monitor atmospheric PAHs in a city scale at the same time.	Protactinium	60-63	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	56-59
19740899-2	2009	To determine whether androgen excess in utero affects follicle development over time, this study examines whether PA exposure, beginning at gestational days 40-44 (early treated) or 100-115 (late treated), alters the decline in serum anti-Mullerian hormone (AMH) levels with age in adult female rhesus monkeys and perturbs their ovarian response to recombinant human FSH (rhFSH) therapy for IVF.	Protactinium	114-116	anti-Mullerian hormone	Macaca mulatta	258-261
19841519-6	2009	It is also found that the RBM dose from mathematical models, i.e. CMP and ICRP 74, is underestimated by -30% in AP geometry and overestimated by 30% in PA geometry for low-energy photons.	Protactinium	152-154	RNA binding motif protein Y-linked family 2 member D, pseudogene	Homo sapiens	26-29
19720758-12	2009	Cross-reactive B-cell epitopes in the PA-binding domains of whole rLF and rEF occur and have been identified; however, the major anthrax toxin-neutralizing humoral responses to these antigens are constituted by non-cross-reactive epitopes.	Protactinium	38-40	RLF zinc finger	Rattus norvegicus	66-69
19789208-12	2009	Total body fat mass, fat percent, serum PTH, and alkaline phosphatase concentrations were higher and 25-hydroxyvitamin D lower in the PA group.	Protactinium	134-136	parathyroid hormone	Homo sapiens	40-43
19789208-15	2009	LRP5 polymorphisms may contribute to bone mass accrual in prepubertal PA children.	Protactinium	70-72	LDL receptor related protein 5	Homo sapiens	0-4
19665604-3	2009	We show here that at 13 months of age, most Pw- or Pa-vaccinated children display Bordetella pertussis-specific T-cell responses, in addition to significant antibody levels, although a higher Th2/Th1 cytokine ratio remained in Pa recipients compared to Pw recipients.	Protactinium	51-53	negative elongation factor complex member C/D	Homo sapiens	196-199
19405149-5	2009	Here I analyze H2AX phosphorylation in immunostained testis sections comparing PAS/cresyl violet counterstained, noncounterstained, and immuno-fluorescence preparations and show several waves of H2AX phosphorylation/dephosphorylation coupled to various developmental phases of spermatogonia and spermatocytes as well as to spermatid differentiation.	Protactinium	79-82	H2A.X variant histone	Homo sapiens	15-19
19746964-6	2009	The RGDS-containing PA nanomatrix expressed significantly greater alkaline phosphatase activity, indicating the early promotion of osteogenic differentiation.	Protactinium	20-22	ral guanine nucleotide dissociation stimulator	Homo sapiens	4-8
19746964-7	2009	A progressive shift toward osteogenic morphology and positive staining for mineral deposition provided further confirmation of the RGDS-containing PA nanomatrix.	Protactinium	147-149	ral guanine nucleotide dissociation stimulator	Homo sapiens	131-135
19805099-5	2009	We present the first structural evidence for an explicit function of PA domains in proteases revealing a vital role in the homo-dimerization of SBT3 and in enzyme activation.	Protactinium	69-71	subtilisin-like protease	Solanum lycopersicum	144-148
19818712-6	2009	However, Rnt1-mediated termination can also enhance the usage of weak pA signals and thereby generate functional mRNA.	Protactinium	70-72	ribonuclease III	Saccharomyces cerevisiae S288C	9-13
19743443-5	2009	The fiber-based portable PA device may replace the conventional SLN(s) excision and histology-based staging.	Protactinium	25-27	sarcolipin	Mus musculus	64-67
19501189-9	2009	Reaction conditions changed the balance of lysophospholipase and transacylation activities, with addition of LPA/PA, pH&gt;8, and elevated temperature markedly increasing transacylation activity; this suggests that lysophospholipase/transacylation activities of cPLA2gamma may be regulated by various factors.	Protactinium	110-112	phospholipase A2 group IVA	Homo sapiens	215-232
19801837-8	2009	The increase in UCP-1 level in BAT of cold-stressed mice was further augmented by PA treatment.	Protactinium	82-84	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	16-21
19801837-9	2009	These results indicate that PA exhibited a thermogenic effect on hypothermia induced by cold stress in mice by additional upregulation of UCP-1 level in BAT, which was already enhanced by hypothermia, and that the active ingredients present in PA are non-alkaloidal low-molecular-weight compounds.	Protactinium	28-30	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	138-143
19304372-12	2009	The highest increment in PA resulted from a PCA3 assay cut-off threshold of 17, where a 5% gain in PA (from 0.68 to 0.73, p=0.04) was recorded.	Protactinium	25-27	prostate cancer associated 3	Homo sapiens	44-48
19304372-12	2009	The highest increment in PA resulted from a PCA3 assay cut-off threshold of 17, where a 5% gain in PA (from 0.68 to 0.73, p=0.04) was recorded.	Protactinium	99-101	prostate cancer associated 3	Homo sapiens	44-48
19304372-14	2009	CONCLUSIONS: PCA3 fulfills the criteria for a novel marker capable of increasing PA of multivariate biopsy models.	Protactinium	81-83	prostate cancer associated 3	Homo sapiens	13-17
19235910-4	2009	We used contingency tables and logistic regression to test for association between PA or either subtype and FcRL3 and other factors that have previously been associated with extraintestinal manifestations in CD.	Protactinium	83-85	Fc receptor like 3	Homo sapiens	108-113
19362059-10	2009	CONCLUSION: Discontinuing PA in patients with history of VUR is a safe practice and should be considered as a management option.	Protactinium	26-28	VUR	Homo sapiens	57-60
19250975-2	2009	In particular, the LPPs are normally considered to regulate signaling by the phospholipase D (PLD) pathway by converting phosphatidate (PA) to diacylglycerol (DAG).	Protactinium	136-138	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	77-92
19250975-2	2009	In particular, the LPPs are normally considered to regulate signaling by the phospholipase D (PLD) pathway by converting phosphatidate (PA) to diacylglycerol (DAG).	Protactinium	136-138	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	94-97
19250975-3	2009	LPP activities do modulate the accumulations of PA and DAG following PLD activation, but this could also involve an effect upstream of PLD activation.	Protactinium	48-50	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	69-72
19250975-5	2009	Consequently, the actions of the LPPs in metabolizing PA formed by PLD1 or PLD2 should depend on the access of this substrate to the active site of the LPPs.	Protactinium	54-56	phospholipase D1	Homo sapiens	67-71
19250975-5	2009	Consequently, the actions of the LPPs in metabolizing PA formed by PLD1 or PLD2 should depend on the access of this substrate to the active site of the LPPs.	Protactinium	54-56	phospholipase D2	Homo sapiens	75-79
19562671-12	2009	Furthermore, Dex-induced glycogen synthesis of PAS-positive HP14.5 cells was significantly inhibited by SFRP3.	Protactinium	47-50	frizzled related protein	Gallus gallus	104-109
19540883-3	2009	The N-glycan structure of beta3GnT2 was identified by glycoamidase A digestion, labeling with 2-aminopyridine (PA), and HPLC mapping.	Protactinium	111-113	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	26-35
19497595-2	2009	Our aim was to determine whether the obesity-associated variant at fat mass and obesity gene (FTO) is more frequent in PA subjects.	Protactinium	119-121	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	94-97
19497595-3	2009	Furthermore, we hypothesized that altered Wnt signaling due to genetic variants at transcription factor 7-like 2 (TCF7L2) could play a role in the polygenic pathogenesis of PA.	Protactinium	173-175	transcription factor 7 like 2	Homo sapiens	83-112
19497595-3	2009	Furthermore, we hypothesized that altered Wnt signaling due to genetic variants at transcription factor 7-like 2 (TCF7L2) could play a role in the polygenic pathogenesis of PA.	Protactinium	173-175	transcription factor 7 like 2	Homo sapiens	114-120
19497595-7	2009	However, the risk allele at TCF7L2 rs7903146 was more frequent in PA subjects than in controls when we restricted the analysis to the subjects with lower weight-for-height than the median of the PA subjects (weight-for-height &lt;108%, corresponding body mass index SD score &lt;0.79; difference in MAFs [95% confidence interval]: 0.12 [-0.001, 0.23]; P = .038).	Protactinium	66-68	transcription factor 7 like 2	Homo sapiens	28-34
19497595-9	2009	In conclusion, the minor variant at FTO rs9939609 seems to play no major role in the increased weight-for-height of PA subjects; but the risk allele at TCF7L2 rs7903146 may have a role in the pathogenesis of PA in lean subjects.	Protactinium	208-210	transcription factor 7 like 2	Homo sapiens	152-158
19950582-5	2009	The fluorensence intensities of bcl-2 in groups of NA-D and NA-S, PA-S and PA-D, FB1 and FB2 were 1.92+/-0.08 and 2.83+/-0.16 (P=0.028); 4.20+/-0.18 and 2.85+/-0.57 (P=0.001); 5.70+/-1.16 and 4.35+/-0.11 (P=0.001), respectively.	Protactinium	66-70	BCL2 apoptosis regulator	Homo sapiens	32-37
19660688-8	2009	The H-PVR patients also had lower PA compliance, systemic arterial compliance (by 47% and 20%, p &lt; 0.001 and p &lt; 0.03), and cardiac index.	Protactinium	34-36	PVR cell adhesion molecule	Homo sapiens	6-9
19517532-1	2009	We describe a method for studying quantitative changes in accessibility of surface lysine residues of the PB1 subunit of the influenza RNA polymerase as a result of association with the PA subunit to form a PB1-PA heterodimer.	Protactinium	186-188	polybromo 1	Homo sapiens	106-109
19443420-2	2009	The present study was undertaken to study the effects of CO2-pneumoperitoneum (CO2-PP) on atelectasis formation, arterial oxygenation, and arterial to end-tidal PCO2-gradient (Pa-E"(CO2)).	Protactinium	176-178	PCO2	Sus scrofa	161-165
19411194-5	2009	Interestingly, an N-terminally truncated AP-2alpha, lacking the activation domain but retaining the DNA binding and dimerization domains, stimulated PA to a level approaching that of full-length AP-2, suggesting that AP-2 overexpression stimulates PA activity by a mechanism involving derepression rather than activation, possibly by neutralizing an inhibitory effect of endogenous AP-2 or AP-2-like factors.	Protactinium	248-250	transcription factor AP-2 alpha	Homo sapiens	41-50
19411194-5	2009	Interestingly, an N-terminally truncated AP-2alpha, lacking the activation domain but retaining the DNA binding and dimerization domains, stimulated PA to a level approaching that of full-length AP-2, suggesting that AP-2 overexpression stimulates PA activity by a mechanism involving derepression rather than activation, possibly by neutralizing an inhibitory effect of endogenous AP-2 or AP-2-like factors.	Protactinium	248-250	transcription factor AP-2 alpha	Homo sapiens	41-45
19383527-1	2009	In this report we have identified for the first time a transacetylase (TAase) in a mesophilic fungi Starkeyomyces koorchalomoides catalyzing the transfer of acetyl group from polyphenolic acetate (PA) to a receptor protein glutathione S-transferase (GST).	Protactinium	197-199	glutathione S-transferase kappa 1	Homo sapiens	223-248
19383527-1	2009	In this report we have identified for the first time a transacetylase (TAase) in a mesophilic fungi Starkeyomyces koorchalomoides catalyzing the transfer of acetyl group from polyphenolic acetate (PA) to a receptor protein glutathione S-transferase (GST).	Protactinium	197-199	glutathione S-transferase kappa 1	Homo sapiens	250-253
19506027-4	2009	We show that PTB promotes both in vitro 3" end cleavage and polyadenylation and recruits directly the splicing factor hnRNP H to G-rich sequences associated with several pA signals.	Protactinium	170-172	polypyrimidine tract binding protein 1	Homo sapiens	13-16
19506027-4	2009	We show that PTB promotes both in vitro 3" end cleavage and polyadenylation and recruits directly the splicing factor hnRNP H to G-rich sequences associated with several pA signals.	Protactinium	170-172	heterogeneous nuclear ribonucleoprotein H2	Homo sapiens	118-125
19411194-0	2009	Overexpression of transcription factor AP-2 stimulates the PA promoter of the human uracil-DNA glycosylase (UNG) gene through a mechanism involving derepression.	Protactinium	59-61	transcription factor AP-2 alpha	Homo sapiens	39-43
19411194-0	2009	Overexpression of transcription factor AP-2 stimulates the PA promoter of the human uracil-DNA glycosylase (UNG) gene through a mechanism involving derepression.	Protactinium	59-61	uracil DNA glycosylase	Homo sapiens	84-106
19411194-0	2009	Overexpression of transcription factor AP-2 stimulates the PA promoter of the human uracil-DNA glycosylase (UNG) gene through a mechanism involving derepression.	Protactinium	59-61	uracil DNA glycosylase	Homo sapiens	108-111
19411194-5	2009	Interestingly, an N-terminally truncated AP-2alpha, lacking the activation domain but retaining the DNA binding and dimerization domains, stimulated PA to a level approaching that of full-length AP-2, suggesting that AP-2 overexpression stimulates PA activity by a mechanism involving derepression rather than activation, possibly by neutralizing an inhibitory effect of endogenous AP-2 or AP-2-like factors.	Protactinium	149-151	transcription factor AP-2 alpha	Homo sapiens	41-50
19411194-5	2009	Interestingly, an N-terminally truncated AP-2alpha, lacking the activation domain but retaining the DNA binding and dimerization domains, stimulated PA to a level approaching that of full-length AP-2, suggesting that AP-2 overexpression stimulates PA activity by a mechanism involving derepression rather than activation, possibly by neutralizing an inhibitory effect of endogenous AP-2 or AP-2-like factors.	Protactinium	149-151	transcription factor AP-2 alpha	Homo sapiens	41-45
19517532-1	2009	We describe a method for studying quantitative changes in accessibility of surface lysine residues of the PB1 subunit of the influenza RNA polymerase as a result of association with the PA subunit to form a PB1-PA heterodimer.	Protactinium	186-188	polybromo 1	Homo sapiens	207-210
19111582-7	2009	In line with this permanent complex formation, S100P pa colocalized with ezrin to plasma membrane protrusions of epithelial cells even in the absence of intracellular Ca2+ transients.	Protactinium	53-55	S100 calcium binding protein P	Homo sapiens	47-52
19230905-9	2009	Median serum IGF-1 concentration adjusted for both age and body mass index SDS was higher in the PA group (24 vs 19 nmol/L; P &lt; .031).	Protactinium	97-99	insulin like growth factor 1	Homo sapiens	13-18
20811101-8	2009	Significantly greater attachment and spreading of hMSCs were observed on ePCL nanofibers coated with PA-RGDS as compared to ePCL nanofibers coated with PA-S (no cell adhesive ligand) and uncoated ePCL nanofibers.	Protactinium	101-103	ral guanine nucleotide dissociation stimulator	Homo sapiens	104-108
19352387-2	2009	This study was conducted to determine patients" outcome according to the expressions of CXCR4, CXCR7 and HIF-1alpha after resection of PA.	Protactinium	135-137	C-X-C motif chemokine receptor 4	Homo sapiens	88-93
19352387-2	2009	This study was conducted to determine patients" outcome according to the expressions of CXCR4, CXCR7 and HIF-1alpha after resection of PA.	Protactinium	135-137	hypoxia inducible factor 1 subunit alpha	Homo sapiens	105-115
19346233-3	2009	CO2 elimination is dependent upon CO2 production and alveolar ventilation, which together determine Pa(CO2).	Protactinium	100-102	complement C2	Homo sapiens	0-3
19346233-8	2009	METHODS: We have developed a ratio, called the ventilatory ratio (VR), which compares actual measurements and predicted values of minute ventilation and Pa(CO2).	Protactinium	153-155	complement C2	Homo sapiens	156-159
18693051-10	2009	By Western blot and ELISA, IR and IGF-IR were detected in PA, dPA and mAD.	Protactinium	58-60	insulin like growth factor 1 receptor	Homo sapiens	34-40
18721193-2	2009	We hypothesized that genetic variation in low density lipoprotein (LDL) receptor-related protein 5 (LRP5), which is involved in Wnt signalling in the adrenal cortex and in cholesterol metabolism, plays a role in the pathogenesis of PA.	Protactinium	232-234	LDL receptor related protein 5	Homo sapiens	46-98
18721193-2	2009	We hypothesized that genetic variation in low density lipoprotein (LDL) receptor-related protein 5 (LRP5), which is involved in Wnt signalling in the adrenal cortex and in cholesterol metabolism, plays a role in the pathogenesis of PA.	Protactinium	232-234	LDL receptor related protein 5	Homo sapiens	100-104
19193801-2	2009	Previous studies have shown that PB1 serves as a core subunit to incorporate PA and PB2 into the polymerase complex by directly interacting with PA and PB2.	Protactinium	77-79	polybromo 1	Homo sapiens	33-36
19008650-3	2009	We found that addition of 50 ng/ml human recombinant leptin improved the rate of PA embryos reaching the blastocyst stage and increased the total cell number of blastocysts compared with the control group.	Protactinium	81-83	leptin	Homo sapiens	53-59
19085970-5	2009	Pa contained a remarkably high density of axons and axonal varicosities immunoreactive for serotonin (5-HT) and orexin/hypocretin (ORX), as well as a moderate density of fibers immunoreactive for corticotropin-releasing hormone (CRH).	Protactinium	0-2	corticoliberin	Macaca fascicularis	196-227
19637624-5	2009	Compared with the control, the levels of IL-2, IFN-gamma, IL-4, and IL-10 expression by splenic lymphocytes from mice immunized with pA and pEA were significantly increased.	Protactinium	133-135	interleukin 2	Mus musculus	41-45
19637624-5	2009	Compared with the control, the levels of IL-2, IFN-gamma, IL-4, and IL-10 expression by splenic lymphocytes from mice immunized with pA and pEA were significantly increased.	Protactinium	133-135	interferon gamma	Mus musculus	47-56
19637624-5	2009	Compared with the control, the levels of IL-2, IFN-gamma, IL-4, and IL-10 expression by splenic lymphocytes from mice immunized with pA and pEA were significantly increased.	Protactinium	133-135	interleukin 4	Mus musculus	58-62
19637624-5	2009	Compared with the control, the levels of IL-2, IFN-gamma, IL-4, and IL-10 expression by splenic lymphocytes from mice immunized with pA and pEA were significantly increased.	Protactinium	133-135	interleukin 10	Mus musculus	68-73
19189049-7	2009	According to the current model, binding of a putative ligand to the PAS domain disinhibits the kinase domain and activates PASKIN auto- and target phosphorylation.	Protactinium	68-71	PAS domain containing serine/threonine kinase	Mus musculus	123-129
19351365-3	2009	Expression of syndecan-1 was related to the histological subtype of tumors and, in the case of malignancy, to lower expression levels observed in AC (22.5%) than in PA (47.5%) or DA (77.5%) (P &lt; 0.05).	Protactinium	165-167	syndecan 1	Homo sapiens	14-24
19351365-4	2009	Syndecan-1 expression correlated inversely with Ki-67 proliferative index: the expression was lower in both types of ameloblastomas (1.5% in DA and 6.4% in PA) than in AC (41.2%; P &lt; 0.05).	Protactinium	156-158	syndecan 1	Homo sapiens	0-10
19082654-3	2009	The goals of this study were to validate two acute-phase proteins, haptoglobin and serum amyloid A (SAA), as biomarkers for PA and determine if the combination of haptoglobin, SAA, and CA 19-9 would improve PA diagnosis over CA 19-9 alone.	Protactinium	207-209	haptoglobin	Homo sapiens	163-174
19082654-14	2009	CONCLUSIONS: These data demonstrate that haptoglobin and SAA are useful for discriminating PA from benign conditions as well as healthy controls when used in a diagnostic screening panel.	Protactinium	91-93	haptoglobin	Homo sapiens	41-52
19082654-14	2009	CONCLUSIONS: These data demonstrate that haptoglobin and SAA are useful for discriminating PA from benign conditions as well as healthy controls when used in a diagnostic screening panel.	Protactinium	91-93	serum amyloid A1 cluster	Homo sapiens	57-60
18981294-7	2009	However, the majority (n=41; 82%) of the pa-tients carried monoallelic changes in TNFRSF13B.	Protactinium	41-43	TNF receptor superfamily member 13B	Homo sapiens	82-91
19196990-2	2009	The two PAS domains within ARNT, PAS-A and PAS-B, are essential for the formation of these complexes because they mediate protein-protein interactions via residues located on their beta-sheet surfaces.	Protactinium	8-11	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	27-31
19085970-5	2009	Pa contained a remarkably high density of axons and axonal varicosities immunoreactive for serotonin (5-HT) and orexin/hypocretin (ORX), as well as a moderate density of fibers immunoreactive for corticotropin-releasing hormone (CRH).	Protactinium	0-2	corticoliberin	Macaca fascicularis	229-232
19085970-7	2009	Pa-projecting neurons were localized in the same nuclei of the hypothalamus, amygdala, and midbrain as CRH neurons, although no double labeling was found.	Protactinium	0-2	corticoliberin	Macaca fascicularis	103-106
19085970-8	2009	The connections of Pa and its innervation by 5-HT, ORX, and CRH suggest that it may relay stress signals between the midbrain and hypothalamus with the accumbens nucleus, basal amygdala, and subgenual cortex as part of a circuit that manages stress and possibly stress-related psychopathologies.	Protactinium	19-21	corticoliberin	Macaca fascicularis	60-63
18940186-1	2009	The aryl hydrocarbon receptor (AhR) is an orphan receptor in the basic helix-loop-helix PAS family of transcriptional regulators.	Protactinium	88-91	aryl hydrocarbon receptor	Homo sapiens	4-29
18940186-1	2009	The aryl hydrocarbon receptor (AhR) is an orphan receptor in the basic helix-loop-helix PAS family of transcriptional regulators.	Protactinium	88-91	aryl hydrocarbon receptor	Homo sapiens	31-34
22495459-16	2009	The group resolved the crystal structure of the carboxyl-terminus of PA in complex with the aminoterminus of PB1 peptides for the first time.	Protactinium	69-71	polybromo 1	Homo sapiens	109-112
22495459-17	2009	This structure mode provides details for the interactions of PA and PB1, as well as the binding sites of PA and RNA.	Protactinium	61-63	polybromo 1	Homo sapiens	68-71
22495459-17	2009	This structure mode provides details for the interactions of PA and PB1, as well as the binding sites of PA and RNA.	Protactinium	105-107	polybromo 1	Homo sapiens	68-71
18990399-4	2009	Rheological measurements have shown that the complex viscosity,  eta( *) , of the I(1) phase is tremendously high ( approximately 10(7) Pas) and it increases with increasing oil concentration, attains a maximum value near the phase boundary, and then decreases drastically in the I(1)+O region.	Protactinium	136-139	endothelin receptor type A	Homo sapiens	65-68
19129502-3	2009	Here, we describe crystal structures of the heterodimer formed by the C-terminal PAS domains from the HIF2alpha and ARNT subunits of the HIF2 transcription factor, both in the absence and presence of an artificial ligand.	Protactinium	81-84	endothelial PAS domain protein 1	Homo sapiens	102-111
19129502-3	2009	Here, we describe crystal structures of the heterodimer formed by the C-terminal PAS domains from the HIF2alpha and ARNT subunits of the HIF2 transcription factor, both in the absence and presence of an artificial ligand.	Protactinium	81-84	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	116-120
19953995-4	2009	Retardation of experimental mammary tumors growth caused by the inhibitors of PA biosynthesis was accompanied with decreased expression of protein products of the NF-kappaB-dependent genes such as c-myc, bcl-xl.	Protactinium	78-80	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	197-202
19059242-3	2009	Cytochrome c peroxidase activity and Trp59 fluorescence increase in the sequence of phosphatidyl choline (PC)--&gt;phosphatidylserine (PS)--&gt;cardiolipin (CL)--&gt;phosphatidic acid (PA).	Protactinium	185-187	cytochrome c, somatic	Homo sapiens	0-12
18999914-1	2009	Abstract In a risk/benefit analysis, currently the use of PAs used in women with a previous history of PTB appears to be worthwhile though the impact on the PTB rate may be minor since 80-90% of women who deliver preterm have no past history.	Protactinium	58-61	polypyrimidine tract binding protein 1	Homo sapiens	103-106
18999914-4	2009	The assessment of the use of PAs to prevent PTB should only relate to previous and subsequent SPTL and not to PTB due to fetomaternal indications.	Protactinium	29-32	polypyrimidine tract binding protein 1	Homo sapiens	44-47
19064121-8	2009	Correlation analysis showed TLR4 correlated well with the expression of MUC5AC (r = 0.684, p &lt;0.01) and AB/PAS-stained area (r = 0.781, p &lt;0.01).	Protactinium	110-113	toll-like receptor 4	Rattus norvegicus	28-32
18936178-4	2009	We found that cells expressing ANTXR1 splice variant 1 (ANTXR1-sv1) bound markedly less PA than did cells expressing a similar level of the shorter splice variant ANTXR1-sv2.	Protactinium	88-90	ANTXR cell adhesion molecule 1	Homo sapiens	31-37
18936178-4	2009	We found that cells expressing ANTXR1 splice variant 1 (ANTXR1-sv1) bound markedly less PA than did cells expressing a similar level of the shorter splice variant ANTXR1-sv2.	Protactinium	88-90	ANTXR cell adhesion molecule 1	Homo sapiens	56-62
18936178-4	2009	We found that cells expressing ANTXR1 splice variant 1 (ANTXR1-sv1) bound markedly less PA than did cells expressing a similar level of the shorter splice variant ANTXR1-sv2.	Protactinium	88-90	ANTXR cell adhesion molecule 1	Homo sapiens	56-62
18936178-6	2009	Introduction of a cytoplasmic domain missense mutation found in the related receptor ANTXR2 in a patient with juvenile hyaline fibromatosis impaired actin association and increased binding of PA to ANTXR1-sv1.	Protactinium	192-194	ANTXR cell adhesion molecule 2	Homo sapiens	85-91
18936178-6	2009	Introduction of a cytoplasmic domain missense mutation found in the related receptor ANTXR2 in a patient with juvenile hyaline fibromatosis impaired actin association and increased binding of PA to ANTXR1-sv1.	Protactinium	192-194	ANTXR cell adhesion molecule 1	Homo sapiens	198-204
19953995-4	2009	Retardation of experimental mammary tumors growth caused by the inhibitors of PA biosynthesis was accompanied with decreased expression of protein products of the NF-kappaB-dependent genes such as c-myc, bcl-xl.	Protactinium	78-80	BCL2 like 1	Homo sapiens	204-210
19953995-5	2009	It was hypothesized that under PA depletion not classic NF-kappaB (p50/p65 heterodimer) but p50/p50 homodimer is mainly created, and this homodimer, because of PA deficiency, is not able to promote transcription of the gene have been tested.	Protactinium	31-33	nuclear factor kappa B subunit 1	Homo sapiens	67-70
19953995-5	2009	It was hypothesized that under PA depletion not classic NF-kappaB (p50/p65 heterodimer) but p50/p50 homodimer is mainly created, and this homodimer, because of PA deficiency, is not able to promote transcription of the gene have been tested.	Protactinium	31-33	RELA proto-oncogene, NF-kB subunit	Homo sapiens	71-74
19953995-5	2009	It was hypothesized that under PA depletion not classic NF-kappaB (p50/p65 heterodimer) but p50/p50 homodimer is mainly created, and this homodimer, because of PA deficiency, is not able to promote transcription of the gene have been tested.	Protactinium	31-33	nuclear factor kappa B subunit 1	Homo sapiens	92-95
19953995-5	2009	It was hypothesized that under PA depletion not classic NF-kappaB (p50/p65 heterodimer) but p50/p50 homodimer is mainly created, and this homodimer, because of PA deficiency, is not able to promote transcription of the gene have been tested.	Protactinium	31-33	nuclear factor kappa B subunit 1	Homo sapiens	92-95
19183802-2	2009	We studied the possibility that urine S100B measurement may identify which PA-affected infants are at risk of early postnatal death.	Protactinium	75-77	S100 calcium binding protein B	Homo sapiens	38-43
19172175-13	2009	Chronically elevated levels of PA in the PAH(enu2) mice were not protective against cancer.	Protactinium	31-33	phenylalanine hydroxylase	Mus musculus	41-44
19030597-3	2008	The most stable structures of monomers of NA and PA were characterized in detail experimentally by matrix-isolation spectroscopy and theoretically (at both the DFT(B3LYP)/6-311++G(d,p) and MP2/6-311++G(d,p) levels).	Protactinium	49-51	tryptase pseudogene 1	Homo sapiens	189-192
19080078-8	2008	The mucin level in the airway mucous membrane was detected by alcian blue(AB)/periodic acid-Schiff(PAS) method.	Protactinium	99-102	solute carrier family 13 member 2	Rattus norvegicus	4-9
18985756-4	2008	We find that initiation of pitx2 in LPM and lefty1 in midline depends on Southpaw, and that casanova (sox32) and two Nodal inhibitors, lefty1 and charon, have distinct roles upstream of PA wave initiation.	Protactinium	186-188	paired-like homeodomain 2	Danio rerio	27-32
18985756-4	2008	We find that initiation of pitx2 in LPM and lefty1 in midline depends on Southpaw, and that casanova (sox32) and two Nodal inhibitors, lefty1 and charon, have distinct roles upstream of PA wave initiation.	Protactinium	186-188	SRY-box transcription factor 32	Danio rerio	92-100
18985756-4	2008	We find that initiation of pitx2 in LPM and lefty1 in midline depends on Southpaw, and that casanova (sox32) and two Nodal inhibitors, lefty1 and charon, have distinct roles upstream of PA wave initiation.	Protactinium	186-188	SRY-box transcription factor 32	Danio rerio	102-107
18985756-4	2008	We find that initiation of pitx2 in LPM and lefty1 in midline depends on Southpaw, and that casanova (sox32) and two Nodal inhibitors, lefty1 and charon, have distinct roles upstream of PA wave initiation.	Protactinium	186-188	lefty1	Danio rerio	135-141
18985756-4	2008	We find that initiation of pitx2 in LPM and lefty1 in midline depends on Southpaw, and that casanova (sox32) and two Nodal inhibitors, lefty1 and charon, have distinct roles upstream of PA wave initiation.	Protactinium	186-188	DAN domain family, member 5	Danio rerio	146-152
18665793-7	2008	In the cell culture model, ameloblast-like cells (LS8) and primary EOE cells responded to the BRGD-PA nanostructures with enhanced proliferation and greater amelogenin, ameloblastin, and integrin expression levels.	Protactinium	99-101	ameloblastin	Mus musculus	169-181
19061381-3	2008	PA vascular activity is mediated through the low-density lipoprotein receptor (LRP).	Protactinium	0-2	low density lipoprotein receptor	Homo sapiens	45-77
18562088-3	2008	However, blocking the PA-induced up-regulation of p21 expression with siRNA did not alter PA-mediated changes in apoptosis and cell cycle, demonstrating that p21 is not responsible for the PA-induced effects.	Protactinium	22-24	cyclin dependent kinase inhibitor 1A	Homo sapiens	50-53
18664531-9	2008	At baseline, the PA group had a lower percentage of CD14+CD16+ monocytes and lower unstimulated production of TNF-alpha than the PI group.	Protactinium	17-19	CD14 molecule	Homo sapiens	52-56
18664531-9	2008	At baseline, the PA group had a lower percentage of CD14+CD16+ monocytes and lower unstimulated production of TNF-alpha than the PI group.	Protactinium	17-19	Fc gamma receptor IIIa	Homo sapiens	57-61
18664531-9	2008	At baseline, the PA group had a lower percentage of CD14+CD16+ monocytes and lower unstimulated production of TNF-alpha than the PI group.	Protactinium	17-19	tumor necrosis factor	Homo sapiens	110-119
18664531-12	2008	The PA group had significantly lower serum CRP than the PI group.	Protactinium	4-6	C-reactive protein	Homo sapiens	43-46
19061381-3	2008	PA vascular activity is mediated through the low-density lipoprotein receptor (LRP).	Protactinium	0-2	LDL receptor related protein 1	Homo sapiens	79-82
18532978-7	2008	In addition, overexpression of MYBL2 in seeds inhibited the biosynthesis of PAs.	Protactinium	76-79	MYB-like 2	Arabidopsis thaliana	31-36
18656438-3	2008	Under the conditions of high-performance liquid chromatography (HPLC) mapping established for pyridylamine (PA)-labeled Gn2 N-glycans, Gn1 glycans are not well retained on reversed-phase HPLC, making simultaneous analysis of Gn1 and Gn2 glycans problematic.	Protactinium	108-110	glycogenin 2	Homo sapiens	120-123
18656438-3	2008	Under the conditions of high-performance liquid chromatography (HPLC) mapping established for pyridylamine (PA)-labeled Gn2 N-glycans, Gn1 glycans are not well retained on reversed-phase HPLC, making simultaneous analysis of Gn1 and Gn2 glycans problematic.	Protactinium	108-110	glycogenin 1	Homo sapiens	135-138
18656438-3	2008	Under the conditions of high-performance liquid chromatography (HPLC) mapping established for pyridylamine (PA)-labeled Gn2 N-glycans, Gn1 glycans are not well retained on reversed-phase HPLC, making simultaneous analysis of Gn1 and Gn2 glycans problematic.	Protactinium	108-110	glycogenin 1	Homo sapiens	225-228
18656438-3	2008	Under the conditions of high-performance liquid chromatography (HPLC) mapping established for pyridylamine (PA)-labeled Gn2 N-glycans, Gn1 glycans are not well retained on reversed-phase HPLC, making simultaneous analysis of Gn1 and Gn2 glycans problematic.	Protactinium	108-110	glycogenin 2	Homo sapiens	233-236
18656438-7	2008	This HPLC, therefore, is a powerful method for identification of the structures of PA-labeled glycans, especially Gn1-type glycans, isolated from the cytosol of animal cells.	Protactinium	83-85	glycogenin 1	Homo sapiens	114-117
18596206-3	2008	Unexpectedly, PA alone, previously believed to only mediate entry of lethal factor or edema factor, was found to be toxic to CHO-TEM8 cells; cells treated with PA alone displayed reduced cell growth and decreased metabolic activity.	Protactinium	14-16	ANTXR cell adhesion molecule 1	Homo sapiens	129-133
18596206-4	2008	PA-treated cells swelled and became permeable to membrane-excluded dye, suggesting that PA formed cell surface pores on CHO-TEM8 cells.	Protactinium	0-2	ANTXR cell adhesion molecule 1	Homo sapiens	124-128
18596206-4	2008	PA-treated cells swelled and became permeable to membrane-excluded dye, suggesting that PA formed cell surface pores on CHO-TEM8 cells.	Protactinium	88-90	ANTXR cell adhesion molecule 1	Homo sapiens	124-128
18596206-5	2008	While CHO-CMG2 cells were not killed by wild-type PA, they were susceptible to the PA variant, F427A.	Protactinium	83-85	ANTXR cell adhesion molecule 2	Homo sapiens	10-14
18713730-3	2008	Using two-hybrid technology to screen for proteins that bound the PA domain we identified CD151, a member of the tetraspanin family of membrane proteins.	Protactinium	66-68	CD151 molecule (Raph blood group)	Homo sapiens	90-95
18657841-2	2008	The heterotrimeric polymerase complex forms through PA interacting with PB1 and PB1 interacting with PB2.	Protactinium	52-54	polybromo 1	Homo sapiens	72-75
18657841-2	2008	The heterotrimeric polymerase complex forms through PA interacting with PB1 and PB1 interacting with PB2.	Protactinium	52-54	polybromo 1	Homo sapiens	80-83
18657841-8	2008	Protease treatment of PA-PB1 complex indicated that its PA subunit was significantly more stable than free PA, suggesting that the linker is protected and it constitutes an essential component of the PA-PB1 interface.	Protactinium	22-24	polybromo 1	Homo sapiens	25-28
18657841-8	2008	Protease treatment of PA-PB1 complex indicated that its PA subunit was significantly more stable than free PA, suggesting that the linker is protected and it constitutes an essential component of the PA-PB1 interface.	Protactinium	22-24	polybromo 1	Homo sapiens	203-206
18727145-4	2008	We tagged two yeast proteins, Erg6p and Num1p, with PA-GFP and demonstrated specific photoactivation of the fusion proteins in live cells.	Protactinium	52-54	sterol 24-C-methyltransferase	Saccharomyces cerevisiae S288C	30-35
18727145-4	2008	We tagged two yeast proteins, Erg6p and Num1p, with PA-GFP and demonstrated specific photoactivation of the fusion proteins in live cells.	Protactinium	52-54	Num1p	Saccharomyces cerevisiae S288C	40-45
18615018-6	2008	Here we report the 2.9 angstrom structure of avian H5N1 influenza A virus PA (PA(C), residues 257-716) in complex with the PA-binding region of PB1 (PB1(N), residues 1-25).	Protactinium	74-76	polybromo 1	Homo sapiens	144-147
18615018-6	2008	Here we report the 2.9 angstrom structure of avian H5N1 influenza A virus PA (PA(C), residues 257-716) in complex with the PA-binding region of PB1 (PB1(N), residues 1-25).	Protactinium	74-76	polybromo 1	Homo sapiens	149-152
18583709-6	2008	Incubating control myocytes with high glucose and palmitic acid (Glu+PA) also increased the phosphorylation of Hsp25, PKCdelta, and PKD in a pattern similar to that seen with diabetes, in addition to augmenting LPL activity.	Protactinium	69-71	heat shock protein family B (small) member 1	Homo sapiens	111-116
18660801-9	2008	The carboxy-terminal domain of PA forms a novel fold, and forms a deep, highly hydrophobic groove into which the amino-terminal residues of PB1 can fit by forming a 3(10) helix.	Protactinium	31-33	polybromo 1	Homo sapiens	140-143
18260106-8	2008	Far-UV CD studies of apo-alpha-PA revealed hallmarks of cold denaturation of the protein at temperatures below 20 degrees C. Moreover, a cooperative thermal denaturation transition with mid-temperature at 10-15 degrees C is revealed by near-UV CD for both PAs.	Protactinium	256-259	aminopeptidase O (putative)	Homo sapiens	21-24
18260106-8	2008	Far-UV CD studies of apo-alpha-PA revealed hallmarks of cold denaturation of the protein at temperatures below 20 degrees C. Moreover, a cooperative thermal denaturation transition with mid-temperature at 10-15 degrees C is revealed by near-UV CD for both PAs.	Protactinium	256-259	parvalbumin	Homo sapiens	31-33
18506539-13	2008	Increased expression of HDAC7 discriminates PA from other pancreatic tumors.	Protactinium	44-46	histone deacetylase 7	Homo sapiens	24-29
18701478-4	2008	In the present work, we isolated PAs able to interact more efficiently with p53 conformational mutants compared with wild-type p53.	Protactinium	33-36	tumor protein p53	Homo sapiens	76-79
18701478-4	2008	In the present work, we isolated PAs able to interact more efficiently with p53 conformational mutants compared with wild-type p53.	Protactinium	33-36	tumor protein p53	Homo sapiens	127-130
18583709-6	2008	Incubating control myocytes with high glucose and palmitic acid (Glu+PA) also increased the phosphorylation of Hsp25, PKCdelta, and PKD in a pattern similar to that seen with diabetes, in addition to augmenting LPL activity.	Protactinium	69-71	protein kinase C delta	Homo sapiens	118-126
18583709-6	2008	Incubating control myocytes with high glucose and palmitic acid (Glu+PA) also increased the phosphorylation of Hsp25, PKCdelta, and PKD in a pattern similar to that seen with diabetes, in addition to augmenting LPL activity.	Protactinium	69-71	protein kinase D1	Homo sapiens	132-135
18583709-6	2008	Incubating control myocytes with high glucose and palmitic acid (Glu+PA) also increased the phosphorylation of Hsp25, PKCdelta, and PKD in a pattern similar to that seen with diabetes, in addition to augmenting LPL activity.	Protactinium	69-71	lipoprotein lipase	Homo sapiens	211-214
18583709-7	2008	In myocytes in which PKD was silenced or a mutant form of PKCdelta was expressed, high Glu+PA were incapable of increasing LPL.	Protactinium	91-93	protein kinase C delta	Homo sapiens	58-66
18325816-5	2008	Genetic analysis of the MAPT gene revealed an A0/A0 genotype, which has been repeatedly associated with the PSP phenotype, and might discriminate between PA and other gait disorders.	Protactinium	154-156	microtubule associated protein tau	Homo sapiens	24-28
18312545-5	2008	On semiquantitative analysis, the number of Olig2-positive cells was significantly higher in PAs (mean labeling index (LI) +/- standard deviation (SD): 46.8+/-15.4%) than in DAs (13.3+/-7.8%) (P&lt;0.001).	Protactinium	93-96	oligodendrocyte transcription factor 2	Homo sapiens	44-49
18312545-6	2008	Many Iba1-positive, microglia/macrophages were observed in PAs (19.9+/-6.5%), similarly to DAs (20.9+/-9.9%).	Protactinium	59-62	allograft inflammatory factor 1	Homo sapiens	5-9
18718103-2	2008	It has been proved that PA produced by lysophosphatide acid acyltransferase (LPAATbeta) was involved in several signalling pathways in tumor cells, leading to the proliferation, apoptosis, migration, invasion, respiratory burst, expression and release of cytokine form tumor cells.	Protactinium	24-26	1-acylglycerol-3-phosphate O-acyltransferase 2	Homo sapiens	77-86
18384810-5	2008	Here, we show that the denaturing temperatures of both hen egg white lysozyme and ribonuclease A are sensitive to the PA of the PIL as much as they are to pH in aqueous solutions.	Protactinium	118-120	serpin family A member 2 (gene/pseudogene)	Homo sapiens	128-131
18374609-6	2008	Moreover, the protein expression level of full-length TrkB or synaptotagmin was positively correlated with PA performance in mice.	Protactinium	107-109	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	54-58
18374609-7	2008	Finally, inhibition of TrkB signaling by K252a abolished the exercise-facilitated PA performance and upregulation of TrkB and synaptotagmin.	Protactinium	82-84	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	23-27
18347032-6	2008	Stimulation of CD4(+) T cells by LFn fusion proteins does not require PA but is enhanced by PA in vitro.	Protactinium	92-94	CD4 antigen	Mus musculus	15-18
18285494-10	2008	Thus, DNA vaccines encoding CRT linked to PA(dIV) may dramatically enhance PA-specific protective antibody responses.	Protactinium	42-44	calreticulin	Homo sapiens	28-31
18292601-4	2008	We observed a dynamic expression pattern for crip2, with expression being detected in the premigratory NCCs in rhombomere 6 (r6), migrating NCCs, ventricular cardiomyocytes, and aortic vessels in PAs 3 to 6.	Protactinium	196-199	cysteine-rich protein 2	Danio rerio	45-50
18429831-6	2008	Mucin production was evident on PAS and colloid iron staining.	Protactinium	32-35	LOC100508689	Homo sapiens	0-5
18204848-11	2008	Our findings could explain tPA generation in wound epidermis is at least partially controlled by changes in local IL-1alpha activity, and will contribute to our understanding the physiological effects of IL-1alpha and TGF-beta1 as well as their interaction of with the PA system during skin wound healing.	Protactinium	28-30	interleukin 1 alpha	Mus musculus	114-123
18237545-4	2008	The SAA-enhanced PA-activity was inhibited by anti-SAA antibodies.	Protactinium	17-19	serum amyloid A1 cluster	Homo sapiens	4-7
18237545-4	2008	The SAA-enhanced PA-activity was inhibited by anti-SAA antibodies.	Protactinium	17-19	serum amyloid A1 cluster	Homo sapiens	51-54
18237545-5	2008	These antibodies also decreased the basal PA-activity of HT-29 cells and neutralized their cytokines (Interleukin-1beta+Interleukin-6)-enhanced PA-activity.	Protactinium	144-146	interleukin 1 beta	Homo sapiens	102-119
18237545-5	2008	These antibodies also decreased the basal PA-activity of HT-29 cells and neutralized their cytokines (Interleukin-1beta+Interleukin-6)-enhanced PA-activity.	Protactinium	144-146	interleukin 6	Homo sapiens	120-133
18237545-6	2008	Using specific chromogenic substrates and the fibrin clot-lysis assay, we found that SAA enhances also the PA-activity mediated by purified urokinase- and tissue-type plasminogen activators.	Protactinium	107-109	serum amyloid A1 cluster	Homo sapiens	85-88
18204848-11	2008	Our findings could explain tPA generation in wound epidermis is at least partially controlled by changes in local IL-1alpha activity, and will contribute to our understanding the physiological effects of IL-1alpha and TGF-beta1 as well as their interaction of with the PA system during skin wound healing.	Protactinium	28-30	interleukin 1 alpha	Mus musculus	204-213
18204848-11	2008	Our findings could explain tPA generation in wound epidermis is at least partially controlled by changes in local IL-1alpha activity, and will contribute to our understanding the physiological effects of IL-1alpha and TGF-beta1 as well as their interaction of with the PA system during skin wound healing.	Protactinium	28-30	transforming growth factor, beta 1	Mus musculus	218-227
18356748-6	2008	In children with PA, the polymorphism associated with higher baseline serum dehydroepiandrosterone (p = 0.03), androstenedione (p = 0.02), plasma ACTH (p = 0.03) levels and with lower birth weight (p = 0.02).	Protactinium	17-19	proopiomelanocortin	Homo sapiens	146-150
18387097-3	2008	Heat treatment (85 degrees C for 16 s) significantly (P &lt; 0.05) affected distribution of PG-594, tPA-647, and uPA-546, resulting in reduced concentrations of PG and PAs in the serum fractions and reciprocal increases in their levels in the nonsedimentable casein fractions.	Protactinium	168-171	plasminogen activator, urokinase	Bos taurus	113-116
18258655-4	2008	AB/PAS+ staining of Munc13-2-deficient airways was not caused by an inflammatory, metaplastic-like response: bronchial-alveolar lavage leucocyte numbers, Muc5ac and Muc5b mRNA levels, and Clara cell ultrastructure (except for increased secretory granule numbers) were all normal.	Protactinium	3-6	unc-13 homolog B	Mus musculus	20-28
18258655-6	2008	Munc13-2 therefore appears to prime a regulated, baseline secretory pathway, such that Clara cell Muc5b, normally secreted soon after synthesis, accumulates in the gene-deficient animals, making them stain AB/PAS+.	Protactinium	209-212	unc-13 homolog B	Mus musculus	0-8
18258655-6	2008	Munc13-2 therefore appears to prime a regulated, baseline secretory pathway, such that Clara cell Muc5b, normally secreted soon after synthesis, accumulates in the gene-deficient animals, making them stain AB/PAS+.	Protactinium	209-212	mucin 5, subtype B, tracheobronchial	Mus musculus	98-103
18166249-7	2008	Further analysis of PA- and EA1-vaccinated mice demonstrated antigen-specific type 1 helper responses including IFN-gamma secretion and lysis of EA1- or PA-loaded macrophages; further, an EA1 T-cell epitope was identified.	Protactinium	20-22	erythrocyte antigen 1	Mus musculus	145-148
18174188-2	2008	Here, we examined 4-alpha-glucanotransferase action of porcine liver GDE on four 6(4)-O-alpha-maltooligosyl-pyridylamino(PA)-maltooctaoses, in the presence or absence of an acceptor, maltohexaose.	Protactinium	121-123	amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase	Homo sapiens	69-72
17698214-5	2008	Furthermore, when an MMP-3 inhibitor was administered prior to PA training, dose-dependent learning deficits were observed, suggesting a causal relationship between learning-induced hippocampal MMP-3 elevation and associative memory formation.	Protactinium	63-65	matrix metallopeptidase 3	Rattus norvegicus	21-26
17698214-5	2008	Furthermore, when an MMP-3 inhibitor was administered prior to PA training, dose-dependent learning deficits were observed, suggesting a causal relationship between learning-induced hippocampal MMP-3 elevation and associative memory formation.	Protactinium	63-65	matrix metallopeptidase 3	Rattus norvegicus	194-199
17712799-6	2008	The proportion of positively stained nuclei at 50 and 60 hr after PA was higher for both H3K14ac (27.2% vs. 4.8% and 64.3% vs. 30%) and HMGN2 (47% vs. 21.3% and 60.6% vs. 46%) in early versus late cleaved embryos derived from small- versus large-follicles, respectively.	Protactinium	66-68	high mobility group nucleosomal binding domain 2	Bos taurus	136-141
18616166-2	2008	In this research, a pair of specific primers and a TaqMan fluorescent probe were designed in the conservative region of ETA gene by the method of bioinformatics analysis, the detection method for PA was successfully developed.	Protactinium	196-198	endothelin receptor type A	Homo sapiens	120-123
18355404-5	2008	When both the Per1 and Per2 genes are dysfunctional by targeted deletion of the PAS heterodimer binding domain, mice lose circadian organization of behaviour upon release into constant environmental conditions.	Protactinium	80-83	period circadian clock 2	Mus musculus	23-27
18166249-7	2008	Further analysis of PA- and EA1-vaccinated mice demonstrated antigen-specific type 1 helper responses including IFN-gamma secretion and lysis of EA1- or PA-loaded macrophages; further, an EA1 T-cell epitope was identified.	Protactinium	20-22	erythrocyte antigen 1	Mus musculus	145-148
18006275-8	2008	Lastly, if PLD2-Y179F is further mutated in residue K758 (PLD2 Y179F-K758R), which renders inactive a catalytic site, DNA synthesis is then abrogated, indicating that the activity of the enzyme (i.e. synthesis of PA) is necessary for the observed effects.	Protactinium	213-215	phospholipase D2	Homo sapiens	11-15
18415985-4	2008	CRTAase catalyzed the acetylation of a receptor protein nNOS, by a model PA 7, 8-diacetoxy-4-methylcoumarin (DAMC), which was visually confirmed by using antiacetyl lysine.	Protactinium	73-75	nitric oxide synthase 1	Homo sapiens	56-60
17905403-2	2008	Here, we demonstrate a differential requirement of the PA subunit for binding to the vRNA and cRNA promoters--specifically, PA is more important for binding to the cRNA than the vRNA promoter.	Protactinium	55-57	vault RNA 1-1	Homo sapiens	85-89
17905403-2	2008	Here, we demonstrate a differential requirement of the PA subunit for binding to the vRNA and cRNA promoters--specifically, PA is more important for binding to the cRNA than the vRNA promoter.	Protactinium	55-57	vault RNA 1-1	Homo sapiens	178-182
17905403-2	2008	Here, we demonstrate a differential requirement of the PA subunit for binding to the vRNA and cRNA promoters--specifically, PA is more important for binding to the cRNA than the vRNA promoter.	Protactinium	124-126	vault RNA 1-1	Homo sapiens	85-89
17905403-2	2008	Here, we demonstrate a differential requirement of the PA subunit for binding to the vRNA and cRNA promoters--specifically, PA is more important for binding to the cRNA than the vRNA promoter.	Protactinium	124-126	vault RNA 1-1	Homo sapiens	178-182
19055748-4	2008	In this study we aimed to determine if the activity of SNAI1 (a member of the Snail family) is correlated with expression of the PA system components and how this correlation can influence tumoural cell migration.	Protactinium	129-131	snail family transcriptional repressor 1	Homo sapiens	55-60
19055748-4	2008	In this study we aimed to determine if the activity of SNAI1 (a member of the Snail family) is correlated with expression of the PA system components and how this correlation can influence tumoural cell migration.	Protactinium	129-131	snail family transcriptional repressor 1	Homo sapiens	78-83
18006275-8	2008	Lastly, if PLD2-Y179F is further mutated in residue K758 (PLD2 Y179F-K758R), which renders inactive a catalytic site, DNA synthesis is then abrogated, indicating that the activity of the enzyme (i.e. synthesis of PA) is necessary for the observed effects.	Protactinium	213-215	phospholipase D2	Homo sapiens	58-62
18296965-6	2008	A significant positive correlation was observed between CSA and PA in both groups (r = 0.832, P &lt; 0.001, and r = 0.682, P &lt; 0.001, for bodybuilders and weightlifters, respectively).	Protactinium	64-66	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	56-59
17937422-8	2008	RESULTS: The only significant variations observed were in the TG levels after PA and PTH levels after both sonographic examination and PA.	Protactinium	135-137	parathyroid hormone	Homo sapiens	85-88
18569451-2	2008	Molecular analysis of one of these mutant lines, Clk1(dg3), revealed an I254N mutation in the PAS domain of the Clock1 protein.	Protactinium	94-97	clock circadian regulator a	Danio rerio	49-53
18569451-2	2008	Molecular analysis of one of these mutant lines, Clk1(dg3), revealed an I254N mutation in the PAS domain of the Clock1 protein.	Protactinium	94-97	clock circadian regulator a	Danio rerio	112-118
18303379-11	2008	DISCUSSION: A defined change of PA was detected by the VCC of the GDx and the instrument was able to reproduce the polarization parameters of the anterior segment and retinal nerve fiber layer parameters of the same eye in 2 different positions with adequate accuracy.	Protactinium	32-34	ubiquitin like 4A	Homo sapiens	66-69
18296965-7	2008	The F/CSA was negatively correlated to PA both for bodybuilders (r = -0.408, P &lt; 0.05) and weightlifters (r = -0.465, P &lt; 0.05).	Protactinium	39-41	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	6-9
18842184-7	2008	We found that eIF1A is activated at the two-cell stage in IVF embryos and at the four-cell stage in PA embryos.	Protactinium	100-102	eukaryotic translation initiation factor 1A X-linked	Homo sapiens	14-19
18991814-8	2008	CONCLUSION: HMG-CoA-reductase inhibitor atorvastatin more effectively lowers concentration of CRP in blood plasma of patients with PA than with IHD what possibly is explained by higher initial level of this marker of inflammatory processes.	Protactinium	131-133	C-reactive protein	Homo sapiens	94-97
17662312-8	2008	Additionally, increased RhoA activation in PA EC with adenoviral infection of RhoA caused an increase in PA EC chemotaxis to MIP-2 (46% increase; p&lt;0.05).	Protactinium	43-45	ras homolog family member A	Mus musculus	24-28
17662312-8	2008	Additionally, increased RhoA activation in PA EC with adenoviral infection of RhoA caused an increase in PA EC chemotaxis to MIP-2 (46% increase; p&lt;0.05).	Protactinium	43-45	ras homolog family member A	Mus musculus	78-82
17662312-8	2008	Additionally, increased RhoA activation in PA EC with adenoviral infection of RhoA caused an increase in PA EC chemotaxis to MIP-2 (46% increase; p&lt;0.05).	Protactinium	43-45	chemokine (C-X-C motif) ligand 2	Mus musculus	125-130
17662312-8	2008	Additionally, increased RhoA activation in PA EC with adenoviral infection of RhoA caused an increase in PA EC chemotaxis to MIP-2 (46% increase; p&lt;0.05).	Protactinium	105-107	ras homolog family member A	Mus musculus	24-28
17662312-8	2008	Additionally, increased RhoA activation in PA EC with adenoviral infection of RhoA caused an increase in PA EC chemotaxis to MIP-2 (46% increase; p&lt;0.05).	Protactinium	105-107	ras homolog family member A	Mus musculus	78-82
17662312-8	2008	Additionally, increased RhoA activation in PA EC with adenoviral infection of RhoA caused an increase in PA EC chemotaxis to MIP-2 (46% increase; p&lt;0.05).	Protactinium	105-107	chemokine (C-X-C motif) ligand 2	Mus musculus	125-130
18067864-4	2007	Overexpression of catalytically inactive PLD, treatment with PA, and prevention of PA dephosphorylation by 1-propranolol significantly suppressed PMA-induced Egr-1 expression.	Protactinium	61-63	early growth response 1	Homo sapiens	158-163
18067864-4	2007	Overexpression of catalytically inactive PLD, treatment with PA, and prevention of PA dephosphorylation by 1-propranolol significantly suppressed PMA-induced Egr-1 expression.	Protactinium	83-85	early growth response 1	Homo sapiens	158-163
17713822-9	2007	CONCLUSIONS: The rate of PA+ remains high after PCRT in patients treated for stage IB2/II cervical carcinoma.	Protactinium	25-28	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	83-86
17471499-4	2007	We also show that xHIF1alpha heterodimerizes with the Xenopus Arnt1 protein (xArnt1) with the proteic complex being mediated by the HLH and PAS domains.	Protactinium	140-143	hypoxia inducible factor 1 subunit alpha L homeolog	Xenopus laevis	18-28
17471499-4	2007	We also show that xHIF1alpha heterodimerizes with the Xenopus Arnt1 protein (xArnt1) with the proteic complex being mediated by the HLH and PAS domains.	Protactinium	140-143	aryl hydrocarbon receptor nuclear translocator S homeolog	Xenopus laevis	62-67
18093530-4	2007	In neonates, NPY could inhibit GABAergic inputs to nearly all NS and PA neurons, while melanocortin regulation was minimal.	Protactinium	69-71	neuropeptide Y	Homo sapiens	13-16
17548183-4	2007	After controlling for demographic factors and other covariates (age, gender, race, body mass index and white blood cell count), hierarchical regression analyses revealed an inverse association between trait PA and stimulated production of IL-6 (DeltaR(2)=.03, b=-.18, p &lt;.04) and IL-10 (DeltaR(2)=.09; b =-.32, p &lt;.01), with the latter association obtained only in men.	Protactinium	207-209	interleukin 6	Homo sapiens	239-243
17548183-4	2007	After controlling for demographic factors and other covariates (age, gender, race, body mass index and white blood cell count), hierarchical regression analyses revealed an inverse association between trait PA and stimulated production of IL-6 (DeltaR(2)=.03, b=-.18, p &lt;.04) and IL-10 (DeltaR(2)=.09; b =-.32, p &lt;.01), with the latter association obtained only in men.	Protactinium	207-209	interleukin 10	Homo sapiens	283-288
17604644-3	2007	SDS-PAGE analysis by PAS staining and Western blot analysis detected the product of the extracellular domain of human IL-13Ralpha2 as glycoprotein from P. pastoris.	Protactinium	21-24	interleukin 13 receptor subunit alpha 2	Homo sapiens	118-130
17724066-5	2007	The protease cleaved PA at the furin cleavage sequence because furin site-modified PA mutants were not cleaved.	Protactinium	21-23	furin (paired basic amino acid cleaving enzyme)	Mus musculus	31-36
17724066-5	2007	The protease cleaved PA at the furin cleavage sequence because furin site-modified PA mutants were not cleaved.	Protactinium	21-23	furin (paired basic amino acid cleaving enzyme)	Mus musculus	63-68
17724066-5	2007	The protease cleaved PA at the furin cleavage sequence because furin site-modified PA mutants were not cleaved.	Protactinium	83-85	furin (paired basic amino acid cleaving enzyme)	Mus musculus	63-68
17698912-8	2007	The weight-for-height adjusted serum insulin concentrations during the oral glucose tolerance test were elevated in the whole PA group, whereas the fasting insulin concentrations were increased and SHBG was decreased only in the PP-PA subgroup.	Protactinium	126-128	insulin	Homo sapiens	37-44
17698377-8	2007	With in situ hybridization, a stronger expression of CaCC1 mRNA was further detected throughout the bronchial tissues from patients with asthma than control subjects (P&lt;0.01); Samples from asthmatics were showed a stronger staining for MUC5AC than those in control subjects (P&lt;0.05); AB-PAS staining revealed more mucins and goblet cells in asthmatic bronchial epithelium and submucosal gland comparing to that in control subjects (P&lt;0.05).	Protactinium	293-296	chloride channel accessory 1	Homo sapiens	53-58
17944675-5	2007	RESULTS: All cases of PA expressed CK13, 14, and 19.	Protactinium	22-24	keratin 13	Homo sapiens	35-39
18201521-6	2007	CD34 immunohistochemical staining combined with PAS staining showed that the arcs and cells in the meshwork were stained positively with CD34 and were encircled by PAS positive extracellular matrix.	Protactinium	164-167	CD34 molecule	Homo sapiens	0-4
17901853-6	2007	CCND1 expression was also evaluated with an immunohistochemical method in tumor tissues of 39 patients of the PA group.	Protactinium	110-112	cyclin D1	Homo sapiens	0-5
17383807-10	2007	The addition of PSA significantly increased the multivariable PA of all models predicting pathologic stages over time (all p&lt;0.03), except for ECE predictions in the first quartile (p=0.1).	Protactinium	62-64	kallikrein related peptidase 3	Homo sapiens	16-19
18201521-8	2007	VEGF immunohistochemical staining combined with PAS staining showed that fibroblast-like cells in the network matrix were stained positively by VEGF and the septa of meshwork and extracellular matrices were stained positively by PAS.	Protactinium	229-232	vascular endothelial growth factor A	Homo sapiens	0-4
17595220-10	2007	We conclude that the impairment of glucose utilization after ANG stimulation is potentiated in leptin-resistant rats as a result of a hyperreactive PA axis, thereby confirming the functional importance of a dysregulation within the HPA axis in metabolic syndrome or obesity.	Protactinium	148-150	angiogenin	Rattus norvegicus	61-64
17590538-5	2007	Like the yeast DPP1 protein, both DPPL1 and DPPL2 proteins show broad substrate specificity, but DGPP is the preferred substrate compared with LPA and PA.	Protactinium	144-146	bifunctional diacylglycerol diphosphate phosphatase/phosphatidate phosphatase	Saccharomyces cerevisiae S288C	15-19
17590538-5	2007	Like the yeast DPP1 protein, both DPPL1 and DPPL2 proteins show broad substrate specificity, but DGPP is the preferred substrate compared with LPA and PA.	Protactinium	144-146	phospholipid phosphatase 5	Homo sapiens	34-39
17590538-5	2007	Like the yeast DPP1 protein, both DPPL1 and DPPL2 proteins show broad substrate specificity, but DGPP is the preferred substrate compared with LPA and PA.	Protactinium	144-146	phospholipid phosphatase 4	Homo sapiens	44-49
17540539-8	2007	Revealing that the PLD/PA pathway mediates survival of macrophages provides a potent strategy to inhibit P2X7R-mediated cytolysis by controlling PA metabolism.	Protactinium	23-25	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	19-22
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	Protactinium	92-94	Janus kinase 1	Homo sapiens	18-22
17592174-7	2007	The expression of CD25-alpha at the cell surface was increased by DHA, SA, and PA but was unaffected by EPA, OA, and LA.	Protactinium	79-81	interleukin 2 receptor subunit alpha	Homo sapiens	18-22
17636280-14	2007	Absence of IGFBP-1 and increase in PR reflect the PA effects of ZK230211.	Protactinium	50-52	progesterone receptor	Homo sapiens	35-37
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	Protactinium	92-94	Janus kinase 3	Homo sapiens	24-28
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	Protactinium	0-2	Janus kinase 1	Homo sapiens	31-35
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	Protactinium	0-2	Janus kinase 3	Homo sapiens	37-41
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	Protactinium	92-94	signal transducer and activator of transcription 5A	Homo sapiens	30-35
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	Protactinium	0-2	signal transducer and activator of transcription 5A	Homo sapiens	43-48
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	Protactinium	92-94	mitogen-activated protein kinase 3	Homo sapiens	37-43
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	Protactinium	0-2	AKT serine/threonine kinase 1	Homo sapiens	54-57
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	Protactinium	0-2	interleukin 2	Homo sapiens	85-89
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	Protactinium	92-94	AKT serine/threonine kinase 1	Homo sapiens	49-52
17592174-11	2007	In conclusion, the inhibitory effect of PA, SA, DHA, and EPA on lymphocyte proliferation observed in our previous study was attributable to a decrease in JAK/STAT, ERK, and Akt pathways activated by IL-2.	Protactinium	40-42	mitogen-activated protein kinase 1	Homo sapiens	164-167
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	Protactinium	92-94	interleukin 2 receptor subunit alpha	Homo sapiens	131-135
17592174-11	2007	In conclusion, the inhibitory effect of PA, SA, DHA, and EPA on lymphocyte proliferation observed in our previous study was attributable to a decrease in JAK/STAT, ERK, and Akt pathways activated by IL-2.	Protactinium	40-42	AKT serine/threonine kinase 1	Homo sapiens	173-176
17318890-5	2007	Patients with PA had significantly increased activities of all antioxidant enzymes, except CAT, and MDA concentration than did the controls.	Protactinium	14-16	catalase	Homo sapiens	91-94
17592174-11	2007	In conclusion, the inhibitory effect of PA, SA, DHA, and EPA on lymphocyte proliferation observed in our previous study was attributable to a decrease in JAK/STAT, ERK, and Akt pathways activated by IL-2.	Protactinium	40-42	interleukin 2	Homo sapiens	199-203
17610480-5	2007	Sodium dodecylsulfate-polyacrylamide gel electrophoresis of purified mucin on a 4-20% gradient gel showed PAS-positive material on the top of the running gel and a distinct smaller-sized species of mucin of higher electrophoretic mobility with background material in between the large and small mucin.	Protactinium	106-109	LOC100508689	Homo sapiens	69-74
17583356-7	2007	In addition, resistance PAs are unique in having mitochondria which dynamically alter production of reactive O(2) species (ROS) in proportion to PO(2), thereby regulating K(+) channel activity and controlling expression through transcription factors, such as HIF-1alpha.	Protactinium	24-27	hypoxia inducible factor 1 subunit alpha	Homo sapiens	259-269
21122293-11	2007	The survival time of pa-tients with negative MTA1 expression was (44.866+-12.946) months, which was significantly higher than that of patients with positive MTA1 expression [(23.714+-7.498) months] (Chi-square=10.006, P=0.002).	Protactinium	21-23	metastasis associated 1	Homo sapiens	45-49
17703668-3	2007	In this study, PA imaging of multiple targets using gold nanorods is demonstrated experimentally using HER2 and CXCR4 as target molecules.	Protactinium	15-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
17703668-3	2007	In this study, PA imaging of multiple targets using gold nanorods is demonstrated experimentally using HER2 and CXCR4 as target molecules.	Protactinium	15-17	C-X-C motif chemokine receptor 4	Homo sapiens	112-117
17477873-10	2007	Comparison of the 43 kDa H. akashiwo Tsg1 with bacterial sensor kinases showed that the algal protein exhibits a moderately maintained PAS motif in the sensor kinase domain as well as highly conserved H, N, G1 and F motifs within the histidine kinase ATP binding site.	Protactinium	135-138	ycf26	Heterosigma akashiwo	37-41
17432846-1	2007	A series of nine mixed-ligand metal-organic frameworks (MOFs) have been prepared by the combination of a bent dipyridyl linker 4-amino-3,5-bis(4-pyridyl)-1,2,4-triazole (bpt) and three benzenedicarboxylate isomers (pa = phthalate, ip = isophthalate, and tp = terephthalate), respectively, with different metal ions such as CoII, NiII, CuII, ZnII, and CdII.	Protactinium	75-77	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	323-327
17363273-7	2007	We determined average time constants of 51 s and 125 s for the decrease of fluorescence in the nucleus due to active bi-directional nuclear transport of pa-GFP-LCL1 and diffusion of pa-GFP, respectively.	Protactinium	153-155	LHY/CCA1-like 1	Arabidopsis thaliana	160-164
17471074-6	2007	Six patients who reported dream recall showed an intraoperative Pa latency less than that of patients who were unable to remember any dreams (P&lt;0.001).	Protactinium	64-66	potassium voltage-gated channel interacting protein 3	Homo sapiens	26-31
17142350-10	2007	Endogenous BMPR2 mRNA levels were greatest in resistance PAs, and expression declined with MCT PAH.	Protactinium	57-60	bone morphogenetic protein receptor type 2	Homo sapiens	11-16
17142350-3	2007	We hypothesized that overexpression of BMPR2 in resistance PAs would ameliorate established monocrotaline PAH.	Protactinium	59-62	bone morphogenetic protein receptor type 2	Homo sapiens	39-44
17195961-8	2007	PA, SA, DHA and EPA decreased the stimulatory effect of IL-2 on lymphocyte proliferation, increasing the percentage of cells in G1 phase and decreasing the proportion of cells in S and G2/M phases.	Protactinium	0-2	interleukin 2	Homo sapiens	56-60
17142350-12	2007	Nebulized intratracheal adenoviral gene therapy with hBMPR2 reliably distributed hBMPR2 to resistance PAs but did not ameliorate PAH.	Protactinium	102-105	bone morphogenetic protein receptor type 2	Homo sapiens	53-59
17337252-6	2007	This isoform contains a unique 22 amino acid residue in 3" end of PAS A domain as is also recognized in chicken ARNT.	Protactinium	66-69	aryl hydrocarbon receptor nuclear translocator	Gallus gallus	112-116
17189321-6	2007	Decreased PA remodeling in ROSI-treated animals was associated with decreased smooth muscle cell proliferation, decreased collagen and elastin deposition, and increased matrix metalloproteinase-2 activity in the PA wall.	Protactinium	10-12	matrix metallopeptidase 2	Rattus norvegicus	169-195
17189321-6	2007	Decreased PA remodeling in ROSI-treated animals was associated with decreased smooth muscle cell proliferation, decreased collagen and elastin deposition, and increased matrix metalloproteinase-2 activity in the PA wall.	Protactinium	212-214	matrix metallopeptidase 2	Rattus norvegicus	169-195
17306503-6	2007	PRINCIPAL CONCLUSIONS: Insulin resistance plays a mechanistic role in maintaining anovulation in a majority of PA female monkeys.	Protactinium	6-8	insulin	Macaca mulatta	23-30
17389524-13	2007	In contrast, when RGC-5 cells were treated with staurosporine along with inhibitors specific to tPA and uPA, proteolytic activities of both PAs were significantly reduced.	Protactinium	140-143	plasminogen activator, tissue	Mus musculus	96-99
17389524-13	2007	In contrast, when RGC-5 cells were treated with staurosporine along with inhibitors specific to tPA and uPA, proteolytic activities of both PAs were significantly reduced.	Protactinium	140-143	plasminogen activator, urokinase	Mus musculus	104-107
17215448-2	2007	Here, we studied the susceptibility of RBC/tPA to PA inhibitors including plasminogen activator inhibitor-1 (PAI-1) that constrain its activity and may reduce the duration of its effect.	Protactinium	44-46	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	74-107
17215448-2	2007	Here, we studied the susceptibility of RBC/tPA to PA inhibitors including plasminogen activator inhibitor-1 (PAI-1) that constrain its activity and may reduce the duration of its effect.	Protactinium	44-46	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	109-114
17341307-9	2007	In WT islets, PA treatment significantly increased UCP2 mRNA and protein expression.	Protactinium	14-16	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	51-55
17115977-7	2007	The discovery of two novel splice variants of BMAL2 confirms the crucial role of the PAS domain and further strengthens the view that co-dependent phosphorylation is of functional significance.	Protactinium	85-88	aryl hydrocarbon receptor nuclear translocator like 2	Homo sapiens	46-51
17341307-11	2007	PA treatment induced carnitine palmitoyltransferase I, acyl CoA oxidase and malonyl CoA decarboxylase mRNA in UCP2KO islets.	Protactinium	0-2	malonyl-CoA decarboxylase	Mus musculus	76-101
17341307-11	2007	PA treatment induced carnitine palmitoyltransferase I, acyl CoA oxidase and malonyl CoA decarboxylase mRNA in UCP2KO islets.	Protactinium	0-2	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	110-114
17341307-13	2007	Knockout of UCP2 protects beta-cells from PA exposure.	Protactinium	42-44	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	12-16
17335347-8	2007	Moreover, we observed efficient PA-mediated uptake into anthrax toxin receptor (ANTXR)-deficient Chinese hamster ovary cells (PR230) that had been stably engineered to express either human ANTXR1 or human ANTXR2 in the presence or absence of siRNA specific for LRP5 or LRP6.	Protactinium	32-34	ANTXR cell adhesion molecule 1	Homo sapiens	189-195
17320352-8	2007	In contrast, correlations between plasma alkaline phosphatase and plasma zinc, between E-MT and plasma zinc, and between E-SOD and E-Zn were observed only in the PA group (r &gt; or = 0.46, P &lt; 0.05).	Protactinium	162-164	superoxide dismutase 1	Homo sapiens	123-126
17543159-5	2007	RESULTS: The mean serum VEGF concentration in patients with active PA was 394.4 pg/ml (394 +/- 171.8), in patients with inactive PA 200.4 pg/ml (200.4 +/- 115.7), and in healthy subjects 214.3 pg/ml (214.3 +/- 162.1).	Protactinium	67-69	vascular endothelial growth factor A	Homo sapiens	24-28
17335347-8	2007	Moreover, we observed efficient PA-mediated uptake into anthrax toxin receptor (ANTXR)-deficient Chinese hamster ovary cells (PR230) that had been stably engineered to express either human ANTXR1 or human ANTXR2 in the presence or absence of siRNA specific for LRP5 or LRP6.	Protactinium	32-34	ANTXR cell adhesion molecule 2	Homo sapiens	205-211
17335347-8	2007	Moreover, we observed efficient PA-mediated uptake into anthrax toxin receptor (ANTXR)-deficient Chinese hamster ovary cells (PR230) that had been stably engineered to express either human ANTXR1 or human ANTXR2 in the presence or absence of siRNA specific for LRP5 or LRP6.	Protactinium	32-34	LDL receptor related protein 5	Homo sapiens	261-265
17335347-8	2007	Moreover, we observed efficient PA-mediated uptake into anthrax toxin receptor (ANTXR)-deficient Chinese hamster ovary cells (PR230) that had been stably engineered to express either human ANTXR1 or human ANTXR2 in the presence or absence of siRNA specific for LRP5 or LRP6.	Protactinium	32-34	LDL receptor related protein 6	Homo sapiens	269-273
17419216-8	2007	PAS staining showing a regularly red dying strap domain at the dermal-epidermal junction.	Protactinium	0-3	serine/threonine kinase receptor associated protein	Homo sapiens	43-48
17152080-6	2007	On the basis of this observation, we applied the PA method to a homology search of two orphan proteins, Latexin and Resuscitation-promoting factor domain.	Protactinium	49-51	latexin	Homo sapiens	104-111
17207881-7	2007	It was demonstrated that the injection of an aqueous solution of PA together with BMP-2 into the back subcutis of rats, resulted in the formation of a transparent 3-D hydrogel at the injected site and induced significant homogeneous ectopic bone formation around the injected site, in marked contrast to BMP-2 injection alone or PA injection alone.	Protactinium	65-67	bone morphogenetic protein 2	Rattus norvegicus	304-309
17207881-7	2007	It was demonstrated that the injection of an aqueous solution of PA together with BMP-2 into the back subcutis of rats, resulted in the formation of a transparent 3-D hydrogel at the injected site and induced significant homogeneous ectopic bone formation around the injected site, in marked contrast to BMP-2 injection alone or PA injection alone.	Protactinium	329-331	bone morphogenetic protein 2	Rattus norvegicus	82-87
17157401-3	2007	We describe an original algorithm which yields a high-quality PA filter and demonstrates how this tool can be used to improve the quality of P300 ERP measurements during event-related fMRI (e-fMRI) experiments.	Protactinium	62-64	E1A binding protein p300	Homo sapiens	141-145
17157401-8	2007	The PA removal procedure was optimised, and then implemented to improve the measured P300 components.	Protactinium	4-6	E1A binding protein p300	Homo sapiens	85-89
17056727-5	2007	We found that SP-A had a concentration-dependent effect on the surface activity of KL(4)-DPPC/POPG/PA membranes but not on that of an animal-derived LES.	Protactinium	99-101	surfactant protein A1	Homo sapiens	14-18
17056727-8	2007	This was due to the fluidizing effect of supraphysiological SP-A concentrations on KL(4)-DPPC/POPG/PA membranes as determined by fluorescence anisotropy measurements, calorimetric studies, and confocal fluorescence microscopy of GUVs.	Protactinium	99-101	surfactant protein A1	Homo sapiens	60-64
17284183-5	2007	PA (68%) and NE (67%) parvocellular neurons also depolarized in response to 10 nm PK2.	Protactinium	0-2	prokineticin 2	Rattus norvegicus	82-85
16466867-4	2007	The expression of PR was significantly lower in progesterone treated ewes than in the PA Group in the superficial gland (P&lt;0.05) in both days studied.	Protactinium	86-88	progesterone receptor	Ovis aries	18-20
17284183-6	2007	However, in contrast to MNC neurons, these effects were maintained in TTX, indicating that PK2 directly affects PA and NE neurons.	Protactinium	112-114	prokineticin 2	Rattus norvegicus	91-94
17284183-7	2007	PK2-induced depolarizations observed in PA and NE neurons were found to be concentration-related and receptor mediated, as experiments performed in the presence of A1MPK1 (a PK2 receptor antagonist) abolished the effects of PK2 on these subpopulations of neurons.	Protactinium	40-42	prokineticin 2	Rattus norvegicus	0-3
17284183-7	2007	PK2-induced depolarizations observed in PA and NE neurons were found to be concentration-related and receptor mediated, as experiments performed in the presence of A1MPK1 (a PK2 receptor antagonist) abolished the effects of PK2 on these subpopulations of neurons.	Protactinium	40-42	prokineticin 2	Rattus norvegicus	174-177
17284183-7	2007	PK2-induced depolarizations observed in PA and NE neurons were found to be concentration-related and receptor mediated, as experiments performed in the presence of A1MPK1 (a PK2 receptor antagonist) abolished the effects of PK2 on these subpopulations of neurons.	Protactinium	40-42	prokineticin 2	Rattus norvegicus	174-177
17621552-7	2007	Expression of hCLCA1 and MUC5AC mRNA and protein was quantified in human airways using real-time PCR and PAS staining.	Protactinium	105-108	chloride channel accessory 1	Homo sapiens	14-20
17594596-6	2007	RESULTS: KAT I and KAT II expression in CAm has been shown in the retina and optic nerve with similar location to PAS-stained sections.	Protactinium	114-117	kynurenine aminotransferase 1	Homo sapiens	9-14
17594596-6	2007	RESULTS: KAT I and KAT II expression in CAm has been shown in the retina and optic nerve with similar location to PAS-stained sections.	Protactinium	114-117	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	9-12
17621552-7	2007	Expression of hCLCA1 and MUC5AC mRNA and protein was quantified in human airways using real-time PCR and PAS staining.	Protactinium	105-108	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	25-31
17344660-6	2007	RESULTS: IL-8 mRNA levels were significantly increased in whole blood both during PA and PI, while MCP-1 mRNA levels were not.	Protactinium	82-84	C-X-C motif chemokine ligand 8	Homo sapiens	9-13
17023418-6	2006	The differential binding of AhR by Arnt and Arnt2 can be ascribed to a single His/Pro amino acid difference in the PASB region of Arnt and Arnt2, suggesting that the PASB/PASB interaction between bHLH-PAS transcription factors plays a selective role for their specific partner molecule.	Protactinium	115-118	aryl hydrocarbon receptor	Homo sapiens	28-31
17518577-9	2007	The combination of bFGF incorporated in a collagen sponge self-assembled PA nanofiber hybrid scaffold is a promising procedure to improve bone regeneration.	Protactinium	73-75	fibroblast growth factor 2	Rattus norvegicus	19-23
17023418-6	2006	The differential binding of AhR by Arnt and Arnt2 can be ascribed to a single His/Pro amino acid difference in the PASB region of Arnt and Arnt2, suggesting that the PASB/PASB interaction between bHLH-PAS transcription factors plays a selective role for their specific partner molecule.	Protactinium	115-118	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	35-39
17023418-6	2006	The differential binding of AhR by Arnt and Arnt2 can be ascribed to a single His/Pro amino acid difference in the PASB region of Arnt and Arnt2, suggesting that the PASB/PASB interaction between bHLH-PAS transcription factors plays a selective role for their specific partner molecule.	Protactinium	115-118	aryl hydrocarbon receptor nuclear translocator 2	Homo sapiens	44-49
17023418-6	2006	The differential binding of AhR by Arnt and Arnt2 can be ascribed to a single His/Pro amino acid difference in the PASB region of Arnt and Arnt2, suggesting that the PASB/PASB interaction between bHLH-PAS transcription factors plays a selective role for their specific partner molecule.	Protactinium	115-118	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	44-48
17023418-6	2006	The differential binding of AhR by Arnt and Arnt2 can be ascribed to a single His/Pro amino acid difference in the PASB region of Arnt and Arnt2, suggesting that the PASB/PASB interaction between bHLH-PAS transcription factors plays a selective role for their specific partner molecule.	Protactinium	115-118	aryl hydrocarbon receptor nuclear translocator 2	Homo sapiens	139-144
16930687-6	2006	When aqueous solution of PA was subcutaneously injected together with bFGF suspension into the back of mice, a transparent 3-D hydrogel was formed at the injected site and induced significant angiogenesis around the injected site, in marked contrast to bFGF injection alone or PA injection alone.	Protactinium	25-27	fibroblast growth factor 2	Mus musculus	253-257
16930687-6	2006	When aqueous solution of PA was subcutaneously injected together with bFGF suspension into the back of mice, a transparent 3-D hydrogel was formed at the injected site and induced significant angiogenesis around the injected site, in marked contrast to bFGF injection alone or PA injection alone.	Protactinium	277-279	fibroblast growth factor 2	Mus musculus	70-74
16762926-3	2006	We show that TEM8 functions as an adhesion molecule mediating cell spreading on immobilized PA and collagen I.	Protactinium	92-94	ANTXR cell adhesion molecule 1	Homo sapiens	13-17
17032197-5	2006	RESULTS: Our data revealed that both MUC4 and IFNgamma were expressed at moderate to high levels in the majority of PA, while being undetectable in NP.	Protactinium	116-118	mucin 4, cell surface associated	Homo sapiens	37-41
17032197-5	2006	RESULTS: Our data revealed that both MUC4 and IFNgamma were expressed at moderate to high levels in the majority of PA, while being undetectable in NP.	Protactinium	116-118	interferon gamma	Homo sapiens	46-54
17054395-3	2006	Since PA can bind to ANTXR2 with reduced affinity in the absence of metal ions, we reasoned that D683 mutant forms of PA might specifically interact with ANTXR2.	Protactinium	6-8	ANTXR cell adhesion molecule 2	Rattus norvegicus	21-27
17054395-3	2006	Since PA can bind to ANTXR2 with reduced affinity in the absence of metal ions, we reasoned that D683 mutant forms of PA might specifically interact with ANTXR2.	Protactinium	118-120	ANTXR cell adhesion molecule 2	Rattus norvegicus	154-160
17054395-6	2006	Moreover, a D683K mutant form of PA that bound specifically to human and rat ANTXR2 mediated killing of rats by anthrax lethal toxin, providing strong evidence for the physiological importance of ANTXR2 in anthrax disease pathogenesis.	Protactinium	33-35	ANTXR cell adhesion molecule 2	Rattus norvegicus	77-83
17054395-6	2006	Moreover, a D683K mutant form of PA that bound specifically to human and rat ANTXR2 mediated killing of rats by anthrax lethal toxin, providing strong evidence for the physiological importance of ANTXR2 in anthrax disease pathogenesis.	Protactinium	33-35	ANTXR cell adhesion molecule 2	Rattus norvegicus	196-202
16679379-6	2006	PAs also increased in diameter by 6-12% in the presence of VEGF (10 nM), and this increase was attenuated by DDMS.	Protactinium	0-3	vascular endothelial growth factor A	Bos taurus	59-63
16679379-10	2006	We conclude that CYP4/20-HETE contributes to VEGF-stimulated NO release and vasodilation in bovine PAs.	Protactinium	99-102	vascular endothelial growth factor A	Bos taurus	45-49
16798009-7	2006	The purified ATR/TEM8 VWA domain exhibits very high affinity to PA based on BIAcore assay.	Protactinium	64-66	ATR serine/threonine kinase	Homo sapiens	13-16
16798009-7	2006	The purified ATR/TEM8 VWA domain exhibits very high affinity to PA based on BIAcore assay.	Protactinium	64-66	ANTXR cell adhesion molecule 1	Homo sapiens	17-21
16968695-8	2006	The phosphorylation-deficient Pah1p exhibits higher PA phosphatase-specific activity than the wild-type Pah1p, indicating that phosphorylation of Pah1p controls PA production.	Protactinium	52-54	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	30-35
16968695-9	2006	Opi1p is a transcriptional repressor of phospholipid biosynthetic genes, responding to PA levels.	Protactinium	87-89	transcriptional regulator OPI1	Saccharomyces cerevisiae S288C	0-5
16956950-3	2006	Numerous independent rounds of selection repeatedly identified six single-amino-acid substitutions that independently confer PA-457 resistance: three at or near the C terminus of CA (CA-H226Y, -L231F, and -L231M) and three at the first and third residues of SP1 (SP1-A1V, -A3T, and -A3V).	Protactinium	125-127	Sp1 transcription factor	Homo sapiens	263-270
16820464-2	2006	Besides Km(r) as a selectable marker, the insertion element InsTet(G-)1 carries the anhydrotetracycline (atc)-regulated outward-directed PA promoter so that atc-dependent conditional gene knockouts or knockdowns are generated.	Protactinium	137-139	allograft inflammatory factor 1	Mus musculus	60-71
16600365-7	2006	When measured to evaluate the osteogenic differentiation of MSC, the alkaline phosphatase (ALP) activity and osteocalcin content became maximum for the PA nanofibers including RGD compared with those without RGD, although both the values were significantly higher compared with those in the static tissue culture plate (2-D culture).	Protactinium	152-154	bone gamma-carboxyglutamate protein	Rattus norvegicus	109-120
16882031-3	2006	In these experiments, PA-oligomers demonstrated an extended half-life in RAW 264.7ANTXR1 macrophages, with SDS-resistant heptamers detected up to 10 h following treatment, while levels of PA-oligomers declined within 3 h in control cells.	Protactinium	22-24	ANTXR cell adhesion molecule 1	Homo sapiens	82-88
16882031-6	2006	Further analysis found that PA cytotoxicity required direct interaction with ANTXR1, oligomerization, channel formation, endosomal acidification, and was independent of the ANTXR1 cytoplasmic tail.	Protactinium	28-30	ANTXR cell adhesion molecule 1	Homo sapiens	77-83
16882031-7	2006	PA intoxication of RAW 264.7ANTXR1 macrophages resulted in caspase-3 activation, with corresponding DNA fragmentation and proteolytic cleavage of poly-ADP-ribose polymerase, as well as activation of Bid, suggesting cell death occurred via apoptosis.	Protactinium	0-2	ANTXR cell adhesion molecule 1	Homo sapiens	28-34
16882031-7	2006	PA intoxication of RAW 264.7ANTXR1 macrophages resulted in caspase-3 activation, with corresponding DNA fragmentation and proteolytic cleavage of poly-ADP-ribose polymerase, as well as activation of Bid, suggesting cell death occurred via apoptosis.	Protactinium	0-2	caspase 3	Homo sapiens	59-68
16882031-7	2006	PA intoxication of RAW 264.7ANTXR1 macrophages resulted in caspase-3 activation, with corresponding DNA fragmentation and proteolytic cleavage of poly-ADP-ribose polymerase, as well as activation of Bid, suggesting cell death occurred via apoptosis.	Protactinium	0-2	poly(ADP-ribose) polymerase 1	Homo sapiens	146-172
16882031-7	2006	PA intoxication of RAW 264.7ANTXR1 macrophages resulted in caspase-3 activation, with corresponding DNA fragmentation and proteolytic cleavage of poly-ADP-ribose polymerase, as well as activation of Bid, suggesting cell death occurred via apoptosis.	Protactinium	0-2	BH3 interacting domain death agonist	Homo sapiens	199-202
16514548-6	2006	Immunohistochemical detection of mCLCA3 and PAS reactions on consecutive tissue sections identified a similar increase in mCLCA3 expressing goblet cells, suggesting that elevated mRNA copy numbers of mCLCA3 are due to goblet cell hyperplasia rather than transcriptional regulatory events.	Protactinium	44-47	chloride channel accessory 1	Mus musculus	122-128
16514548-6	2006	Immunohistochemical detection of mCLCA3 and PAS reactions on consecutive tissue sections identified a similar increase in mCLCA3 expressing goblet cells, suggesting that elevated mRNA copy numbers of mCLCA3 are due to goblet cell hyperplasia rather than transcriptional regulatory events.	Protactinium	44-47	chloride channel accessory 1	Mus musculus	122-128
16910479-12	2006	CONCLUSIONS: In laparoscopic colorectal surgery, Pa(CO2) should be checked for at least the first 60 minutes to confirm adequate ventilation.	Protactinium	49-51	complement C2	Homo sapiens	52-55
16995472-6	2006	RESULTS: The p53 gene mutation has been shown in 16 (61.5%) of the PA patients (9 in exon 5 and 7 in exon 7) and in 2 (8.6%) of CP patients (1 in exon 5 and 1 in exon 8; p &lt; 0.001).	Protactinium	67-69	tumor protein p53	Homo sapiens	13-16
16995451-0	2006	Expression of mucin-2 and correlation with PAS-alcian blue stain in Barrett"s esophagus.	Protactinium	43-46	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	14-21
16786106-14	2006	At a concentration of 10 nmol/L, NPY inhibited inward and outward I(Na/Ca) from (0.27+/-0.11) pA/pF and (0.45+/-0.12) pA/pF to (0.06+/-0.01) pA/pF and (0.27+/-0.09) pA/pF, respectively (P&lt;0.05, n=4).	Protactinium	94-96	neuropeptide Y	Rattus norvegicus	33-36
16756998-3	2006	Toxin assembly initiates when molecules of PA bind mammalian receptors ANTXR1/2 and are cleaved by surface proteases into 20 kDa and 63 kDa fragments.	Protactinium	43-45	ANTXR cell adhesion molecule 1	Homo sapiens	71-77
16786106-14	2006	At a concentration of 10 nmol/L, NPY inhibited inward and outward I(Na/Ca) from (0.27+/-0.11) pA/pF and (0.45+/-0.12) pA/pF to (0.06+/-0.01) pA/pF and (0.27+/-0.09) pA/pF, respectively (P&lt;0.05, n=4).	Protactinium	118-120	neuropeptide Y	Rattus norvegicus	33-36
16786106-14	2006	At a concentration of 10 nmol/L, NPY inhibited inward and outward I(Na/Ca) from (0.27+/-0.11) pA/pF and (0.45+/-0.12) pA/pF to (0.06+/-0.01) pA/pF and (0.27+/-0.09) pA/pF, respectively (P&lt;0.05, n=4).	Protactinium	118-120	neuropeptide Y	Rattus norvegicus	33-36
16786106-14	2006	At a concentration of 10 nmol/L, NPY inhibited inward and outward I(Na/Ca) from (0.27+/-0.11) pA/pF and (0.45+/-0.12) pA/pF to (0.06+/-0.01) pA/pF and (0.27+/-0.09) pA/pF, respectively (P&lt;0.05, n=4).	Protactinium	118-120	neuropeptide Y	Rattus norvegicus	33-36
16768407-3	2006	The RGDS cell adhesion epitope was used as a model bioactive signal on PA molecules for potential biomedical applications.	Protactinium	71-73	ral guanine nucleotide dissociation stimulator	Homo sapiens	4-8
16704425-1	2006	Neuronal PAS domain protein 2 (NPAS2) is a circadian rhythm-associated transcription factor with two heme-binding sites on two PAS domains.	Protactinium	9-12	neuronal PAS domain protein 2	Homo sapiens	31-36
16753896-4	2006	Furthermore, the same PA groups showed astroglial cells with enhanced GFAP immunoreactivity, evidencing a typical astroglial reaction with a clear hypertrophy of these cells.	Protactinium	22-24	glial fibrillary acidic protein	Rattus norvegicus	70-74
16731910-4	2006	Using a synthesis/assembly system for chimeric HIV type 1 Gag proteins, we have replicated the activity of PA-457 in vitro.	Protactinium	107-109	Pr55(Gag)	Human immunodeficiency virus 1	58-61
16806845-5	2006	In nanos2(-/pA) mice, the number of germ cell-depleted seminiferous tubules was increased when compared with that of nanos2pA/pA mice, indicating a dose-dependent defect in spermatogenesis.	Protactinium	12-14	nanos C2HC-type zinc finger 2	Mus musculus	3-9
16285023-7	2006	In the pressor assay, [Lys(Car)(4), Pen(6)]-PA and [Dab(Car)(4), Pen(6)]-PA were somewhat weaker antagonists of arginine vasopressin than [Pen(6)]-PA; [Dap(Car)(4), Pen(6)]-PA showed only a faint trace of pressor agonistic activity.	Protactinium	42-46	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	36-39
16464940-3	2006	We recently reported two sisters with PA carrying a heterozygous mutation of BMP15 gene (locus Xp11.2), but the prevalence of BMP15 variations in the POF population is unknown.	Protactinium	38-40	bone morphogenetic protein 15	Homo sapiens	77-82
16638992-3	2006	The effect of annexin A5 on the release of urokinase-type plasminogen activator (uPA) from cultured RCE cells was determined by zymography, fluorogenic assay of PA activity, and enzyme-linked immunosorbent assay.	Protactinium	82-84	annexin A5	Oryctolagus cuniculus	14-24
16638992-3	2006	The effect of annexin A5 on the release of urokinase-type plasminogen activator (uPA) from cultured RCE cells was determined by zymography, fluorogenic assay of PA activity, and enzyme-linked immunosorbent assay.	Protactinium	82-84	urokinase-type plasminogen activator	Oryctolagus cuniculus	43-79
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	plasminogen activator, urokinase	Mus musculus	72-103
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	plasminogen activator, tissue	Mus musculus	150-154
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	plasminogen activator, urokinase	Mus musculus	105-109
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	plasminogen activator, tissue	Mus musculus	115-148
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	plasminogen	Mus musculus	82-93
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	plasminogen	Mus musculus	170-173
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	264-304
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	306-311
16611153-4	2006	The central components of the PA system are the proteolytic activators, urokinase-plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA), plasminogen (plg) and its degradation product, plasmin, together with the major inhibitors of this system, plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2).	Protactinium	30-32	serine (or cysteine) peptidase inhibitor, clade B, member 2	Mus musculus	313-318
18458380-7	2006	The alkaline phosphatase activity and osteocalcin content of MSC cultured in the PA nanofibers significantly increased compared with the static culture method.	Protactinium	81-83	bone gamma-carboxyglutamate protein	Homo sapiens	38-49
16321564-3	2006	PAs and PLGAs demonstrated higher levels of OPN than normal salivary gland tissue, while ACC, although showing a trend towards increased OPN, was not significantly different.	Protactinium	0-3	secreted phosphoprotein 1	Homo sapiens	44-47
16316672-4	2006	The purified PA-Hoc was assembled in vitro on hoc(-) phage particles.	Protactinium	13-15	PKD domain-containing protein	Escherichia phage T4	16-19
16817498-7	2006	DFS was significantly prolonged in patients treated with PA with respect to IFN.	Protactinium	57-59	interferon alpha 1	Homo sapiens	76-79
16448859-6	2006	BK-induced release of NO was 160.4+/-10.3 nmol/L in PA (n=8) and 103.0+/-14.7 nmol/L in PV (n=8, p&lt;0.001) with longer releasing duration in PA than in PV (14.3+/-1.3 vs. 12.1+/-0.8 min, p&lt;0.01).	Protactinium	52-54	kininogen 1	Homo sapiens	0-2
16448859-6	2006	BK-induced release of NO was 160.4+/-10.3 nmol/L in PA (n=8) and 103.0+/-14.7 nmol/L in PV (n=8, p&lt;0.001) with longer releasing duration in PA than in PV (14.3+/-1.3 vs. 12.1+/-0.8 min, p&lt;0.01).	Protactinium	143-145	kininogen 1	Homo sapiens	0-2
16316672-4	2006	The purified PA-Hoc was assembled in vitro on hoc(-) phage particles.	Protactinium	13-15	PKD domain-containing protein	Escherichia phage T4	46-49
16174719-9	2005	After ACTH injection, PA females exhibited higher circulating levels of DHEA, androstenedione, and corticosterone but comparable levels of 17alpha-hydroxyprogesterone, cortisol, the sulfoconjugate of DHEA, and testosterone compared with controls.	Protactinium	22-24	proopiomelanocortin	Homo sapiens	6-10
16898513-12	2006	We conclude that an empirical combination treatment of clarithromycine and ceftazidime is appropriate and effective in children with UTI caused by PA.	Protactinium	147-149	alpha-1-microglobulin/bikunin precursor	Homo sapiens	133-136
16373854-4	2005	The administration of Cu/Zn superoxide dismutase (SOD) markedly reduced the CH-enhanced maximal PA constrictor response to ET-1, demonstrating the contribution of superoxide to CH-enhanced PA constrictor responses.	Protactinium	96-98	superoxide dismutase 1, soluble	Mus musculus	50-53
16373854-4	2005	The administration of Cu/Zn superoxide dismutase (SOD) markedly reduced the CH-enhanced maximal PA constrictor response to ET-1, demonstrating the contribution of superoxide to CH-enhanced PA constrictor responses.	Protactinium	96-98	endothelin 1	Mus musculus	123-127
16373854-5	2005	Using mice that are completely deficient in gp91phox (a subunit protein of the superoxide producing nicotinamide adenine dinucleotide phosphate [NADPH] oxidase), we found that CH-enhanced PA constriction to ET-1 was completely blocked (decreases in mean [+/- SE] maximal isometric tension from 5.43 +/- 0.35 to 3.33 +/- 0.19 mN; n = 7; p &lt; 0.01).	Protactinium	188-190	cytochrome b-245, beta polypeptide	Mus musculus	44-52
16373854-5	2005	Using mice that are completely deficient in gp91phox (a subunit protein of the superoxide producing nicotinamide adenine dinucleotide phosphate [NADPH] oxidase), we found that CH-enhanced PA constriction to ET-1 was completely blocked (decreases in mean [+/- SE] maximal isometric tension from 5.43 +/- 0.35 to 3.33 +/- 0.19 mN; n = 7; p &lt; 0.01).	Protactinium	188-190	endothelin 1	Mus musculus	207-211
16263282-3	2006	Here, we report the synthesis of stereoisomers of PA 8:0 analogs and their biological evaluation at LPA GPCR, PPARgamma, and ATX.	Protactinium	50-52	peroxisome proliferator activated receptor gamma	Homo sapiens	110-119
16263282-3	2006	Here, we report the synthesis of stereoisomers of PA 8:0 analogs and their biological evaluation at LPA GPCR, PPARgamma, and ATX.	Protactinium	50-52	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	125-128
16223872-4	2006	1) Pretraining administration of the 5-HT(1A) receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide] facilitated PA retention at low doses (0.01 and 0.03 mg/kg) but impaired PA retention at higher doses (0.1-1.0 mg/kg), consistent with previous findings in the rat.	Protactinium	69-71	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	37-54
16223872-4	2006	1) Pretraining administration of the 5-HT(1A) receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide] facilitated PA retention at low doses (0.01 and 0.03 mg/kg) but impaired PA retention at higher doses (0.1-1.0 mg/kg), consistent with previous findings in the rat.	Protactinium	139-141	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	37-54
16752945-5	2006	It is produced by ex vivo exposure of dendritic cell precursors to PA 2024, a recombinant fusion protein composed of the PAP target fused to granulocyte-macrophage colony-stimulating factor (GM-CSF) and incorporated into Dendreon"s proprietary Antigen Delivery Cassette.	Protactinium	67-69	colony stimulating factor 2	Homo sapiens	141-189
16752945-5	2006	It is produced by ex vivo exposure of dendritic cell precursors to PA 2024, a recombinant fusion protein composed of the PAP target fused to granulocyte-macrophage colony-stimulating factor (GM-CSF) and incorporated into Dendreon"s proprietary Antigen Delivery Cassette.	Protactinium	67-69	colony stimulating factor 2	Homo sapiens	191-197
17333617-6	2006	About 50 % of double-labeled (Fos-ir and NADPH-diaphorase reactive) cells were found in Pa nucleus.	Protactinium	88-90	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	30-33
16179805-10	2006	PAS and silver staining revealed that p21-/- mice had typical features of MC proliferative GN with focal segmental tuft necrosis, focal mesangiolysis and focal mesangial hypercellularity.	Protactinium	0-3	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	38-41
16381065-8	2006	Thus, negative-ion MSn (n = 2, 3) spectral matching was demonstrated to be useful for the structural assignment of these four monosialylated PA N-glycan isomers.	Protactinium	141-143	moesin	Homo sapiens	19-22
16365240-6	2005	Epidermal growth factor receptor and ezrin expression in sodium butyrate (SB)-treated PA cell line PANC-1 was determined using immunocytochemistry.	Protactinium	86-88	epidermal growth factor receptor	Homo sapiens	0-32
16365240-6	2005	Epidermal growth factor receptor and ezrin expression in sodium butyrate (SB)-treated PA cell line PANC-1 was determined using immunocytochemistry.	Protactinium	86-88	ezrin	Homo sapiens	37-42
16257928-9	2005	The autoregulatory slope increased as Pa(CO2)) increased from 30 to 60 mm Hg.	Protactinium	38-40	complement C2	Homo sapiens	41-44
16331131-9	2005	Similarly, GEE2 revealed that the main factors (at TP1 and TP2) predicting the development of Ad (at TP3) were PA (beta=-0.14; P&lt;0.001) followed by AF (beta=-0.10; P&lt;0.05).	Protactinium	111-113	transition protein 1	Homo sapiens	51-54
16331131-9	2005	Similarly, GEE2 revealed that the main factors (at TP1 and TP2) predicting the development of Ad (at TP3) were PA (beta=-0.14; P&lt;0.001) followed by AF (beta=-0.10; P&lt;0.05).	Protactinium	111-113	transition protein 2	Homo sapiens	59-62
16221887-7	2005	These phenomena correlate with a defect in Atg9 trafficking from the mitochondria to the PAS.	Protactinium	89-92	autophagy protein ATG9	Saccharomyces cerevisiae S288C	43-47
16459463-7	2005	The median serum sex hormone binding globulin (SHBG) level was higher in controls than in both PA and PCOS groups (49.85, 38.60 and 21.30 nmol/l, respectively).	Protactinium	95-97	sex hormone binding globulin	Homo sapiens	17-45
16459463-7	2005	The median serum sex hormone binding globulin (SHBG) level was higher in controls than in both PA and PCOS groups (49.85, 38.60 and 21.30 nmol/l, respectively).	Protactinium	95-97	sex hormone binding globulin	Homo sapiens	47-51
16195220-8	2005	Reverse-transcription polymerase chain reaction (RT-PCR) studies revealed that the iron-containing PA coal downregulated levels of transferrin receptor (TfR) mRNA in A549 cells, which was partially restored by the addition of calcite.	Protactinium	99-101	transferrin receptor	Homo sapiens	131-151
16199613-2	2005	Mutations in a permease-like protein, TRIGALACTOSYLDIACYLGLYCEROL1 (TGD1), in Arabidopsis thaliana caused the accumulation of triacylglycerols, oligogalactolipids, and PA.	Protactinium	168-170	trigalactosyldiacylglycerol 1	Arabidopsis thaliana	38-66
16199613-2	2005	Mutations in a permease-like protein, TRIGALACTOSYLDIACYLGLYCEROL1 (TGD1), in Arabidopsis thaliana caused the accumulation of triacylglycerols, oligogalactolipids, and PA.	Protactinium	168-170	trigalactosyldiacylglycerol 1	Arabidopsis thaliana	68-72
16199613-5	2005	Isolated tgd1 mutant chloroplasts showed a decreased ability to incorporate PA into galactolipids.	Protactinium	76-78	trigalactosyldiacylglycerol 1	Arabidopsis thaliana	9-13
16195220-8	2005	Reverse-transcription polymerase chain reaction (RT-PCR) studies revealed that the iron-containing PA coal downregulated levels of transferrin receptor (TfR) mRNA in A549 cells, which was partially restored by the addition of calcite.	Protactinium	99-101	transferrin receptor	Homo sapiens	153-156
15960610-10	2005	Taken together, these data are consistent with an important role for LPP2 and LPP3 in regulating an intracellular pool of PA and S1P respectively, that may govern the apoptotic status of the cell upon serum deprivation.	Protactinium	122-124	phospholipid phosphatase 2	Homo sapiens	69-73
15960610-10	2005	Taken together, these data are consistent with an important role for LPP2 and LPP3 in regulating an intracellular pool of PA and S1P respectively, that may govern the apoptotic status of the cell upon serum deprivation.	Protactinium	122-124	phospholipid phosphatase 3	Homo sapiens	78-82
16177368-8	2005	Robust anti-PA immunoglobulin G and neutralizing antibodies were detected by 2 to 4 weeks following administration of AdC7PA to naive or Ad5 preimmunized mice, whereas low anti-PA titers were detected in Ad5-preimmunized mice following administration of Ad5PA.	Protactinium	12-14	Alzheimer disease, familial, type 5	Homo sapiens	137-140
15935490-10	2005	[Nphe(1), (pF)Phe(4), Aib(7), Aib(11), Arg(14), Lys(15)] N/OFQ-NH(2) was the best antagonist with pA(2)=8.39 and showed high binding affinity with pK(i)=9.99.	Protactinium	98-100	prepronociceptin	Mus musculus	57-62
15947289-6	2005	In comparison with control animals, early treatment with SOD at 5 and 10 mg/kg improved Pa(O(2)) at 4 hours (167 +/- 44 and 269 +/- 33 mm Hg, respectively; p &lt; 0.05 vs. control), but did not decrease lung edema or improve CL.	Protactinium	88-91	superoxide dismutase 1	Homo sapiens	57-60
16320587-6	2005	RESULTS: After the culture, CD1a and CD83 positive cell rates of the PA group inreased significantly, reaching (19.63 +/- 3.61)%, (9.28 +/- 4.31) % respectively, much higher than that of the control, but lower than that of the GTI group.	Protactinium	69-71	CD1a molecule	Homo sapiens	28-32
16320587-6	2005	RESULTS: After the culture, CD1a and CD83 positive cell rates of the PA group inreased significantly, reaching (19.63 +/- 3.61)%, (9.28 +/- 4.31) % respectively, much higher than that of the control, but lower than that of the GTI group.	Protactinium	69-71	CD83 molecule	Homo sapiens	37-41
16054502-7	2005	Recent observations suggest that PAI-1, the main inhibitor of PAs, shows greater expression in the isthmus compared to the ampulla and the local generation of plasmin is inhibited.	Protactinium	62-65	serpin family E member 1	Homo sapiens	33-38
16162727-9	2005	Variables associated with HVR in MMT patients are body height (t = 3.2, p = 0.002) and Pa(CO2) (t = - 2.8, p = 0.008).	Protactinium	87-89	complement C2	Homo sapiens	90-93
16054502-7	2005	Recent observations suggest that PAI-1, the main inhibitor of PAs, shows greater expression in the isthmus compared to the ampulla and the local generation of plasmin is inhibited.	Protactinium	62-65	plasminogen	Homo sapiens	159-166
16048955-0	2005	Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.	Protactinium	137-139	FA complementation group B	Homo sapiens	23-26
15936961-5	2005	We previously identified two PAS proteins highly expressed in the testis: a novel isoform of the hypoxia-inducible factor (HIF)-1alpha and PASKIN, a PAS-Ser/Thr kinase related to bacterial oxygen sensing PAS-domain proteins.	Protactinium	29-32	hypoxia inducible factor 1 subunit alpha	Homo sapiens	97-134
16118571-8	2005	CONCLUSION: The PAaccum reduces SBP in hypertension and prehypertension but does not appear to be related to the EE(PA-C).	Protactinium	16-18	selenium binding protein 1	Homo sapiens	32-35
16059740-6	2005	Similar results were seen in the trapezius muscle (T) but additionally, in T the proportion of fibers expressing developmental myosin isoforms was higher in the PAS group compared to the P group.	Protactinium	161-164	myosin heavy chain 14	Homo sapiens	127-133
16200845-11	2005	Serum leptin levels were influenced by BMI (p = 0.001), basal 17-OHP (p = 0.002) and stimulated 17-OHP (p = 0.019) in patients with PA.	Protactinium	132-134	leptin	Homo sapiens	6-12
15936961-5	2005	We previously identified two PAS proteins highly expressed in the testis: a novel isoform of the hypoxia-inducible factor (HIF)-1alpha and PASKIN, a PAS-Ser/Thr kinase related to bacterial oxygen sensing PAS-domain proteins.	Protactinium	29-32	PAS domain containing serine/threonine kinase	Homo sapiens	139-145
15910598-8	2005	CONCLUSION: The strong association of the presence of a fibrotic focus with CA9 expression and lower survival demonstrates that hypoxia-driven angiogenesis plays an important role in the progression of PA.	Protactinium	202-204	carbonic anhydrase 9	Homo sapiens	76-79
16078925-10	2005	A significantly higher capacity for up regulation of CD62P, CD63, and PAC-1 upon TRAP stimulation was found for stdPCs and hcPCs in PAS-27a compared to PLTs in T-Sol.	Protactinium	132-135	selectin P	Homo sapiens	53-58
16078925-10	2005	A significantly higher capacity for up regulation of CD62P, CD63, and PAC-1 upon TRAP stimulation was found for stdPCs and hcPCs in PAS-27a compared to PLTs in T-Sol.	Protactinium	132-135	CD63 molecule	Homo sapiens	60-64
16078925-10	2005	A significantly higher capacity for up regulation of CD62P, CD63, and PAC-1 upon TRAP stimulation was found for stdPCs and hcPCs in PAS-27a compared to PLTs in T-Sol.	Protactinium	132-135	ADCYAP receptor type I	Homo sapiens	70-75
16078925-11	2005	TRAP-stimulated PLTs in stdPCs and hcPCs suspended in PAS-27a showed significantly higher potential for down regulation of CD42a than the T-Sol concentrates.	Protactinium	54-57	glycoprotein IX platelet	Homo sapiens	123-128
15947281-9	2005	CONCLUSIONS: We conclude that the level of brainstem NHE3 expression-most likely via intracellular pH modulation-contributes to the individual control of breathing and Pa(CO2) in conscious rabbits by adjusting the set point and the loop gain of the system.	Protactinium	168-170	sodium/hydrogen exchanger 3	Oryctolagus cuniculus	53-57
18970101-4	2005	OPA-NAC reacted on the fibre with possible primary aliphatic amines present in the samples, particularly with PA which is a direct interferent in the determination of DMA with FMOC.	Protactinium	1-3	synuclein alpha	Homo sapiens	4-7
15855232-7	2005	Studies using PA-GFP-tagged channels were consistent with the FRAP results.	Protactinium	14-16	mechanistic target of rapamycin kinase	Homo sapiens	62-66
15855232-8	2005	Following photoactivation of a small region of plasma membrane PA-GFP-Kv2.1 remained restricted to the photoactivation ROI, while PA-GFP-Kv1.4 rapidly diffused throughout the cell surface.	Protactinium	63-65	potassium voltage-gated channel subfamily B member 1	Homo sapiens	70-75
16158921-1	2005	We have demonstrated that phenylacetate (PA)induced cell cycle arrest in human prostate cancer is mediated by increase of p27.	Protactinium	41-43	dynactin subunit 6	Homo sapiens	122-125
16158921-2	2005	In this study, we further investigated the mechanism of PA-induced p27 expression in prostate cancer cells (LNCaP, androgen-independent LNCaP [AIDL] and PC-3).	Protactinium	56-58	dynactin subunit 6	Homo sapiens	67-70
16158921-7	2005	Our results suggest that PA attenuated Skp2 expression, thereby inhibiting ubiquitination and promoting p27 accumulation in all three prostate cancer cell lines.	Protactinium	25-27	S-phase kinase associated protein 2	Homo sapiens	39-43
16158921-7	2005	Our results suggest that PA attenuated Skp2 expression, thereby inhibiting ubiquitination and promoting p27 accumulation in all three prostate cancer cell lines.	Protactinium	25-27	dynactin subunit 6	Homo sapiens	104-107
15789358-2	2005	Using surface plasmon resonance technology we demonstrated the capacity of the poly(A):poly(U) (pA:pU) motif to bind with high affinity to a totally synthetic Tat protein and to inhibit more efficiently the Tat/transactivation response element (TAR) RNA interaction as compared to the poly(I):poly(C) (pI:pC) motif.	Protactinium	96-98	tyrosine aminotransferase	Homo sapiens	159-162
15789358-2	2005	Using surface plasmon resonance technology we demonstrated the capacity of the poly(A):poly(U) (pA:pU) motif to bind with high affinity to a totally synthetic Tat protein and to inhibit more efficiently the Tat/transactivation response element (TAR) RNA interaction as compared to the poly(I):poly(C) (pI:pC) motif.	Protactinium	96-98	tyrosine aminotransferase	Homo sapiens	207-210
15764838-4	2005	The injection of AVP4-9 ameliorated PA task performance impairment induced by DCG-IV, an mGluR2/3 agonist.	Protactinium	36-38	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	89-95
15832052-10	2005	Patients with PA receiving high-dose inhaled corticosteroid (ICS) had higher EBC IL-4 concentration than those on low-dose ICS (p = 0.007).	Protactinium	14-16	interleukin 4	Homo sapiens	81-85
15574796-8	2005	Depletion of PAs reduced rectification suggesting that endogenous PAs play a critical role in functional regulation of AMPARs.	Protactinium	13-16	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	119-125
15574796-8	2005	Depletion of PAs reduced rectification suggesting that endogenous PAs play a critical role in functional regulation of AMPARs.	Protactinium	66-69	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	119-125
15574796-10	2005	These results provide further support for the idea that excitatory synapses on immature neocortical pyramidal neurons ubiquitously contain AMPA receptors lacking the GluR2 subunit and that the level of endogenous PAs plays an important role in modulating AMPAR-dependent neurotransmission.	Protactinium	213-216	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	255-260
15829255-2	2005	Pre-training administration of the 5-HT1A receptor agonist 8-OH-DPAT impaired WM performance and facilitated PA retention at low doses (0.01 and 0.03 mg/kg) and impaired PA retention at higher doses (0.1-1.0 mg/kg).	Protactinium	65-67	5-hydroxytryptamine receptor 1A	Homo sapiens	35-50
15829255-3	2005	The 5-HT1A receptor antagonist NAD-299 produced a dose-dependent facilitation of PA retention.	Protactinium	81-83	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
15810888-5	2005	Skin mast cell density in Tsk mice was significantly increased from 12 weeks of age, compared to that in pa/pa mice.	Protactinium	88-90	fibrillin 1	Mus musculus	26-29
15525798-3	2005	Diacylglycerol kinase inhibitor II diminished Ang II-induced and diC8-phosphatidic acid (PA)-increased Akt phosphorylation, suggesting that PLD-dependent Akt activation is mediated by PA.	Protactinium	89-91	AKT serine/threonine kinase 1	Rattus norvegicus	103-106
15525798-3	2005	Diacylglycerol kinase inhibitor II diminished Ang II-induced and diC8-phosphatidic acid (PA)-increased Akt phosphorylation, suggesting that PLD-dependent Akt activation is mediated by PA.	Protactinium	89-91	AKT serine/threonine kinase 1	Rattus norvegicus	154-157
15525798-3	2005	Diacylglycerol kinase inhibitor II diminished Ang II-induced and diC8-phosphatidic acid (PA)-increased Akt phosphorylation, suggesting that PLD-dependent Akt activation is mediated by PA.	Protactinium	184-186	AKT serine/threonine kinase 1	Rattus norvegicus	154-157
16000849-6	2005	Of interest was the localization of both Ang1 and Ang2 in scattered PAS positive adenohypophysial cells rather than in endothelial cells.	Protactinium	68-71	angiogenin	Rattus norvegicus	41-45
16000849-6	2005	Of interest was the localization of both Ang1 and Ang2 in scattered PAS positive adenohypophysial cells rather than in endothelial cells.	Protactinium	68-71	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	50-54
16000849-8	2005	Dual immunostaining for Ang1 and the anterior pituitary hormones that show PAS positivity demonstrated colocalization of Ang1 with follicle stimulating hormone and luteinizing hormone.	Protactinium	75-78	angiogenin	Rattus norvegicus	121-125
15764838-6	2005	High doses of AVP4-9 exacerbated the PA task performance impairment induced by LY341495 (an mGluR2/3 antagonist), and PMA injection (1 mug) also exacerbated the impairment induced by the antagonist.	Protactinium	37-39	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	92-98
15695119-11	2005	PAs were high-expressors of tenascin-C with a significant difference relative to ACCs (p=0.03).	Protactinium	0-3	tenascin C	Homo sapiens	28-38
15823178-8	2005	The number of PAS/alcian blue-positive airway epithelial cells and serum IgE were elevated in COX-2 (-/-) mice.	Protactinium	14-17	prostaglandin-endoperoxide synthase 2	Mus musculus	94-99
15504760-11	2004	Systemic CGRP and TES induced an increase in PA diameter that was not significantly inhibited by BIBN4096BS.	Protactinium	45-47	calcitonin-related polypeptide alpha	Rattus norvegicus	9-13
15451025-4	2005	The identity of each protein was established by isolating the protein from lysates of untreated and insulin-treated adipocytes with an antibody specific for the protein and showing that the PAS antibody reacted only with the protein in the immunoprecipitate from insulin-treated cells.	Protactinium	190-193	insulin	Homo sapiens	100-107
15451025-4	2005	The identity of each protein was established by isolating the protein from lysates of untreated and insulin-treated adipocytes with an antibody specific for the protein and showing that the PAS antibody reacted only with the protein in the immunoprecipitate from insulin-treated cells.	Protactinium	190-193	insulin	Homo sapiens	263-270
15722572-2	2005	The purpose of this study was to compare the prevalence of K-ras and c-erbB-2 mutations in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases.	Protactinium	91-93	KRAS proto-oncogene, GTPase	Homo sapiens	59-64
15722572-2	2005	The purpose of this study was to compare the prevalence of K-ras and c-erbB-2 mutations in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases.	Protactinium	91-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-77
15722572-5	2005	RESULTS: The K-ras gene mutation has been shown in 20 (76.9%) PA cases and in 8 (34.8%) CP cases (p&lt;0.01).	Protactinium	62-64	KRAS proto-oncogene, GTPase	Homo sapiens	13-18
15722572-6	2005	Prevalence of c-erbB-2 amplification in patients with PA was 17 (65.3%), which was not different from CP, 16 (56.5%) (p=0.58).	Protactinium	54-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-22
15608650-2	2005	We demonstrate that Per2(Brdm1) mutant mice, which have a deletion in the PAS domain of the Per2 protein, show alterations in the glutamatergic system.	Protactinium	74-77	period circadian clock 2	Mus musculus	20-24
15608650-2	2005	We demonstrate that Per2(Brdm1) mutant mice, which have a deletion in the PAS domain of the Per2 protein, show alterations in the glutamatergic system.	Protactinium	74-77	period circadian clock 2	Mus musculus	92-96
15547724-5	2004	Combined administration of SAM486A and alpha-difluoromethylornithine (DFMO), a selective inhibitor of ornithine decarboxylase (ODC), exerted greater antiproliferative and anti-invasive effects and induced an overall greater suppression of cellular PA levels than the individual treatments.	Protactinium	248-250	ornithine decarboxylase 1	Homo sapiens	127-130
15563701-6	2004	MUC5AC expression was significantly associated with both PAS staining and ErbB3 expression; no correlation was observed between either mucin or ErbB receptor expression and neutrophil counts.	Protactinium	57-60	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	0-6
16076647-3	2005	Both PAS domains of NPAS2 were found to bind heme as a prosthetic group, form a gas-regulated sensor, and exert heme-status control of DNA binding in vitro.	Protactinium	5-8	neuronal PAS domain protein 2	Mus musculus	20-25
15381157-8	2005	In agreement, our observations demonstrate that MT1-MMP proteolysis of PA makes the MT1-MMP-expressing aggressive invasive cells resistant to the cytotoxic effect of a bipartite PA/FP59 toxin.	Protactinium	71-73	matrix metallopeptidase 14	Homo sapiens	48-55
15381157-8	2005	In agreement, our observations demonstrate that MT1-MMP proteolysis of PA makes the MT1-MMP-expressing aggressive invasive cells resistant to the cytotoxic effect of a bipartite PA/FP59 toxin.	Protactinium	71-73	matrix metallopeptidase 14	Homo sapiens	84-91
16381734-0	2005	Radiation protection potential of MOX-fuel doped with 231Pa and Cs radioisotopes.	Protactinium	57-59	monooxygenase DBH like 1	Homo sapiens	34-37
15569923-5	2004	ARAP3 deficiency produced by antisense expression of an ARAP3 EST impaired entry of PA and its bound toxigenic moieties into both human and mouse cells, resulting in reduced toxin sensitivity.	Protactinium	84-86	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3	Homo sapiens	0-5
15545361-8	2004	In contrast to the behavior during heat treatment, PAS 6 and PAS 7 were stable during high-pressure treatment, and they remained associated with the MFGM.	Protactinium	51-54	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	149-153
15545361-8	2004	In contrast to the behavior during heat treatment, PAS 6 and PAS 7 were stable during high-pressure treatment, and they remained associated with the MFGM.	Protactinium	61-64	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	149-153
15486938-0	2004	Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin.	Protactinium	26-29	serpin family A member 1	Homo sapiens	100-118
15479785-1	2004	Aryl hydrocarbon receptor nuclear translocator (ARNT) belongs to the basic helix-loop-helix Per-Arnt-Sim (bHLH PAS) protein which dimerizes with other PAS proteins.	Protactinium	111-114	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	96-100
15479785-1	2004	Aryl hydrocarbon receptor nuclear translocator (ARNT) belongs to the basic helix-loop-helix Per-Arnt-Sim (bHLH PAS) protein which dimerizes with other PAS proteins.	Protactinium	111-114	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	0-46
15479785-1	2004	Aryl hydrocarbon receptor nuclear translocator (ARNT) belongs to the basic helix-loop-helix Per-Arnt-Sim (bHLH PAS) protein which dimerizes with other PAS proteins.	Protactinium	111-114	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	48-52
15470045-7	2004	We further show that immunodomination of PA(224-233)-specific TCD8+ by nucleoprotein 366-374-specific TCD8+ plays a critical role in the phenomena, and that this is unlikely to be mediated by TCD8+ lysis of APCs or other cells.	Protactinium	41-43	amyloid P component, serum	Homo sapiens	207-211
15373839-1	2004	In haem-regulated phosphodiesterase (PDE) from Escherichia coli (Ec DOS), haem is bound to the PAS domain, and the redox state of the haem iron regulates catalysis by the PDE domain.	Protactinium	95-98	phosphodiesterase	Escherichia coli	18-35
15373839-1	2004	In haem-regulated phosphodiesterase (PDE) from Escherichia coli (Ec DOS), haem is bound to the PAS domain, and the redox state of the haem iron regulates catalysis by the PDE domain.	Protactinium	95-98	phosphodiesterase	Escherichia coli	37-40
15373839-1	2004	In haem-regulated phosphodiesterase (PDE) from Escherichia coli (Ec DOS), haem is bound to the PAS domain, and the redox state of the haem iron regulates catalysis by the PDE domain.	Protactinium	95-98	phosphodiesterase	Escherichia coli	171-174
15528865-4	2004	The diagnosis was confirmed by histological evaluation, positive cytokeratin immunostain, and mucin production demonstrated by PAS and Alcian blue stain.	Protactinium	127-130	LOC100508689	Homo sapiens	94-99
15274694-4	2004	It was found that there was a significant multiple regression relationship between the uCP [g/kg dry matter (DM)] and the CNCPS crude protein fractions, i.e. PA (% DM), PB1 (% DM), PB2 (% DM), PB3 (% DM) and PC (% DM) of the feed samples.	Protactinium	158-160	uncoupling protein 1	Homo sapiens	87-90
15271293-11	2004	However, apparently certain extracellular phospholipases such as secretory PLA2 (sPLA2-IIA), membrane-associated PA-selective PLA1 (mPA-PLA1), lecithin-cholesterol acyltransferase (LCAT), and lysoPLD are involved in LPA production.	Protactinium	113-115	lipase H	Homo sapiens	126-130
15271293-11	2004	However, apparently certain extracellular phospholipases such as secretory PLA2 (sPLA2-IIA), membrane-associated PA-selective PLA1 (mPA-PLA1), lecithin-cholesterol acyltransferase (LCAT), and lysoPLD are involved in LPA production.	Protactinium	113-115	lipase, member H	Mus musculus	132-140
15363889-9	2004	Our observation suggests that LE-PAS shares a similar mode of function with HLH-PAS proteins such as single minded or trachealess indicating that LE-PAS also has constitutive or developmental functions which may be critical for regulating the transcriptional control of limbic patterning and function.	Protactinium	33-36	neuronal PAS domain protein 4	Mus musculus	146-152
15358653-8	2004	Anti-PA-specific IgG subclass concentrations were the following: for IgG1, 79.6 microg/ml; for IgG2, 35.3 microg/ml; for IgG3, 3.2 microg/ml; and for IgG4, 25.3 microg/ml.	Protactinium	5-7	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	121-125
15308710-0	2004	The PA subunit is required for efficient nuclear accumulation of the PB1 subunit of the influenza A virus RNA polymerase complex.	Protactinium	4-6	polybromo 1	Homo sapiens	69-72
15308710-4	2004	Although it has been reported that PB1 alone accumulates in the nucleus, we demonstrate that PB1 requires the coexpression of PA for efficient nuclear accumulation.	Protactinium	126-128	polybromo 1	Homo sapiens	93-96
15453273-5	2004	In hippocampus of rats with PA, the stress proteins protein disulfide isomerase A3 precursor and stress-induced phosphoprotein-1 were significantly increased, whereas the microtubule-associated protein dynamin-1 was significantly reduced.	Protactinium	28-30	dynamin 1	Rattus norvegicus	202-211
15274694-5	2004	uCP = (9.95 +/-2.73)PA + (2.92 +/- 1.36)PB(1) + (7.24 +/- 0.86)PB(2) + (8.20 +/- 3.33)PB(3) + (17.67 +/- 3.79) PC + (63.26 +/- 18.02), r2 = 0.90, n = 30, p &lt; 0.0001.	Protactinium	20-24	uncoupling protein 1	Homo sapiens	0-3
15126453-1	2004	In Pseudomonas aeruginosa, the small RNA-binding, regulatory protein RsmA is a negative control element in the formation of several extracellular products (e.g., pyocyanin, hydrogen cyanide, PA-IL lectin) as well as in the production of N-acylhomoserine lactone quorum-sensing signal molecules.	Protactinium	191-193	carbon storage regulator	Pseudomonas aeruginosa PAO1	69-73
15280401-10	2004	In multivariate analysis, only high expression of MUC1/DF3 was found to be a significant independent risk factor for the recurrence of PA (p = 0.021).	Protactinium	135-137	mucin 1, cell surface associated	Homo sapiens	50-54
15280401-11	2004	CONCLUSIONS: Expression of MUC1/DF3 in PA is a useful marker to predict its recurrence.	Protactinium	39-41	mucin 1, cell surface associated	Homo sapiens	27-31
15255942-5	2004	In addition, exogenous PAs were able to increase DNA synthesis and to activate PKC zeta and p70S6K.	Protactinium	23-26	protein kinase C zeta	Homo sapiens	79-87
15255942-5	2004	In addition, exogenous PAs were able to increase DNA synthesis and to activate PKC zeta and p70S6K.	Protactinium	23-26	ribosomal protein S6 kinase B1	Homo sapiens	92-98
15608367-2	2004	The purpose of the study was to compare the prevalence of p16 and K-ras mutation in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases.	Protactinium	84-86	cyclin dependent kinase inhibitor 2A	Homo sapiens	58-61
15608367-2	2004	The purpose of the study was to compare the prevalence of p16 and K-ras mutation in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases.	Protactinium	84-86	KRAS proto-oncogene, GTPase	Homo sapiens	66-71
15608367-6	2004	Prevalence of p16 mutations in patients with PA was 18 (78,3%) and with CP - 7 (33,3%) (p&lt;0,01).	Protactinium	45-47	cyclin dependent kinase inhibitor 2A	Homo sapiens	14-17
15144472-9	2004	The median MDC concentration in EBC was higher in PA (117 pg/mL) as compared with IA (106 pg/mL) and controls (105 pg/mL; P=0.003 for both).	Protactinium	50-52	C-C motif chemokine ligand 22	Homo sapiens	11-14
15144472-10	2004	The median plasma MDC concentration in PA (648 pg/mL) was also higher than that in IA (520 pg/mL; P=0.002) and controls (490 pg/mL; P=0.008).	Protactinium	39-41	C-C motif chemokine ligand 22	Homo sapiens	18-21
15144472-11	2004	The median plasma TARC concentration was also increased in PA as compared with IA (72 pg/mL vs. 35 pg/mL; P=0.004).	Protactinium	59-61	C-C motif chemokine ligand 17	Homo sapiens	18-22
15144472-12	2004	MDC concentrations in EBC were lower in patients with PA who received high-dose inhaled corticosteroid (P=0.005).	Protactinium	54-56	C-C motif chemokine ligand 22	Homo sapiens	0-3
15144472-15	2004	CONCLUSIONS: Our results suggest that MDC in EBC and MDC and TARC in plasma are increased in children with PA as compared with IA or control.	Protactinium	107-109	C-C motif chemokine ligand 22	Homo sapiens	38-41
15144472-15	2004	CONCLUSIONS: Our results suggest that MDC in EBC and MDC and TARC in plasma are increased in children with PA as compared with IA or control.	Protactinium	107-109	C-C motif chemokine ligand 22	Homo sapiens	53-56
15144472-15	2004	CONCLUSIONS: Our results suggest that MDC in EBC and MDC and TARC in plasma are increased in children with PA as compared with IA or control.	Protactinium	107-109	C-C motif chemokine ligand 17	Homo sapiens	61-65
15293452-6	2004	All three plasmids induced PA-specific humoral immune responses, predominantly IgG1 antibodies, in mice.	Protactinium	27-29	LOC105243590	Mus musculus	79-83
15293452-7	2004	Spleen cells collected from plasmid-vaccinated BALB/c mice produced PA-specific interleukin-4, interleukin-5, and interferon-gamma in vitro.	Protactinium	68-70	interleukin 4	Mus musculus	80-93
15293452-7	2004	Spleen cells collected from plasmid-vaccinated BALB/c mice produced PA-specific interleukin-4, interleukin-5, and interferon-gamma in vitro.	Protactinium	68-70	interferon gamma	Mus musculus	114-130
15218996-8	2004	Positive correlations were found between IL-9R-positive-cells with IL-9-positive cells and hCLCA1-positive cells, and between PAS-positive cells with hCLCA1-positive cells and IL-9R-positive cells.	Protactinium	126-129	chloride channel accessory 1	Homo sapiens	150-156
15554154-14	2004	Differential PA metabolization during aging through PIP2-dependent PLD/PAP2/DGL2 activities could be related to alterations in the neural signal transduction mechanisms.	Protactinium	13-15	regenerating islet-derived 3 alpha	Rattus norvegicus	71-75
15121839-3	2004	This effect is due to the reduced efficiency of mRNA 3" end cleavage, and in vitro analysis reveals that PTB competes with CstF for recognition of the pA signal"s pyrimidine-rich downstream sequence element.	Protactinium	151-153	polypyrimidine tract binding protein 1	Homo sapiens	105-108
15121839-5	2004	The pA signal of the C2 complement gene unusually possesses a PTB-dependent upstream sequence, so that knockdown of PTB expression by RNA interference reduces C2 mRNA expression even though PTB overexpression still inhibits polyadenylation.	Protactinium	4-6	polypyrimidine tract binding protein 1	Homo sapiens	62-65
15121839-5	2004	The pA signal of the C2 complement gene unusually possesses a PTB-dependent upstream sequence, so that knockdown of PTB expression by RNA interference reduces C2 mRNA expression even though PTB overexpression still inhibits polyadenylation.	Protactinium	4-6	polypyrimidine tract binding protein 1	Homo sapiens	116-119
15121839-5	2004	The pA signal of the C2 complement gene unusually possesses a PTB-dependent upstream sequence, so that knockdown of PTB expression by RNA interference reduces C2 mRNA expression even though PTB overexpression still inhibits polyadenylation.	Protactinium	4-6	polypyrimidine tract binding protein 1	Homo sapiens	116-119
15471431-5	2004	In the cytoplasm smaller and larger PAS-positive granules were present and constantly reactive to S-100 and NSE antibodies.	Protactinium	36-39	enolase 2	Homo sapiens	108-111
15079089-3	2004	PA has been shown to bind to two cellular receptors: anthrax toxin receptor/tumor endothelial marker 8 and capillary morphogenesis protein 2 (CMG2).	Protactinium	0-2	ANTXR cell adhesion molecule 2	Homo sapiens	107-140
15194392-11	2004	The K-ras mutations were detected in the paraffin-embedded PA, but not in the prepared islets or in the peripheral blood.	Protactinium	59-61	KRAS proto-oncogene, GTPase	Homo sapiens	4-9
14769825-8	2004	These results support the hypothesis that LPA activates protein translation through the action of PLD1-generated PA on mTOR and the PI3K/Akt pathway whereas PDGF acts through P13K/Akt independent of PLD1.	Protactinium	43-45	phospholipase D1	Homo sapiens	98-102
15300954-6	2004	Interestingly, we found that the primary amino acid sequence of Rim15 includes in its amino-terminal part a conserved PAS domain, known to act as a sensor for a variety of stimuli, We propose that Rim15 has evolved to integrate nutrient signals (transduced via TOR and PKA) and redox and/or oxidative stress signals to appropriately induce a transcriptional program that ensures survival in G0.	Protactinium	118-121	protein kinase RIM15	Saccharomyces cerevisiae S288C	64-69
15300954-6	2004	Interestingly, we found that the primary amino acid sequence of Rim15 includes in its amino-terminal part a conserved PAS domain, known to act as a sensor for a variety of stimuli, We propose that Rim15 has evolved to integrate nutrient signals (transduced via TOR and PKA) and redox and/or oxidative stress signals to appropriately induce a transcriptional program that ensures survival in G0.	Protactinium	118-121	protein kinase RIM15	Saccharomyces cerevisiae S288C	197-202
15203431-6	2004	Pearson"s correlational analysis was used to test the strength of association between PA components and viral load or CD4+ cell count.	Protactinium	86-88	CD4 molecule	Homo sapiens	118-121
15224966-7	2004	Additionally, it has been found that in mitochondria of the TNF (tumor necrosis factor)-sensitive cells (WEHI-164 line), the content of PA is larger than in mitochondria of the TNF-insensitive cells (C6 line), with this difference being mainly provided by PA incorporated in phosphatidylethanolamine and especially, cardiolipin.	Protactinium	136-138	tumor necrosis factor	Homo sapiens	60-63
15224966-7	2004	Additionally, it has been found that in mitochondria of the TNF (tumor necrosis factor)-sensitive cells (WEHI-164 line), the content of PA is larger than in mitochondria of the TNF-insensitive cells (C6 line), with this difference being mainly provided by PA incorporated in phosphatidylethanolamine and especially, cardiolipin.	Protactinium	136-138	tumor necrosis factor	Homo sapiens	65-86
15224966-7	2004	Additionally, it has been found that in mitochondria of the TNF (tumor necrosis factor)-sensitive cells (WEHI-164 line), the content of PA is larger than in mitochondria of the TNF-insensitive cells (C6 line), with this difference being mainly provided by PA incorporated in phosphatidylethanolamine and especially, cardiolipin.	Protactinium	256-258	tumor necrosis factor	Homo sapiens	60-63
15224966-7	2004	Additionally, it has been found that in mitochondria of the TNF (tumor necrosis factor)-sensitive cells (WEHI-164 line), the content of PA is larger than in mitochondria of the TNF-insensitive cells (C6 line), with this difference being mainly provided by PA incorporated in phosphatidylethanolamine and especially, cardiolipin.	Protactinium	256-258	tumor necrosis factor	Homo sapiens	65-86
14769825-8	2004	These results support the hypothesis that LPA activates protein translation through the action of PLD1-generated PA on mTOR and the PI3K/Akt pathway whereas PDGF acts through P13K/Akt independent of PLD1.	Protactinium	43-45	mechanistic target of rapamycin kinase	Homo sapiens	119-123
14769825-8	2004	These results support the hypothesis that LPA activates protein translation through the action of PLD1-generated PA on mTOR and the PI3K/Akt pathway whereas PDGF acts through P13K/Akt independent of PLD1.	Protactinium	43-45	AKT serine/threonine kinase 1	Homo sapiens	137-140
12928580-1	2003	The hypoxia-inducible factor 1alpha (HIF-1alpha), a member of the PAS superfamily, is a global regulator of cellular and systemic O(2) homeostasis as well as embryonic development.	Protactinium	66-69	hypoxia inducible factor 1 subunit alpha	Homo sapiens	4-35
14960639-7	2004	The SLN identification rates with the PA technique were 98.3% and 95%, respectively, for radiotracer and blue dye.	Protactinium	38-40	sarcolipin	Homo sapiens	4-7
14960639-9	2004	At lymphoscintigraphy, SLN visualization required the acquisition of late images (3 h after the injection) in 20% of patients who received PA injections and 39.5% of patients who received SD/PT injections.	Protactinium	139-141	sarcolipin	Homo sapiens	23-26
14573704-3	2003	We show that PA-457 potently inhibits replication of both WT and drug-resistant HIV-1 isolates and demonstrate that the compound acts by disrupting a late step in Gag processing involving conversion of the capsid precursor (p25) to mature capsid protein (p24).	Protactinium	13-15	transmembrane p24 trafficking protein 9	Homo sapiens	224-227
14573704-3	2003	We show that PA-457 potently inhibits replication of both WT and drug-resistant HIV-1 isolates and demonstrate that the compound acts by disrupting a late step in Gag processing involving conversion of the capsid precursor (p25) to mature capsid protein (p24).	Protactinium	13-15	transmembrane p24 trafficking protein 2	Homo sapiens	255-258
14573704-6	2003	Consistent with the effect on Gag processing, we found that mutations conferring resistance to PA-457 map to the p25 to p24 cleavage site.	Protactinium	95-97	transmembrane p24 trafficking protein 9	Homo sapiens	113-116
14573704-6	2003	Consistent with the effect on Gag processing, we found that mutations conferring resistance to PA-457 map to the p25 to p24 cleavage site.	Protactinium	95-97	transmembrane p24 trafficking protein 2	Homo sapiens	120-123
14576548-7	2003	The AT1 antagonist ZD 7155 partially restored impaired hypotension-induced PA dilation after FPI (19 +/- 1 and 34 +/- 1 vs. 5 +/- 1 and 7 +/- 1 vs. 12 +/- 1 and 20 +/- 3% for PA dilation during moderate and severe hypotension in sham control, FPI, and FPI + ZD 7155 animals, respectively).	Protactinium	75-77	angiotensin II receptor type 1	Sus scrofa	4-7
14576525-5	2003	RESULTS: Histology showed that the mucin balls were PAS positive, indicating that glycoproteins form a major component.	Protactinium	52-55	LOC100508689	Homo sapiens	35-40
12949227-4	2003	Treating the vessels with VEGF induced a time- and concentration-dependent increase in Pa.	Protactinium	87-89	vascular endothelial growth factor A	Homo sapiens	26-30
15025351-5	2003	Neutral mucin (PAS positive) was more frequently observed in benign prostatic lesions (93.3%) as compared to carcinoma (36%) while acid mucin (AB positive) was found more in carcinoma prostate (68%) as compared to benign prostatic lesions (16%).	Protactinium	15-18	LOC100508689	Homo sapiens	8-13
14642771-7	2003	Regulation of DPP1 correlates with the expression of DGPP phosphatase activity and the cellular levels of DGPP and PA.	Protactinium	115-117	bifunctional diacylglycerol diphosphate phosphatase/phosphatidate phosphatase	Saccharomyces cerevisiae S288C	14-18
12881221-1	2003	Myoglobin-deficient mice are viable and have preserved cardiac function due to their ability to mount a complex compensatory response involving increased vascularization and the induction of the hypoxia gene program (hypoxia-inducible factor-1alpha, endothelial PAS, heat shock protein27, etc.).	Protactinium	262-265	myoglobin	Mus musculus	0-9
12928580-1	2003	The hypoxia-inducible factor 1alpha (HIF-1alpha), a member of the PAS superfamily, is a global regulator of cellular and systemic O(2) homeostasis as well as embryonic development.	Protactinium	66-69	hypoxia inducible factor 1 subunit alpha	Homo sapiens	37-47
14633445-7	2003	(2) The mean current density of BKCa from asthmatic model group [(44 +/- 17) pA/pF, n = 8] under pulse protocol was significantly lower than that of the control group [(73 +/- 20) pA/pF, n = 10, P &lt; 0.01], and SNP significantly increased the mean current density of the asthmatic model group to [(79 +/- 16) pA/pF, n = 10, P &lt; 0.01], which was close to control group (P &gt; 0.05); under ramp protocol, the current densities of control and asthmatic model group were [(75 +/- 19) pA/pF, n = 10] and [(46 +/- 16) pA/pF, n = 8] respectively, there was significant difference between two groups (P &lt; 0.01), SNP treatment significantly increased current density of asthmatic model group to [(82 +/- 21) pA/pF, n = 8, P &lt; 0.01].	Protactinium	77-79	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	32-36
14633445-7	2003	(2) The mean current density of BKCa from asthmatic model group [(44 +/- 17) pA/pF, n = 8] under pulse protocol was significantly lower than that of the control group [(73 +/- 20) pA/pF, n = 10, P &lt; 0.01], and SNP significantly increased the mean current density of the asthmatic model group to [(79 +/- 16) pA/pF, n = 10, P &lt; 0.01], which was close to control group (P &gt; 0.05); under ramp protocol, the current densities of control and asthmatic model group were [(75 +/- 19) pA/pF, n = 10] and [(46 +/- 16) pA/pF, n = 8] respectively, there was significant difference between two groups (P &lt; 0.01), SNP treatment significantly increased current density of asthmatic model group to [(82 +/- 21) pA/pF, n = 8, P &lt; 0.01].	Protactinium	180-182	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	32-36
14633445-7	2003	(2) The mean current density of BKCa from asthmatic model group [(44 +/- 17) pA/pF, n = 8] under pulse protocol was significantly lower than that of the control group [(73 +/- 20) pA/pF, n = 10, P &lt; 0.01], and SNP significantly increased the mean current density of the asthmatic model group to [(79 +/- 16) pA/pF, n = 10, P &lt; 0.01], which was close to control group (P &gt; 0.05); under ramp protocol, the current densities of control and asthmatic model group were [(75 +/- 19) pA/pF, n = 10] and [(46 +/- 16) pA/pF, n = 8] respectively, there was significant difference between two groups (P &lt; 0.01), SNP treatment significantly increased current density of asthmatic model group to [(82 +/- 21) pA/pF, n = 8, P &lt; 0.01].	Protactinium	180-182	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	32-36
12885817-12	2003	CONCLUSION: Children with PAs with an MIB-1 LI of more than 2.0 have a shortened PFS.	Protactinium	26-29	MIB E3 ubiquitin protein ligase 1	Homo sapiens	38-43
14748540-0	2003	The mutation in the N-terminal domain of RGS4 disrupts PA-conferred inhibitory effect on GAP activity.	Protactinium	55-57	regulator of G protein signaling 4	Homo sapiens	41-45
14748540-2	2003	In this present study, we demonstrate that PA is the most efficient candidate to inhibit GAP activity of RGS4.	Protactinium	43-45	regulator of G protein signaling 4	Homo sapiens	105-109
14748540-3	2003	The functional significance of N-terminus of RGS4 in respose to PA-granted inhibition on GAP activity has been studied with the site mutation in the N-terminus of RGS4.	Protactinium	64-66	regulator of G protein signaling 4	Homo sapiens	45-49
14748540-3	2003	The functional significance of N-terminus of RGS4 in respose to PA-granted inhibition on GAP activity has been studied with the site mutation in the N-terminus of RGS4.	Protactinium	64-66	regulator of G protein signaling 4	Homo sapiens	163-167
14748540-5	2003	However, RGS4L23E diminishes the inhibition of GAP activity by PA compared with the wild type RGS4, whereas RGSR22E abrogates the inhibitory effect by PA on GAP activity.	Protactinium	63-65	regulator of G protein signaling 4	Homo sapiens	9-13
14748540-7	2003	It is suggested that the functional pertinence between the N-terminus and RGS domain may be important to modulate PA-conferred inhibitory effect on its GAP activity.	Protactinium	114-116	paired like homeodomain 2	Homo sapiens	74-77
12944446-7	2003	Mean bias between PA continuous and PA intermittent and Aorta continuous and PA intermittent was 0.15 L x min(-1) (2SD of differences between methods = 1.39 L x min(-1)) and 0.08 L x min(-1) (2SD of differences between methods = 1.43 L x min(-1)).	Protactinium	18-20	CD59 molecule (CD59 blood group)	Homo sapiens	106-112
12885817-14	2003	This initial study suggests that the MIB-1 LI identifies a more aggressive subset of PAs.	Protactinium	85-88	MIB E3 ubiquitin protein ligase 1	Homo sapiens	37-42
12958811-4	2003	Abundant intracellular and extracellular acid mucin produced by the solid papillary tumor cells was proven histochemically by: PAS, PAS-D, mucicarmine and alcian blue.	Protactinium	127-130	LOC100508689	Homo sapiens	46-51
12857804-5	2003	The expression of meristematic homeobox genes KNOTTED-LIKE IN ARABIDOPSIS (KNAT2, KNAT6), and SHOOT MERISTEMLESS was also increased in pas mutants.	Protactinium	135-138	homeobox knotted-like protein	Arabidopsis thaliana	75-80
12857804-5	2003	The expression of meristematic homeobox genes KNOTTED-LIKE IN ARABIDOPSIS (KNAT2, KNAT6), and SHOOT MERISTEMLESS was also increased in pas mutants.	Protactinium	135-138	homeobox protein knotted-1-like 6	Arabidopsis thaliana	82-87
12857804-7	2003	The KNAT2 expression pattern defines an enlarged meristematic zone in pas mutants that can be mimicked in wild type by cytokinin treatment.	Protactinium	70-73	homeobox knotted-like protein	Arabidopsis thaliana	4-9
12857804-8	2003	Cytokinin induction of the primary cytokinin response markers, ARABIDOPSIS RESPONSE REGULATOR (ARR5 and ARR6), was enhanced and lasted longer in pas mutants, suggesting that PAS genes in wild type repress cytokinin responses.	Protactinium	145-148	response regulator 5	Arabidopsis thaliana	95-99
12857804-8	2003	Cytokinin induction of the primary cytokinin response markers, ARABIDOPSIS RESPONSE REGULATOR (ARR5 and ARR6), was enhanced and lasted longer in pas mutants, suggesting that PAS genes in wild type repress cytokinin responses.	Protactinium	145-148	response regulator 6	Arabidopsis thaliana	104-108
12810083-5	2003	We also demonstrated that Co(2+) binds to both PAS domains in the N-terminal region of HIF1alpha.	Protactinium	47-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	87-96
12810083-6	2003	These observations imply that the stability of HIF1alpha is regulated by an additional pathway through the cobalt binding of PAS domains.	Protactinium	125-128	hypoxia inducible factor 1 subunit alpha	Homo sapiens	47-56
12835473-14	2003	In simulations, 25-60 pA of Ca2+ current exiting a point source was required to reproduce frog sparks.	Protactinium	22-24	carbonic anhydrase 2	Rattus norvegicus	28-31
12832676-5	2003	RESULTS: LPS, IL-1alpha, and TNF-alpha promoted the formation of O(2)(*-) from PA compared with untreated controls in a time and dose dependent manner, an effect markedly enhanced by removal of the endothelium but completely inhibited by the NADPH oxidase inhibitor diphenylene iodonium chloride (DPI).	Protactinium	79-81	interleukin 1 alpha	Sus scrofa	14-23
12832676-5	2003	RESULTS: LPS, IL-1alpha, and TNF-alpha promoted the formation of O(2)(*-) from PA compared with untreated controls in a time and dose dependent manner, an effect markedly enhanced by removal of the endothelium but completely inhibited by the NADPH oxidase inhibitor diphenylene iodonium chloride (DPI).	Protactinium	79-81	tumor necrosis factor	Sus scrofa	29-38
12690037-10	2003	In addition, lipoxygenase inhibitors reduce phenylephrine-induced constriction of PA rings.	Protactinium	82-84	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	13-25
12846485-3	2003	Truncated analogues of PA from the C-terminus were systematically prepared ending in either the free acid or the amide, i.e. PA1-9 acid, PA1-8 acid, PA1-7 acid, PA1-6 acid, PA1-8 amide, PA1-7 amide and PA1-6 amide.	Protactinium	23-25	Paxip1-associated glutamate-rich protein 1	Rattus norvegicus	125-130
12846485-3	2003	Truncated analogues of PA from the C-terminus were systematically prepared ending in either the free acid or the amide, i.e. PA1-9 acid, PA1-8 acid, PA1-7 acid, PA1-6 acid, PA1-8 amide, PA1-7 amide and PA1-6 amide.	Protactinium	23-25	Paxip1-associated glutamate-rich protein 1	Rattus norvegicus	125-128
12736354-8	2003	When these transgenic mice are treated with doxycycline in adulthood to switch off nAChR expression, baseline PA is maintained even after transgene expression is abolished.	Protactinium	110-112	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	83-88
12700348-6	2003	A recombinant CMG2 protein bound PA and mediated toxin internalization when expressed on receptor-deficient cells.	Protactinium	33-35	ANTXR cell adhesion molecule 2	Homo sapiens	14-18
12700348-7	2003	Binding between the CMG2 VWA/I domain and PA was shown to be direct and metal-dependent, although the cation specificity of this interaction is different than that observed with ATR/TEM8.	Protactinium	42-44	ANTXR cell adhesion molecule 2	Homo sapiens	20-24
12700348-9	2003	Finally, a soluble version of the CMG2 VWA/I domain inhibited intoxication of cells expressing endogenous toxin receptors when it was added to PA at a 3:1 ratio.	Protactinium	143-145	ANTXR cell adhesion molecule 2	Homo sapiens	34-38
12657615-5	2003	RESULTS: Members of the Plg/PA system were present both in human and murine CNV.	Protactinium	28-30	plasminogen	Homo sapiens	24-27
12725734-2	2003	Because PER, dCLK, and CYC each contain a PAS domain, it has been assumed that these interaction domains are important for negative feedback.	Protactinium	42-45	period	Drosophila melanogaster	8-11
12725734-2	2003	Because PER, dCLK, and CYC each contain a PAS domain, it has been assumed that these interaction domains are important for negative feedback.	Protactinium	42-45	Clock	Drosophila melanogaster	13-17
12725734-2	2003	Because PER, dCLK, and CYC each contain a PAS domain, it has been assumed that these interaction domains are important for negative feedback.	Protactinium	42-45	cycle	Drosophila melanogaster	23-26
12725734-3	2003	However, a critical role for PAS-PAS interactions in Drosophila clock function has not been shown.	Protactinium	29-32	Clock	Drosophila melanogaster	64-69
12725734-3	2003	However, a critical role for PAS-PAS interactions in Drosophila clock function has not been shown.	Protactinium	33-36	Clock	Drosophila melanogaster	64-69
12725734-6	2003	We mapped the dCLK:CYC inhibition domain (CCID) of PER and discovered that it lies in the C terminus, downstream of the PAS domain.	Protactinium	120-123	period	Drosophila melanogaster	51-54
15621862-5	2003	Another protein with a mass of 30,923 amu was detected along the HPLC pattern and MS data of its tryptic digest suggested that it corresponds to the dimer of Pa, the isoform of PRP-1 with a substitution Arg-Cys at 103 position.	Protactinium	158-160	prion protein	Homo sapiens	177-180
12657615-8	2003	CONCLUSIONS: Together with previous work done by the authors, this study indicates that choroidal neovascularization is extremely sensitive to the modulation of Plg/PA system activity.	Protactinium	165-167	plasminogen	Mus musculus	161-164
12824001-6	2003	In PA- and PG-deficient mice, TNF/GalN still induced hepatitis, as well as increased clotting time and FG breakdown.	Protactinium	3-5	tumor necrosis factor	Mus musculus	30-33
12820434-7	2003	Reduced phosphorylation of the retinoblastoma protein (Rb) and CDK2 activity, increased expression of p21Cip1 and enhanced binding of p21Cip1 to CDK2 were observed following treatment with PA.	Protactinium	189-191	cyclin dependent kinase 2	Homo sapiens	63-67
12820434-7	2003	Reduced phosphorylation of the retinoblastoma protein (Rb) and CDK2 activity, increased expression of p21Cip1 and enhanced binding of p21Cip1 to CDK2 were observed following treatment with PA.	Protactinium	189-191	cyclin dependent kinase inhibitor 1A	Homo sapiens	102-109
12820434-8	2003	CONCLUSION: Overall, these results suggest that p21Cip1 is a critical target in PA-mediated cell growth inhibition in RCC cells playing a key role in CDK2 inactivation, hypophosphorylation of pRb and subsequent G1 cell cycle arrest.	Protactinium	80-82	cyclin dependent kinase inhibitor 1A	Homo sapiens	48-55
12820434-7	2003	Reduced phosphorylation of the retinoblastoma protein (Rb) and CDK2 activity, increased expression of p21Cip1 and enhanced binding of p21Cip1 to CDK2 were observed following treatment with PA.	Protactinium	189-191	cyclin dependent kinase inhibitor 1A	Homo sapiens	134-141
12820434-8	2003	CONCLUSION: Overall, these results suggest that p21Cip1 is a critical target in PA-mediated cell growth inhibition in RCC cells playing a key role in CDK2 inactivation, hypophosphorylation of pRb and subsequent G1 cell cycle arrest.	Protactinium	80-82	cyclin dependent kinase 2	Homo sapiens	150-154
12820434-8	2003	CONCLUSION: Overall, these results suggest that p21Cip1 is a critical target in PA-mediated cell growth inhibition in RCC cells playing a key role in CDK2 inactivation, hypophosphorylation of pRb and subsequent G1 cell cycle arrest.	Protactinium	80-82	RB transcriptional corepressor 1	Homo sapiens	192-195
12820434-7	2003	Reduced phosphorylation of the retinoblastoma protein (Rb) and CDK2 activity, increased expression of p21Cip1 and enhanced binding of p21Cip1 to CDK2 were observed following treatment with PA.	Protactinium	189-191	cyclin dependent kinase 2	Homo sapiens	145-149
12725318-6	2003	Compared with the non-PA group, the PA group was significantly correlated with delay at diagnosis, large size of the tumor, late TNM stage, extension to the skin or chest wall and administration with oophorectomy.	Protactinium	36-38	teneurin transmembrane protein 1	Homo sapiens	129-132
12604800-4	2003	The D2 mutation resulted in the reduction of PA- or NS-specific vRNA and mRNA levels in PA- or NS-recombinant viruses, respectively.	Protactinium	45-47	vault RNA 1-1	Homo sapiens	64-68
12604800-4	2003	The D2 mutation resulted in the reduction of PA- or NS-specific vRNA and mRNA levels in PA- or NS-recombinant viruses, respectively.	Protactinium	88-90	vault RNA 1-1	Homo sapiens	64-68
12620640-5	2003	In contrast, immunization with Pa failed to activate pro-inflammatory IL-1 responses but resulted in increased IL-1 receptor antagonist (IL-1ra) production.	Protactinium	31-33	interleukin 1 receptor antagonist	Mus musculus	111-135
12620640-5	2003	In contrast, immunization with Pa failed to activate pro-inflammatory IL-1 responses but resulted in increased IL-1 receptor antagonist (IL-1ra) production.	Protactinium	31-33	interleukin 1 receptor antagonist	Mus musculus	137-143
12502991-10	2003	In patients of the PA + PCEA group in the postoperative period, production of IL-1beta, IL-6, IL-1ra, and IL-10 was significantly less elevated, while IL-2 production was significantly less suppressed.	Protactinium	19-21	interleukin 1 beta	Homo sapiens	78-86
12565846-9	2003	The results of site-directed mutagenesis suggest that AP2 and c-Ets sites in this region are involved in pA promoter activity, which in turn suggests that the hST3Gal IV gene is regulated in a tissue-restricted fashion at the level of transcription.	Protactinium	105-107	transcription factor AP-2 alpha	Homo sapiens	54-57
12565846-9	2003	The results of site-directed mutagenesis suggest that AP2 and c-Ets sites in this region are involved in pA promoter activity, which in turn suggests that the hST3Gal IV gene is regulated in a tissue-restricted fashion at the level of transcription.	Protactinium	105-107	tumor-suppressor, HELA cell type	Homo sapiens	159-163
12543376-4	2003	In the present work, we have found that binding of Ca(2+) to PA incorporated into the membrane of sulforhodamine B (SRB)-loaded liposomes results in an instant release of a part of SRB, with the quantity of SRB released depending on the concentration of PA and Ca(2+).	Protactinium	61-63	chaperonin containing TCP1 subunit 4	Homo sapiens	98-114
12543376-4	2003	In the present work, we have found that binding of Ca(2+) to PA incorporated into the membrane of sulforhodamine B (SRB)-loaded liposomes results in an instant release of a part of SRB, with the quantity of SRB released depending on the concentration of PA and Ca(2+).	Protactinium	61-63	chaperonin containing TCP1 subunit 4	Homo sapiens	116-119
12543376-4	2003	In the present work, we have found that binding of Ca(2+) to PA incorporated into the membrane of sulforhodamine B (SRB)-loaded liposomes results in an instant release of a part of SRB, with the quantity of SRB released depending on the concentration of PA and Ca(2+).	Protactinium	61-63	chaperonin containing TCP1 subunit 4	Homo sapiens	181-184
12543376-4	2003	In the present work, we have found that binding of Ca(2+) to PA incorporated into the membrane of sulforhodamine B (SRB)-loaded liposomes results in an instant release of a part of SRB, with the quantity of SRB released depending on the concentration of PA and Ca(2+).	Protactinium	61-63	chaperonin containing TCP1 subunit 4	Homo sapiens	181-184
12543376-4	2003	In the present work, we have found that binding of Ca(2+) to PA incorporated into the membrane of sulforhodamine B (SRB)-loaded liposomes results in an instant release of a part of SRB, with the quantity of SRB released depending on the concentration of PA and Ca(2+).	Protactinium	254-256	chaperonin containing TCP1 subunit 4	Homo sapiens	98-114
12543376-4	2003	In the present work, we have found that binding of Ca(2+) to PA incorporated into the membrane of sulforhodamine B (SRB)-loaded liposomes results in an instant release of a part of SRB, with the quantity of SRB released depending on the concentration of PA and Ca(2+).	Protactinium	254-256	chaperonin containing TCP1 subunit 4	Homo sapiens	116-119
12543376-4	2003	In the present work, we have found that binding of Ca(2+) to PA incorporated into the membrane of sulforhodamine B (SRB)-loaded liposomes results in an instant release of a part of SRB, with the quantity of SRB released depending on the concentration of PA and Ca(2+).	Protactinium	254-256	chaperonin containing TCP1 subunit 4	Homo sapiens	181-184
12543376-4	2003	In the present work, we have found that binding of Ca(2+) to PA incorporated into the membrane of sulforhodamine B (SRB)-loaded liposomes results in an instant release of a part of SRB, with the quantity of SRB released depending on the concentration of PA and Ca(2+).	Protactinium	254-256	chaperonin containing TCP1 subunit 4	Homo sapiens	181-184
12543376-7	2003	Along with Ca(2+), some other bivalent cations (Ba(2+), Sr(2+), Mn(2+), Ni(2+), Co(2+)) also induce SRB release upon binding to PA-containing liposomes, while Mg(2+) turns out to be relatively ineffective.	Protactinium	128-130	chaperonin containing TCP1 subunit 4	Homo sapiens	100-103
12609503-1	2003	We identified a novel spontaneous mouse model of human congenital muscular dystrophy with laminin alpha2 chain deficiency, named dy(Pas)/dy(Pas).	Protactinium	132-135	laminin, alpha 2	Mus musculus	90-104
12609503-1	2003	We identified a novel spontaneous mouse model of human congenital muscular dystrophy with laminin alpha2 chain deficiency, named dy(Pas)/dy(Pas).	Protactinium	140-143	laminin, alpha 2	Mus musculus	90-104
12586544-6	2003	Interestingly, the rapid degradation of NF-kappaB inhibitor IkappaBalpha induced by Pa- and beta-endorphin was reversed by a pretreatment with H-89 and cyclosporin A, inhibitors of protein kinase A (PKA) and protein phosphatase 2B (PP2B), respectively.	Protactinium	84-86	NFKB inhibitor alpha	Homo sapiens	60-72
12502991-10	2003	In patients of the PA + PCEA group in the postoperative period, production of IL-1beta, IL-6, IL-1ra, and IL-10 was significantly less elevated, while IL-2 production was significantly less suppressed.	Protactinium	19-21	interleukin 6	Homo sapiens	88-92
12502991-10	2003	In patients of the PA + PCEA group in the postoperative period, production of IL-1beta, IL-6, IL-1ra, and IL-10 was significantly less elevated, while IL-2 production was significantly less suppressed.	Protactinium	19-21	interleukin 1 receptor antagonist	Homo sapiens	94-100
12502991-10	2003	In patients of the PA + PCEA group in the postoperative period, production of IL-1beta, IL-6, IL-1ra, and IL-10 was significantly less elevated, while IL-2 production was significantly less suppressed.	Protactinium	19-21	interleukin 10	Homo sapiens	106-111
12502991-10	2003	In patients of the PA + PCEA group in the postoperative period, production of IL-1beta, IL-6, IL-1ra, and IL-10 was significantly less elevated, while IL-2 production was significantly less suppressed.	Protactinium	19-21	interleukin 2	Homo sapiens	151-155
12515324-8	2002	These findings indicate that PA and MMA alter the dynamic regulation of NF-H assembly in the cytoskeletal fraction.	Protactinium	29-31	neurofilament heavy chain	Rattus norvegicus	72-76
12503697-12	2002	However, the reduction in Pa,CO2 correlated with the reduction of serum leptin concentration.	Protactinium	26-28	leptin	Homo sapiens	72-78
12466359-4	2002	The objective of this study was to determine whether boys with PA show alterations in insulin sensitivity and the IGF system.	Protactinium	63-65	insulin	Homo sapiens	86-93
12466359-11	2002	Total IGF-I, P(0), ratio of P(0) and fasting insulin level, and log insulin area under the curve were higher, and SHBG was lower in the boys with PA, compared with controls.	Protactinium	146-148	insulin	Homo sapiens	68-75
12466359-11	2002	Total IGF-I, P(0), ratio of P(0) and fasting insulin level, and log insulin area under the curve were higher, and SHBG was lower in the boys with PA, compared with controls.	Protactinium	146-148	sex hormone binding globulin	Homo sapiens	114-118
12466359-14	2002	Prepubertal boys with PA show differences in the IGF system and decreased insulin sensitivity, independent of obesity, as observed in girls with PA.	Protactinium	22-24	insulin	Homo sapiens	74-81
12466359-15	2002	These findings suggest that both boys and girls with PA should be monitored for the development of insulin resistance and associated complications, including diabetes mellitus and cardiovascular disease.	Protactinium	53-55	insulin	Homo sapiens	99-106
12673129-5	2003	About half of these treated colonies also displayed methylation of the internal ABL Pa promoter, a CML-specific epigenetic alteration, which was used in this study as a marker for BCR-ABL translocation-containing cells.	Protactinium	84-86	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	180-187
12479728-8	2002	All PAs were found negative for Ki-67 and p53.	Protactinium	4-7	tumor protein p53	Homo sapiens	42-45
12466246-5	2002	Ac-RYYRIK-NH(2) 0.032 microM and naloxone benzoylhydrazone 5 microM antagonized the effect of nociceptin/orphanin FQ in striatal slices of the guinea-pig (apparent pA(2) 9.1 and 6.8) and the mouse (apparent pA(2) 9.2 and 7.5) and strongly attenuated the effect of nociceptin/orphanin FQ 0.1 microM in guinea-pig retinal discs.	Protactinium	164-166	prepronociceptin	Mus musculus	105-116
12414876-10	2002	The reduced (basal) ACTH secretion and the diminished secretory process regularity of the ACTH/cortisol ensemble conjointly suggest that hypocretin deficiency induces changes in the interplay between PA hormones.	Protactinium	200-202	proopiomelanocortin	Homo sapiens	90-94
12495244-5	2002	Ego-high PA boys and task-low PA boys exerted the most effort on the moderate course; ego-low PA boys exerted least effort on the moderate and very difficult courses.	Protactinium	9-11	eosinophil granule ontogeny transcript	Homo sapiens	0-3
12427882-3	2002	Casein zymography was used to determine PA-dependent plasminogen activation in the CSF.	Protactinium	40-42	colony stimulating factor 2	Homo sapiens	83-86
12372422-4	2002	PDE8B1 encodes an 885 amino acid enzyme, containing an N-terminal REC domain, a PAS domain, and a C-terminal catalytic domain.	Protactinium	80-83	phosphodiesterase 8B	Homo sapiens	0-6
12372422-5	2002	PDE8B2 and PDE8B3 both have deletion in the PAS domain and encode 838 and 788 amino acid proteins, respectively.	Protactinium	44-47	phosphodiesterase 8B	Homo sapiens	0-5
12213382-4	2002	In this review we describe the current state of knowledge with respect to naturally occurring AhR ligands and present and discuss the first theoretical model of the AhR LBD based on crystal structures of homologous PAS family members.	Protactinium	215-218	aryl hydrocarbon receptor	Homo sapiens	165-168
12383086-2	2002	The N-terminal region of phot1 and phot2 contains two specialized PAS domains, designated LOV1 and LOV2, which function as binding sites for the chromophore flavin mononucleotide (FMN).	Protactinium	66-69	phototropin 1	Arabidopsis thaliana	25-30
12383086-2	2002	The N-terminal region of phot1 and phot2 contains two specialized PAS domains, designated LOV1 and LOV2, which function as binding sites for the chromophore flavin mononucleotide (FMN).	Protactinium	66-69	phototropin 2	Arabidopsis thaliana	35-40
12383086-2	2002	The N-terminal region of phot1 and phot2 contains two specialized PAS domains, designated LOV1 and LOV2, which function as binding sites for the chromophore flavin mononucleotide (FMN).	Protactinium	66-69	NAC domain containing protein 35	Arabidopsis thaliana	90-94
12217395-1	2002	Phospholipase D (PLD) catalyses the hydrolysis of phosphatidylcholine to generate the lipid second messenger, phosphatidate (PA).	Protactinium	125-127	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	0-15
12198141-9	2002	In TraR, the gene fusion is between a GAF/PAS domain and a DNA-binding domain, resulting in a specific transcriptional regulator involved in quorum sensing.	Protactinium	42-45	transcriptional regulator TraR	Agrobacterium tumefaciens	3-7
12190994-9	2002	Furthermore, histopathological analysis of the kidney showed that mesangial sclerosis, hyalin deposits and deposition of PAS-positive substance were significantly lower in Dmo1-F344/F344 animals (p &lt; 0.05).	Protactinium	121-124	Body weight QTL 115	Rattus norvegicus	172-176
12218985-7	2002	Only monocyte chemoattractant protein-1 levels were greater in affected PAs compared with sham PAs at 3 hours, 1 day, and 2 days (137 +/- 13 pg/mg protein, 285 +/- 40 pg/mg protein, and 249 +/- 36 pg/mg protein versus 101 +/- 6 pg/mg protein, 150 +/- 36 pg/mg protein, and 92 +/- 3 pg/mg protein; P &lt;.01 for all).	Protactinium	72-75	C-C motif chemokine ligand 2	Rattus norvegicus	5-39
12218985-12	2002	CONCLUSION: PE is associated with an early influx of polymorphonuclears and macrophages and monocyte chemoattractant protein-1 elevation within the PA wall.	Protactinium	148-150	C-C motif chemokine ligand 2	Rattus norvegicus	92-126
12217395-1	2002	Phospholipase D (PLD) catalyses the hydrolysis of phosphatidylcholine to generate the lipid second messenger, phosphatidate (PA).	Protactinium	125-127	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	17-20
12217395-4	2002	Primary alcohols specifically interfere with the production of PLD-derived PA and are found to be potent inhibitors of antigen-stimulated exocytosis.	Protactinium	75-77	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	63-66
12217395-7	2002	ARF proteins and PLD-derived PA synergistically regulate the activity of a Type I PIP 5-kinasealpha.	Protactinium	29-31	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	17-20
12217395-8	2002	It is suggested that ARF, by activating PLD and PIP 5-kinase activities regulate PA and PI(4,5)P(2) levels, and both are critical components of the exocytosis machinery in mast cells.	Protactinium	81-83	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	40-43
12212959-6	2002	Pa,O2 increased to acceptable levels with an O2 supply of 2 L x min(-1) at rest and 4 L x min(-1) during 20 W exercise.	Protactinium	0-2	CD59 molecule (CD59 blood group)	Homo sapiens	64-70
14993386-5	2002	In PDE2A, cGMP binds to a well-defined pocket in one of the two GAF domains that is analogous to the ligand-binding pocket of the distantly related PAS domains of photoactive yellow protein and FixL.	Protactinium	148-151	phosphodiesterase 2A	Homo sapiens	3-8
14993386-5	2002	In PDE2A, cGMP binds to a well-defined pocket in one of the two GAF domains that is analogous to the ligand-binding pocket of the distantly related PAS domains of photoactive yellow protein and FixL.	Protactinium	148-151	fibroblast growth factor 9	Homo sapiens	64-67
12169270-9	2002	Using the compound R54494, a DAG-kinase inhibitor, insulin-induced PKCzeta activation was also suppressed, this activity being restored by addition of PA.	Protactinium	151-153	insulin	Homo sapiens	51-58
12169270-9	2002	Using the compound R54494, a DAG-kinase inhibitor, insulin-induced PKCzeta activation was also suppressed, this activity being restored by addition of PA.	Protactinium	151-153	protein kinase C zeta	Homo sapiens	67-74
12169270-10	2002	In summary, these data indicate that PLCgamma, activated at least partially by PI3-kinase, is a link between insulin receptor and PKCzeta through the production of PA and could mediate insulin-induced glucose uptake and GLUT4 translocation.	Protactinium	164-166	insulin receptor	Homo sapiens	109-125
12169270-10	2002	In summary, these data indicate that PLCgamma, activated at least partially by PI3-kinase, is a link between insulin receptor and PKCzeta through the production of PA and could mediate insulin-induced glucose uptake and GLUT4 translocation.	Protactinium	164-166	protein kinase C zeta	Homo sapiens	130-137
12169270-10	2002	In summary, these data indicate that PLCgamma, activated at least partially by PI3-kinase, is a link between insulin receptor and PKCzeta through the production of PA and could mediate insulin-induced glucose uptake and GLUT4 translocation.	Protactinium	164-166	insulin	Homo sapiens	109-116
12169270-10	2002	In summary, these data indicate that PLCgamma, activated at least partially by PI3-kinase, is a link between insulin receptor and PKCzeta through the production of PA and could mediate insulin-induced glucose uptake and GLUT4 translocation.	Protactinium	164-166	solute carrier family 2 member 4	Homo sapiens	220-225
12212959-6	2002	Pa,O2 increased to acceptable levels with an O2 supply of 2 L x min(-1) at rest and 4 L x min(-1) during 20 W exercise.	Protactinium	0-2	CD59 molecule (CD59 blood group)	Homo sapiens	90-96
12147794-8	2002	RESULTS: Both CR and PA were positively correlated with platelet count and fibrinogen level.	Protactinium	21-23	fibrinogen beta chain	Homo sapiens	75-85
11927597-8	2002	Nevertheless, our results raise the possibility that Pa-UDGa may be a functional analog of hUNG2 for PCNA-dependent postreplicative removal of misincorporated uracil.	Protactinium	53-55	uracil DNA glycosylase	Homo sapiens	91-96
12119223-4	2002	GM-CSF-treated patients showed improvement in Pa(O(2))/FI(O(2)) over 5 days (p = 0.02) and increased peripheral blood neutrophils (p = 0.08), whereas alveolar neutrophils decreased (p = 0.02).	Protactinium	46-48	colony stimulating factor 2	Homo sapiens	0-6
11927597-8	2002	Nevertheless, our results raise the possibility that Pa-UDGa may be a functional analog of hUNG2 for PCNA-dependent postreplicative removal of misincorporated uracil.	Protactinium	53-55	proliferating cell nuclear antigen	Homo sapiens	101-105
12029369-7	2002	It also demonstrates that both proximal and eag/PAS domains in the amino terminus contribute to set the gating characteristics of HERG channels.	Protactinium	48-51	potassium voltage-gated channel subfamily H member 2	Homo sapiens	130-134
12065325-7	2002	In contrast, transfection of constitutively active MLCK elevated Pa, which was abolished by ML-7.	Protactinium	65-67	myosin light chain kinase, smooth muscle	Bos taurus	51-55
12115498-9	2002	Moreover, Flp exerted similar inhibitory activity on VEGF induction by PA or DFX, suggesting that this compound targets an essential step in the signaling pathway that leads to VEGF expression.	Protactinium	71-73	vascular endothelial growth factor A	Homo sapiens	53-57
12022877-5	2002	PA containing bound MgADP supports elongation of the actin filament barbed end, indicating that ATP hydrolysis is not necessary for PA elongation of filaments.	Protactinium	0-2	actin epsilon 1	Bos taurus	53-58
12115498-4	2002	In this study, we analyzed the effects of hypoxia, a common feature of solid tumors and a major drive to tumor angiogenesis, and of PA, a tryptophan catabolite produced under inflammatory conditions and endowed with several biologic properties, on the production of the angiogenic activator VEGF by advanced-stage human NB cell lines.	Protactinium	132-134	vascular endothelial growth factor A	Homo sapiens	291-295
12115498-6	2002	VEGF upregulation by PA involved iron chelation because iron sulfate prevented this effect whereas the iron-chelating agent DFX induced VEGF production.	Protactinium	21-23	vascular endothelial growth factor A	Homo sapiens	0-4
12069808-8	2002	In the case of PA, S1P and C1P, the products are diacylglycerol (DAG), sphingosine and ceramide, respectively.	Protactinium	15-17	membrane bound transcription factor peptidase, site 1	Homo sapiens	19-30
12008021-7	2002	In one line of PA transgenic mice, hIL-2R-GFP was properly expressed in PV-containing neurons in the cerebellum, thalamic reticular nucleus, globus pallidus and cerebral cortex, though ectopic expression was observed in a particular subset of cerebellar astrocytes.	Protactinium	15-17	parvalbumin	Mus musculus	72-74
12010780-9	2002	In isolated peripheral tissues of mice, rats and guinea-pigs, and in rat cerebral cortex synaptosomes preloaded with [(3)H]-5-HT, UFP-101 competitively antagonized the effects of N/OFQ with pA(2) values in the range of 7.3 - 7.7.	Protactinium	190-192	prepronociceptin	Mus musculus	179-184
12008021-8	2002	Another line of PA transgenic mice showed a selective and mosaic expression of hIL-2R-GFP in PV-containing Purkinje, basket and stellate cells in the cerebellum.	Protactinium	16-18	parvalbumin	Mus musculus	93-95
11924587-10	2002	The polymeric surfaces with immobilized PAS had better nonthrombogenic characteristics as indicated by the low platelet adhesion, high adsorption of albumin relatively to fibrinogen and low thrombus formation, making them potentially good candidates for biomedical applications.	Protactinium	40-43	fibrinogen beta chain	Homo sapiens	171-181
12067238-5	2002	We also showed that cells strongly expressing zif268 mRNA accumulated in patches in area 36 during learning of the PA task.	Protactinium	115-117	early growth response 1	Homo sapiens	46-52
11954950-4	2002	Though the %PA (PA/VA) after the procedure showed significant negative correlation with the subsequent change in cPA, it did not correlate with the subsequent change in cVA.	Protactinium	12-14	carboxypeptidase A1	Homo sapiens	113-116
12008951-9	2002	The data presented propose that of the FGFs studied (FGF-1, -2, -4, -5, and -7), FGF-2 is the most attractive target for therapeutical strategies aimed at diminishing the contribution of stromal fibroblasts in the PA-directed breast tumor proteolysis.	Protactinium	214-216	fibroblast growth factor 2	Homo sapiens	81-86
11891190-8	2002	Our data highlight the complexities of PA function, and suggest that approaches either to target u-PA or to enhance local t-PA activity in joints may be of therapeutic benefit in rheumatoid arthritis.	Protactinium	39-41	plasminogen activator, urokinase	Mus musculus	97-101
12014665-6	2002	Those muciphages were PAS- CD68- and lysozyme-positive.	Protactinium	22-25	CD68 molecule	Homo sapiens	27-31
11886960-10	2002	Finally, as expected, PA activity was increased in synovial tissues from PAI-1(-/-) mice, as shown by zymographic analysis.	Protactinium	22-24	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	73-78
11744730-7	2002	To examine the role of PLD in the regulation of PI(4,5)P(2) synthesis, we used butanol to diminish the PLD-derived PA.	Protactinium	115-117	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	103-106
11744730-14	2002	We therefore conclude that both PA derived from the PLD pathway and ARF proteins, by directly activating PIP 5-kinase, contribute to the regulation of PI(4,5)P(2) synthesis at the plasma membrane in HL60 cells.	Protactinium	32-34	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	52-55
11744730-14	2002	We therefore conclude that both PA derived from the PLD pathway and ARF proteins, by directly activating PIP 5-kinase, contribute to the regulation of PI(4,5)P(2) synthesis at the plasma membrane in HL60 cells.	Protactinium	32-34	prolactin induced protein	Homo sapiens	105-108
11762832-13	2002	By decreasing the amount of HCO-60 and citric acid, the PA of G-CSF decreased.	Protactinium	56-58	colony stimulating factor 3	Canis lupus familiaris	62-67
12405290-7	2002	In the PA system, uPAR antigen levels were significantly higher in tumors with COX-2 expression than in tumors without (P = 0.0233).	Protactinium	7-9	plasminogen activator, urokinase receptor	Homo sapiens	18-22
11928812-2	2002	The present study deals with the effects of PAs on the expression of fibronectin (FN), a heterodimeric extracellular matrix (ECM) protein that can be modulated in different ways by various mitogens.	Protactinium	44-47	fibronectin 1	Homo sapiens	69-80
11928812-2	2002	The present study deals with the effects of PAs on the expression of fibronectin (FN), a heterodimeric extracellular matrix (ECM) protein that can be modulated in different ways by various mitogens.	Protactinium	44-47	fibronectin 1	Homo sapiens	82-84
11928812-3	2002	The kinetics of FN gene response was examined in quiescent fibroblasts upon PA stimulation (30 min -24 h).	Protactinium	76-78	fibronectin 1	Homo sapiens	16-18
11928812-6	2002	These differences are probably due to the differential enzymatic action of t-PA and u-PA on FN, which might be related to a differential role of the two PAs in several physiopathological conditions.	Protactinium	153-156	plasminogen activator, tissue type	Homo sapiens	75-79
11928812-6	2002	These differences are probably due to the differential enzymatic action of t-PA and u-PA on FN, which might be related to a differential role of the two PAs in several physiopathological conditions.	Protactinium	153-156	plasminogen activator, urokinase	Homo sapiens	84-88
11928812-6	2002	These differences are probably due to the differential enzymatic action of t-PA and u-PA on FN, which might be related to a differential role of the two PAs in several physiopathological conditions.	Protactinium	153-156	fibronectin 1	Homo sapiens	92-94
11784293-3	2002	The three structures reveal a highly conserved structural framework in evolutionary rather distant PAS domains, provide a more general view of how these domains can recognize their ligands and suggest a structure-function relationship that we exploited to build a three-dimensional model of the ligand binding domain (LBD) of the mouse aryl hydrocarbon receptor (mAhR).	Protactinium	99-102	aryl-hydrocarbon receptor	Mus musculus	336-361
11784293-3	2002	The three structures reveal a highly conserved structural framework in evolutionary rather distant PAS domains, provide a more general view of how these domains can recognize their ligands and suggest a structure-function relationship that we exploited to build a three-dimensional model of the ligand binding domain (LBD) of the mouse aryl hydrocarbon receptor (mAhR).	Protactinium	99-102	aryl-hydrocarbon receptor	Mus musculus	363-367
12523623-6	2002	These findings show that the resistance of E. coli 1941 to the combinations of beta-lactams with beta-lactamase inhibitors is related to high-level production of TEM-1 enzyme expressed from the strong promoters Pa and Pb.	Protactinium	211-213	hypothetical protein	Escherichia coli	162-167
11788683-3	2002	Hyperinsulinemia, elevated total IGF-I, and decreased IGF-binding protein-1 (IGFBP-1) have also been reported in PA. Dysregulation of the IGF system may be involved in the pathogenesis of PA and its progression to PCOS.	Protactinium	113-115	insulin like growth factor 1	Homo sapiens	33-38
11788683-3	2002	Hyperinsulinemia, elevated total IGF-I, and decreased IGF-binding protein-1 (IGFBP-1) have also been reported in PA. Dysregulation of the IGF system may be involved in the pathogenesis of PA and its progression to PCOS.	Protactinium	113-115	insulin like growth factor binding protein 1	Homo sapiens	54-75
11788683-3	2002	Hyperinsulinemia, elevated total IGF-I, and decreased IGF-binding protein-1 (IGFBP-1) have also been reported in PA. Dysregulation of the IGF system may be involved in the pathogenesis of PA and its progression to PCOS.	Protactinium	113-115	insulin like growth factor binding protein 1	Homo sapiens	77-84
11788683-11	2002	These results suggest altered regulation of the insulin/IGF system in prepubertal girls with PA and a possible role for free IGF-I in the pathogenesis of the hyperandrogenism of PA as well as its progression to PCOS.	Protactinium	93-95	insulin	Homo sapiens	48-55
11788683-11	2002	These results suggest altered regulation of the insulin/IGF system in prepubertal girls with PA and a possible role for free IGF-I in the pathogenesis of the hyperandrogenism of PA as well as its progression to PCOS.	Protactinium	178-180	insulin like growth factor 1	Homo sapiens	125-130
11717280-5	2001	The H. influenzae ArcB, however, lacks the PAS domain present in the region of E. coli ArcB linking the transmembrane to the cytosolic catalytic domains.	Protactinium	43-46	hypothetical protein	Escherichia coli	18-22
12192614-5	2002	Our results showed that self-reported schizotypy scores in both questionnaires were significantly related to COMT genotype (P = 0.028 for the PAS and P = 0.015 for the SPQ) with individuals homozygous for the high activity allele showing the highest scores.	Protactinium	142-145	catechol-O-methyltransferase	Homo sapiens	109-113
11868388-8	2002	Findings on AhR/Arnt and HIF1 systems demonstrating that they are members of the same PAS family seem to support this hypothesis.	Protactinium	86-89	aryl hydrocarbon receptor	Homo sapiens	12-15
11868388-8	2002	Findings on AhR/Arnt and HIF1 systems demonstrating that they are members of the same PAS family seem to support this hypothesis.	Protactinium	86-89	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	16-20
11868388-8	2002	Findings on AhR/Arnt and HIF1 systems demonstrating that they are members of the same PAS family seem to support this hypothesis.	Protactinium	86-89	hypoxia inducible factor 1 subunit alpha	Homo sapiens	25-29
12934248-15	2002	CONCLUSIONS: These findings suggest the existence of an active and intense occurrence of immunocellular mechanisms in the production and evolution of severe HChC, in which T-lymphocytes CD4+ intervene, with production and secretion of PAS+ substances; Besides, macrophages, and mast cells, in that order.	Protactinium	235-239	CD4 molecule	Homo sapiens	186-189
11813843-8	2001	We examined the expression of VEGF in the resected lung tissue of 4 patients with PA using immunohistochemistry.	Protactinium	82-84	vascular endothelial growth factor A	Homo sapiens	30-34
11717280-0	2001	Redox signal transduction by the ArcB sensor kinase of Haemophilus influenzae lacking the PAS domain.	Protactinium	90-93	hypothetical protein	Escherichia coli	33-37
11717280-5	2001	The H. influenzae ArcB, however, lacks the PAS domain present in the region of E. coli ArcB linking the transmembrane to the cytosolic catalytic domains.	Protactinium	43-46	hypothetical protein	Escherichia coli	87-91
11717280-7	2001	Our results demonstrate that the ArcB protein of H. influenzae mediates signal transduction in response to redox conditions of growth despite the absence of the PAS domain.	Protactinium	161-164	hypothetical protein	Escherichia coli	33-37
11687302-5	2001	In order to shed light on the molecular mechanisms, we isolated six MN Pc-1 binding proteins, pA, pB, pD, pE, pF and pG, from nuclear extracts of NIH3T3 cells treated with okadaic acid.	Protactinium	94-96	minisatellite 6 hypermutable	Mus musculus	71-75
11597585-2	2001	We identified a novel protein PIPS (Per1 interacting protein of the suprachiasmatic nucleus) with the yeast two-hybrid system using PAS domain of rat Per1 (rPer1) as a bait.	Protactinium	132-135	G protein-coupled receptor associated sorting protein 1	Rattus norvegicus	30-34
11597585-2	2001	We identified a novel protein PIPS (Per1 interacting protein of the suprachiasmatic nucleus) with the yeast two-hybrid system using PAS domain of rat Per1 (rPer1) as a bait.	Protactinium	132-135	period circadian regulator 1	Rattus norvegicus	156-161
11824759-0	2001	1H, 13C and 15N chemical shift assignments of the N-terminal PAS domain of mNPAS2.	Protactinium	61-64	neuronal PAS domain protein 2	Mus musculus	75-81
11504728-3	2001	Overexpression of Cwh8p in the yeast double mutant strain, lacking LPP1/DPP1, resulted in an impressive increase in Dol-P-P phosphatase activity, a relatively small increase in Dol-P phosphatase activity, but no change in phosphatidate (PA) phosphatase activity in microsomal fractions.	Protactinium	237-239	dolichyldiphosphatase	Saccharomyces cerevisiae S288C	18-23
11791727-2	2001	Among these ionization methods, FAB-MS and FAB-MS/MS gave reproducible and predictable spectra carrying information on sequence and branching of sialyl oligosaccharides after derivatization with 2-aminopyridine (PA).	Protactinium	212-214	FA complementation group B	Homo sapiens	32-35
11791727-2	2001	Among these ionization methods, FAB-MS and FAB-MS/MS gave reproducible and predictable spectra carrying information on sequence and branching of sialyl oligosaccharides after derivatization with 2-aminopyridine (PA).	Protactinium	212-214	FA complementation group B	Homo sapiens	43-46
11922137-8	2001	Thus, our results indicate that neuroserpin reduces microglial activation and, therefore, the PA activity and has a neuroprotective role after focal ischemic stroke.	Protactinium	94-96	serine (or cysteine) peptidase inhibitor, clade I, member 1	Mus musculus	32-43
11687302-6	2001	While pA and pB bound to the G-rich strand of Pc-1, pD, pE, pF and pG bound to the complementary C-rich strand.	Protactinium	6-8	minisatellite 6 hypermutable	Mus musculus	46-50
11706993-1	2001	Phospholipase D (PLD) catalyses the hydrolysis of phosphatidylcholine to generate the lipid second messenger, phosphatidate (PA) and choline.	Protactinium	125-127	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	0-15
11706993-1	2001	Phospholipase D (PLD) catalyses the hydrolysis of phosphatidylcholine to generate the lipid second messenger, phosphatidate (PA) and choline.	Protactinium	125-127	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	17-20
11706993-6	2001	A signalling role of phospholipase D via PA and indirectly via PIP2 in regulating membrane traffic and actin dynamics is indicated by the available data.	Protactinium	41-43	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	21-36
11535516-4	2001	In one third (11 of 34) of the patients, PA antibodies showed a marked decrease (less than 50%) in reactivity with KO compared with wild-type GPIIb-IIIa.	Protactinium	41-43	integrin subunit alpha 2b	Homo sapiens	142-147
11703413-3	2001	We studied the presence of GP V-specific PA-IgG by direct monoclonal antibody-specific immobilization of platelet antigens (MAIPA) with the monoclonal antibody SW16.	Protactinium	41-43	glycoprotein V platelet	Homo sapiens	27-31
11703413-5	2001	PA-IgG against GP V (ratio &gt; or = 1.5) was noted in 15 (22%) patients.	Protactinium	0-2	glycoprotein V platelet	Homo sapiens	15-19
11703413-6	2001	The degree of PA-IgG measured by PIFT, and of GP IIbIIIa-and/or GP IbIX-specific PA-IgG measured by direct MAIPA, correlated directly with the GP V-specific PA-IgG (P &lt; 0.001).	Protactinium	14-16	glycoprotein V platelet	Homo sapiens	143-147
11703413-8	2001	Although this patient had strongly positive GP V-specific PA-IgG, she remained negative in GP IIbIIIa- and GP IbIX-specific direct MAIPA.	Protactinium	58-60	glycoprotein V platelet	Homo sapiens	44-48
11703413-9	2001	Two patients studied because of thrombocytopenia associated with gold therapy had strongly positive GP V-specific PA-IgG.	Protactinium	114-116	glycoprotein V platelet	Homo sapiens	100-104
11703413-10	2001	In one patient with rheumatoid arthritis and severe gold-induced thrombocytopenia, the amount of GP V-specific PA-IgG decreased during the recovery phase.	Protactinium	111-113	glycoprotein V platelet	Homo sapiens	97-101
11535516-9	2001	The present data suggest that certain PA anti-GPIIb-IIIa autoantibodies recognize epitopes close to the ligand-binding site in GPIIb, but not in GPIIIa.	Protactinium	38-40	integrin subunit alpha 2b	Homo sapiens	46-51
11535516-9	2001	The present data suggest that certain PA anti-GPIIb-IIIa autoantibodies recognize epitopes close to the ligand-binding site in GPIIb, but not in GPIIIa.	Protactinium	38-40	integrin subunit alpha 2b	Homo sapiens	127-132
11470706-1	2001	OBJECTIVE: To investigate the efficacy and safety of treating submacular hemorrhages secondary to age-related macular degeneration (ARMD) with intravitreous recombinant tissue plasminogen activator (rt-PA) and gas under various conditions.	Protactinium	202-204	chromosome 20 open reading frame 181	Homo sapiens	169-197
11483758-0	2001	Functional analysis of PA binding by influenza a virus PB1: effects on polymerase activity and viral infectivity.	Protactinium	23-25	polybromo 1	Homo sapiens	55-58
11483758-4	2001	Biochemical studies addressing the molecular anatomy of the P complexes have revealed direct interactions between PB1 and PB2 as well as between PB1 and PA.	Protactinium	153-155	polybromo 1	Homo sapiens	145-148
11483758-5	2001	Previous studies have shown that the N-terminal 48 amino acids of PB1, termed domain alpha, contain the residues required for binding PA.	Protactinium	134-136	polybromo 1	Homo sapiens	66-69
11443048-4	2001	This higher excitability is partly based on an upregulation of the Na(+) current density (608.2 +/- 123.2 pA/pF in NHE1 mutant vs. 334.7 +/- 63.7 pA/pF in wild type in HCO/CO(2)).	Protactinium	106-108	solute carrier family 9 (sodium/hydrogen exchanger), member 1	Mus musculus	115-119
11559572-9	2001	Furthermore, the percentage of BCR-ABL RNA-positive colonies was almost same among the colonies not displaying Pa methylation as among the colonies in which this methylation was found.	Protactinium	111-113	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	31-38
12536594-2	2001	METHODS: We used phenylacetate(PA) as substrate and investigated the hydrolysis of PA catalyzed by serum PON or HDL-PON.	Protactinium	83-85	paraoxonase 1	Homo sapiens	105-108
12536594-2	2001	METHODS: We used phenylacetate(PA) as substrate and investigated the hydrolysis of PA catalyzed by serum PON or HDL-PON.	Protactinium	83-85	paraoxonase 1	Homo sapiens	116-119
11483758-6	2001	We report here the refined mapping of the amino acid sequences within this small region of PB1 that are indispensable for binding PA by deletion mutagenesis of PB1 in a two-hybrid assay.	Protactinium	130-132	polybromo 1	Homo sapiens	91-94
11483758-6	2001	We report here the refined mapping of the amino acid sequences within this small region of PB1 that are indispensable for binding PA by deletion mutagenesis of PB1 in a two-hybrid assay.	Protactinium	130-132	polybromo 1	Homo sapiens	160-163
11483758-7	2001	Subsequently, we used site-directed mutagenesis to identify the critical amino acid residues of PB1 for interaction with PA in vivo.	Protactinium	121-123	polybromo 1	Homo sapiens	96-99
11483758-10	2001	A strong correlation was observed between a functional PA binding site on PB1 and P activity.	Protactinium	55-57	polybromo 1	Homo sapiens	74-77
11483758-12	2001	Interestingly, mutations that rendered PB1 unable to bind PA were either nonviable or severely growth impaired.	Protactinium	58-60	polybromo 1	Homo sapiens	39-42
11483758-13	2001	These data are consistent with an essential role for the N terminus of PB1 in binding PA, P activity, and virus growth.	Protactinium	86-88	polybromo 1	Homo sapiens	71-74
11507205-7	2001	The interaction of PA and hCLE was also observed with purified proteins in vitro by using pull-down and pep-spot experiments.	Protactinium	19-21	RNA transcription, translation and transport factor	Homo sapiens	26-30
11507205-8	2001	Mapping of the interaction showed that hCLE interacts with PA subunit at two regions (positions 493 to 512 and 557 to 574) in the PA protein sequence.	Protactinium	59-61	RNA transcription, translation and transport factor	Homo sapiens	39-43
11507205-8	2001	Mapping of the interaction showed that hCLE interacts with PA subunit at two regions (positions 493 to 512 and 557 to 574) in the PA protein sequence.	Protactinium	130-132	RNA transcription, translation and transport factor	Homo sapiens	39-43
11771854-4	2001	The administration of tamoxifen, an estrogen receptor antagonist, prevented the reduction of hepatic MT content by PA.	Protactinium	115-117	estrogen receptor 1	Homo sapiens	36-53
11522018-2	2001	In suspensions of thrombin-activated WP sheared immediately (tau0), all three ligands were required for optimal aggregation at all G, as shown by a 50-70% inhibition of capture efficiencies of PA (measured from initial rates of PA), by antibodies (Abs) directed against each protein.	Protactinium	193-195	coagulation factor II, thrombin	Homo sapiens	18-26
11508860-9	2001	In healthy individuals, PA of CD64+ Neu was higher, than of CD64- cells (P = 0.021).	Protactinium	24-26	Fc gamma receptor Ia	Homo sapiens	30-34
11508860-10	2001	In septic patients, decreased PA was detected in CD64+ Mo and Neu (P = 0.013 and P = 0.040, respectively).	Protactinium	30-32	Fc gamma receptor Ia	Homo sapiens	49-53
11463601-7	2001	Furthermore, the serum ST2 levels during asthma exacerbation statistically correlated with the percentage of predicted peak expiratory flow (r = -0.634, p = 0.004) and Pa(CO(2)) (r = 0.516, p = 0.003).	Protactinium	168-170	ST2	Homo sapiens	23-26
11459942-8	2001	We further demonstrate that the N-terminal PAS domain is a cis regulator of PASK catalytic activity.	Protactinium	43-46	PAS domain containing serine/threonine kinase	Homo sapiens	76-80
11459942-9	2001	When the PAS domain-containing region is removed, enzyme activity is significantly increased, and supplementation of the purified PAS-A domain in trans selectively inhibits PASK catalytic activity.	Protactinium	9-12	PAS domain containing serine/threonine kinase	Homo sapiens	173-177
11410776-4	2001	Immunohistochemically, E-cadherin expression was completely lost in 7/8 UC cases, whereas half the PA cases revealed a strong reactivity for E-cadherin.	Protactinium	99-101	cadherin 1	Homo sapiens	141-151
11401957-9	2001	Significantly, Pa neither increased IL-1beta nor induced behavioral changes in mice, but did induce the anti-inflammatory cytokine IL-10.	Protactinium	15-17	interleukin 1 beta	Mus musculus	36-44
11401957-9	2001	Significantly, Pa neither increased IL-1beta nor induced behavioral changes in mice, but did induce the anti-inflammatory cytokine IL-10.	Protactinium	15-17	interleukin 10	Mus musculus	131-136
11523138-11	2001	Mucin lake was stained with alcian blue and PAS.	Protactinium	44-47	LOC100508689	Homo sapiens	0-5
11257309-2	2001	Intravenous injections of alpha-CGRP and beta-CGRP (5-200 pmol/kg) induced a dose-related increase in PA flow and a dose-related decrease in its resistance.	Protactinium	102-104	calcitonin related polypeptide beta	Homo sapiens	41-50
11442492-5	2001	Samples with a high PA (&gt; median of the whole group) were more likely to produce interleukin 3, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF) (56%, 43% and 50%) than cells with a low PA (33%, 36% and 36%; n.s.).	Protactinium	20-22	interleukin 3	Homo sapiens	84-97
11442492-5	2001	Samples with a high PA (&gt; median of the whole group) were more likely to produce interleukin 3, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF) (56%, 43% and 50%) than cells with a low PA (33%, 36% and 36%; n.s.).	Protactinium	20-22	colony stimulating factor 2	Homo sapiens	99-147
11442492-5	2001	Samples with a high PA (&gt; median of the whole group) were more likely to produce interleukin 3, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF) (56%, 43% and 50%) than cells with a low PA (33%, 36% and 36%; n.s.).	Protactinium	20-22	colony stimulating factor 2	Homo sapiens	149-155
11442492-5	2001	Samples with a high PA (&gt; median of the whole group) were more likely to produce interleukin 3, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF) (56%, 43% and 50%) than cells with a low PA (33%, 36% and 36%; n.s.).	Protactinium	20-22	colony stimulating factor 2	Homo sapiens	152-155
11442492-5	2001	Samples with a high PA (&gt; median of the whole group) were more likely to produce interleukin 3, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF) (56%, 43% and 50%) than cells with a low PA (33%, 36% and 36%; n.s.).	Protactinium	20-22	colony stimulating factor 3	Homo sapiens	175-180
11442492-6	2001	The effect of priming by exogenous GM-CSF or G-CSF was significantly more pronounced in samples with a low PA than in rapidly proliferating samples (P &lt; 0.01).	Protactinium	107-109	colony stimulating factor 2	Homo sapiens	35-41
11442492-6	2001	The effect of priming by exogenous GM-CSF or G-CSF was significantly more pronounced in samples with a low PA than in rapidly proliferating samples (P &lt; 0.01).	Protactinium	107-109	colony stimulating factor 3	Homo sapiens	45-50
11278644-7	2001	Moreover, an equimolar mixture of purified mutant PA (PA-I) and wild-type PA showed complete inhibition of toxin activity both in vitro on J774A.1 cells and in vivo in Fischer 344 rats thereby exhibiting a dominant negative effect.	Protactinium	50-52	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	54-58
11371609-6	2001	Here we demonstrate that npl1, like nph1, noncovalently binds the chromophore flavin mononucleotide (FMN) within two specialized PAS domains, termed LOV domains.	Protactinium	129-132	phototropin 2	Arabidopsis thaliana	25-29
11371609-6	2001	Here we demonstrate that npl1, like nph1, noncovalently binds the chromophore flavin mononucleotide (FMN) within two specialized PAS domains, termed LOV domains.	Protactinium	129-132	phototropin 1	Arabidopsis thaliana	36-40
11758807-4	2001	PA activity in the cell lysate was increased by treatment with IL-1beta.	Protactinium	0-2	interleukin 1 beta	Homo sapiens	63-71
11758807-5	2001	Further, PA activity released by phosphatidylinositol-specific phospholipase C, which detaches the GPI anchor, was also increased by IL-1beta.	Protactinium	9-11	interleukin 1 beta	Homo sapiens	133-141
11397901-3	2001	Recently, in prepubertal girls with PA, a fasting glucose to insulin ratio (FGIR) of less than 7 was found to be predictive of insulin resistance as determined by the frequently sampled iv glucose tolerance test.	Protactinium	36-38	insulin	Homo sapiens	61-68
11392434-6	2001	Pa and Pb waveforms were present 100 percent of the time in response to the 90 dB nHL presentation.	Protactinium	0-2	regulator of telomere elongation helicase 1	Homo sapiens	82-85
11392434-7	2001	The prevalence of Pa and Pb to the 70 dB nHL presentation varied from 86 to 95 percent.	Protactinium	18-20	regulator of telomere elongation helicase 1	Homo sapiens	41-44
11392434-8	2001	The prevalence of Pa and Pb to the 50 dB nHL stimulus never reached 100 percent, ranging in prevalence from 77 to 68 percent.	Protactinium	18-20	regulator of telomere elongation helicase 1	Homo sapiens	41-44
11296260-3	2001	Both basal activity and MyoD transactivation of the Pa promoter require binding of the upstream stimulating factors (USF) to E1.	Protactinium	52-54	myogenic differentiation 1	Mus musculus	24-28
11376560-3	2001	Among the PA system factors, both the levels of uPAR and PAI-1 were significantly higher in larger tumors than in smaller ones, and were also significantly higher in tumors that invaded subserosa, serosa or adjacent organs than in mucosal, submucosal tumors or in tumors that invaded the muscle layer.	Protactinium	10-12	plasminogen activator, urokinase receptor	Homo sapiens	48-52
11376560-3	2001	Among the PA system factors, both the levels of uPAR and PAI-1 were significantly higher in larger tumors than in smaller ones, and were also significantly higher in tumors that invaded subserosa, serosa or adjacent organs than in mucosal, submucosal tumors or in tumors that invaded the muscle layer.	Protactinium	10-12	serpin family E member 1	Homo sapiens	57-62
11301361-10	2001	In the group treated with CCl4 followed by pHGF, serum GOT and GPT levels were significantly lower than in the CCl4-treated group, and abundant PAS-positive hepatocytes were observed.	Protactinium	144-147	C-C motif chemokine ligand 4	Rattus norvegicus	26-30
11296577-1	2001	OBJECTIVE: Intravenous recombinant tissue plasminogen activator (rt-PA) is the only therapy of proven value for patients with acute ischemic stroke (AIS).	Protactinium	68-70	chromosome 20 open reading frame 181	Homo sapiens	35-63
11260718-5	2001	Here we describe ADAGIO1 (ADO1), a gene of Arabidopsis thaliana that encodes a protein containing a PAS domain.	Protactinium	100-103	Galactose oxidase/kelch repeat superfamily protein	Arabidopsis thaliana	17-24
11260718-5	2001	Here we describe ADAGIO1 (ADO1), a gene of Arabidopsis thaliana that encodes a protein containing a PAS domain.	Protactinium	100-103	Galactose oxidase/kelch repeat superfamily protein	Arabidopsis thaliana	26-30
11226160-5	2001	Mutations of the FRQ coiled-coil that inhibit self-association also prevent its interaction with two other key components of the NEUROSPORA: circadian clock, namely WC-1 and WC-2, the two PAS domain-containing transcription factors.	Protactinium	188-191	ATPase copper transporting beta	Homo sapiens	165-169
11426604-7	2001	The fibers spun at about eta &gt; 3.0 Pas had the best properties with respect to bioactivity, especially when they were heat-treated at 175 degrees C. It was found that surface structure in a nanometer scale was the most important factor controlling the in vitro bioactivity of heat-treated silica fibers.	Protactinium	38-41	endothelin receptor type A	Homo sapiens	25-28
11226161-0	2001	WC-2 mediates WC-1-FRQ interaction within the PAS protein-linked circadian feedback loop of Neurospora.	Protactinium	46-49	ATPase copper transporting beta	Homo sapiens	14-18
11091086-1	2000	We have isolated a novel gene from Xenopus, denominated xSim, which encodes a protein of 760 amino acids containing a basic helix-loop-helix (bHLH) motif contiguous to a PAS domain characteristic of an emerging family of transcriptional regulators so called bHLH/PAS.	Protactinium	170-173	SIM bHLH transcription factor 2 S homeolog	Xenopus laevis	56-60
11950150-5	2001	The HIF-1 complex, which contains an alpha and beta subunit (both basic helix-loop-helix proteins of the PAS family) is formed in hypoxia and modulates gene expression through hypoxia response elements.	Protactinium	105-108	Hypoxia-inducible factor 1	Caenorhabditis elegans	4-9
11950153-11	2001	We also tested the ability of Ad5-Kv2.1 to increase Kv2.1 channel expression and function in human PAs ex vivo.	Protactinium	99-102	potassium voltage-gated channel subfamily B member 1	Homo sapiens	34-39
11950153-11	2001	We also tested the ability of Ad5-Kv2.1 to increase Kv2.1 channel expression and function in human PAs ex vivo.	Protactinium	99-102	potassium voltage-gated channel subfamily B member 1	Homo sapiens	52-57
11874082-10	2001	The presence of mucin and glycogen was studied by histochemical reaction, PAS, PAS diastase and mucicarmine.	Protactinium	74-77	LOC100508689	Homo sapiens	16-21
11874082-10	2001	The presence of mucin and glycogen was studied by histochemical reaction, PAS, PAS diastase and mucicarmine.	Protactinium	79-82	LOC100508689	Homo sapiens	16-21
11244291-9	2001	The plasma BNP level in pa- tients with cardiac events was significantly higher than in those without (521.0 +/- 156.0 vs. 126.8 +/- 20.1 pg/ml, p&lt;0.001), despite more frequent treatment with angiotensin-converting enzyme inhibitors (75 vs. 28%, p&lt;0.05).	Protactinium	24-26	natriuretic peptide B	Homo sapiens	11-14
11114720-2	2000	The transcriptional activation is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric member of the basic helix-loop-helix PAS family, composed of alpha and beta subunits.	Protactinium	139-142	hypoxia inducible factor 1 subunit alpha	Homo sapiens	50-76
11069292-0	2000	Phytochrome B binds with greater apparent affinity than phytochrome A to the basic helix-loop-helix factor PIF3 in a reaction requiring the PAS domain of PIF3.	Protactinium	140-143	phytochrome B	Arabidopsis thaliana	0-13
11069292-0	2000	Phytochrome B binds with greater apparent affinity than phytochrome A to the basic helix-loop-helix factor PIF3 in a reaction requiring the PAS domain of PIF3.	Protactinium	140-143	phytochrome interacting factor 3	Arabidopsis thaliana	107-111
11069292-0	2000	Phytochrome B binds with greater apparent affinity than phytochrome A to the basic helix-loop-helix factor PIF3 in a reaction requiring the PAS domain of PIF3.	Protactinium	140-143	phytochrome interacting factor 3	Arabidopsis thaliana	154-158
11069292-7	2000	Conversely, deletion mapping and point mutation analysis of PIF3 for determinants involved in recognition of phyB indicates that the PAS domain of PIF3 is a major contributor to this interaction, but that a second determinant in the C-terminal domain is also necessary.	Protactinium	133-136	phytochrome B	Arabidopsis thaliana	109-113
11069292-7	2000	Conversely, deletion mapping and point mutation analysis of PIF3 for determinants involved in recognition of phyB indicates that the PAS domain of PIF3 is a major contributor to this interaction, but that a second determinant in the C-terminal domain is also necessary.	Protactinium	133-136	phytochrome interacting factor 3	Arabidopsis thaliana	147-151
11114720-2	2000	The transcriptional activation is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric member of the basic helix-loop-helix PAS family, composed of alpha and beta subunits.	Protactinium	139-142	hypoxia inducible factor 1 subunit alpha	Homo sapiens	78-83
11090714-1	2000	A single blinded randomized controlled trial to compare the reactogenicity and immunogenicity of adult formulated dTpa and monovalent pa vaccines with a licensed Td vaccine.	Protactinium	51-53	tan	Drosophila melanogaster	114-118
11036271-5	2000	We found that BDNF was upregulated selectively in area 36 of IT cortex during PA learning, but not in areas involved in earlier stages of visual processing.	Protactinium	78-80	brain derived neurotrophic factor	Homo sapiens	14-18
11045459-4	2000	On the other hand, pyrimidine analogs (PA series, 10 and 11) of potent RXR agonists (retinoid synergists) with a diphenylamine skeleton (DA series, 8 and 9) exhibited potent retinoid synergistic activity in HL-60 cell differentiation assay and activated RXRs.	Protactinium	39-41	retinoid X receptor alpha	Homo sapiens	71-74
11082325-3	2000	To address this, the bystander effect was further evaluated in a panel of cell lines mixed with homologous HSV-TK-expressing cell lines, a SW620.TK cell line, or a high connexin43-expressing PA-317.TK cell line.	Protactinium	191-193	gap junction protein alpha 1	Homo sapiens	169-179
11025203-4	2000	The AINT C-terminus mediates interaction with the PAS domain of ARNT in yeast and interacts in vitro with ARNT and ARNT2 specifically.	Protactinium	50-53	transforming, acidic coiled-coil containing protein 3	Mus musculus	4-8
11025203-4	2000	The AINT C-terminus mediates interaction with the PAS domain of ARNT in yeast and interacts in vitro with ARNT and ARNT2 specifically.	Protactinium	50-53	aryl hydrocarbon receptor nuclear translocator	Mus musculus	64-68
10898955-5	2000	Caspase inhibitors prevented Pa-induced apoptosis, Bcl-2 depletion, and DNase activation.	Protactinium	29-31	BCL2 apoptosis regulator	Homo sapiens	51-56
11060270-2	2000	The objective of the study was to evaluate the existing relationship between PSA plasma levels and BS findings in patients with a recently diagnosed PA in order to assess whether BS may be omitted on the basis of the PSA levels in these patients.	Protactinium	149-151	kallikrein related peptidase 3	Homo sapiens	77-80
11060270-9	2000	CONCLUSION: According to our experience, there is a significant association between PSA plasma levels and the BS results in patients with recently diagnosed PA.	Protactinium	157-159	kallikrein related peptidase 3	Homo sapiens	84-87
10938328-6	2000	Functional ROMK1, quantified as the nonnative inward current at -144 mV in 5.4 mM external K(+) blockable by 500 microM Ba(2+), ranged from 1 to 40 pA/pF.	Protactinium	148-150	potassium inwardly-rectifying channel, subfamily J, member 1	Rattus norvegicus	11-16
10898955-2	2000	Pa-induced apoptosis of isolated monocytes, as indicated by internucleosomal DNA cleavage, increased annexin V binding capacity and cleavage of caspase substrates, such as poly(ADP)ribosylpolymerase.	Protactinium	0-2	annexin A5	Homo sapiens	101-110
10898955-3	2000	In addition, Bcl-2 protein levels were downregulated during Pa-induced cell death.	Protactinium	60-62	BCL2 apoptosis regulator	Homo sapiens	13-18
10964693-3	2000	The deduced BMAL2 product contains a bHLH-PAS domain in its N-terminal region and a variable C-terminus.	Protactinium	42-45	aryl hydrocarbon receptor nuclear translocator like 2	Homo sapiens	12-17
10950939-0	2000	Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.	Protactinium	79-81	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	98-105
10866950-2	2000	Selective deletion of the HERG-specific sequence (HERG Delta138-373) located between the conserved initial amino terminus (the eag or PAS domain) and the first transmembrane helix accelerates channel activation and shifts its voltage dependence to hyperpolarized values.	Protactinium	134-137	potassium voltage-gated channel subfamily H member 2	Homo sapiens	26-30
10866950-2	2000	Selective deletion of the HERG-specific sequence (HERG Delta138-373) located between the conserved initial amino terminus (the eag or PAS domain) and the first transmembrane helix accelerates channel activation and shifts its voltage dependence to hyperpolarized values.	Protactinium	134-137	potassium voltage-gated channel subfamily H member 2	Homo sapiens	50-54
10864977-2	2000	In an attempt to better understand how organisms sense environmental changes, we have characterized a novel member of the PAS superfamily, MOP9 (member of PAS superfamily), that maps to human chromosome 12p11.22-11.23.	Protactinium	122-125	aryl hydrocarbon receptor nuclear translocator like 2	Homo sapiens	139-143
10779450-2	2000	We found that the Pa promoter of c-abl was methylated in 81% (17/21) of the white blood cells (WBCs) of CML patients, which correlates with previous reports.	Protactinium	18-20	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	33-38
11207581-2	2000	Proteolytic activation of protective antigen (PA; 83 kDa, the B moiety of the toxin) by furin was the rate-limiting step in internalization of LeTx and promoted clearance of PA from the cell surface.	Protactinium	46-48	furin (paired basic amino acid cleaving enzyme)	Mus musculus	88-93
11207581-3	2000	A furin-resistant form of PA remained at the cell surface for at least 90 min.	Protactinium	26-28	furin (paired basic amino acid cleaving enzyme)	Mus musculus	2-7
10954203-5	2000	Normal skin and skin with telangiectases showed a punctate PA activity, consisting of both uPA and tPA activity.	Protactinium	59-61	plasminogen activator, urokinase	Homo sapiens	91-94
10954203-5	2000	Normal skin and skin with telangiectases showed a punctate PA activity, consisting of both uPA and tPA activity.	Protactinium	59-61	plasminogen activator, tissue type	Homo sapiens	99-102
10847686-3	2000	Map-based cloning of ZTL identified a novel 609 amino acid polypeptide consisting of an amino-terminal PAS domain, an F box and six carboxy-terminal kelch repeats.	Protactinium	103-106	Galactose oxidase/kelch repeat superfamily protein	Arabidopsis thaliana	21-24
10847686-4	2000	The PAS region is highly similar to the PAS domain of the Arabidopsis blue-light receptor NPH1, and the Neurospora circadian-associated protein WHITE COLLAR-1 (WC-1).	Protactinium	4-7	phototropin 1	Arabidopsis thaliana	90-94
10847686-4	2000	The PAS region is highly similar to the PAS domain of the Arabidopsis blue-light receptor NPH1, and the Neurospora circadian-associated protein WHITE COLLAR-1 (WC-1).	Protactinium	40-43	phototropin 1	Arabidopsis thaliana	90-94
10764309-6	2000	There were inverse correlations between Pa(O(2)) and circulating TNF-alpha and sTNF-R levels in patients with COPD (TNF-alpha; r = -0.426, p = 0.0297; sTNF-R55: r = -0.587, p = 0.0027; sTNF-R75: r = -0.573, p = 0.0035).	Protactinium	40-42	tumor necrosis factor	Homo sapiens	65-74
10764309-6	2000	There were inverse correlations between Pa(O(2)) and circulating TNF-alpha and sTNF-R levels in patients with COPD (TNF-alpha; r = -0.426, p = 0.0297; sTNF-R55: r = -0.587, p = 0.0027; sTNF-R75: r = -0.573, p = 0.0035).	Protactinium	40-42	tumor necrosis factor	Homo sapiens	116-125
10704841-9	2000	A direct interaction between Drifter and Trh proteins, mediated by the PAS domain of Trh and the POU domain of Drifter, was demonstrated.	Protactinium	71-74	thyrotropin releasing hormone	Homo sapiens	41-44
10683255-2	2000	Both preparations gave in SDS-PAGE two major PAS-stained bands (GP2 and GP3), which migrated as 60- and 33-kDa species, respectively, compared to reference proteins, or as 44- and 23-kDa molecules, compared to human glycophorins.	Protactinium	45-48	glycoprotein 2	Homo sapiens	64-67
10683255-3	2000	Some less abundant slower migrating PAS-stained components, antigenically related to GP2 and GP3, also were detected.	Protactinium	36-39	glycoprotein 2	Homo sapiens	85-88
10678951-6	2000	In contrast, neutrophil infiltration and IL-1beta production were not observed following challenge of mice immunized with the Th2-inducing Pa.	Protactinium	139-141	heart and neural crest derivatives expressed 2	Mus musculus	126-129
10678951-7	2000	Conversely, during infection local production of IL-6 and IL-1ra was significantly greater in mice immunized with Pa than in those immunized with Pw.	Protactinium	114-116	interleukin 6	Mus musculus	49-53
10678951-7	2000	Conversely, during infection local production of IL-6 and IL-1ra was significantly greater in mice immunized with Pa than in those immunized with Pw.	Protactinium	114-116	interleukin 1 receptor antagonist	Mus musculus	58-64
10678951-9	2000	Furthermore, the levels of IL-1beta, IL-6, and IL-1ra in Pa-immunized IL-4(-/-) mice were comparable to those in mice immunized with Pw.	Protactinium	57-59	interleukin 1 receptor antagonist	Mus musculus	47-53
10678951-9	2000	Furthermore, the levels of IL-1beta, IL-6, and IL-1ra in Pa-immunized IL-4(-/-) mice were comparable to those in mice immunized with Pw.	Protactinium	57-59	interleukin 4	Mus musculus	70-74
10704841-9	2000	A direct interaction between Drifter and Trh proteins, mediated by the PAS domain of Trh and the POU domain of Drifter, was demonstrated.	Protactinium	71-74	thyrotropin releasing hormone	Homo sapiens	85-88
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	96-99	aryl hydrocarbon receptor nuclear translocator	Mus musculus	43-47
10685032-1	2000	The product of the LPP1 gene in Saccharomyces cerevisiae is a membrane-associated enzyme that catalyzes the Mg(2+)-independent dephosphorylation of phosphatidate (PA), diacylglycerol pyrophosphate (DGPP), and lysophosphatidate (LPA).	Protactinium	163-165	phosphatidate phosphatase LPP1	Saccharomyces cerevisiae S288C	19-23
10685032-2	2000	The LPP1-encoded lipid phosphatase was overexpressed 681-fold in Sf-9 insect cells and used to examine the enzymological properties of the enzyme using PA, DGPP, and LPA as substrates.	Protactinium	152-154	phosphatidate phosphatase LPP1	Saccharomyces cerevisiae S288C	4-8
10685032-7	2000	The LPP1-encoded enzyme exhibited saturation kinetics with respect to the surface concentrations of PA (K(m)=0.05 mol%), DGPP (K(m)=0.07 mol%), and LPA (K(m)=0.08 mol%).	Protactinium	100-102	phosphatidate phosphatase LPP1	Saccharomyces cerevisiae S288C	4-8
10685032-11	2000	The enzymological properties of the LPP1-encoded enzyme differed significantly from those of the S. cerevisiae DPP1-encoded lipid phosphatase, a related enzyme that also utilizes PA, DGPP, and LPA as substrates.	Protactinium	179-181	phosphatidate phosphatase LPP1	Saccharomyces cerevisiae S288C	36-40
10685032-11	2000	The enzymological properties of the LPP1-encoded enzyme differed significantly from those of the S. cerevisiae DPP1-encoded lipid phosphatase, a related enzyme that also utilizes PA, DGPP, and LPA as substrates.	Protactinium	179-181	bifunctional diacylglycerol diphosphate phosphatase/phosphatidate phosphatase	Saccharomyces cerevisiae S288C	111-115
10649830-6	2000	Thus, the 5-HT1A receptor antagonists WAY 100635 and (-)-pindolol blocked the PA deficit by 8-OH-DPAT.	Protactinium	78-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
10649830-7	2000	The impairment of PA caused by PCA was attenuated by WAY 100635 and (-)-pindolol, suggesting an involvement of the 5-HT1A receptor.	Protactinium	18-20	5-hydroxytryptamine receptor 1A	Rattus norvegicus	115-121
18967814-0	2000	Electrochemistry and electrocatalysis with myoglobin in biomembrane-like surfactant-polymer 2C12N+PA- composite films.	Protactinium	98-100	myoglobin	Homo sapiens	43-52
11697821-9	2000	A significant reduction of the processed form of p21ras and rhoB proteins in the membrane fraction of cells exposed to PA and PB was observed.	Protactinium	119-121	HRas proto-oncogene, GTPase	Homo sapiens	49-55
11697821-9	2000	A significant reduction of the processed form of p21ras and rhoB proteins in the membrane fraction of cells exposed to PA and PB was observed.	Protactinium	119-121	ras homolog family member B	Homo sapiens	60-64
10570320-6	1999	Pure caspase-3 cleaved the Pa protein into a 130-kDa fragment corresponding to the largest of these three products.	Protactinium	27-29	caspase 3	Homo sapiens	5-14
10570320-7	1999	Peptide sequence analysis of a tryptic digest from immunoaffinity-purified Pa showed 100% identity to human RNA helicase A (RHA).	Protactinium	75-77	DExH-box helicase 9	Homo sapiens	108-122
10570320-7	1999	Peptide sequence analysis of a tryptic digest from immunoaffinity-purified Pa showed 100% identity to human RNA helicase A (RHA).	Protactinium	75-77	DExH-box helicase 9	Homo sapiens	124-127
10570320-8	1999	The identity of Pa with RHA was further confirmed by immunoblotting with rabbit anti-RHA Ab using anti-Pa immunoprecipitates as substrates.	Protactinium	16-18	DExH-box helicase 9	Homo sapiens	24-27
10570320-8	1999	The identity of Pa with RHA was further confirmed by immunoblotting with rabbit anti-RHA Ab using anti-Pa immunoprecipitates as substrates.	Protactinium	16-18	DExH-box helicase 9	Homo sapiens	85-88
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	96-99	aryl-hydrocarbon receptor	Mus musculus	179-182
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	96-99	hypoxia inducible factor 1, alpha subunit	Mus musculus	189-221
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	233-236	aryl hydrocarbon receptor nuclear translocator	Mus musculus	43-47
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	233-236	aryl hydrocarbon receptor nuclear translocator	Mus musculus	82-86
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	233-236	aryl-hydrocarbon receptor	Mus musculus	87-90
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	233-236	aryl-hydrocarbon receptor	Mus musculus	152-177
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	233-236	aryl-hydrocarbon receptor	Mus musculus	179-182
10746533-6	2000	In a second experiment, Pa responses to angiotensin II (0.1 microg), hypoxic pulmonary vasoconstriction (HPV, 3% O2 for 10 minutes), or phenylephrine (0.1 microg) were assessed to determine the specificity of ropivacaine effects on TXA2 receptors.	Protactinium	24-26	angiotensinogen	Rattus norvegicus	40-54
10801075-3	2000	The data obtained demonstrate that the growth factor activity of PAs is associated with: - a rapid transient activation of early response genes, c-fos, c-jun and c-myc; - the subsequent coordinated down-regulation of p53 and p21CIP1; - the constant expression of the MEK1 mRNA in every phase of the cell cycle.	Protactinium	65-68	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	145-150
10801075-3	2000	The data obtained demonstrate that the growth factor activity of PAs is associated with: - a rapid transient activation of early response genes, c-fos, c-jun and c-myc; - the subsequent coordinated down-regulation of p53 and p21CIP1; - the constant expression of the MEK1 mRNA in every phase of the cell cycle.	Protactinium	65-68	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	152-157
10801075-3	2000	The data obtained demonstrate that the growth factor activity of PAs is associated with: - a rapid transient activation of early response genes, c-fos, c-jun and c-myc; - the subsequent coordinated down-regulation of p53 and p21CIP1; - the constant expression of the MEK1 mRNA in every phase of the cell cycle.	Protactinium	65-68	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	162-167
10801075-3	2000	The data obtained demonstrate that the growth factor activity of PAs is associated with: - a rapid transient activation of early response genes, c-fos, c-jun and c-myc; - the subsequent coordinated down-regulation of p53 and p21CIP1; - the constant expression of the MEK1 mRNA in every phase of the cell cycle.	Protactinium	65-68	tumor protein p53	Homo sapiens	217-220
10801075-3	2000	The data obtained demonstrate that the growth factor activity of PAs is associated with: - a rapid transient activation of early response genes, c-fos, c-jun and c-myc; - the subsequent coordinated down-regulation of p53 and p21CIP1; - the constant expression of the MEK1 mRNA in every phase of the cell cycle.	Protactinium	65-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	225-232
10801075-3	2000	The data obtained demonstrate that the growth factor activity of PAs is associated with: - a rapid transient activation of early response genes, c-fos, c-jun and c-myc; - the subsequent coordinated down-regulation of p53 and p21CIP1; - the constant expression of the MEK1 mRNA in every phase of the cell cycle.	Protactinium	65-68	mitogen-activated protein kinase kinase 1	Homo sapiens	267-271
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	233-236	hypoxia inducible factor 1, alpha subunit	Mus musculus	189-221
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	96-99	aryl hydrocarbon receptor nuclear translocator	Mus musculus	82-86
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	96-99	aryl-hydrocarbon receptor	Mus musculus	87-90
10630574-1	1999	The aryl hydrocarbon nuclear translocator (Arnt) is a basic helix-loop-helix (per/Arnt/Ahr/sim) PAS-containing protein that can heterodimerize with the aryl hydrocarbon receptor (AhR), the hypoxia-inducible factor-1 alpha, and other PAS-containing proteins to form transcriptionally active complexes.	Protactinium	96-99	aryl-hydrocarbon receptor	Mus musculus	152-177
10457348-3	1999	Urokinase PA expression was activated after contact with fibrin and initiation of cell-cell interactions that were mediated by E-cadherin.	Protactinium	10-12	cadherin 1	Homo sapiens	127-137
10513988-3	1999	The question as to whether a direct interaction between PA-type modulators and Pgp takes place was addressed by means of Pgp ATPase measurements and transport studies.	Protactinium	56-58	ATP binding cassette subfamily B member 1	Homo sapiens	79-82
10544057-1	1999	The arylhydrocarbon receptor (AhR) and the arylhydrocarbon receptor nuclear translocator (ARNT) are members of the PAS gene family mediating toxic effects of xenobiotics such as dioxin and polychlorinated biphenyls.	Protactinium	115-118	aryl hydrocarbon receptor	Oryctolagus cuniculus	30-33
10544057-1	1999	The arylhydrocarbon receptor (AhR) and the arylhydrocarbon receptor nuclear translocator (ARNT) are members of the PAS gene family mediating toxic effects of xenobiotics such as dioxin and polychlorinated biphenyls.	Protactinium	115-118	aryl hydrocarbon receptor nuclear translocator	Oryctolagus cuniculus	43-88
10544057-1	1999	The arylhydrocarbon receptor (AhR) and the arylhydrocarbon receptor nuclear translocator (ARNT) are members of the PAS gene family mediating toxic effects of xenobiotics such as dioxin and polychlorinated biphenyls.	Protactinium	115-118	aryl hydrocarbon receptor nuclear translocator	Oryctolagus cuniculus	90-94
10484592-10	1999	It is unclear why the contractile sensitivity in females was not reduced by Ex as in the males, because Ex significantly affected responses to TEA and ET-1 stimulation of [(32)P]PA production in both males and females.	Protactinium	178-180	endothelin-1	Sus scrofa	151-155
10515511-3	1999	An understanding of the relationship among Pa, Pt, and upper and lower airway resistance, and how these values fluctuate during speech, could aid in interpretation and modeling of speech aerodynamics.	Protactinium	43-45	activation induced cytidine deaminase	Homo sapiens	142-145
10433921-3	1999	Dioxin and other aryl hydrocarbons bind to the PAS domain of Ahr, causing Ahr to translocate to the nucleus, where it dimerizes with another bHLH-PAS protein, the aryl hydrocarbon receptor nuclear translocator (Arnt).	Protactinium	47-50	spineless	Drosophila melanogaster	61-64
10433921-3	1999	Dioxin and other aryl hydrocarbons bind to the PAS domain of Ahr, causing Ahr to translocate to the nucleus, where it dimerizes with another bHLH-PAS protein, the aryl hydrocarbon receptor nuclear translocator (Arnt).	Protactinium	47-50	spineless	Drosophila melanogaster	74-77
10433921-3	1999	Dioxin and other aryl hydrocarbons bind to the PAS domain of Ahr, causing Ahr to translocate to the nucleus, where it dimerizes with another bHLH-PAS protein, the aryl hydrocarbon receptor nuclear translocator (Arnt).	Protactinium	47-50	tango	Drosophila melanogaster	163-209
10433921-3	1999	Dioxin and other aryl hydrocarbons bind to the PAS domain of Ahr, causing Ahr to translocate to the nucleus, where it dimerizes with another bHLH-PAS protein, the aryl hydrocarbon receptor nuclear translocator (Arnt).	Protactinium	47-50	tango	Drosophila melanogaster	211-215
10528802-7	1999	From these results we conclude that: (1) inhibition of IFN-gamma synthesis, as well as IFN-gamma-induced expression of costimulatory molecules and NK-cell effector functions may lead to suppression of specific and non-specific defense mechanisms, respectively, which are necessary for elimination of PA bacteria; (2) enhancement of IFN-gamma synthesis induced by P-ExA in a combination with IL-1alpha may cause harmful, Th1 cells dependent, inflammatory reactions of the host (septic shock, tissue damage) during infection with Pseudomonas aeruginosa.	Protactinium	300-302	interferon gamma	Homo sapiens	87-96
10528802-7	1999	From these results we conclude that: (1) inhibition of IFN-gamma synthesis, as well as IFN-gamma-induced expression of costimulatory molecules and NK-cell effector functions may lead to suppression of specific and non-specific defense mechanisms, respectively, which are necessary for elimination of PA bacteria; (2) enhancement of IFN-gamma synthesis induced by P-ExA in a combination with IL-1alpha may cause harmful, Th1 cells dependent, inflammatory reactions of the host (septic shock, tissue damage) during infection with Pseudomonas aeruginosa.	Protactinium	300-302	interferon gamma	Homo sapiens	87-96
10408444-4	1999	The mPer genes share a conserved PAS domain (a dimerization domain found in Per, Arnt and Sim) and show a circadian expression pattern in the suprachiasmatic nucleus.	Protactinium	33-36	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	81-85
10403839-4	1999	Of the three splice variants, mBMAL1b extends for 1878 bp in the coding sequence, which is 91% identical to that of hBMAL1b; its deduced amino acid sequence is 626 residues long and is 98% identical to that of hBMAL1b, and sequence identities in the bHLH, PAS-A, and PAS-B regions are 98, 100, and 100%, respectively.	Protactinium	256-259	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	30-37
10403839-4	1999	Of the three splice variants, mBMAL1b extends for 1878 bp in the coding sequence, which is 91% identical to that of hBMAL1b; its deduced amino acid sequence is 626 residues long and is 98% identical to that of hBMAL1b, and sequence identities in the bHLH, PAS-A, and PAS-B regions are 98, 100, and 100%, respectively.	Protactinium	267-270	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	30-37
10403839-6	1999	mBMAL1b" encodes 632 amino acids and contains the bHLH/PAS domains.	Protactinium	55-58	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	0-7
10415153-4	1999	Twitcher/IL-6-deficient mice had a more severe disease than regular twitcher mice: they had an earlier onset day of twitching, a greater number of PAS-positive cells, a greater susceptibility to LPS, an exaggerated gliotic response around some vessels, an elevated level of TNF-alpha, and a compromised blood-brain barrier, which was evaluated by three independent measures.	Protactinium	147-150	interleukin 6	Mus musculus	9-13
10504054-8	1999	Increases in PA expression by RA have been reported to involve RAR alpha and RAR beta expression.	Protactinium	13-15	retinoic acid receptor alpha	Homo sapiens	63-72
10504054-8	1999	Increases in PA expression by RA have been reported to involve RAR alpha and RAR beta expression.	Protactinium	13-15	retinoic acid receptor beta	Homo sapiens	77-85
10413464-3	1999	Mapping studies indicate that XAP2 requires the PAS, hsp90, and ligand binding domain(s) of the AhR for binding, and that both proteins directly interact in the absence of hsp90.	Protactinium	48-51	aryl hydrocarbon receptor interacting protein	Homo sapiens	30-34
10413464-3	1999	Mapping studies indicate that XAP2 requires the PAS, hsp90, and ligand binding domain(s) of the AhR for binding, and that both proteins directly interact in the absence of hsp90.	Protactinium	48-51	aryl hydrocarbon receptor	Homo sapiens	96-99
10408444-5	1999	To assess the in vivo function of mPer2, we generated and characterized a deletion mutation in the PAS domain of the mouse mPer2 gene.	Protactinium	99-102	period circadian clock 2	Mus musculus	123-128
10397301-4	1999	Endothelial cells (ECs) synthesize fibrinolytic proteins, t-PA, u-PA, and PAs inhibitor, PAI-1.	Protactinium	74-77	serpin family E member 1	Homo sapiens	89-94
10375402-2	1999	Purified human liver microsomal cytochromes P450 (P450)-P450 1A2 and P450 2E1-were shown to have appreciable PLD activity, hydrolyzing phosphatidylcholine but not other phospholipids, generating PA and choline.	Protactinium	195-197	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	44-48
10375402-2	1999	Purified human liver microsomal cytochromes P450 (P450)-P450 1A2 and P450 2E1-were shown to have appreciable PLD activity, hydrolyzing phosphatidylcholine but not other phospholipids, generating PA and choline.	Protactinium	195-197	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	50-54
10375402-2	1999	Purified human liver microsomal cytochromes P450 (P450)-P450 1A2 and P450 2E1-were shown to have appreciable PLD activity, hydrolyzing phosphatidylcholine but not other phospholipids, generating PA and choline.	Protactinium	195-197	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	50-54
10375402-2	1999	Purified human liver microsomal cytochromes P450 (P450)-P450 1A2 and P450 2E1-were shown to have appreciable PLD activity, hydrolyzing phosphatidylcholine but not other phospholipids, generating PA and choline.	Protactinium	195-197	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	50-54
10375402-2	1999	Purified human liver microsomal cytochromes P450 (P450)-P450 1A2 and P450 2E1-were shown to have appreciable PLD activity, hydrolyzing phosphatidylcholine but not other phospholipids, generating PA and choline.	Protactinium	195-197	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	109-112
10414402-5	1999	Measurement of Ptc,O2 underestimated arterial oxygen tension (Pa,O2) and this underestimation increased with the level of Pa,O2 (p&lt;0.01).	Protactinium	62-64	ret proto-oncogene	Homo sapiens	15-18
10338505-4	1999	Soluble, monomeric scFv were characterized for affinity and screened for their capacity to disrupt receptor-mediated binding of PA.	Protactinium	128-130	immunglobulin heavy chain variable region	Homo sapiens	19-23
10338505-6	1999	Two scFv had similar affinities for natural PA83 and a novel, recombinant, 32-kDa carboxy-terminal PA fragment (PA32).	Protactinium	44-46	immunglobulin heavy chain variable region	Homo sapiens	4-8
10347097-5	1999	Normal porcine PAs in attached collagen gels were characterized by increasing activity of MMP-2 and MMP-9 assessed by zymography and TN deposition detected by Western immunoblotting and densitometric analysis of immunoreactivity.	Protactinium	15-18	matrix metallopeptidase 2	Rattus norvegicus	90-95
10347097-5	1999	Normal porcine PAs in attached collagen gels were characterized by increasing activity of MMP-2 and MMP-9 assessed by zymography and TN deposition detected by Western immunoblotting and densitometric analysis of immunoreactivity.	Protactinium	15-18	matrix metallopeptidase 9	Rattus norvegicus	100-105
10347097-5	1999	Normal porcine PAs in attached collagen gels were characterized by increasing activity of MMP-2 and MMP-9 assessed by zymography and TN deposition detected by Western immunoblotting and densitometric analysis of immunoreactivity.	Protactinium	15-18	tenascin C	Rattus norvegicus	133-135
10347097-6	1999	PAs on floating collagen showed reduced activity of both MMPs and deposition of TN.	Protactinium	0-3	matrix metallopeptidase 2	Rattus norvegicus	57-61
10347097-6	1999	PAs on floating collagen showed reduced activity of both MMPs and deposition of TN.	Protactinium	0-3	tenascin C	Rattus norvegicus	80-82
10323382-3	1999	The aim of the present study was to search for defects in the CYP21 gene in children with PA and to detect possible correlations of the molecular defect to pertinent hormonal and clinical data.	Protactinium	90-92	cytochrome P450 family 21 subfamily A member 2	Homo sapiens	62-67
20229337-3	1999	The results showed that there was Na(+)/H(+) exchange activity in the plasma membrane of PA, FCS stimulated DNA synthesis measured by(3)H-TdR incorporation, and the activation of Na(+) /H(+) exchanger resulted in pHi increase (nearly 0.2 pH unit) within 2 min.	Protactinium	89-91	glucose-6-phosphate isomerase	Rattus norvegicus	213-216
20229337-8	1999	These results demonstrated that the activation of Na(+) /H(+) exchange and the resulting pHi increase are the early events related to both proliferation and differentiation of PA.	Protactinium	176-178	glucose-6-phosphate isomerase	Rattus norvegicus	89-92
10229663-10	1999	Taken together, these results suggest that phospholipase D-derived PA is involved in changing the affinity of the CD11b/CD18 integrin for its ligands.	Protactinium	67-69	integrin subunit alpha M	Homo sapiens	114-119
10229663-10	1999	Taken together, these results suggest that phospholipase D-derived PA is involved in changing the affinity of the CD11b/CD18 integrin for its ligands.	Protactinium	67-69	integrin subunit beta 2	Homo sapiens	120-124
10414402-5	1999	Measurement of Ptc,O2 underestimated arterial oxygen tension (Pa,O2) and this underestimation increased with the level of Pa,O2 (p&lt;0.01).	Protactinium	122-124	ret proto-oncogene	Homo sapiens	15-18
10391119-4	1999	The tissue levels of MPO increased on 1, 2, 5 and 6 days post-administration (PA) of acetic acid and declined to the control levels by day 7 PA.	Protactinium	78-80	myeloperoxidase	Rattus norvegicus	21-24
10235448-5	1999	PAs with improved fibrin-specificity (staphylokinase, the TNK variant of tissue-type PA [tPA], and the PA from the saliva of the Desmodus rotundus bat) induced rapid lysis in concentration ranges (80-, 260-, and 3,500-fold ranges, respectively) much wider than that for tPA (a 35-fold range).	Protactinium	0-3	plasminogen activator, tissue type	Homo sapiens	89-92
10235448-5	1999	PAs with improved fibrin-specificity (staphylokinase, the TNK variant of tissue-type PA [tPA], and the PA from the saliva of the Desmodus rotundus bat) induced rapid lysis in concentration ranges (80-, 260-, and 3,500-fold ranges, respectively) much wider than that for tPA (a 35-fold range).	Protactinium	0-3	plasminogen activator, tissue type	Homo sapiens	270-273
10394824-3	1999	The effect of hyperoxaemia (arterial oxygen tension (Pa,O2) &gt; 13.3 kPa) on EPO secretion has not been thoroughly studied and is not fully understood.	Protactinium	53-55	erythropoietin	Homo sapiens	78-81